<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Eur J Clin Microbiol Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Eur. J. Clin. Microbiol. Infect. Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        European Journal of Clinical Microbiology &amp; Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0934-9723
      </issn>
      <issn pub-type="epub">
       1435-4373
      </issn>
      <publisher>
       <publisher-name>
        Springer Berlin Heidelberg
       </publisher-name>
       <publisher-loc>
        Berlin/Heidelberg
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28695355
      </article-id>
      <article-id pub-id-type="pmc">
       7087918
      </article-id>
      <article-id pub-id-type="publisher-id">
       3043
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s10096-017-3043-3
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Original Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ko
         </surname>
         <given-names>
          J.-H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          M. A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Seok
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          G. E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          J. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cho
         </surname>
         <given-names>
          S. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ha
         </surname>
         <given-names>
          Y. E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Baek
         </surname>
         <given-names>
          J. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          S. H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          J.-M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          Y.-J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jo
         </surname>
         <given-names>
          I. J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff7">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chung
         </surname>
         <given-names>
          C. R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff8">
         8
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hahn
         </surname>
         <given-names>
          M.-J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff9">
         9
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          C.-I.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chung
         </surname>
         <given-names>
          D. R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          J.-H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          E.-S.
         </given-names>
        </name>
        <address>
         <phone>
          +82-2-3410-2703
         </phone>
         <email>
          eskang@skku.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff10">
         10
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Peck
         </surname>
         <given-names>
          K. R.
         </given-names>
        </name>
        <address>
         <phone>
          +82-2-3410-0329
         </phone>
         <email>
          krpeck@skku.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2181 989X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.264381.a
         </institution-id>
         <institution>
          Division of Infectious Diseases, Department of Medicine, Samsung Medical Center,
         </institution>
         <institution>
          Sungkyunkwan University School of Medicine,
         </institution>
        </institution-wrap>
        81 Irwon-ro, Gangnam-gu, Seoul, 135-710 Republic of Korea
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0004 0624 2238
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.413897.0
         </institution-id>
         <institution>
          Present Address: Division of Infectious Diseases, Department of Internal Medicine, Armed Forces Capital Hospital,
         </institution>
        </institution-wrap>
        Seongnam, South Korea
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2218 4662
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.6363.0
         </institution-id>
         <institution>
          Institute of Virology, Charité - Universitätsmedizin Berlin,
         </institution>
        </institution-wrap>
        Helmut-Ruska-Haus Charitéplatz 1, 10117 Berlin, Germany
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.452463.2
         </institution-id>
         <institution>
          German Centre for Infection Research,
         </institution>
        </institution-wrap>
        Braunschweig, Germany
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea
       </aff>
       <aff id="Aff6">
        <label>
         6
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2181 989X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.264381.a
         </institution-id>
         <institution>
          Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center,
         </institution>
         <institution>
          Sungkyunkwan University School of Medicine,
         </institution>
        </institution-wrap>
        Seoul, Republic of Korea
       </aff>
       <aff id="Aff7">
        <label>
         7
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2181 989X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.264381.a
         </institution-id>
         <institution>
          Department of Emergency Medicine, Samsung Medical Center,
         </institution>
         <institution>
          Sungkyunkwan University School of Medicine,
         </institution>
        </institution-wrap>
        Seoul, Republic of Korea
       </aff>
       <aff id="Aff8">
        <label>
         8
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2181 989X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.264381.a
         </institution-id>
         <institution>
          Department of Critical Care Medicine, Samsung Medical Center,
         </institution>
         <institution>
          Sungkyunkwan University School of Medicine,
         </institution>
        </institution-wrap>
        Seoul, Republic of Korea
       </aff>
       <aff id="Aff9">
        <label>
         9
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2181 989X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.264381.a
         </institution-id>
         <institution>
          Department of Molecular Cell Biology, Center for Molecular Medicine, Samsung Biomedical Research Institute,
         </institution>
         <institution>
          Sungkyunkwan University School of Medicine,
         </institution>
        </institution-wrap>
        Suwon, 440-746 South Korea
       </aff>
       <aff id="Aff10">
        <label>
         10
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2181 989X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.264381.a
         </institution-id>
         <institution>
          Department of Laboratory Medicine and Genetics, Samsung Medical Center,
         </institution>
         <institution>
          Sungkyunkwan University School of Medicine,
         </institution>
        </institution-wrap>
        Seoul, Republic of Korea
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        7
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       36
      </volume>
      <issue>
       11
      </issue>
      <fpage>
       2179
      </fpage>
      <lpage>
       2186
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         4
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         4
        </day>
        <month>
         6
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © Springer-Verlag GmbH Germany 2017
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        To provide optimal cut-off values of anti-Middle East respiratory syndrome coronavirus (MERS-CoV) serologic tests, we evaluated performance of ELISA IgG, ELISA IgA, IFA IgM, and IFA IgG using 138 serum samples of 49 MERS-CoV-infected patients and 219 serum samples of 219 rRT-PCR-negative MERS-CoV-exposed healthcare personnel and patients. The performance analysis was conducted for two different purposes: (1) prediction of neutralization activity in MERS-CoV-infected patients, and (2) epidemiologic surveillance of MERS-CoV infections among MERS-CoV-exposed individuals. To evaluate performance according to serum collection time, we used ‘days post onset of illness (
        <italic>
         dpoi
        </italic>
        )’ and ‘days post exposure (
        <italic>
         dpex
        </italic>
        )’ assessing neutralization activity and infection diagnosis, respectively. Performance of serologic tests improved with delayed sampling time, being maximized after a seroconversion period. In predicting neutralization activity, ELISA IgG tests showed optimal performance using sera collected after 21
        <italic>
         dpoi
        </italic>
        at cut-off values of OD ratio 0.4 (sensitivity 100% and specificity 100%), and ELISA IgA showed optimal performance using sera collected after 14
        <italic>
         dpoi
        </italic>
        at cut-off value of OD ratio 0.2 (sensitivity 85.2% and specificity 100%). In diagnosis of MERS-CoV infection, ELISA IgG exhibited optimal performance using sera collected after 28
        <italic>
         dpex
        </italic>
        , at a cut-off value of OD ratio 0.2 (sensitivity 97.3% and specificity 92.9%). These new breakpoints are markedly lower than previously suggested values (ELISA IgG OD ratio 1.1, sensitivity 34.8% and specificity 100% in the present data set), and the performance data help serologic tests to be practically used in the field of MERS management.
       </p>
       <sec>
        <title>
         Electronic supplementary material
        </title>
        <p>
         The online version of this article (doi:10.1007/s10096-017-3043-3) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        Serology
       </kwd>
       <kwd>
        Antibody
       </kwd>
       <kwd>
        Sensitivity
       </kwd>
       <kwd>
        Specificity
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Samsung Biomedical Research Institute
         </institution>
        </funding-source>
        <award-id>
         SMX1161321
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K. R.
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Antigone
         </institution>
        </funding-source>
        <award-id>
         278976
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Prepare
         </institution>
        </funding-source>
        <award-id>
         602525
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer-Verlag GmbH Germany 2017
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p id="Par2">
      Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel beta coronavirus that may cause lethal respiratory disease [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. Anti-MERS-CoV serologic tests including enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay (IFA) are available as commercial kits, and have been used for various purposes including epidemiologic investigations, evaluation of antibody kinetics, and assessing feasibility of convalescent plasma infusion therapy [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      –
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. The manufacturer’s instructions provided relatively high cut-off values for positivity to warrant specificity, which were derived from limited positive samples (ELISA IgG, Euroimmun, Lübeck, Germany; 4 MERS patient samples and 500 negative controls) [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. In previously conducted serologic studies, cut-off values were differently applied depending on the purpose of serologic tests: several epidemiologic studies applied low cut-off values to increase sensitivity of the test [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ], while others followed the manufacturer’s instructions [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. Also, as not all confirmed MERS-CoV-infected patients mounted robust neutralization activity [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ], the performance of serologic tests should be separately analyzed depending on the purposes of the tests: predicting neutralization activity in MERS-CoV-infected patients and diagnosing MERS-CoV infection in epidemiologic surveillance. To provide optimal cut-off values depending on the purposes of the tests, we evaluated performance of various anti-MERS-CoV serologic tests using 138 serum samples of 49 MERS-CoV-infected patients and 219 serum samples of 219 rRT-PCR-negative MERS-CoV-exposed healthcare personnel (HCP) and patients.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Performance analysis depending on the purposes of serologic tests
      </title>
      <p id="Par3">
       The performance analysis included sensitivity, specificity, positive predictive value, and negative predictive value, and was conducted under two different purposes of serologic tests: (1) prediction of neutralization activity in MERS-CoV-infected patients, and (2) epidemiologic surveillance of MERS-CoV infections among MERS-CoV-exposed individuals. Plaque reduction neutralization test (PRNT) and sputum real-time reverse transcriptase polymerase chain reaction (rRT-PCR) for MERS-CoV were used as gold standards for assessing neutralization activity and diagnosing MERS-CoV infection, respectively.
      </p>
      <p id="Par4">
       MERS-CoV exposure dates and symptom onsets of collected serum samples were clearly identified owing to thorough contact investigation and monitoring of exposed individuals [
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
       ]. To provide a common point of reference, we used ‘days post onset of illness (
       <italic>
        dpoi
       </italic>
       )’ assessing neutralization activity since symptom onset could be clearly identified among MERS-CoV-infected patients. Meanwhile, as epidemiologic surveillances are usually conducted on the basis of exposure events, we applied ‘days post exposure (
       <italic>
        dpex
       </italic>
       )’ assessing diagnostic performance of serologic tests in epidemiologic surveillance.
      </p>
      <p id="Par5">
       To compare performances of serologic tests depending on serum collection time, each test was evaluated at three different timepoints: (1) regardless of serum collection time, (2) after 14
       <italic>
        dpoi
       </italic>
       (or 21
       <italic>
        dpex
       </italic>
       ), and (3) after 21
       <italic>
        dpoi
       </italic>
       (or 28
       <italic>
        dpex
       </italic>
       ).
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Study population and samples
      </title>
      <p id="Par6">
       During the 2015 Korean MERS outbreak, we obtained 138 serum samples from 49 MERS-CoV infected patients. Study population included 42 patients who were managed at a 1950-bed tertiary care university hospital [
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
       ], and seven patients who donated sera for plasma infusion therapy or serologic testing. MERS-CoV infections were confirmed on the basis of rRT-PCR assays targeting upstream of the E gene (upE) and the open-reading frame gene 1a (ORF1a) [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. Epidemiologic investigation data and electronic medical records were reviewed to obtain exact exposure date and symptom onset. One or two serum samples were collected per week of illness during hospitalization. Follow-up serum samples were obtained up to 6 months from symptom onset at an outpatient clinic. Sera of 219 rRT-PCR-negative MERS-CoV-exposed HCP and patients were used as negative control samples [
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ]. Collected samples were stored at −70 °C for about three months before testing. The Institutional Review Board of Samsung Medical Center approved the present study.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Serologic tests for anti-MERS-CoV antibody
      </title>
      <sec id="Sec6">
       <title>
        ELISA IgG and IgA
       </title>
       <p id="Par7">
        Anti-MERS-CoV ELISA IgG and IgA (Euroimmun, Lübeck, Germany) were based on soluble MERS-CoV spike protein S1 domain expressed in HEK-293 T cells [
        <xref ref-type="bibr" rid="CR6">
         6
        </xref>
        ,
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        –
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ]. Sera were tested according to the manufacturer’s instructions with 1:100 dilutions. Secondary detection was done with peroxidase-labeled anti-human IgG and IgA. ELISA IgG was initially tested in all of the collected serum samples, and other serologic tests including ELISA IgA, IFA, and PRNT were selectively performed depending on ELISA IgG (using optical density (OD) ratio cut-off value of 0.2) and sputum rRT-PCR results (Table
        <xref ref-type="table" rid="Tab1">
         1
        </xref>
        ). Since IFA IgG was limitedly tested among an rRT-PCR-negative population, diagnostic performance for epidemiologic surveillance of IFA IgG could not be evaluated.
        <table-wrap id="Tab1">
         <label>
          Table 1
         </label>
         <caption>
          <p>
           Number of individuals and serum samples that underwent serologic testing
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th rowspan="2">
             Performance analysis
            </th>
            <th rowspan="2">
             Number of sera and patients
            </th>
            <th colspan="5">
             Anti-MERS-CoV serologic tests
            </th>
           </tr>
           <tr>
            <th>
             ELISA IgG
            </th>
            <th>
             ELISA IgA
            </th>
            <th>
             IFA IgM
            </th>
            <th>
             IFA IgG
            </th>
            <th>
             PRNT
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td>
             Prediction of neutralization activity
            </td>
            <td>
             138 sera from 49 MERS-CoV-infected patients
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
            <td>
             O
             <sup>
              *
             </sup>
            </td>
            <td>
             O
             <sup>
              †
             </sup>
            </td>
            <td>
             O
            </td>
           </tr>
           <tr>
            <td rowspan="4">
             Epidemiologic surveillance
            </td>
            <td>
             158 sera from 158 MERS-CoV-exposed, rRT-PCR-negative HCP, ELISA IgG OD ratio &lt; 0.2
            </td>
            <td>
             O
            </td>
            <td>
             X
            </td>
            <td>
             X
            </td>
            <td>
             X
            </td>
            <td>
             X
            </td>
           </tr>
           <tr>
            <td>
             11 sera from 11 MERS-CoV-exposed, rRT-PCR-negative HCP, ELISA IgG OD ratio ≥ 0.2
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
            <td>
             O
             <sup>
              ‡
             </sup>
            </td>
            <td>
             O
            </td>
           </tr>
           <tr>
            <td>
             43 sera from 43 MERS-CoV-exposed, rRT-PCR-negative patients, ELISA IgG OD ratio &lt; 0.2
            </td>
            <td>
             O
            </td>
            <td>
             X
            </td>
            <td>
             O
            </td>
            <td>
             X
            </td>
            <td>
             X
            </td>
           </tr>
           <tr>
            <td>
             7 sera from 7 MERS-CoV-exposed, rRT-PCR-negative patients, ELISA IgG OD ratio ≥ 0.2
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
            <td>
             O
            </td>
           </tr>
           <tr>
            <td colspan="2">
             Total tested serum samples
            </td>
            <td>
             357
            </td>
            <td>
             156
            </td>
            <td>
             194
            </td>
            <td>
             89
            </td>
            <td>
             156
            </td>
           </tr>
           <tr>
            <td colspan="2">
             Total tested individuals
            </td>
            <td>
             268
            </td>
            <td>
             67
            </td>
            <td>
             110
            </td>
            <td>
             48
            </td>
            <td>
             67
            </td>
           </tr>
          </tbody>
         </table>
         <table-wrap-foot>
          <p>
           ELISA IgG was initially tested in all collected samples, and other serologic tests were selectively performed depending on rRT-PCR and ELISA IgG results. A 0.2 OD ratio cut-off value was applied for ELISA, which was approximately three-fold compared with the median (0.06) value of 41 healthy individuals
          </p>
          <p>
           <sup>
            *
           </sup>
           Five sera that were collected late were not tested.
           <sup>
            †
           </sup>
           To compare performance in predicting neutralizing activity with ELISA IgG, anti-MERS-CoV IFA IgG was tested with titration from 1:50 to 1:1000 dilutions in selected sera of MERS-CoV-infected patients: 18 sera from 18 patients collected between 14 and 27
           <italic>
            dpoi
           </italic>
           (presumed window period of seroconversion) and 53 sera from 12 patients whose sera were serially collected at least four times.
           <sup>
            ‡
           </sup>
           To substantiate ELISA results, IFA IgG was tested in these samples at a 1:100 dilution, which was not included in performance analysis.
          </p>
          <p>
           <italic>
            MERS-CoV
           </italic>
           Middle East respiratory syndrome coronavirus,
           <italic>
            ELISA
           </italic>
           enzyme-linked immunosorbent assay,
           <italic>
            IFA
           </italic>
           immunofluorescence assay,
           <italic>
            PRNT
           </italic>
           plaque reduction neutralization test,
           <italic>
            rRT-PCR
           </italic>
           real-time reverse transcriptase polymerase chain reaction,
           <italic>
            HCP
           </italic>
           healthcare personnel,
           <italic>
            OD
           </italic>
           optical density,
           <italic>
            dpoi
           </italic>
           days post onset of illness
          </p>
         </table-wrap-foot>
        </table-wrap>
       </p>
      </sec>
      <sec id="Sec7">
       <title>
        IFA IgG and IgM
       </title>
       <p id="Par8">
        Anti-MERS-CoV IFA IgG and IgM (Euroimmun) were performed with slides carrying Vero cells infected with full MERS-CoV [
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="CR15">
         15
        </xref>
        ]. Sera were tested according to the manufacturer’s instructions with 1:10 and 1:100 dilutions for IFA IgM and IgG, respectively.
       </p>
       <p id="Par9">
        For comparison of the performance of IFA IgG with that of ELISA IgG, 71 sera were selected for titration from 1:50 to 1:1000 dilutions, including sera collected between 14 and 27
        <italic>
         dpoi
        </italic>
        (presumed window period of seroconversion) [
        <xref ref-type="bibr" rid="CR4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="CR5">
         5
        </xref>
        ], and sera of patients who were serially sampled at least four times (Table
        <xref ref-type="table" rid="Tab1">
         1
        </xref>
        ).
       </p>
      </sec>
      <sec id="Sec8">
       <title>
        PRNT
       </title>
       <p id="Par10">
        MERS-CoV PRNT was performed as previously described [
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ]. Pre-dilution before setting up the log2-dilution series was 1:10, defining 1:20 as the lowest possible significant titer for categorizing a sample as positive [
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        ].
       </p>
      </sec>
     </sec>
     <sec id="Sec9">
      <title>
       Statistical analysis
      </title>
      <p id="Par11">
       Cut-off values with optimal sensitivity and specificity were analyzed per 0.1 OD ratio or each IFA intensity. Areas under the curve (AUCs) were calculated using the receiver operating characteristic (ROC) curve. R-3.3.1 for Windows (RStudio, Boston, MA, USA) was used for all statistical analyses.
      </p>
     </sec>
    </sec>
    <sec id="Sec10">
     <title>
      Results
     </title>
     <sec id="Sec11">
      <title>
       Performance of serologic tests in predicting neutralization activity
      </title>
      <p id="Par12">
       The performance of serologic tests improved with delayed sampling time, being maximized when sera collected after 21
       <italic>
        dpoi
       </italic>
       were used (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       a). In predicting neutralization activity, ELISA IgG and IFA IgM tests showed optimal performance using sera collected after 21
       <italic>
        dpoi,
       </italic>
       at cut-off values of OD ratio 0.4 and weekly-positive IFA intensity, respectively (Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ). Especially, ELISA IgG showed 100% sensitivity and 100% specificity at this time point, while ELISA IgG and IFA IgM exhibited slightly lower performance (area under the curve (AUC) 1.000, 0.996, and 0.917, respectively). Meanwhile, ELISA IgA showed optimal performance using sera collected after 14
       <italic>
        dpoi
       </italic>
       at cut-off value of OD ratio 0.2. Detailed performance values depending on serum collection time and cut-off values are presented in Supplementary Tables
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       to
       <xref ref-type="media" rid="MOESM1">
        3
       </xref>
       . IFA IgG showed optimal performance with cut-off value of 1:500 dilutions, and overall performance was not superior to ELISA IgG (Supplementary Table
       <xref ref-type="media" rid="MOESM1">
        4
       </xref>
       ).
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Changes in ROC curves of anti-MERS-CoV ELISA IgG antibodies for prediction of neutralizing activity and diagnosis of MERS-CoV infection depending on serum collection time. (
          <bold>
           a
          </bold>
          ) ROC curve of ELISA IgG OD ratios predicting neutralization activity in MERS-CoV-infected patients. When sera collected after 21
          <italic>
           dpoi
          </italic>
          were used, both sensitivity and specificity increased to 100%. An ELISA OD ratio of 0.420 was the best cut-off value based on the ROC curve, and 0.4 was the optimal value on the basis of a 0.1 OD ratio. (
          <bold>
           b
          </bold>
          ) ROC curve of ELISA IgG OD ratios for the diagnosis of MERS-CoV infection in a MERS-CoV-exposed population. When sera collected after 28
          <italic>
           dpex
          </italic>
          were used, sensitivity and specificity increased to 97.3 and 98.2, respectively. An ELISA OD ratio of 0.262 was the best cut-off value based on the ROC curve, and 0.2 was the optimal value on the basis of a 0.1 OD ratio.
          <italic>
           ROC
          </italic>
          receiver operating characteristic,
          <italic>
           MERS-CoV
          </italic>
          Middle East respiratory syndrome coronavirus,
          <italic>
           ELISA
          </italic>
          enzyme-linked immunosorbent assay,
          <italic>
           OD
          </italic>
          optical density,
          <italic>
           dpoi
          </italic>
          days post onset of illness,
          <italic>
           dpex
          </italic>
          days post exposure
         </p>
        </caption>
        <graphic id="MO1" xlink:href="10096_2017_3043_Fig1_HTML">
        </graphic>
       </fig>
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Performance of anti-MERS-CoV antibody tests in predicting neutralization activity
         </p>
        </caption>
        <graphic id="MO2" position="anchor" xlink:href="10096_2017_3043_Tab2_HTML">
        </graphic>
        <table-wrap-foot>
         <p>
          Data are expressed as a percentage of each predictive value according to various cut-off values. Cut-off values with optimal sensitivity and specificity analyzed per 0.1 OD ratio (ELISA) or IFA intensity are presented as gray-scale. AUCs were calculated from the ROC curve. The population of this analysis is 49 MERS-CoV-infected patients confirmed by rRT-PCR (Table
          <xref ref-type="table" rid="Tab1">
           1
          </xref>
          ). The neutralization activity of sera was confirmed by PRNT and a 1:20 dilution was defined as the lowest significant titer.
         </p>
         <p>
          <italic>
           MERS-CoV
          </italic>
          Middle East respiratory syndrome coronavirus,
          <italic>
           ELISA
          </italic>
          enzyme-linked immunosorbent assay,
          <italic>
           AUC
          </italic>
          area under the curve,
          <italic>
           PPV
          </italic>
          positive predictive value,
          <italic>
           NPV
          </italic>
          negative predictive value,
          <italic>
           dpoi
          </italic>
          days post onset of illness,
          <italic>
           IFA
          </italic>
          immunofluorescence assay,
          <italic>
           w+
          </italic>
          weak positive,
          <italic>
           OD
          </italic>
          optical density,
          <italic>
           ROC
          </italic>
          receiver operating characteristic,
          <italic>
           rRT-PCR
          </italic>
          real-time reverse transcriptase polymerase chain reaction,
          <italic>
           PRNT
          </italic>
          plaque reduction neutralization test
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Performance of serologic tests in diagnosing MERS-CoV infection
      </title>
      <p id="Par13">
       In diagnosing MERS-CoV infection, ELISA IgG, ELISA IgA, and IFA IgM tests showed optimal performance using sera collected after 28
       <italic>
        dpex
       </italic>
       , at cut-off value of OD ratio 0.2, OD ratio 0.2, and weakly-positive IFA intensity, respectively (Table
       <xref ref-type="table" rid="Tab3">
        3
       </xref>
       ). Most values of rRT-PCR-negative MERS-CoV-exposed individuals were under these cut-off values, discriminating MERS-CoV-infected and non-infected individuals (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       ). Overall, ELISA IgG showed better performance than ELISA IgA or IFA IgM for diagnosing MERS-CoV infection (AUC 0.982, 0.914, and 0.875, respectively, when sera collected after 28
       <italic>
        dpex
       </italic>
       were used). Performance of serologic tests improved with delayed sampling time, being maximized when sera collected after 28
       <italic>
        dpex
       </italic>
       were used (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       b and Supplementary Tables
       <xref ref-type="media" rid="MOESM1">
        5
       </xref>
       to
       <xref ref-type="media" rid="MOESM1">
        7
       </xref>
       ). In addition, the specificity of ELISA IgG, ELISA IgA, and IFA IgM tests was 100% regardless of serum collection time, at cut-off value of OD ratio 0.5, OD ratio 0.3, and IFA intensity 1+, respectively.
       <table-wrap id="Tab3">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Performance of anti-MERS-CoV antibody tests in epidemiologic surveillance of MERS-CoV infection
         </p>
        </caption>
        <graphic id="MO3" position="anchor" xlink:href="10096_2017_3043_Tab3_HTML">
        </graphic>
        <table-wrap-foot>
         <p>
          Data are expressed as a percentage of each predictive value according to various cut-off values. Cut-off values with optimal sensitivity and specificity analyzed per 0.1 OD ratio (ELISA) or IFA intensity are presented as gray-scale. AUCs were calculated from the ROC curve. The population this analysis is 268 MERS-CoV-exposed individuals (Table
          <xref ref-type="table" rid="Tab1">
           1
          </xref>
          ). Diagnosis of MERS-CoV infection was confirmed by positive rRT-PCR assay of respiratory specimens.
         </p>
         <p>
          <italic>
           MERS-CoV
          </italic>
          Middle East respiratory syndrome coronavirus,
          <italic>
           ELISA
          </italic>
          enzyme-linked immunosorbent assay,
          <italic>
           AUC
          </italic>
          area under the curve,
          <italic>
           PPV
          </italic>
          positive predictive value,
          <italic>
           NPV
          </italic>
          negative predictive value,
          <italic>
           dpex
          </italic>
          days post exposure,
          <italic>
           IFA
          </italic>
          immunofluorescence assay,
          <italic>
           w+
          </italic>
          weak positive,
          <italic>
           OD
          </italic>
          optical density,
          <italic>
           ROC
          </italic>
          receiver operating characteristic,
          <italic>
           rRT-PCR
          </italic>
          real-time reverse transcriptase polymerase chain reaction
         </p>
        </table-wrap-foot>
       </table-wrap>
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Distribution of anti-MERS-CoV IgG, IgA, and IgM antibody values according to test population. (
          <bold>
           a
          </bold>
          ) Distribution of anti-MERS-CoV ELISA IgG. (
          <bold>
           b
          </bold>
          ) Distribution of anti-MERS-CoV ELISA IgA. (
          <bold>
           c
          </bold>
          ) Distribution of anti-MERS-CoV IFA IgM. MERS-CoV-infected patients are classified according to the severity groups: asymptomatic infection (group 0), symptomatic infection without pneumonia (group 1), pneumonia without respiratory failure (group 2), and pneumonia progressing to respiratory failure (group 3). The distribution of anti-MERS-CoV antibodies of group 0 patients was similar to those of rRT-PCR-negative MERS-CoV-exposed individuals. Most values of MERS-CoV non-infected patients were under the optimal cut-off value for MERS diagnosis.
          <italic>
           MERS-CoV
          </italic>
          Middle East respiratory syndrome coronavirus,
          <italic>
           ELISA
          </italic>
          enzyme-linked immunosorbent assay,
          <italic>
           OD
          </italic>
          optical density,
          <italic>
           IFA
          </italic>
          immunofluorescence assay
         </p>
        </caption>
        <graphic id="MO4" xlink:href="10096_2017_3043_Fig2_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec13">
     <title>
      Discussion
     </title>
     <p id="Par14">
      Neutralization testing is a gold standard method for detecting antiviral antibodies, especially exhibiting virus-killing function. However, neutralization tests against MERS-CoV cannot be readily performed worldwide as it requires biosafety level 3 facilities, skilled experts, and carries a potential risk of infection [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. To reduce such risks and workloads, previous anti-MERS-CoV serologic studies applied step-wise approaches using ELISA and IFA, which are relatively easy and safe to test [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. To make anti-MERS-CoV serologic tests more practical, we assessed performance of ELISA and IFA tests for two clinical purposes and suggested optimal cut-off values.
     </p>
     <p id="Par15">
      As previous cut-off values for positivity were provided for diagnosis of MERS-CoV infection [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ], we firstly suggest cut-off values for predicting neutralization activity. In the present analysis, both ELISA IgG and IgA excellently predicted neutralization activity (using sera collected after 21
      <italic>
       dpoi
      </italic>
      , AUC 1.000 and 0.996, respectively). Of note, ELISA IgG showed 100% sensitivity and 100% specificity at this time point, with OD ratio cut-off value of 0.4. Predicting neutralization activity is extremely important in selecting donors and recipients of convalescent plasma infusion therapy, which is a potential treatment for MERS-CoV infection [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. In the present analysis, even after 21
      <italic>
       dpoi
      </italic>
      , 19.5% (8/41, Supplementary Table
      <xref ref-type="media" rid="MOESM1">
       1
      </xref>
      ) of collected sera did not have neutralization activity, which emphasizes importance of antibody testing before collecting convalescent plasma. In addition, measurement of neutralization activity is also important in selecting recipients and evaluating effect of convalescent plasma infusion. Using ELSIA tests with performance data from the present analysis, evaluation of neutralization activity can be performed in the field of MERS patient management without delay.
     </p>
     <p id="Par16">
      Diagnosing MERS-CoV infections using anti-MERS-CoV serologic tests has been practically used for post-exposure epidemiologic studies or sero-prevalence investigations in endemic regions [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. To increase sensitivity of ELISA as a screening test, several epidemiologic studies applied low cut-off values of OD ratio, usually a three-fold value of negative controls (ELISA IgG OD ratios 0.2 to 0.3, depending on study sites) [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. In the present analysis, we demonstrated that an ELISA IgG cut-off value of OD ratio 0.2 actually showed optimal performance with high specificity of 92 to 94%. This is visually well demonstrated in Fig.
      <xref ref-type="fig" rid="Fig2">
       2
      </xref>
      ; an ELISA IgG cut-off value of OD ratio 0.2 optimally discriminated negative controls and symptomatic infections (groups 1 to 3), while ELISA IgA and IFA IgM show inferior performance differentiating negative controls and mild patients (group 1). Asymptomatic patients (group 0) did not show any serologic responses, which make serologic diagnosis inapplicable. The manufacturer’s instructions provided a significantly higher break point for MERS diagnosis to warrant specificity (for ELISA IgG, borderline OD ratio cut-off of 0.8–1.1 and positive ≥1.1) [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. However, we demonstrated that ELISA IgG exhibits 100% specificity from the cut-off value of OD ratio 0.5 (Supplementary Table
      <xref ref-type="media" rid="MOESM1">
       5
      </xref>
      ), while previous cut-off value of OD ratio 1.1 showed extremely low sensitivity of 34.8%. Therefore, we suggest ELISA IgG OD ratio 0.2 as a new break point for MERS-CoV diagnosis for general application, while OD ratio 0.5 can be applied for maximal specificity. In addition, we recommend taking at least a 28-day interval from MERS-exposure to serum sampling for post-exposure serologic investigations, to warrant seroconversion. In our unpublished data, seroconversion occurred around the third week of illness or the fourth week after exposure (18
      <italic>
       dpoi
      </italic>
      in median, ranged 14–24
      <italic>
       ;
      </italic>
      22
      <italic>
       dpex
      </italic>
      in median, ranged 18–30
      <italic>
       ;
      </italic>
      Ko et al., data under review).
     </p>
     <p id="Par17">
      Although ELISA IgG showed slightly higher AUC than IFA IgG (Supplementary Table
      <xref ref-type="media" rid="MOESM1">
       4
      </xref>
      ), the number of IFA tested samples was not sufficient, which limited comparison of performance between the two different methods. However, performance of ELISA IgG was at least not inferior to that of IFA IgG, which implies that additional confirmation by IFA after ELISA screening is not mandatory. In addition, considering the cross-reactivity of the serologic tests to other coronaviruses [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ], the performance for MERS diagnosis could be affected by the local epidemiology of human coronavirus infections.
     </p>
     <p id="Par18">
      In conclusion, in a performance analysis using 138 serum samples form 49 MERS-CoV-infected patients, ELISA IgG showed optimal performance in predicting neutralization activity and diagnosing MERS-CoV infection at cut-off values of OD ratio 0.4 and 0.2, respectively. With this performance analysis, anti-MERS-CoV serologic tests can be practically used in the field of MERS management.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Electronic supplementary material
     </title>
     <sec id="Sec14">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="10096_2017_3043_MOESM1_ESM.docx">
         <label>
          ESM 1
         </label>
         <caption>
          <p>
           (DOCX 48 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        Jae-Hoon Ko and Marcel A. Müller contributed equally to this article as first authors.
       </p>
      </fn>
      <fn>
       <p>
        Eun-Suk Kang and Kyong Ran Peck contributed equally to this article
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       We would like to express our sincerest condolences to the patients and families who suffered from the MERS outbreak. We also greatly appreciate the HCP and staff members at Samsung Medical Center and all other hospitals who worked together to overcome the MERS outbreak. Finally, we would like to thank Jinseob Kim for statistical advice and figure development, as well as Mingu Kang for IFA testing.
      </p>
     </ack>
     <notes notes-type="ethics">
      <title>
       Compliance with ethical standards
      </title>
      <notes notes-type="funding">
       <title>
        Funding
       </title>
       <p id="Par19">
        This work was supported by a Samsung Biomedical Research Institute (SBRI) grant [#SMX1161321]. CD reports funding by EU grants Antigone (GA no. 278976) and Prepare (GA no. 602525).
       </p>
      </notes>
      <notes notes-type="COI-statement">
       <title>
        Conflicts of interest
       </title>
       <p id="Par20">
        There are no potential conflicts of interest relevant to this article to report.
       </p>
      </notes>
      <notes>
       <title>
        Ethical approval
       </title>
       <p id="Par21">
        This study was approved by the Institutional Review Board of Samsung Medical Center.
       </p>
      </notes>
      <notes>
       <title>
        Informed consent
       </title>
       <p id="Par22">
        As a retrospective study, the Institutional Review Board waived informed consent in the present study.
       </p>
      </notes>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Luke
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Raviprakash
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Johani
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Al-Dawood
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Al-Qahtani
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Al-Omari
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           FG
          </given-names>
         </name>
         <name>
          <surname>
           Fowler
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bouchama
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Shindo
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Al-Khairy
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Carson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Taha
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Sadat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alahmadi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1554
        </fpage>
        <lpage>
         1561
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2209.151164
        </pub-id>
        <pub-id pub-id-type="pmid">
         27532807
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Baek
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Seok
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           YE
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Jo
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Hahn
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serologic evaluation of MERS screening strategy for healthcare personnel during a hospital-associated outbreak
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2017
        </year>
        <volume>
         38
        </volume>
        <fpage>
         234
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="doi">
         10.1017/ice.2016.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         27841103
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Chun
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Bang
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Man Poon
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         2186
        </fpage>
        <lpage>
         2189
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2112.151421
        </pub-id>
        <pub-id pub-id-type="pmid">
         26583829
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Binger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Steinhagen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         62
        </volume>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Turkestani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Aldabbagh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Shangiti
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Wikramaratna
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Alrabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <fpage>
         559
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)70090-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="other">
        Euroimmun (2014) Anti-MERS-CoV ELISA (IgG) Test instruction, EUROIMMUN, Lübeck, Germany, El_2604G_A_UK_C01.doc, Version: 06/10/2014
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           YE
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Huh
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           NY
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Jo
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name>
          <surname>
           Suh
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Control of an outbreak of Middle East respiratory syndrome in a tertiary Hospital in Korea
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         2016
        </year>
        <volume>
         165
        </volume>
        <fpage>
         87
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="doi">
         10.7326/M15-2495
        </pub-id>
        <pub-id pub-id-type="pmid">
         27272273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           YE
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Huh
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients
        </article-title>
        <source>
         J Inf Secur
        </source>
        <year>
         2016
        </year>
        <volume>
         73
        </volume>
        <fpage>
         468
        </fpage>
        <lpage>
         475
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case definition and management of patients with MERS coronavirus in Saudi Arabia
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         911
        </fpage>
        <lpage>
         913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(14)70918-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         25253396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM, Muth D, Muller MA, Drexler JF, Zambon M, Osterhaus AD, Fouchier RM, Drosten C (2012) Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 17
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hossain
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Hajomar
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        <volume>
         371
        </volume>
        <fpage>
         828
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Demmers
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Steinhagen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2015
        </year>
        <volume>
         53
        </volume>
        <fpage>
         2951
        </fpage>
        <lpage>
         2955
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.01368-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26157150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="other">
        Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, Kreher P, Lattwein E, Eschbach-Bludau M, Nitsche A, Bleicker T, Landt O, Schweiger B, Drexler JF, Osterhaus AD, Haagmans BL, Dittmer U, Bonin F, Wolff T, Drosten C (2012) Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 17
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Kiem
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Seol
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Son
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YS
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <name>
          <surname>
           Rhee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           BN
          </given-names>
         </name>
         <name>
          <surname>
           Bang
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Wi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surveillance of the Middle East respiratory syndrome (MERS) coronavirus (CoV) infection in healthcare workers after contact with confirmed MERS patients: incidence and risk factors of MERS-CoV seropositivity
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         880
        </fpage>
        <lpage>
         886
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cmi.2016.07.017
        </pub-id>
        <pub-id pub-id-type="pmid">
         27475739
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       cid
      </journal-id>
      <journal-id journal-id-type="hwp">
       cid
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1058-4838
      </issn>
      <issn pub-type="epub">
       1537-6591
      </issn>
      <publisher>
       <publisher-name>
        Oxford University Press
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24829216
      </article-id>
      <article-id pub-id-type="pmc">
       4834865
      </article-id>
      <article-id pub-id-type="doi">
       10.1093/cid/ciu359
      </article-id>
      <article-id pub-id-type="publisher-id">
       ciu359
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Articles and Commentaries
        </subject>
       </subj-group>
       <subj-group subj-group-type="category-oup-series">
        <subject>
         Editor's Choice
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus: A Serologic, Epidemiologic, and Clinical Description
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al-Abdallat
         </surname>
         <given-names>
          Mohammad Mousa
         </given-names>
        </name>
        <author-comment>
         <title>
          a
         </title>
         <p>
          M. M. A.-A. and D. C. P. contributed equally to this work.
         </p>
        </author-comment>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
        <!--<email>dvp6@cdc.gov</email>-->
        <xref ref-type="corresp" rid="d697534e577">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Payne
         </surname>
         <given-names>
          Daniel C.
         </given-names>
        </name>
        <author-comment>
         <title>
          a
         </title>
         <p>
          M. M. A.-A. and D. C. P. contributed equally to this work.
         </p>
        </author-comment>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Alqasrawi
         </surname>
         <given-names>
          Sultan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rha
         </surname>
         <given-names>
          Brian
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
        <xref ref-type="aff" rid="af3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tohme
         </surname>
         <given-names>
          Rania A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Abedi
         </surname>
         <given-names>
          Glen R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al Nsour
         </surname>
         <given-names>
          Mohannad
         </given-names>
        </name>
        <xref ref-type="aff" rid="af5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Iblan
         </surname>
         <given-names>
          Ibrahim
         </given-names>
        </name>
        <xref ref-type="aff" rid="af6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jarour
         </surname>
         <given-names>
          Najwa
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Farag
         </surname>
         <given-names>
          Noha H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af7">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Haddadin
         </surname>
         <given-names>
          Aktham
         </given-names>
        </name>
        <xref ref-type="aff" rid="af8">
         8
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al-Sanouri
         </surname>
         <given-names>
          Tarek
         </given-names>
        </name>
        <xref ref-type="aff" rid="af8">
         8
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tamin
         </surname>
         <given-names>
          Azaibi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Harcourt
         </surname>
         <given-names>
          Jennifer L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kuhar
         </surname>
         <given-names>
          David T.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af9">
         9
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Swerdlow
         </surname>
         <given-names>
          David L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Erdman
         </surname>
         <given-names>
          Dean D.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pallansch
         </surname>
         <given-names>
          Mark A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Haynes
         </surname>
         <given-names>
          Lia M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gerber
         </surname>
         <given-names>
          Susan I.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <on-behalf-of>
        for the Jordan MERS-CoV Investigation Team
       </on-behalf-of>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sabri
         </surname>
         <given-names>
          Nabil
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al Azhari
         </surname>
         <given-names>
          Mohammad
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Khazali
         </surname>
         <given-names>
          Hala
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al Maayah
         </surname>
         <given-names>
          Mohammad
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bilbeisi
         </surname>
         <given-names>
          Adel
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dawood
         </surname>
         <given-names>
          Naim
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al Zubi
         </surname>
         <given-names>
          Bilal
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Meflih
         </surname>
         <given-names>
          Jawad
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mounds
         </surname>
         <given-names>
          Tony
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Fitzner
         </surname>
         <given-names>
          Julia
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Eltom
         </surname>
         <given-names>
          Akram
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mafi
         </surname>
         <given-names>
          Ali
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Miao
         </surname>
         <given-names>
          Congrong
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Caidi
         </surname>
         <given-names>
          Hayat
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Trivedi
         </surname>
         <given-names>
          Suvang
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kamili
         </surname>
         <given-names>
          Shifaq
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hall
         </surname>
         <given-names>
          Aron J.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Curns
         </surname>
         <given-names>
          Aaron
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Moore
         </surname>
         <given-names>
          Jessica
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pham
         </surname>
         <given-names>
          Huong
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zimmerman
         </surname>
         <given-names>
          Chris
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Farnon
         </surname>
         <given-names>
          Eileen
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Giorgi
         </surname>
         <given-names>
          Genessa
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gerber
         </surname>
         <given-names>
          Russell
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <aff id="af1">
       <label>
        1
       </label>
       <addr-line>
        Communicable
       </addr-line>
       <addr-line>
        Diseases Directorate
       </addr-line>
       ,
       <institution>
        Jordan Ministry of Health
       </institution>
       ,
       <addr-line>
        Amman
       </addr-line>
      </aff>
      <aff id="af2">
       <label>
        2
       </label>
       <addr-line>
        Division of Viral Diseases, National Center for Immunization and Respiratory Diseases
       </addr-line>
      </aff>
      <aff id="af3">
       <label>
        3
       </label>
       <addr-line>
        Epidemic Intelligence Service
       </addr-line>
      </aff>
      <aff id="af4">
       <label>
        4
       </label>
       <addr-line>
        Global Immunization Division
       </addr-line>
       ,
       <institution>
        Center for Global Health, Centers for Disease Control and Prevention
       </institution>
       ,
       <addr-line>
        Atlanta, Georgia
       </addr-line>
      </aff>
      <aff id="af5">
       <label>
        5
       </label>
       <institution>
        Eastern Mediterranean Public Health Network
       </institution>
      </aff>
      <aff id="af6">
       <label>
        6
       </label>
       <addr-line>
        Field Epidemiology Training Program
       </addr-line>
       ,
       <institution>
        Jordan Ministry of Health
       </institution>
       ,
       <addr-line>
        Amman
       </addr-line>
      </aff>
      <aff id="af7">
       <label>
        7
       </label>
       <addr-line>
        Division of High-Consequence Pathogens and Pathology
       </addr-line>
       ,
       <institution>
        National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention
       </institution>
       ,
       <addr-line>
        Atlanta, Georgia
       </addr-line>
      </aff>
      <aff id="af8">
       <label>
        8
       </label>
       <addr-line>
        Directorate of Laboratories
       </addr-line>
       ,
       <institution>
        Jordan Ministry of Health
       </institution>
       ,
       <addr-line>
        Amman
       </addr-line>
      </aff>
      <aff id="af9">
       <label>
        9
       </label>
       <addr-line>
        Division of Healthcare Quality Promotion
       </addr-line>
       ,
       <institution>
        National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention
       </institution>
       ,
       <addr-line>
        Atlanta, Georgia
       </addr-line>
      </aff>
      <author-notes>
       <fn fn-type="con" id="AN1">
        <label>
         a
        </label>
        <p>
         M. M. A.-A. and D. C. P. contributed equally to this work.
        </p>
       </fn>
       <corresp id="d697534e577">
        Correspondence: Daniel C. Payne, PhD, MSPH, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS-A34, Atlanta, GA 30333 (
        <email>
         dvp6@cdc.gov
        </email>
        ).
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        01
       </day>
       <month>
        11
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date iso-8601-date="2014-05-14" pub-type="epub">
       <day>
        14
       </day>
       <month>
        5
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        14
       </day>
       <month>
        5
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>
       59
      </volume>
      <issue>
       9
      </issue>
      <fpage>
       1225
      </fpage>
      <lpage>
       1233
      </lpage>
      <history>
       <date date-type="received">
        <day>
         27
        </day>
        <month>
         3
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="accepted">
        <day>
         7
        </day>
        <month>
         5
        </month>
        <year>
         2014
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="ciu359.pdf">
      </self-uri>
      <related-article ext-link-type="pubmed" id="d35e530" page="1234" related-article-type="article-reference" vol="59" xlink:href="25091312">
      </related-article>
      <abstract abstract-type="teaser">
       <p>
        Novel serological tests allowed for the detection of otherwise unrecognized cases of Middle East respiratory syndrome coronavirus infection among contacts in a hospital-associated respiratory illness outbreak in Jordan in April 2012, resulting in a total of 9 test-positive cases.
       </p>
      </abstract>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        <bold>
         <italic>
          Background.
         </italic>
        </bold>
        In April 2012, the Jordan Ministry of Health investigated an outbreak of lower respiratory illnesses at a hospital in Jordan; 2 fatal cases were retrospectively confirmed by real-time reverse transcription polymerase chain reaction (rRT-PCR) to be the first detected cases of Middle East respiratory syndrome (MERS-CoV).
       </p>
       <p>
        <bold>
         <italic>
          Methods.
         </italic>
        </bold>
        Epidemiologic and clinical characteristics of selected potential cases were assessed through serum blood specimens, medical record reviews, and interviews with surviving outbreak members, household contacts, and healthcare personnel. Cases of MERS-CoV infection were identified using 3 US Centers for Disease Control and Prevention serologic tests for detection of anti–MERS-CoV antibodies.
       </p>
       <p>
        <bold>
         <italic>
          Results.
         </italic>
        </bold>
        Specimens and interviews were obtained from 124 subjects. Seven previously unconfirmed individuals tested positive for anti–MERS-CoV antibodies by at least 2 of 3 serologic tests, in addition to 2 fatal cases identified by rRT-PCR. The case-fatality rate among the 9 total cases was 22%. Six subjects were healthcare workers at the outbreak hospital, yielding an attack rate of 10% among potentially exposed outbreak hospital personnel. There was no evidence of MERS-CoV transmission at 2 transfer hospitals having acceptable infection control practices.
       </p>
       <p>
        <bold>
         <italic>
          Conclusions.
         </italic>
        </bold>
        Novel serologic tests allowed for the detection of otherwise unrecognized cases of MERS-CoV infection among contacts in a Jordanian hospital-associated respiratory illness outbreak in April 2012, resulting in a total of 9 test-positive cases. Serologic results suggest that further spread of this outbreak to transfer hospitals did not occur. Most subjects had no major, underlying medical conditions; none were on hemodialysis. Our observed case-fatality rate was lower than has been reported from outbreaks elsewhere.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        Middle East respiratory syndrome
       </kwd>
       <kwd>
        novel coronavirus
       </kwd>
       <kwd>
        Jordan
       </kwd>
       <kwd>
        seroepidemiology
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     <related-article ext-link-type="pubmed" id="RA1" page="1234" related-article-type="article-reference" vol="59" xlink:href="25091312">
      <bold>
       (See the Editorial Commentary by Lucey on pages 1234–6.)
      </bold>
     </related-article>
    </p>
    <p>
     In April 2012, the Jordan Ministry of Health (JMoH) investigated a cluster of 13 suspected pneumonia cases among healthcare personnel, of which 2 were fatal, at a hospital in the city of Zarqa [
     <xref ref-type="bibr" rid="CIU359C1">
      1
     </xref>
     ]. Despite testing for multiple potential pathogens, the investigation did not identify a known etiology for these infections. Following the discovery of Middle East respiratory syndrome coronavirus (MERS-CoV) in September 2012 [
     <xref ref-type="bibr" rid="CIU359C2">
      2
     </xref>
     ], specimens from the 2 fatal cases in Jordan were retrospectively tested and both yielded positive results for MERS-CoV by real-time reverse transcription polymerase chain reaction (rRT-PCR), and were reported to the World Health Organization (WHO). These were the first confirmed human cases of infection with this emergent virus, which continues to appear as sporadic cases and clusters internationally, and which is now the focus of worldwide public health investigation and response [
     <xref ref-type="bibr" rid="CIU359C3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CIU359C4">
      4
     </xref>
     ].
    </p>
    <p>
     Using newly developed serologic assays to determine MERS-CoV antibody responses among case contacts in this outbreak, epidemiologists from the JMoH, US Centers for Disease Control and Prevention (CDC), and regional partners conducted a retrospective seroepidemiologic investigation to (1) confirm whether surviving outbreak members had presence of antibodies to MERS-CoV, (2) ascertain whether viral transmission occurred among household contacts or to other healthcare personnel, and (3) describe the clinical features of all detected MERS-CoV infections in Jordan.
    </p>
    <sec id="s2" sec-type="methods">
     <title>
      METHODS
     </title>
     <sec id="s2a">
      <title>
       Epidemiologic Investigation Methods
      </title>
      <p>
       We interviewed and collected serum specimens from available members of the initial outbreak (who were admitted to the focal outbreak hospital during the period from 15 March to 30 April 2012 with fever and dry cough, and with radiological evidence of pneumonia), their household contacts (who reported usually sleeping under the same roof as a defined outbreak member during February–April 2012), a sample of healthcare personnel from 3 medical institutions that admitted outbreak subjects (nonsystematic enrollment, with preference toward those reporting close contact with outbreak members), and field investigators from the JMoH. Hospitalized subjects meeting the initial outbreak case definition were subsequently transferred from the focal outbreak hospital to 2 other hospitals in Amman. Participating healthcare personnel were employed at one of these hospitals or at JMoH during February–April 2012.
      </p>
      <p>
       Epidemiologic data were obtained through medical record reviews and personal interviews during our May 2013 investigation. Interviews were conducted in Arabic, and documented contact history (with outbreak members, household members, visiting travelers, and animals) and occupational exposures. We conducted medical record reviews and key informant interviews with clinicians who provided medical care to patients with suspected infection and heads of infection control units at each medical institution and at the JMoH. Informed consent was obtained prior to serum collection and interviews. As a public health response to a disease outbreak, this investigation did not require institutional review board review.
      </p>
     </sec>
     <sec id="s2b">
      <title>
       Laboratory Investigation Methods
      </title>
      <p>
       All work with live MERS-CoV was done in CDC Biosafety Level 3 (BSL-3) containment facilities in Atlanta, Georgia. Serum samples were inactivated using 2 × 10
       <sup>
        6
       </sup>
       rads γ-irradiation and stored at −80°C until use.
      </p>
      <p>
       To maximize specificity, we defined MERS-CoV antibody positivity as subjects having correlated, positive laboratory results from the HKU5.2N screening enzyme-linked immunosorbent assay (ELISA), as well as confirmed positive results by either the MERS-CoV immunofluorescence assay (IFA) or the MERS-CoV microneutralization assay (MNT) (
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Table 1
       </xref>
       ). An initial indeterminate test result was recorded for those subjects having only a single, uncorrelated positive test result.
      </p>
     </sec>
     <sec id="s2c">
      <title>
       Antibody Detection by HKU5.2 Nucleocapsid ELISA and MERS-CoV IFA and MNT
      </title>
      <p>
       Genetic sequencing data indicate that MERS-CoV is a β-coronavirus (subgroup 2c) similar to the bat CoVs HKU4 and HKU5. The recombinant btHKU5.2 nucleocapsid protein–based ELISA was developed by the CDC to detect the presence of antibodies that cross-react with the HKU5.2 N protein in serum samples from possible MERS cases. If cross-reactive antibodies were detected in serum samples, then confirmation of MERS-specific antibodies was determined by either MERS-CoV MNT or IFA. Pi-BatCoV HKU5.2 nucleocapsid (N) gene in pET-28b (+) plasmid was provided by Dr Susanna Lau, University of Hong Kong. His-tagged recombinant protein was expressed in
       <italic>
        Escherichia coli
       </italic>
       and purified by metal affinity chromatography. Recombinant HKU5.2N protein indirect ELISA was developed using a modified version of the severe acute respiratory syndrome (SARS) CoV N ELISA described by Haynes et al [
       <xref ref-type="bibr" rid="CIU359C5">
        5
       </xref>
       ]. Sera were considered positive when the optical density (OD) values were at or above the 0.43 cutoff value (mean absorbance at 405 nm of sera from US blood donors plus 3 standard deviations). The overall specificity of the assay was determined after screening 545 serum samples from donors in the United States and the Middle East and persons with other non-MERS respiratory infections (eg, human coronavirus [hCoV] OC43, hCoV-229E, SARS-CoV, hCoV-NL63, rhinovirus, human metapneumovirus, H1N1). The assay specificity was 96.7% (527/545). Serum from HKU1 human serum was not available for evaluation; however, HKU1 mouse hyperimmune serum did not cross-react with the HKU5.2 N protein. At a screening dilution of 1:400, sera with OD values at or near the cutoff were titered with serial 4-fold dilutions (1:100–1:6400) and further evaluated using MERS-CoV (Hu/Jordan-N3/2012) (GenBank KC776174.1) IFA and MNT.
      </p>
     </sec>
     <sec id="s2d">
      <title>
       MERS-CoV Immunofluorescence
      </title>
      <p>
       Indirect immunofluorescence was performed by screening sera at a dilution of 1:50 or 1:100 on paraformaldehyde-fixed, acetone-methanol–permeabilized, MERS-CoV–infected or –uninfected control Vero cells. The source of the positive control for this assay was a serum sample from a patient infected with MERS-CoV Hu/England-N1/2012 (provided by M. Zambon, Public Health England). Antihuman immunoglobulin (Ig) G, IgM, and IgA fluorescein isothiocyanate conjugate was used and specific fluorescence was detected under an immunofluorescence microscope. A positive result was scored when fluorescent intensity equaled or was higher than that of the positive control. A weakly positive result was scored when fluorescent intensity was lower than that of the positive control.
      </p>
     </sec>
     <sec id="s2e">
      <title>
       MERS-CoV Microneutralization
      </title>
      <p>
       Serum samples were tested for the presence of neutralizing antibodies to MERS-CoV using a modified MNT method described for SARS-CoV [
       <xref ref-type="bibr" rid="CIU359C6">
        6
       </xref>
       ]. The neutralization titer was measured as the reciprocal of the highest serum dilution that completely inhibited Vero cell monolayer lysis in at least 1 of the 3 triplicate wells. Controls were included for each MNT assay performed, including the input virus back titration and mock-infected cells. All assay results were confirmed in 3 separate assays, and representative data are presented.
      </p>
     </sec>
     <sec id="s2f">
      <title>
       Statistical Methods
      </title>
      <p>
       Tests of statistical significance were performed between the MERS-CoV antibody–positive and –negative subjects, including Fisher exact test and χ
       <sup>
        2
       </sup>
       tests for categorical variables using SAS software version 9.3 (SAS Institute, Cary, North Carolina).
      </p>
     </sec>
    </sec>
    <sec id="s3" sec-type="results">
     <title>
      RESULTS
     </title>
     <p>
      Serologic specimens and interviews were obtained from 124 subjects. We obtained serologic specimens and data from 9 of the 11 (82%) surviving members meeting the initial outbreak case definition; the remaining 2 subjects were unable to be interviewed (1 member was lost to follow-up and 1 did not consent) (Figure
      <xref ref-type="fig" rid="CIU359F1">
       1
      </xref>
      ). We also enrolled 26 household contacts and 89 subjects who did not meet the initial outbreak case definition who worked in healthcare and allied professions. Among the healthcare personnel interviewed, 58% were nurses, 21% were physicians, and the remaining were allied health professionals; approximately half were employed at the focal outbreak hospital.
     </p>
     <fig id="CIU359F1" orientation="portrait" position="float">
      <label>
       Figure 1.
      </label>
      <caption>
       <p>
        Venn diagram of numbers of subjects in the Middle East respiratory syndrome coronavirus (MERS-CoV) investigation. *Tested positive by serologic antibody and/or real-time reverse transcription polymerase chain reaction.
       </p>
      </caption>
      <graphic xlink:href="ciu35901">
      </graphic>
     </fig>
     <p>
      Seven of the 124 subjects tested positive for anti-MERS-CoV antibodies by both HKU5.2 ELISA and IFA (Table
      <xref ref-type="table" rid="CIU359TB1">
       1
      </xref>
      and
      <xref ref-type="supplementary-material" rid="sup1">
       Supplementary Figure 1
      </xref>
      ), and all but 1 also had detectable neutralizing antibody titers as determined by MNT. The subject who did not have detectable neutralizing antibodies was test-positive both by HKU5.2N ELISA and by a confirmative IFA. Demographic and epidemiologic comparisons of seropositive and seronegative subjects are provided in
      <xref ref-type="supplementary-material" rid="sup1">
       Supplementary Table 2
      </xref>
      .
     </p>
     <table-wrap id="CIU359TB1" orientation="portrait" position="float">
      <label>
       Table 1.
      </label>
      <caption>
       <p>
        Serological Data for Positive and Indeterminate Specimens
        <sup>
         a
        </sup>
        in Jordan Investigation Subjects
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="char" span="1"/>
        <col align="left" span="1"/>
        <col align="char" span="1"/>
        <col align="left" span="1"/>
        <col align="center" span="1"/>
       </colgroup>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Subject Number
         </th>
         <th align="center" colspan="1" rowspan="1">
          HKU5.2N ELISA Titer
          <sup>
           b
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1">
          MERS-CoV_Jordan IFA
          <sup>
           c
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1">
          MERS-CoV_Jordan MNT
          <sup>
           d
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1">
          Initial Interpretation
          <sup>
           e
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1">
          Final Interpretation
          <sup>
           f
          </sup>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 01
          <sup>
           g
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          1600
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          80
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 02
         </td>
         <td colspan="1" rowspan="1">
          &gt;6400
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          160
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 03
         </td>
         <td colspan="1" rowspan="1">
          400
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          20
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 04
         </td>
         <td colspan="1" rowspan="1">
          &gt;6400
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          80
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 06
         </td>
         <td colspan="1" rowspan="1">
          1600
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          20
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 09
         </td>
         <td colspan="1" rowspan="1">
          400
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          40
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak member 11
         </td>
         <td colspan="1" rowspan="1">
          1600
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Household member 303
         </td>
         <td colspan="1" rowspan="1">
          1600
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          80
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak
          <sup>
           h
          </sup>
          member 05
         </td>
         <td colspan="1" rowspan="1">
          &lt;100
         </td>
         <td colspan="1" rowspan="1">
          Weakly positive/negative
          <sup>
           i
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak
          <sup>
           h
          </sup>
          member 07
         </td>
         <td colspan="1" rowspan="1">
          &lt;100
         </td>
         <td colspan="1" rowspan="1">
          Weakly positive/negative
          <sup>
           i
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak
          <sup>
           h
          </sup>
          member 10
         </td>
         <td colspan="1" rowspan="1">
          &lt;100
         </td>
         <td colspan="1" rowspan="1">
          Weakly positive/negative
          <sup>
           i
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Outbreak
          <sup>
           h
          </sup>
          member 12
          <sup>
           g,j
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          &lt;100
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Healthcare personnel 308
         </td>
         <td colspan="1" rowspan="1">
          400
         </td>
         <td colspan="1" rowspan="1">
          Weakly positive/negative
          <sup>
           i
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Positive
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Healthcare personnel 330
         </td>
         <td colspan="1" rowspan="1">
          400
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Healthcare personnel 361
         </td>
         <td colspan="1" rowspan="1">
          400
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Healthcare personnel 390
         </td>
         <td colspan="1" rowspan="1">
          400
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Household contact 299
         </td>
         <td colspan="1" rowspan="1">
          1600
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
         <td colspan="1" rowspan="1">
          &lt;20
         </td>
         <td colspan="1" rowspan="1">
          Indeterminate
         </td>
         <td colspan="1" rowspan="1">
          Negative
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="TN1">
        <p>
         Abbreviations: ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescence assay; MERS-CoV, Middle East respiratory syndrome coronavirus; MNT, microneutralization titer.
        </p>
       </fn>
       <fn id="TN2">
        <p>
         <sup>
          a
         </sup>
         Outbreak member 08 was lost to follow-up, and outbreak member 13 did not consent. Outbreak members 01 and 12 were previously laboratory-confirmed positive by real-time reverse transcription polymerase chain reaction (rRT-PCR) and died. Serum samples from outbreak members 01 and 12 were collected prior to death and stored.
        </p>
       </fn>
       <fn id="TN3">
        <p>
         <sup>
          b
         </sup>
         Serum specimens with optical density (OD) values ≥0.43 at a 1:400 dilution against HKU5.2N ELISA were considered to be positive. Specimens were further titered against HKU5.2N at 1:100, 1:400, 1:1600, and 1:6400 dilutions. The antibody titer was taken to be the highest antibody dilution above the cutoff OD that yielded a ratio of the absorbance of the positive serum and negative serum (P/N) &gt; 3. The value is the reciprocal of the dilution.
        </p>
       </fn>
       <fn id="TN4">
        <p>
         <sup>
          c
         </sup>
         Serum specimens that were positive by HKU5.2N ELISA were screened at either 1:50 or 1:100 by indirect IFA using MERS-CoV_Jordan–infected Vero cells.
        </p>
       </fn>
       <fn id="TN5">
        <p>
         <sup>
          d
         </sup>
         MNT is the highest serum sample dilution that protects at least 1 of 3 wells from complete lysis of the cell monolayers. A sample with a &lt;20 titer was considered negative for the presence of MERS-CoV neutralizing antibodies. Sera from MERS cases were used as positive controls and had neutralizing titers ranging from 1:20 to 1:160.
        </p>
       </fn>
       <fn id="TN6">
        <p>
         <sup>
          e
         </sup>
         Initial interpretation: 2 criteria constitute a positive test result: HKU5.2N ELISA must be positive and the MERS-CoV_Jordan indirect IFA assay must be positive. An indeterminate test result was recorded when only 1 of the criteria was achieved.
        </p>
       </fn>
       <fn id="TN7">
        <p>
         <sup>
          f
         </sup>
         Final interpretation: All positive and indeterminant specimens were screened by MERS-CoV_Jordan MNT and/or rescreened by MERS-CoV IFA. Two criteria constitute a positive result: HKU5.2N ELISA must be positive and the MERS-CoV_Jordan IFA or MNT must be positive.
        </p>
       </fn>
       <fn id="TN8">
        <p>
         <sup>
          g
         </sup>
         Fatal MERS-CoV cases.
        </p>
       </fn>
       <fn id="TN9">
        <p>
         <sup>
          h
         </sup>
         Outbreak members conformed to the original outbreak definition; however, some were retrospectively determined to be MERS-CoV test negative. They were part of the original, defined outbreak that our investigation used to trace a priori contacts and exposures, so this descriptive title is retained.
        </p>
       </fn>
       <fn id="TN10">
        <p>
         <sup>
          i
         </sup>
         HKU5.2 N ELISA OD values for serum specimens from outbreak members 05, 07, and 10 and from healthcare personnel 308 were near the assay cutoff OD value and rescreened by serial dilution. These serum samples were initially weakly positive by IFA and considered initially indeterminate. Upon rescreen by IFA, the samples were determined to be negative for the presence of MERS-CoV antibodies.
        </p>
       </fn>
       <fn id="TN11">
        <p>
         <sup>
          j
         </sup>
         Although outbreak member 12 was positive for MERS-CoV by rRT-PCR, his sera were antibody negative. Presumably, this subject died before an antibody response was detectable. This case is considered to be confirmed by current WHO MERS-CoV diagnostic guidelines.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Sera from the 2 fatal cases (designated outbreak subjects 01 and 12) having positive rRT-PCR tests were also tested by the 3 described serology tests. A serum sample from outbreak subject 01 (taken 16 days after onset of respiratory symptoms) was positive by HKU5.2N ELISA and IFA and had detectable MERS-CoV neutralizing antibodies. Two serum specimens from outbreak subject 12 (collected 26 and 32 days after onset) were negative for anti–MERS-CoV antibodies.
     </p>
     <p>
      Of the 7 subjects found to be positive for anti–MERS-CoV antibodies during this investigation, 6 were surviving members of the initial outbreak group and 1 was previously unrecognized. Thus, including the 2 fatal cases previously detected and reported, a total of 9 individuals in this outbreak had evidence of MERS-CoV infections by acute rRT-PCR tests (n = 2) or convalescent antibody tests (n = 7). The case-fatality rate among all test-positive subjects was 22% (2 of 9). We documented that each serologic test–positive subject had unprotected MERS-CoV exposure(s) to at least 1 rRT-PCR test-positive subject. An additional 8 subjects had single positive test results by either HKU5.2N ELISA or IFA, but their MERS-CoV antibody status was considered indeterminate because both tests were not positive (Table
      <xref ref-type="table" rid="CIU359TB1">
       1
      </xref>
      ).
     </p>
     <sec id="s3a">
      <title>
       Healthcare Personnel
      </title>
      <p>
       We obtained specimens and data from a total of 97 healthcare personnel who worked during February–April, 2012, representing a majority of intensive care (intensive care unit [ICU] and coronary care unit [CCU]) personnel at the outbreak hospital as well as other personnel having close contact with initial outbreak investigation members (Figure
       <xref ref-type="fig" rid="CIU359F1">
        1
       </xref>
       ). These included 8 surviving outbreak members who were healthcare personnel at the focal outbreak hospital and were not lost to follow-up, 49 other personnel at the focal outbreak hospital, 16 personnel at transfer hospital A, 20 personnel at transfer hospital B, and JMoH's 4 outbreak investigators. Of the 57 healthcare personnel at the focal outbreak hospital who survived and the 1 who died, 6 (10%) had cases of MERS-CoV. Our investigation provided no evidence of MERS-CoV infections or transmission events among personnel at the 2 receiving transfer hospitals, even though some patients were transferred temporally close to their symptom onset dates. Interviews with surviving subjects and family members revealed that transmission opportunities among healthcare personnel were not restricted to the workplace.
      </p>
     </sec>
     <sec id="s3b">
      <title>
       Household Contacts
      </title>
      <p>
       We obtained serologic specimens from members of 11 households, including those from the initial outbreak group and another 26 subjects who had resided in those outbreak member households during the outbreak period. One household was lost to follow-up, and 1 did not consent for participation. From one of these households was the symptomatic wife of an initial outbreak investigation member who tested positive for MERS-CoV antibodies. Twelve household subjects were children &lt;18 years old, all of whom were serologically test negative.
      </p>
     </sec>
     <sec id="s3c">
      <title>
       Summary of Underlying Conditions, Symptoms, and Clinical Findings
      </title>
      <p>
       A summary of underlying conditions for test-positive subjects, including the 2 fatal cases initially identified by rRT-PCR (outbreak members 01 and 12), is presented in Table
       <xref ref-type="table" rid="CIU359TB2">
        2
       </xref>
       . Of the 9 test-positive subjects, 66% were male, with a median age of 40 years (range, 25–60 years) at illness onset. We found no evidence of underlying immunodeficiency or immunosuppressant medications/therapies among any of these subjects. One subject had an atrial septal defect, 2 had a history of hypertension, 2 were smokers at the time of illness, and 1 reported a pregnancy of 5 months’ gestation. Although diabetes mellitus has been observed as a potential risk factor for MERS-CoV [
       <xref ref-type="bibr" rid="CIU359C7">
        7
       </xref>
       ], none of the subjects reported here had a prior diagnosis of diabetes mellitus and, based on serum glucose values taken during their hospitalizations, none had indications of undiagnosed diabetes mellitus.
      </p>
      <table-wrap id="CIU359TB2" orientation="portrait" position="float">
       <label>
        Table 2.
       </label>
       <caption>
        <p>
         Underlying Conditions and Presenting Symptomatologies for Test-Positive Middle East Respiratory Syndrome-Coronavirus Subjects
         <sup>
          a
         </sup>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
        </colgroup>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="2">
           Characteristic
          </th>
          <th align="center" colspan="9" rowspan="1">
           Test-Positive MERS-CoV Subjects
           <hr/>
          </th>
         </tr>
         <tr>
          <th align="left" colspan="1" rowspan="1">
           01
          </th>
          <th align="center" colspan="1" rowspan="1">
           02
          </th>
          <th align="center" colspan="1" rowspan="1">
           03
          </th>
          <th align="center" colspan="1" rowspan="1">
           04
          </th>
          <th align="center" colspan="1" rowspan="1">
           06
          </th>
          <th align="center" colspan="1" rowspan="1">
           09
          </th>
          <th align="center" colspan="1" rowspan="1">
           11
          </th>
          <th align="center" colspan="1" rowspan="1">
           12
          </th>
          <th align="center" colspan="1" rowspan="1">
           HHM-303
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="1" rowspan="1">
           Age at symptom onset, y
          </td>
          <td colspan="1" rowspan="1">
           40
          </td>
          <td colspan="1" rowspan="1">
           31
          </td>
          <td colspan="1" rowspan="1">
           60
          </td>
          <td colspan="1" rowspan="1">
           35
          </td>
          <td colspan="1" rowspan="1">
           46
          </td>
          <td colspan="1" rowspan="1">
           45
          </td>
          <td colspan="1" rowspan="1">
           41
          </td>
          <td colspan="1" rowspan="1">
           25
          </td>
          <td colspan="1" rowspan="1">
           39
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Sex
          </td>
          <td colspan="1" rowspan="1">
           Female
          </td>
          <td colspan="1" rowspan="1">
           Male
          </td>
          <td colspan="1" rowspan="1">
           Male
          </td>
          <td colspan="1" rowspan="1">
           Male
          </td>
          <td colspan="1" rowspan="1">
           Male
          </td>
          <td colspan="1" rowspan="1">
           Male
          </td>
          <td colspan="1" rowspan="1">
           Female
          </td>
          <td colspan="1" rowspan="1">
           Male
          </td>
          <td colspan="1" rowspan="1">
           Female
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Underlying conditions
          </td>
          <td colspan="1" rowspan="1">
           None
          </td>
          <td colspan="1" rowspan="1">
           Atrial septal defect
          </td>
          <td colspan="1" rowspan="1">
           Hypertension
          </td>
          <td colspan="1" rowspan="1">
           Hypertension
          </td>
          <td colspan="1" rowspan="1">
           None
          </td>
          <td colspan="1" rowspan="1">
           None
          </td>
          <td colspan="1" rowspan="1">
           None
          </td>
          <td colspan="1" rowspan="1">
           None
          </td>
          <td colspan="1" rowspan="1">
           Pregnancy
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Smoking status
          </td>
          <td colspan="1" rowspan="1">
           Current
          </td>
          <td colspan="1" rowspan="1">
           Past
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           Current
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Presenting symptoms
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Cough
           <break>
           </break>
           Dyspnea
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Malaise
           <break>
           </break>
           Chest pain
           <break>
           </break>
           Cough
           <break>
           </break>
           Dyspnea
          </td>
          <td colspan="1" rowspan="1">
           Cough
           <break>
           </break>
           Malaise
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Cough
           <break>
           </break>
           Chest pain
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Cough
           <break>
           </break>
           Dyspnea
           <break>
           </break>
           Chest pain
           <break>
           </break>
           Sore throat
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Cough
           <break>
           </break>
           Dyspnea
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Chills
           <break>
           </break>
           Malaise
           <break>
           </break>
           Chest pain
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Cough
           <break>
           </break>
           Dyspnea
          </td>
          <td colspan="1" rowspan="1">
           Fever
           <break>
           </break>
           Rhinorrhea
           <break>
           </break>
           Headache
           <break>
           </break>
           Cough
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="TN12">
         <p>
          Abbreviations: HHM, household member; MERS-CoV, Middle East respiratory syndrome coronavirus; ND, not documented.
         </p>
        </fn>
        <fn id="TN13">
         <p>
          <sup>
           a
          </sup>
          All information for HHM-303, who did not present to medical care, and the ages for all subjects except outbreak member 12 were obtained from patient or informant interview. All other information was gathered from medical records.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       The most common presenting symptoms, as documented in medical charts, included fever (89%), cough (89%), dyspnea (56%), chest pain (44%), and malaise (33%). Eight subjects presented for hospital care a median of 5 days after symptom onset (range, 1–14 days). Of these patients, 7 (88%) had cough, 7 (88%) had documented fever (temperature (≥38.0°C), 6 (75%) had dyspnea, 5 (63%) had chest pain, and 5 (63%) had malaise at some point during their disease course. Less common symptoms included chills (38%), wheezing (25%), and diarrhea, vomiting, sore throat, palpitations, and confusion (13% each).
      </p>
      <p>
       Seven subjects had abnormal chest radiographic findings reported within 3 days of presentation, and 3 of those 7 had bilateral findings. Of the remaining 4 subjects with initial unilateral findings, 3 went on to develop bilateral infiltrates later in their hospitalization, documented either by chest radiography or computed tomography (CT). One subject (outbreak member 12) received an initial diagnosis of pericarditis, and a CT scan with abnormal pulmonary findings was reported 4 days later (Table
       <xref ref-type="table" rid="CIU359TB3">
        3
       </xref>
       ).
      </p>
      <table-wrap id="CIU359TB3" orientation="portrait" position="float">
       <label>
        Table 3.
       </label>
       <caption>
        <p>
         Documented Clinical Findings Among Test-Positive Middle East Respiratory Syndrome-Coronavirus Subjects at the Time of Initial Presentation for Medical Care
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
        </colgroup>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="2">
           Finding
          </th>
          <th align="center" colspan="8" rowspan="1">
           Test-Positive MERS-CoV Subjects
           <hr/>
          </th>
         </tr>
         <tr>
          <th align="left" colspan="1" rowspan="1">
           01
          </th>
          <th align="center" colspan="1" rowspan="1">
           02
          </th>
          <th align="center" colspan="1" rowspan="1">
           03
          </th>
          <th align="center" colspan="1" rowspan="1">
           04
          </th>
          <th align="center" colspan="1" rowspan="1">
           06
          </th>
          <th align="center" colspan="1" rowspan="1">
           09
          </th>
          <th align="center" colspan="1" rowspan="1">
           11
          </th>
          <th align="center" colspan="1" rowspan="1">
           12
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="9" rowspan="1">
           Clinical course
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Days ill before hospital presentation
          </td>
          <td colspan="1" rowspan="1">
           7
          </td>
          <td colspan="1" rowspan="1">
           10
          </td>
          <td colspan="1" rowspan="1">
           9
          </td>
          <td colspan="1" rowspan="1">
           2
          </td>
          <td colspan="1" rowspan="1">
           1
          </td>
          <td colspan="1" rowspan="1">
           3
          </td>
          <td colspan="1" rowspan="1">
           2
          </td>
          <td colspan="1" rowspan="1">
           14
          </td>
         </tr>
         <tr>
          <td colspan="9" rowspan="1">
           Clinical interventions
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Intensive care (CCU or ICU admission)
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
          <td colspan="1" rowspan="1">
           No
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
          <td colspan="1" rowspan="1">
           No
          </td>
          <td colspan="1" rowspan="1">
           No
          </td>
          <td colspan="1" rowspan="1">
           No
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Respiratory support
          </td>
          <td colspan="1" rowspan="1">
           MV
          </td>
          <td colspan="1" rowspan="1">
           Mask
           <sup>
            a
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           Mask
           <sup>
            a
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           Mask
           <sup>
            a
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           Mask
           <sup>
            a
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           MV
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Pressor support (dopamine or norepinephrine)
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Complications
           <sup>
            b
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           Yes
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Days hospitalized
          </td>
          <td colspan="1" rowspan="1">
           11
          </td>
          <td colspan="1" rowspan="1">
           16
          </td>
          <td colspan="1" rowspan="1">
           0
          </td>
          <td colspan="1" rowspan="1">
           8
          </td>
          <td colspan="1" rowspan="1">
           6
          </td>
          <td colspan="1" rowspan="1">
           10
          </td>
          <td colspan="1" rowspan="1">
           4
          </td>
          <td colspan="1" rowspan="1">
           22
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Disposition
          </td>
          <td colspan="1" rowspan="1">
           Death
          </td>
          <td colspan="1" rowspan="1">
           Discharge
          </td>
          <td colspan="1" rowspan="1">
           Refused admission
          </td>
          <td colspan="1" rowspan="1">
           Discharge
          </td>
          <td colspan="1" rowspan="1">
           Discharge
          </td>
          <td colspan="1" rowspan="1">
           Discharge
          </td>
          <td colspan="1" rowspan="1">
           Discharge
          </td>
          <td colspan="1" rowspan="1">
           Death
          </td>
         </tr>
         <tr>
          <td colspan="9" rowspan="1">
           Laboratory measurements
           <sup>
            c
           </sup>
          </td>
         </tr>
         <tr>
          <td colspan="9" rowspan="1">
           Initial (range)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           WBC, ×10
           <sup>
            9
           </sup>
           /L
          </td>
          <td colspan="1" rowspan="1">
           8.1 (4.9–17.6)
          </td>
          <td colspan="1" rowspan="1">
           ND (5.8–9.2)
          </td>
          <td colspan="1" rowspan="1">
           4.0 (4.0)
          </td>
          <td colspan="1" rowspan="1">
           7.1 (5.2–7.1)
          </td>
          <td colspan="1" rowspan="1">
           6.6 (3.9–8.3)
          </td>
          <td colspan="1" rowspan="1">
           2.8 (2.8–4.9)
          </td>
          <td colspan="1" rowspan="1">
           5.8 (5.8)
          </td>
          <td colspan="1" rowspan="1">
           19.2 (5.3–35)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Neutrophils, ×10
           <sup>
            9
           </sup>
           /L
          </td>
          <td colspan="1" rowspan="1">
           ND (6.9–16.5)
          </td>
          <td colspan="1" rowspan="1">
           ND (6.6)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           5.5 (3.2–5.5)
          </td>
          <td colspan="1" rowspan="1">
           ND (1.6)
          </td>
          <td colspan="1" rowspan="1">
           1.6 (1.6–3.2)
          </td>
          <td colspan="1" rowspan="1">
           4.2 (4.2)
          </td>
          <td colspan="1" rowspan="1">
           ND (1.0–31.92)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Lymphocytes, ×10
           <sup>
            9
           </sup>
           /L
          </td>
          <td colspan="1" rowspan="1">
           ND (0.3–1.1)
          </td>
          <td colspan="1" rowspan="1">
           ND (0.5–1.7)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           1.4 (1.3–1.4)
          </td>
          <td colspan="1" rowspan="1">
           ND (2.0)
          </td>
          <td colspan="1" rowspan="1">
           0.9 (0.9–1.0)
          </td>
          <td colspan="1" rowspan="1">
           1.0 (1.0)
          </td>
          <td colspan="1" rowspan="1">
           ND (0.7–2.1)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Hemoglobin, g/dL
          </td>
          <td colspan="1" rowspan="1">
           11.1 (8.9–10.8)
          </td>
          <td colspan="1" rowspan="1">
           ND (12–14.4)
          </td>
          <td colspan="1" rowspan="1">
           15.0 (15.0)
          </td>
          <td colspan="1" rowspan="1">
           12.3 (10.5–12.3)
          </td>
          <td colspan="1" rowspan="1">
           14.6 (14.3–14.6)
          </td>
          <td colspan="1" rowspan="1">
           12.1 (12.1–14.4)
          </td>
          <td colspan="1" rowspan="1">
           9.5 (9.5)
          </td>
          <td colspan="1" rowspan="1">
           11.1 (9.5–12.2)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Platelets, ×10
           <sup>
            9
           </sup>
           /L
          </td>
          <td colspan="1" rowspan="1">
           277 (120–302)
          </td>
          <td colspan="1" rowspan="1">
           ND (184–216)
          </td>
          <td colspan="1" rowspan="1">
           222 (222)
          </td>
          <td colspan="1" rowspan="1">
           260 (215–260)
          </td>
          <td colspan="1" rowspan="1">
           295 (191–295)
          </td>
          <td colspan="1" rowspan="1">
           172 (134–183)
          </td>
          <td colspan="1" rowspan="1">
           229 (229)
          </td>
          <td colspan="1" rowspan="1">
           419 (122–605)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           ALT, U/L
          </td>
          <td colspan="1" rowspan="1">
           ND (40–62)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND (26)
          </td>
          <td colspan="1" rowspan="1">
           ND (59)
          </td>
          <td colspan="1" rowspan="1">
           29
          </td>
          <td colspan="1" rowspan="1">
           8 (8)
          </td>
          <td colspan="1" rowspan="1">
           24 (24–353)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           AST, U/L
          </td>
          <td colspan="1" rowspan="1">
           ND (93–96)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           23 (23–62)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Blood urea, mmol/L
          </td>
          <td colspan="1" rowspan="1">
           6.8 (6.1–37.5)
          </td>
          <td colspan="1" rowspan="1">
           ND (9.3)
          </td>
          <td colspan="1" rowspan="1">
           12.9 (12.9)
          </td>
          <td colspan="1" rowspan="1">
           ND (3.7–9.3)
          </td>
          <td colspan="1" rowspan="1">
           8.2 (4.6–11.1)
          </td>
          <td colspan="1" rowspan="1">
           9.6 (3.7–9.6)
          </td>
          <td colspan="1" rowspan="1">
           5 (5)
          </td>
          <td colspan="1" rowspan="1">
           7.5 (7.5–20.3)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Serum creatinine, μmol/L
          </td>
          <td colspan="1" rowspan="1">
           71 (35–133)
          </td>
          <td colspan="1" rowspan="1">
           ND (62)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND (82–115)
          </td>
          <td colspan="1" rowspan="1">
           97 (90–150)
          </td>
          <td colspan="1" rowspan="1">
           106 (103–106)
          </td>
          <td colspan="1" rowspan="1">
           62 (62)
          </td>
          <td colspan="1" rowspan="1">
           72 (40–178)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           PT, sec
          </td>
          <td colspan="1" rowspan="1">
           13 (13–21.5)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           14 (14)
          </td>
          <td colspan="1" rowspan="1">
           14 (13.2–14)
          </td>
          <td colspan="1" rowspan="1">
           ND (13.2–15)
          </td>
          <td colspan="1" rowspan="1">
           16 (13.6–16)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND (12.7–34.5)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           PTT, sec
          </td>
          <td colspan="1" rowspan="1">
           26 (26–38.1)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           30 (30)
          </td>
          <td colspan="1" rowspan="1">
           25 (25–27.3)
          </td>
          <td colspan="1" rowspan="1">
           ND (29.3–35)
          </td>
          <td colspan="1" rowspan="1">
           37 (23.2–37)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND (29.9–50.8)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           INR
          </td>
          <td colspan="1" rowspan="1">
           1.0 (1.0–1.82)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           1.07 (1.07)
          </td>
          <td colspan="1" rowspan="1">
           1.07 (1.02–1.07)
          </td>
          <td colspan="1" rowspan="1">
           ND (1.02–1.2)
          </td>
          <td colspan="1" rowspan="1">
           1.35 (1.06–1.35)
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           ND (0.97–3.52)
          </td>
         </tr>
         <tr>
          <td colspan="9" rowspan="1">
           Chest radiography
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Findings within 3 d of presentation
          </td>
          <td colspan="1" rowspan="1">
           Right side opacity
          </td>
          <td colspan="1" rowspan="1">
           Right lobar pneumonia
          </td>
          <td colspan="1" rowspan="1">
           Bilateral consolidation; pneumonia
          </td>
          <td colspan="1" rowspan="1">
           Bilateral lobar pneumonia
          </td>
          <td colspan="1" rowspan="1">
           Right side bronchial congestions with bronchovascular markings
          </td>
          <td colspan="1" rowspan="1">
           Left side consolidation, right side infiltrate
          </td>
          <td colspan="1" rowspan="1">
           ND
          </td>
          <td colspan="1" rowspan="1">
           Elevated diaphragmatic level, right side; cardiomegaly
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="TN14">
         <p>
          Subject Household Member (HHM)-303 had no medical chart as she did not present to medical care.
         </p>
        </fn>
        <fn id="TN15">
         <p>
          Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCU, coronary care unit; ICU, intensive care unit; INR, international normalized ratio; MERS-CoV, Middle East respiratory syndrome coronavirus; MV, mechanical ventilation; ND, not documented; PT, prothrombin time; PTT, partial thromboplastin time; WBC, white blood cell.
         </p>
        </fn>
        <fn id="TN16">
         <p>
          <sup>
           a
          </sup>
          Received supplemental oxygen by mask without mechanical ventilation.
         </p>
        </fn>
        <fn id="TN17">
         <p>
          <sup>
           b
          </sup>
          Subject 01 had hyperkalemia, ventricular tachycardia, disseminated intravascular coagulation cardiac arrest. Subject 12 had pericarditis, pleural and pericardial effusion, and supraventricular tachycardia.
         </p>
        </fn>
        <fn id="TN18">
         <p>
          <sup>
           c
          </sup>
          Laboratory measurements at hospital presentation and the range over the course of illness are shown.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       Seven of the 8 subjects (88%) who presented to medical care were admitted; 1 refused admission. Six subjects (75%) required respiratory support with at least supplemental oxygen, and 4 subjects (50%) received intensive care (in CCU or ICU), but only the 2 (25%) patients who died required mechanical ventilation, of which 1 patient also required pressor support (dopamine and norepinephrine) for cardiorespiratory failure. Complications among hospitalized subjects were also limited to the 2 patients who died, 1 of whom had hyperkalemia with associated ventricular tachycardia, disseminated intravascular coagulation, and eventual cardiac arrest; the other had pericarditis, pericardial and pleural effusions, and supraventricular tachycardia late in the course of illness.
      </p>
      <p>
       Although leukopenia (&lt;4.0 × 10
       <sup>
        9
       </sup>
       /L) was observed in 2 subjects, lymphopenia (&lt;1.5 × 10
       <sup>
        9
       </sup>
       /L) was observed in 6 of the 7 subjects who had documented complete blood counts with differentials (86%). Elevated leukocyte counts (&gt;11 × 10
       <sup>
        9
       </sup>
       /L) were observed during the course for 2 subjects (25%), both of whom died. These 2 subjects also had laboratory abnormalities consistent with multiorgan system failure late in the course of disease. These included evidence of elevated alanine aminotransferase and aspartate aminotransferase (&gt;40 U/L) and significant coagulopathy with an international normalized ratio of &gt;1.5, as well as thrombocytopenia (&lt;140 × 10
       <sup>
        9
       </sup>
       /L). In addition, the 2 subjects who died had elevated serum creatinine measurements (≥133 µmol/L) on the day of their deaths. A third case had an isolated elevated creatinine measurement, but had a subsequent normal value the following day. No patient received hemodialysis (Table
       <xref ref-type="table" rid="CIU359TB3">
        3
       </xref>
       ).
      </p>
      <p>
       Outbreak member 01 died 17 days after onset of symptoms (on day 11 of hospitalization) and outbreak member 12 died 35 days after onset of symptoms (on day 22 of hospitalization). The remaining 7 subjects survived, and the 5 who were hospitalized were discharged following a median of 8 days (range, 4–16 days). Despite having respiratory symptoms, the pregnant household subject did not seek medical care due to concerns regarding receiving chest radiography and medications. This pregnancy resulted in stillbirth during the course of her illness [
       <xref ref-type="bibr" rid="CIU359C8">
        8
       </xref>
       ].
      </p>
      <p>
       Surviving subjects and the family members of deceased patients reported that contact with animals was rare in this urbanized area, and no contact with camels was identified among subjects having early symptom onsets. Furthermore, none of the subjects had traveled to, or had received visitors from, the Arabian Peninsula shortly prior to symptom onset.
      </p>
     </sec>
     <sec id="s3d">
      <title>
       Infection Control
      </title>
      <p>
       At the focal outbreak hospital, there were no physical barriers between CCU and ICU beds, spaced approximately 3 meters, with the exception of cloth drapes in the CCU. Isolation or negative-pressure rooms were not present, and infection control compliance issues were reported during the outbreak. Infection control insufficiencies were not noted at the 2 receiving transfer hospitals.
      </p>
     </sec>
    </sec>
    <sec id="s4" sec-type="discussion">
     <title>
      DISCUSSION
     </title>
     <p>
      We used novel serologic assays to determine antibody responses of subjects from a MERS-CoV outbreak investigation in Jordan, including the earliest cases of this emerging virus yet discovered. In addition to 2 fatal cases confirmed by rRT-PCR and reported to WHO, we discovered 7 previously unconfirmed and unreported MERS-CoV infections. Detection of these 7 additional antibody-positive subjects, including healthcare personnel from the focal outbreak hospital and a family contact of 1 antibody-positive subject, and the establishment of contacts with MERS-CoV infected subjects when potentially infectious, suggests that human-to-human transmission of MERS-CoV occurred. Although community exposures were possible, healthcare-associated transmission was a plausible explanation for healthcare personnel infections. MERS-CoV infections were not detected among healthcare personnel at a transfer hospital having better adherence to infection control measures.
     </p>
     <p>
      Compared with published descriptions of Saudi Arabian and French cases [
      <xref ref-type="bibr" rid="CIU359C9">
       9–12
      </xref>
      ], among the 9 total Jordanian cases identified through our collaborative investigation, subjects were younger and had fewer underlying medical conditions, and there was a lower case-fatality rate. Although all subjects with MERS-CoV infection in our investigation had acute respiratory illnesses during the outbreak period, 78% of those who were infected survived. Most subjects had no underlying medical conditions and none were on hemodialysis or had indications of diabetes mellitus. One newly detected subject, who was a household contact, did not seek medical care. Our data support the probability that, in outbreak settings, infections may remain undetected among subjects who have mild symptoms, lack predisposing conditions, or have barriers to accessing appropriate diagnostic care. Therefore, the true MERS-CoV case-fatality rate may be lower than that based on symptomatic, hospitalized cases alone.
     </p>
     <p>
      The presenting symptoms we observed were largely consistent with those of previously described MERS-CoV cases [
      <xref ref-type="bibr" rid="CIU359C13">
       13–16
      </xref>
      ] and included fever with respiratory symptoms such as cough and dyspnea, and associated infiltrates on chest radiography. On initial presentation, many subjects did not have evidence of bilateral pneumonia. Although gastrointestinal symptoms such as vomiting and diarrhea were documented for 2 subjects, we did not observe these as presenting symptoms, as they were in Saudi Arabian and French cases. Once hospitalized, lymphopenia, a prominent laboratory feature among previously described cases, was observed in the majority of our subjects. However, other laboratory abnormalities observed in previous reports, such as thrombocytopenia, were limited mostly to the 2 fatal cases late in the course of illness, consistent with multiorgan system failure. Also, unlike previously reported cases, renal failure was not a prominent clinical feature among our subjects, as renal dysfunction was observed only in the 2 fatal cases on the day of death.
     </p>
     <p>
      Rapid isolation of patients with suspected MERS-CoV and rigorous infection control practices at the receiving transfer hospitals may have been important in preventing transmission at these locations. Hospitals should have established policies and procedures for the rapid identification of suspected or known MERS-CoV cases and implementation of appropriate infection prevention measures. The CDC recommends standard, contact, and airborne precautions for the management of hospitalized patients with known or suspected MERS-CoV infection [
      <xref ref-type="bibr" rid="CIU359C17">
       17
      </xref>
      ].
     </p>
     <p>
      One Jordanian patient was initially hospitalized with pericarditis, a manifestation similar to 1 MERS-CoV case occurring in the Kingdom of Saudi Arabia [
      <xref ref-type="bibr" rid="CIU359C9">
       9
      </xref>
      ]. Although this Jordanian patient's serologic specimens tested negative for MERS-CoV antibodies at periods throughout his hospital stay, 1 acute specimen collected several days before death was confirmed positive for the virus by rRT-PCR. These laboratory findings and the patient's exposure in the CCU, where he was situated in the bed directly next to another patient with rRT-PCR–confirmed MERS-CoV, collectively suggest the likelihood that the patient was nosocomially infected with MERS-CoV and died before an antibody response was detectable.
     </p>
     <p>
      Based on the knowledge of SARS-CoV antibody responses, IgG and neutralizing antibodies to SARS-CoV peaked 4 months following a patient's recovery from acute infection [
      <xref ref-type="bibr" rid="CIU359C18">
       18
      </xref>
      ]. Antibody levels did decline over time, but detectable SARS-CoV neutralizing antibodies persisted up to 2 years after onset of SARS-CoV symptoms [
      <xref ref-type="bibr" rid="CIU359C19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CIU359C20">
       20
      </xref>
      ]. Approximately 13 months had passed between our May 2013 investigation and the April 2012 outbreak. Although this was sufficient time for infected subjects to produce an antibody response to MERS-CoV, the role of waning immunity on the antibody response [
      <xref ref-type="bibr" rid="CIU359C21">
       21
      </xref>
      ] and whether persistence of these antibodies is important for protection from reinfection remain unclear.
     </p>
     <p>
      We implemented a rigorous case definition based on an ELISA-positive result plus at least 1 correlating assay result to maximize specificity. Infections with SARS-CoV triggered humoral and cellular immune responses in all studied humans [
      <xref ref-type="bibr" rid="CIU359C22">
       22
      </xref>
      ], and high titers of neutralizing antibodies were observed in response to SARS-CoV infections, but such characteristics of the MERS-CoV immunologic response remain unknown. As for those indeterminate laboratory findings among subjects with documented MERS-CoV exposure(s) but having only an ELISA-positive result and mild or absent respiratory symptoms, it is possible that the viral exposure to these subjects did not trigger a long-lasting IFA- or MNT-recognizable immune response.
     </p>
     <p>
      Because obtaining appropriate lower respiratory specimens from subjects having mild or asymptomatic infections is challenging, the use of serologic assays to identify otherwise undetected cases of MERS-CoV has been demonstrated to be a useful tool. Serological surveys have been conducted in retrospective case investigations around instances of MERS-CoV importations in Europe [
      <xref ref-type="bibr" rid="CIU359C23">
       23
      </xref>
      ], as well as for establishing estimates of MERS-CoV seroprevalence among populations at risk [
      <xref ref-type="bibr" rid="CIU359C24">
       24
      </xref>
      ]. Further validation of serologic assays and assessments of how they complement rRT-PCR testing is needed.
     </p>
     <p>
      Our investigation was unable to find evidence of any exposure (either zoonotic contacts, human contacts from the Arabian Peninsula, or among hospitalized contacts preceding the earliest symptomatic cases) that might explain the origin of the virus. The precise route(s) of MERS-CoV transmission remains unclear overall, but several MERS-CoV sequences have been identified in dromedary camel nasal secretions, including one that is indistinguishable from that found in infected humans [
      <xref ref-type="bibr" rid="CIU359C25">
       25
      </xref>
      ].
     </p>
     <p>
      In conclusion, the Jordan respiratory illness outbreak in April 2012 resulted in a total of 9 test-positive MERS-CoV subjects. The source of the virus in these earliest known MERS-CoV cases remains unknown. Compared with other reports, the improved survivability we observed is perhaps related to the youth and relative lack of underlying illnesses among the subjects we investigated. Infection control practices at both transfer receiving hospitals may have been important in preventing MERS-CoV transmission in those facilities. Since the discovery of the MERS-CoV, enhanced surveillance for severe acute respiratory illnesses in Jordan has been implemented. International severe acute respiratory infection surveillance, collaborative investigations, and vigilance among healthcare providers are necessary components for addressing and preventing the further spread of MERS-CoV worldwide.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supplementary Material
     </title>
     <supplementary-material content-type="local-data" id="sup1">
      <label>
       Supplementary Data
      </label>
      <media xlink:href="ciu359_Supplementary_Data.zip">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
    </sec>
    <back>
     <ack>
      <title>
       Notes
      </title>
      <p>
       <bold>
        <italic>
         Members of the Jordan MERS-CoV Investigation Team.
        </italic>
       </bold>
       Dr Nabil Sabri, Dr Mohammad Al Azhari, Dr Hala Khazali, Dr Mohammad Al Maayah, Dr Adel Bilbeisi, Dr Naim Dawood, Dr Bilal Al Zubi (Jordan Ministry of Health); Dr Jawad Meflih (Eastern Mediterranean Public Health Network); Dr Tony Mounds, Dr Julia Fitzner, Dr Akram Eltom, Dr Ali Mafi, (World Health Organization); Congrong Miao, Dr Hayat Caidi, Suvang Trivedi, Shifaq Kamili, Dr Aron J. Hall, Aaron Curns, Jessica Moore, Huong Pham, Dr Chris Zimmerman (National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention [CDC]); Dr Eileen Farnon, Dr Genessa Giorgi, and Dr Russell Gerber (Center for Global Health, CDC
       <bold>
        )
       </bold>
       .
      </p>
      <p>
       <bold>
        <italic>
         Acknowledgments.
        </italic>
       </bold>
       The authors thank the directors and staff of the 3 hospitals in this investigation; Dr Ray R. Arthur, Sudhir Bunga, Catherine C. Chow, Kira A. Christian, Serena Fuller, C. J. McKnight, Myron G. Schultz (Global Disease Detection Operations Center, Division of Global Health Protection, Center for Global Health, CDC) for outbreak investigation logistical support; Dr Maha Talaat and Dr Emad Mohareb (Naval Medical Research Unit 3) for consultation; and Dr Maria Zambon (Public Health England), Dr Thorsten Wolff (the Robert Koch Institute), Dr Susanna Lau (University of Hong Kong), Dr Ella Mendelson (Israel Ministry of Health), and Dr Emad M. Elassal for providing serum and isolates. Positive control sera from MERS-CoV–infected patients were provided by Public Health England and by the Robert Koch Institute. A clinical isolate of MERS-CoV (Hu/Jordan-N3/2012) was provided by the Jordan Ministry of Health and Naval Medical Research Unit 3 (Cairo, Egypt).
      </p>
      <p>
       <bold>
        <italic>
         Author contributions.
        </italic>
       </bold>
       D. C. P. had full access to all the data in the study and had final responsibility for the decision to submit for publication.
      </p>
      <p>
       <bold>
        <italic>
         Disclaimer.
        </italic>
       </bold>
       The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.
      </p>
      <p>
       <bold>
        <italic>
         Financial support.
        </italic>
       </bold>
       This work was supported by the US Global Disease Detection Operations Center Outbreak Response Contingency Fund.
      </p>
      <p>
       <bold>
        <italic>
         Potential conflicts of interest.
        </italic>
       </bold>
       All authors: No potential conflicts of interest.
      </p>
      <p>
       All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
      </p>
     </ack>
     <ref-list>
      <title>
       References
      </title>
      <ref id="CIU359C1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Abdallat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sayaydeh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation
        </article-title>
        <source>
         East Mediterr Health J
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         S12
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <collab>
         Centers for Disease Control and Prevention
        </collab>
        <article-title>
         Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV)—worldwide, 2012-2013
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <year>
         2013
        </year>
        <volume>
         62
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         23302815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C4">
       <label>
        4
       </label>
       <element-citation publication-type="confproc">
        <collab>
         World Health Organization
        </collab>
        <source>
         Global Alert and Response (GAR): novel coronavirus infection—update (Middle East respiratory syndrome coronavirus)
        </source>
        <conf-loc>
         ,
        </conf-loc>
        <publisher-loc>
         Geneva, Switzerland
        </publisher-loc>
        <publisher-name>
         WHO
        </publisher-name>
        <comment>
         Available at:
         <uri xlink:href="http://www.who.int/csr/disease/coronavirus_infections/en" xlink:type="simple">
          http://www.who.int/csr/disease/coronavirus_infections/en
         </uri>
         . Accessed 2 May 2014
        </comment>
       </element-citation>
      </ref>
      <ref id="CIU359C5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Miao
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Harcourt
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        <year>
         2007
        </year>
        <volume>
         14
        </volume>
        <fpage>
         331
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         17229882
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Murakami
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         2536
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         14983044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Hinedi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ghandour
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): a case-controlled study of hospitalized patients
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         59
        </volume>
        <fpage>
         160
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         24723278
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Stillbirth during infection with Middle East respiratory syndrome coronavirus (MERS-CoV) [Epub ahead of print]
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="CIU359C9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Arifi
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         2014
        </year>
        <volume>
         160
        </volume>
        <fpage>
         389
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="pmid">
         24474051
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guery
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           el Mansouf
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2013
        </year>
        <volume>
         381
        </volume>
        <fpage>
         2265
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         23727167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         752
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           McGreer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2013
        </year>
        <volume>
         369
        </volume>
        <fpage>
         886
        </fpage>
       </element-citation>
      </ref>
      <ref id="CIU359C13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guberina
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Witzke
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Timm
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A patient with severe respiratory failure caused by novel human coronavirus
        </article-title>
        <source>
         Infection
        </source>
        <year>
         2014
        </year>
        <volume>
         42
        </volume>
        <fpage>
         203
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         23900771
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         745
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
        </article-title>
        <source>
         Euro Surveill
        </source>
        <year>
         2012
        </year>
        <volume>
         17
        </volume>
        <comment>
         pii:20290 Available at:
         <uri xlink:href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20290" xlink:type="simple">
          http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20290
         </uri>
         . Accessed 2 May 2014
        </comment>
       </element-citation>
      </ref>
      <ref id="CIU359C16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="CIU359C17">
       <label>
        17
       </label>
       <element-citation publication-type="other">
        <collab>
         US Centers for Disease Control and Prevention
        </collab>
        <article-title>
         Interim infection and prevention control recommendations for hospitalized patients with Middle Eastern respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <comment>
         Available at:
         <uri xlink:href="http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html" xlink:type="simple">
          http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html
         </uri>
         Accessed 2 May 2014
        </comment>
       </element-citation>
      </ref>
      <ref id="CIU359C18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disappearance of antibodies to SARS-associated coronavirus after recovery
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2007
        </year>
        <volume>
         357
        </volume>
        <fpage>
         1162
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         17855683
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lie
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Two year prospective study of the humoral immune response of patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2006
        </year>
        <volume>
         193
        </volume>
        <fpage>
         792
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         16479513
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <fpage>
         49
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         16423201
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibodies in patients with severe acute respiratory syndrome associated coronavirus infection
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         190
        </volume>
        <fpage>
         1119
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="pmid">
         15319862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         3
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="CIU359C23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reuss
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Litterst
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Contact investigation for imported case of Middle East respiratory syndrome, Germany
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         620
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         24655721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CIU359C24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hofmann-Winkler
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Albuali
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Lack of MERS coronavirus neutralizing antibodies in humans, Eastern Province, Saudi Arabia
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         20134
        </fpage>
        <lpage>
         6
        </lpage>
       </element-citation>
      </ref>
      <ref id="CIU359C25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jain
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e01146
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         24781747
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       BMC Vet Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       BMC Vet. Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        BMC Veterinary Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1746-6148
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26232106
      </article-id>
      <article-id pub-id-type="pmc">
       4522128
      </article-id>
      <article-id pub-id-type="publisher-id">
       500
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s12917-015-0500-z
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Methodology Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Development of an indirect ELISA, blocking ELISA, fluorescent microsphere immunoassay and fluorescent focus neutralization assay for serologic evaluation of exposure to North American strains of Porcine Epidemic Diarrhea Virus
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Okda
         </surname>
         <given-names>
          Faten
         </given-names>
        </name>
        <address>
         <email>
          faten.okda@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Xiaodong
         </given-names>
        </name>
        <address>
         <email>
          xiaodong.liu@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Singrey
         </surname>
         <given-names>
          Aaron
         </given-names>
        </name>
        <address>
         <email>
          aaron.singrey@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Clement
         </surname>
         <given-names>
          Travis
         </given-names>
        </name>
        <address>
         <email>
          travis.clement@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          Julie
         </given-names>
        </name>
        <address>
         <email>
          julie.nelson@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Christopher-Hennings
         </surname>
         <given-names>
          Jane
         </given-names>
        </name>
        <address>
         <email>
          jane.hennings@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          Eric A.
         </given-names>
        </name>
        <address>
         <email>
          eric.nelson@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Lawson
         </surname>
         <given-names>
          Steven
         </given-names>
        </name>
        <address>
         <phone>
          605-688-5171
         </phone>
         <email>
          steven.lawson@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.263791.8
         </institution-id>
         <institution-id institution-id-type="ISNI">
          000000012167853X
         </institution-id>
         <institution>
          Veterinary &amp; Biomedical Sciences Department,
         </institution>
         <institution>
          South Dakota State University,
         </institution>
        </institution-wrap>
        Brookings, SD USA
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.419725.c
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121518157
         </institution-id>
         <institution>
          National Research Center,
         </institution>
        </institution-wrap>
        Giza, Egypt
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        1
       </day>
       <month>
        8
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        1
       </day>
       <month>
        8
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <elocation-id>
       180
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         27
        </day>
        <month>
         4
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         20
        </day>
        <month>
         7
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © Okda et al. 2015
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p id="Par1">
         Recent, severe outbreaks of porcine epidemic diarrhea virus (PEDV) in Asia and North America highlight the need for well-validated diagnostic tests for the identification of PEDV infected animals and evaluation of their immune status to this virus. PEDV was first detected in the U.S. in May 2013 and spread rapidly across the country. Some serological assays for PEDV have been previously described, but few were readily available in the U.S. Several U.S. laboratories quickly developed indirect fluorescent antibody (IFA) assays for the detection of antibodies to PEDV in swine serum, indicating prior exposure. However, the IFA has several disadvantages, including low throughput and relatively subjective interpretation. Different serologic test formats have advantages and disadvantages, depending on the questions being asked, so a full repertoire of tests is useful. Therefore, the objective of this study was to develop and validate multiple improved serological assays for PEDV, including an indirect ELISA (iELISA); a highly specific monoclonal antibody-based blocking ELISA (bELISA); fluorescent microsphere immunoassays (FMIA) that can be multiplexed to monitor exposure to multiple antigens and pathogens simultaneously; and a fluorescent focus neutralization assay (FFN) to measure functional virus neutralizing antibodies.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p id="Par2">
         A recombinant North American nucleoprotein (NP) based iELISA was developed and validated along with a bELISA using newly developed PEDV-NP specific biotinylated monoclonal antibodies (mAbs) and an FMIA using magnetic beads coupled with expressed NA PEDV-NP. Receiver operating characteristic (ROC) analysis was performed using swine serum samples (iELISA n = 1486, bELISA n = 1186, FMIA n = 1420). The ROC analysis for the FMIA showed estimated sensitivity and specificity of 98.2 and 99.2 %, respectively. The iELISA and bELISA showed a sensitivity and specificity of 97.9 and 97.6 %; and 98.2 and 98.9 %, respectively. Inter-rater (kappa) agreement was calculated to be 0.941 between iELISA and IFA, 0.945 between bELISA and IFA and 0.932 between FMIA and IFA. Similar comparative kappa values were observed between the iELISA, bELISA and FMIA, which demonstrated a significant level of testing agreement among the three assays. No cross-reactivity with the closely related coronaviruses, transmissible gastroenteritis virus (TGEV) or porcine respiratory coronavirus (PRCV) was noted with these assays. All three assays detected seroconversion of naïve animals within 6–9 days post exposure. The FFN assay allows relative quantitation of functional neutralizing antibodies in serum, milk or colostrum samples.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p id="Par3">
         Well-validated iELISA, bELISA and FMIA assays for the detection of PEDV antibodies were developed and showed good correlation with IFA and each other. Each assay format has advantages that dictate how they will be used in the field. Newly developed mAbs to the PEDV-NP were used in the bELISA and for expediting FFN testing in the detection and quantitation of neutralizing antibodies. In addition, these PEDV mAbs are useful for immunohistochemistry, fluorescent antibody staining and other antigen-based tests. Measurement of neutralizing antibody responses using the FFN assay may provide a valuable tool for assessment of vaccine candidates or protective immunity.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Porcine epidemic diarrhea virus (PEDV)
       </kwd>
       <kwd>
        Serology
       </kwd>
       <kwd>
        ELISA
       </kwd>
       <kwd>
        Fluorescent microsphere immunoassay (FMIA)
       </kwd>
       <kwd>
        Fluorescent Focus Neutralization (FFN)
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p id="Par46">
      Porcine epidemic diarrhea virus (PEDV) was first described in Europe in the 1970s with more recent and severe outbreaks in Asia [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. The virus was identified in the United States in May 2013, causing severe diarrhea and vomiting in pigs across age groups, with high mortality of up to 90−95 % in suckling pigs [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. PEDV is an enveloped, single stranded RNA virus belonging to the
      <italic>
       Coronaviridae
      </italic>
      family. The coronaviruses taxonomically form a subfamily (
      <italic>
       Coronavirinae
      </italic>
      ) within the order
      <italic>
       Nidovirales
      </italic>
      . Recently, the International Committee on Taxonomy of Viruses (ICTV) recognized four genera within the
      <italic>
       Coronavirinae
      </italic>
      subfamily:
      <italic>
       Alphacoronavirus
      </italic>
      ,
      <italic>
       Betacoronavirus
      </italic>
      ,
      <italic>
       Gammacoronavirus
      </italic>
      , and
      <italic>
       Deltacoronavirus
      </italic>
      [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. PEDV belongs to the genus
      <italic>
       Alphacoronavirus
      </italic>
      along with other swine viruses including transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV).
     </p>
     <p id="Par47">
      The genome is composed of a large ~28 Kb molecule consisting of a 5′ untranslated region (UTR), a 3′ UTR, and at least seven open reading frames (ORFs) encoding three nonstructural proteins: ORF1ab (pp1a and pp1ab) and ORF3, an accessory protein. The four major structural proteins of the mature virion include the spike (S) glycoprotein (Mr 150–220 kDa), the nucleoprotein (NP) (Mr 45–57 kDa) that is associated with the positive stranded RNA providing integral support for its helical structure, the glycosylated membrane protein (M) (Mr 20–30 kDa), and the glycosylated envelope protein (E) (Mr 7 kDa) [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      –
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ].
     </p>
     <p id="Par48">
      Coronaviruses are taxonomically assigned to different genera based on their rooted phylogeny and calculated evolutionary distance for seven highly conserved genomic domains within ORF 1ab [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. The genetic diversity of coronaviruses may be due to their high frequency of recombination [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. The heterogeneity among coronavirus subfamilies is well documented [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ], and the factors that contribute to PEDV’s ability to gain or lose parts of its transcriptome are believed to have contributed to quasispecies with novel traits that are able to adapt to new hosts, ecological niches and zoonotic events. The exact origin of PEDV in North America is not entirely clear, but there is evidence of genetic similarities to Chinese PEDV strains [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ].
     </p>
     <p id="Par49">
      Recently, a novel NA PEDV recombinant strain was identified (S INDEL) containing both insertions and deletions within the N-terminal domain of the ORF 3 and S1 genes. Specifically, sequence alignment indicated spike gene nucleotide deletions at positions 164–169 that correspond to amino acid deletions at positions 55 and 56 in addition to substitutions at positions 23 (I), 31 (H), 57 (K), and 59 (E) as compared to the CV777strain [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ].
     </p>
     <p id="Par50">
      The relatedness of several PEDV strains circulating in China was evaluated by Li et al. [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ] using phylogenic analysis of the NP gene and no insertions or deletions were noted. Sequence comparison with other European and Korean PEDV strains obtained from GenBank indicated that the NP genes were highly conserved (94.7−97.7 %) even though these strains originated from different geographic regions [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. In addition to being highly conserved among PEDV variants, the NP is the most abundant viral protein expressed in PEDV infected cells [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ]. In contrast, the spike protein is presented on the viral surface and subject to various host immune pressures, which predisposes it to a greater range of genetic heterogeneity including insertions and deletions. Because the NP protein is highly abundant in virus infected cells, it provides an attractive target for the development of antigen-based serological assays. Taken together, this evidence provided rationale for using it as our antigen of choice for the iELISA, bELISA and FMIA.
     </p>
     <p id="Par51">
      In response to the recent outbreaks of highly virulent PEDV in North America (NA), PCR assays were quickly developed to detect the presence of PEDV RNA in intestine or fecal material. These assays provide an important tool in control of the virus; however, well-validated, high-throughput assays to detect antibodies following infection would provide additional valuable diagnostic tools for the swine industry. The ability to detect and evaluate antibody responses using serologic tests is important in efforts to answer basic production related questions. These questions may include whether a production site is naïve or has historically experienced a PEDV exposure, even though a producer has not seen obvious clinical signs; the level of immune response sows may have in relation to vaccination, initial wild-type virus infection or intentional feedback exposure; and whether sow immunity is inadequate when clinical infection occurs in individual litters after initial PEDV exposure in a herd.
     </p>
     <p id="Par52">
      One of the most pressing issues of PEDV disease is maintaining herd site biosecurity through exclusion measures to prevent viral entrance into swine units. However, PEDV infection may not always be obvious in finishing pigs so the widespread transport of these animals may represent additional risks. Thus, sensitive serological tests provide a valuable tool in the detection of recent infection to avoid the introduction of these animals into naïve herds.
     </p>
     <p id="Par53">
      Since PEDV was widespread in Europe in the 1970s and 1990s and more recently in Asia, various serologic tests have been developed and subjected to varying degrees of validation [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      –
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ]. However, few assays have been developed using antigens associated with contemporary strains currently circulating across NA. The need to develop more sensitive serological assays has become paramount in order to address questions regarding PEDV infections and epidemiological transmission patterns, as well as to analyze disease progression.
     </p>
     <p id="Par54">
      Currently, serum virus neutralization (SVN) tests are the most widely employed serological assays used to detect PEDV antibodies. It is a test that is highly specific and useful for screening of antibody titer post vaccination [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. However, the test is expensive and labor intensive, requiring manual reading and interpretation of virus induced cytopathic effect (CPE) endpoints. Moreover, serum cytotoxicity can be mistaken for viral CPE, giving rise to false interpretations at lower serum dilutions.
     </p>
     <p id="Par55">
      Several laboratories have generated in-house indirect ELISAs using either virus derived antigen or recombinant structural proteins. Early indirect ELISAs were developed using Vero cell derived, whole virus preparations [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ] or Vero cell expressed viral proteins [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. These methods may be problematic because serum from animals vaccinated with cell culture derived PEDV may cross-react with cellular components of ELISA antigen, causing low specificity and high background. Other groups have used recombinantly expressed, purified, structural S and NP proteins for iELISA serodiagnosis, but because low numbers of experimentally derived samples were used to evaluate the performance of the assay, full validation of the diagnostic sensitivities and specificities could not be assessed [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ].
     </p>
     <p id="Par56">
      Both the iELISA and bELISA formats have proven useful for the serodiagnosis of experimental and natural infections. Blocking or competitive ELISAs have been shown to be especially useful where a higher level of specificity is required. The increased specificity has been shown to be dependent on both the isotype and on the target specificity of the monoclonal or polyclonal antibodies [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ]. Various laboratories have developed sensitive blocking ELISAs, and Carvajal et al. [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ] demonstrated their bELISA was able to detect an antibody response 3 to 5 days earlier than IFA, which suggested higher sensitivity of the bELISA. In addition, the bELISA is valuable as a confirmatory test where unexpected positive results appear in presumably negative herds.
     </p>
     <p id="Par57">
      The fluorescent microsphere immunoassay is based on fluidic, particle array technology (Luminex Corp., Austin, TX) and has become increasingly standardized and accepted in applications involving the serologic diagnosis of autoimmune and animal infectious diseases [
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. There are distinct advantages of the FMIA over the ELISA, which include higher sensitivity, higher sample throughput analysis, and the ability to multiplex and monitor exposure to multiple pathogens simultaneously in a single sample. In addition, multiple bead sets in the FMIA could be added to a standardized assay against newer virus subtypes that continue to emerge in the field or to assess antigenic/phylogenetic differences between genera of coronaviruses.
     </p>
     <p id="Par58">
      In this study, we report the adaptation of a recombinant, highly purified, NA PEDV-NP antigen to the development of iELISA, bELISA and FMIA platforms for the detection of PEDV antibodies in serum. These assays provide high throughput serological tests designed to address PEDV disease diagnostics. They were fully validated using a large number of serum samples of known status, and validation of the tests was detailed using methods for the validation of serological assays for the diagnosis of infectious diseases previously described by Jacobson for the Office International des Epizooties [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. In addition, a fluorescent focus neutralization (FFN) assay was developed for the rapid evaluation of neutralizing antibody responses.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Ethics Statement
      </title>
      <p id="Par59">
       Procedures involving animals were approved by the South Dakota State University Institutional Animal Care and Use Committee (IACUC) under approval numbers 13-054A and 04-A034. Time course swine serum samples provided by Kansas State University were part of a separate PEDV challenge study conducted at the Biosecurity Research Institute approved by the Kansas State University Institutional Animal Care and Use Committee. All other serum samples were obtained as routine diagnostic sample submissions at the South Dakota ADRDL.
      </p>
      <sec id="Sec4">
       <title>
        Animal samples for assay validation and time-course serological evaluation
       </title>
       <p id="Par60">
        For time course studies, serum samples from experimentally infected animals were obtained courtesy of Dr. Richard Hesse (Kansas State University Veterinary Diagnostic Laboratory, National Pork Board Grant #13-228). Thirty-three PEDV naïve 3-week-old feeder pigs were obtained from a private, high-health status swine production farm. . Of the 33 pigs, 23 were inoculated with PEDV at 4 weeks of age via intranasal and oral routes with a pool of gut derived intestinal contents that had been used as “feedback” inocula for controlled exposure of a sow herd. Serum was collected prior to challenge and at days 0, 6, 9, 14, 21, 28, 35 and 43 days post-infection (DPI). Multiple aliquots of all samples collected were shared with requesting laboratories to expand diagnostic testing and vaccine development capabilities.
       </p>
       <p id="Par61">
        To accurately assess the diagnostic sensitivity and specificity of the assays, samples of known serostatus for PEDV were used. This included sera from multiple animal populations including experimentally infected animals and serum samples from animals with known historical exposure to PEDV that were submitted to the South Dakota Animal Disease Research and Diagnostic Laboratory (ADRDL). PEDV negative sample sets included samples from PEDV negative control pigs used in experimental studies and selected high biosecurity herds with no history of PEDV. In addition, archived serum samples collected prior to the emergence of PEDV in the U.S., including samples testing positive for the related swine coronaviruses TGEV and PRCV (n= &gt; 50), were used. The exact number of positive and negative sera used for sensitivity and specificity calculations per assay with statistical testing agreement calculations based on serum numbers is listed in Table
        <xref ref-type="table" rid="Tab1">
         1
        </xref>
        . The majority of these sera were identical among assays, but limited serum volume did not allow for use of all sera samples among all assays.
        <table-wrap id="Tab1">
         <label>
          Table 1
         </label>
         <caption>
          <p>
           Evaluation of statistical agreement among serological testing platforms. Multiple comparison, inter-rater agreement (kappa association) was calculated among all four tests. Kappa values shown represent a statistical measure of test agreement and were calculated using MedCalc version 11.1.1.0
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th>
            </th>
            <th>
             FMIA
            </th>
            <th>
             bELISA
            </th>
            <th>
             Indirect ELISA
            </th>
            <th>
             IFA
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td>
             IFA
            </td>
            <td>
             0.932
            </td>
            <td>
             0.945
            </td>
            <td>
             0.941
            </td>
            <td>
             1
            </td>
           </tr>
           <tr>
            <td>
             iELISA
            </td>
            <td>
             0.919
            </td>
            <td>
             0.923
            </td>
            <td>
             1
            </td>
            <td>
             0.941
            </td>
           </tr>
           <tr>
            <td>
             bELISA
            </td>
            <td>
             0.941
            </td>
            <td>
             1
            </td>
            <td>
             0.923
            </td>
            <td>
             0.945
            </td>
           </tr>
           <tr>
            <td>
             FMIA
            </td>
            <td>
             1
            </td>
            <td>
             0.941
            </td>
            <td>
             0.919
            </td>
            <td>
             0.932
            </td>
           </tr>
           <tr>
            <td>
             Number Positive Serum Samples
            </td>
            <td>
             158
            </td>
            <td>
             158
            </td>
            <td>
             158
            </td>
            <td>
             158
            </td>
           </tr>
           <tr>
            <td>
             Number Negative Serum Samples
            </td>
            <td>
             361
            </td>
            <td>
             361
            </td>
            <td>
             361
            </td>
            <td>
             361
            </td>
           </tr>
           <tr>
            <td>
             Total Serum Samples Tested
            </td>
            <td>
             519
            </td>
            <td>
             519
            </td>
            <td>
             519
            </td>
            <td>
             519
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
      </sec>
      <sec id="Sec5">
       <title>
        Antigen production, expression of recombinant PEDV-NP protein
       </title>
       <p id="Par62">
        The development and validation of the iELISA and bELISA made use of a recombinantly expressed full length NA PEDV-NP. The NP open reading frame (ORF) of PEDV was amplified from RNA extracted directly from intestinal contents by RT-PCR from a case submitted to the South Dakota ADRDL. It was subsequently directionally cloned into the
        <italic>
         E. coli,
        </italic>
        pET 28a(+), plasmid expression vector (Novagen, Madison, WI), then transformed into BL21-Codon Plus (DE3)-RP competent cells (Stratagene, La Jolla, CA) for protein expression. Primers used for the amplification of the full length (1323 bp) nucleoprotein were: PEDV-NP-fwd (5′-
        <underline>
         CGCGGATCC
        </underline>
        ATGGCTTCTGTCAGTTTTCAG-3′); PEDV-NP-rev (5′-
        <underline>
         CACACTCGAG
        </underline>
        ATTTCCTGTGTCGAAGATCTC-3′). Next, 20 μl of transformed cells were plated onto Luria-Bertani agar plates containing 50 μg of kanamycin/ml and incubated overnight. The following morning, colonies from the agar plates were added to 1 L of pre-warmed 2X yeast extract tryptone (YT) culture medium containing 50 μg kanamycin/ml and allowed to grow to an OD
        <sub>
         600
        </sub>
        of 0.5 at 37 °C. PEDV-NP expression was induced using isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 1.0 mM to induce transcription of the Lac operon, and the
        <italic>
         E. coli
        </italic>
        was allowed to incubate for an additional 8 h at 37 °C with shaking at 200 RPM. The agar was strained out and bacteria pelleted by centrifugation at 12,000 g for 10 min at 4 °C. The pellet was resuspended in 40 ml of lysis buffer solution (B-PER, Pierce, Rockford, IL), incubated for 15 min at 20–22 °C, then centrifuged at 12,000 g to separate the soluble from insoluble proteins. The PEDV-NP recombinant protein was expressed as insoluble periplasmic inclusion bodies. The resulting 441 amino acid recombinant protein was denatured using 8 M urea, subsequently purified three times using nickel-NTA affinity column chromatography and refolded back to its native conformational state. Individual affinity column elutions were collected, pooled and confirmed by SDS-PAGE, then aliquoted/frozen at −80 °C. The correct nucleotide sequence was confirmed by sequence and restriction endonuclease analysis. The average protein yield produced by the pET28a-PEDV-NP plasmid construct was calculated to be 11 mg PEDV-NP per liter of 2XYT under the aforementioned conditions. The recombinant protein was detected and a predicted molecular weight of 51 kDa was confirmed via Western Blotting using convalescent sera, a 6X histidine-specific mAb (Novagen, Madison, WI) and a PEDV-NP specific mAb (Figs.
        <xref ref-type="fig" rid="Fig1">
         1
        </xref>
        and
        <xref ref-type="fig" rid="Fig2">
         2
        </xref>
        ).
        <fig id="Fig1">
         <label>
          Fig. 1
         </label>
         <caption>
          <p>
           Purification of antibody capture antigen. SDS-PAGE/Coomassie blue staining of
           <italic>
            E. coli
           </italic>
           expressed and purified NA PEDV-NP antigen used to coat ELISA microtiter plates and FMIA microspheres. Molecular weight ladder (MW) PEDV-NP (51 kDa)
          </p>
         </caption>
         <graphic id="MO1" xlink:href="12917_2015_500_Fig1_HTML">
         </graphic>
        </fig>
        <fig id="Fig2">
         <label>
          Fig. 2
         </label>
         <caption>
          <p>
           Antigen/antibody specificity. Western blot analysis showing detection of recombinant expressed NA PEDV-NP protein and specificity of the monoclonal antibody used in the bELISA. L- Molecular weight ladder. A- anti-PEDV-NP mAb 6–29. B- anti-polyhistidine mAb. C- anti PEDV-NP convalescent swine serum
          </p>
         </caption>
         <graphic id="MO2" xlink:href="12917_2015_500_Fig2_HTML">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec id="Sec6">
       <title>
        mAb production and biotinylation
       </title>
       <p id="Par63">
        Two separate mAbs were developed in our laboratory (SD6-29 and SD17-103) that recognize both the native conformation of the PEDV-NP and the full length, linear, recombinant protein used in all antibody capture assays. Hybridomas were produced as previously described [
        <xref ref-type="bibr" rid="CR26">
         26
        </xref>
        ,
        <xref ref-type="bibr" rid="CR27">
         27
        </xref>
        ]. Immunoglobulin isotyping of the resulting mAbs was performed using a commercial lateral flow assay (Serotec, Raleigh, NC). Subsequently, mouse ascites fluid was produced in pristane-primed mice, and the antibodies were purified and biotinylated for use as the detection moiety for the bELISA [
        <xref ref-type="bibr" rid="CR23">
         23
        </xref>
        ]. The conjugated antibody solution was quantified via the Lowry protein method, and carrier BSA was added to a final concentration of 10 mg/ml, then aliquoted and stored at −20 °C.
       </p>
      </sec>
      <sec id="Sec7">
       <title>
        IFA
       </title>
       <p id="Par64">
        Vero-76 cells (ATCC CRL-1587) were cultured with MEM + 10 % FBS for 48–72 h until fully confluent in 96-well plates, then washed twice with MEM. Subsequently, alternating rows of 96-well plates were inoculated with the cell culture adapted PEDV NVSL-CO strain of PEDV (PEDV USA/Colorado/2013, GenBank accession number KF272920) at a multiplicity of infection (MOI) of 0.05 with MEM supplemented with 1.5 μg/ml trypsin (TPCK treated, bovine derived (Sigma, St. Louis, MO)). After incubation at 37 °C for 20–24 h, monolayers were fixed with 80 % acetone for 20 min. Serum samples were initially serially diluted from 1:40 to 1:320 with PBS in duplicate wells, and 100 μls of the diluted serum were added to each well. The plates were incubated at 37 °C for 1 h and then rinsed 3X with PBS. Next, fluorescein isothiocyanate (FITC)-conjugated goat anti-swine IgG (KPL, West Chester, PA) was prepared at a dilution of 1:15 with PBS and 50 μl added to each well. After 1 h of incubation at 37 °C, plates were rinsed 3X with PBS and examined using fluorescent microscopy. For each individual test, each PEDV infected well was compared to its respective uninfected partner well, and a positive sample was indicated if a PEDV specific fluorescent signal was observed at a serum dilution of 1:40 or greater. All samples were tested in duplicate, and the antibody titer was expressed as the mean of all replicates.
       </p>
      </sec>
      <sec id="Sec8">
       <title>
        iELISA
       </title>
       <p id="Par65">
        The serological PEDV-NP indirect ELISA was performed by coating alternate wells of Immulon 1B, 96-well, microtiter plates (Thermo Labsystems, Franklin, MA) with 250 ng/well of purified, recombinantly expressed PEDV-NP antigen. The optimal dilution of the recombinant protein and secondary detection antibody was determined by a checkerboard titration that gave the highest signal to noise ratio. In addition, a single lot of pooled convalescent serum from PEDV infected pigs was used to generate quality control standards that gave high and low optical density (high OD = 2.0 to 2.5; low OD = 0.5 to 1.0; and negative OD &lt; 0.2). PEDV-NP recombinant protein was diluted to 2.5 μg/ml in 15 mM sodium carbonate-35 mM sodium bicarbonate- antigen coating buffer (ACB) pH 9.6. Odd-numbered columns were coated with 100 μl of ACB plus antigen, while the even-numbered columns were coated with ACB without antigen, serving as background control. The plates were incubated for one hour at 37 °C, then washed 3X with PBS plus 0.05 % tween
        <sub>
         20
        </sub>
        (PBST). Each well was then blocked with 200 μl of sample milk diluent (PBST plus 5 % nonfat dry milk, (SMD)) and allowed to incubate overnight at 4 °C. The following day, the plates were washed 3X with 300 μl of PBST. Test and control sera were diluted 1/50 in SMD, mixed, and 100 μl of the solution was added to each well. The plates were incubated for 1 h at 20–22 °C. Next, 100 μl of biotinylated, goat anti-swine detection antibody (Bethyl Laboratories, TX) was added at a concentration of 200 ng/ml of PBST and allowed to incubate at 20–22 °C for 1 h. The plate was washed 3X with 300 μl of PBST, then 100 μl of streptavidin-HRP conjugate (Pierce, Rockford, IL) was added and incubated for another hour at 20–22 °C, then washed and developed with 3,3′,5,5′- tetramethylbenzidine, peroxidase substrate (TMB) (Surmodics, Eden Prairie, MN). Color development progressed until the positive control attained a standard OD and was stopped using 2 N H
        <sub>
         2
        </sub>
        SO
        <sub>
         4
        </sub>
        . Colorimetric development was quantified spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek Instruments Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, Westbrook, ME). The raw data was normalized and transformed into an Excel spreadsheet. Sample to Positive (S/P) ratios were calculated using the following formula: S/P = optical density (OD) of sample - OD of buffer/OD of positive control - OD of buffer.
       </p>
      </sec>
      <sec id="Sec9">
       <title>
        bELISA
       </title>
       <p id="Par66">
        The serological bELISA was performed using Immulon 1B, 96-well microtiter plates (Thermo Labsystems, Franklin, MA). Alternate wells of each plate were coated with 500 ng per well of expressed PEDV-NP antigen. The optimal dilution of the recombinant protein and mAb antibody was determined by a checkerboard titration that gave the highest signal to noise ratio with an OD reading of approximately 2.0, in the absence of swine serum/competitor antibody. First, PEDV-NP recombinant protein was diluted to 2.5 μg/ml of ACB. Odd-numbered columns were coated with 100 μl of ACB plus antigen, while the even-numbered columns were coated with ACB without antigen serving as background control. The plates were incubated for 1 h at 37 °C, washed 3 times with PBST, then placed at 4 °C overnight. The following day, each well was blocked with 300 μl of SMD and incubated one hour at 37 °C. Plates were washed 3 times with PBST, and 100 μl of test and control sera were diluted 1/3 with PBST + 0.1 % nonfat dry milk and added to each of the duplicate wells. Plates were incubated 1 h at 37 °C. During sample incubation, PEDV-NP specific biotinylated, mAbs (SD6-29 and SD17-103) were adjusted to equal titers and mixed together in a 1:1 ratio. Next, 100 μl of a 1:40,000 dilution of the antibody detection mixture was added to the microtiter plate containing the competitive swine antibody, then swirled and incubated for an additional 30 min at 37 °C. The plates were washed 3 times, and 100 μl of high sensitivity, streptavidin-horseradish peroxidase conjugate (Pierce, Rockford, IL) was added to all wells of the microtiter plate for 1 h at 37 °C.
       </p>
       <p id="Par67">
        Plates were washed 4 times with PBST, and 100 μl of TMB was added to all wells and gently swirled. After approximately15 min, color development progressed until the negative control attained a standard OD of approximately 2.0 and was subsequently stopped using 2 N H
        <sub>
         2
        </sub>
        SO
        <sub>
         4
        </sub>
        . Colorimetric development was quantified spectrophotometrically at 450 nm with an ELx800 microplate reader (BioTek Instruments Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, Westbrook, ME). The raw data was normalized and transformed into a Excel spreadsheet, and the percent inhibition (PI) ratio was calculated using the following formula: PI = 1-{(OD of sample - OD of buffer)/(OD of negative control – OD of buffer)} X 100.
       </p>
      </sec>
      <sec id="Sec10">
       <title>
        Preparation of PEDV-NP coupled microspheres for the FMIA
       </title>
       <p id="Par68">
        A two-step carbodiimide coupling procedure was used to couple NA PEDV-NP protein to Luminex™ microspheres. Briefly, the coupling of fluorescent microsphere was performed by washing 3.125 × 10
        <sup>
         6
        </sup>
        microspheres twice with 250 μl activation buffer (0.1MNaH
        <sub>
         2
        </sub>
        PO
        <sub>
         4
        </sub>
        , pH6.2) and sonicating them for 60 s after each wash. Microspheres were activated for 20 min at 20–22 °C in 500 μl activation buffer containing 2.5 mg
        <italic>
         N
        </italic>
        -hydroxysulfosuccinimide (sulfo-NHS) and 2.5 mg
        <italic>
         N
        </italic>
        -(3- dimethylaminopropyl)-
        <italic>
         N
        </italic>
        -ethylcarbodiimide (EDC) (Pierce Chemical, Rockford, IL). Activated microspheres were washed twice with PBS and sonicated. Coupling was initiated by the addition of 12.5 μg of recombinant NA PEDV-NP protein, brought to a final volume of 500 μl with PBS and incubated in the dark for 3 h at 20–22 °C with rotation. Coupled microspheres were washed once with 1 ml of PBS plus 0.05 % NaN
        <sub>
         3
        </sub>
        and 1.0 % bovine serum albumin (PBS-NB). Next, the microspheres were blocked with 1 ml of PBS-NB for 30 min to reduce nonspecific binding. Microspheres were then washed twice with PBS-NB and resuspended in PBS-NB to a final concentration of 2.0 × 10
        <sup>
         6
        </sup>
        antigen-coupled microspheres/ml.
       </p>
      </sec>
      <sec id="Sec11">
       <title>
        FMIA
       </title>
       <p id="Par69">
        A 96-well hydrophilic membrane filter plate was blocked for 2 min with 150 μl of PBS-NB, and then the liquid was aspirated via vacuum manifold. The plates were wetted with 20 μl of PBS-NB buffer to prevent drying. Next, 50 μl of serum (diluted 1:50 in PBS-NB) was added to duplicate wells of the filter plate along with 50 μl of PBS-NB containing 2.5 × 10
        <sup>
         3
        </sup>
        antigen-coupled microspheres. Since the microspheres and reporter moieties are light sensitive, all incubations were performed in the dark by sealing the plate with foil. Subsequently, the FMIA plate was incubated at 20–22 °C for 1 h on a plate shaker rotating at 600 rpm. The plate was washed 3 times with 200 μl of PBST. Next, 50 μl of anti-swine, biotinylated IgA (heavy &amp; light chain, diluted in PBS-NB; Bethyl Laboratories) or IgG-FC specific polyclonal antibodies (diluted 1:2,000 dilution in PBS-NB; Bethyl Laboratories) were added to the filter plate and incubated at 20–22 °C for 1 h. NP IgM and IgG isotype-specific antibody levels were detected using PEDV-NP coated microspheres, but speciated by means of individual and separate IgM and IgG-specific secondary antibodies. Since validation was performed using serum, and because IgA is present in very low amounts, IgA specific secondary antibodies were not used at this step. After incubation with the secondary antibodies, 50 μl of streptavidin phycoerythrin (2.5 μg/ml in PBS-NB, Molecular Probes) was added to each well and incubated for 30 min at 20–22 °C with shaking. The supernatant was aspirated, and the plate was washed 3 times with PBST. Finally, the microspheres were resuspended in 125 μl of PBST per well and transferred to a clear 96-well polystyrene optical plate. Coupled microspheres were analyzed through a dual-laser Bio-Rad Bio-Plex 200 instrument. The median fluorescent intensity (MFI) for 100 microspheres corresponding to each individual bead analyte was recorded for each well. All reported MFI measurements were normalized via F - F
        <sub>
         0
        </sub>
        , where F
        <sub>
         0
        </sub>
        was the background signal determined from the fluorescence measurement of a test sample in uncoated beads and F was the MFI for a serological test sample using antigen-coated beads.
       </p>
      </sec>
      <sec id="Sec12">
       <title>
        Establishment of serological reference standards for ELISA and FMIA development
       </title>
       <p id="Par70">
        Four serological reference serum sets were constructed as standards termed high, medium, low and negative to serve as internal quality control standards and to mathematically normalize individual samples for objective comparisons between testing platforms. The high-labeled standard was designed to generate an OD above 2.0 for the iELISA and bELISA and an MFI of approximately 25,000 for the FMIA. The high standard was used exclusively for the mathematical determination of the serological response (S/P ratio) of samples used for test validation. The medium standard generated a response of between 1.5 and 2.0 OD for the two ELISAs and approximately 10,000 MFI for the FMIA. The low standard was designed to deliver a signal slightly above threshold level for all 3 tests, and the negative serum generated an OD or MFI to a background level of less than 0.2 OD for the ELISAs and 600 MFI for the FMIA.
       </p>
      </sec>
      <sec id="Sec13">
       <title>
        Validation methods for the determination of diagnostic sensitivity, specificity, repeatability and threshold cutoff level
       </title>
       <p id="Par71">
        To accurately assess the diagnostic sensitivity and specificity of the assays, samples of known serostatus for PEDV were used. This included sera from multiple animal populations including experimentally infected animals and serum samples submitted to the South Dakota ADRDL. PEDV negative sample sets included samples from selected high biosecurity herds with no history of PEDV and archived serum samples collected prior to the emergence of PEDV in the U.S., including samples testing positive for the related swine coronaviruses TGEV and PRCV. Known positive samples were collected from pigs that were naturally infected at least 3 weeks prior to collection and were previously positive by PCR. The negative-testing sample population (uninfected animals) consisted of maximally 980 PEDV negative serum samples, while the positive-testing (infected) population was composed of 516 serum samples. Receiver operating characteristic (ROC) analysis was calculated for each assay to assess diagnostic performance, which included determination of sensitivity, specificity and threshold cutoff using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).
       </p>
       <p id="Par72">
        The repeatability of each assay was assessed by running the same internal quality control serum standards in multiple replicates within the same run or between runs. For the iELISA and the bELISA, the intra-assay repeatability was calculated for 48 replicates on 3 separate plates, then repeated over a 3-day period for inter-assay repeatability assessment. The values for each assay were expressed as a mean, standard deviation and percent coefficient of variation (CV%) for repeated measure.
       </p>
      </sec>
      <sec id="Sec14">
       <title>
        Measurement of statistical testing agreement
       </title>
       <p id="Par73">
        Multiple comparison, inter-rater agreement (kappa measure of association) was calculated among all four tests (bELISA, iELISA, FMIA and IFA) using IBM, SPSS version 20 software (SPSS Inc., Chicago, IL). The sample cohort used was a well-characterized set of serum samples collected from “positive testing” experimentally infected pigs over time courtesy of Dr. Richard Hesse (n = 158) and from archived experimental control uninfected PEDV “negative testing” animals. The interpretation of kappa can be rated as follows: Kappa less than 0.0, “poor” agreement; between 0.0 and 0.20, “slight” agreement; between 0.21 and 0.40, “fair” agreement; between 0.41 and 0.60, “moderate” agreement; between 0.61 and 0.80, “substantial” agreement; and between 0.81 and 1.0, “almost perfect” agreement [
        <xref ref-type="bibr" rid="CR28">
         28
        </xref>
        ,
        <xref ref-type="bibr" rid="CR29">
         29
        </xref>
        ].
       </p>
      </sec>
      <sec id="Sec15">
       <title>
        FFN
       </title>
       <p id="Par74">
        A PEDV virus neutralization assay using a FFN format was developed for rapid detection of neutralizing antibodies produced in response to PEDV infection. The FFN was evaluated using serum samples or rennet treated milk and colostrum samples. Heat-inactivated samples were diluted in a 2-fold dilution series starting at 1:10 in MEM plus 1.5 μg/ml TPCK-treated trypsin in 96-well plates. An equal amount of cell culture adapted PEDV stock at a concentration of 100 foci forming units/100 μl was added to each well and plates incubated for 1 h at 37 °C. The virus/sample mixture was then added to washed confluent monolayers of Vero-76 cells and incubated for 2 h at 37 °C. Plates were washed again with MEM/TPCK-trypsin medium and incubated 20–24 h to allow for replication of non-neutralized virus. Plates were then fixed with 80 % acetone and stained with FITC conjugated mAb SD6-29 to allow visualization of infected cells. Endpoint neutralization titers were determined as the highest serum, milk or colostrum dilution resulting in a 90 % or greater reduction in fluorescent foci relative to controls.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="Sec16">
     <title>
      Results
     </title>
     <sec id="Sec17">
      <title>
       Expression of recombinant PEDV-NP antigen
      </title>
      <p id="Par75">
       As shown in Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       , the purity of the recombinant protein was assessed via SDS-PAGE and gave a band that migrated corresponding to the expected molecular mass of 51 kDa upon staining with Coomassie brilliant blue R250. The protein yield of the IPTG induced
       <italic>
        E. coli
       </italic>
       culture was calculated to be approximately 11 mg PEDV-NP/liter of 2XYT medium with a purity of greater than 95 %. The identity of the protein was further characterized by Western blot using convalescent swine serum, an anti-His mAb and an anti-PEDV-NP mAb (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       ).
      </p>
     </sec>
     <sec id="Sec18">
      <title>
       Diagnostic sensitivity, specificity, repeatability and threshold cutoff level
      </title>
      <p id="Par76">
       To optimize the serologic assays, various antigen and serum dilutions were used to determine optimum concentrations. All 3 tests were optimized in a checkerboard fashion to maximize signal-to-noise ratios. It was determined by antigen titration that the optimal coating of Luminex™/FMIA microspheres was achieved at a concentration of 12.5 μg protein per 3.125 × 10
       <sup>
        6
       </sup>
       microspheres. Similarly, the optimum coating of both the iELISA and bELISA plates was achieved at a concentration of 250 ng/well. In addition, to determine the optimum serum dilution for each of the testing platforms, a well-characterized PEDV “high” positive serum standard was serially diluted in a log
       <sub>
        2
       </sub>
       titration against antigen coated microspheres (FMIA) or antigen coated ELISA wells at a fixed concentration. Figure
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       shows concentration-dependent OD or MFI signals of various serum standards. Overall, sample absorbance increased inversely proportional to the serum dilution. However, based upon the highest signal-to-noise ratio, it was determined that the optimal serum dilution for the bELISA was 1/3, while the iELISA and FMIA each demonstrated an optimum dilution of 1/50 as indicated by arrows (Fig.
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       ).
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Serum dilution optimization for both ELISA assays and FMIA. Reference serum standard was titrated 2-fold in antigen coated wells at a fixed concentration in order to gauge a maximum signal-to-noise ratio for each assay
          <bold>
           a
          </bold>
          iELISA,
          <bold>
           b
          </bold>
          bELISA,
          <bold>
           c
          </bold>
          FMIA. Arrows show the optimum dilution of swine serum from which the highest signal to noise ratio was achieved
         </p>
        </caption>
        <graphic id="MO3" xlink:href="12917_2015_500_Fig3_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par77">
       ROC analysis to determine sensitivity, specificity and threshold cut-off levels was performed using large numbers of swine serum samples and demonstrated excellent agreement (&gt;0.91 kappa scores) between assays with good intra and inter assay repeatability (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ). None of the known positive TGEV or PRCV samples tested was shown to cross-react.
      </p>
      <p id="Par78">
       The optimal cutoff values and corresponding sensitivity and specificity of each individual test are presented in Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       . Specifically, ROC analysis for the iELISA and bELISA showed similar sensitivity and specificity of 97.9 and 97.6 %; and 98.2 and 98.9 %, respectively. The ROC analysis for the FMIA showed estimated sensitivity and specificity of 98.2 and 99.2 %, respectively. Although the FMIA showed an identical sensitivity as the bELISA, it demonstrated the highest degree of specificity of all three assays at 99.2 %. This observation was not surprising given that FMIA technology inherently imparts greater sensitivity and a larger dynamic range than the ELISA platform [
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ].
       <fig id="Fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Receiver operator characteristic (ROC) validation and determination of diagnostic sensitivity and specificity of the PEDV-NP iELISA, bELISA and FMIA assays. Diagnostic sensitivity and specificity were calculated using serum samples from a known PED-uninfected and PED-infected population. ROC analysis was performed using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). In each panel, the dot plot on the left represents the negative testing population, and the dot plot on the right represents the positive population. The horizontal line bisecting the dot plots represents the cutoff value that gives the optimal diagnostic sensitivity and specificity.
          <bold>
           a
          </bold>
          Serum iELISA,
          <bold>
           b
          </bold>
          Serum bELISA,
          <bold>
           c
          </bold>
          Serum FMIA
         </p>
        </caption>
        <graphic id="MO4" xlink:href="12917_2015_500_Fig4_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par79">
       In addition to determining cutoff values, sensitivities and specificities, multiple comparison tests were performed to calculate the degree of agreement among the ELISA, FMIA and IFA tests. Specifically, the Kappa test demonstrated all diagnostic platforms had kappa values greater than 0.91, which demonstrates that all 4 tests are in “almost perfect” agreement with each other.
      </p>
     </sec>
     <sec id="Sec19">
      <title>
       Assessment of repeatability
      </title>
      <p id="Par80">
       The iELISA and bELISA demonstrated slightly lower %CVs than the FMIA with 3.7 %, 6.8 %, 10.7 % intra-assay variability for bELISA, iELISA and FMIA respectively. Inter-assay %CVs were 5.0, 5.6 and 7.7 % for the bELISA, iELISA and FMIA respectively. Nonetheless, all the CVs were 10.7 % or less, which demonstrated that the tests were highly repeatable in a diagnostic application.
      </p>
     </sec>
     <sec id="Sec20">
      <title>
       Evaluation of a kinetic PEDV antibody response
      </title>
      <p id="Par81">
       As shown in Fig.
       <xref ref-type="fig" rid="Fig5">
        5
       </xref>
       , a mean antibody response to PEDV-NP could be detected as early as 9 DPI for both the iELISA and bELISA. The FMIA detected PEDV-NP antibodies slightly earlier at 6 DPI. All 3 tests detected the duration of antibody out to the 43 DPI time-point in this study but demonstrated a decline in detectable antibody after 21 DPI.
       <fig id="Fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Kinetic time course antibody evaluation. Antibody time course kinetics were calculated for each of the ELISAs and FMIA using serum samples from experimentally infected pigs collected at weekly intervals. The horizontal line indicates the diagnostic cutoff for each test. All three tests demonstrate similar kinetic curve responses via their calculated S/P values.
          <bold>
           a
          </bold>
          Antibody kinetic time course via iELISA,
          <bold>
           b
          </bold>
          Antibody kinetic time course via bELISA,
          <bold>
           c
          </bold>
          Antibody kinetic time course via FMIA
         </p>
        </caption>
        <graphic id="MO5" xlink:href="12917_2015_500_Fig5_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec21">
      <title>
       Application of the FMIA to isotype PEDV-NP specific antibodies
      </title>
      <p id="Par82">
       High levels of PEDV-NP specific IgM antibodies were observed at 7 DPI compared to IgG (Fig.
       <xref ref-type="fig" rid="Fig6">
        6
       </xref>
       ). However, the IgM antibodies decreased to barely detectable levels by 20 DPI. IgG continued to increase linearly to 20 DPI. There is a concomitant appearance of neutralizing antibodies by 14 DPI.
       <fig id="Fig6">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          FFN antibody and FMIA isotype time course evaluation. Using serum collected over time from experimentally infected pigs, the FMIA demonstrates the kinetic nucleoprotein-directed, isotype-specific response of IgG and IgM in serum. In addition, the data show a concomitant appearance of neutralizing antibodies as soon as 14 DPI
         </p>
        </caption>
        <graphic id="MO6" xlink:href="12917_2015_500_Fig6_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec22">
      <title>
       FFN
      </title>
      <p id="Par83">
       The FFN assay was initially evaluated using sequential serum samples from experimentally inoculated piglets. Additional evaluation was conducted using 250 serum samples from known PEDV naïve herds and 250 samples from herds with documented PEDV exposure, collected at least 3 weeks after initial PCR diagnosis and whole herd feedback. Experimentally inoculated piglets demonstrated detectable seroconversion by 14 DPI (Fig.
       <xref ref-type="fig" rid="Fig6">
        6
       </xref>
       ). Essentially all samples from PEDV naïve animals had serum FFN endpoint titers of &lt;1:20 while most samples from the PEDV positive set had endpoint titers ranging from 1:40 to 1:1280 (data not shown). Further evaluation of the FFN included serum, milk and colostrum samples from 27 sows from a herd that had experienced an acute PEDV outbreak 6 to 7 weeks prior to farrowing. All animals were exposed to live virus twice within the first week of the outbreak, followed by one dose of Harrisvaccines Porcine Epidemic Diarrhea Vaccine, RNA (Harrisvaccines, Inc., Ames, IA) at 1 week pre-farrow. Serum and colostrum samples were tested at the time of farrowing, followed by serum and milk samples at 1 week and 2 weeks later. As shown in Fig.
       <xref ref-type="fig" rid="Fig7">
        7
       </xref>
       , mean colostrum titers were approximately 4-fold higher than serum titers at the time of farrowing. At later time-points, serum and milk titers were similar in magnitude, although substantial animal to animal variation was apparent.
       <fig id="Fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Assessment of neutralizing antibody titers in different sample matrices following PEDV exposure. FFN titers were detected in various sample matrices including colostrum (n = 25), milk (n = 23) and serum (n = 27) collected at the time of farrowing and weekly for two weeks post-farrowing. Error bars indicate a 95 % confident interval for mean titers indicated by horizontal lines
         </p>
        </caption>
        <graphic id="MO7" xlink:href="12917_2015_500_Fig7_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec23">
     <title>
      Discussion
     </title>
     <p id="Par84">
      Overall, this repertoire of assays is useful for initial identification and efficient, high throughput quantitation of PEDV antibodies. We evaluated all three diagnostic platforms against a well characterized IFA and compared the individual serum IgM and IgG kinetic antibody responses in an FMIA to the appearance of neutralizing antibody as detected by the FFN assay. Each of the antibody-capture assays was validated using a large number of serum samples (n &gt;1100) based upon the assay validation methods of Jacobson, which is supported by the Office International des Epizooties [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ].
     </p>
     <p id="Par85">
      Since PEDV was first identified in the U.S. in May 2013, it has spread rapidly to at least 33 states (
      <ext-link ext-link-type="uri" xlink:href="http://www.aasv.org/">
       www.aasv.org
      </ext-link>
      ) and has been reported in Mexico and Canada [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ]. The virus causes severe gastroenteritis, destroying villus enterocytes in pigs of all ages, and is characterized by vomiting and diarrhea, leading to subsequent dehydration, high mortality rates and economic losses, particularly in nursery piglets [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ]. A variety of serological tests have been developed against PEDV, but they vary by antigen used and in the degree of validation. In addition, few have used North American NP based antigens or compared the array of serologic assays described here. In the current study, four tests (IFA, bELISA, iELISA, FMIA) showed strong correlation. Each has advantages, which dictate how they will be used in the field. In addition, newly developed NP mAbs were used in the bELISA and for expediting FFN testing in the detection of neutralizing antibodies.
     </p>
     <p id="Par86">
      In the development of the ELISAs and FMIA, the full length NA PEDV-NP gene was amplified directly from RNA extracted from PEDV-infected ileal tissue. Multiple sequence alignment analysis showed that the amplified NP gene shared a 100 % nucleotide homology with that of the US Colorado strain isolated in 2013 (Genbank accession no. 13–019349). Several authors confirm that the NP carries multiple antigenic determinants that are conserved among the
      <italic>
       Coronaviridae
      </italic>
      [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. However, we performed one-way cross-reactivity testing using serum from TGEV and PRCV, and no antibody cross-reactivity was detected within any of our assays. In addition to being highly conserved among various PEDV variants, the NP is the most abundant viral protein expressed in PEDV infected cells, making it an attractive target antigen [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ]. Using Western blotting experiments, we confirmed the finding of Hou et al. [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ], in which they observed the level of expression of NP protein to be significantly higher than the level of the spike protein. Our study demonstrated that it is possible to achieve a protein yield of over 10 mg per liter of culture with a purity of greater than 95 %.
     </p>
     <p id="Par87">
      The recombinant NP has previously been identified as a useful antigen in other ELISAs developed to detect antibodies in pigs located in China and Korea [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. In a study by Hou et al. [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ], the authors showed similar sensitivities and specificities of their iELISA compared to the iELISA described in this study. However, smaller numbers of known positive and negative samples were evaluated than in the current study.
     </p>
     <p id="Par88">
      Since no test has 100 % specificity, a bELISA was developed that is useful for confirmatory testing due to its higher inherent specificity than the iELISA [
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ]. Blocking or competitive ELISAs have been constructed using monoclonal antibodies in PEDV serodiagnosis, and the specific methodology can affect the overall specificity and performance of the assay. Our method was based upon coating plates with highly purified NA PEDV-NP, then using a combination of two separate NA, anti- PEDV-NP specific, biotinylated, monoclonal antibodies as the blocking/competitive detection step. This allows the capture of anti-NP antibodies at higher quantities and those with a greater range of antigen specificities. The analytical specificity of the NP-based bELISA is also dependent on the affinity of the mAbs used. The antibodies used in this study are directed against conserved epitopes on the nucleocapsid protein without any evidence of cross-reactivity to any other genera of
      <italic>
       Alphacoronavirus
      </italic>
      tested. A previous assessment of antigenic cross-reactivity was performed using these same mAbs against different strains of PEDV and TGEV [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. In that study, the authors reported that both mAbs used in the bELISA reacted with all PEDV strains tested, namely the homologous US isolate PC22A and the heterologous strains S INDEL IOWA 106, S 197DEL PC177 and CV777, at similar titers. Neither of the PEDV-NP mAbs cross-reacted with either the TGEV Miller or Purdue strains. Not only were the bELISA mAbs tested for heterologous cross-reactivity, but all three diagnostic platforms were evaluated in their ability to capture antibody against TGEV and PRCV, and there was no cross-reactivity to either heterologous virus.
     </p>
     <p id="Par89">
      Serology testing with IFA, iELISA, bELISA or FMIA is useful in determining whether pigs were previously infected with PEDV, or if piglets have acquired antibodies through colostrum (eg. passive antibody transfer). However, tests that evaluate the functionality of the antibodies such as the FFN are needed to determine if the detected immune response could be helpful in providing protection to nursing piglets. Neutralizing antibodies may be protective through actions including blocking uptake of the virus into cells, preventing virus binding to receptors on cells, preventing uncoating of the virus genomes in endosomes and/or causing aggregation of virus particles. For enveloped viruses, such as PEDV, lysis of the virus may also occur when antiviral antibodies and serum complement disrupt the viral membrane. For these reasons, an FFN-based virus neutralization assay was developed to assess levels of PEDV neutralizing antibodies in serum, milk or colostrum samples. The FFN provides a more rapid determination of neutralizing antibody levels than is possible with traditional virus neutralization assays that rely on visualization of virus-induced CPE after three or more days incubation to allow for full development of PEDV CPE. The direct observation of fluorescent stained infected cells, or lack of stained infected cells in the case of virus neutralization, allows for simple endpoint determination. This feature is particularly valuable when dealing with a fastidious, trypsin-dependent virus such as PEDV where CPE-based endpoints may not be obvious or may be confused with trypsin-induced CPE in the cell monolayer. Although neutralizing antibodies present in the serum would not be expected to provide direct protection from a strictly enteric infection such as PEDV, our data suggest a correlation between detectable neutralizing antibody levels in the serum and those present in milk and colostrum of previously exposed or vaccinated sows.
     </p>
     <p id="Par90">
      Some correlation between PEDV neutralization results and ELISA results exists as described in the literature. One study performed a comparative analysis between a whole-virus antigen ELISA and a serum neutralization test for the serodiagnosis of PEDV [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ]. The presence of antibodies was confirmed by each test, and an overall testing agreement of 84.2 % was demonstrated using 1024 field serum samples. Furthermore, a pairwise correlation was performed that showed corrected cutoff values between the ELISA OD and SN titers having an R value of 0.837, indicating that the CPE-based neutralization test had roughly the same reliability as the ELISA test [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ].
     </p>
     <p id="Par91">
      Newer technologies such as the FMIA are useful for the detection of antibodies against multiple antigens simultaneously for surveillance purposes. FMIA are bead based assays for simultaneous high throughput detection of antibodies to multiple antigens. The FMIA differs from the ELISA since it involves a fluid incubation step with “beads suspended in solution, which allows for higher surface area exposure in 3 dimensions” [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. Therefore, there is a shorter diffusion path to antibody binding sites on the antigen coated beads resulting in rapid reaction times. Instead of a method using an enzymatic reaction such as with the ELISA, the FMIA detection is with laser technology, which results in a shorter detection time. This PEDV antigen specific bead set can be “mixed” with additional coated beads to other antigens, such as SIV, PCV2, PRRSV or other pathogens, for simultaneous detection of antibodies to these antigens. In addition, an FMIA could be developed for differentiation of wild-type infected vs vaccinated animals (DIVA) if proteins used in the vaccine were different from those produced in a wild-type infection.
     </p>
     <p id="Par92">
      Individual kinetic serum IgG and IgM levels were measured by FMIA in experimentally infected animals over time. The appearance of the IgM subclass is considered an immunological parameter of early infection and generally appears prior to the appearance of IgG, and this was confirmed in our study. This was in contrast to the data of Woo et al. [
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ], which was unable to detect IgM antibodies using their NP-based indirect ELISA. IgG antibodies may be more easily detected as they are characterized by higher antigen affinity but lower avidity than IgM [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. Further understanding of various antibody profiles will provide important information on the ability of vaccines to stimulate a protective immune response.
     </p>
    </sec>
    <sec id="Sec24">
     <title>
      Conclusions
     </title>
     <p id="Par93">
      These well-validated NA PEDV iELISA, bELISA, FMIA and FFN assays are useful for a range of serological investigations. They can serve as a complement to nucleic acid detection and determine the PEDV status of asymptomatic individuals for cost-effective tools in management strategies and monitoring virus exposure within the herd. The FMIA will be useful for isotyping the antibody responses and in multiplexing for determining exposure to multiple pathogens simultaneously. In addition, the FFN is useful for determining whether the antibodies measured are providing a biological function of blocking virus infectivity. Work is ongoing to further validate these assays on other sample matrices such as milk and colostrum for measuring passive transfer of antibodies and oral fluids for pen-based surveillance.
     </p>
    </sec>
    <back>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list>
       <def-item>
        <term>
         PEDV
        </term>
        <def>
         <p id="Par4">
          Porcine epidemic diarrhea virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IFA
        </term>
        <def>
         <p id="Par5">
          Immunofluorescent assay
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         iELISA
        </term>
        <def>
         <p id="Par6">
          Indirect enzyme linked immunosorbent assay
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         bELISA
        </term>
        <def>
         <p id="Par7">
          Blocking enzyme linked immunosorbent assay
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         FMIA
        </term>
        <def>
         <p id="Par8">
          Fluorescent microsphere immunoassay
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         FFN
        </term>
        <def>
         <p id="Par9">
          Fluorescent Focus Neutralization
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ORF
        </term>
        <def>
         <p id="Par10">
          Open reading frame
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         UTR
        </term>
        <def>
         <p id="Par11">
          Untranslated region
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         NP
        </term>
        <def>
         <p id="Par12">
          Nucleoprotein
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         S
        </term>
        <def>
         <p id="Par13">
          Spike
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         E
        </term>
        <def>
         <p id="Par14">
          Envelope
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         mAb
        </term>
        <def>
         <p id="Par15">
          Monoclonal antibody
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ROC
        </term>
        <def>
         <p id="Par16">
          Receiver operator characteristic
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         TGEV
        </term>
        <def>
         <p id="Par17">
          Transmissible gastroenteritis virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PRCV
        </term>
        <def>
         <p id="Par18">
          Porcine respiratory coronavirus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         NA
        </term>
        <def>
         <p id="Par19">
          North American
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CPE
        </term>
        <def>
         <p id="Par20">
          Cytopathic effect
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         DPI
        </term>
        <def>
         <p id="Par21">
          Days post-infection
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ADRDL
        </term>
        <def>
         <p id="Par22">
          Animal Disease Research and Diagnostic Laboratory
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         RT-PCR
        </term>
        <def>
         <p id="Par23">
          Reverse transcriptase polymerase chain reaction
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         OD
        </term>
        <def>
         <p id="Par24">
          Optical density
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IPTG
        </term>
        <def>
         <p id="Par25">
          Isopropyl β-D-1-thiogalactopyranoside
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SDS-PAGE
        </term>
        <def>
         <p id="Par26">
          Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IACUC
        </term>
        <def>
         <p id="Par27">
          Institutional Animal Care and Use Committee
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         HAT medium
        </term>
        <def>
         <p id="Par28">
          Hypoxanthine-aminopterin-thymidine medium
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         DMSO
        </term>
        <def>
         <p id="Par29">
          Dimethyl sulfoxide
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         BSA
        </term>
        <def>
         <p id="Par30">
          Bovine serum albumin
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MEM
        </term>
        <def>
         <p id="Par31">
          Modified Eagles Medium
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         FBS
        </term>
        <def>
         <p id="Par32">
          Fetal bovine serum
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         NVSL
        </term>
        <def>
         <p id="Par33">
          National Veterinary Services Laboratories
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MOI
        </term>
        <def>
         <p id="Par34">
          Multiplicity of infection
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         TPCK
        </term>
        <def>
         <p id="Par35">
          L-1-Tosylamide-2-phenylethyl chloromethyl ketone
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         FITC
        </term>
        <def>
         <p id="Par36">
          Fluorescein isothiocyanate
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ACB
        </term>
        <def>
         <p id="Par37">
          Antigen coating buffer
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SMD
        </term>
        <def>
         <p id="Par38">
          Sample milk diluent
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         HRP
        </term>
        <def>
         <p id="Par39">
          Horseradish peroxidase
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         TMB
        </term>
        <def>
         <p id="Par40">
          3,3′,5,5′- tetramethylbenzidine
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PI
        </term>
        <def>
         <p id="Par41">
          Percent inhibition
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MFI
        </term>
        <def>
         <p id="Par42">
          Median fluorescent intensity
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SIV
        </term>
        <def>
         <p id="Par43">
          Swine influenza virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PCV-2
        </term>
        <def>
         <p id="Par44">
          Porcine circovirus type 2
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PRRSV
        </term>
        <def>
         <p id="Par45">
          Porcine reproductive and respiratory syndrome virus
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <fn-group>
      <fn>
       <p>
        <bold>
         Competing interests
        </bold>
       </p>
       <p>
        The authors declare that they have no competing interests.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Authors’ contributions
        </bold>
       </p>
       <p>
        FO: Conducted ELISA and FMIA development/validation, statistical analysis and co-wrote paper. XL: Conducted ELISA and FMIA development/validation. AS: Assisted with sample acquisition, assay development and study design. TC: Assisted with sample acquisition and study design. JN: Conducted virus neutralization assay development and testing. JCH: Assisted with study design and co-wrote paper. EAN: Developed study concept and design, edited paper. SL: Directed assay development and validation, co-wrote paper. All authors read and approved the final manuscript.
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       Funding for this work was provided by the South Dakota Agricultural Experiment Station, the South Dakota Animal Disease Research and Diagnostic Laboratory and the National Pork Board through grants 13–263 and 14–038. The authors thank Dr. Sabrina Swenson and Melinda Jenkins-Moore of the National Veterinary Services Laboratories for providing the cell culture adapted PEDV-CO isolate and Dr. Richard Hesse of the Kansas State University Veterinary Diagnostic Laboratory for providing serum samples from PEDV challenge studies. The authors also thank numerous swine producers and practitioners for providing field samples and herd history information.
      </p>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paudel
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hyun
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of antibody response of killed and live vaccines against porcine epidemic diarrhea virus in a field study
        </article-title>
        <source>
         Vet Quart
        </source>
        <year>
         2014
        </year>
        <volume>
         34
        </volume>
        <fpage>
         194
        </fpage>
        <lpage>
         200
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/01652176.2014.973999
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Debouck
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experimental infection of pigs with a new porcine enteric coronavirus, CV 777
        </article-title>
        <source>
         Am J Vet Res
        </source>
        <year>
         1980
        </year>
        <volume>
         41
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         219
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         6245603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stevenson
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Hoang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Burrough
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Madson
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Emergence of Porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences
        </article-title>
        <source>
         J Vet Diagn Invest
        </source>
        <year>
         2013
        </year>
        <volume>
         25
        </volume>
        <fpage>
         649
        </fpage>
        <lpage>
         654
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1040638713501675
        </pub-id>
        <pub-id pub-id-type="pmid">
         23963154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Carstens
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         2012
        </year>
        <volume>
         157
        </volume>
        <fpage>
         1411
        </fpage>
        <lpage>
         1422
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-012-1299-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         22481600
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Sequence and phylogenetic analysis of nucleocapsid genes of porcine epidemic diarrhea virus (PEDV) strains in China
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         158
        </volume>
        <fpage>
         1267
        </fpage>
        <lpage>
         1273
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-012-1592-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23389550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodak
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Valıcek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Smıd
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Nevorankova
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         An ELISA optimized for porcine epidemic diarrhoea virus detection in faeces
        </article-title>
        <source>
         Vet Microbiol
        </source>
        <year>
         2005
        </year>
        <volume>
         105
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetmic.2004.09.020
        </pub-id>
        <pub-id pub-id-type="pmid">
         15607079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C-M
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Oka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Vlasova
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Esseili
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antigenic Relationships among Porcine Epidemic Diarrhea Virus and Transmissible Gastroenteritis Virus Strains
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         3332
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.03196-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25589635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           de Graaf
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lauber
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Stalin Raj
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Moh Zaki
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2012
        </year>
        <volume>
         3
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         e00473
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         23170002
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Schaad
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Stohlman
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Establishing a genetic recombination map for murine coronavirus strain A59 complementation groups
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1990
        </year>
        <volume>
         177
        </volume>
        <fpage>
         646
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0042-6822(90)90530-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         2164728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        Huang Y-W, Dickerman AW, Piñeyro P, Li L, Fang L, Kiehne R, et al. Origin, evolution, and genotyping of emergent porcine epidemic diarrhea virus strains in the United States. mBio. 2013; 4(5) doi:10.1128/mBio.00737-13.
       </mixed-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        Marthaler D, Bruner L, Collins J, Rossow K. Third strain of porcine epidemic diarrhea virus, United States. Emerg Infect Dis. 2014; 20(12). doi:10.3201/eid2012.140908.
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus immunogens
        </article-title>
        <source>
         Vet Microbiol
        </source>
        <year>
         1993
        </year>
        <volume>
         37
        </volume>
        <fpage>
         285
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0378-1135(93)90030-B
        </pub-id>
        <pub-id pub-id-type="pmid">
         8116187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sturman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
        </person-group>
        <article-title>
         The molecular biology of coronaviruses
        </article-title>
        <source>
         Adv Virus Res
        </source>
        <year>
         1983
        </year>
        <volume>
         28
        </volume>
        <fpage>
         35
        </fpage>
        <lpage>
         122
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0065-3527(08)60721-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         6362367
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           de Bouck
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new coronavirus-like particle associated with diarrhea in swine
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         1978
        </year>
        <volume>
         58
        </volume>
        <fpage>
         243
        </fpage>
        <lpage>
         247
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/BF01317606
        </pub-id>
        <pub-id pub-id-type="pmid">
         83132
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wyler
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enzyme-linked immunosorbent assay for the detection of porcine epidemic diarrhea coronavirus antibodies in swine sera
        </article-title>
        <source>
         Vet Microbiol
        </source>
        <year>
         1990
        </year>
        <volume>
         21
        </volume>
        <fpage>
         263
        </fpage>
        <lpage>
         273
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0378-1135(90)90037-V
        </pub-id>
        <pub-id pub-id-type="pmid">
         2154877
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knuchel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ackermann
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
         <name>
          <surname>
           Kihm
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        <article-title>
         An ELISA for detection of antibodies against porcine epidemic diarrhoea virus (PEDV) based on the specific solubility of the viral surface glycoprotein
        </article-title>
        <source>
         Vet Micro
        </source>
        <year>
         1992
        </year>
        <volume>
         32
        </volume>
        <fpage>
         117
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0378-1135(92)90100-8
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carvajal
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lanza
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Diego
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Rubio
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Carmenes
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a blocking ELISA using monoclonal antibodies for the detection of porcine epidemic diarrhea virus and its antibodies
        </article-title>
        <source>
         J Vet Diag Invest
        </source>
        <year>
         1995
        </year>
        <volume>
         7
        </volume>
        <fpage>
         60
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/104063879500700109
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Suo
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           Y-S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a porcine epidemic diarrhea virus M protein-based ELISA for virus detection
        </article-title>
        <source>
         Biotechnol Lett
        </source>
        <year>
         2011
        </year>
        <volume>
         33
        </volume>
        <fpage>
         215
        </fpage>
        <lpage>
         220
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10529-010-0420-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         20882317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           X-L
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           L-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and evaluation of enzyme-linked immunosorbent assay based on recombinant nucleocapsid protein for detection of porcine epidemic diarrhea (PEDV) antibodies
        </article-title>
        <source>
         Vet Microbiol
        </source>
        <year>
         2007
        </year>
        <volume>
         123
        </volume>
        <fpage>
         86
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetmic.2007.02.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         17368968
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           PF
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y-W
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Holtkamp
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Opriessnig
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of antibodies against porcine epidemic diarrhea virus in serum and colostrum by indirect ELISA
        </article-title>
        <source>
         Vet J
        </source>
        <year>
         2014
        </year>
        <volume>
         202
        </volume>
        <fpage>
         33
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tvjl.2014.07.018
        </pub-id>
        <pub-id pub-id-type="pmid">
         25135339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Moon
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparison of an enzyme-linked immunosorbent assay with serum neutralization test for serodiagnosis of porcine epidemic diarrhea virus infection
        </article-title>
        <source>
         J Vet Sci
        </source>
        <year>
         2005
        </year>
        <volume>
         6
        </volume>
        <fpage>
         349
        </fpage>
        <lpage>
         352
        </lpage>
        <pub-id pub-id-type="pmid">
         16294000
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Debouck
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine epidemic diarrhea: Kinetics of actively and passively acquired serum antibodies and the effect of reinfection
        </article-title>
        <source>
         Proc Int Pig Vet Soc Congr
        </source>
        <year>
         1984
        </year>
        <volume>
         8
        </volume>
        <fpage>
         53
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lunney
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zuckermann
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Osorio
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Welbon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of an 8-plex Luminex assay to detect swine cytokines for vaccine development: Assessment of immunity after porcine reproductive and respiratory syndrome virus (PRRSV) vaccination
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2010
        </year>
        <volume>
         28
        </volume>
        <fpage>
         5383
        </fpage>
        <lpage>
         5391
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2010.05.016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Langenhorst
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kittawornrat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Zimmerman
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of a fluorescent microsphere immunoassay for detection of antibodies against PRRSV using oral fluid samples as an alternative to serum-based assays
        </article-title>
        <source>
         Clin and Vacc Imm
        </source>
        <year>
         2012
        </year>
        <volume>
         19
        </volume>
        <fpage>
         180
        </fpage>
        <lpage>
         189
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CVI.05372-11
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Validation of serological assays for diagnosis of infectious diseases
        </article-title>
        <source>
         Rev Sci Tech Of Int Epizoot
        </source>
        <year>
         1998
        </year>
        <volume>
         17
        </volume>
        <fpage>
         469
        </fpage>
        <lpage>
         526
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Christopher-Hennings
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Drew
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wensvoort
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Benfield
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differentiation of U.S. and European Isolates of Porcine Reproductive and Respiratory Syndrome Virus by Monoclonal Antibodies
        </article-title>
        <source>
         J Clin Micro
        </source>
        <year>
         1993
        </year>
        <volume>
         31
        </volume>
        <fpage>
         3184
        </fpage>
        <lpage>
         3189
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galfre
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Howe
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Milstein
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Butcher
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies to major histocompatibility antigens produced by hybrid cell lines
        </article-title>
        <source>
         Nature (London)
        </source>
        <year>
         1977
        </year>
        <volume>
         266
        </volume>
        <fpage>
         550
        </fpage>
        <lpage>
         552
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/266550a0
        </pub-id>
        <pub-id pub-id-type="pmid">
         558524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Landis
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         The measurement of observer agreement for categorical data
        </article-title>
        <source>
         Biometrics
        </source>
        <year>
         1977
        </year>
        <volume>
         33
        </volume>
        <fpage>
         159
        </fpage>
        <lpage>
         174
        </lpage>
        <pub-id pub-id-type="doi">
         10.2307/2529310
        </pub-id>
        <pub-id pub-id-type="pmid">
         843571
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kristersson
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Seitzer
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Renneker
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Merza
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and laboratory evaluation of a lateral flow device (LFD) for the serodiagnosis of Theileria annulata infection
        </article-title>
        <source>
         Parasitol Res
        </source>
        <year>
         2010
        </year>
        <volume>
         107
        </volume>
        <fpage>
         1241
        </fpage>
        <lpage>
         1248
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00436-010-1994-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         20680339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Christopher-Hennings
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Araujo
          </surname>
          <given-names>
           KPC
          </given-names>
         </name>
         <name>
          <surname>
           Carlos
          </surname>
          <given-names>
           CJH
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Opportunities for bead-based multiplex assays in veterinary diagnostic laboratories
        </article-title>
        <source>
         J Vet Diagn Invest
        </source>
        <year>
         2013
        </year>
        <volume>
         25
        </volume>
        <fpage>
         671
        </fpage>
        <lpage>
         691
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1040638713507256
        </pub-id>
        <pub-id pub-id-type="pmid">
         24153036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vlasova
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Marthaler
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Culhane
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Rossow
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         <name>
          <surname>
           Rovira
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Distinct characteristics and complex evolution of PEDV Strains, North America, May 2013-February 2014
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1620
        </fpage>
        <lpage>
         1628
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2010.140491
        </pub-id>
        <pub-id pub-id-type="pmid">
         25279722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Scheuer
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of US Porcine Epidemic Diarrhea Virus Strain PC21A in Gnotobiotic Pigs
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         662
        </fpage>
        <lpage>
         665
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2004.131685
        </pub-id>
        <pub-id pub-id-type="pmid">
         24795932
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Lutz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic relationships among homologous structural nucleotide sequences of porcine, feline and canine coronaviruses
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         1982
        </year>
        <volume>
         37
        </volume>
        <fpage>
         1148
        </fpage>
        <lpage>
         1155
        </lpage>
        <pub-id pub-id-type="pmid">
         6182101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yaling
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ederveen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Egberink
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine epidemic diarrhea virus (CV777) and feline infectious peritonitis virus (FIPV) are antigenically related
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         1988
        </year>
        <volume>
         102
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/BF01315563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schrijver
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Kramps
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Critical factors affecting the diagnostic reliability of enzyme-linked immunosorbent assay formats
        </article-title>
        <source>
         Rev Sci Tech Of Int Epizoot
        </source>
        <year>
         1998
        </year>
        <volume>
         17
        </volume>
        <fpage>
         550
        </fpage>
        <lpage>
         561
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus
        </article-title>
        <source>
         Clin Diagn Lab Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         11
        </volume>
        <fpage>
         665
        </fpage>
        <lpage>
         668
        </lpage>
        <pub-id pub-id-type="pmid">
         15242938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Travers
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Walport
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Distribution and Functions of Immunoglobulin Classes
        </article-title>
        <source>
         Janeway’s Immunobiology
        </source>
        <year>
         2008
        </year>
        <edition>
         7
        </edition>
        <publisher-loc>
         New York
        </publisher-loc>
        <publisher-name>
         Garland Science
        </publisher-name>
        <fpage>
         400
        </fpage>
        <lpage>
         401
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       mSphere
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       mSphere
      </journal-id>
      <journal-id journal-id-type="hwp">
       msph
      </journal-id>
      <journal-id journal-id-type="pmc">
       msph
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       mSphere
      </journal-id>
      <journal-title-group>
       <journal-title>
        mSphere
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2379-5042
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30867325
      </article-id>
      <article-id pub-id-type="pmc">
       6416363
      </article-id>
      <article-id pub-id-type="publisher-id">
       mSphere00017-19
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/mSphere.00017-19
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
       <subj-group subj-group-type="overline">
        <subject>
         Clinical Science and Epidemiology
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Evaluation of the Serologic Cross-Reactivity between Transmissible Gastroenteritis Coronavirus and Porcine Respiratory Coronavirus Using Commercial Blocking Enzyme-Linked Immunosorbent Assay Kits
       </article-title>
       <alt-title alt-title-type="running-head">
        Serologic Cross-Reactivity between TGEV and PRCV
       </alt-title>
       <alt-title alt-title-type="short-authors">
        Magtoto et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Magtoto
         </surname>
         <given-names>
          Ronaldo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Poonsuk
         </surname>
         <given-names>
          Korakrit
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="no">
        <name>
         <surname>
          Baum
         </surname>
         <given-names>
          David
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="no">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Jianqiang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="no">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Qi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="no">
        <name>
         <surname>
          Ji
         </surname>
         <given-names>
          Ju
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="no">
        <name>
         <surname>
          Piñeyro
         </surname>
         <given-names>
          Pablo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="no">
        <name>
         <surname>
          Zimmerman
         </surname>
         <given-names>
          Jeffrey
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes" equal-contrib="no">
        <name>
         <surname>
          Giménez-Lirola
         </surname>
         <given-names>
          Luis G.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        <addr-line>
         College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
        </addr-line>
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        <addr-line>
         College of Liberal Arts and Sciences, Iowa State University, Ames, Iowa, USA
        </addr-line>
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Papasian
         </surname>
         <given-names>
          Christopher J.
         </given-names>
        </name>
        <role>
         Editor
        </role>
        <aff>
         UMKC School of Medicine
        </aff>
       </contrib>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Luis G. Giménez-Lirola,
        <email>
         luisggl@iastate.edu
        </email>
        .
       </corresp>
       <fn fn-type="equal">
        <p>
         R.M. and K.P. contributed equally to this article.
        </p>
       </fn>
       <fn fn-type="other">
        <p>
         <bold>
          Citation
         </bold>
         Magtoto R, Poonsuk K, Baum D, Zhang J, Chen Q, Ji J, Piñeyro P, Zimmerman J, Giménez-Lirola LG. 2019. Evaluation of the serologic cross-reactivity between transmissible gastroenteritis coronavirus and porcine respiratory coronavirus using commercial blocking enzyme-linked immunosorbent assay kits. mSphere 4:e00017-19.
         <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mSphere.00017-19">
          https://doi.org/10.1128/mSphere.00017-19
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        13
       </day>
       <month>
        3
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <season>
        Mar-Apr
       </season>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       4
      </volume>
      <issue>
       2
      </issue>
      <elocation-id>
       e00017-19
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         8
        </day>
        <month>
         1
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         28
        </day>
        <month>
         2
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2019 Magtoto et al.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <copyright-holder>
        Magtoto et al.
       </copyright-holder>
       <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open-access article distributed under the terms of the
         <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          Creative Commons Attribution 4.0 International license
         </ext-link>
         .
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="mSphere.00017-19.pdf">
      </self-uri>
      <abstract abstract-type="precis">
       <p>
        Current measures to prevent TGEV from entering a naive herd include quarantine and testing for TGEV-seronegative animals. However, TGEV serology is complicated due to the cross-reactivity with PRCV, which circulates subclinically in most swine herds worldwide. Conventional serological tests cannot distinguish between TGEV and PRCV antibodies; however, blocking ELISAs using antigen containing a large deletion in the amino terminus of the PRCV S protein permit differentiation of PRCV and TGEV antibodies. Several commercial TGEV/PRCV blocking ELISAs are available, but performance comparisons have not been reported in recent research. This study demonstrates that the serologic cross-reactivity between TGEV and PRCV affects the accuracy of commercial blocking ELISAs. Individual test results must be interpreted with caution, particularly in the event of suspect results. Therefore, commercial TGEV/PRCV blocking ELISAs should only be applied on a herd basis.
       </p>
      </abstract>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        This study compared the performances of three commercial transmissible gastroenteritis virus/porcine respiratory coronavirus (TGEV/PRCV) blocking enzyme-linked immunosorbent assays (ELISAs) using serum samples (
        <italic>
         n
        </italic>
        = 528) collected over a 49-day observation period from pigs inoculated with TGEV strain Purdue (
        <italic>
         n
        </italic>
        = 12), TGEV strain Miller (
        <italic>
         n
        </italic>
        = 12), PRCV (
        <italic>
         n
        </italic>
        = 12), or with virus-free culture medium (
        <italic>
         n
        </italic>
        = 12). ELISA results were evaluated both with “suspect” results interpreted as positive and then as negative. All commercial kits showed excellent diagnostic specificity (99 to 100%) when testing samples from pigs inoculated with virus-free culture medium. However, analyses revealed differences between the kits in diagnostic sensitivity (percent TGEV- or PRCV-seropositive pigs), and all kits showed significant (
        <italic>
         P &lt;
        </italic>
        0.05) cross-reactivity between TGEV and PRCV serum antibodies, particularly during early stages of the infections. Serologic cross-reactivity between TGEV and PRCV seemed to be TGEV strain dependent, with a higher percentage of PRCV-false-positive results for pigs inoculated with TGEV Purdue than for TGEV Miller. Moreover, the overall proportion of false positives was higher when suspect results were interpreted as positive, regardless of the ELISA kit evaluated.
       </p>
       <p>
        <bold>
         IMPORTANCE
        </bold>
        Current measures to prevent TGEV from entering a naive herd include quarantine and testing for TGEV-seronegative animals. However, TGEV serology is complicated due to the cross-reactivity with PRCV, which circulates subclinically in most swine herds worldwide. Conventional serological tests cannot distinguish between TGEV and PRCV antibodies; however, blocking ELISAs using antigen containing a large deletion in the amino terminus of the PRCV S protein permit differentiation of PRCV and TGEV antibodies. Several commercial TGEV/PRCV blocking ELISAs are available, but performance comparisons have not been reported in recent research. This study demonstrates that the serologic cross-reactivity between TGEV and PRCV affects the accuracy of commercial blocking ELISAs. Individual test results must be interpreted with caution, particularly in the event of suspect results. Therefore, commercial TGEV/PRCV blocking ELISAs should only be applied on a herd basis.
       </p>
      </abstract>
      <kwd-group>
       <title>
        KEYWORDS
       </title>
       <kwd>
        ELISA
       </kwd>
       <kwd>
        transmissible gastroenteritis virus
       </kwd>
       <kwd>
        antibody
       </kwd>
       <kwd>
        cross-reactivity
       </kwd>
       <kwd>
        porcine respiratory coronavirus
       </kwd>
       <kwd>
        serum
       </kwd>
       <kwd>
        swine
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group id="award1">
        <funding-source>
         <institution-wrap>
          <institution>
           National Pork Board
          </institution>
          <institution-id>
           https://doi.org/10.13039/100008370
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id>
         NPB #15-142
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Giménez-Lirola
          </surname>
          <given-names>
           Luis G.
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <counts>
       <fig-count count="3">
       </fig-count>
       <table-count count="2">
       </table-count>
       <equation-count count="1">
       </equation-count>
       <ref-count count="40">
       </ref-count>
       <page-count count="12">
       </page-count>
       <word-count count="7843">
       </word-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         cover-date
        </meta-name>
        <meta-value>
         March/April 2019
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="s1" sec-type="intro">
     <title>
      INTRODUCTION
     </title>
     <p>
      Transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV) are enveloped single-stranded positive-sense RNA viruses belonging to the
      <named-content content-type="genus-species">
       Alphacoronavirus 1
      </named-content>
      species within the genus
      <named-content content-type="genus-species">
       Alphacoronavirus
      </named-content>
      in the family
      <italic>
       Coronaviridae
      </italic>
      . Transmissible gastroenteritis virus is a highly contagious virus that causes enteric disease characterized by vomiting, severe diarrhea, and high mortality in piglets in TGEV/PRCV-naive herds. The virus was first described by Doyle and Hutchings in 1946 in the United States and subsequently reported worldwide (
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      <xref ref-type="bibr" rid="B2">
       –
      </xref>
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      ). Porcine respiratory coronavirus is a naturally occurring spike gene deletion (170 to 190 kDa) mutant of TGEV first isolated in Belgium in 1984 (
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ). It infects the upper respiratory tract, tonsils, or lungs, with limited intestinal replication (
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ). Porcine respiratory coronavirus itself does not appear to be an important primary pathogen, with the exception of its contribution to the porcine respiratory disease complex (
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ).
     </p>
     <p>
      TGEV and PRCV share biological and molecular features but differ in their epidemiology, clinical presentation, and pathogenesis. Real-time reverse transcription-PCR (rRT-PCR) and multiplex microarray hybridization using primers targeting the 5′ region of the S gene spanning the deletion region in PCRV strain are commonly used for the diagnosis of TGEV and differentiation of TGEV and PRCV (
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      <xref ref-type="bibr" rid="B8">
       –
      </xref>
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ). Serum antibodies provide serological evidence of TGEV or PRCV infection, but PRCV-infected pigs produce antibodies that cross-react and cross-neutralize TGEV, i.e., conventional serological tests cannot differentiate between TGEV- and PRCV-infected animals. This presents a complication for TGEV seroprevalence studies and serological surveys of sows or slaughterhouse swine tested for international trade (
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ).
     </p>
     <p>
      To address the issue of cross-reactivity, monoclonal antibodies targeting antigenic regions of TGEV that have been deleted from the PRCV S protein (
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      <xref ref-type="bibr" rid="B12">
       –
      </xref>
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      ) have been used to develop blocking enzyme-linked immunosorbent assays (ELISAs) for TGEV/PRCV differential serodiagnosis (
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      <xref ref-type="bibr" rid="B18">
       –
      </xref>
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ). Several commercial TGEV/PRCV blocking ELISAs are available, but comparative test performances have not been reported in recent publications. In this study, the diagnostic test performances of three commercial TGEV/PRCV blocking ELISA kits were evaluated using serum samples of precisely known porcine coronavirus immune status.
     </p>
    </sec>
    <sec id="s2" sec-type="results">
     <title>
      RESULTS
     </title>
     <sec id="s2.1">
      <title>
       Clinical observations and virus shedding.
      </title>
      <p>
       Mild watery diarrhea was observed in pigs inoculated with TGEV Miller strain between 2 to 4 days postinoculation (dpi). No clinical signs were observed in pigs from the negative-control, TGEV Purdue, and PRCV-inoculated groups throughout the experiment. All animals survived until the end of the study (42 dpi).
      </p>
      <p>
       All fecal samples collected from pigs in the TGEV strain Purdue, TGEV strain Miller, PRCV-inoculated, and negative-control groups were tested by rRT-PCR and found to be TGEV and PRCV negative prior to the inoculations. Likewise, all oral fluid samples, with the exception of one false-positive (threshold cycle [
       <italic>
        C
        <sub>
         T
        </sub>
       </italic>
       ], 35.5) result in the TGEV Purdue group, were negative before inoculation. The detection of TGEV (S and N genes) and PRCV (N gene) in pen-based feces and oral fluids by rRT-PCR is shown in
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       . Transmissible gastroenteritis virus was detected in feces between 3 and 28 dpi by rRT-PCR in pigs inoculated with TGEV strain Miller (
       <xref ref-type="fig" rid="fig1">
        Fig. 1A
       </xref>
       and
       <xref ref-type="fig" rid="fig1">
        C
       </xref>
       ). No significant fecal shedding was detected in pigs inoculated with TGEV strain Purdue or PRCV throughout the study (
       <xref ref-type="fig" rid="fig1">
        Fig. 1A
       </xref>
       and
       <xref ref-type="fig" rid="fig1">
        C
       </xref>
       ). Viral shedding was specifically detected by rRT-PCR in oral fluid samples collected from pigs inoculated with TGEV strain Purdue (1 to 21 dpi), TGEV strain Miller (1 to 9 dpi), and PRCV (1 to 7 dpi) (
       <xref ref-type="fig" rid="fig1">
        Fig. 1B
       </xref>
       and
       <xref ref-type="fig" rid="fig1">
        D
       </xref>
       ).
      </p>
      <fig id="fig1" orientation="portrait" position="float">
       <label>
        FIG 1
       </label>
       <caption>
        <p>
         Detection of transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV) in pen-based feces and oral fluid samples by TGEV spike (S) and TGEV/PRCV nucleocapsid (N) gene-specific rRT-PCRs, as follows: S gene-specific PCR results in feces samples (A), S gene-specific PCR results in oral fluid samples (B), N gene-specific PCR results in feces samples (C), and N gene-specific PCR results in oral fluid samples (D). Results presented as mean adjusted quantification cycle (
         <italic>
          C
          <sub>
           T
          </sub>
         </italic>
         ) (35 – sample
         <italic>
          C
          <sub>
           T
          </sub>
         </italic>
         ) of positive samples.
        </p>
       </caption>
       <graphic xlink:href="mSphere.00017-19-f0001">
       </graphic>
      </fig>
     </sec>
     <sec id="s2.2">
      <title>
       TGEV antibody response over the course of the experimental inoculation.
      </title>
      <p>
       Serum samples collected from all groups of pigs prior to inoculation were antibody negative for porcine coronaviruses (TGEV, PRCV, porcine epidemic diarrhea virus [PEDV], and porcine delta coronavirus [PDCoV]). All pigs in the negative-control group remained TGEV and PRCV seronegative throughout the monitoring period when tested with any of the three TGEV/PRCV differential blocking ELISA kits evaluated in this study (Swinecheck TGEV/PRCV Recombinant [Biovet], INgezim Corona Diferencial [Ingenasa], and Svanovir TGEV/PRCV-Ab [Svanova] assays).
      </p>
      <p>
       The percentages of TGEV antibody-positive serum samples reported by the three commercial ELISA kits evaluated over the 50-day study period for pigs inoculated with TGEV strains Purdue and Miller are presented in
       <xref ref-type="fig" rid="fig2">
        Fig. 2A
       </xref>
       to
       <xref ref-type="fig" rid="fig2">
        F
       </xref>
       , respectively. Suspect results are presented as positives or negatives. The first TGEV-specific antibody detection was reported between 7 and 10 dpi in both TGEV-inoculated groups (strains Purdue and Miller). The number of TGEV antibody-positive pigs detected increased through the study, regardless of the ELISA kit used.
      </p>
      <fig id="fig2" orientation="portrait" position="float">
       <label>
        FIG 2
       </label>
       <caption>
        <p>
         TGEV antibody detection rate (%) of the 3 commercial TGEV/PRCV blocking ELISA kits evaluated in this study, Swinecheck TGEV/PRCV Recombinant (Biovet, Canada) (A, D, and G), INgezim Corona Diferencial (Ingenasa, Spain) (B, E, and H), and Svanovir TGEV/PRCV-Ab (Svanova, Sweden) (C, F, and I). Results are presented considering suspect results to be positive (red bars) or negative (green bars).
        </p>
       </caption>
       <graphic xlink:href="mSphere.00017-19-f0002">
       </graphic>
      </fig>
      <p>
       For the TGEV Purdue inoculation group, no significant differences (
       <italic>
        P &gt;
       </italic>
       0.05) were found in the percentages of TGEV-seropositive pigs reported by the three ELISAs regardless of the time postinoculation and interpretation of suspect results. In contrast, for the TGEV Miller inoculation group, we found that a significantly higher (
       <italic>
        P &lt;
       </italic>
       0.05) percentage of TGEV-seropositive animals was detected by the Swinecheck TGEV/PRCV Recombinant ELISA than by both the INgezim Corona Diferencial ELISA (dpi 10) and Svanovir TGEV/PRCV-Ab ELISA (10, 17, and 21 dpi) only when suspect results were interpreted as negative.
      </p>
      <p>
       A nonspecific TGEV antibody response to PRCV-inoculated pigs was reported by the three ELISA kits between 7 and 42 dpi (
       <xref ref-type="fig" rid="fig2">
        Fig. 2G
       </xref>
       to
       <xref ref-type="fig" rid="fig2">
        I
       </xref>
       ). No significant differences in the percentages of TGEV false positives were found between ELISAs over the monitoring period when TGEV suspect results were interpreted as negative (
       <italic>
        P &gt;
       </italic>
       0.05). However, the overall proportion of false positives was higher when suspect results were interpreted as positive, regardless of the ELISA kit evaluated. Moreover, the percentage of TGEV-false-positive results reported by the Svanovir TGEV/PRCV-Ab ELISA was significantly greater (
       <italic>
        P &lt;
       </italic>
       0.05) than those obtained with the Swinecheck TGEV/PRCV Recombinant ELISA (14, 21, and 35 dpi) and INgezim Corona Diferencial ELISA (21 to 35 dpi).
      </p>
     </sec>
     <sec id="s2.3">
      <title>
       PRCV antibody response over the course of the experimental inoculation.
      </title>
      <p>
       With the exception of one false-positive result reported (42 dpi) by the INgezim Corona Diferencial ELISA kit, the negative-control group remained seronegative for PRCV by the three commercial ELISAs throughout the study.
      </p>
      <p>
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       shows the percentage of PRCV serum samples detected by the three commercial ELISAs in PRCV-inoculated (specific detection;
       <xref ref-type="fig" rid="fig3">
        Fig. 3G
       </xref>
       to
       <xref ref-type="fig" rid="fig3">
        I
       </xref>
       ) and TGEV-inoculated (nonspecific detection;
       <xref ref-type="fig" rid="fig3">
        Fig. 3A
       </xref>
       to
       <xref ref-type="fig" rid="fig3">
        F
       </xref>
       ) animals over the course of the study.
      </p>
      <fig id="fig3" orientation="portrait" position="float">
       <label>
        FIG 3
       </label>
       <caption>
        <p>
         Porcine respiratory coronavirus (PRCV) antibody detection rate (%) of the 3 commercial TGEV/PRCV blocking ELISA kits evaluated in this study, Swinecheck TGEV/PRCV Recombinant (Biovet, Canada) (A, D, and G), INgezim Corona Diferencial (Ingenasa, Spain) (B, E, and H), and Svanovir TGEV/PRCV-Ab (Svanova, Sweden) (C, F, and I). Results are presented considering suspect results to be positive (red bars) or negative (green bars).
        </p>
       </caption>
       <graphic xlink:href="mSphere.00017-19-f0003">
       </graphic>
      </fig>
      <p>
       On PRCV-inoculated animals, an early PRCV-specific antibody response was first detected at 7 to 10 dpi by the three commercial ELISAs and lasted through 42 dpi (
       <xref ref-type="fig" rid="fig3">
        Fig. 3G
       </xref>
       to
       <xref ref-type="fig" rid="fig3">
        I
       </xref>
       ). An analysis of the proportion of PRCV-seropositive animals showed significant differences between ELISA kits over time following PRCV inoculation, regardless of the interpretation of suspect results (
       <italic>
        P &lt;
       </italic>
       0.05). The percentage of PRCV-seropositive animals detected by the Svanovir TGEV/PRCV-Ab ELISA was significantly lower than those with both the Swinecheck TGEV/PRCV Recombinant ELISA (dpi 14 to 35) and INgezim Corona Diferencial ELISA (dpi 17 to 21 and 28) (
       <italic>
        P &lt;
       </italic>
       0.05). No differences were found between the Swinecheck TGEV/PRCV Recombinant and INgezim Corona Diferencial ELISAs.
      </p>
      <p>
       On TGEV-inoculated animals, a nonspecific PRCV serum antibody response was detected by the three commercial ELISAs. This serologic cross-reactivity seemed to be TGEV strain dependent, with a higher percentage of PRCV-false-positive results in the TGEV strain Purdue-inoculated group (
       <xref ref-type="fig" rid="fig3">
        Fig. 3A
       </xref>
       to
       <xref ref-type="fig" rid="fig3">
        C
       </xref>
       ) than in the TGEV strain Miller group (
       <xref ref-type="fig" rid="fig3">
        Fig. 3D
       </xref>
       to
       <xref ref-type="fig" rid="fig3">
        F
       </xref>
       ). The cross-reactivity appeared more marked at early stages postexposure (7 to 14 dpi). No differences were found between ELISA kits over the course of the study, except at 7 dpi when the proportion of PRCV-false-positive animals detected by the Svanovir TGEV/PRCV-Ab ELISA was significantly greater (
       <italic>
        P &lt;
       </italic>
       0.05) than that by the INgezim Corona Diferencial ELISA regardless of the interpretation of suspect results.
      </p>
     </sec>
     <sec id="s2.4">
      <title>
       Comparative diagnostic performance of the TGEV/PRCV differential ELISAs.
      </title>
      <p>
       The analytical specificity and diagnostic sensitivity and specificity of the three commercial differential TGEV/PRCV ELISA kits evaluated in this study are presented in
       <xref ref-type="table" rid="tab1">
        Table 1
       </xref>
       . Diagnostic parameters are presented relative to the interpretation of suspect results as positive or negative.
      </p>
      <table-wrap id="tab1" orientation="portrait" position="float">
       <label>
        TABLE 1
       </label>
       <caption>
        <p>
         Estimated diagnostic sensitivity, diagnostic specificity, and analytical specificity of the 3 commercial TGEV/PRCV blocking ELISA kits evaluated in this study
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
        </colgroup>
        <thead>
         <tr>
          <th colspan="1" rowspan="3">
           Parameter
          </th>
          <th colspan="1" rowspan="3">
           Group
          </th>
          <th colspan="6" rowspan="1">
           % (95 confidence interval [%]) by assay and suspect result categorization
           <hr/>
          </th>
         </tr>
         <tr>
          <th colspan="3" rowspan="1">
           Suspect results as positive
           <hr/>
          </th>
          <th colspan="3" rowspan="1">
           Suspect results as negative
           <hr/>
          </th>
         </tr>
         <tr>
          <th colspan="1" rowspan="1">
           Swinecheck
          </th>
          <th colspan="1" rowspan="1">
           INgezim
          </th>
          <th colspan="1" rowspan="1">
           Svanovir
          </th>
          <th colspan="1" rowspan="1">
           Swinecheck
          </th>
          <th colspan="1" rowspan="1">
           INgezim
          </th>
          <th colspan="1" rowspan="1">
           Svanovir
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="1" rowspan="4">
           Diagnostic sensitivity
           <xref ref-type="table-fn" rid="ngtab1.1">
            <sup>
             <italic>
              a
             </italic>
            </sup>
           </xref>
          </td>
          <td colspan="1" rowspan="1">
           TGEV Purdue
          </td>
          <td colspan="1" rowspan="1">
           65 (63, 95)
          </td>
          <td colspan="1" rowspan="1">
           65 (49, 81)
          </td>
          <td colspan="1" rowspan="1">
           79 (61, 90)
          </td>
          <td colspan="1" rowspan="1">
           51 (36, 70)
          </td>
          <td colspan="1" rowspan="1">
           54 (38, 72)
          </td>
          <td colspan="1" rowspan="1">
           50 (33, 67)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           TGEV Miller
          </td>
          <td colspan="1" rowspan="1">
           94 (81, 99)
          </td>
          <td colspan="1" rowspan="1">
           93 (81, 99)
          </td>
          <td colspan="1" rowspan="1">
           78 (60, 89)
          </td>
          <td colspan="1" rowspan="1">
           94 (81, 99)
          </td>
          <td colspan="1" rowspan="1">
           82 (67, 94)
          </td>
          <td colspan="1" rowspan="1">
           54 (38, 72)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           TGEV
           <xref ref-type="table-fn" rid="ngtab1.4">
            <sup>
             <italic>
              d
             </italic>
            </sup>
           </xref>
          </td>
          <td colspan="1" rowspan="1">
           80 (64, 92)
          </td>
          <td colspan="1" rowspan="1">
           79 (64, 92)
          </td>
          <td colspan="1" rowspan="1">
           78 (60, 89)
          </td>
          <td colspan="1" rowspan="1">
           73 (55, 86)
          </td>
          <td colspan="1" rowspan="1">
           68 (64, 92)
          </td>
          <td colspan="1" rowspan="1">
           53 (36, 70)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           PRCV
          </td>
          <td colspan="1" rowspan="1">
           86 (71, 95)
          </td>
          <td colspan="1" rowspan="1">
           85 (71, 95)
          </td>
          <td colspan="1" rowspan="1">
           28 (14, 15)
          </td>
          <td colspan="1" rowspan="1">
           86 (71, 95)
          </td>
          <td colspan="1" rowspan="1">
           81 (64, 92)
          </td>
          <td colspan="1" rowspan="1">
           28 (14, 15)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="2">
           Diagnostic specificity
           <xref ref-type="table-fn" rid="ngtab1.2">
            <sup>
             <italic>
              b
             </italic>
            </sup>
           </xref>
          </td>
          <td colspan="1" rowspan="1">
           TGEV
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           PRCV
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           99 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           99 (90, 100)
          </td>
          <td colspan="1" rowspan="1">
           100 (90, 100)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="4">
           Analytical specificity
           <xref ref-type="table-fn" rid="ngtab1.3">
            <sup>
             <italic>
              c
             </italic>
            </sup>
           </xref>
          </td>
          <td colspan="1" rowspan="1">
           TGEV Purdue
          </td>
          <td colspan="1" rowspan="1">
           63 (46, 79)
          </td>
          <td colspan="1" rowspan="1">
           70 (52, 83)
          </td>
          <td colspan="1" rowspan="1">
           71 (52, 84)
          </td>
          <td colspan="1" rowspan="1">
           63 (46, 79)
          </td>
          <td colspan="1" rowspan="1">
           70 (52, 84)
          </td>
          <td colspan="1" rowspan="1">
           72 (55, 86)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           TGEV Miller
          </td>
          <td colspan="1" rowspan="1">
           91 (78, 98)
          </td>
          <td colspan="1" rowspan="1">
           95 (81, 99)
          </td>
          <td colspan="1" rowspan="1">
           76 (58, 88)
          </td>
          <td colspan="1" rowspan="1">
           92 (78, 98)
          </td>
          <td colspan="1" rowspan="1">
           95 (81, 99)
          </td>
          <td colspan="1" rowspan="1">
           84 (67, 94)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           TGEV
           <xref ref-type="table-fn" rid="ngtab1.4">
            <sup>
             <italic>
              d
             </italic>
            </sup>
           </xref>
          </td>
          <td colspan="1" rowspan="1">
           77 (61, 90)
          </td>
          <td colspan="1" rowspan="1">
           82 (67, 94)
          </td>
          <td colspan="1" rowspan="1">
           73 (55, 86)
          </td>
          <td colspan="1" rowspan="1">
           77 (61, 90)
          </td>
          <td colspan="1" rowspan="1">
           82 (67, 94)
          </td>
          <td colspan="1" rowspan="1">
           78 (61, 90)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           PRCV
          </td>
          <td colspan="1" rowspan="1">
           82 (67, 94)
          </td>
          <td colspan="1" rowspan="1">
           84 (67, 94)
          </td>
          <td colspan="1" rowspan="1">
           39 (23, 57)
          </td>
          <td colspan="1" rowspan="1">
           87 (71, 95)
          </td>
          <td colspan="1" rowspan="1">
           93 (78, 98)
          </td>
          <td colspan="1" rowspan="1">
           95 (81, 99)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn fn-type="other" id="ngtab1.1">
         <label>
          a
         </label>
         <p>
          The diagnostic sensitivity of each kit was calculated according to diagnosed and true statuses of each group on dpi 14 to 42 (considered positive status).
         </p>
        </fn>
        <fn fn-type="other" id="ngtab1.2">
         <label>
          b
         </label>
         <p>
          The diagnostic specificity of each test was calculated according to diagnosed TGEV or PRCV status in the negative-control group on dpi −7 and 42.
         </p>
        </fn>
        <fn fn-type="other" id="ngtab1.3">
         <label>
          c
         </label>
         <p>
          The analytical specificity of each test was calculated according to TGEV or PRCV status across groups between dpi 7 and 42.
         </p>
        </fn>
        <fn fn-type="other" id="ngtab1.4">
         <label>
          d
         </label>
         <p>
          Combined results from pigs inoculated with both TGEV Purdue and Miller strains.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       Overall, the diagnostic sensitivity for the TGEV Miller inoculation group was higher than for the TGEV Purdue group, independent of the commercial ELISA kit evaluated. The Swinecheck TGEV/PRCV Recombinant ELISA kit showed the highest diagnostic sensitivity for antibody detection in pigs inoculated with TGEV strain Miller (94%), regardless of the interpretation of suspect results. The diagnostic sensitivity for the TGEV strain Purdue-inoculated group was higher with the Svanovir TGEV/PRCV-Ab ELISA kit (79%) when suspect results were considered positive, while it was slightly higher with the INgezim Corona Diferencial ELISA kit (54%) when suspect results were interpreted as negative.
      </p>
      <p>
       The diagnostic sensitivities for PRCV antibody detection obtained with both Swinecheck TGEV/PRCV Recombinant ELISA (86%) and INgezim Corona Diferencial ELISA (81 to 85%) were greater than that of the Svanovir TGEV/PRCV-Ab ELISA kit (28%). With the exception of the INgezim Corona Diferencial ELISA, the diagnostic sensitivity calculated for each ELISA kit was not affected by the interpretation of suspect results (positive versus negative).
      </p>
      <p>
       The three commercial ELISAs showed 100% diagnostic specificity for both TGEV and PRCV detection, with the exception for one PRCV-false-positive result reported by the INgezim Corona Diferencial ELISA, which resulted in a diagnostic specificity of 99.2% for PRCV detection. The diagnostic specificity of any of the evaluated ELISA kits was unaffected by the interpretation of suspect results.
      </p>
      <p>
       The INgezim Corona Diferencial ELISA kit showed the highest analytical specificity (less cross-reactivity) for TGEV-specific antibody detection (82.3%). For all three commercial ELISAs, we found higher cross-reactivity to PRCV within the TGEV Purdue inoculation group than in the TGEV Miller group. The highest analytical specificity for PRCV was obtained with the INgezim Corona Diferencial ELISA (84%) when suspect results were interpreted as positive or with the Svanovir TGEV/PRCV-Ab ELISA kit (95%) when suspect results were interpreted as negative; however, the Svanovir TGEV/PRCV-Ab ELISA kit showed the lowest analytical specificity (39%) of the kits when suspect results were interpreted as positive.
      </p>
     </sec>
    </sec>
    <sec id="s3" sec-type="discussion">
     <title>
      DISCUSSION
     </title>
     <p>
      The greatest risk of introducing TGEV is through the importation of pigs from endemically infected countries. Seronegative pigs of all ages are susceptible to infection with TGEV (
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22">
       22
      </xref>
      ), with the route of infection typically being oral or oral-nasal (
      <xref ref-type="bibr" rid="B23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B24">
       24
      </xref>
      ). To prevent TGEV from entering a naive herd, it is important to introduce only animals from TGEV-free and serologically negative herds, along with disciplined biosecurity. Therefore, quarantine and testing for TGEV-seronegative animals are requirements for export/import into a herd. Moreover, the detection of TGEV antibodies, particularly in reproductive animals, can assist in diagnosis and control of the disease. However, TGEV serology is complicated by cross-reactivity with PRCV (
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ), an S protein deletion mutant of TGEV with altered tissue tropism (nonenteropathogenic but respiratory) that circulates subclinically in most swine herds worldwide (
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ). This cross-reactivity may explain why a region endemic for PRCV has less TGEV-associated disease (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ). Porcine respiratory coronavirus does not cause significant losses in swine except for its contribution to the porcine respiratory disease complex. Historically, PRCV diagnosis was based on recognition of respiratory disease in growing pigs that have high antibody titers to TGEV but have had no clinical enteric disease or lesions of atrophic enteritis. Conventional serological tests, such as virus neutralization, indirect fluorescent antibody, agar-gel precipitation, indirect immunoperoxidase, radioimmunoprecipitation, and some ELISAs based on polyclonal TGEV antibodies, cannot be used for differentiation between TGEV and PRCV, because the two viruses share antigenic determinants located on the spike (S), membrane (M), nucleoprotein (N), and envelope (E) structural proteins (
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      ). The exception is a large deletion (227 amino acids in length) in the amino terminus of the PRCV S protein that is responsible for the loss of hemagglutination activity (
      <xref ref-type="bibr" rid="B29">
       29
      </xref>
      ). This deletion provided the opportunity to develop blocking enzyme-linked immunosorbent assays for differentiation of PRCV and TGEV infections and laid the basis for the commercial TGEV/PRCV differential ELISAs that are currently available (
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      <xref ref-type="bibr" rid="B18">
       –
      </xref>
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ). Few field reports have described the use of TGEV/PRCV blocking ELISAs to differentiate antibodies to TGEV and PRCV and their utility at the herd level (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="B31">
       31
      </xref>
      ). However, no previous reports have compared the diagnostic performances of different commercially available TGEV/PRCV blocking ELISAs. In this study, we assessed and compared the diagnostic performances (sensitivity, specificity, and cross-reactivity) of three commercial differential TGEV/PRCV blocking ELISA kits (i.e., Swinecheck TGEV/PRCV Recombinant ELISA [Biovet, Canada]; INgezim Corona Diferencial ELISA [Ingenasa, Spain]; and Svanovir TGEV/PRCV-Ab ELISA kit [Svanova, Sweden]) at the individual pig level using experimental samples of precisely known porcine coronavirus immune status. The use of samples with the same disease/immune status allowed for accurate interpretation of test results, including those that were discordant or unexpected.
     </p>
     <p>
      Molecular diagnostic methods (e.g.,
      <italic>
       in situ
      </italic>
      hybridization and multiplex rRT-PCR) targeting both the conserved and PRCV deletion regions are utilized to differentiate TGEV and PRCV in infected pigs (
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="B33">
       33
      </xref>
      ). Specimens primarily used for TGEV virus detection include feces and intestinal contents, and those for PRCV detection include nasal swabs or lung homogenates. In this study, the verification and monitoring of the TGEV or PRCV viral shedding status were performed using rRT-PCR testing of pen-based feces and oral fluids. This process provided further information on the dynamics of viral shedding in feces versus oral fluids. Viral shedding was detected in both feces and oral fluids. However, for pigs inoculated with PRCV and, interestingly, for TGEV Purdue, virus shedding was only detected in oral fluids. This could be related to differences in pathogenicity and tissue tropism, which were beyond the scope of this study. These results indicated that oral fluids may replace feces as a more suitable specimen for direct detection and surveillance of TGEV/PRCV by rRT-PCR.
     </p>
     <p>
      Overall, we observed differences in the test performances of the three commercial ELISA kits evaluated in this study. However, the differences were more marked for the Svanovir TGEV/PRCV-Ab ELISA kit, compared to either the Swinecheck TGEV/PRCV Recombinant ELISA or the INgezim Corona Diferencial ELISA, for which test performance was comparable. This could be due to differences/similarities in assay design. For instance, both the Swinecheck TGEV/PRCV Recombinant ELISA and the INgezim Corona Diferencial ELISA use a TGEV recombinant S protein antigen on a plate, while the Svanovir TGEV/PRCV-Ab ELISA claims to use noninfectious TGEV antigen of an unknown source, which could detect antibodies to a variety of viral proteins. The way the antigen is presented may also affect assay performance. The antigen can either be bound directly to the plate wells (as in the Swinecheck TGEV/PRCV Recombinant ELISA and Svanovir TGEV/PRCV-Ab ELISA) or may be captured by antigen-specific antibodies immobilized on the plate (as in the INgezim Corona Diferencial ELISA). In addition, the Svanovir TGEV/PRCV-Ab ELISA is the only kit using unlabeled TGEV and TGEV/PRCV mouse monoclonal antibodies (MAbs), which requires an additional incubation step with anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody. Undisclosed differences in buffer composition could also be involved in the differences in assay performance among the kits.
     </p>
     <p>
      All three ELISA kits showed higher diagnostic sensitivity in the detection of anti-TGEV antibodies in pigs inoculated with TGEV strain Miller (77.9 to 94.4%) than in pigs inoculated with TGEV strain Purdue (65.3 to 78.9%), regardless of the kit used. The differences in diagnostic sensitivity among TGEV-inoculated groups could be due to strain-related differences in virulence, which may have impacted the magnitude of the immune response. Indeed, in this study, pigs inoculated with TGEV strain Miller showed mild watery diarrhea between 2 and 4 dpi, while no clinical signs or viral shedding in feces were observed in the pigs inoculated with TGEV Purdue.
     </p>
     <p>
      The diagnostic specificity of the three commercial ELISA kits was evaluated on pigs of precisely known negative porcine coronavirus immune status (i.e., the porcine coronavirus negative-control group) to rule out potential cross-reactivity with other porcine coronaviruses (i.e., pigs virologically and serologically negative for PEDV, PDCoV, porcine hemagglutinating encephalomyelitis virus [PHEV], TGEV, and PRCV). All three kits evaluated in this study showed excellent diagnostic specificity, ranging from 99% (Svanovir TGEV/PRCV-Ab ELISA) to 100% (Swinecheck TGEV/PRCV Recombinant ELISA and INgezim Corona Diferencial ELISA). These results were consistent with previous reports in the field where a TGEV/PRCV blocking ELISA (i.e., Swinecheck and Biovet) showed a diagnostic specificity of 100% in wild boar populations historically free from coronavirus disease (
      <xref ref-type="bibr" rid="B34">
       34
      </xref>
      ). With the final goal of maximizing both diagnostic sensitivity and specificity (but understanding that there is a balance between the two parameters), diagnostic specificity is of paramount importance during TGEV/PRCV screening due to the impact of false-positive results on global pig trade operations. The false-positive rate of any diagnostic test is a function of the specificity of the test and the prevalence of the disease.
     </p>
     <p>
      The assessment of the selectivity of the antigen-antibody response (analytical specificity) was conducted on each of the three commercial blocking ELISAs using a panel of heterologous monotypic known-status-positive sera generated under experimental conditions. Specifically, in this study, the analysis of the analytical specificity was circumscribed to the cross-reactivity between TGEV (strains Purdue and Miller) and PRCV. However, the potential cross-reactivity between TGEV/PRCV against other swine coronaviruses has previously been reported (
      <xref ref-type="bibr" rid="B35">
       35
      </xref>
      ). A test was considered analytically specific for TGEV or PRCV when it did not react against heterologous positive sera. As with the diagnostic sensitivity, the overall analytical specificity varied among and across kits and groups of inoculation, even with intrakit variations depending upon the interpretation of suspect results. Serological cross-reactivity between TGEV and PRCV was previously reported by use of an immunoblotting assay based on TGEV/PRCV structural proteins (S, M, and N) and polyclonal antisera (
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      ). This study further confirms that the serological cross-reactivity between TGEV and PRCV is significant even when using TGEV/PRCV differential blocking ELISAs. Overall, in this study, we observed a poor analytical specificity (i.e., high cross-reactivity) for PRCV antibody detection in pigs exposed to TGEV strain Purdue (63 to 72%), with no significant differences among kits. However, with the exception of the Svanovir TGEV/PRCV-Ab ELISA (76 to 84%), we found an acceptable analytical specificity for PRCV antibody detection in pigs exposed to TGEV Miller using the Swinecheck TGEV/PRCV Recombinant ELISA (91 to 92%) and the INgezim Corona Diferencial ELISA (95%). Current TGEV/PRCV differential immunoassays are based on a blocking ELISA format, which is inherently more specific than indirect ELISAs. In the blocking ELISA format, the degree to which specific antibodies in the test serum sample prevent binding of an agent-specific MAb is measured. Therefore, the higher the levels of specific antibodies are in a serum sample, the lower the likelihood for cross-reactivity. In fact, the overall higher TGEV antibody detection rate observed within the group inoculated with TGEV strain Miller correlates with the lower cross-reactivity against PRCV. That would also explain the overall higher rate of serologic cross-reactivity (regardless of the ELISA kit used) reported during the first few weeks postinoculation, when specific antibody levels are still low.
     </p>
     <p>
      Previous reports indicated that the accuracy of the commercial TGEV/PRCV blocking ELISAs for differentiating between U.S. TGEV and PRCV strains was low (
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ). Individual test results must be interpreted with caution, particularly in the event of “suspect” results. We have demonstrated that interpretation of suspect results can impact significantly the diagnostic performance of any of the commercial kits evaluated in this study, with differences in their robustness in response to changes in the interpretation of suspect results. While analytical specificity improved overall when suspect results were interpreted as negative, this often comes at the cost of diagnostic sensitivity. In the event of suspect, undetermined, or unexpected positive results, it is recommended that serology testing on paired serum samples be conducted, in which a second sample should be drawn 10 to 14 days after the first sample collection. Paired serum samples should be tested together to maximize the diagnostic value of test results. Moreover, false-positive results reported at early stages postexposure (when animals are actively shedding virus) could be confirmed by rRT-PCR on oral fluid specimens, as evidenced in this study.
     </p>
     <p>
      The presence of TGEV remains a barrier to international livestock trade (
      <xref ref-type="bibr" rid="B36">
       36
      </xref>
      ). The blocking ELISA format alone was determined to be useful in large swine populations for the detection of TGEV-infected herds. Moreover, the ability to specifically detect PRCV antibodies minimized the probability of false-positive TGEV results and subsequent exclusion of those herds for trading. However, this study demonstrates that the serologic cross-reactivity between TGEV and PRCV at the individual pig level affects the accuracy of commercial blocking ELISAs. Therefore, it is important to remember that the TGEV/PRCV blocking ELISAs should only be applied on a herd basis (
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ).
     </p>
    </sec>
    <sec id="s4" sec-type="materials|methods">
     <title>
      MATERIALS AND METHODS
     </title>
     <sec id="s4.1">
      <title>
       Experimental design.
      </title>
      <p>
       “Known-status” serum samples (
       <italic>
        n
       </italic>
       = 528) collected from pigs experimentally inoculated with TGEV Purdue (
       <italic>
        n
       </italic>
       = 12), TGEV Miller (
       <italic>
        n
       </italic>
       = 12), PRCV (
       <italic>
        n
       </italic>
       = 12), or with culture medium (minimum essential medium [MEM] Life Technologies, Carlsbad, CA) (negative control;
       <italic>
        n
       </italic>
       = 12) were used to evaluate the diagnostic performance (diagnostic sensitivity and specificity) and antibody cross-reactivity (analytical specificity) of the following three commercial TGEV/PRCV blocking ELISAs: (i) Swinecheck TGEV/PRCV Recombinant (Biovet, Canada), (ii) INgezim Corona Diferencial (Ingenasa, Spain), and (iii) Svanovir TGEV/PRCV-Ab (Svanova, Sweden). Commercial ELISAs were performed and the test results interpreted according to the manufacturer’s instructions.
      </p>
     </sec>
     <sec id="s4.2">
      <title>
       Viral inoculum.
      </title>
      <p>
       Swine testicle (ST) cell culture adapted to TGEV Purdue (ATCC VR-763), TGEV Miller (ATCC VR-1740), and PRCV (ATCC VR-2384) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). In brief, ST cells (ATCC CRL-1746) were cultured in 25-cm
       <sup>
        2
       </sup>
       flasks (Corning, Corning, NY) using MEM (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies), 2 mM
       <sc>
        l
       </sc>
       -glutamine (Sigma-Aldrich, St. Louis, MO), 0.05 mg/ml gentamicin (Life Technologies), 10 units/ml penicillin (Life Technologies), 10 µg/ml streptomycin (Sigma-Aldrich), and 0.25 µg/ml amphotericin (Sigma-Aldrich). At 100% confluence of the cell monolayer, the maintenance medium was decanted, and the monolayer was washed twice with maintenance medium. Thereafter, each flask of cells was inoculated with 500 µl of each virus mixed with postinoculation medium, i.e., MEM supplemented with 0.3% tryptose phosphate broth (Sigma-Aldrich) and 0.02% yeast extract (Sigma-Aldrich). The cells were incubated at 37°C with 5% CO
       <sub>
        2
       </sub>
       for 2 h to allow virus adsorption. After incubation, 5 ml of postinoculation medium was added to each flask without removing viral inoculum. The flasks were incubated at 37°C with 5% CO
       <sub>
        2
       </sub>
       and subjected to one freeze-thaw cycle at −80°C when 80% cytopathic effect (CPE) was observed. Cell debris was removed by centrifugation at 3,000 ×
       <italic>
        g
       </italic>
       for 10 min at 4°C, and the virus content was harvested by collecting the supernatant. Virus titration was performed on confluent ST cell monolayers grown in 96-well plates (Costar; Corning) using a method described elsewhere (
       <xref ref-type="bibr" rid="B37">
        37
       </xref>
       ).
      </p>
     </sec>
     <sec id="s4.3">
      <title>
       Animals.
      </title>
      <p>
       The animal study was conducted at the Iowa State University (ISU) Livestock Infection Disease Isolation Facility (LIDIF) with the approval of the Iowa State University Office for Responsible Research. Forty-eight 7-week-old conventional pigs were acquired from a commercial wean-to-finish farm with no history of porcine coronavirus infection. During the herd prescreening process and prior to the beginning of the study, fecal and nasal swabs from all animals were tested for TGEV, PRCV, porcine hemagglutinating encephalomyelitis virus (PHEV), porcine epidemic diarrhea virus (PEDV), and porcine delta coronavirus (PDCoV) by real-time reverse transcription-PCR (rRT-PCR) assays. Serum samples were tested for all of the pathogens listed above using antibody-based methods, as described elsewhere (
       <xref ref-type="bibr" rid="B38">
        38
       </xref>
       <xref ref-type="bibr" rid="B39">
        –
       </xref>
       <xref ref-type="bibr" rid="B40">
        40
       </xref>
       ).
      </p>
      <p>
       Upon arrival, all animals were ear-tagged and randomly assigned to one of four inoculation groups (
       <italic>
        n
       </italic>
       = 12 per group in the TGEV Miller, TGEV Purdue, PRCV, and negative-control groups). Pigs within each group were housed in pens of 2 pigs in the same room. Each pen was equipped with nipple drinkers, and pigs were fed twice daily with an antibiotic-free commercial diet (Heartland Co-op, West Des Moines, IA, USA). Details regarding viral dose and route of inoculation for each group are presented in
       <xref ref-type="table" rid="tab2">
        Table 2
       </xref>
       . The infectious dose used for each virus was previously determined in a pilot study (data not shown) with the objective of stimulating a humoral response effectively. Pigs were evaluated clinically twice daily throughout the study. The TGEV and PRCV infectious status of every pig was established and monitored throughout the study by rRT-PCR tests on fecal and oral fluid samples and ELISA-based tests on serum samples.
      </p>
      <table-wrap id="tab2" orientation="portrait" position="float">
       <label>
        TABLE 2
       </label>
       <caption>
        <p>
         TGEV and PRCV strains used, inoculum doses, and routes of inoculation
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
        </colgroup>
        <thead>
         <tr>
          <th colspan="1" rowspan="2">
           Inoculation group
          </th>
          <th colspan="1" rowspan="2">
           Strain
          </th>
          <th colspan="1" rowspan="2">
           GenBank accession no.
          </th>
          <th colspan="2" rowspan="1">
           Virus propagation
           <hr/>
          </th>
          <th colspan="4" rowspan="1">
           Inocula (per pig)
           <hr/>
          </th>
         </tr>
         <tr>
          <th colspan="1" rowspan="1">
           Cell line
          </th>
          <th colspan="1" rowspan="1">
           Virus passage no.
          </th>
          <th colspan="1" rowspan="1">
           Virus titer (TCID
           <sub>
            50
           </sub>
           /ml)
           <xref ref-type="table-fn" rid="ngtab2.1">
            <sup>
             <italic>
              a
             </italic>
            </sup>
           </xref>
          </th>
          <th colspan="1" rowspan="1">
           Virus culture vol (ml)
          </th>
          <th colspan="1" rowspan="1">
           Total vol (ml)
           <xref ref-type="table-fn" rid="ngtab2.2">
            <sup>
             <italic>
              b
             </italic>
            </sup>
           </xref>
          </th>
          <th colspan="1" rowspan="1">
           Inoculation route
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="1" rowspan="1">
           TGEV Miller
          </td>
          <td colspan="1" rowspan="1">
           ATCC VR-1740
          </td>
          <td colspan="1" rowspan="1">
           <ext-link assigning-authority="genbank" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/DQ811785">
            DQ811785
           </ext-link>
          </td>
          <td colspan="1" rowspan="1">
           Swine testicle (ATCC CRL-1746)
          </td>
          <td colspan="1" rowspan="1">
           16
          </td>
          <td colspan="1" rowspan="1">
           4.0 × 10
           <sup>
            6
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           35
          </td>
          <td colspan="1" rowspan="1">
           40
          </td>
          <td colspan="1" rowspan="1">
           Orogastric
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           TGEV Purdue
          </td>
          <td colspan="1" rowspan="1">
           ATCC VR-763
          </td>
          <td colspan="1" rowspan="1">
           <ext-link assigning-authority="genbank" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/DQ811789">
            DQ811789
           </ext-link>
          </td>
          <td colspan="1" rowspan="1">
           Swine testicle (ATCC CRL-1746)
          </td>
          <td colspan="1" rowspan="1">
           12
          </td>
          <td colspan="1" rowspan="1">
           2.4 × 10
           <sup>
            8
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           30
          </td>
          <td colspan="1" rowspan="1">
           35
          </td>
          <td colspan="1" rowspan="1">
           Orogastric
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           PRCV
          </td>
          <td colspan="1" rowspan="1">
           ATCC VR-2384
          </td>
          <td colspan="1" rowspan="1">
           <ext-link assigning-authority="genbank" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/DQ811787">
            DQ811787
           </ext-link>
          </td>
          <td colspan="1" rowspan="1">
           Swine testicle (ATCC CRL-1746)
          </td>
          <td colspan="1" rowspan="1">
           18
          </td>
          <td colspan="1" rowspan="1">
           4.0 × 10
           <sup>
            5
           </sup>
          </td>
          <td colspan="1" rowspan="1">
           15
          </td>
          <td colspan="1" rowspan="1">
           20
          </td>
          <td colspan="1" rowspan="1">
           Nasal (10 ml per nostril)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Sham (culture medium)
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           20
          </td>
          <td colspan="1" rowspan="1">
           Oronasal
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn fn-type="other" id="ngtab2.1">
         <label>
          a
         </label>
         <p>
          TCID
          <sub>
           50
          </sub>
          , 50% tissue culture infectious dose.
         </p>
        </fn>
        <fn fn-type="other" id="ngtab2.2">
         <label>
          b
         </label>
         <p>
          TGEV strains were mixed with milk replacer (Esbilac; PetAg, Inc., Hampshire, IL) or culture medium (PRCV).
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec id="s4.4">
      <title>
       Sample collection.
      </title>
      <p>
       Blood samples were collected on −7, 0, 3, 7, 10, 14, 17, 21, 28, 35, and 42 days postinoculation (dpi) from the jugular vein or cranial vena cava using a single-use blood collection system (Becton Dickinson, Franklin Lakes, NJ) and serum separation tubes (Kendall, Mansfield, MA). Serum was separated by centrifugation at 1,500 ×
       <italic>
        g
       </italic>
       for 5 min, aliquoted into 2-ml cryogenic tubes (Greiner Bio-One GmbH, Frickenhausen, Germany), and stored at −80°C until use.
      </p>
      <p>
       Floor fecal samples were collected daily from each pen (2 pigs per pen) within each inoculation group (6 pens per group) from −7 to 42 dpi. Approximately 2 ml of feces was placed in a 2-ml cryogenic tube (BD Falcon). Fecal samples (100 µl) from each group on the same day postinoculation were pooled into a 2-ml cryogenic tube (BD Falcon) at the end of the study for rRT-PCR testing.
      </p>
      <p>
       Oral fluid samples were collected from each pen within each inoculation group twice a day (7:00 a.m. and 1:00 p.m.) from −7 to 42 dpi. In brief, 3-strand 1.6-cm 100% cotton rope (Web Rigging Supply, Inc., Carrollton, GA) was hung from a bracket fixed to one side of each pen for 30 min, during which time the pigs chewed on and interacted with the rope. After 30 min, the wet end of the rope was severed, sealed in a plastic bag, and then passed through a clothes wringer (Dyna-Jet, Overland Park, KS). The oral fluid accumulated in the bottom of the bag was decanted into 50-ml conical tubes (Corning), aliquoted into 2-ml cryogenic tubes (Greiner Bio-One GmbH), and stored at −80°C.
      </p>
     </sec>
     <sec id="s4.5">
      <title>
       Real-time reverse transcription-PCR.
      </title>
      <p>
       Feces and oral fluid samples were submitted to the ISU Veterinary Diagnostic Library (VDL) for porcine coronavirus screening by rRT-PCR. Transmissible gastroenteritis virus-specific spike (S) and TGEV/PRCV-specific nucleocapsid (N) genes were targeted and amplified by dually labeled probe-based rRT-PCR. In brief, sample RNA was extracted and eluted using the Ambion MagMAX viral RNA isolation kit (Life Technologies) and a KingFisher 96 magnetic particle processor (Thermo Fisher Scientific) following the procedures provided by the manufacturers. The TGEV S gene and the TGEV/PRCV N gene-based rRT-PCR were modified from previous procedures (
       <xref ref-type="bibr" rid="B40">
        40
       </xref>
       ) and performed routinely at the ISU-VDL using the TaqMan Fast 1-step mastermix (Thermo Fisher Scientific). The RT-PCRs were conducted on an ABI 7500 Fast instrument (Life Technologies) as follows: 50°C for 5 min, 95°C for 20 s, 95°C for 3 s (40 cycles), and 60°C for 30 s. The rRT-PCR results were analyzed using an automatic baseline, with a threshold value of 0.1. A quantification cycle (
       <italic>
        C
        <sub>
         T
        </sub>
       </italic>
       ) value of &lt;35 was considered positive for both S and N gene-based rRT-PCR. Samples were considered positive for TGEV when both S and N genes were rRT-PCR positive. For PRCV, samples were considered positive when the S gene rRT-PCR was negative and the N gene rRT-PCR was positive. Transmissible gastroenteritis virus and PRCV
       <italic>
        C
        <sub>
         T
        </sub>
       </italic>
       data were reported as “adjusted
       <italic>
        C
        <sub>
         T
        </sub>
       </italic>
       ,” calculated as shown in the following equation:
       <disp-formula id="uFD1">
        <alternatives>
         <graphic orientation="portrait" position="float" xlink:href="mSphere.00017-19-m0001.jpg">
         </graphic>
         <mml:math id="um1">
          <mml:mrow>
           <mml:mtext>
            Adjusted
           </mml:mtext>
           <mml:mo>
           </mml:mo>
           <mml:msub>
            <mml:mrow>
             <mml:mi>
              C
             </mml:mi>
            </mml:mrow>
            <mml:mrow>
             <mml:mi>
              T
             </mml:mi>
            </mml:mrow>
           </mml:msub>
           <mml:mo>
            =
           </mml:mo>
           <mml:mrow>
            <mml:mo stretchy="true">
             (
            </mml:mo>
            <mml:mrow>
             <mml:mtext>
              cutoff
             </mml:mtext>
             <mml:mo>
             </mml:mo>
             <mml:msub>
              <mml:mrow>
               <mml:mi>
                C
               </mml:mi>
              </mml:mrow>
              <mml:mrow>
               <mml:mi>
                T
               </mml:mi>
              </mml:mrow>
             </mml:msub>
             <mml:mo>
             </mml:mo>
             <mml:mtext>
              value
             </mml:mtext>
             <mml:mo>
              −
             </mml:mo>
             <mml:mtext>
              sample
             </mml:mtext>
             <mml:mo>
             </mml:mo>
             <mml:msub>
              <mml:mrow>
               <mml:mi>
                C
               </mml:mi>
              </mml:mrow>
              <mml:mrow>
               <mml:mi>
                T
               </mml:mi>
              </mml:mrow>
             </mml:msub>
             <mml:mo>
             </mml:mo>
             <mml:mtext>
              value
             </mml:mtext>
            </mml:mrow>
            <mml:mo stretchy="true">
             )
            </mml:mo>
           </mml:mrow>
          </mml:mrow>
         </mml:math>
        </alternatives>
       </disp-formula>
      </p>
     </sec>
     <sec id="s4.6">
      <title>
       TGEV/PRCV differential blocking ELISAs.
      </title>
      <p>
       Serum samples were tested for TGEV- and PRCV-specific antibodies using the following three commercially available TGEV/PRCV differential blocking ELISA kits: (i) Swinecheck TGEV/PRCV Recombinant (Biovet, Canada), (ii) INgezim Corona Diferencial (Ingenasa, Spain), and (iii) Svanovir TGEV/PRCV-Ab (Svanova, Sweden). All assays were performed according to the manufacturers’ instructions. The pig serum samples and controls were first added to the TGEV antigen-coated wells for the first incubation step. In the INgezim Corona Diferencial ELISA, plate wells are coated with a recombinant TGEV S protein which is captured by a specific monoclonal antibody (MAb). The Swinecheck TGEV/PRCV Recombinant ELISA is also based on a recombinant TGEV S protein but directly coated on plate wells, while the Svanovir TGEV/PRCV-Ab ELISA uses noninfectious TGEV antigen (source unknown) as a coating antigen. If anti-TGEV or anti-PRCV antibodies are present in the test sample, they will bind to the viral (TGEV) antigen in the wells and block the antigenic sites. In contrast, if anti-TGEV or anti-PRCV antibodies are absent in the test sample, these sites will remain free. Then, after a washing step to eliminate unbound antibodies, a horseradish peroxidase (HRP)-conjugated mouse anti-TGEV MAb targeting the N-terminal region of the S glycoprotein that is deleted in PRCV, or an anti-TGEV/PRCV MAb that binds to conserved regions of both TGEV and PRCV, is added into the first well (odd column) or second well (even column), respectively, and attaches to specific free sites of the virus. Thus, when antibodies in the test sample occupy the binding sites on the antigen, the binding of the conjugated MAbs is blocked. If anti-TGEV or anti-PRCV antibodies are absent in the test sample, these sites will remain free. The amount of antibody in the test sample that is bound to the TGEV antigen is inversely proportional to the intensity of the color. Antibody ELISA results were expressed as the percentage of inhibition (Swinecheck TGEV/PRCV and Svanovir TGEV/PRCV-Ab) or optical density (INgezim Corona Diferencial) and interpreted (positive, negative, or suspect/inconclusive) for TGEV and PRCV according to the manufacturers’ instructions. The diagnostic sensitivity, diagnostic specificity, and analytical specificity of the three commercial ELISAs were calculated based on the true status of the samples compared to the specific detection of TGEV (Miller and/or Purdue) and/or PRCV antibodies. Specifically, porcine coronavirus-negative serum samples (
       <italic>
        n
       </italic>
       = 204) were used to estimate diagnostic specificity for the three ELISA kits. Serum samples positive for TGEV (Purdue and Miller strains) (
       <italic>
        n
       </italic>
       = 144) collected between 14 and 42 dpi and PRCV-positive samples (
       <italic>
        n
       </italic>
       = 72) collected between 14 and 42 dpi were used to calculate the time of detection, antibody detection over time, and the overall diagnostic sensitivity of the three ELISA kits for TGEV and PRCV Ab detection, respectively.
      </p>
     </sec>
     <sec id="s4.7">
      <title>
       Data analysis.
      </title>
      <p>
       Analyses were conducted using commercial statistical software (SAS version 6.1.7601; Microsoft Corporation, USA). The percentage of results for TGEV/PRCV ELISA were interpreted (positive, negative, or suspect) according to the manufacturer’s recommendations. The percentage of seropositive animals per day postinoculation detected by each kit were analyzed in two ways, by considering suspect results to be positive or by considering suspect results to be negative. Significant differences (
       <italic>
        P &lt;
       </italic>
       0.05) in ELISA-positive rates relative to TGEV (Purdue or Miller strains) and PRCV were calculated using Pearson’s chi-square test or Fisher’s exact test. The diagnostic sensitivity and specificity of the three commercial ELISAs were evaluated based on experimental serum samples of precisely known porcine coronavirus immune status (i.e., samples collected on &lt;7 dpi were negative, and serum samples collected on &gt;7 dpi were positive). Analytical specificity (bidirectional cross-reactivity) between TGEV versus PRCV was evaluated using samples (
       <italic>
        n
       </italic>
       = 288) collected between 7 and 42 dpi from animals inoculated with TGEV strain Purdue (
       <italic>
        n
       </italic>
       = 96), TGEV strain Miller (
       <italic>
        n
       </italic>
       = 96), and PRCV (
       <italic>
        n
       </italic>
       = 96) in each given case. Figures were created using commercial graphics software (SigmaPlot version 12.5; Systat Software, Inc.).
      </p>
     </sec>
    </sec>
    <back>
     <ack>
      <title>
       ACKNOWLEDGMENTS
      </title>
      <p>
       This work was funded in part through the Iowa Pork Producers Association through the National Pork Board (Pork Checkoff Funds, grant 15-142; Des Moines, IA) and the Iowa State University Veterinary Diagnostic Laboratory (Ames, IA).
      </p>
      <p>
       The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.
      </p>
      <p>
       We declare no conflicting interests with respect to authorship or the publication of this article.
      </p>
     </ack>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="B1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Doyle
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hutchings
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
        </person-group>
        <year>
         1946
        </year>
        <article-title>
         A transmissible gastroenteritis in pigs
        </article-title>
        .
        <source>
         J Am Vet Med Assoc
        </source>
        <volume>
         108
        </volume>
        :
        <fpage>
         257
        </fpage>
        –
        <lpage>
         259
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21020443
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Van der Zeijst
          </surname>
          <given-names>
           BAM
          </given-names>
         </name>
        </person-group>
        <year>
         1995
        </year>
        <chapter-title>
         Molecular basis of transmissible gastroenteritis virus epidemiology
        </chapter-title>
        ,
        <fpage>
         337
        </fpage>
        –
        <lpage>
         376
        </lpage>
        .
        <italic>
         In
        </italic>
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Siddell
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
        </person-group>
        (ed),
        <source>
         The Coronaviridae
        </source>
        .
        <publisher-name>
         Plenum Press
        </publisher-name>
        ,
        <publisher-loc>
         New York, NY
        </publisher-loc>
        .
       </mixed-citation>
      </ref>
      <ref id="B3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sestak
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         2008
        </year>
        <chapter-title>
         Porcine coronaviruses
        </chapter-title>
        <italic>
         In
        </italic>
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Morilla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yoon
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zimmerman
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        (ed),
        <source>
         Trends in emerging viral infections of swine
        </source>
        .
        <publisher-name>
         Iowa State Press
        </publisher-name>
        ,
        <publisher-loc>
         Ames, IA
        </publisher-loc>
        .
       </mixed-citation>
      </ref>
      <ref id="B4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pensaert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Callebaut
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vergote
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <year>
         1986
        </year>
        <article-title>
         Isolation of a porcine respiratory, non-enteric coronavirus related to transmissible gastroenteritis
        </article-title>
        .
        <source>
         Vet Q
        </source>
        <volume>
         8
        </volume>
        :
        <fpage>
         257
        </fpage>
        –
        <lpage>
         261
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1080/01652176.1986.9694050
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         3018993
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cox
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <year>
         1989
        </year>
        <article-title>
         Porcine respiratory coronavirus related to transmissible gastroenteritis virus
        </article-title>
        .
        <source>
         Agri-Practice
        </source>
        <volume>
         10
        </volume>
        :
        <fpage>
         17
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Opriessnig
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Giménez-Lirola
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Halbur
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <year>
         2011
        </year>
        <article-title>
         Polymicrobial respiratory disease in pigs
        </article-title>
        .
        <source>
         Anim Health Res Rev
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         133
        </fpage>
        –
        <lpage>
         148
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1017/S1466252311000120
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22152290
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Costantini
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lewis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alsop
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Templeton
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         2004
        </year>
        <article-title>
         Respiratory and fecal shedding of porcine respiratory coronavirus (PRCV) in sentinel weaned pigs and sequence of the partial S-gene of the PRCV isolates
        </article-title>
        .
        <source>
         Arch Virol
        </source>
        <volume>
         149
        </volume>
        :
        <fpage>
         957
        </fpage>
        –
        <lpage>
         974
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s00705-003-0245-z
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         15098110
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chang
          </surname>
          <given-names>
           KO
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sestak
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Parwani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         2000
        </year>
        <article-title>
         Development of a reverse transcription-nested polymerase chain reaction assay for differential diagnosis of transmissible gastroenteritis virus and porcine respiratory coronavirus from feces and nasal swabs of infected pigs
        </article-title>
        .
        <source>
         J Vet Diagn Invest
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         385
        </fpage>
        –
        <lpage>
         388
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1177/104063870001200418
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10907874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hayes
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lewis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Parwani
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chang
          </surname>
          <given-names>
           KO
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         2000
        </year>
        <article-title>
         Molecular characterization and pathogenesis of transmissible gastroenteritis coronavirus (TGEV) and porcine respiratory coronavirus (PRCV) field isolates co-circulating in a swine herd
        </article-title>
        .
        <source>
         Arch Virol
        </source>
        <volume>
         145
        </volume>
        :
        <fpage>
         1133
        </fpage>
        –
        <lpage>
         1147
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s007050070114
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10948987
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ogawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Taira
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hirai
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Takeuchi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nagao
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ishikawa
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tuchiya
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nunoya
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ueda
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <year>
         2009
        </year>
        <article-title>
         Multiplex PCR and multiplex RT-PCR for inclusive detection of major swine DNA and RNA viruses in pigs with multiple infections
        </article-title>
        .
        <source>
         J Virol Methods
        </source>
        <volume>
         160
        </volume>
        :
        <fpage>
         210
        </fpage>
        –
        <lpage>
         214
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jviromet.2009.05.010
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         19467264
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Callebaut
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Correa
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pensaert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jiménez
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <year>
         1988
        </year>
        <article-title>
         Antigenic differentiation between transmissible gastroenteritis virus of swine and a related porcine respiratory coronavirus
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <volume>
         69
        </volume>
        :
        <fpage>
         1725
        </fpage>
        –
        <lpage>
         1730
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-69-7-1725
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         2839605
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Delmas
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Laude
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <year>
         1990
        </year>
        <article-title>
         Assembly of coronavirus spike protein into trimers and its role in epitope expression
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         64
        </volume>
        :
        <fpage>
         5367
        </fpage>
        –
        <lpage>
         5375
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2170676
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sánchez
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jiménez
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Laviada
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Correa
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Suñé
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bullido
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gebauer
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smerdou
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Callebaut
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Escribano
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <year>
         1990
        </year>
        <article-title>
         Antigenic homology among coronaviruses related to transmissible gastroenteritis virus
        </article-title>
        .
        <source>
         Virology
        </source>
        <volume>
         174
        </volume>
        :
        <fpage>
         410
        </fpage>
        –
        <lpage>
         417
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0042-6822(90)90094-8
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         1689525
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sestak
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Meister
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hayes
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lewis
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Myers
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         1999
        </year>
        <article-title>
         Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins
        </article-title>
        .
        <source>
         Vet Immunol Immunopathol
        </source>
        <volume>
         70
        </volume>
        :
        <fpage>
         203
        </fpage>
        –
        <lpage>
         221
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0165-2427(99)00074-4
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10507362
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sestak
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shoup
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         1999
        </year>
        <article-title>
         Evaluation of the baculovirus-expressed S glycoprotein of transmissible gastroenteritis virus (TGEV) as antigen in a competition ELISA to differentiate porcine respiratory coronavirus from TGEV antibodies in pigs
        </article-title>
        .
        <source>
         J Vet Diagn Invest
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         205
        </fpage>
        –
        <lpage>
         214
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1177/104063879901100301
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10353350
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Simkins
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Weilnau
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bias
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         1992
        </year>
        <article-title>
         Antigenic variation among transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus strains detected with monoclonal antibodies to the S protein of TGEV
        </article-title>
        .
        <source>
         Am J Vet Res
        </source>
        <volume>
         53
        </volume>
        :
        <fpage>
         1253
        </fpage>
        –
        <lpage>
         1258
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1379786
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Simkins
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Weilnau
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Van Cott
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Brim
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         1993
        </year>
        <article-title>
         Competition ELISA, using monoclonal antibodies to the transmissible gastroenteritis virus (TGEV) S protein, for serologic differentiation of pigs infected with TGEV or porcine respiratory coronavirus
        </article-title>
        .
        <source>
         Am J Vet Res
        </source>
        <volume>
         54
        </volume>
        :
        <fpage>
         254
        </fpage>
        –
        <lpage>
         259
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8381626
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bernard
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bottreau
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Aynaud
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Have
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Szymansky
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <year>
         1989
        </year>
        <article-title>
         Natural infection with the porcine respiratory coronavirus induces protective lactogenic immunity against transmissible gastroenteritis
        </article-title>
        .
        <source>
         Vet Microbiol
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         8
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0378-1135(89)90013-8
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         2560280
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Callebaut
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hooyberghs
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <year>
         1989
        </year>
        <article-title>
         A competitive inhibition ELISA for the differentiation of serum antibodies from pigs infected with transmissible gastroenteritis virus (TGEV) or with the TGEV-related porcine respiratory coronavirus
        </article-title>
        .
        <source>
         Vet Microbiol
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         9
        </fpage>
        –
        <lpage>
         19
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0378-1135(89)90003-5
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         2548322
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Garwes
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Stewart
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cartwright
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Brown
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <year>
         1988
        </year>
        <article-title>
         Differentiation of porcine coronavirus from transmissible gastroenteritis virus
        </article-title>
        .
        <source>
         Vet Rec
        </source>
        <volume>
         122
        </volume>
        :
        <fpage>
         86
        </fpage>
        –
        <lpage>
         87
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1136/vr.122.4.86
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         2451340
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Frederick
          </surname>
          <given-names>
           GT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bohl
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cross
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
        </person-group>
        <year>
         1976
        </year>
        <article-title>
         Pathogenicity of an attenuated strain of transmissible gastroenteritis virus for newborn pigs
        </article-title>
        .
        <source>
         Am J Vet Res
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         165
        </fpage>
        –
        <lpage>
         169
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         176906
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Turgeon
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Morin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jolette
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Higgins
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Marsolais
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           DiFranco
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <year>
         1980
        </year>
        <article-title>
         Coronavirus-like particles associated with diarrhea in baby pigs in Quebec
        </article-title>
        .
        <source>
         Can Vet J
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         100
        </fpage>
        –
        <lpage>
         xxiii
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7363267
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Underdahl
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mebus
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Torres-Medina
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <year>
         1975
        </year>
        <article-title>
         Recovery of transmissible gastroenteritis virus from chronically infected experimental pigs
        </article-title>
        .
        <source>
         Am J Vet Res
        </source>
        <volume>
         36
        </volume>
        :
        <fpage>
         1473
        </fpage>
        –
        <lpage>
         1476
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         171980
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cox
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Callebaut
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <year>
         1993
        </year>
        <article-title>
         Intestinal protection against challenge with transmissible gastroenteritis virus of pigs immune after infection with the porcine respiratory coronavirus
        </article-title>
        .
        <source>
         Vaccine
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         267
        </fpage>
        –
        <lpage>
         272
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0264-410X(93)90028-V
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         8382421
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sestak
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yeo
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <chapter-title>
         Coronaviruses
        </chapter-title>
        , p
        <fpage>
         501
        </fpage>
        –
        <lpage>
         524
        </lpage>
        .
        <italic>
         In
        </italic>
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Zimmerman
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Karriker
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ramirez
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schwartz
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Stevenson
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
        </person-group>
        (ed),
        <source>
         Diseases of swine
        </source>
        ,
        <edition>
         10th ed
        </edition>
        <publisher-name>
         John Wiley &amp; Sons
        </publisher-name>
        ,
        <publisher-loc>
         Chichester, United Kingdom
        </publisher-loc>
        .
       </mixed-citation>
      </ref>
      <ref id="B26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oh
          </surname>
          <given-names>
           YI
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cho
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kang
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Choi
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hyun
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
        </person-group>
        <year>
         2011
        </year>
        <article-title>
         Sero-surveillance of transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV) in South Korea
        </article-title>
        .
        <source>
         J Bacteriol Virol
        </source>
        <volume>
         41
        </volume>
        :
        <fpage>
         189
        </fpage>
        –
        <lpage>
         193
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.4167/jbv.2011.41.3.189
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="B27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sánchez
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gebauer
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Suñé
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mendez
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dopazo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <year>
         1992
        </year>
        <article-title>
         Genetic evolution and tropism of transmissible gastroenteritis coronaviruses
        </article-title>
        .
        <source>
         Virology
        </source>
        <volume>
         190
        </volume>
        :
        <fpage>
         92
        </fpage>
        –
        <lpage>
         105
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0042-6822(92)91195-Z
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         1326823
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Godet
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           L’Haridon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vautherot
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Laude
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <year>
         1992
        </year>
        <article-title>
         TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions
        </article-title>
        .
        <source>
         Virology
        </source>
        <volume>
         188
        </volume>
        :
        <fpage>
         666
        </fpage>
        –
        <lpage>
         675
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0042-6822(92)90521-P
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         1316677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schultze
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Krempl
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ballesteros
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shaw
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schauer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Herrler
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <year>
         1996
        </year>
        <article-title>
         Transmissible gastroenteritis coronavirus, but not the related porcine respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) binding activity
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         70
        </volume>
        :
        <fpage>
         5634
        </fpage>
        –
        <lpage>
         5637
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8764078
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chae
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Min
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Choi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cho
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <year>
         2000
        </year>
        <article-title>
         Seroprevalence of porcine respiratory coronavirus in selected Korean pigs
        </article-title>
        .
        <source>
         Prev Vet Med
        </source>
        <volume>
         46
        </volume>
        :
        <fpage>
         293
        </fpage>
        –
        <lpage>
         296
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0167-5877(00)00154-9
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10960715
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Carman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Josephson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McEwen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Maxie
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Antochi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Eernisse
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nayar
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Halbur
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Erickson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nilsson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <year>
         2002
        </year>
        <article-title>
         Field validation of a commercial blocking ELISA to differentiate antibody to transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus and to identify TGEV-infected swine herds
        </article-title>
        .
        <source>
         J Vet Diagn Invest
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         97
        </fpage>
        –
        <lpage>
         105
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1177/104063870201400202
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         11939346
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Paton
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ibata
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sands
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McGoldrick
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <year>
         1997
        </year>
        <article-title>
         Detection of transmissible gastroenteritis virus by RT-PCR and differentiation from porcine respiratory coronavirus
        </article-title>
        .
        <source>
         J Virol Methods
        </source>
        <volume>
         66
        </volume>
        :
        <fpage>
         303
        </fpage>
        –
        <lpage>
         309
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0166-0934(97)00055-4
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         9255741
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sirinarumitr
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paul
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kluge
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Halbur
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <year>
         1996
        </year>
        <article-title>
         In situ hybridization technique for the detection of swine enteric and respiratory coronaviruses, transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV), in formalin-fixed paraffin-embedded tissues
        </article-title>
        .
        <source>
         J Virol Methods
        </source>
        <volume>
         56
        </volume>
        :
        <fpage>
         149
        </fpage>
        –
        <lpage>
         160
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/0166-0934(95)01901-4
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         8882645
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hälli
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ala-Kurikka
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nokireki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Skrzypczak
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Raunio-Saarnisto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Peltoniemi
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heinonen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         Prevalence of and risk factors associated with viral and bacterial pathogens in farmed European wild boar
        </article-title>
        .
        <source>
         Vet J
        </source>
        <volume>
         194
        </volume>
        :
        <fpage>
         98
        </fpage>
        –
        <lpage>
         101
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.tvjl.2012.03.008
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22516920
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Oka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vlasova
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Esseili
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Antigenic relationships among porcine epidemic diarrhea virus and transmissible gastroenteritis virus strains
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         89
        </volume>
        :
        <fpage>
         3332
        </fpage>
        –
        <lpage>
         3342
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/JVI.03196-14
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25589635
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mullan
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Davies
          </surname>
          <given-names>
           GT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cutler
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <year>
         1994
        </year>
        <article-title>
         Simulation of the economic impact of transmissible gastroenteritis on commercial pig production in Australia
        </article-title>
        .
        <source>
         Aust Vet J
        </source>
        <volume>
         71
        </volume>
        :
        <fpage>
         151
        </fpage>
        –
        <lpage>
         154
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/j.1751-0813.1994.tb03370.x
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         8067950
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Reed
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muench
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <year>
         1938
        </year>
        <article-title>
         A simple method of estimating fifty per cent endpoints
        </article-title>
        .
        <source>
         Am J Epidemiol
        </source>
        <volume>
         27
        </volume>
        :
        <fpage>
         493
        </fpage>
        –
        <lpage>
         497
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1093/oxfordjournals.aje.a118408
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="B38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Madson
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Magstadt
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Arruda
          </surname>
          <given-names>
           PHE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hoang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bower
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bhandari
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Burrough
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gauger
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pillatzki
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Stevenson
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wilberts
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Brodie
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Harmon
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Main
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yoon
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Pathogenesis of porcine epidemic diarrhea virus isolate (US/Iowa/18984/2013) in 3-week-old weaned pigs
        </article-title>
        .
        <source>
         Vet Microbiol
        </source>
        <volume>
         174
        </volume>
        :
        <fpage>
         60
        </fpage>
        –
        <lpage>
         68
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.vetmic.2014.09.002
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25278366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gimenez-Lirola
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Carrillo-Avila
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Magtoto
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poonsuk
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baum
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Piñeyro
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zimmerman
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <year>
         2017
        </year>
        <article-title>
         Reactivity of porcine epidemic diarrhea virus structural proteins to antibodies against porcine enteric coronaviruses: diagnostic implications
        </article-title>
        .
        <source>
         J Clin Microbiol
        </source>
        <volume>
         55
        </volume>
        :
        <fpage>
         1426
        </fpage>
        –
        <lpage>
         1436
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/JCM.02507-16
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         28202790
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pyo
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tark
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hyun
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
        </person-group>
        <year>
         2007
        </year>
        <article-title>
         Multiplex real-time RT-PCR for the simultaneous detection and quantification of transmissible gastroenteritis virus and porcine epidemic diarrhea virus
        </article-title>
        .
        <source>
         J Virol Methods
        </source>
        <volume>
         146
        </volume>
        :
        <fpage>
         172
        </fpage>
        –
        <lpage>
         177
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jviromet.2007.06.021
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         17697717
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Diagn Microbiol Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Diagn. Microbiol. Infect. Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        Diagnostic Microbiology and Infectious Disease
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0732-8893
      </issn>
      <issn pub-type="epub">
       1879-0070
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28821364
      </article-id>
      <article-id pub-id-type="pmc">
       7127792
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0732-8893(17)30221-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.diagmicrobio.2017.07.006
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Ko
         </surname>
         <given-names>
          Jae-Hoon
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="fn" rid="fn0005">
         1
        </xref>
        <xref ref-type="fn" rid="fn0010">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          Marcel A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
        <xref ref-type="fn" rid="fn0005">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Seok
         </surname>
         <given-names>
          Hyeri
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          Ga Eun
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0025">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          Ji Yeon
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0030">
        <name>
         <surname>
          Cho
         </surname>
         <given-names>
          Sun Young
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0035">
        <name>
         <surname>
          Ha
         </surname>
         <given-names>
          Young Eun
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0040">
        <name>
         <surname>
          Baek
         </surname>
         <given-names>
          Jin Yang
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0045">
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          So Hyun
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0050">
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          Ji-Man
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0025">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0055">
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          Yae-Jean
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0025">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0060">
        <name>
         <surname>
          Jo
         </surname>
         <given-names>
          Ik Joon
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0030">
         f
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0065">
        <name>
         <surname>
          Chung
         </surname>
         <given-names>
          Chi Ryang
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0035">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0070">
        <name>
         <surname>
          Hahn
         </surname>
         <given-names>
          Myong-Joon
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0040">
         h
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0075">
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          Christian
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0080">
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          Cheol-In
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0085">
        <name>
         <surname>
          Chung
         </surname>
         <given-names>
          Doo Ryeon
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0090">
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          Jae-Hoon
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0095">
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          Eun-Suk
         </given-names>
        </name>
        <email>
         eskang@skku.edu
        </email>
        <xref ref-type="aff" rid="af0045">
         i
        </xref>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
        <xref ref-type="fn" rid="fn0015">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0100">
        <name>
         <surname>
          Peck
         </surname>
         <given-names>
          Kyong Ran
         </given-names>
        </name>
        <email>
         krpeck@skku.edu
        </email>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="corresp" rid="cr0010">
         ⁎⁎
        </xref>
        <xref ref-type="fn" rid="fn0015">
         3
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       <label>
        a
       </label>
       Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
      </aff>
      <aff id="af0010">
       <label>
        b
       </label>
       Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany
      </aff>
      <aff id="af0015">
       <label>
        c
       </label>
       German Centre for Infection Research, Germany
      </aff>
      <aff id="af0020">
       <label>
        d
       </label>
       Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea
      </aff>
      <aff id="af0025">
       <label>
        e
       </label>
       Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
      </aff>
      <aff id="af0030">
       <label>
        f
       </label>
       Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
      </aff>
      <aff id="af0035">
       <label>
        g
       </label>
       Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
      </aff>
      <aff id="af0040">
       <label>
        h
       </label>
       Department of Molecular Cell Biology, Center for Molecular Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea
      </aff>
      <aff id="af0045">
       <label>
        i
       </label>
       Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author. Tel.: +82-2-3410-2703; fax: +82-2-3410-2719.
        <email>
         eskang@skku.edu
        </email>
       </corresp>
       <corresp id="cr0010">
        <label>
         ⁎⁎
        </label>
        Corresponding author. Tel.: +82-2-3410-0329; fax: +82-2-3410-0064.
        <email>
         krpeck@skku.edu
        </email>
       </corresp>
       <fn id="fn0005">
        <label>
         1
        </label>
        <p id="np0020">
         These authors contributed equally to this article as first authors.
        </p>
       </fn>
       <fn id="fn0010">
        <label>
         2
        </label>
        <p id="np0025">
         Present address: Division of Infectious Diseases, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea.
        </p>
       </fn>
       <fn id="fn0015">
        <label>
         3
        </label>
        <p id="np0030">
         These corresponding authors contributed equally to this article.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        14
       </day>
       <month>
        7
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        10
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        14
       </day>
       <month>
        7
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       89
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       106
      </fpage>
      <lpage>
       111
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         4
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         5
        </day>
        <month>
         7
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         7
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2017 Elsevier Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <p>
        We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively;
        <italic>
         P
        </italic>
        = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (
        <italic>
         P
        </italic>
        = 0.003).
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="ab0010">
       <title>
        Highlights
       </title>
       <p>
        <list id="l0005" list-type="simple">
         <list-item id="li0005">
          <label>
           •
          </label>
          <p id="p0005">
           Serologic responses of 42 MERS-CoV-infected patients were evaluated.
          </p>
         </list-item>
         <list-item id="li0010">
          <label>
           •
          </label>
          <p id="p0010">
           Patients were divided into 4 disease severity groups.
          </p>
         </list-item>
         <list-item id="li0015">
          <label>
           •
          </label>
          <p id="p0015">
           The seroconversion rate gradually increased with increasing disease severity.
          </p>
         </list-item>
         <list-item id="li0020">
          <label>
           •
          </label>
          <p id="p0020">
           Seventy-five percent of deceased patients did not show seroconversion by the third week.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="ks0005">
       <title>
        Keywords
       </title>
       <kwd>
        Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        Prognosis
       </kwd>
       <kwd>
        Antibody
       </kwd>
       <kwd>
        Serologic response
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0025">
      Since the first reported case of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 (
      <xref ref-type="bibr" rid="bb0115">
       Zaki et al., 2012
      </xref>
      ), small and large outbreaks have occurred, resulting in 1917 MERS-CoV infections and 677 related deaths to date (
      <xref ref-type="bibr" rid="bb0110">
       WHO, 2017
      </xref>
      ). To understand this fatal respiratory viral infection, several serologic investigations have been conducted (
      <xref ref-type="bibr" rid="bb0030">
       Corman et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0070">
       Min et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0095">
       Park et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0100">
       Payne et al., 2016
      </xref>
      ). However, practical analysis of serodiagnostic parameters for clinical usage was limited in previous studies, due to insufficient sample size or clinical information. We managed 45 MERS-CoV-infected patients, which is the largest number of patients as a single center during the 2015 Korean MERS outbreak (total 186 patients identified) (
      <xref ref-type="bibr" rid="bb0015">
       Cho et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0045">
       Kim et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0090">
       Park et al., 2016
      </xref>
      ), and reported that MERS-CoV-infected patients experienced 4 distinct clinical courses, ranging from asymptomatic infection to severe pneumonia requiring mechanical ventilation (
      <xref ref-type="bibr" rid="bb0055">
       Ko et al., 2016
      </xref>
      ). Based on these findings, we evaluated serologic response of 42 MERS-CoV-infected patients according to the disease severity to investigate potential role of serodiagnostic parameters as prognostic markers.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Material and methods
     </title>
     <sec id="s0015">
      <label>
       2.1
      </label>
      <title>
       Study population and samples
      </title>
      <p id="p0030">
       Among 45 MERS-CoV-infected patients who were admitted to Samsung Medical Center, a 1950-bed tertiary care university hospital, during the 2015 Korean MERS outbreak (
       <xref ref-type="bibr" rid="bb0055">
        Ko et al., 2016
       </xref>
       ), we obtained sera from 42 patients. MERS-CoV infections were confirmed on the basis of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays targeting upstream of the E gene (upE) and the open-reading frame gene 1a (ORF1a) (
       <xref ref-type="bibr" rid="bb0035">
        Corman et al., 2012a
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0060">
        Madani, 2014
       </xref>
       ). Epidemiologic investigation data and electronic medical records were reviewed to obtain exact exposure date, symptom onset, clinical course, and outcome data for the patients. One or 2 residual serum samples per week of illness were used for serologic testing during hospitalization periods. Follow-up serum samples obtained at outpatient clinics were also tested up to 6 months from symptom onset. The institutional review board of Samsung Medical Center approved the present study.
      </p>
     </sec>
     <sec id="s0020">
      <label>
       2.2
      </label>
      <title>
       Patient grouping according to the disease severity
      </title>
      <p id="p0035">
       The clinical course of MERS-CoV-infected patients was assessed 6 weeks after symptom onset and patients were divided into 4 disease severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3) (
       <xref ref-type="bibr" rid="bb0055">
        Ko et al., 2016
       </xref>
       ). For practical purposes, respiratory failure was defined as the need for mechanical ventilation. Only patients in Group 3 experienced fatal outcomes (5/13, 38.5%), and interval from symptom onset to death was 27 days in median (IQR 19–35.5). Proportion of underlying immunocompromising conditions including diabetes, solid cancer, or hematologic malignancies was not different between groups (
       <xref ref-type="bibr" rid="bb0055">
        Ko et al., 2016
       </xref>
       ). The distinct clinical presentation of the 4 severity groups are presented in Supplementary Figs. 1 and 2, and Supplementary Table 1, in addition to the previous report (
       <xref ref-type="bibr" rid="bb0055">
        Ko et al., 2016
       </xref>
       ).
      </p>
     </sec>
     <sec id="s0025">
      <label>
       2.3
      </label>
      <title>
       Definitions
      </title>
      <p id="p0040">
       Seroconversion status was determined based on neutralization activity: if none of the serum samples from a MERS-CoV-infected patient, necessarily including sera obtained after the third week of illness, showed neutralization activity, the patient was considered to have negative seroconversion; if none of the serum samples obtained by the end of the third week of illness showed neutralization activity and no samples were available for neutralization tests thereafter, the patient was considered to have an indeterminate response (i.e. interpretation not applicable); if any serum showed neutralization activity, the patient was considered to have positive seroconversion. Patients with an indeterminate response were excluded from calculation of the seroconversion rate. This definition is based on the premise that no patients had previous exposure to MERS-CoV, as this was the first MERS outbreak in Korea as a non-endemic country.
      </p>
      <p id="p0045">
       During the outbreak, MERS-CoV exposure dates and symptom onsets were clearly identified in most patients, owing to thorough contact investigation and monitoring of exposed individuals (
       <xref ref-type="bibr" rid="bb0015">
        Cho et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0090">
        Park et al., 2016
       </xref>
       ). MERS-related symptoms included fever, myalgia, cough, sputum, and diarrhea. To provide a common point of reference, we used ‘days post onset of illness (
       <italic>
        dpoi
       </italic>
       )’ to evaluate MERS-CoV-infected patients. For asymptomatic patients, the day of diagnosis of MERS-CoV infection was considered as day of symptom onset (
       <xref ref-type="bibr" rid="bb0055">
        Ko et al., 2016
       </xref>
       ).
      </p>
     </sec>
     <sec id="s0030">
      <label>
       2.4
      </label>
      <title>
       Serologic tests for MERS-CoV antibody
      </title>
      <sec id="s0035">
       <label>
        2.4.1
       </label>
       <title>
        Enzyme-linked immunosorbent assay (ELISA) IgG and IgA
       </title>
       <p id="p0050">
        Anti-MERS-CoV ELISA IgG and IgA (Euroimmun, Lübeck, Germany) were based on soluble MERS-CoV spike protein S1 domain expressed in HEK-293 T cells (
        <xref ref-type="bibr" rid="bb0075">
         Muller et al., 2014
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0080">
         Muller et al., 2015
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0085">
         Muth et al., 2015
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0105">
         Raj et al., 2013
        </xref>
        ). Sera were tested according to the manufacturer's instructions with 1:100 dilutions. Secondary detection was done with peroxidase-labeled anti-human IgG and IgA. Cutoff values of OD ratio 0.4 for ELISA IgG and 0.2 for ELISA IgA were applied in the present study, as these values exhibited optimal performance in predicting neutralization activity (
        <xref ref-type="bibr" rid="bb9005">
         Ko et al., 2017
        </xref>
        ).
       </p>
      </sec>
      <sec id="s0040">
       <label>
        2.4.2
       </label>
       <title>
        IFA IgM
       </title>
       <p id="p0055">
        Anti-MERS-CoV IFA IgM (Euroimmun) was performed with slides carrying Vero cells infected with full MERS-CoV (
        <xref ref-type="bibr" rid="bb0040">
         Corman et al., 2012b
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0065">
         Meyer et al., 2014
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0075">
         Muller et al., 2014
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0080">
         Muller et al., 2015
        </xref>
        ). Sera were tested according to the manufacturer's instructions with 1:10 dilutions. Weekly positive IFA intensity was considered cutoff intensity value of IFA IgM, which exhibited optimal performance in predicting neutralization activity (
        <xref ref-type="bibr" rid="bb9005">
         Ko et al., 2017
        </xref>
        ).
       </p>
      </sec>
      <sec id="s0045">
       <label>
        2.4.3
       </label>
       <title>
        PRNT
       </title>
       <p id="p0060">
        MERS-CoV PRNT was performed as previously described (
        <xref ref-type="bibr" rid="bb0065">
         Meyer et al., 2014
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0075">
         Muller et al., 2014
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0080">
         Muller et al., 2015
        </xref>
        ). Pre-dilution before setting up the log2-dilution series was 1:10, defining 1:20 as the lowest possible significant titer for categorizing a sample as positive (
        <xref ref-type="bibr" rid="bb0065">
         Meyer et al., 2014
        </xref>
        ).
       </p>
      </sec>
     </sec>
     <sec id="s0050">
      <label>
       2.5
      </label>
      <title>
       Statistical analysis
      </title>
      <p id="p0065">
       For comparison of clinical variables between groups, one-way analysis of variance (ANOVA) or Kruskal-Wallis test was used for continuous variables, and chi-square or Fisher's exact test was used for categorical variables. Six-week survival probability was calculated using the Kaplan–Meier method. The Cox proportional hazard model and log-rank test were used to examine the association of seroconversion status with the 6-week mortality of MERS patients having pneumonia. All
       <italic>
        P
       </italic>
       -values were 2-tailed, and those &lt;0.05 were considered to be statistically significant. R-3.3.1 for Windows (RStudio, Boston, MA, USA) was used for all statistical analyses.
      </p>
     </sec>
    </sec>
    <sec id="s0055">
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec id="s0060">
      <label>
       3.1
      </label>
      <title>
       Serologic response of MERS-CoV infection according to the disease severity
      </title>
      <p id="p0070">
       Seroconversion status of 42 MERS-CoV-infected patients is summarized in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       . None of the Group 0 patients showed seroconversion, and the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in groups 0, 1, 2, and 3, respectively;
       <italic>
        P
       </italic>
       = 0.001). Seroconversion was observed from 14 to 24
       <italic>
        dpoi
       </italic>
       (18
       <italic>
        dpoi
       </italic>
       in median), mostly during the third week of illness (88.0% of seroconverted patients with a known timeline). Group 3 patients showed slightly delayed timing of seroconversion compared to Group 2 patients (18.5 and 17.5
       <italic>
        dpoi
       </italic>
       in median, respectively, without statistical significance), and seroconversion during the fourth week of illness was exclusively observed in Group 3.
       <table-wrap id="t0005" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Seroconversion status of MERS-CoV-infected patients according to the disease severity group.
         </p>
        </caption>
        <alt-text id="al0015">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Variables
           </th>
           <th colspan="4">
            Classification by the disease severity
            <hr/>
           </th>
          </tr>
          <tr>
           <th>
            Group 0
            <italic>
             Asymptomatic
            </italic>
            (n = 3)
           </th>
           <th>
            Group 1
            <italic>
             Symptomatic
            </italic>
            (n = 10)
           </th>
           <th>
            Group 2
            <italic>
             Pneumonia
            </italic>
            (n = 18)
           </th>
           <th>
            Group 3
            <italic>
             Resp. failure
            </italic>
            (n = 11)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Negative seroconversion
           </td>
           <td>
            3 (100%)
           </td>
           <td align="char">
            2 (20.0%)
           </td>
           <td align="char">
            1 (5.6%)
           </td>
           <td align="char">
            0 (0.0%)
           </td>
          </tr>
          <tr>
           <td>
            Indeterminate response
           </td>
           <td>
            0 (0.0%)
           </td>
           <td align="char">
            5 (50.0%)
           </td>
           <td align="char">
            2 (11.1%)
           </td>
           <td align="char">
            2 (18.2%)
           </td>
          </tr>
          <tr>
           <td>
            Positive seroconversion
           </td>
           <td>
            0 (0.0%)
           </td>
           <td align="char">
            3 (30.0%)
           </td>
           <td align="char">
            15 (83.3%)
           </td>
           <td align="char">
            9 (81.8%)
           </td>
          </tr>
          <tr>
           <td>
            Timing unknown
            <xref ref-type="table-fn" rid="tf0005">
             ⁎
            </xref>
           </td>
           <td>
            N/A
           </td>
           <td align="char">
            0/3 (0.0%)
           </td>
           <td align="char">
            1/15 (6.7%)
           </td>
           <td align="char">
            1/9 (11.1%)
           </td>
          </tr>
          <tr>
           <td>
            Second week of illness
           </td>
           <td>
            N/A
           </td>
           <td align="char">
            0/3 (0.0%)
           </td>
           <td align="char">
            1/14 (7.1%)
            <xref ref-type="table-fn" rid="tf0010">
             †
            </xref>
           </td>
           <td align="char">
            0/8 (0.0%)
           </td>
          </tr>
          <tr>
           <td>
            Third week of illness
           </td>
           <td>
            N/A
           </td>
           <td align="char">
            3/3 (100%)
           </td>
           <td align="char">
            13/14 (92.9%)
           </td>
           <td align="char">
            6/8 (75.0%)
           </td>
          </tr>
          <tr>
           <td>
            Fourth week of illness
           </td>
           <td>
            N/A
           </td>
           <td align="char">
            0/3 (0.0%)
           </td>
           <td align="char">
            0/14 (0.0%)
           </td>
           <td align="char">
            2/8 (25.0%)
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             dpoi
            </italic>
           </td>
           <td>
            N/A
           </td>
           <td align="char">
            17 (16–18)
           </td>
           <td align="char">
            17.5 (14–20)
           </td>
           <td align="char">
            18.5 (15–24)
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             dpex
            </italic>
           </td>
           <td>
            N/A
           </td>
           <td align="char">
            22 (20–24)
           </td>
           <td align="char">
            21.5 (19–30)
           </td>
           <td align="char">
            24 (18–27)
           </td>
          </tr>
          <tr>
           <td>
            Seroconversion rate
            <xref ref-type="table-fn" rid="tf0015">
             ‡
            </xref>
           </td>
           <td>
            0/0 (0.0%)
           </td>
           <td align="char">
            3/5 (60.0%)
           </td>
           <td align="char">
            15/16 (93.8%)
           </td>
           <td align="char">
            9/9 (100%)
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="sp0045">
          <p>
           Data are expressed as the number (%) of patients or median (range).
          </p>
         </fn>
         <fn id="sp0050">
          <p>
           Seroconversion was confirmed by PRNT and a 1:20 dilution was defined as the lowest significant titer.
          </p>
         </fn>
         <fn id="sp0055">
          <p>
           Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; Resp., respiratory;
           <italic>
            dpoi
           </italic>
           , days post onset of illness;
           <italic>
            dpex
           </italic>
           , days post exposure; IQR, interquartile range; PRNT, plaque reduction neutralization test.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tf0005">
          <label>
           ⁎
          </label>
          <p id="np0005">
           The timing of seroconversion was uncertain for 2 patients as the only sera available were collected after several months (
           <italic>
            dpoi
           </italic>
           79 and 140).
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tf0010">
          <label>
           †
          </label>
          <p id="np0010">
           At
           <italic>
            dpoi
           </italic>
           14.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tf0015">
          <label>
           ‡
          </label>
          <p id="np0015">
           Patients with an indeterminate response were excluded from seroconversion rate analysis.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="p0075">
       Serologic responses of seroconverted patients are depicted according to the severity groups with 7-day intervals in
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       . Serologic response occurred from the third week of illness, and antibody response is weaker in patients with mild symptomatic patients (Group 1) than patients with pneumonia (Groups 2 and 3). Group 2 patients showed robust increment of antibody titer during the third week (compared to the 2nd week, the median OD ratios of ELISA IgG and IgA increased more than 3-fold, and IFA IgM and PRNT increased from negative to 2+ and 1:80, respectively), and the titers did not significantly increase thereafter (in comparison of the median values of third week and fourth week, no statistical significance was observed). Meanwhile, Group 3 patients showed delayed and continuous increment of antibody titers from the third week: the median values of each serologic test were significantly higher during the fourth week compared to those of the third week in Group 3 (all
       <italic>
        P
       </italic>
       &lt; 0.05). In comparison between Groups 2 and 3, antibody titers of Group 3 patients during the third week were numerically lower than those of Group 2, although only ELISA IgG showed statistically significant difference (
       <italic>
        P
       </italic>
       = 0.016). The antibody titers of Group 3 patients continuously increased, showing numerically higher titers compared to those of Group 2 patients during the fourth week (without statistical significance). Detailed serologic test results for each patient are presented according to timeline and severity groups in Supplementary Tables 2 to 5.
       <fig id="f0005">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Serologic responses of seroconverted MERS-CoV-infected patients, according to the severity groups with 7-day intervals.
         </p>
         <p>
          The serologic responses of seroconverted MERS-CoV-infected patients are depicted according to the severity groups: symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). The mean values of each serologic test for 7-day intervals are presented in box-plots. The antibody titers of symptomatic patients rise after the 2nd week. Although PRNT titers were not statistically different between groups by the third week of illness, peak antibody response increased as severity increases.
         </p>
         <p>
          (a) ELISA IgG in Group 1. (b) ELISA IgG in Group 2. (c) ELISA IgG in Group 3. (d) ELISA IgA in Group 1. (e) ELISA IgA in Group 2. (f) ELISA IgA in Group 3. (g) IFA IgM in Group 1. (h) IFA IgM in Group 2. (i) IFA IgM in Group 3. (j) PRNT in Group 1. (k) PRNT in Group 2. (l) PRNT in Group 3.
         </p>
         <p>
          Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; ELISA, enzyme linked immunosorbent assay; OD, optical density; IFA, immunofluorescence assay; PRNT, plaque reduction neutralization test.
         </p>
        </caption>
        <alt-text id="al0005">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0065">
      <label>
       3.2
      </label>
      <title>
       Impaired Serologic Response of Fatal MERS Pneumonia
      </title>
      <p id="p0080">
       As seroconversion rates were low in mild severity groups (0% in Group 0 and 60% in Group 1), outcome analysis was performed in patients having pneumonia (Groups 2 and 3). Only 25% of deceased patients showed seroconversion by the end of the third week of illness, while 100% of survived patients seroconverted (
       <italic>
        P
       </italic>
       = 0.003,
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       ). This difference also could be discriminated by ELISA IgG (with OD ratio cutoff value of 0.4,
       <italic>
        P
       </italic>
       = 0.003) and ELISA IgA (with OD ratio cutoff value of 0.2,
       <italic>
        P
       </italic>
       = 0.010). IFA IgM response was not significantly different between survivors and non-survivors (with intensity cutoff value of weakly positive,
       <italic>
        P
       </italic>
       = 0.135). In a Kaplan–Meier analysis comparing seroconverted patients and non-converted patients by the third week of illness, seroconverted patients showed significantly higher survival probability compared to patients with negative seroconversion (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ,
       <italic>
        P
       </italic>
       &lt; 0.001 by log-rank test). Negative seroconversion in pneumonia patients by the third week of illness showed a hazard ratio of 27.83 (95% CI 2.76–280.21,
       <italic>
        P
       </italic>
       = 0.005, by the Cox proportional hazard model) in predicting 6-week mortality.
       <table-wrap id="t0010" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Seroconversion rates by the end of third week of illness according to outcome of MERS-CoV-infected patients having pneumonia (Groups 2 and 3).
         </p>
        </caption>
        <alt-text id="al0020">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Serologic tests
           </th>
           <th>
            Survived (n = 18)
           </th>
           <th>
            Deceased (n = 4)
           </th>
           <th>
            <italic>
             P
            </italic>
            value
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            PRNT (≥ 1:20 dilution)
           </td>
           <td align="char">
            18 (100%)
           </td>
           <td align="char">
            1 (25%)
           </td>
           <td align="char">
            0.003
           </td>
          </tr>
          <tr>
           <td>
            ELISA IgG (OD ratio cutoff ≥0.4)
           </td>
           <td align="char">
            18 (100%)
           </td>
           <td align="char">
            1 (25%)
           </td>
           <td align="char">
            0.003
           </td>
          </tr>
          <tr>
           <td>
            ELISA IgA(OD ratio cutoff ≥0.2)
           </td>
           <td align="char">
            17 (94.4%)
           </td>
           <td align="char">
            1 (25%)
           </td>
           <td align="char">
            0.010
           </td>
          </tr>
          <tr>
           <td>
            IFA IgM (Intensity cutoff ≥ w+)
           </td>
           <td align="char">
            16 (88.9%)
           </td>
           <td align="char">
            2 (50%)
           </td>
           <td align="char">
            0.135
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="sp0065">
          <p>
           Data are expressed as the number (%) of patients. The population of this analysis is 22 MERS-CoV-infected patients with pneumonia (Groups 2 and 3) whose sera were collected during the third week of illness.
          </p>
         </fn>
         <fn id="sp0070">
          <p>
           Abbreviation: MERS-CoV, Middle East respiratory syndrome coronavirus; PRNT, plaque reduction neutralization test; ELISA, enzyme-linked immunosorbent assay; OD, optical density; IFA, immunofluorescence assay; w+, weak positive.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
       <fig id="f0010">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Survival probability of MERS-CoV-infected patients having pneumonia according to the seroconversion status by the third week of illness.
         </p>
         <p>
          Survival probability according to the seroconversion status was evaluated in MERS-CoV-infected patients having pneumonia, whose seroconversion status during the third week of illness is identifiable. Seroconverted patients showed significantly higher survival probability compared to patients with negative seroconversion (
          <italic>
           P
          </italic>
          &lt; 0.001 by log-rank test). Seroconversion was confirmed by PRNT and a 1:20 dilution was defined as the lowest significant titer.
         </p>
         <p>
          Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; PRNT, plaque reduction neutralization test.
         </p>
        </caption>
        <alt-text id="al0010">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="s0070">
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p id="p0085">
      Since previous hospital-associated outbreaks of MERS occurred in endemic countries, where primary infections flow from community into hospitals, detailed clinical data of each patient were hard to obtain (
      <xref ref-type="bibr" rid="bb0030">
       Corman et al., 2016
      </xref>
      ). However, during the 2015 Korean MERS outbreak, the first outbreak in a non-endemic country, epidemiologic links and entire clinical course of each patients could be clearly identified (
      <xref ref-type="bibr" rid="bb0055">
       Ko et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0090">
       Park et al., 2016
      </xref>
      ). Owing to the detailed epidemiologic and clinical information about patients, we could find out different serologic response depending on disease severity and outcome.
     </p>
     <p id="p0090">
      Although different seroconversion rates depending on disease severity can be inferred from previous serologic investigation (
      <xref ref-type="bibr" rid="bb0070">
       Min et al., 2016
      </xref>
      ), the number of evaluated MERS patients was limited to 14 and neutralization testing was not performed. In that study, a robust increment of ELISA IgG titer with a 3-fold increase in OD ratio was exclusively observed among patients with severe pneumonia, while mild infections exhibited a modest increment in OD ratio, if any. Likewise, we noted that asymptomatic MERS-CoV-infected cases did not show serologic response including PRNT within 6 months, and the seroconversion rate increased with the disease severity. Although the number of asymptomatic patients was limited to 3 in the present analysis, it is less likely that asymptomatic patients will experience seroconversion considering that even Group 1 patients with obvious MERS-related symptoms showed low seroconversion rate of 60%. This finding correlates with another serologic study that evaluated 11 rRT-PCR-confirmed MERS patients (
      <xref ref-type="bibr" rid="bb0020">
       Choe et al., 2017
      </xref>
      ). In that study, antibody titers in 4 of 6 patients with mild illness were undetectable. In addition, most contact surveys of MERS-CoV could not detect additional rRT-PCR-negative PRNT-positive MERS-CoV infections (
      <xref ref-type="bibr" rid="bb0005">
       Breakwell et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0010">
       Buchholz et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0025">
       Choi et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0050">
       Ko et al., 2017
      </xref>
      ). These findings imply that serologic surveys to detect subclinical infections among asymptomatic individuals would not be effective.
     </p>
     <p id="p0095">
      Serologic response was delayed in Group 3 patients, and negative seroconversion by the third week of illness was associated with fatal outcome among patients with MERS pneumonia (HR 27.83, 95% CI 2.76–280.21,
      <italic>
       P
      </italic>
      = 0.005). Delayed commencement of serologic response in severe disease was also suggested by previous report by Park et al. (
      <xref ref-type="bibr" rid="bb0095">
       Park et al., 2015
      </xref>
      ). Although seroconversion timing was not statistically significantly delayed in Group 3 patients in the present study, delayed increment of IgG, IgA, and IgM titers after the third week was demonstrated in Group 3. However, the delayed serologic response in Group 3 could not be used as predictor for respiratory failure, as respiratory failure progressed during the 2nd week of illness (12
      <italic>
       dpoi
      </italic>
      in median).
     </p>
     <p id="p0100">
      Meanwhile, negative seroconversion in MERS pneumonia by the third week of illness was associated with fatal outcome in the present analysis. Impaired serologic response in deceased patient was also noted in the paper of Corman et al., but insufficient clinical information, especially day of symptom onset, hampered more detailed analysis in association with timeline (
      <xref ref-type="bibr" rid="bb0030">
       Corman et al., 2016
      </xref>
      ). In this study, we could obtain exact clinical information including day of symptom onset, and figured it out that seroconversion status by the third week of illness (by 21
      <italic>
       dpoi
      </italic>
      ) can serve as a prognostic marker. Another important point is that MERS-CoV-infected patients in the present analysis died later than previous reports, probably owing to antiviral therapy or aggressive critical care including extracorporeal membrane oxygenation (ECMO). The median interval from symptom onset to death was 27 days in the present study, which is much longer than 11.5 days in previous reports (
      <xref ref-type="bibr" rid="bb0120">
       Zumla et al., 2015
      </xref>
      ). Although rapidly deteriorating MERS cases would die before the third week of illness, there certainly is a population that benefit from prognosis prediction by serologic response. Aggressive managements including ECMO should be considered for pneumonia patients without seroconversion by the third week of illness. Although seroconversion status can be confirmed by neutralization tests, it cannot be readily performed worldwide (
      <xref ref-type="bibr" rid="bb0030">
       Corman et al., 2016
      </xref>
      ). In the present analysis, seroconversion status of the third week assessed by ELISA IgG and IgA was similar with that by PRNT. These ELISA tests can be practically used for predicting poor prognosis of MERS pneumonia in the field of patient management.
     </p>
     <p id="p0105">
      As a retrospective study, serum samples of each patient could not be collected with same interval. However, we applied strict criteria for seroconversion, excluding patients who did not have follow-up samples after the third week of illness as indeterminate response. In the previous report with the same patient population, we also suggest predictive factors for disease progression using clinical variables within 3 days from symptom onset (
      <xref ref-type="bibr" rid="bb0055">
       Ko et al., 2016
      </xref>
      ). Together with the present paper, these factors could be used complementarily in managing MERS-CoV-infected patients. In addition, although we identified that seroconversion status by the third week was associated with fatal outcomes of MERS pneumonia, we could not perform multivariate analysis due to limited sample size. This finding need to be further evaluated with enough patient numbers of MERS pneumonia.
     </p>
    </sec>
    <sec id="s0075">
     <label>
      5
     </label>
     <title>
      Conclusions
     </title>
     <p id="p0110">
      In conclusion, in a serologic investigation of 42 MERS-CoV-infected patients, mild cases showed low seroconversion rates, while fatal cases showed impaired serologic responses.
     </p>
    </sec>
    <sec id="s0080">
     <title>
      Funding
     </title>
     <p id="p0115">
      This work was supported by a Samsung Biomedical Research Institute (SBRI) grant [#SMX1161321]. CD reports funding by EU grants Antigone (GA no. 278976) and Prepare (GA no. 602525).
     </p>
    </sec>
    <sec id="s0085">
     <title>
      Conflicts of Interest
     </title>
     <p id="p0120">
      There are no potential conflicts of interest relevant to this article to report.
     </p>
    </sec>
    <back>
     <ref-list id="bi0005">
      <title>
       References
      </title>
      <ref id="bb0005">
       <element-citation id="rf0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breakwell
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chea
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lack of transmission among close contacts of patient with case of Middle East respiratory syndrome imported into the United States, 2014
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1128
        </fpage>
        <lpage>
         1134
        </lpage>
        <pub-id pub-id-type="pmid">
         26079176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0010">
       <element-citation id="rf0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sanewski
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wevering
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer-Balci
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         18
        </volume>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bb0015">
       <element-citation id="rf0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         388
        </volume>
        <year>
         2016
        </year>
        <fpage>
         994
        </fpage>
        <lpage>
         1001
        </lpage>
        <pub-id pub-id-type="pmid">
         27402381
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0020">
       <element-citation id="rf0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bang
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         23
        </volume>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bb0025">
       <element-citation id="rf0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Joh
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea
        </article-title>
        <source>
         Infect Chemother
        </source>
        <volume>
         48
        </volume>
        <year>
         2016
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         27433382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0030">
       <element-citation id="rf0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         62
        </volume>
        <year>
         2016
        </year>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0035">
       <element-citation id="rf0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Eschbach-Bludau
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         17
        </volume>
        <year>
         2012
        </year>
       </element-citation>
      </ref>
      <ref id="bb0040">
       <element-citation id="rf0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Costabel
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Timm
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Binger
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         17
        </volume>
        <year>
         2012
        </year>
       </element-citation>
      </ref>
      <ref id="bb0045">
       <element-citation id="rf0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The characteristics of Middle Eastern respiratory syndrome coronavirus transmission dynamics in South Korea
        </article-title>
        <source>
         Osong Public Health Res Perspect
        </source>
        <volume>
         7
        </volume>
        <year>
         2016
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         26981343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0050">
       <element-citation id="rf0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Baek
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Seok
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serologic evaluation of MERS screening strategy for healthcare personnel during a hospital-associated outbreak
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         38
        </volume>
        <year>
         2017
        </year>
        <fpage>
         234
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="pmid">
         27841103
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb9005">
       <element-citation id="rf9005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Seok
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests
        </article-title>
        <source>
         Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests
        </source>
        <year>
         2017
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0055">
       <element-citation id="rf0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients
        </article-title>
        <source>
         J Infect
        </source>
        <volume>
         73
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         468
        </fpage>
        <lpage>
         475
        </lpage>
        <pub-id pub-id-type="pmid">
         27519621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0060">
       <element-citation id="rf0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case definition and management of patients with MERS coronavirus in Saudi Arabia
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         14
        </volume>
        <year>
         2014
        </year>
        <fpage>
         911
        </fpage>
        <lpage>
         913
        </lpage>
        <pub-id pub-id-type="pmid">
         25253396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0065">
       <element-citation id="rf0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         552
        </fpage>
        <lpage>
         559
        </lpage>
        <pub-id pub-id-type="pmid">
         24655412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0070">
       <element-citation id="rf0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Min
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheon
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           N.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sohn
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Aigerim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity
        </article-title>
        <source>
         Sci Rep
        </source>
        <volume>
         6
        </volume>
        <year>
         2016
        </year>
        <fpage>
         25359
        </fpage>
        <pub-id pub-id-type="pmid">
         27146253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0075">
       <element-citation id="rf0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jores
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Younan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liljander
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus neutralizing antibodies in camels, eastern Africa, 1983-1997
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         2093
        </fpage>
        <lpage>
         2095
        </lpage>
        <pub-id pub-id-type="pmid">
         25425139
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0080">
       <element-citation id="rf0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Turkestani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         15
        </volume>
        <year>
         2015
        </year>
        <fpage>
         559
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0085">
       <element-citation id="rf0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2951
        </fpage>
        <lpage>
         2955
        </lpage>
        <pub-id pub-id-type="pmid">
         26157150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0090">
       <element-citation id="rf0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Control of an outbreak of Middle East respiratory syndrome in a tertiary Hospital in Korea
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         165
        </volume>
        <year>
         2016
        </year>
        <fpage>
         87
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         27272273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0095">
       <element-citation id="rf0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chun
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2186
        </fpage>
        <lpage>
         2189
        </lpage>
        <pub-id pub-id-type="pmid">
         26583829
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0100">
       <element-citation id="rf0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Rha
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Nsour
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistence of antibodies against Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1824
        </fpage>
        <lpage>
         1826
        </lpage>
        <pub-id pub-id-type="pmid">
         27332149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0105">
       <element-citation id="rf0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0110">
       <element-citation id="rf0110" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         WHO, Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <ext-link ext-link-type="uri" id="ir0010" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
         http://www.who.int/emergencies/mers-cov/en/
        </ext-link>
        <year>
         2017
        </year>
        <comment>
         [accessed on March 14, 2017]
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0115">
       <element-citation id="rf0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0120">
       <element-citation id="rf0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         386
        </volume>
        <year>
         2015
        </year>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="s0090" sec-type="supplementary-material">
      <label>
       Appendix A
      </label>
      <title>
       Supplementary data
      </title>
      <p id="p0130">
       <supplementary-material content-type="local-data" id="ec0005">
        <caption>
         <p>
          Supplementary materials
         </p>
        </caption>
        <media xlink:href="mmc1.docx">
         <alt-text>
          Image 1
         </alt-text>
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ac0005">
      <title>
       Acknowledgements
      </title>
      <p>
       We would like to express our sincerest condolences to the patients and families who suffered from the MERS outbreak. We also greatly appreciate the HCP and staff members at Samsung Medical Center and all other hospitals who worked together to overcome the MERS outbreak. Finally, we would like to thank Jinseob Kim for statistical advice and figure development, as well as Mingu Kang for IFA testing.
      </p>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="s0095">
       <label>
        Appendix A
       </label>
       <p id="p0135">
        Supplementary data to this article can be found online at
        <ext-link ext-link-type="doi" id="ir0005" xlink:href="10.1016/j.diagmicrobio.2017.07.006">
         http://dx.doi.org/10.1016/j.diagmicrobio.2017.07.006
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Vector Borne Zoonotic Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Vector Borne Zoonotic Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       vbz
      </journal-id>
      <journal-title-group>
       <journal-title>
        Vector Borne and Zoonotic Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1530-3667
      </issn>
      <issn pub-type="epub">
       1557-7759
      </issn>
      <publisher>
       <publisher-name>
        Mary Ann Liebert, Inc., publishers
       </publisher-name>
       <publisher-loc>
        140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30676269
      </article-id>
      <article-id pub-id-type="pmc">
       6396572
      </article-id>
      <article-id pub-id-type="publisher-id">
       10.1089/vbz.2017.2191
      </article-id>
      <article-id pub-id-type="doi">
       10.1089/vbz.2017.2191
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans? A Systematic Literature Review
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dawson
         </surname>
         <given-names>
          Patrick
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Malik
         </surname>
         <given-names>
          Mamunur Rahman
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Parvez
         </surname>
         <given-names>
          Faruque
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Morse
         </surname>
         <given-names>
          Stephen S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="corresp" rid="corr1">
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         <sup>
          1
         </sup>
        </label>
        Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
       </aff>
       <aff id="aff2">
        <label>
         <sup>
          2
         </sup>
        </label>
        Infectious Hazard Management, Department of Health Emergency, World Health Organization Eastern Mediterranean Regional Office (WHO/EMRO), Cairo, Egypt.
       </aff>
       <aff id="aff3">
        <label>
         <sup>
          3
         </sup>
        </label>
        Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="corr1">
        Address correspondence to: Stephen S. Morse, Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032
        <email>
         ssm20@cumc.columbia.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        01
       </day>
       <month>
        3
       </month>
       <year>
        2019
       </year>
       <!--string-date: March 2019-->
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        2
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        26
       </day>
       <month>
        2
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>
       19
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       174
      </fpage>
      <lpage>
       192
      </lpage>
      <permissions>
       <copyright-statement>
        © Patrick Dawson et al. 2019; Published by Mary Ann Liebert, Inc.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          http://creativecommons.org/licenses/by-nc/4.0/
         </ext-link>
         ) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="vbz.2017.2191.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        <bold>
         <italic>
          Background:
         </italic>
        </bold>
        Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in humans in 2012. A systematic literature review was conducted to synthesize current knowledge and identify critical knowledge gaps.
       </p>
       <p>
        <bold>
         <italic>
          Materials and Methods:
         </italic>
        </bold>
        We conducted a systematic review on MERS-CoV using PRISMA guidelines. We identified 407 relevant, peer-reviewed publications and selected 208 of these based on their contributions to four key areas: virology; clinical characteristics, outcomes, therapeutic and preventive options; epidemiology and transmission; and animal interface and the search for natural hosts of MERS-CoV.
       </p>
       <p>
        <bold>
         <italic>
          Results:
         </italic>
        </bold>
        Dipeptidyl peptidase 4 (DPP4/CD26) was identified as the human receptor for MERS-CoV, and a variety of molecular and serological assays developed. Dromedary camels remain the only documented zoonotic source of human infection, but MERS-like CoVs have been detected in bat species globally, as well as in dromedary camels throughout the Middle East and Africa. However, despite evidence of camel-to-human MERS-CoV transmission and cases apparently related to camel contact, the source of many primary cases remains unknown. There have been sustained health care-associated human outbreaks in Saudi Arabia and South Korea, the latter originating from one traveler returning from the Middle East. Transmission mechanisms are poorly understood; for health care, this may include environmental contamination. Various potential therapeutics have been identified, but not yet evaluated in human clinical trials. At least one candidate vaccine has progressed to Phase I trials.
       </p>
       <p>
        <bold>
         <italic>
          Conclusions:
         </italic>
        </bold>
        There has been substantial MERS-CoV research since 2012, but significant knowledge gaps persist, especially in epidemiology and natural history of the infection. There have been few rigorous studies of baseline prevalence, transmission, and spectrum of disease. Terms such as “camel exposure” and the epidemiological relationships of cases should be clearly defined and standardized. We strongly recommend a shared and accessible registry or database. Coronaviruses will likely continue to emerge, arguing for a unified “One Health” approach.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        Keywords
       </title>
       <kwd>
        MERS
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        coronaviruses
       </kwd>
       <kwd>
        zoonotic disease
       </kwd>
       <kwd>
        severe acute respiratory infection (SARI)
       </kwd>
       <kwd>
        MERS epidemiology
       </kwd>
      </kwd-group>
      <counts>
       <fig-count count="2">
       </fig-count>
       <table-count count="1">
       </table-count>
       <ref-count count="255">
       </ref-count>
       <page-count count="19">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <sec id="s001" sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      September 2012 saw the identification of a novel human coronavirus, now known as Middle East respiratory syndrome coronavirus (MERS-CoV) (ProMED-mail 2012, Zaki et al.
      <xref ref-type="bibr" rid="B250">
       2012
      </xref>
      ). MERS-CoV is a beta-coronavirus distinct from but genetically related to the SARS (severe acute respiratory syndrome) coronavirus (Hilgenfeld and Peiris
      <xref ref-type="bibr" rid="B110">
       2013
      </xref>
      , de Wit et al.
      <xref ref-type="bibr" rid="B75">
       2016
      </xref>
      ).
     </p>
     <p>
      As MERS was identified a few years after the 2003 SARS outbreak, which spread across continents and raised pandemic concerns, there has been continuing concern about the pandemic potential of MERS-CoV (Hilgenfeld and Peiris
      <xref ref-type="bibr" rid="B110">
       2013
      </xref>
      , de Wit et al.
      <xref ref-type="bibr" rid="B75">
       2016
      </xref>
      ). To assess and anticipate potential epidemic spread of MERS-CoV, it is essential to better understand the virology; human clinical characteristics, possible therapeutic and preventive options; epidemiology and transmission; and animal interfaces and possible origins and natural hosts.
     </p>
     <p>
      MERS was first identified in a patient with lower respiratory disease by a physician in Saudi Arabia, and subsequently, the virus was identified and characterized from this patient's sputum sample by researchers in Saudi Arabia and at Erasmus Medical Center in the Netherlands. Since then (to December 2018), 2266 laboratory-confirmed MERS-CoV cases and 804 deaths across 27 countries (35.5% crude case fatality rate [CFR]) have been reported to the WHO (
      <xref ref-type="fig" rid="f1">
       Fig. 1
      </xref>
      ), with the majority of cases (1888) and deaths (730) reported from Saudi Arabia (World Health Organization
      <xref ref-type="bibr" rid="B239">
       2018a
      </xref>
      , World Health Organization/EMRO
      <xref ref-type="bibr" rid="B241">
       2018
      </xref>
      ). Cases continue to occur (World Health Organization/EMRO
      <xref ref-type="bibr" rid="B241">
       2018
      </xref>
      ).
     </p>
     <fig fig-type="figure" id="f1" orientation="portrait" position="float">
      <label>
       <bold>
        FIG. 1.
       </bold>
      </label>
      <caption>
       <p>
        <bold>
         (A)
        </bold>
        Map of countries having at least one laboratory-confirmed human MERS-CoV case, 2012–2016.
        <italic>
         Darker shades
        </italic>
        indicate greater numbers of laboratory-confirmed cases.
        <bold>
         (B)
        </bold>
        <italic>
         Inset
        </italic>
        of
        <xref ref-type="fig" rid="f1">
         Fig. 1A
        </xref>
        showing Gulf countries having at least one laboratory-confirmed human MERS-CoV case.
        <italic>
         Darker shades
        </italic>
        indicate greater numbers of laboratory-confirmed cases. Data Source: World Health Organization (
        <uri xlink:href="http://www.who.int/emergencies/mers-cov/en" xlink:type="simple">
         www.who.int/emergencies/mers-cov/en
        </uri>
        <italic>
         and
        </italic>
        <uri xlink:href="http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf" xlink:type="simple">
         www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf
        </uri>
        ). This map was generated using R software (
        <italic>
         R Foundation
        </italic>
        for Statistical Computing, Vienna, Austria) and the “googleVis” package (Gesmann et al.
        <xref ref-type="bibr" rid="B95">
         2017
        </xref>
        ). MERS-CoV, Middle East respiratory syndrome coronavirus.
       </p>
      </caption>
      <graphic xlink:href="fig-1">
      </graphic>
     </fig>
     <p>
      Although the first known MERS-CoV cases were from Jordan (confirmed retrospectively, and the source is still unknown) (Hijawi et al.
      <xref ref-type="bibr" rid="B109">
       2013
      </xref>
      ), about 80% of MERS-CoV cases originate from or passed through Saudi Arabia. The infection is likely zoonotic; although origins and transmission are poorly understood, the dromedary camel is the one documented source of human zoonotic infection (Memish et al.
      <xref ref-type="bibr" rid="B160">
       2014e
      </xref>
      ).
     </p>
     <p>
      A systematic review of MERS-CoV research was conducted to survey our current understanding of MERS-CoV and to identify research gaps in four major areas: (1) virology; (2) clinical characteristics, outcomes, and therapeutic and preventive options; (3) epidemiology and transmission; and (4) animal interface and the search for natural hosts of MERS-CoV.
     </p>
    </sec>
    <sec id="s002" sec-type="materials|methods">
     <title>
      Materials and Methods
     </title>
     <p>
      We conducted a systematic literature review, using Embase, Google Scholar, MEDLINE/PubMed, supplemented by Thomson-Reuters “Web of Science”™ (all databases), to identify peer-reviewed published articles on MERS-CoV available by July 14, 2017. All searches were for articles published from 2012 onward, since MERS was first identified in 2012. The following search terms were used in all the databases for matches in title only (Google Scholar), title or abstract (Embase and MEDLINE/PubMed), or topic (“Web of Science”): “novel coronavirus,” “novel coronavirus EMC,” “novel coronavirus Erasmus,” “hCoV-EMC,” “MERS-CoV” (a PubMed “MeSH” term), “MERS coronavirus,” “Middle East Respiratory Syndrome,” and “Middle East Respiratory Syndrome Coronavirus” (a PubMed MeSH term).
     </p>
     <p>
      We reviewed the titles and abstracts of all resulting citations to identify relevant articles for this systematic review, following PRISMA guidelines (
      <xref ref-type="fig" rid="f2">
       Fig. 2
      </xref>
      ) (Moher et al.
      <xref ref-type="bibr" rid="B169">
       2009
      </xref>
      ). For all nonduplicate articles, excluding opinion and editorial pieces, on MERS-CoV or a related topic, we retrieved the full-text version and indexed the citation. Inclusion criteria were peer-reviewed primary research articles about MERS-CoV published between 2012 and mid-July 2017 (inclusive, with periodic updates to 2018) and adding unique information about MERS-CoV to the knowledge base within at least one of the four key themes: (1) virology; (2) clinical characteristics, outcomes, and therapeutic and preventive options; (3) epidemiology and transmission; and (4) animal interface and search for natural hosts of MERS-CoV.
     </p>
     <fig fig-type="figure" id="f2" orientation="portrait" position="float">
      <label>
       <bold>
        FIG. 2.
       </bold>
      </label>
      <caption>
       <p>
        Study selection diagram for systematic literature review on MERS-CoV (*For complete search terms and applicable date ranges, see the
        <xref ref-type="sec" rid="s002">
         Materials and Methods
        </xref>
        section.).
       </p>
      </caption>
      <graphic xlink:href="fig-2">
      </graphic>
     </fig>
     <p>
      Only English language publications (or with an English-language abstract available) were included. Of the 3364 titles retrieved, 407 were unique (nonduplicate), scientific research works relevant to MERS-CoV, and of these, 208 were originally included in the review based on the inclusion criteria (some interim updates have been made during article preparation).
     </p>
    </sec>
    <sec id="s003" sec-type="results">
     <title>
      Results
     </title>
     <sec id="s004">
      <title>
       Virology
      </title>
      <p>
       The pathogen causing MERS has been identified as a coronavirus, now named MERS-CoV, classified in the family
       <italic>
        Coronaviridae
       </italic>
       (subfamily
       <italic>
        Coronavirinae
       </italic>
       ) (ICTV
       <xref ref-type="bibr" rid="B118">
        2016
       </xref>
       ). Coronaviruses are a family of enveloped, approximately spherical, positive-sense, single-stranded RNA viruses with genome length 26–32 kilobases (kb). Of the four described coronavirus genera, alpha- and beta-coronaviruses are believed to originate from bat species, whereas gamma- and delta-coronaviruses are believed to be of avian origin (Woo et al.
       <xref ref-type="bibr" rid="B236">
        2012
       </xref>
       ).
      </p>
      <p>
       Within the beta-coronavirus genus, four lineages have been described: A, B (which includes SARS-CoV), C, and D. MERS-CoV is a beta-coronavirus of lineage C (Cotten et al.
       <xref ref-type="bibr" rid="B69">
        2013
       </xref>
       ), the first of this lineage known to infect humans. There are two main recognized clades (genetic sublineages) of MERS-CoV, clade A, which includes the earliest known MERS-CoV strains (EMC/2012 and Jordan-N3/2012), and clade B, which includes newer cases (Cotten et al.
       <xref ref-type="bibr" rid="B69">
        2013
       </xref>
       ), although additional genotypes are revealed by genomic sequencing (Chu et al.
       <xref ref-type="bibr" rid="B56">
        2015
       </xref>
       ), suggesting the existence of additional clades.
      </p>
      <p>
       The genome of MERS-CoV is ∼30 kb and encodes 10 proteins: 2 replicase polyproteins (ORFs 1a and 1b), including the RNA-dependent RNA polymerase (RdRp); 4 structural proteins: envelope (E), M (membrane), N (nucleocapsid), and S (surface spike glycoprotein), and 4 nonstructural proteins (ORFs 3, 4a, 4b, and 5) (Kim et al.
       <xref ref-type="bibr" rid="B128">
        2015
       </xref>
       ; review: de Wit et al.
       <xref ref-type="bibr" rid="B75">
        2016
       </xref>
       ).
      </p>
      <p>
       Particular attention has understandably focused on the S (spike) surface protein, which confers receptor specificity (Qian et al.
       <xref ref-type="bibr" rid="B200">
        2013
       </xref>
       ) and is considered the major determinant of coronavirus host range (Graham and Baric
       <xref ref-type="bibr" rid="B99">
        2010
       </xref>
       , Hulswit et al.
       <xref ref-type="bibr" rid="B116">
        2016
       </xref>
       ). The main route of entry for MERS-CoV is dipeptidyl peptidase 4 (DPP4, also known as CD26) on the host cell surface (Raj et al.
       <xref ref-type="bibr" rid="B202">
        2013
       </xref>
       ), which is utilized by the receptor-binding domain of the MERS-CoV spike protein (Chen et al.
       <xref ref-type="bibr" rid="B54">
        2013
       </xref>
       , Raj et al.
       <xref ref-type="bibr" rid="B202">
        2013
       </xref>
       ,
       <xref ref-type="bibr" rid="B203">
        2014
       </xref>
       ).
      </p>
      <p>
       The virus readily replicates in A549 (human lung), Huh-7 (human liver), and the widely used Vero E6 (African green monkey kidney) cell lines (Raj et al.
       <xref ref-type="bibr" rid="B202">
        2013
       </xref>
       , Eckerle et al.
       <xref ref-type="bibr" rid="B85">
        2014
       </xref>
       ), among others. Culture,
       <italic>
        in vitro
       </italic>
       and
       <italic>
        ex vivo
       </italic>
       , has also been used to help determine cell tropism and identify potential natural hosts of the virus. MERS-CoV can infect a variety of human cell types and tissues in culture, including macrophages, fibroblasts, and endothelial cells (Scobey et al.
       <xref ref-type="bibr" rid="B214">
        2013
       </xref>
       , Tao et al.
       <xref ref-type="bibr" rid="B226">
        2013
       </xref>
       , Hin et al.
       <xref ref-type="bibr" rid="B111">
        2016
       </xref>
       ). In an
       <italic>
        ex vivo
       </italic>
       study using human lung explants, MERS-CoV infected both alveolar epithelial cells and macrophages (Type II pneumocytes), with resulting alveolar damage (Hocke et al.
       <xref ref-type="bibr" rid="B112">
        2013
       </xref>
       ).
      </p>
      <p>
       Interestingly, although kidney failure is frequently described in fatal cases and the virus grows well in a number of kidney and liver cell lines, in the one autopsy report that has been published, viral antigen was detected by immunohistochemical staining only in pneumocytes and lung interstitial epithelial cells, and not in the kidney or other extrapulmonary sites (Ng et al.
       <xref ref-type="bibr" rid="B179">
        2016
       </xref>
       ).
      </p>
      <p>
       Replication was demonstrated in goat, camel (Eckerle et al.
       <xref ref-type="bibr" rid="B85">
        2014
       </xref>
       ), and equid origin cell lines (Meyer et al.
       <xref ref-type="bibr" rid="B163">
        2015
       </xref>
       ), but was not detected in cattle, sheep, or rodent cell lines tested (Eckerle et al.
       <xref ref-type="bibr" rid="B85">
        2014
       </xref>
       ).
      </p>
      <p>
       Given the interest in bats as a natural host for many coronaviruses, especially since SARS, and the currently unknown origin of MERS-CoV, several bat cell lines have been tested to determine if they could support MERS-CoV replication (Müller et al.
       <xref ref-type="bibr" rid="B177">
        2012
       </xref>
       , Cai et al.
       <xref ref-type="bibr" rid="B46">
        2014
       </xref>
       , Eckerle et al.
       <xref ref-type="bibr" rid="B85">
        2014
       </xref>
       ).
      </p>
      <p>
       As a broad generalization, the virus was reported to replicate well (roughly comparable with growth in Vero E6 cells) in kidney and lung cells from
       <italic>
        Rousettus aegyptiacus
       </italic>
       and other Old World pteropid (fruit) bats (Müller et al.
       <xref ref-type="bibr" rid="B177">
        2012
       </xref>
       , Cai et al.
       <xref ref-type="bibr" rid="B46">
        2014
       </xref>
       ), to a lesser degree in cell lines from Old World insectivorous bats (Müller et al.
       <xref ref-type="bibr" rid="B177">
        2012
       </xref>
       , Eckerle et al.
       <xref ref-type="bibr" rid="B85">
        2014
       </xref>
       ), and very little, if at all, in lung cells from several New World bats (Müller et al.
       <xref ref-type="bibr" rid="B177">
        2012
       </xref>
       , Cai et al.
       <xref ref-type="bibr" rid="B46">
        2014
       </xref>
       ). However, as a caveat, no replication was found in the
       <italic>
        Rousettus aegyptiacus
       </italic>
       embryo cell lines tested (Cai et al.
       <xref ref-type="bibr" rid="B46">
        2014
       </xref>
       ).
      </p>
      <p>
       Adaptation to cells from other bat species that are normally refractory to infection because of having a somewhat different DPP4 protein was recently demonstrated
       <italic>
        in vitro
       </italic>
       (Letko et al.
       <xref ref-type="bibr" rid="B142">
        2018
       </xref>
       ), resulting from selection of spike protein mutations that permitted binding to the new DPP4. A similar change, from bat to human-type receptor, was observed with SARS in 2003 (Letko et al.
       <xref ref-type="bibr" rid="B142">
        2018
       </xref>
       ).
      </p>
      <p>
       Animal models for MERS-CoV include transgenic mice expressing human DPP4 (Cockrell et al.
       <xref ref-type="bibr" rid="B59">
        2014
       </xref>
       , Zhao et al.
       <xref ref-type="bibr" rid="B253">
        2014
       </xref>
       , Agrawal et al.
       <xref ref-type="bibr" rid="B8">
        2015
       </xref>
       ), which develop respiratory disease and are the most widely used model; marmosets (Falzarano et al.
       <xref ref-type="bibr" rid="B88">
        2014
       </xref>
       ); rhesus macaques (de Wit et al.
       <xref ref-type="bibr" rid="B74">
        2013
       </xref>
       , Munster et al.
       <xref ref-type="bibr" rid="B178">
        2013
       </xref>
       , Yao et al.
       <xref ref-type="bibr" rid="B247">
        2014
       </xref>
       ); camels (Barlan et al.
       <xref ref-type="bibr" rid="B37">
        2014
       </xref>
       ); horses (Barlan et al.
       <xref ref-type="bibr" rid="B37">
        2014
       </xref>
       ), and alpacas (Adney et al.
       <xref ref-type="bibr" rid="B6">
        2016
       </xref>
       ). However, there is no animal model that clearly mimics human clinical MERS (review: Baseler et al.
       <xref ref-type="bibr" rid="B38">
        2016
       </xref>
       ).
      </p>
      <sec id="s005">
       <title>
        Diagnostic assays
       </title>
       <p>
        The main laboratory assays for MERS-CoV are molecular tests to detect viral RNA, and serology (for prior infection) (CDC
        <xref ref-type="bibr" rid="B49">
         2014
        </xref>
        , World Health Organization
        <xref ref-type="bibr" rid="B240">
         2018b
        </xref>
        ).
       </p>
       <p>
        Reverse transcription PCR either real time or conventional, is now standard. For diagnostic screening, PCR primer sets to regions upstream of the E gene (“up-E”) are most frequently used, with ORF1a or ORF1b for confirmation (Corman et al.
        <xref ref-type="bibr" rid="B61">
         2012a
        </xref>
        ,
        <xref ref-type="bibr" rid="B62">
         2012b
        </xref>
        ). Sensitivity was reported as ∼3.4 viral gene copies/25 μL reaction for up-E and ∼64 copies for ORF1b, with specificity approaching 100% using a test panel of other known coronaviruses and clinical respiratory samples (Corman et al.
        <xref ref-type="bibr" rid="B61">
         2012a
        </xref>
        ). ORF1a PCR was reported to have comparable sensitivity and specificity to up-E (Corman et al.
        <xref ref-type="bibr" rid="B62">
         2012b
        </xref>
        ). Commercial kits are available, with comparable results reported (Corman et al.
        <xref ref-type="bibr" rid="B66">
         2014c
        </xref>
        , Seong et al.
        <xref ref-type="bibr" rid="B216">
         2016
        </xref>
        , Mohamed et al.
        <xref ref-type="bibr" rid="B168">
         2017
        </xref>
        ).
       </p>
       <p>
        For sequencing, tests have been developed that may be better suited for strain differentiation, targeting regions of the RdRp (RNA polymerase) or N (nucleocapsid) genes (Corman et al.
        <xref ref-type="bibr" rid="B62">
         2012b
        </xref>
        ); there are a number of publications reporting on their use (Corman et al.
        <xref ref-type="bibr" rid="B62">
         2012b
        </xref>
        ; CDC
        <xref ref-type="bibr" rid="B49">
         2014
        </xref>
        , Lu et al.
        <xref ref-type="bibr" rid="B145">
         2014
        </xref>
        ).
       </p>
       <p>
        Another PCR test, targeting the S (spike) region, was developed to monitor circulation of MERS-CoV variants (Abd et al.
        <xref ref-type="bibr" rid="B1">
         2013
        </xref>
        , Smits et al.
        <xref ref-type="bibr" rid="B221">
         2015
        </xref>
        ). Other types of nucleic acid tests have also been used (Shirato et al.
        <xref ref-type="bibr" rid="B219">
         2014
        </xref>
        ), as has immunohistochemistry (Ng et al.
        <xref ref-type="bibr" rid="B179">
         2016
        </xref>
        ).
       </p>
       <p>
        Serologic samples are usually screened using enzyme-linked immunosorbent assay (ELISA) (Reusken et al.
        <xref ref-type="bibr" rid="B205">
         2013a
        </xref>
        ). If the sample is ELISA positive, CDC and other agencies formerly recommended confirmatory testing, first by immunofluorescence assay (IFA) and then by the gold standard plaque-reduction neutralization test or microneutralization (CDC
        <xref ref-type="bibr" rid="B49">
         2014
        </xref>
        ), but now recommend going directly to microneutralization assay (CDC
        <xref ref-type="bibr" rid="B49">
         2014
        </xref>
        , revised). Other serological tests such as pseudoparticle neutralization (Perera et al.
        <xref ref-type="bibr" rid="B194">
         2013
        </xref>
        ) and array-based serology (Reusken et al.
        <xref ref-type="bibr" rid="B205">
         2013a
        </xref>
        ) have also been developed.
       </p>
       <p>
        Unfortunately, there are pitfalls in serology, including cross-reactivity and false negatives. In 2014, CDC preliminarily reported a MERS-CoV case with a positive ELISA and IFA, but later retracted the case report due to a negative microneutralization result (Breakwell et al.
        <xref ref-type="bibr" rid="B42">
         2015
        </xref>
        ). Consequently, CDC no longer recommends IFA but instead now recommends using two different ELISA tests, with microneutralization for confirmation (CDC
        <xref ref-type="bibr" rid="B49">
         2014
        </xref>
        , revised). Conversely, low or waning antibody response after infection, which would yield false negatives, has also been reported (Alshukairi et al.
        <xref ref-type="bibr" rid="B24">
         2016
        </xref>
        , Choe et al.
        <xref ref-type="bibr" rid="B55">
         2017
        </xref>
        ). False negatives are further discussed below in the section on Host Response.
       </p>
      </sec>
     </sec>
     <sec id="s006">
      <title>
       Clinical characteristics and outcomes
      </title>
      <p>
       Clinical findings have been described and reviewed in detail (Assiri et al.
       <xref ref-type="bibr" rid="B32">
        2013a
       </xref>
       , Saad et al.
       <xref ref-type="bibr" rid="B212">
        2014
       </xref>
       , Rasmussen et al.
       <xref ref-type="bibr" rid="B204">
        2015
       </xref>
       , World Health Organization
       <xref ref-type="bibr" rid="B238">
        2015
       </xref>
       ). The incubation period is ∼5–7 days (in some cases up to 12 days) (Assiri et al.
       <xref ref-type="bibr" rid="B32">
        2013a
       </xref>
       ,
       <xref ref-type="bibr" rid="B33">
        2013b
       </xref>
       ). Fever, cough, shortness of breath, and pneumonia (with abnormal chest radiography) are the most frequently noted signs; myalgia, diarrhea, vomiting, abdominal pain, chills or rigors, or malaise are also seen (Assiri et al.
       <xref ref-type="bibr" rid="B32">
        2013a
       </xref>
       , Drosten et al.
       <xref ref-type="bibr" rid="B80">
        2013
       </xref>
       , Eckerle et al.
       <xref ref-type="bibr" rid="B86">
        2013
       </xref>
       , Guery et al.
       <xref ref-type="bibr" rid="B100">
        2013
       </xref>
       , Ajlan et al.
       <xref ref-type="bibr" rid="B9">
        2014
       </xref>
       , Arabi et al.
       <xref ref-type="bibr" rid="B30">
        2014
       </xref>
       , Faure et al.
       <xref ref-type="bibr" rid="B90">
        2014
       </xref>
       , Kapoor et al.
       <xref ref-type="bibr" rid="B122">
        2014
       </xref>
       , Scheuplein et al.
       <xref ref-type="bibr" rid="B213">
        2015
       </xref>
       , Hunter et al.
       <xref ref-type="bibr" rid="B117">
        2016
       </xref>
       ). Renal failure or pulmonary failure and shock were commonly described in severe and fatal cases. Overall CFR is ∼35.5% (World Health Organization
       <xref ref-type="bibr" rid="B239">
        2018a
       </xref>
       ).
      </p>
      <p>
       Viral excretion from the respiratory tract has been documented through the first month of illness (Memish et al.
       <xref ref-type="bibr" rid="B159">
        2014d
       </xref>
       , Poissy et al.
       <xref ref-type="bibr" rid="B195">
        2014
       </xref>
       , Spanakis et al.
       <xref ref-type="bibr" rid="B223">
        2014
       </xref>
       ), with greater viral loads detected in lower respiratory tract specimens compared with upper respiratory tract (Drosten et al.
       <xref ref-type="bibr" rid="B80">
        2013
       </xref>
       , Guery et al.
       <xref ref-type="bibr" rid="B100">
        2013
       </xref>
       , Kapoor et al.
       <xref ref-type="bibr" rid="B122">
        2014
       </xref>
       ). Viral excretion for short periods was reported in urine and stool, although viral loads were low (Drosten et al.
       <xref ref-type="bibr" rid="B80">
        2013
       </xref>
       ). There was at least one report that MERS-CoV secondary cases (individuals infected by a primary case) clear infection earlier than primary cases (Memish et al.
       <xref ref-type="bibr" rid="B159">
        2014d
       </xref>
       ).
      </p>
      <p>
       Disease outcomes differed by age and comorbidities (Assiri et al.
       <xref ref-type="bibr" rid="B32">
        2013a
       </xref>
       ,
       <xref ref-type="bibr" rid="B33">
        2013b
       </xref>
       , Khalid et al.
       <xref ref-type="bibr" rid="B124">
        2014
       </xref>
       , Saad et al.
       <xref ref-type="bibr" rid="B212">
        2014
       </xref>
       , Alsahafi and Cheng
       <xref ref-type="bibr" rid="B22">
        2016
       </xref>
       ). Most cases in Saudi Arabia have occurred among men, ages 45 or older, and those living in areas of lower relative humidity and high temperature (Alghamdi et al.
       <xref ref-type="bibr" rid="B17">
        2014
       </xref>
       ). A review of 939 cases in Saudi Arabia found that CFR increases with age, from 12.5% among those 19 years or younger to 86.2% among those 80 years or older (Alsahafi and Cheng
       <xref ref-type="bibr" rid="B22">
        2016
       </xref>
       ). Mortality was more frequent and rapid in individuals with comorbidities such as diabetes, chronic renal disease, and, in one study, higher body mass index (Assiri et al.
       <xref ref-type="bibr" rid="B32">
        2013a
       </xref>
       ,
       <xref ref-type="bibr" rid="B33">
        2013b
       </xref>
       , Al-Tawfiq et al.
       <xref ref-type="bibr" rid="B13">
        2014
       </xref>
       , Khalid et al.
       <xref ref-type="bibr" rid="B124">
        2014
       </xref>
       , Saad et al.
       <xref ref-type="bibr" rid="B212">
        2014
       </xref>
       , Alsahafi and Cheng
       <xref ref-type="bibr" rid="B22">
        2016
       </xref>
       ). More severe disease has been associated with higher viral load (Feikin et al.
       <xref ref-type="bibr" rid="B91">
        2015
       </xref>
       ).
      </p>
      <p>
       There are a handful of case reports on MERS outcomes in other vulnerable populations, including three cases in pregnant women and one in an HIV-positive individual.
      </p>
      <p>
       In the three documented cases of pregnant women with MERS-CoV infection, one woman in her second trimester of pregnancy (∼5 months) experienced a stillbirth; the mother survived (Payne et al.
       <xref ref-type="bibr" rid="B191">
        2014
       </xref>
       ). The two other women were reported to be in their third trimester (32 weeks) when they presented with MERS. A healthy infant was delivered in each of these cases, although one mother died despite interferon (IFN) treatment (Malik et al.
       <xref ref-type="bibr" rid="B152">
        2016
       </xref>
       ), and one recovered despite the severity of her symptoms (Alserehi et al.
       <xref ref-type="bibr" rid="B23">
        2016
       </xref>
       ). Both were apparently healthy before infection and in their 30s. It is therefore possible that infection during the third trimester may be associated with better fetal outcomes, while other factors may be more critical for maternal outcome, but the numbers are too small to generalize.
      </p>
      <p>
       There has been at least one published case of an individual with HIV/AIDS acquiring MERS-CoV (Shalhoub et al.
       <xref ref-type="bibr" rid="B217">
        2015
       </xref>
       ). This patient was probably infected with MERS-CoV during a hospital stay and subsequently shed virus for 38 days. The patient recovered after treatment (Shalhoub et al.
       <xref ref-type="bibr" rid="B217">
        2015
       </xref>
       ).
      </p>
     </sec>
     <sec id="s007">
      <title>
       Host response
      </title>
      <p>
       There have been a number of studies on immune function (Corman et al.
       <xref ref-type="bibr" rid="B63">
        2016
       </xref>
       , Zhao et al.
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ). Neutralizing antibodies were detected in many patients, but several studies suggested that neutralizing antibodies induced during infection did not appear to be protective (Corman et al.
       <xref ref-type="bibr" rid="B63">
        2016
       </xref>
       , Zhao et al.
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ), and it has been suggested that higher antibody titers may be more closely correlated with greater viral load and consequently worse prognosis (Zhao et al.
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ).
      </p>
      <p>
       Kinetics of response may also be important. An antibody kinetics study with 17 patients in South Korea (from the same research group that later reported waning antibody titers in patients over a 1-year follow-up) found that most patients produced a robust neutralizing IgG antibody response beginning at about 2 weeks and peaking by about 3 weeks; delayed response was generally correlated with a less favorable prognosis (Park et al.
       <xref ref-type="bibr" rid="B188">
        2015
       </xref>
       ).
      </p>
      <p>
       Persistence of antibody generally seems to follow a similar pattern. Detectable neutralizing antibody titers (≥20) have been reported in some patients up to 34 months (Payne et al.
       <xref ref-type="bibr" rid="B192">
        2016
       </xref>
       ). However, results varied considerably even within this group, and most reports indicate that duration of antibody response, as well as its magnitude, seemed most closely correlated with disease severity and that antibodies could be low or even absent in mild or asymptomatic infection (Alshukairi et al.
       <xref ref-type="bibr" rid="B24">
        2016
       </xref>
       , Choe et al.
       <xref ref-type="bibr" rid="B55">
        2017
       </xref>
       ). These reports of low or waning antibody titers, especially in asymptomatic or mildly symptomatic individuals, may make serology problematic as a marker of population prevalence.
      </p>
      <p>
       There is evidence that innate immunity, including IFNs and cytokines, and cellular immunity by CD8
       <sup>
        +
       </sup>
       (presumably “killer”) T cells may play important roles in host defense and recovery (Faure et al.
       <xref ref-type="bibr" rid="B90">
        2014
       </xref>
       , Zhao et al.
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ). Zhao et al. (
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ) compared the role of antibodies and T cells in human MERS cases, and found that survivors mounted a vigorous CD8
       <sup>
        +
       </sup>
       T cell response even in the absence of a detectable antibody response.
      </p>
      <p>
       Macrophages also appear to play an important role, but there are limited and somewhat ambiguous data from the mouse model (Coleman et al.
       <xref ref-type="bibr" rid="B60">
        2017
       </xref>
       ), human cells (Zhou et al.
       <xref ref-type="bibr" rid="B255">
        2014
       </xref>
       ), and patients (Faure et al.
       <xref ref-type="bibr" rid="B90">
        2014
       </xref>
       ). With a number of viruses, it is not unusual for resting macrophages to be permissive for replication but for macrophages to show antiviral activity after activation (such as by IFN-γ) (Morse and Morahan
       <xref ref-type="bibr" rid="B173">
        1981
       </xref>
       ). Dendritic cells have been reported to produce IFN in response to infection (Scheuplein et al.
       <xref ref-type="bibr" rid="B213">
        2015
       </xref>
       ).
      </p>
      <p>
       One challenge to overcome is the effect of the virus on host defenses. A caveat is that much of this research (although not all) has been done
       <italic>
        in vitro
       </italic>
       and may not necessarily be comparable with the immunological results described above in patients. MERS-CoV has been reported to inhibit host innate immunity (Lau et al.
       <xref ref-type="bibr" rid="B133">
        2013
       </xref>
       ). Impaired IFN and cytokine responses may mediate some of these effects, based on assays on cells from MERS patients (Faure et al.
       <xref ref-type="bibr" rid="B90">
        2014
       </xref>
       , Scheuplein et al.
       <xref ref-type="bibr" rid="B213">
        2015
       </xref>
       ), although the numbers of patients were small.
       <italic>
        In vitro
       </italic>
       studies have shown that MERS-CoV could downregulate expression of IFN-stimulated gene subsets (Yang et al.
       <xref ref-type="bibr" rid="B246">
        2013
       </xref>
       ), chemokines (Mielech et al.
       <xref ref-type="bibr" rid="B165">
        2014
       </xref>
       ), and IFN-β. Another study found that MERS-CoV may cause delayed induction of proinflammatory cytokines together with suppression of the host's innate antiviral response (Lau et al.
       <xref ref-type="bibr" rid="B134">
        2013
       </xref>
       ).
      </p>
      <p>
       Virus replication in human monocyte-derived macrophages has been described, with increased expression of tumor necrosis factor α (up to a 3-fold increase over normal levels), interleukin 6 (up to almost a 6-fold increase), interleukin 12, IFN-γ, and chemokines (some at a 10-fold or more increase and even more prominently than with SARS-CoV) being reported (Zhou et al.
       <xref ref-type="bibr" rid="B255">
        2014
       </xref>
       ).
      </p>
     </sec>
     <sec id="s008">
      <title>
       Therapeutic and preventive options
      </title>
      <p>
       Currently, the main treatment strategy is symptomatic supportive care; mechanical ventilation and ICU admission are usually required for severe cases.
      </p>
      <p>
       Published data on applied therapeutic regimens for MERS-CoV patients are scarce, but there have been efforts to develop interventions.
      </p>
      <p>
       Two case reports have documented the use of a combination of ribavirin and IFN α2b as a therapy for MERS-CoV patients, with divergent results. In one report, this therapy was given to five patients but all five died. However, all five patients had comorbidities and were diagnosed late in the course of their illness, suggesting the therapy may have been delivered too late to prove effective (Al-Tawfiq et al.
       <xref ref-type="bibr" rid="B13">
        2014
       </xref>
       ). In another report, this therapy was given to one patient who eventually recovered (Khalid et al.
       <xref ref-type="bibr" rid="B123">
        2015
       </xref>
       ).
      </p>
      <p>
       In a retrospective cohort study of 44 patients with severe MERS (requiring ventilatory support), treatment with ribavirin and pegylated IFN α2a (note, not 2b) appeared to increase short-term survival (14 days), although by 28 days only 10 of the patients were still living (6/20 survivors in treated group compared with 4/24 surviving in the comparison group) (Omrani et al.
       <xref ref-type="bibr" rid="B186">
        2014
       </xref>
       ).
      </p>
      <p>
       Among promising studies evaluating therapies in animal models, one
       <italic>
        in vivo
       </italic>
       study found that the combination of ribavirin and IFN α2b therapy significantly improved outcomes among MERS-CoV-infected rhesus monkeys (Falzarano et al.
       <xref ref-type="bibr" rid="B87">
        2013
       </xref>
       ). In another study, using the common marmoset model, lopinavir/ritonavir and IFN α1b (separately and in combination) also proved promising (Chan et al.
       <xref ref-type="bibr" rid="B51">
        2015
       </xref>
       ).
      </p>
      <p>
       Although neutralizing antibodies induced during infection did not appear to be protective during natural infection (Corman et al.
       <xref ref-type="bibr" rid="B63">
        2016
       </xref>
       , Zhao et al.
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ), human convalescent sera containing neutralizing antibodies conferred dose-dependent protection in a mouse model (Zhao et al.
       <xref ref-type="bibr" rid="B252">
        2017
       </xref>
       ). The readily available sera from MERS-immune camels apparently were also an effective treatment for MERS-infected mice and reduced the severity of pathological changes in murine lung tissue (Zhao et al.
       <xref ref-type="bibr" rid="B254">
        2015
       </xref>
       ). Several monoclonal antibodies (mAbs) (Mou et al.
       <xref ref-type="bibr" rid="B174">
        2013
       </xref>
       , Ohnuma et al.
       <xref ref-type="bibr" rid="B184">
        2013
       </xref>
       , Du et al.
       <xref ref-type="bibr" rid="B83">
        2014
       </xref>
       , Jiang et al.
       <xref ref-type="bibr" rid="B120">
        2014
       </xref>
       , Tang et al.
       <xref ref-type="bibr" rid="B225">
        2014
       </xref>
       , Ying et al.
       <xref ref-type="bibr" rid="B249">
        2014
       </xref>
       , Houser et al.
       <xref ref-type="bibr" rid="B114">
        2016
       </xref>
       ) and conventional antibodies (Zhao et al.
       <xref ref-type="bibr" rid="B251">
        2013
       </xref>
       ) have demonstrated effective neutralization of MERS-CoV, and could serve as potential therapeutic agents, at least in the interim.
      </p>
      <p>
       High-throughput screening and other methods have identified additional promising compounds in several classes (Chan et al.
       <xref ref-type="bibr" rid="B52">
        2013
       </xref>
       , de Wilde et al.
       <xref ref-type="bibr" rid="B73">
        2013
       </xref>
       ,
       <xref ref-type="bibr" rid="B72">
        2014
       </xref>
       , Gao et al.
       <xref ref-type="bibr" rid="B93">
        2013
       </xref>
       , Shirato et al.
       <xref ref-type="bibr" rid="B218">
        2013
       </xref>
       , Adedeji et al.
       <xref ref-type="bibr" rid="B5">
        2014
       </xref>
       , Dyall et al.
       <xref ref-type="bibr" rid="B84">
        2014
       </xref>
       , Hart et al.
       <xref ref-type="bibr" rid="B103">
        2014
       </xref>
       , Lu et al.
       <xref ref-type="bibr" rid="B146">
        2014
       </xref>
       , Lundin et al.
       <xref ref-type="bibr" rid="B147">
        2014
       </xref>
       , Tao et al.
       <xref ref-type="bibr" rid="B227">
        2014
       </xref>
       , Wrensch et al.
       <xref ref-type="bibr" rid="B242">
        2014
       </xref>
       , Corti et al.
       <xref ref-type="bibr" rid="B68">
        2015
       </xref>
       , Liu et al.
       <xref ref-type="bibr" rid="B143">
        2015
       </xref>
       ). These include inhibitors against both viral (Kilianski et al.
       <xref ref-type="bibr" rid="B126">
        2013
       </xref>
       , Lei et al.
       <xref ref-type="bibr" rid="B139">
        2014
       </xref>
       , Kumar et al.
       <xref ref-type="bibr" rid="B131">
        2017
       </xref>
       ) and host (Gierer et al.
       <xref ref-type="bibr" rid="B97">
        2015
       </xref>
       ) proteases needed to process the virus. However, it was reported that inhibiting proprotein convertases inhibits host cell processing of the spike protein but did not affect viral infectivity or cell-to-cell spread (Gierer et al.
       <xref ref-type="bibr" rid="B97">
        2015
       </xref>
       ).
      </p>
      <p>
       Other targets studied have included viral entry inhibitors (Zhao et al.
       <xref ref-type="bibr" rid="B251">
        2013
       </xref>
       , Du et al. 2015) and protein 4a, which the researchers found suppressed innate antiviral response (Siu et al.
       <xref ref-type="bibr" rid="B220">
        2014
       </xref>
       ).
      </p>
      <sec id="s009">
       <title>
        Vaccine development
       </title>
       <p>
        Development of a human (and possibly camel) vaccine for MERS-CoV should be a key priority, given concerns about its spread and pandemic potential, but vaccine development can be a long process that is often driven by economics (Modjarrad
        <xref ref-type="bibr" rid="B167">
         2016
        </xref>
        ).
       </p>
       <p>
        Much of the focus thus far has centered on the identification of the residues within the receptor-binding domain of the spike protein, conferring the best chance of protection (Du et al.
        <xref ref-type="bibr" rid="B81">
         2013a
        </xref>
        ,
        <xref ref-type="bibr" rid="B82">
         2013b
        </xref>
        , Lan et al.
        <xref ref-type="bibr" rid="B132">
         2014
        </xref>
        , Ma et al.
        <xref ref-type="bibr" rid="B148">
         2014a
        </xref>
        ,
        <xref ref-type="bibr" rid="B149">
         2014b
        </xref>
        ). A number of other antigens, some in viral vectors, have been tested in the laboratory (Song et al.
        <xref ref-type="bibr" rid="B222">
         2013
        </xref>
        , Kim et al.
        <xref ref-type="bibr" rid="B127">
         2014
        </xref>
        ).
       </p>
       <p>
        A replication defective full-length cDNA clone of the MERS-CoV genome has been developed for identifying future vaccine candidates (Almazán et al.
        <xref ref-type="bibr" rid="B20">
         2013
        </xref>
        ). Vaccine candidates for dromedary camels have also been investigated, and have been reported to elicit protective responses (using the MERS-CoV spike protein in a poxvirus vector) (Haagmans et al.
        <xref ref-type="bibr" rid="B102">
         2016
        </xref>
        ).
       </p>
       <p>
        There are special challenges to developing a MERS vaccine. The sporadic nature of human MERS-CoV infection and the difficulty of identifying suitable animal models for challenge studies make controlled trials difficult. Disease in camels usually appears mild (Adney et al.
        <xref ref-type="bibr" rid="B7">
         2014
        </xref>
        ), reducing the economic incentive for immunization. A camel vaccine could also be given in combination with a required vaccine, e.g., rabies, as suggested by Wirblich et al. (
        <xref ref-type="bibr" rid="B235">
         2017
        </xref>
        ), or camelpox, as suggested by Haagmans et al. (
        <xref ref-type="bibr" rid="B102">
         2016
        </xref>
        ).
       </p>
       <p>
        Correlates of protection and duration of immunity are also uncertain. There are reports of strong antibody responses (Haagmans et al.
        <xref ref-type="bibr" rid="B102">
         2016
        </xref>
        ), but it has been suggested that the presence of neutralizing antibodies may not be protective in camels (Hemida et al.
        <xref ref-type="bibr" rid="B107">
         2014
        </xref>
        ) or humans (Corman et al.
        <xref ref-type="bibr" rid="B63">
         2016
        </xref>
        , Zhao et al.
        <xref ref-type="bibr" rid="B252">
         2017
        </xref>
        ), and waning antibody titers have been reported in humans who have recovered from MERS-CoV infection (Choe et al.
        <xref ref-type="bibr" rid="B55">
         2017
        </xref>
        ). On the contrary, the reports of protection of mice by passive transfer of neutralizing antibodies suggest that this might be overcome by optimizing timing and dose (Zhao et al.
        <xref ref-type="bibr" rid="B252">
         2017
        </xref>
        ).
       </p>
       <p>
        Research on MERS-CoV vaccine candidates is ongoing, and at least one candidate vaccine has now progressed to a Phase I human clinical trial (Modjarrad
        <xref ref-type="bibr" rid="B167">
         2016
        </xref>
        , CEPI
        <xref ref-type="bibr" rid="B50">
         2017
        </xref>
        ). In a promising development, the recently launched Coalition for Epidemic Preparedness Innovations (CEPI) has listed MERS vaccine as one of its initial targets.
       </p>
      </sec>
     </sec>
     <sec id="s010">
      <title>
       Epidemiology and transmission
      </title>
      <p>
       The source of infection for most primary cases (the first known human case in a potential or putative chain of transmission) remains unknown. Baseline incidence and prevalence are unknown as only clinical cases or those found through contact tracing are generally identified. The few population-based studies that have been done appear to show low prevalence in the general population. A serological study of 10,009 individuals in Saudi Arabia found 15 seropositive for MERS-CoV, 7 of whom were occupationally camel-exposed (shepherds and slaughterhouse workers) (Müller et al.
       <xref ref-type="bibr" rid="B176">
        2015
       </xref>
       ), although the occupational samples were collected for a separate study and therefore may not be representative. In another study of 57,363 persons with suspected MERS-CoV infection tested by Saudi Arabia from April 2015 to February 2016, only 384 (0.7%) tested positive (Bin Saeed et al.
       <xref ref-type="bibr" rid="B41">
        2017
       </xref>
       ).
      </p>
      <p>
       Most work has been done on symptomatic MERS patients because they are most likely to be detected and identified. Even so, one analysis suggested that at least 62% of even symptomatic cases were undetected (Cauchemez et al.
       <xref ref-type="bibr" rid="B48">
        2014
       </xref>
       ), and a study using data from travelers suggested that there may have been as many as 3250 severe cases from September 2012 to January 2016, about 2.3 times the number of cases confirmed (O'Hagan et al.
       <xref ref-type="bibr" rid="B182">
        2016
       </xref>
       ).
      </p>
      <p>
       Determination of primary versus secondary cases is also challenging. One estimate is that 61% of MERS-CoV are primary cases, who tend to be mostly middle-aged males, compared with secondary cases who tend to be younger and distributed more evenly by sex (Gossner et al.
       <xref ref-type="bibr" rid="B98">
        2016
       </xref>
       ). The official overall CFR stands at ∼35.5% (World Health Organization
       <xref ref-type="bibr" rid="B239">
        2018a
       </xref>
       ). However, it has been suggested that the CFR among primary cases, estimated to be 74%, is likely inflated due to detection bias; CFR among secondary cases is estimated to be 20% (Cauchemez et al.
       <xref ref-type="bibr" rid="B48">
        2014
       </xref>
       ).
      </p>
      <p>
       The main known exposures are health care-associated infections and contact with camels. Aside from the health care setting, the mechanisms for the introduction of the virus into human populations are poorly understood. Occupational exposure risks are also poorly characterized, both in health care and for those who work with camels.
      </p>
      <p>
       As with SARS, many cases have been health care facility-associated (Drosten et al.
       <xref ref-type="bibr" rid="B79">
        2015
       </xref>
       ), but the mechanism of infection is unclear for many individuals (Fanoy et al.
       <xref ref-type="bibr" rid="B89">
        2014
       </xref>
       ). Active case finding, typically among perceived risk groups or those hospitalized with pneumonia, has been used with varying success to identify cases (Gierer et al.
       <xref ref-type="bibr" rid="B96">
        2013
       </xref>
       , Aburizaiza et al.
       <xref ref-type="bibr" rid="B4">
        2014
       </xref>
       , Memish et al.
       <xref ref-type="bibr" rid="B156">
        2014a
       </xref>
       ).
      </p>
      <p>
       Nosocomial transmission due to inadequate infection control is well established as a significant driver of MERS-CoV infections in humans (Al-Abdallat et al.
       <xref ref-type="bibr" rid="B11">
        2014
       </xref>
       , Maltezou and Tsiodras
       <xref ref-type="bibr" rid="B154">
        2014
       </xref>
       , Oboho et al.
       <xref ref-type="bibr" rid="B183">
        2015
       </xref>
       , Alraddadi et al.
       <xref ref-type="bibr" rid="B21">
        2016
       </xref>
       , Assiri et al.
       <xref ref-type="bibr" rid="B31">
        2016
       </xref>
       , Hastings et al.
       <xref ref-type="bibr" rid="B104">
        2016
       </xref>
       ), notably during the spring 2014 outbreak in Saudi Arabia and the late spring 2015 outbreak in South Korea. A review (Maltezou and Tsiodras
       <xref ref-type="bibr" rid="B154">
        2014
       </xref>
       ) of 536 known MERS-CoV cases at the time of the review using publicly available data found 11 possible or confirmed health care-associated transmission events leading to substantial morbidity and mortality, often involving patients having comorbidities.
      </p>
      <p>
       Infection control lapses were apparently responsible for virtually all reported health care transmission events, highlighting the need for strengthened infection control capacity worldwide. However, specific breaches in infection control were usually not identified and probably varied (Maltezou and Tsiodras
       <xref ref-type="bibr" rid="B154">
        2014
       </xref>
       ). Some high-risk procedures were identified, usually aerosol generating procedures, including hemodialysis and respiratory intensive care (Assiri et al.
       <xref ref-type="bibr" rid="B33">
        2013b
       </xref>
       ).
      </p>
      <p>
       Secondarily infected health care workers tended to have milder symptoms and better prognoses. In the 2014 outbreak in Saudi Arabia, one study analyzed 191 symptomatic cases of MERS-CoV and found that 20.9% were health care workers (additional infected health care workers were asymptomatic, so that 30.6% of the 255 total cases analyzed were health care workers), and most patients had contact with a health care facility (Oboho et al.
       <xref ref-type="bibr" rid="B183">
        2015
       </xref>
       ). In a cluster of 9 MERS-CoV cases in Jordan, 6 were health care workers at the outbreak hospital, and no MERS-CoV transmission was detected at 2 transfer hospitals with adequate infection control (Al-Abdallat et al.
       <xref ref-type="bibr" rid="B11">
        2014
       </xref>
       ).
      </p>
      <p>
       A health care-associated outbreak occurred in South Korea in the late spring of 2015 through July 2015, arising from one infected individual returning from the Gulf states (Cowling et al.
       <xref ref-type="bibr" rid="B71">
        2015
       </xref>
       , Hui et al.
       <xref ref-type="bibr" rid="B115">
        2015
       </xref>
       , Park et al.
       <xref ref-type="bibr" rid="B189">
        2015
       </xref>
       ). An analysis of 185 South Korean MERS-CoV cases using publicly available data delineated three generations of secondary infections (more than half of the cases were from the second generation) (Lee and Wong
       <xref ref-type="bibr" rid="B138">
        2015
       </xref>
       ). Overall, 154 cases were hospital-associated (Lee and Wong
       <xref ref-type="bibr" rid="B138">
        2015
       </xref>
       ), primarily affecting non-health care workers, spread by conditions such as close contact with the patients in crowded hospital or emergency rooms (Lee
       <xref ref-type="bibr" rid="B137">
        2015b
       </xref>
       ) and patients switching facilities (Lee
       <xref ref-type="bibr" rid="B136">
        2015a
       </xref>
       ,
       <xref ref-type="bibr" rid="B137">
        2015b
       </xref>
       ).
      </p>
      <p>
       Direct contact could be inferred in only about 10% of the cases, and some authors suggested that fomite transmission could be important (Lee and Wong
       <xref ref-type="bibr" rid="B138">
        2015
       </xref>
       , Seo et al.
       <xref ref-type="bibr" rid="B215">
        2016
       </xref>
       , also reviewed in Otter et al.
       <xref ref-type="bibr" rid="B187">
        2016
       </xref>
       ). Earlier reports demonstrated that MERS-CoV is relatively stable in the environment, reported recoverable on surfaces after 48 h at 20°C and 48% relative humidity and for at least 12 h at 30°C with 30% humidity (van Doremalen et al.
       <xref ref-type="bibr" rid="B231">
        2013
       </xref>
       ), or in liquid at 25°C after 2 h (Leclercq et al.
       <xref ref-type="bibr" rid="B135">
        2014
       </xref>
       ). In a study of four laboratory-confirmed MERS-CoV patient rooms in two South Korean hospitals, MERS-CoV viral RNA was found on environmental surfaces, including bedsheets and medical equipment, up to 5 days after a patient's last PCR-positive respiratory specimen; viable virus was also detected (Seo et al.
       <xref ref-type="bibr" rid="B215">
        2016
       </xref>
       ).
      </p>
      <p>
       However, there were apparently few reports of infections in hospital laundry or maintenance workers, contrary to what would be expected for environmental transmission. It is possible that they were not identified or reported. We could find only two publications specifically mentioning infection in hospital cleaners (Hastings et al.
       <xref ref-type="bibr" rid="B104">
        2016
       </xref>
       , Liu et al.
       <xref ref-type="bibr" rid="B144">
        2016
       </xref>
       ). Hastings et al. (
       <xref ref-type="bibr" rid="B104">
        2016
       </xref>
       ) investigated a 2014 outbreak in King Fahd General Hospital and reported 1 MERS-CoV case among 1295 maintenance or housekeeping personnel. However, it appears that only symptomatic cases were tested, and specific details on this case were not provided.
      </p>
      <p>
       Many reports from contact tracing identified family members, friends, coworkers, and other persons who had close contact with the patient. These include reports from Saudi Arabia (Memish et al.
       <xref ref-type="bibr" rid="B162">
        2013b
       </xref>
       , Omrani et al.
       <xref ref-type="bibr" rid="B185">
        2013
       </xref>
       , Drosten et al.
       <xref ref-type="bibr" rid="B77">
        2014
       </xref>
       ), as well as the United Kingdom (Pebody et al.
       <xref ref-type="bibr" rid="B193">
        2012
       </xref>
       , Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team
       <xref ref-type="bibr" rid="B105">
        2013
       </xref>
       , Thomas et al.
       <xref ref-type="bibr" rid="B228">
        2014
       </xref>
       ), Iran (Yavarian et al.
       <xref ref-type="bibr" rid="B248">
        2015
       </xref>
       ), Tunisia (Abroug et al.
       <xref ref-type="bibr" rid="B3">
        2014
       </xref>
       ), China (Wu et al.
       <xref ref-type="bibr" rid="B243">
        2015
       </xref>
       ), Greece (Tsiodras et al.
       <xref ref-type="bibr" rid="B229">
        2014
       </xref>
       ), Germany (Buchholz et al.
       <xref ref-type="bibr" rid="B45">
        2013
       </xref>
       , Reuss et al.
       <xref ref-type="bibr" rid="B211">
        2014
       </xref>
       ), Malaysia (Premila Devi et al.
       <xref ref-type="bibr" rid="B197">
        2014
       </xref>
       ), France (Mailles et al.
       <xref ref-type="bibr" rid="B150">
        2013
       </xref>
       ), and Italy (Puzelli et al.
       <xref ref-type="bibr" rid="B199">
        2013
       </xref>
       ).
      </p>
      <p>
       Family clusters were identified in a number of these reports, but at most only a small percentage of contacts became cases, suggesting that close contact is not as important a risk factor as health care-associated transmission, and direct human-to-human transmission appears limited. Although the outbreak in South Korea also involved close contact among family members and other patients in hospital rooms, this may be more appropriately categorized as health care-associated transmission (Kang et al.
       <xref ref-type="bibr" rid="B121">
        2017
       </xref>
       ).
      </p>
      <p>
       However, there is relatively little information on asymptomatic individuals, most of whom are detected by contact tracing. In one study, an asymptomatic health care worker excreted MERS-CoV for over 5 weeks (Al-Gethamy et al.
       <xref ref-type="bibr" rid="B12">
        2015
       </xref>
       ). In the spring 2014 outbreak in Saudi Arabia, an estimated 25.1% of laboratory-confirmed MERS-CoV was asymptomatic (Oboho et al.
       <xref ref-type="bibr" rid="B183">
        2015
       </xref>
       ). An analysis of 65 MERS-CoV patients in United Arab Emirates found that 35% were asymptomatic, and 1 individual yielded positive lower respiratory tract specimens for more than 2 weeks (Hosani et al.
       <xref ref-type="bibr" rid="B113">
        2016
       </xref>
       ). Al Hammadi et al. reported two asymptomatic men who had contact with infected camels; infection was confirmed by PCR in both men, and in all eight camels in the group (Al Hammadi et al.
       <xref ref-type="bibr" rid="B10">
        2015
       </xref>
       ). However, the actual frequency of asymptomatic individuals compared with symptomatic individuals is largely unknown.
      </p>
      <p>
       Parameters for transmission dynamics are important for mathematical modeling of spread. Due to the heterogeneity in transmission, an important characteristic of infection dynamics, R
       <sub>
        0
       </sub>
       (the basic reproductive rate in a susceptible population), has been difficult to pinpoint. Estimates have ranged from 0.50 to 0.69 (Breban et al.
       <xref ref-type="bibr" rid="B43">
        2013
       </xref>
       , Poletto et al.
       <xref ref-type="bibr" rid="B196">
        2014
       </xref>
       ) to between 0.8 and 1.3 (Cauchemez et al.
       <xref ref-type="bibr" rid="B48">
        2014
       </xref>
       ). R
       <sub>
        0
       </sub>
       &gt; 1 is required for an outbreak to be self-sustaining (Anderson and May
       <xref ref-type="bibr" rid="B25">
        1991
       </xref>
       ). For specific locations, one model suggested an R
       <sub>
        0
       </sub>
       of 3.5–6.7 in Jeddah and 2.0–2.8 in Riyadh (Majumder et al.
       <xref ref-type="bibr" rid="B151">
        2014
       </xref>
       ), but these likely did not correct for effect of superspreading in health care settings (Kucharski and Althaus
       <xref ref-type="bibr" rid="B130">
        2015
       </xref>
       ). One mathematical model suggested the risk of secondary transmission following an imported MERS-CoV case is 22.7% (95% CI: 19.2–25.1%), with the risks of generations 2, 3, and 4 estimated to be 10.5%, 6.1%, and 3.9%, respectively (Nishiura et al.
       <xref ref-type="bibr" rid="B180">
        2015
       </xref>
       ).
      </p>
      <sec id="s011">
       <title>
        Travel-related cases
       </title>
       <p>
        Despite the mass gathering of individuals at the annual Hajj pilgrimage (Khan et al.
        <xref ref-type="bibr" rid="B125">
         2013
        </xref>
        ), to date it has not resulted in any known MERS-CoV transmission events (Barasheed et al.
        <xref ref-type="bibr" rid="B36">
         2014
        </xref>
        , Benkouiten et al.
        <xref ref-type="bibr" rid="B40">
         2014
        </xref>
        , Gautret et al.
        <xref ref-type="bibr" rid="B94">
         2014
        </xref>
        , Memish et al.
        <xref ref-type="bibr" rid="B157">
         2014b
        </xref>
        ,
        <xref ref-type="bibr" rid="B158">
         2014c
        </xref>
        , Aberle et al.
        <xref ref-type="bibr" rid="B2">
         2015
        </xref>
        , Annan et al.
        <xref ref-type="bibr" rid="B26">
         2015
        </xref>
        ), confirming modeling estimates for the 2014 Hajj (Lessler et al.
        <xref ref-type="bibr" rid="B141">
         2014
        </xref>
        ). Two travelers returning to the Netherlands from a separate pilgrimage (Umrah) in May 2014 were found to have MERS-CoV (Kraaij-Dirkzwager et al.
        <xref ref-type="bibr" rid="B129">
         2014
        </xref>
        ). Many of the travel-related cases have been tabulated (Pavli et al.
        <xref ref-type="bibr" rid="B190">
         2014
        </xref>
        , Sridhar et al.
        <xref ref-type="bibr" rid="B224">
         2015
        </xref>
        , Carias et al.
        <xref ref-type="bibr" rid="B47">
         2016
        </xref>
        ). In all these cases, casual transmission (outside of family and health care settings) has not been observed.
       </p>
      </sec>
     </sec>
     <sec id="s012">
      <title>
       The animal interface and search for natural and reservoir hosts of MERS-CoV
      </title>
      <p>
       Dromedary camels are the only documented zoonotic source of human infection, and there is considerable circumstantial evidence supporting camel-to-human transmission, including evidence of camels and humans becoming infected with an identical MERS-CoV (Azhar et al.
       <xref ref-type="bibr" rid="B34">
        2014
       </xref>
       , Ferguson and Kerkhove
       <xref ref-type="bibr" rid="B92">
        2014
       </xref>
       , Memish et al.
       <xref ref-type="bibr" rid="B160">
        2014e
       </xref>
       ). Identical genomic sequences of MERS-CoV were isolated from a camel owner who died from MERS-CoV and his camel who had rhinorrhea at that time; identical MERS-CoV RNA fragments were later detected in the air at the camel barn (Azhar et al.
       <xref ref-type="bibr" rid="B35">
        2014
       </xref>
       ). Serology suggested that the camel was infected before the owner (Azhar et al.
       <xref ref-type="bibr" rid="B34">
        2014
       </xref>
       ). Critics have suggested that the identical sequences may be due to cross-contamination (Drosten et al.
       <xref ref-type="bibr" rid="B78">
        2014
       </xref>
       ), but the authors maintain that the isolates were collected on different days and processed in different facilities. Other epidemiologic investigations have found similar evidence, but directionality was not implied (Ferguson and Kerkhove
       <xref ref-type="bibr" rid="B92">
        2014
       </xref>
       , Memish et al.
       <xref ref-type="bibr" rid="B160">
        2014e
       </xref>
       ).
      </p>
      <p>
       In outbreak sites, viral genomic sequences from camels have matched those published for humans, and one analysis of MERS-CoV among camels showed that many of the camel viruses can be classified into clades that correlate with human outbreaks (Alagaili et al.
       <xref ref-type="bibr" rid="B15">
        2014
       </xref>
       ). Interestingly, three dromedary camel strains of MERS-CoV had similar viral replication competence to human strains in Vero-E6 cells and human respiratory tract explants (Chan et al.
       <xref ref-type="bibr" rid="B53">
        2014
       </xref>
       ).
      </p>
      <p>
       This evidence suggests that camels would appear involved in cross-species transmission of MERS-CoV, although the precise mechanism and frequency remain uncertain.
      </p>
      <p>
       Occupational exposure to camels would seem a particularly strong risk factor for infection, but its relative importance and relative risk of different exposures are not well documented (Hemida et al.
       <xref ref-type="bibr" rid="B106">
        2015
       </xref>
       ). As camels are widely used in the region for a variety of purposes, many people have contact with camels, and exposure is often invoked in nonoccupational primary cases. Assessment of camel exposure is further complicated by the varying and sometimes vague definitions used to classify camel exposure, and the multiple types of possible exposures. Even so, it has been hypothesized that camel exposure is commonly underreported (Gossner et al.
       <xref ref-type="bibr" rid="B98">
        2016
       </xref>
       ). There is a critical need for clearer definitions and measurements of “camel exposure,” and to standardize methodology.
      </p>
      <p>
       Evidence to date indicates that MERS-like coronaviruses have been circulating in camels since at least the 1980s, before the first detection of MERS-CoV in humans (Müller et al.
       <xref ref-type="bibr" rid="B175">
        2014
       </xref>
       ). Seropositivity has been found consistently in African and Middle Eastern camels since 1983 (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ). There is virologic evidence of MERS-CoV infection in camels in Qatar (Ferguson and Kerkhove
       <xref ref-type="bibr" rid="B92">
        2014
       </xref>
       , Haagmans et al.
       <xref ref-type="bibr" rid="B101">
        2014
       </xref>
       , Raj et al.
       <xref ref-type="bibr" rid="B201">
        2014
       </xref>
       ), Egypt (Chu et al.
       <xref ref-type="bibr" rid="B58">
        2014
       </xref>
       , Ali et al.
       <xref ref-type="bibr" rid="B18">
        2017a
       </xref>
       , 2017b), Oman (Nowotny and Kolodziejek
       <xref ref-type="bibr" rid="B181">
        2014
       </xref>
       ), Saudi Arabia (Hemida et al.
       <xref ref-type="bibr" rid="B107">
        2014
       </xref>
       ), Sudan, and elsewhere (Chu et al.
       <xref ref-type="bibr" rid="B56">
        2015
       </xref>
       , Ali et al.
       <xref ref-type="bibr" rid="B18">
        2017a
       </xref>
       ).
      </p>
      <table-wrap id="T1" orientation="portrait" position="float">
       <label>
        Table 1.
       </label>
       <caption>
        <p>
         Location, Methods, and Results of Recent Middle East Respiratory Syndrome Coronavirus Camel Seroprevalence Studies
        </p>
       </caption>
       <!--OASIS TABLE HERE-->
       <table frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="left">
           <italic>
            Countries (reference)
           </italic>
          </th>
          <th align="center">
           <italic>
            Year(s)
           </italic>
          </th>
          <th align="center">
           <italic>
            Test(s) used
           </italic>
           <sup>
            <xref ref-type="table-fn" rid="tf1">
             a
            </xref>
           </sup>
          </th>
          <th align="center">
           <italic>
            No. of samples
           </italic>
          </th>
          <th align="center">
           <italic>
            No. of positives (%)
           </italic>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Egypt (Perera et al.
           <xref ref-type="bibr" rid="B194">
            2013
           </xref>
           )
          </td>
          <td align="center">
           2013
          </td>
          <td align="left">
           ppNT
          </td>
          <td align="center">
           110
          </td>
          <td align="center">
           108 (98.2)
          </td>
         </tr>
         <tr>
          <td align="left" rowspan="2">
           Egypt, Somalia, Sudan (Müller et al.
           <xref ref-type="bibr" rid="B175">
            2014
           </xref>
           )
          </td>
          <td align="center" rowspan="2">
           1983–1997
          </td>
          <td align="left">
           rELISA
          </td>
          <td align="center" rowspan="2">
           189
          </td>
          <td align="center">
           159 (84.1)
          </td>
         </tr>
         <tr>
          <td align="left">
           MNT
          </td>
          <td align="center">
           153 (81.0)
          </td>
         </tr>
         <tr>
          <td align="left">
           Egypt, Sudan, others (Ali et al.
           <xref ref-type="bibr" rid="B18">
            2017a
           </xref>
           )
          </td>
          <td align="center">
           2015–2016
          </td>
          <td align="left">
           MNT
          </td>
          <td align="center">
           1031
          </td>
          <td align="center">
           871 (84.5)
           <sup>
            <xref ref-type="table-fn" rid="tf2">
             b
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left">
           Ethiopia (Reusken et al.
           <xref ref-type="bibr" rid="B208">
            2014b
           </xref>
           )
          </td>
          <td align="center">
           2010–2011
          </td>
          <td align="left">
           S1 microarray
          </td>
          <td align="center">
           188
          </td>
          <td align="center">
           181 (96.3)
           <sup>
            <xref ref-type="table-fn" rid="tf3">
             c
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left">
           Jordan (Reusken et al.
           <xref ref-type="bibr" rid="B206">
            2013b
           </xref>
           )
          </td>
          <td align="center">
           2013
          </td>
          <td align="left">
           Nt
          </td>
          <td align="center">
           11
          </td>
          <td align="center">
           11 (100.0)
          </td>
         </tr>
         <tr>
          <td align="left" rowspan="3">
           Kenya (Corman et al.
           <xref ref-type="bibr" rid="B65">
            2014b
           </xref>
           )
          </td>
          <td align="center" rowspan="3">
           1992–2013
          </td>
          <td align="left">
           rELISA
          </td>
          <td align="center" rowspan="3">
           774
          </td>
          <td align="center">
           228 (29.5)
          </td>
         </tr>
         <tr>
          <td align="left">
           IFA
          </td>
          <td align="center">
           213 (27.5)
          </td>
         </tr>
         <tr>
          <td align="left">
           MNT
          </td>
          <td align="center">
           133 (17.2)
          </td>
         </tr>
         <tr>
          <td align="left">
           Nigeria (Reusken et al.
           <xref ref-type="bibr" rid="B208">
            2014b
           </xref>
           )
          </td>
          <td align="center">
           2010–2011
          </td>
          <td align="left">
           S1 microarray
          </td>
          <td align="center">
           358
          </td>
          <td align="center">
           337 (94.1)
           <sup>
            <xref ref-type="table-fn" rid="tf3">
             c
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left">
           Oman (Reusken et al.
           <xref ref-type="bibr" rid="B209">
            2013c
           </xref>
           )
          </td>
          <td align="center">
           2013
          </td>
          <td align="left">
           PRNT
          </td>
          <td align="center">
           50
          </td>
          <td align="center">
           50 (100.0)
          </td>
         </tr>
         <tr>
          <td align="left" rowspan="2">
           Saudi Arabia (Alagaili et al.
           <xref ref-type="bibr" rid="B15">
            2014
           </xref>
           )
          </td>
          <td align="center">
           1992–2010
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="center">
           264
          </td>
          <td align="center">
           230 (87.1)
          </td>
         </tr>
         <tr>
          <td align="center">
           2013
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="center">
           203
          </td>
          <td align="center">
           150 (73.9)
          </td>
         </tr>
         <tr>
          <td align="left">
           Saudi Arabia (Hemida et al.
           <xref ref-type="bibr" rid="B107">
            2014
           </xref>
           )
          </td>
          <td align="center">
           1993
          </td>
          <td align="left">
           ppNT
          </td>
          <td align="center">
           131
          </td>
          <td align="center">
           118 (90.1)
          </td>
         </tr>
         <tr>
          <td align="left">
           Saudi Arabia (Hemida et al.
           <xref ref-type="bibr" rid="B108">
            2013
           </xref>
           )
          </td>
          <td align="center">
           2012–2013
          </td>
          <td align="left">
           ppNT
          </td>
          <td align="center">
           310
          </td>
          <td align="center">
           280 (90.3)
          </td>
         </tr>
         <tr>
          <td align="left">
           Tunisia (Reusken et al.
           <xref ref-type="bibr" rid="B208">
            2014b
           </xref>
           )
          </td>
          <td align="center">
           2009
          </td>
          <td align="left">
           S1 microarray
          </td>
          <td align="center">
           204
          </td>
          <td align="center">
           99 (48.5)
           <sup>
            <xref ref-type="table-fn" rid="tf3">
             c
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" rowspan="2">
           United Arab Emirates (Meyer et al.
           <xref ref-type="bibr" rid="B164">
            2014
           </xref>
           )
          </td>
          <td align="center" rowspan="2">
           2003, 2013
          </td>
          <td align="left">
           rIFA
          </td>
          <td align="center" rowspan="2">
           651
          </td>
          <td align="center">
           632 (97.1)
          </td>
         </tr>
         <tr>
          <td align="left">
           Nt
          </td>
          <td align="center">
           509 (80.5)
          </td>
         </tr>
         <tr>
          <td align="left">
           United Arab Emirates (Alexandersen et al.
           <xref ref-type="bibr" rid="B16">
            2014
           </xref>
           )
          </td>
          <td align="center">
           2005
          </td>
          <td align="left">
           Nt
          </td>
          <td align="center">
           11
          </td>
          <td align="center">
           9 (81.8)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="tf1">
         <label>
          <sup>
           a
          </sup>
         </label>
         <p>
          ppNT, pseudoparticle neutralization; rELISA, recombinant enzyme-linked immunosorbent assay; MNT, microneutralization; PRNT, plaque reduction neutralization test; rIFA, recombinant immunofluorescence assay; Nt, serum neutralization.
         </p>
        </fn>
        <fn id="tf2">
         <label>
          <sup>
           b
          </sup>
         </label>
         <p>
          Seroprevalence reported higher in camels imported from Sudan (543/594; 88.7%) and East Africa (71/98; 72.4%) than resident (257/339; 5.8%); total 41/1078 nasal swabs reported PCR positive, 35/41 from Sudan.
         </p>
        </fn>
        <fn id="tf3">
         <label>
          <sup>
           c
          </sup>
         </label>
         <p>
          The exact number was not reported, and has been imputed from the reported percentages.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       Increasing genomic evidence suggests a diversity of coronaviruses in camels throughout the Middle East and Africa, including in major source countries for camel imports to the Middle East, cross-neutralizing with MERS-CoV but having divergent sequences and probably not human pathogens (Chu et al.
       <xref ref-type="bibr" rid="B56">
        2015
       </xref>
       ,
       <xref ref-type="bibr" rid="B57">
        2018
       </xref>
       ). This may explain the high apparent seropositivity in camels in Africa in the absence of known human cases of MERS.
      </p>
      <p>
       Maintenance of the virus in the camel population remains an open question. Symptomatic MERS-CoV infection has been documented in both calves and adult camels (Adney et al.
       <xref ref-type="bibr" rid="B7">
        2014
       </xref>
       ), and viral shedding was detected in nasal secretions up to 7 days postinoculation with MERS-CoV (Adney et al.
       <xref ref-type="bibr" rid="B7">
        2014
       </xref>
       ), as well as in milk and possibly feces (Hemida et al.
       <xref ref-type="bibr" rid="B107">
        2014
       </xref>
       , Reusken et al.
       <xref ref-type="bibr" rid="B207">
        2014a
       </xref>
       ). Camel milk has been suggested as a possible source of infection for both humans and camel foals (Hemida et al.
       <xref ref-type="bibr" rid="B107">
        2014
       </xref>
       , Reusken et al.
       <xref ref-type="bibr" rid="B207">
        2014a
       </xref>
       , van Doremalen et al.
       <xref ref-type="bibr" rid="B230">
        2014
       </xref>
       ). One study demonstrated that added MERS-CoV can survive in milk for at least 48 h at both 4°C and 22°C, although not detected after pasteurization (van Doremalen et al.
       <xref ref-type="bibr" rid="B232">
        2014
       </xref>
       ).
      </p>
      <p>
       Other possible livestock hosts for MERS-CoV have been investigated, and have generally been negative (Hemida et al.
       <xref ref-type="bibr" rid="B108">
        2013
       </xref>
       , Perera et al.
       <xref ref-type="bibr" rid="B194">
        2013
       </xref>
       , Reusken et al.
       <xref ref-type="bibr" rid="B206">
        2013b
       </xref>
       ,
       <xref ref-type="bibr" rid="B209">
        2013c
       </xref>
       , Alagaili et al.
       <xref ref-type="bibr" rid="B15">
        2014
       </xref>
       , Alexandersen et al.
       <xref ref-type="bibr" rid="B16">
        2014
       </xref>
       , van Doremalen et al.
       <xref ref-type="bibr" rid="B230">
        2014
       </xref>
       , Meyer et al.
       <xref ref-type="bibr" rid="B163">
        2015
       </xref>
       ). One study found 15 seropositive alpacas, which are members of the camelid family, in Qatar (Reusken et al.
       <xref ref-type="bibr" rid="B210">
        2016
       </xref>
       ). Experimentally infected alpacas in one study demonstrated upper respiratory tract infection, viral shedding, and transmission to other alpacas (Adney et al.
       <xref ref-type="bibr" rid="B6">
        2016
       </xref>
       ).
      </p>
      <p>
       The search for the origins and natural hosts of MERS-CoV continues. Bat species across the world are known to host a wide variety of coronaviruses, including beta-coronaviruses (the genus to which MERS-CoV belongs) (Anthony et al.
       <xref ref-type="bibr" rid="B29">
        2013
       </xref>
       , Corman et al.
       <xref ref-type="bibr" rid="B67">
        2013
       </xref>
       , Lelli et al.
       <xref ref-type="bibr" rid="B140">
        2013
       </xref>
       , Memish et al.
       <xref ref-type="bibr" rid="B161">
        2013a
       </xref>
       ), and bats tend to show greater coronavirus diversity than other mammals (Drexler et al.
       <xref ref-type="bibr" rid="B76">
        2014
       </xref>
       , Anthony et al.
       <xref ref-type="bibr" rid="B27">
        2017
       </xref>
       ). Consequently, much research has focused on the possible origin of MERS-CoV in bats. Possibly further supporting this hypothesis, in bat cell lines MERS-CoV has been reported to replicate only in those cell lines that express DPP4, the functional human receptor for the virus, and not in bat cell lines lacking DPP4 expression (Raj et al.
       <xref ref-type="bibr" rid="B202">
        2013
       </xref>
       , Cai et al.
       <xref ref-type="bibr" rid="B46">
        2014
       </xref>
       ).
      </p>
      <p>
       It is possible that MERS-CoV itself may be a relatively new introduction in humans. A phylogenetic analysis utilizing 65 complete or partially complete MERS-CoV genomic sequences (32 from Saudi Arabian cases in 2013) estimated that the most recent common ancestor was in March 2012 (95% CI: December 2011–June 2012) (Cotten et al.
       <xref ref-type="bibr" rid="B70">
        2014
       </xref>
       ).
      </p>
      <p>
       One study, from analysis of an S1 subunit in its spike gene, suggested that MERS-CoV may have arisen from intraspike recombination between two ancestral coronaviruses (Corman et al. 2014).
      </p>
      <p>
       The virus has not been isolated from a bat, although a portion of MERS-CoV RNA sequence apparently was identified in a bat (the insectivorous bat
       <italic>
        Taphozous perforatus
       </italic>
       , the Egyptian tomb bat) in Saudi Arabia in the same site as an early human case (100% nucleotide match, although this was only ∼180 nucleotides in the relatively well-conserved RdRp region) (Memish et al.
       <xref ref-type="bibr" rid="B161">
        2013a
       </xref>
       ). MERS-like coronaviruses, including the closely related HKU4, which also uses a DPP4 receptor, and HKU5, first identified by Woo et al. in 2006 (Woo et al.
       <xref ref-type="bibr" rid="B237">
        2006
       </xref>
       , Lau et al.
       <xref ref-type="bibr" rid="B133">
        2013
       </xref>
       , Matthews et al.
       <xref ref-type="bibr" rid="B155">
        2014
       </xref>
       , Wang et al.
       <xref ref-type="bibr" rid="B234">
        2014
       </xref>
       ), and others have been identified in bat species in China (Matthews et al.
       <xref ref-type="bibr" rid="B155">
        2014
       </xref>
       , Yang et al.
       <xref ref-type="bibr" rid="B244">
        2014
       </xref>
       ), Mexico (Anthony et al.
       <xref ref-type="bibr" rid="B29">
        2013
       </xref>
       ), South Africa (Ithete et al.
       <xref ref-type="bibr" rid="B119">
        2013
       </xref>
       , Corman et al.
       <xref ref-type="bibr" rid="B64">
        2014a
       </xref>
       ), and Uganda (Anthony et al.
       <xref ref-type="bibr" rid="B28">
        2017
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="s013" sec-type="discussion">
     <title>
      Discussion and Conclusions
     </title>
     <p>
      Since the detection of MERS-CoV in 2012, a large body of research has been amassed, as evidenced by the hundreds of unique results from our database searches. The virus has rapidly been characterized, and its functional human receptor swiftly identified. Species and cellular tropism studies have complemented clinical investigations, and laboratory work has provided further insights on MERS-CoV pathogenesis.
     </p>
     <p>
      Observational research from outbreaks in the Middle East and South Korea has generated a growing repository of clinical data, basic epidemiology, and genome sequences. Other studies have evaluated the roles of human/animal interfaces, health care settings, family clusters, and travel in MERS-CoV transmission. Furthermore, bats have been implicated as the possible origin of MERS-CoV, while dromedary camels have been shown to be likely sources of many human infections. There has been progress in developing therapeutics and vaccines. Although these have not yet progressed to full clinical trials, they could in the foreseeable future.
     </p>
     <p>
      A major reason we undertook this review was to determine what gaps still exist. Of the publications we originally identified, the largest category (80 publications) was in laboratory or basic science studies, followed by surveillance (59), animal interfaces (55), clinical aspects and health care (50), therapeutics and vaccines (42), while human transmission and epidemiology was one of the sparsest (35, including investigations of hospital outbreaks and travel-related cases), noting that these categories are not necessarily exclusive and there is overlap.
     </p>
     <p>
      In general, continued surveillance for MERS-CoV in affected countries should continue, prioritizing surveillance in humans, camels, and bats, given their apparent importance. As serology may not be reliable, due to cross-reactions and possibly waning antibodies, virologic surveillance and sequencing should also be attempted on selected specimens whenever feasible.
     </p>
     <p>
      Although the role of bats is yet to be fully elucidated, and evidence is lacking that bats are a source of human infection, the diversity of coronaviruses, including MERS-like coronaviruses, in bat species across the globe indicates that continued research and ongoing surveillance of coronaviruses in bats are justified (Lau et al.
      <xref ref-type="bibr" rid="B133">
       2013
      </xref>
      , Lelli et al.
      <xref ref-type="bibr" rid="B140">
       2013
      </xref>
      , Yang et al.
      <xref ref-type="bibr" rid="B245">
       2014
      </xref>
      ).
     </p>
     <p>
      A number of key gaps remain in epidemiology, including transmission, population-based incidence or prevalence rates, and geographic and demographic distributions of infections. Based on the limited human seroprevalence data so far, it seems likely that population prevalence is low, but the baseline should be established. It is also not clear whether seropositivity is a reliable indicator of prior infection. The finding of variable low antibody titers at 1 year postinfection (Choe et al.
      <xref ref-type="bibr" rid="B55">
       2017
      </xref>
      ) indicates that methods other than traditional serosurveys may be required (Reusken et al.
      <xref ref-type="bibr" rid="B205">
       2013a
      </xref>
      , Malik et al.
      <xref ref-type="bibr" rid="B153">
       2016
      </xref>
      ). If serology is not reliable, this raises the question of how to screen populations. There are methods that are both more sensitive and more specific for antibody detection (Mishra et al.
      <xref ref-type="bibr" rid="B166">
       2018
      </xref>
      ), as well as assays of cellular immunity (Zhao et al.
      <xref ref-type="bibr" rid="B252">
       2017
      </xref>
      ), but are costlier and more difficult for population screening.
     </p>
     <p>
      Contact tracing has identified asymptomatic infections, but studies of their frequency and transmissibility have been limited. Many of those infected are health care workers in whom these questions could be systematically studied. Relatively little is known about the natural history of human asymptomatic infections. Further studies of virus shedding, seroconversion, and transmission in asymptomatic infections are needed. Some evidence suggests that secondary cases have lower average CFRs and that subsequent links in the chain of MERS-CoV infection may decrease in severity.
     </p>
     <p>
      Exposure in most primary cases is still largely inferential at best. While camels are apparently often the likely source, the definitions of camel exposure are varied, preventing clear epidemiological inferences. Definitions of the exposures and the methodology and metrics for determining exposure should be clarified and standardized. Even if camels are a principal source of human infections, this would still not explain a substantial portion of primary human cases that did not have apparent camel exposure before infection. This raises questions about how and where these other primary cases acquired MERS-CoV infection, whether through other animal species, unidentified zoonotic exposure, unrecognized infectious persons (such as asymptomatic infectious individuals), or environmental contamination.
     </p>
     <p>
      Consequently, clarifying the routes of transmission remains crucial and should receive emphasis. To date, there is no compelling evidence of direct human-to-human transmission, such as through droplets, but secondary infection has been reported. It is often unclear how health care workers become infected. There is possible evidence of environmental contamination (fomites) in health care settings (nosocomial transmission) and close contact with an active MERS-CoV case.
     </p>
     <p>
      Various infection control lapses have been documented, but rarely a specific event or route (Ben Embarek and Van Kerkhove
      <xref ref-type="bibr" rid="B39">
       2015
      </xref>
      , Alraddadi et al.
      <xref ref-type="bibr" rid="B21">
       2016
      </xref>
      , Van Kerkhove et al.
      <xref ref-type="bibr" rid="B233">
       2016
      </xref>
      ). Rigorous infection control therefore remains essential and could prevent many secondary cases. In the interim, better documentation or identification of the specific lapses that led to infection would be of great value in understanding mechanisms of transmission and is one of the greatest knowledge gaps. Much of the evidence for fomite transmission, for example, remains anecdotal (Van Kerkhove et al.
      <xref ref-type="bibr" rid="B233">
       2016
      </xref>
      ).
     </p>
     <p>
      The mechanisms supporting chains of human MERS-CoV transmission need to be more fully evaluated. These gaps indicate a need for additional research, and also for consistent terminology and clear definitions. Although the epidemiological literature on MERS-CoV is large, much of it is fragmented and inconsistently reported. It is often difficult to deduce the sequence of infections, relationships between cases, or specific exposures. A comprehensive and consistent database or registry should be a priority.
     </p>
     <p>
      Genome sequencing has proved useful in several respects. Genome sequencing was used to help determine viral circulation and ancestry (Cotten et al.
      <xref ref-type="bibr" rid="B70">
       2014
      </xref>
      ), and to differentiate apparently similar and serologically cross-reacting coronaviruses in camels, addressing the (still unresolved) question of why MERS seems regionally limited, while many camels are imported from other places (Chu et al.
      <xref ref-type="bibr" rid="B56">
       2015
      </xref>
      ,
      <xref ref-type="bibr" rid="B57">
       2018
      </xref>
      ). It has also been used to reconstruct the transmission events and help to establish chains of infection (Assiri et al.
      <xref ref-type="bibr" rid="B33">
       2013b
      </xref>
      , Cotten et al.
      <xref ref-type="bibr" rid="B69">
       2013
      </xref>
      ), but it must be noted that there is a pressing need for more rigorous conventional epidemiology as well to validate the methodologies. These approaches might well serve a complementary function in advancing our understanding.
     </p>
     <p>
      There remains a need for effective therapeutics and vaccines. Treatment remains symptomatic, with insufficient clinical data on other therapeutic options. These options will always be limited in number, but their development should be approached more systematically with shared protocols and critical comparison of results. As a number of drug and vaccine candidates have been identified, there may be more options available for future clinical trials. There appear to be efforts underway to develop some clinical trials based on standardized protocols. This is needed, despite the challenges presented by the sporadic nature of the cases, and the relative rarity of clinical MERS.
     </p>
     <p>
      There were several limitations in this systematic review of MERS-CoV. Only publications in English or with English language abstracts were eligible for inclusion, although most of the cases have been in Arabic-speaking areas and Korea. However, hundreds of English language reports were available from countries around the world, including the Middle East and South Korea, minimizing this concern. Second, this review contains publications indexed by these databases by July 2017, so it is possible that some publications, especially recently published articles or manuscripts still in production, were unintentionally excluded from the review. We updated our literature review periodically during the preparation of this article to minimize the number of missed publications. Third, “gray literature” was not included, such as government reports and technical documents, and most meeting abstracts, although it is likely that important findings would have been submitted for journal publication.
     </p>
     <p>
      As an emerging infection of zoonotic origin (Morse
      <xref ref-type="bibr" rid="B170">
       1995
      </xref>
      ), a unified One Health approach that engages the human health, livestock and companion animal, wildlife, and environment sectors will be crucial in dealing with MERS (Morse
      <xref ref-type="bibr" rid="B171">
       2012
      </xref>
      , Morse et al.
      <xref ref-type="bibr" rid="B172">
       2012
      </xref>
      ). It could serve as an excellent case study for epidemiology and response to a new zoonotic, or emerging, infection.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank the WHO/EMRO for commissioning this work, and the anonymous reviewers of the article for thoughtful and incisive suggestions. SSM gratefully acknowledges support by the Arts &amp; Letters Foundation.
      </p>
     </ack>
     <sec id="s014">
      <title>
       Disclaimer
      </title>
      <p>
       The funder had no role in developing the content of this article. The contents are the responsibility of the authors and do not necessarily reflect the views of the entities with which they are affiliated.
      </p>
     </sec>
     <sec id="s015" sec-type="COI-statement">
      <title>
       Author Disclosure Statement
      </title>
      <p>
       No competing financial interests exist.
      </p>
     </sec>
     <ref-list content-type="parsed">
      <title>
       References
      </title>
      <ref id="B1">
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abd El Wahed
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Heidenreich
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hufert
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Reverse transcription recombinase polymerase amplification assay for the detection of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         PLoS Curr Outbreaks
        </source>
        <year>
         2013
        </year>
        ; Available at:
        <uri xlink:href="http://currents.plos.org/outbreaks/index.html%3Fp=22591.html" xlink:type="simple">
         http://currents.plos.org/outbreaks/index.html%3Fp=22591.html
        </uri>
        accessed
        <date-in-citation>
         <month>
          1
         </month>
         ,
         <year>
          2019
         </year>
        </date-in-citation>
       </mixed-citation>
      </ref>
      <ref id="B2">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aberle
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Popow-Kraupp
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kreidl
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Laferl
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Influenza A and B viruses but not MERS-CoV in Hajj Pilgrims, Austria, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         726
        </fpage>
        –
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         25811672
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B3">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abroug
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Slim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ouanes-Besbes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kacem
          </surname>
          <given-names>
           M-AH
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections, Tunisia, 2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1527
        </fpage>
        –
        <lpage>
         1530
        </lpage>
        <pub-id pub-id-type="pmid">
         25148113
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B4">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aburizaiza
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mattes
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Investigation of anti–Middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, Fall 2012
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        :
        <fpage>
         243
        </fpage>
        –
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="pmid">
         24218504
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B5">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adedeji
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kassim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Evaluation of SSYA10–001 as a replication inhibitor of Severe Acute Respiratory Syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         4894
        </fpage>
        –
        <lpage>
         4898
        </lpage>
        <pub-id pub-id-type="pmid">
         24841268
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B6">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bielefeldt-Ohmann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1031
        </fpage>
        –
        <lpage>
         1037
        </lpage>
        <pub-id pub-id-type="pmid">
         27070385
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B7">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           VR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1999
        </fpage>
        –
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B8">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B-H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         3659
        </fpage>
        –
        <lpage>
         3670
        </lpage>
        <pub-id pub-id-type="pmid">
         25589660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B9">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ajlan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahyad
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jamjoom
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alharthy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infection: Chest CT findings
        </article-title>
        .
        <source>
         AJR Am J Roentgenol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         203
        </volume>
        :
        <fpage>
         782
        </fpage>
        –
        <lpage>
         787
        </lpage>
        <pub-id pub-id-type="pmid">
         24918624
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B10">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Hammadi
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hosani
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         2197
        </fpage>
        –
        <lpage>
         2200
        </lpage>
        <pub-id pub-id-type="pmid">
         26584223
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B11">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rha
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: A serologic, epidemiologic, and clinical description
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         1225
        </fpage>
        –
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B12">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Gethamy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hussain
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         60
        </volume>
        :
        <fpage>
         973
        </fpage>
        –
        <lpage>
         974
        </lpage>
        <pub-id pub-id-type="pmid">
         25516193
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B13">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hinedi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ghandour
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Khairalla
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: A case-control study of hospitalized patients
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         160
        </fpage>
        –
        <lpage>
         165
        </lpage>
        <pub-id pub-id-type="pmid">
         24723278
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B14">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dib
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         42
        </fpage>
        –
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         24406736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B15">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e00884
        </fpage>
        –
        <lpage>
         00814
        </lpage>
        <pub-id pub-id-type="pmid">
         24570370
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B16">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alexandersen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Soule
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005
        </article-title>
        .
        <source>
         Transbound Emerg Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         61
        </volume>
        :
        <fpage>
         105
        </fpage>
        –
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="pmid">
         24456414
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B17">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           IG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hussain
          </surname>
          <given-names>
           II
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Almalki
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive epidemiological analysis of data from the Saudi Ministry of Health
        </article-title>
        .
        <source>
         Int J Gen Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         417
        </fpage>
        –
        <lpage>
         423
        </lpage>
        <pub-id pub-id-type="pmid">
         25187734
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B18">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2017a
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         30487
        </fpage>
        <pub-id pub-id-type="pmid">
         28333616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B19">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt
        </article-title>
        .
        <source>
         Emerg Microbes Infect.
        </source>
        <year>
         2017
        </year>
        <month>
         1
        </month>
        <day>
         4
        </day>
        ;
        <volume>
         6
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         e1
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1038/emi.2016.130
        </pub-id>
        <pub-id pub-id-type="pmid">
         28050021
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B20">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zuñiga
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         e00650
        </fpage>
        –
        <lpage>
         00613
        </lpage>
        <pub-id pub-id-type="pmid">
         24023385
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B21">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Almarashi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         49
        </fpage>
        –
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         26692185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B22">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alsahafi
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiology of Middle East respiratory syndrome coronavirus in the Kingdom of Saudi Arabia, 2012–2015
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         45
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         26875601
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B23">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alserehi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome
        </article-title>
        .
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         105
        </fpage>
        <pub-id pub-id-type="pmid">
         26936356
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B24">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dada
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Antibody response and disease severity in healthcare worker MERS survivors
        </article-title>
        .
        <source>
         Emerg infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1113
        </fpage>
        –
        <lpage>
         1115
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B25">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           May
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <source>
         Infectious Diseases of Humans: Dynamics and Control
        </source>
        .
        <publisher-loc>
         Oxford, UK
        </publisher-loc>
        :
        <publisher-name>
         Oxford University Press
        </publisher-name>
        ,
        <year>
         1991
        </year>
       </mixed-citation>
      </ref>
      <ref id="B26">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Owusu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Marfo
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Larbi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         High prevalence of common respiratory viruses and no evidence of Middle East respiratory syndrome coronavirus in Hajj pilgrims returning to Ghana, 2013
        </article-title>
        .
        <source>
         Trop Med Int Health
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         807
        </fpage>
        –
        <lpage>
         812
        </lpage>
        <pub-id pub-id-type="pmid">
         25688471
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B27">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anthony
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilardi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         e00373
        </fpage>
        –
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="pmid">
         28377531
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B28">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anthony
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Greig
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kramer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Global patterns in coronavirus diversity
        </article-title>
        .
        <source>
         Virus Evol
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         vex012
        </fpage>
        <pub-id pub-id-type="pmid">
         28630747
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B29">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anthony
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ojeda-Flores
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rico-Chavez
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Navarrete-Macias
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Coronaviruses in bats from Mexico
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         1028
        </fpage>
        –
        <lpage>
         1038
        </lpage>
        <pub-id pub-id-type="pmid">
         23364191
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B30">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Arifi
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Najm
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Ann Intern Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         160
        </volume>
        :
        <fpage>
         389
        </fpage>
        –
        <lpage>
         397
        </lpage>
        <pub-id pub-id-type="pmid">
         24474051
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B31">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Saeed
          </surname>
          <given-names>
           AAB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdalla
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         32
        </fpage>
        –
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         26692003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B32">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Rabiah
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2013a
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         752
        </fpage>
        –
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B33">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2013b
        </year>
        ;
        <volume>
         369
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B34">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         370
        </volume>
        :
        <fpage>
         2499
        </fpage>
        –
        <lpage>
         2506
        </lpage>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B35">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohrab
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e01450
        </fpage>
        –
        <lpage>
         01414
        </lpage>
        <pub-id pub-id-type="pmid">
         25053787
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B36">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barasheed
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rashid
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfelali
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tashani
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Viral respiratory infections among Hajj pilgrims in 2013
        </article-title>
        .
        <source>
         Virol Sin
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         29
        </volume>
        :
        <fpage>
         364
        </fpage>
        –
        <lpage>
         371
        </lpage>
        <pub-id pub-id-type="pmid">
         25413828
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B37">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sarkar
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         4953
        </fpage>
        –
        <lpage>
         4961
        </lpage>
        <pub-id pub-id-type="pmid">
         24554656
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B38">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comparative review of animal models of Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Vet Pathol
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         53
        </volume>
        :
        <fpage>
         521
        </fpage>
        –
        <lpage>
         531
        </lpage>
        <pub-id pub-id-type="pmid">
         26869154
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B39">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ben Embarek
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): Current situation 3 years after the virus was first identified
        </article-title>
        .
        <source>
         Wkly Epidemiol Rec
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         245
        </fpage>
        –
        <lpage>
         250
        </lpage>
        <pub-id pub-id-type="pmid">
         25980038
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B40">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benkouiten
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Charrel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Belhouchat
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Drali
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Respiratory viruses and bacteria among pilgrims during the 2013 Hajj
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1821
        </fpage>
        –
        <lpage>
         1827
        </lpage>
        <pub-id pub-id-type="pmid">
         25341199
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B41">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bin Saeed
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alzahrani
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Salameh
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015–February 2016
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         682
        </fpage>
        –
        <lpage>
         685
        </lpage>
        <pub-id pub-id-type="pmid">
         28322710
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B42">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breakwell
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chea
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Lack of transmission among close contacts of patient with case of Middle East Respiratory Syndrome imported into the United States, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         1128
        </fpage>
        –
        <lpage>
         1134
        </lpage>
        <pub-id pub-id-type="pmid">
         26079176
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B43">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breban
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interhuman transmissibility of Middle East respiratory syndrome coronavirus: Estimation of pandemic risk
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         694
        </fpage>
        –
        <lpage>
         699
        </lpage>
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B44">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jain
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           IS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e01146
        </fpage>
        –
        <lpage>
         01114
        </lpage>
        <pub-id pub-id-type="pmid">
         24781747
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B45">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanewski
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October–November 2012
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20406
        </fpage>
        <pub-id pub-id-type="pmid">
         23449231
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B46">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mazur
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         CD26/DPP4 cell-surface expression in bat cells correlates with bat cell susceptibility to Middle East respiratory syndrome coronavirus (MERS-CoV) infection and evolution of persistent infection
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e112060
        </fpage>
        <pub-id pub-id-type="pmid">
         25409519
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B47">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carias
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Hagan
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jewett
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gambhir
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Exportations of symptomatic cases of MERS-CoV infection to countries outside the Middle East
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         723
        </fpage>
        –
        <lpage>
         725
        </lpage>
        <pub-id pub-id-type="pmid">
         27358972
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B48">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: Quantification of the extent of the epidemic, surveillance biases, and transmissibility
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         50
        </fpage>
        –
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         24239323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B49">
       <mixed-citation publication-type="web">
        <collab>
         CDC
        </collab>
        .
        <article-title>
         CDC Laboratory Testing for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
        </article-title>
        <year>
         2014
        </year>
        (updated
        <month>
         6
        </month>
        <day>
         26
        </day>
        ,
        <year>
         2018
        </year>
        ). Available at:
        <uri xlink:href="http://www.cdc.gov/coronavirus/mers/lab/lab-testing.html" xlink:type="simple">
         www.cdc.gov/coronavirus/mers/lab/lab-testing.html
        </uri>
        (Accessed
        <date-in-citation>
         <month>
          8
         </month>
         <day>
          1
         </day>
         ,
         <year>
          2017
         </year>
         and
         <month>
          7
         </month>
         <day>
          23
         </day>
         ,
         <year>
          2018
         </year>
        </date-in-citation>
        )
       </mixed-citation>
      </ref>
      <ref id="B50">
       <mixed-citation publication-type="web">
        <collab>
         CEPI (Coalition for Epidemic Preparedness Innovations)
        </collab>
        .
        <article-title>
         Pipeline dataset for MERS-CoV
        </article-title>
        . Available at:
        <uri xlink:href="http://cepi.net/sites/default/files/Pipeline" xlink:type="simple">
         http://cepi.net/sites/default/files/Pipeline
        </uri>
        dataset for
        <uri xlink:href="http://MERS-CoV.pdf" xlink:type="simple">
         MERS-CoV.pdf
        </uri>
        (Accessed
        <date-in-citation>
         <season>
          Aug.
         </season>
         <day>
          1
         </day>
         ,
         <year>
          2017
         </year>
         and
         <month>
          8
         </month>
         <day>
          8
         </day>
         ,
         <year>
          2018
         </year>
        </date-in-citation>
        )
       </mixed-citation>
      </ref>
      <ref id="B51">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF-W
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M-L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        :
        <fpage>
         1904
        </fpage>
        –
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B52">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JFW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RYT
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KKW
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome
        </article-title>
        .
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         67
        </volume>
        :
        <fpage>
         606
        </fpage>
        –
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B53">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           RWY
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: An in-vitro and ex-vivo study
        </article-title>
        .
        <source>
         Lancet Respir Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         813
        </fpage>
        –
        <lpage>
         822
        </lpage>
        <pub-id pub-id-type="pmid">
         25174549
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B54">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rajashankar
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         10777
        </fpage>
        –
        <lpage>
         10783
        </lpage>
        <pub-id pub-id-type="pmid">
         23903833
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B55">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         1079
        </fpage>
        –
        <lpage>
         1084
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B56">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Oladipo
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuranga
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         30086
        </fpage>
       </mixed-citation>
      </ref>
      <ref id="B57">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           KPY
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Miguel
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         115
        </volume>
        :
        <fpage>
         3144
        </fpage>
        –
        <lpage>
         3149
        </lpage>
        <pub-id pub-id-type="pmid">
         29507189
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B58">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           LLM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS coronaviruses in dromedary camels, Egypt
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1049
        </fpage>
        –
        <lpage>
         1053
        </lpage>
        <pub-id pub-id-type="pmid">
         24856660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B59">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         5195
        </fpage>
        –
        <lpage>
         5199
        </lpage>
        <pub-id pub-id-type="pmid">
         24574399
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B60">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sisk
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Halasz
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         CD8
         <sup>
          +
         </sup>
         T cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         91
        </volume>
        :
        <fpage>
         e01825
        </fpage>
        –
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         27795435
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B61">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Detection of a novel human coronavirus by realtime reverse-transcription polymerase chain reaction
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2012a
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         20285
        </fpage>
        <pub-id pub-id-type="pmid">
         23041020
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B62">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Costabel
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Timm
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2012b
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         20334
        </fpage>
        <pub-id pub-id-type="pmid">
         23231891
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B63">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         477
        </fpage>
        –
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B64">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Schoeman
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014a
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         11297
        </fpage>
        –
        <lpage>
         11303
        </lpage>
        <pub-id pub-id-type="pmid">
         25031349
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B65">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jores
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Younan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992–2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014b
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1319
        </fpage>
        –
        <lpage>
         1322
        </lpage>
        <pub-id pub-id-type="pmid">
         25075637
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B66">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ölschläger
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wendtner
          </surname>
          <given-names>
           C-M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Performance and clinical validation of the RealStar
         <sup>
          ®
         </sup>
         MERS-CoV Kit for detection of Middle East respiratory syndrome coronavirus RNA
        </article-title>
        .
        <source>
         J Clin Virol
        </source>
        <year>
         2014c
        </year>
        ;
        <volume>
         60
        </volume>
        :
        <fpage>
         168
        </fpage>
        –
        <lpage>
         171
        </lpage>
        <pub-id pub-id-type="pmid">
         24726679
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B67">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rasche
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Diallo
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Highly diversified coronaviruses in neotropical bats
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         1984
        </fpage>
        –
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="pmid">
         23761408
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B68">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedotti
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Simonelli
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         112
        </volume>
        :
        <fpage>
         10473
        </fpage>
        –
        <lpage>
         10478
        </lpage>
        <pub-id pub-id-type="pmid">
         26216974
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B69">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive genomic study
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         1993
        </fpage>
        –
        <lpage>
         2002
        </lpage>
        <pub-id pub-id-type="pmid">
         24055451
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B70">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e01062
        </fpage>
        –
        <lpage>
         01013
        </lpage>
        <pub-id pub-id-type="pmid">
         24549846
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B71">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         21163
        </fpage>
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B72">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jochmans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Posthuma
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         4875
        </fpage>
        –
        <lpage>
         4884
        </lpage>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B73">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudshoorn
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-a treatment
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         1749
        </fpage>
        –
        <lpage>
         1760
        </lpage>
        <pub-id pub-id-type="pmid">
         23620378
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B74">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         110
        </volume>
        :
        <fpage>
         16598
        </fpage>
        –
        <lpage>
         16603
        </lpage>
        <pub-id pub-id-type="pmid">
         24062443
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B75">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and MERS: Recent insights into emerging coronaviruses
        </article-title>
        .
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         523
        </fpage>
        –
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B76">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         101
        </volume>
        :
        <fpage>
         45
        </fpage>
        –
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         24184128
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B77">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus (Letter)
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         371
        </volume>
        :
        <fpage>
         1359
        </fpage>
        –
        <lpage>
         1360
        </lpage>
        <pub-id pub-id-type="pmid">
         25271615
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B78">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         371
        </volume>
        :
        <fpage>
         828
        </fpage>
        –
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B79">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hussain
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         60
        </volume>
        :
        <fpage>
         369
        </fpage>
        –
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="pmid">
         25323704
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B80">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hartmann
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         745
        </fpage>
        –
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B81">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: Implication for developing therapeutics and vaccines
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <year>
         2013a
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         e81587
        </fpage>
        <pub-id pub-id-type="pmid">
         24324708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B82">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        , G,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013b
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         9939
        </fpage>
        –
        <lpage>
         9942
        </lpage>
        <pub-id pub-id-type="pmid">
         23824801
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B83">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         7045
        </fpage>
        –
        <lpage>
         7053
        </lpage>
        <pub-id pub-id-type="pmid">
         24719424
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B84">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Venkataraman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         4885
        </fpage>
        –
        <lpage>
         4893
        </lpage>
        <pub-id pub-id-type="pmid">
         24841273
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B85">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lenk
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Replicative capacity of MERS coronavirus in livestock cell lines
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         276
        </fpage>
        –
        <lpage>
         279
        </lpage>
        <pub-id pub-id-type="pmid">
         24457147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B86">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gotthardt
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East respiratory syndrome (MERS) coronavirus infection
        </article-title>
        .
        <source>
         Virol J
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         359
        </fpage>
        <pub-id pub-id-type="pmid">
         24364985
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B87">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        .
        <source>
         Nat Med
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         1313
        </fpage>
        –
        <lpage>
         1318
        </lpage>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B88">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wit
          </surname>
          <given-names>
           Ed
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         e1004250
        </fpage>
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B89">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fanoy
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Sande
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kraaij-Dirkzwager
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dirksen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Travel-related MERS-CoV cases: An assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014
        </article-title>
        .
        <source>
         Emerg Themes Epidemiol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         16
        </fpage>
        <pub-id pub-id-type="pmid">
         25328533
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B90">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faure
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Goffard
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fournier
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Distinct immune response in two MERS-CoV-infected patients: Can we go from bench to bedside?
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e88716
        </fpage>
        <pub-id pub-id-type="pmid">
         24551142
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B91">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feikin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Qutub
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shabouni
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Association of higher MERS-CoV virus load with severe disease and death, Saudi Arabia, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         2029
        </fpage>
        –
        <lpage>
         2035
        </lpage>
        <pub-id pub-id-type="pmid">
         26488195
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B92">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kerkhove
          </surname>
          <given-names>
           MDV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of MERS-CoV in dromedary camels
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         93
        </fpage>
        –
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         24355867
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B93">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         13134
        </fpage>
        –
        <lpage>
         13140
        </lpage>
        <pub-id pub-id-type="pmid">
         24067982
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B94">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Charrel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Benkouiten
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Belhouchat
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Lack of MERS coronavirus but prevalence of influenza virus in French pilgrims after 2013 Hajj
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         728
        </fpage>
        –
        <lpage>
         730
        </lpage>
        <pub-id pub-id-type="pmid">
         24656283
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B95">
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gesmann
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           de Castillo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Introduction to googleVis 0.6.2
        </article-title>
        .
        <year>
         2017
        </year>
        Available at
        <uri xlink:href="http://cran.r-project.org/web/packages/googleVis/vignettes/googleVis.pdf" xlink:type="simple">
         https://cran.r-project.org/web/packages/googleVis/vignettes/googleVis.pdf
        </uri>
        [E-pub online]
       </mixed-citation>
      </ref>
      <ref id="B96">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann-Winkler
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Albuali
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Lack of MERS coronavirus neutralizing antibodies in humans, Eastern Province, Saudi Arabia
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         2034
        </fpage>
        –
        <lpage>
         2036
        </lpage>
        <pub-id pub-id-type="pmid">
         24274664
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B97">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Inhibition of proprotein convertases abrogates processing of the Middle Eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         211
        </volume>
        :
        <fpage>
         889
        </fpage>
        –
        <lpage>
         897
        </lpage>
        <pub-id pub-id-type="pmid">
         25057042
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B98">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gossner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Danielson
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gervelmeyer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Berthe
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Zoonoses Public Health
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         63
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         25545147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B99">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombination, reservoirs, and the modular Spike: Mechanisms of coronavirus cross-species transmission
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         84
        </volume>
        :
        <fpage>
         3134
        </fpage>
        –
        <lpage>
         3146
        </lpage>
        <pub-id pub-id-type="pmid">
         19906932
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B100">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guery
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           el Mansouf
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Séjourné
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: A report of nosocomial transmission
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         381
        </volume>
        :
        <fpage>
         2265
        </fpage>
        –
        <lpage>
         2272
        </lpage>
        <pub-id pub-id-type="pmid">
         23727167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B101">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           SHS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: An outbreak investigation
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         140
        </fpage>
        –
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B102">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         77
        </fpage>
        –
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B103">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         95
        </volume>
        :
        <fpage>
         571
        </fpage>
        –
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B104">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hastings
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tokars
          </surname>
          <given-names>
           JI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdel Aziz
          </surname>
          <given-names>
           IZAM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           KZ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Outbreak of Middle East respiratory syndrome at tertiary care hospital, Jeddah, Saudi Arabia, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         794
        </fpage>
        –
        <lpage>
         801
        </lpage>
        <pub-id pub-id-type="pmid">
         27089550
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B105">
       <mixed-citation publication-type="journal">
        <collab>
         Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team
        </collab>
        .
        <article-title>
         Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         20427
        </fpage>
       </mixed-citation>
      </ref>
      <ref id="B106">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Naeem
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chin
          </surname>
          <given-names>
           AWH
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Lack of Middle East respiratory syndrome coronavirus transmission from infected camels
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         699
        </fpage>
        –
        <lpage>
         701
        </lpage>
        <pub-id pub-id-type="pmid">
         25811546
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B107">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           LLM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus in dromedary camel herd, Saudi Arabia
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1231
        </fpage>
        –
        <lpage>
         1234
        </lpage>
        <pub-id pub-id-type="pmid">
         24964193
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B108">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alhammadi
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20659
        </fpage>
        <pub-id pub-id-type="pmid">
         24342517
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B109">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdallat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sayaydeh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: Epidemiological findings from a retrospective investigation
        </article-title>
        .
        <source>
         East Mediterr Health J
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         S12
        </fpage>
        –
        <lpage>
         S18
        </lpage>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B110">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilgenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         100
        </volume>
        :
        <fpage>
         286
        </fpage>
        –
        <lpage>
         295
        </lpage>
        <pub-id pub-id-type="pmid">
         24012996
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B111">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hin Chu
          </surname>
          <given-names>
           JZ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           BH-Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF-W
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         213
        </volume>
        :
        <fpage>
         904
        </fpage>
        –
        <lpage>
         914
        </lpage>
        <pub-id pub-id-type="pmid">
         26203058
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B112">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hocke
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Becher
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Knepper
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peter
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Emerging human Middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs
        </article-title>
        .
        <source>
         Am J Respir Crit Care Med
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         188
        </volume>
        :
        <fpage>
         882
        </fpage>
        –
        <lpage>
         886
        </lpage>
        <pub-id pub-id-type="pmid">
         24083868
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B113">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hosani
          </surname>
          <given-names>
           FIA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mulla
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Response to emergence of Middle East respiratory syndrome coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1162
        </fpage>
        –
        <lpage>
         1168
        </lpage>
        <pub-id pub-id-type="pmid">
         27314227
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B114">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houser
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gretebeck
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)–specific human monoclonal antibody protects rabbits from MERS-CoV infection
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         213
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         26452396
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B115">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spread of MERS to South Korea and China
        </article-title>
        .
        <source>
         Lancet Respir Med
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         509
        </fpage>
        –
        <lpage>
         510
        </lpage>
        <pub-id pub-id-type="pmid">
         26050550
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B116">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hulswit
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus spike protein and tropism changes
        </article-title>
        .
        <source>
         Adv Virus Res
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         96
        </volume>
        :
        <fpage>
         29
        </fpage>
        –
        <lpage>
         57
        </lpage>
        <pub-id pub-id-type="pmid">
         27712627
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B117">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Bandar
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         647
        </fpage>
        –
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B118">
       <mixed-citation publication-type="web">
        <collab>
         ICTV
        </collab>
        .
        <article-title>
         Virus Taxonomy: 2016 Release
        </article-title>
        . Available at:
        <uri xlink:href="http://talk.ictvonline.org/taxonomy" xlink:type="simple">
         https://talk.ictvonline.org/taxonomy
        </uri>
        (Accessed
        <date-in-citation>
         <month>
          8
         </month>
         <day>
          1
         </day>
         ,
         <year>
          2017
         </year>
        </date-in-citation>
        )
       </mixed-citation>
      </ref>
      <ref id="B119">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Stoffberg
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Close relative of Human Middle East respiratory syndrome coronavirus in bat, South Africa
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         1698
        </fpage>
        –
        <lpage>
         1699
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B120">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein
        </article-title>
        .
        <source>
         Sci Transl Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         234
        </fpage>
        –
        <lpage>
         259
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B121">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical and epidemiologic characteristics of spreaders of Middle East respiratory syndrome coronavirus during the 2015 outbreak in Korea
        </article-title>
        .
        <source>
         J Korean Med Sci
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         744
        </fpage>
        –
        <lpage>
         749
        </lpage>
        <pub-id pub-id-type="pmid">
         28378546
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B122">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dearth
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         1511
        </fpage>
        –
        <lpage>
         1518
        </lpage>
        <pub-id pub-id-type="pmid">
         25100864
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B123">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Rabiah
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Mobeireek
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon-a2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: A preliminary report of two cases
        </article-title>
        .
        <source>
         Antivir Ther
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         87
        </fpage>
        –
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         24831606
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B124">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabiah
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alismaili
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle Eastern respiratory syndrome corona virus (MERS CoV): Case reports from a tertiary care hospital in Saudi Arabia
        </article-title>
        .
        <source>
         Ann Saudi Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         396
        </fpage>
        –
        <lpage>
         400
        </lpage>
        <pub-id pub-id-type="pmid">
         25827696
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B125">
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sears
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Brownstein
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Potential for the international spread of Middle East respiratory syndrome in association with mass gatherings in Saudi Arabia
        </article-title>
        .
        <source>
         PLoS Currents Outbreaks
        </source>
        <year>
         2013
        </year>
        ; Available at:
        <uri xlink:href="http://currents.plos.org/outbreaks/index.html%3Fp=21609.html" xlink:type="simple">
         http://currents.plos.org/outbreaks/index.html%3Fp=21609.html
        </uri>
        accessed
        <date-in-citation>
         <month>
          1
         </month>
         ,
         <year>
          2019
         </year>
        </date-in-citation>
       </mixed-citation>
      </ref>
      <ref id="B126">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kilianski
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         11955
        </fpage>
        –
        <lpage>
         11962
        </lpage>
        <pub-id pub-id-type="pmid">
         23986593
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B127">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Okada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kenniston
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice
        </article-title>
        .
        <source>
         Vaccine
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         5975
        </fpage>
        –
        <lpage>
         5982
        </lpage>
        <pub-id pub-id-type="pmid">
         25192975
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B128">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y-J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           Y-J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           D-W
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J-S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Complete genome sequence of Middle East respiratory syndrome coronavirus KOR/KNIH/002_05_2015, isolated in South Korea
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e00787
        </fpage>
        –
        <lpage>
         00715
        </lpage>
        <pub-id pub-id-type="pmid">
         26272558
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B129">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kraaij-Dirkzwager
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Timen
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dirksen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gelinck
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20817
        </fpage>
        <pub-id pub-id-type="pmid">
         24906375
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B130">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         21167
        </fpage>
        <pub-id pub-id-type="pmid">
         26132768
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B131">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shie
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ku
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         141
        </volume>
        :
        <fpage>
         101
        </fpage>
        –
        <lpage>
         106
        </lpage>
        <pub-id pub-id-type="pmid">
         28216367
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B132">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e112602
        </fpage>
        <pub-id pub-id-type="pmid">
         25405618
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B133">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           CCY
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           CPY
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         2679
        </fpage>
        –
        <lpage>
         2690
        </lpage>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B134">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           KSM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CSF
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Genetic characterization of Betacoronavirus Lineage C viruses in bats reveals marked sequence divergence in the spike protein of
         <italic>
          Pipistrellus
         </italic>
         bat coronavirus HKU5 in Japanese pipistrelle: Implications for the origin of the novel Middle East Respiratory Syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         8638
        </fpage>
        –
        <lpage>
         8650
        </lpage>
        <pub-id pub-id-type="pmid">
         23720729
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B135">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leclercq
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Batejat
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Burguiere
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J-C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heat inactivation of the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         585
        </fpage>
        –
        <lpage>
         586
        </lpage>
        <pub-id pub-id-type="pmid">
         25074677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B136">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Better understanding on MERS corona virus outbreak in Korea
        </article-title>
        .
        <source>
         J Korean Med Sci
        </source>
        <year>
         2015a
        </year>
        ;
        <volume>
         30
        </volume>
        :
        <fpage>
         835
        </fpage>
        –
        <lpage>
         836
        </lpage>
        <pub-id pub-id-type="pmid">
         26130942
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B137">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emergency medical services in response to the Middle East respiratory syndrome outbreak in Korea
        </article-title>
        .
        <source>
         J Korean Med Assoc
        </source>
        <year>
         2015b
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         611
        </fpage>
        –
        <lpage>
         616
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B138">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         38
        </volume>
        :
        <fpage>
         65
        </fpage>
        –
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="pmid">
         26216766
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B139">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mesters
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Anemüller
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         109
        </volume>
        :
        <fpage>
         72
        </fpage>
        –
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         24992731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B140">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lelli
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Papetti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabelli
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosti
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Detection of coronaviruses in bats of various species in Italy
        </article-title>
        .
        <source>
         Viruses
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         2679
        </fpage>
        –
        <lpage>
         2689
        </lpage>
        <pub-id pub-id-type="pmid">
         24184965
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B141">
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lessler
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ridriguez-Barraquer
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Garske
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Estimating potential incidence of MERS-CoV associated with Hajj pilgrims to Saudi Arabia, 2014
        </article-title>
        .
        <source>
         PLoS Currents Outbreaks
        </source>
        <year>
         2014
        </year>
        Available at:
        <uri xlink:href="http://currents.plos.org/outbreaks/index.html%3Fp=44225.html" xlink:type="simple">
         http://currents.plos.org/outbreaks/index.html%3Fp=44225.html
        </uri>
        accessed
        <date-in-citation>
         <month>
          1
         </month>
         ,
         <year>
          2019
         </year>
        </date-in-citation>
       </mixed-citation>
      </ref>
      <ref id="B142">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Letko
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           McMinn
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Seifert
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Adaptive evolution of MERS-CoV to species variation in DPP4
        </article-title>
        .
        <source>
         Cell Rep
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         1730
        </fpage>
        –
        <lpage>
         1737
        </lpage>
        <pub-id pub-id-type="pmid">
         30110630
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B143">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         742
        </fpage>
        –
        <lpage>
         744
        </lpage>
        <pub-id pub-id-type="pmid">
         25331705
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B144">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T-C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           Y-T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu J
          </surname>
          <given-names>
           T-S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Comparative epidemiology of human infections with Middle East respiratory syndrome and Severe Acute respiratory syndrome coronaviruses among healthcare personnel
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         e0149988
        </fpage>
        <pub-id pub-id-type="pmid">
         26930074
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B145">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
        </article-title>
        .
        <source>
         Nat Commun
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         3067
        </fpage>
        <pub-id pub-id-type="pmid">
         24473083
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B146">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Whitaker
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sakthivel
          </surname>
          <given-names>
           SKK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamili
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Clin Microbiol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         52
        </volume>
        :
        <fpage>
         67
        </fpage>
        –
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         24153118
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B147">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lundin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bergstrom
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kann
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         e1004166
        </fpage>
        <pub-id pub-id-type="pmid">
         24874215
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B148">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
        </article-title>
        .
        <source>
         Vaccine
        </source>
        <year>
         2014a
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         2100
        </fpage>
        –
        <lpage>
         2108
        </lpage>
        <pub-id pub-id-type="pmid">
         24560617
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B149">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
        </article-title>
        .
        <source>
         Vaccine
        </source>
        <year>
         2014b
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         6170
        </fpage>
        –
        <lpage>
         6176
        </lpage>
        <pub-id pub-id-type="pmid">
         25240756
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B150">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mailles
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Blanckaert
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chaud
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         First cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20502
        </fpage>
        <pub-id pub-id-type="pmid">
         23787161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B151">
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rivers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lofgren
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fisman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: Insights from publicly available data
        </article-title>
        .
        <source>
         PLoS Currents Outbreaks
        </source>
        <year>
         2014
        </year>
        ; Available at:
        <uri xlink:href="http://currents.plos.org/outbreaks/index.html%3Fp=40801.html" xlink:type="simple">
         http://currents.plos.org/outbreaks/index.html%3Fp=40801.html
        </uri>
        accessed
        <date-in-citation>
         <month>
          1
         </month>
         ,
         <year>
          2019
         </year>
        </date-in-citation>
       </mixed-citation>
      </ref>
      <ref id="B152">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           El Masry
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ravi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sayed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         515
        </fpage>
        –
        <lpage>
         517
        </lpage>
        <pub-id pub-id-type="pmid">
         26890613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B153">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Elkholy
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hassounah
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: Current knowledge and future considerations
        </article-title>
        .
        <source>
         East Mediterr Health J
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         537
        </fpage>
        –
        <lpage>
         546
        </lpage>
        <pub-id pub-id-type="pmid">
         27714748
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B154">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maltezou
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: Implications for health care facilities
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         42
        </volume>
        :
        <fpage>
         1261
        </fpage>
        –
        <lpage>
         1265
        </lpage>
        <pub-id pub-id-type="pmid">
         25465253
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B155">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         874
        </fpage>
        –
        <lpage>
         882
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B156">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: A prospective descriptive study
        </article-title>
        .
        <source>
         Clin Microbiol Infect
        </source>
        <year>
         2014a
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="pmid">
         24460984
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B157">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Turkestani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Shangiti
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Etiology of severe community-acquired pneumonia during the 2013 Hajj—Part of the MERS-CoV surveillance program
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2014b
        </year>
        ;
        <volume>
         25
        </volume>
        :
        <fpage>
         186
        </fpage>
        –
        <lpage>
         190
        </lpage>
        <pub-id pub-id-type="pmid">
         24970703
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B158">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Prevalence of MERS-CoV nasal carriage and compliance with the Saudi health recommendations among pilgrims attending the 2013 Hajj
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2014c
        </year>
        ;
        <volume>
         210
        </volume>
        :
        <fpage>
         1067
        </fpage>
        –
        <lpage>
         1072
        </lpage>
        <pub-id pub-id-type="pmid">
         24620019
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B159">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfi
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: An observational analysis with infection control implications
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2014d
        </year>
        ;
        <volume>
         29
        </volume>
        :
        <fpage>
         307
        </fpage>
        –
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         25448335
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B160">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014e
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1012
        </fpage>
        –
        <lpage>
         1015
        </lpage>
        <pub-id pub-id-type="pmid">
         24857749
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B161">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2013a
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         1819
        </fpage>
        –
        <lpage>
         1823
        </lpage>
        <pub-id pub-id-type="pmid">
         24206838
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B162">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Hakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2013b
        </year>
        ;
        <volume>
         368
        </volume>
        :
        <fpage>
         2487
        </fpage>
        –
        <lpage>
         2494
        </lpage>
        <pub-id pub-id-type="pmid">
         23718156
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B163">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           García-Bocanegra
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Serologic assessment of possibility for MERS-CoV infection in equids
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         181
        </fpage>
        –
        <lpage>
         182
        </lpage>
        <pub-id pub-id-type="pmid">
         25531820
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B164">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedaries, United Arab Emirates, 2003 and 2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         552
        </fpage>
        –
        <lpage>
         558
        </lpage>
        <pub-id pub-id-type="pmid">
         24655412
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B165">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kilianski
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baez-Santos
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS-CoV papain-like protease has deISGylating and deubiquitinating activities
        </article-title>
        .
        <source>
         Virology
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         450–451
        </volume>
        :
        <fpage>
         64
        </fpage>
        –
        <lpage>
         70
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B166">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Caciula
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Thakkar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Diagnosis of Zika virus infection by peptide array and enzyme-linked immunosorbent assay
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e00095
        </fpage>
        –
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         29511073
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B167">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV vaccine candidates in development: The current landscape
        </article-title>
        .
        <source>
         Vaccine
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         2982
        </fpage>
        –
        <lpage>
         2987
        </lpage>
        <pub-id pub-id-type="pmid">
         27083424
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B168">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mohamed
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           AlHetheel
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mohamud
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Aldosari
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical validation of 3 commercial real-time reverse transcriptase polymerase chain reaction assays for the detection of Middle East respiratory syndrome coronavirus from upper respiratory tract specimens
        </article-title>
        .
        <source>
         Diagn Microbiol Infect Dis
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         320
        </fpage>
        –
        <lpage>
         324
        </lpage>
        <pub-id pub-id-type="pmid">
         28104327
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B169">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Liberati
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tetzlaff
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Altman
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         339
        </volume>
        :
        <fpage>
         b2535
        </fpage>
        <pub-id pub-id-type="pmid">
         19622551
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B170">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors in the emergence of infectious diseases
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         1995
        </year>
        ;
        <volume>
         1
        </volume>
        :
        <fpage>
         7
        </fpage>
        –
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="pmid">
         8903148
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B171">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public health disease surveillance networks
        </article-title>
        .
        <source>
         Microbiol Spectr
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         1
        </volume>
        :OH-0002-2012
       </mixed-citation>
      </ref>
      <ref id="B172">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           JAK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Woolhouse
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Parrish
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Prediction and prevention of the next pandemic zoonosis
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         380
        </volume>
        :
        <fpage>
         1956
        </fpage>
        –
        <lpage>
         1965
        </lpage>
        <pub-id pub-id-type="pmid">
         23200504
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B173">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Morahan
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activated macrophages mediate interferon-independent inhibition of Herpes simplex virus
        </article-title>
        .
        <source>
         Cell Immunol
        </source>
        <year>
         1981
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         72
        </fpage>
        –
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         6164494
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B174">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van Kuppeveld
          </surname>
          <given-names>
           FJM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         9379
        </fpage>
        –
        <lpage>
         9383
        </lpage>
        <pub-id pub-id-type="pmid">
         23785207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B175">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jores
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         2093
        </fpage>
        –
        <lpage>
         2095
        </lpage>
        <pub-id pub-id-type="pmid">
         25425139
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B176">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: A nationwide, cross-sectional, serological study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         559
        </fpage>
        –
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B177">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Human coronavirus EMC does not require the SARS-Coronavirus receptor and maintains broad replicative capability in mammalian cell lines
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e00515
        </fpage>
        –
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         23232719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B178">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia from human coronavirus in a macaque model
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         368
        </volume>
        :
        <fpage>
         1560
        </fpage>
        –
        <lpage>
         1562
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B179">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Keating
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014
        </article-title>
        .
        <source>
         Am J Pathol
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         186
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B180">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mizumoto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ejima
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Assessing the risk of observing multiple generations of Middle East respiratory syndrome (MERS) cases given an imported case
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         21181
        </fpage>
        <pub-id pub-id-type="pmid">
         26212063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B181">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nowotny
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kolodziejek
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20781
        </fpage>
        <pub-id pub-id-type="pmid">
         24786259
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B182">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Hagan
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Carias
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rudd
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Estimation of severe Middle East respiratory syndrome cases in the Middle East, 2012–2016
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1797
        </fpage>
        –
        <lpage>
         1799
        </lpage>
        <pub-id pub-id-type="pmid">
         27648640
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B183">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—A link to health care facilities
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         372
        </volume>
        :
        <fpage>
         846
        </fpage>
        –
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B184">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohnuma
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hatano
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Inhibition of Middle East respiratory syndrome coronavirus infection by Anti-CD26 monoclonal antibody
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         13892
        </fpage>
        –
        <lpage>
         13899
        </lpage>
        <pub-id pub-id-type="pmid">
         24067970
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B185">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Matin
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Haddad
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Nakhli
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         e668
        </fpage>
        –
        <lpage>
         e672
        </lpage>
        <pub-id pub-id-type="pmid">
         23916548
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B186">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bahloul
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         1090
        </fpage>
        –
        <lpage>
         1095
        </lpage>
        <pub-id pub-id-type="pmid">
         25278221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B187">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Donskey
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Douthwaite
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: The possible role of dry surface contamination
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         92
        </volume>
        :
        <fpage>
         235
        </fpage>
        –
        <lpage>
         250
        </lpage>
        <pub-id pub-id-type="pmid">
         26597631
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B188">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ryu
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         21169
        </fpage>
        <pub-id pub-id-type="pmid">
         26132766
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B189">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         2186
        </fpage>
        –
        <lpage>
         2189
        </lpage>
        <pub-id pub-id-type="pmid">
         26583829
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B190">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pavli
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Maltezou
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): Prevention in travelers
        </article-title>
        .
        <source>
         Travel Med Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         602
        </fpage>
        –
        <lpage>
         608
        </lpage>
        <pub-id pub-id-type="pmid">
         25457301
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B191">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Nsour
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Stillbirth during infection with Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        :
        <fpage>
         1870
        </fpage>
        –
        <lpage>
         1872
        </lpage>
        <pub-id pub-id-type="pmid">
         24474813
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B192">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Persistence of antibodies against Middle East Respiratory Syndrome coronavirus
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1824
        </fpage>
        –
        <lpage>
         1826
        </lpage>
        <pub-id pub-id-type="pmid">
         27332149
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B193">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pebody
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         20292
        </fpage>
        <pub-id pub-id-type="pmid">
         23078799
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B194">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20574
        </fpage>
        <pub-id pub-id-type="pmid">
         24079378
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B195">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Goffard
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Parmentier-Decrucq
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Favory
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases
        </article-title>
        .
        <source>
         J Clin Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         61
        </volume>
        :
        <fpage>
         275
        </fpage>
        –
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         25073585
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B196">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poletto
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pelat
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lévy-Bruhl
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yazdanpanah
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20699
        </fpage>
        <pub-id pub-id-type="pmid">
         24556346
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B197">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Premila Devi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Noraini
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Norhayati
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chee Kheong
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Laboratory-confirmed case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Malaysia: Preparedness and response, April 2014
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20797
        </fpage>
        <pub-id pub-id-type="pmid">
         24832116
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B198">
       <mixed-citation publication-type="book">
        <collab>
         ProMED-mail
        </collab>
        .
        <publisher-name>
         NOVEL CORONAVIRUS—SAUDI ARABIA: HUMAN ISOLATE
        </publisher-name>
        Available at
        <uri xlink:href="http://www.promedmail.org/direct.php?id=20120920.1302733" xlink:type="simple">
         www.promedmail.org/direct.php?id=20120920.1302733
        </uri>
        Archive Number: 20120920.21302733. (Accessed
        <date-in-citation>
         <month>
          8
         </month>
         <day>
          1
         </day>
         ,
         <year>
          2017
         </year>
        </date-in-citation>
        )
       </mixed-citation>
      </ref>
      <ref id="B199">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Puzelli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Azzi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Santini
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Di Martino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Investigation of an imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20564
        </fpage>
        <pub-id pub-id-type="pmid">
         23987829
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B200">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dominguez
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         e76469
        </fpage>
        <pub-id pub-id-type="pmid">
         24098509
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B201">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           EABA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lamers
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from dromedary camel, Qatar, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1339
        </fpage>
        –
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B202">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           DHW
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         495
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B203">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           JMA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         1834
        </fpage>
        –
        <lpage>
         1838
        </lpage>
        <pub-id pub-id-type="pmid">
         24257613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B204">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Swerdlow
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: Update for clinicians
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         60
        </volume>
        :
        <fpage>
         1686
        </fpage>
        –
        <lpage>
         1689
        </lpage>
        <pub-id pub-id-type="pmid">
         25701855
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B205">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Specific serology for emerging human coronaviruses by protein microarray
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013a
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20441
        </fpage>
        <pub-id pub-id-type="pmid">
         23594517
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B206">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ababneh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013b
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20662
        </fpage>
        <pub-id pub-id-type="pmid">
         24342516
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B207">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2014a
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20829
        </fpage>
        <pub-id pub-id-type="pmid">
         24957745
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B208">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Feyisa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Messadi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ularamu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Geographic distribution of MERS coronavirus among dromedary camels, Africa
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014b
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1370
        </fpage>
        –
        <lpage>
         1374
        </lpage>
        <pub-id pub-id-type="pmid">
         25062254
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B209">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2013c
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         859
        </fpage>
        –
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B210">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Schilp
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bruin
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS-CoV infection of alpaca in a region where MERS-CoV is endemic
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1129
        </fpage>
        –
        <lpage>
         1131
        </lpage>
        <pub-id pub-id-type="pmid">
         27070501
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B211">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reuss
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Litterst
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Contact investigation for imported case of Middle East respiratory syndrome, Germany
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         620
        </fpage>
        –
        <lpage>
         625
        </lpage>
        <pub-id pub-id-type="pmid">
         24655721
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B212">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrania
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bahloul
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: A single-center experience in Saudi Arabia
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         29
        </volume>
        :
        <fpage>
         301
        </fpage>
        –
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         25303830
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B213">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scheuplein
          </surname>
          <given-names>
           VA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Seifried
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Malczyk
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         3859
        </fpage>
        –
        <lpage>
         3869
        </lpage>
        <pub-id pub-id-type="pmid">
         25609809
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B214">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         110
        </volume>
        :
        <fpage>
         16157
        </fpage>
        –
        <lpage>
         16162
        </lpage>
        <pub-id pub-id-type="pmid">
         24043791
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B215">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seo
          </surname>
          <given-names>
           YB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Heo
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           M-S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         755
        </fpage>
        –
        <lpage>
         760
        </lpage>
        <pub-id pub-id-type="pmid">
         26679623
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B216">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seong
          </surname>
          <given-names>
           M-W
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         External quality assessment of MERS-CoV molecular diagnostics during the 2015 Korean outbreak
        </article-title>
        .
        <source>
         Ann Lab Med
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         230
        </fpage>
        –
        <lpage>
         234
        </lpage>
        <pub-id pub-id-type="pmid">
         26915611
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B217">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           AlZahrani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Simhairi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: A case report
        </article-title>
        .
        <source>
         J Clin Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         69
        </fpage>
        –
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         25542475
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B218">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         12552
        </fpage>
        –
        <lpage>
         12561
        </lpage>
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B219">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yano
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Senba
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Akachi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP)
        </article-title>
        .
        <source>
         Virol J
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         139
        </fpage>
        <pub-id pub-id-type="pmid">
         25103205
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B220">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           K-L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K-S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         4866
        </fpage>
        –
        <lpage>
         4876
        </lpage>
        <pub-id pub-id-type="pmid">
         24522921
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B221">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pas
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CBEM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Reliable typing of MERS-CoV variants with a small genome fragment
        </article-title>
        .
        <source>
         J Clin Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         64
        </volume>
        :
        <fpage>
         83
        </fpage>
        –
        <lpage>
         87
        </lpage>
        <pub-id pub-id-type="pmid">
         25728084
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B222">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Fux
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         11950
        </fpage>
        –
        <lpage>
         11954
        </lpage>
        <pub-id pub-id-type="pmid">
         23986586
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B223">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spanakis
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
        </article-title>
        .
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         528
        </fpage>
        –
        <lpage>
         532
        </lpage>
        <pub-id pub-id-type="pmid">
         25288266
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B224">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sridhar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Parola
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Imported cases of Middle East respiratory syndrome: An update
        </article-title>
        .
        <source>
         Travel Med Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         106
        </fpage>
        –
        <lpage>
         109
        </lpage>
        <pub-id pub-id-type="pmid">
         25477148
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B225">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X-C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Stanhope
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        :
        <fpage>
         e2018
        </fpage>
        –
        <lpage>
         e2026
        </lpage>
        <pub-id pub-id-type="pmid">
         24778221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B226">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           TE
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Morimoto
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         9953
        </fpage>
        –
        <lpage>
         9958
        </lpage>
        <pub-id pub-id-type="pmid">
         23824802
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B227">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Blocking of exchange proteins directly activated by cAMP leads to reduced replication of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         3902
        </fpage>
        –
        <lpage>
         3910
        </lpage>
        <pub-id pub-id-type="pmid">
         24453361
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B228">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Boddington
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Enhanced MERS coronavirus surveillance of travelers from the Middle East to England
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1562
        </fpage>
        –
        <lpage>
         1564
        </lpage>
        <pub-id pub-id-type="pmid">
         25148267
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B229">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baka
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Mentis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Iliopoulos
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A case of imported Middle East respiratory syndrome coronavirus infection and public health response, Greece, April 2014
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20782
        </fpage>
        <pub-id pub-id-type="pmid">
         24786258
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B230">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Karesh
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stability of Middle East respiratory syndrome coronavirus in milk
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1263
        </fpage>
        –
        <lpage>
         1264
        </lpage>
        <pub-id pub-id-type="pmid">
         24960335
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B231">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20590
        </fpage>
        <pub-id pub-id-type="pmid">
         24084338
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B232">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         9220
        </fpage>
        –
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="pmid">
         24899185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B233">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           MJS
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ben Embarek
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interpreting results from environmental contamination studies of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         63
        </volume>
        :
        <fpage>
         1142
        </fpage>
        <pub-id pub-id-type="pmid">
         27432840
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B234">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
        </article-title>
        .
        <source>
         Cell Host Microbe
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         328
        </fpage>
        –
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B235">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wirblich
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Drishya
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Abraham
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         One-health: A safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         91
        </volume>
        :
        <fpage>
         e02040
        </fpage>
        –
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         27807241
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B236">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         3995
        </fpage>
        –
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B237">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           KSM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           RWS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Molecular diversity of coronaviruses in bats
        </article-title>
        .
        <source>
         Virology
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         180
        </fpage>
        –
        <lpage>
         187
        </lpage>
        <pub-id pub-id-type="pmid">
         16647731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B238">
       <mixed-citation publication-type="web">
        <collab>
         World Health Organization
        </collab>
        <year>
         2015
        </year>
        <article-title>
         Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected
        </article-title>
        .
        <year>
         2015
        </year>
        Available at [E-pub online:
        <uri xlink:href="http://www.who.int/csr/disease/coronavirus_infections/case-management-ipc/en" xlink:type="simple">
         www.who.int/csr/disease/coronavirus_infections/case-management-ipc/en
        </uri>
        ]
       </mixed-citation>
      </ref>
      <ref id="B239">
       <mixed-citation publication-type="book">
        <collab>
         World Health Organization
        </collab>
        <year>
         2018a
        </year>
        <article-title>
         WHO MERS-CoV global summary and assessment of risk—August 2018
        </article-title>
        . Available at [E-pub online:
        <uri xlink:href="http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf" xlink:type="simple">
         www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf
        </uri>
        ;
        <publisher-name>
         MERS
        </publisher-name>
        webpage online:
        <uri xlink:href="http://www.who.int/emergencies/mers-cov/en" xlink:type="simple">
         www.who.int/emergencies/mers-cov/en
        </uri>
        ]
       </mixed-citation>
      </ref>
      <ref id="B240">
       <mixed-citation publication-type="web">
        <collab>
         World Health Organization
        </collab>
        <year>
         2018b
        </year>
        <article-title>
         Laboratory testing for Middle East respiratory syndrome coronavirus—Interim guidance (revised), January 2018
        </article-title>
        . Available at [E-pub online:
        <uri xlink:href="http://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en" xlink:type="simple">
         www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en
        </uri>
        ]
       </mixed-citation>
      </ref>
      <ref id="B241">
       <mixed-citation publication-type="web">
        <collab>
         World Health Organization/EMRO (Eastern Mediterranean Regional Office)
        </collab>
        <year>
         2018
        </year>
        Available at MERS situation update [E-pub online:
        <uri xlink:href="http://www.emro.who.int/health-topics/mers-cov/situation-update.html" xlink:type="simple">
         www.emro.who.int/health-topics/mers-cov/situation-update.html
        </uri>
        ]
       </mixed-citation>
      </ref>
      <ref id="B242">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrensch
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: Evidence for cholesterol-independent mechanisms
        </article-title>
        .
        <source>
         Viruses
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         3683
        </fpage>
        –
        <lpage>
         3698
        </lpage>
        <pub-id pub-id-type="pmid">
         25256397
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B243">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Imported case of MERS-CoV infection identified in China, May 2015: Detection and lesson learned
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         21158
        </fpage>
        <pub-id pub-id-type="pmid">
         26111235
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B244">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS-related betacoronavirus in
         <italic>
          Vespertilio superans
         </italic>
         bats, China
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1260
        </fpage>
        –
        <lpage>
         1262
        </lpage>
        <pub-id pub-id-type="pmid">
         24960574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B245">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        :
        <fpage>
         12516
        </fpage>
        –
        <lpage>
         12521
        </lpage>
        <pub-id pub-id-type="pmid">
         25114257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists
        </article-title>
        .
        <source>
         Protein Cell
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         951
        </fpage>
        –
        <lpage>
         961
        </lpage>
        <pub-id pub-id-type="pmid">
         24318862
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B247">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        :
        <fpage>
         236
        </fpage>
        –
        <lpage>
         242
        </lpage>
        <pub-id pub-id-type="pmid">
         24218506
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B248">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yavarian
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Rezaei
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Shadab
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Soroush
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Cluster of middle east respiratory syndrome coronavirus infections in Iran, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         362
        </fpage>
        –
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="pmid">
         25626079
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B249">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ju
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Prabakaran
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         7796
        </fpage>
        –
        <lpage>
         7805
        </lpage>
        <pub-id pub-id-type="pmid">
         24789777
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B250">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           ADME
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B251">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
        </article-title>
        .
        <source>
         Virol J
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         266
        </fpage>
        <pub-id pub-id-type="pmid">
         23978242
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B252">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses
        </article-title>
        .
        <source>
         Sci Immunol
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         eaan5393
        </fpage>
        <pub-id pub-id-type="pmid">
         28778905
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B253">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        :
        <fpage>
         4970
        </fpage>
        –
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B254">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         6117
        </fpage>
        –
        <lpage>
         6120
        </lpage>
        <pub-id pub-id-type="pmid">
         25787284
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B255">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        ,
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        :
        <fpage>
         1331
        </fpage>
        –
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Microbiol Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Microbiol. Rev
      </journal-id>
      <journal-id journal-id-type="hwp">
       cmr
      </journal-id>
      <journal-id journal-id-type="pmc">
       cmr
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       CMR
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Microbiology Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0893-8512
      </issn>
      <issn pub-type="epub">
       1098-6618
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25810418
      </article-id>
      <article-id pub-id-type="pmc">
       4402954
      </article-id>
      <article-id pub-id-type="publisher-id">
       00102-14
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/CMR.00102-14
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Reviews
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
       </article-title>
       <alt-title alt-title-type="running-head">
        Middle East Respiratory Syndrome Coronavirus
       </alt-title>
       <alt-title alt-title-type="short-authors">
        Chan et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper F. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e53">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Susanna K. P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e76">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          To
         </surname>
         <given-names>
          Kelvin K. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e105">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Vincent C. C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e131">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick C. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e151">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e171">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        State Key Laboratory of Emerging Infectious Diseases and Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        Carol Yu Centre for Infection, Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Kwok-Yung Yuen,
        <email>
         kyyuen@hku.hk
        </email>
        .
       </corresp>
       <fn fn-type="other">
        <p>
         <bold>
          Citation
         </bold>
         Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. 25 March 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev doi:
         <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CMR.00102-14">
          10.1128/CMR.00102-14
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        3
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        4
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       28
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       465
      </fpage>
      <lpage>
       522
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2015, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri content-type="pdf" xlink:href="zcm002152507465.pdf">
      </self-uri>
      <abstract>
       <title>
        SUMMARY
       </title>
       <p>
        The source of the severe acute respiratory syndrome (SARS) epidemic was traced to wildlife market civets and ultimately to bats. Subsequent hunting for novel coronaviruses (CoVs) led to the discovery of two additional human and over 40 animal CoVs, including the prototype lineage C betacoronaviruses,
        <named-content content-type="genus-species">
         Tylonycteris
        </named-content>
        bat CoV HKU4 and
        <named-content content-type="genus-species">
         Pipistrellus
        </named-content>
        bat CoV HKU5; these are phylogenetically closely related to the Middle East respiratory syndrome (MERS) CoV, which has affected more than 1,000 patients with over 35% fatality since its emergence in 2012. All primary cases of MERS are epidemiologically linked to the Middle East. Some of these patients had contacted camels which shed virus and/or had positive serology. Most secondary cases are related to health care-associated clusters. The disease is especially severe in elderly men with comorbidities. Clinical severity may be related to MERS-CoV's ability to infect a broad range of cells with DPP4 expression, evade the host innate immune response, and induce cytokine dysregulation. Reverse transcription-PCR on respiratory and/or extrapulmonary specimens rapidly establishes diagnosis. Supportive treatment with extracorporeal membrane oxygenation and dialysis is often required in patients with organ failure. Antivirals with potent
        <italic>
         in vitro
        </italic>
        activities include neutralizing monoclonal antibodies, antiviral peptides, interferons, mycophenolic acid, and lopinavir. They should be evaluated in suitable animal models before clinical trials. Developing an effective camel MERS-CoV vaccine and implementing appropriate infection control measures may control the continuing epidemic.
       </p>
      </abstract>
      <counts>
       <fig-count count="10">
       </fig-count>
       <table-count count="12">
       </table-count>
       <equation-count count="0">
       </equation-count>
       <ref-count count="345">
       </ref-count>
       <page-count count="58">
       </page-count>
       <word-count count="46818">
       </word-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Immunol Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J Immunol Res
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JIR
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Immunology Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2314-8861
      </issn>
      <issn pub-type="epub">
       2314-7156
      </issn>
      <publisher>
       <publisher-name>
        Hindawi
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30906787
      </article-id>
      <article-id pub-id-type="pmc">
       6398027
      </article-id>
      <article-id pub-id-type="doi">
       10.1155/2019/1386740
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Al Kahlout
         </surname>
         <given-names>
          Reham A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Nasrallah
         </surname>
         <given-names>
          Gheyath K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Farag
         </surname>
         <given-names>
          Elmoubasher A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Lingshu
         </given-names>
        </name>
        <xref ref-type="aff" rid="I4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lattwein
         </surname>
         <given-names>
          Erik
         </given-names>
        </name>
        <xref ref-type="aff" rid="I5">
         <sup>
          5
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          Marcel A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I6">
         <sup>
          6
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="false" contrib-id-type="orcid">
         http://orcid.org/0000-0002-1056-4761
        </contrib-id>
        <name>
         <surname>
          El Zowalaty
         </surname>
         <given-names>
          Mohamed E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I7">
         <sup>
          7
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al Romaihi
         </surname>
         <given-names>
          Hamad E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Graham
         </surname>
         <given-names>
          Barney S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al Thani
         </surname>
         <given-names>
          Asmaa A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="false" contrib-id-type="orcid">
         http://orcid.org/0000-0001-7592-2788
        </contrib-id>
        <name>
         <surname>
          Yassine
         </surname>
         <given-names>
          Hadi M.
         </given-names>
        </name>
        <email>
         hyassine@qu.edu.qa
        </email>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
      </contrib-group>
      <aff id="I1">
       <sup>
        1
       </sup>
       Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar
      </aff>
      <aff id="I2">
       <sup>
        2
       </sup>
       Biomedical Research Center, Qatar University, Doha, Qatar
      </aff>
      <aff id="I3">
       <sup>
        3
       </sup>
       Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar
      </aff>
      <aff id="I4">
       <sup>
        4
       </sup>
       Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA
      </aff>
      <aff id="I5">
       <sup>
        5
       </sup>
       Euroimmun AG, Luebeck, Germany
      </aff>
      <aff id="I6">
       <sup>
        6
       </sup>
       Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany
      </aff>
      <aff id="I7">
       <sup>
        7
       </sup>
       Virology and Microbiology Research Laboratory, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa
      </aff>
      <author-notes>
       <fn fn-type="other">
        <p>
         Academic Editor: Peirong Jiao
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        18
       </day>
       <month>
        2
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       2019
      </volume>
      <elocation-id>
       1386740
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         3
        </day>
        <month>
         9
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         29
        </day>
        <month>
         11
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         27
        </day>
        <month>
         12
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2019 Reham A. Al Kahlout et al.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) could be asymptomatic or cause mild influenza-like illness. Therefore, the prevalence of MERS-CoV infections in the general population could be underestimated, which necessitates active surveillance to determine the epidemiological importance of asymptomatic cases. The aim of this study is to evaluate the performance of various serological assays and to estimate the seroprevalence of anti-MERS-CoV antibodies in high- and low-risk groups in Qatar. A total of 4858 samples were screened, including 4719 samples collected from healthy blood donors (BD) over a period of five years (2012-2016), 135 samples from baseline case contacts (CC) collected from individuals in close contact with three positive PCR-confirmed patients (CP), and four samples from MERS-CoV CP. Initial screening using anti-MERS-CoV IgG (IgG rS1-ELISA kit) revealed ten reactive samples from BD (10/4719, 0.21%), one from CC (1/135, 0.74%), and three from CP (3/4, 75%). Samples from CP but not from BD were also reactive by whole-virus anti-MERS-CoV IgG (
        <italic>
         n
        </italic>
        = 3/4) and IgM (
        <italic>
         n
        </italic>
        = 1/4) indirect immunefluorescent tests (IIFT) and pseudoparticle neutralization test (ppNT). The reactive sample from CC was also confirmed by ppNT. Surprisingly, one out of thirteen (7.7%) randomly selected IgG rS1-ELISA-negative BD samples from the initial screening was reactive by the IgM-IIFT (but not by the IgG-IIFT) and was subsequently confirmed by ppNT. All IgG rS1-ELISA-reactive samples from BD exhibited considerable reactivity to the four circulating human coronaviruses (HKU1, OC43, 229E, and NL63). Cross-reactivity with SARS was only reported for samples from CP using IgG and IgM-IIFT. In conclusion, we report a low prevalence of anti-MERS antibodies in the general population, which coincides with the low number of all reported cases by the time of our study (2017) in Qatar (
        <italic>
         n
        </italic>
        = 21). The false-positive results and the observed cross-reactivity between MERS-CoV and other circulating human coronavirus necessitate more detailed evaluation of available serological assays.
       </p>
      </abstract>
      <funding-group>
       <award-group>
        <funding-source>
         Qatar University
        </funding-source>
        <award-id>
         QUUG-BRC-2017-1
        </award-id>
        <award-id>
         QUST-CAS-FALL-15/16-33
        </award-id>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <title>
      1. Background
     </title>
     <p>
      Middle East respiratory syndrome coronavirus (MERS-CoV) is a human beta-coronavirus (HCoV) that is originally identified in the Kingdom of Saudi Arabia (KSA) in 2012. So far, the WHO has reported 2229 cases of MERS-CoV infections in 27 countries, with a fatality rate of about 36% (
      <italic>
       n
      </italic>
      = 791) [
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      ].
     </p>
     <p>
      MERS-CoV-specific antibodies are widely found in dromedary camels (
      <italic>
       Camelus dromedarius
      </italic>
      ) along with viral shedding of similar viruses detected in human. Accordingly, dromedaries are considered the primary source of MERS-CoV transmission to humans, although the original source for the virus is still unknown [
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      –
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ].
     </p>
     <p>
      Phylogenetic analysis groups coronaviruses into four genera: alpha-, beta-, gamma-, and delta-coronaviruses. Bats are considered the natural reservoirs of these viruses. Although SARS-CoV is closely related to bat CoV (BtCoV) HKU3, and MERS-CoV is closely related to Pipistrellus BtCoV HKU5 and Tylonycteris BtCoV HKU4, the serologic and antigenic relationship between these viruses is unclear. Generally, coronaviruses across subgroups demonstrate a low level of cross-reactivity for the S protein and limited preservation of cross-neutralizing epitopes [
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ]. However, few studies have demonstrated cross-reactivity among these Betacoronavirus. It has been shown that mouse hyperimmune sera to SARS-CoV harbor low levels of neutralizing activity against MERS-CoV [
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ]. Further, sera samples from SARS patients demonstrated 60.7% (17/28) binding and 25% (7/28) neutralizing activities to MERS-CoV, suggesting cross-reactivity within subgroup viruses [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ].
     </p>
     <p>
      Following its first isolation, several laboratory diagnostic tests for MERS-CoV have been developed [
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      –
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      ]. Molecular tests such as RT-PCR and sequencing are majorly used in diagnosing MERS-CoV infections [
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      ]. The United States Centers for Disease Control and Prevention (CDC) limits the use of serological tests for investigational or surveillance settings and not for diagnosis [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ]. They established a two-phase serological test approach to detect anti-MERS antibodies based on ELISA (targeting S1 antigen) followed by whole-virus IgG and IgM IIFT and microneutralization test for confirmation. The microneutralization assay is highly specific and it is the gold standard for measuring specific neutralizing antibodies against MERS-CoV in sera samples. Nonetheless, compared with the ELISA and IIFT, the microneutralization assay requires a BSL3 facility, which is not available at many places, and it is labor-intensive and time-consuming, requiring at least 5 days before results are available [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ].
     </p>
     <p>
      In the State of Qatar, twenty-one cases have been reported until 2017, including seven deaths (33.3%). Interestingly, 95% (
      <italic>
       n
      </italic>
      = 20) of the cases in Qatar were reported in males compared to only one female case. Thirteen of the MERS cases were reported in camel farm owners and workers, and five were suspected human-to-human transmissions, of which three were nosocomial infections (Ministry of Public Health-Qatar, personal communication).
     </p>
     <p>
      Qatar was the first nation to report on the isolation and full genome sequencing of MERS-CoV from camels [
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      ]. In a separate study from Qatar, Reusken et al. reported that ~ 7% (20/294) of persons with camel contact have antibodies reactive with MERS-CoV S1 antigen, compared to zero reactive in control or noncase contact samples. Using 90% plaque-reduction neutralization test (PRNT90), only 10 of the 20 (5%) MERS-CoV S1 antibody-reactive samples were confirmed positive [
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ].
     </p>
     <p>
      Due to the uncertain epidemiological picture of MERS-CoV among Qatar population, we designed a staged serologic surveillance study for MERS-CoV consisting of initial screening by anti-MERS-CoV IgG rS1-ELISA kit followed by evaluation of reactive samples using whole-virus indirect immunofluorescence assays (IgM- and IgG-IIFT) and ppNT. We also tested the cross-reactivity of IgG rS1-ELISA-reactive samples with the four circulating human coronaviruses using ELISA and IIFT. This study targeted three groups: (i) low-risk group constituted of 4719 samples obtained from blood donors (BD) collected over a period of five years (2012-2016), (ii) high-risk group represented by 135 samples obtained from baseline case contacts (CC) collected from individuals who were in close contact with confirmed cases during the acute phase (first week), and (iii) four samples from PCR-confirmed MERS-CoV patients (CP). The high-risk group is defined by the individuals that were in direct contact with the confirmed cases either at work, house, or hospital (medical staff), prior or after symptom development. Our findings suggest that MERS-CoV is not heavily circulated among the population of Qatar. Additionally, the presence of antibody responses to other human coronaviruses resulted in false-positive results in binding assays, which mandate the need for more evaluation studies of the currently available diagnostic serological assays.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      2. Methodology
     </title>
     <sec id="sec2.1">
      <title>
       2.1. Patient Samples
      </title>
      <p>
       In total, 4858 plasma samples were analyzed in this study. Samples were distributed as follows: 4719 plasma samples were collected from BD during previous studies [
       <xref ref-type="bibr" rid="B16">
        16
       </xref>
       –
       <xref ref-type="bibr" rid="B20">
        20
       </xref>
       ] over a period of five years (2012-2016; age: 19-88 years; mean age 37 years), 135 plasma samples were collected from individuals that were in CC to four CP (age: 14-49 years; mean age 31 years), and four plasma samples were collected from CP (age: 30-70 years; mean age 52). The CC individuals represented the patient's family members, healthcare workers, and camel farm coworkers. Samples from CC were collected within the first week of the patient's admission to hospital. This study was approved by Qatar University-IRB Review Exemption No. QU-QU-IRB 622-E/16.
      </p>
     </sec>
     <sec id="sec2.2">
      <title>
       2.2. Serological Testing
      </title>
      <p>
       Initially, all plasma samples were screened for the presence of anti-MERS-CoV (S1 subunit) IgG using a commercial IgG rS1-ELISA kit (rS1-ELISA, Euroimmun, cat no. EI 2604-9601G). Since samples from CC were collected within the first week of primary case identification, these samples (
       <italic>
        n
       </italic>
       = 135) were also tested for the presence of IgM antibodies using whole-virus anti-MERS-CoV IgM IIFT kit (IgM-IIFT) (Euroimmun, cat no. FI 2604-1010 M). The anti-MERS-CoV (IgM/IgG) IIFT is based on MERS-CoV-infected eukaryotic cells and the anti-MERS-CoV ELISA (IgG) on purified S1 antigens of MERS-CoV. As recommended by the WHO, all borderline and reactive samples were then tested for the presence of anti-MERS-CoV antibodies using whole-virus indirect immunofluorescence assay (IgM- and IgG-IIFT) (Euroimmun, cat no. FI 2604-1010). Further, the borderline and reactive samples in addition to 13 randomly selected IgG rS1-ELISA-negative samples (served as negative controls) were screened with an in-house recombinant-S1 protein IIFA IgG (rS1-IIFA; Institute of Virology, Charité - Universitätsmedizin Berlin, Germany; as described by Corman et al. 2012 [
       <xref ref-type="bibr" rid="B8">
        8
       </xref>
       ]) in order to reduce the possibility of cross-reactivity of human sera with the full MERS virus antigens presented by Vero cells in whole-virus IIFT. Final confirmation was performed using pseudoparticle neutralization test (ppNT) against two MERS-CoV strains, the EMC strain (GenBank JX869059) and the Jordan N3 strain (GenBank KC776174), as previously described [
       <xref ref-type="bibr" rid="B21">
        21
       </xref>
       ]. The determination of cross-reactivity of borderline and reactive samples against other human coronaviruses was performed using: (i) commercially available whole-virus IgM/IgG IIFT for SARS-CoV (Euroimmun, cat no. FI 2601-1010 G/M), (ii) prototype whole-virus IgG IIFT kit for HCoV-229E (Euroimmun, prototype kit), (iii) in-house ELISA for HKU1-CoV using recombinant S1 protein (Sino Biological Inc., catalog # 40021-V08H), and (iv) IgG rS1-IIFT for all other human-CoV (Institute of Virology, Charité - Universitätsmedizin Berlin, Germany) [
       <xref ref-type="bibr" rid="B22">
        22
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <title>
      3. Results
     </title>
     <p>
      The demography and characteristic profiles of the study population are summarized in
      <xref ref-type="table" rid="tab1">
       Table 1
      </xref>
      . Initial screening for anti-MERS-CoV antibodies using IgG rS1-ELISA revealed 10/4719 (0.21%) and 1/135 (0.74%) reactive samples from BD (three borderline and seven positive samples) and CC, respectively. On the other hand, 3/4 CP (75.0%) were reactive with IgG rS1-ELISA assay (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ;
      <xref ref-type="table" rid="tab2">
       Table 2
      </xref>
      ). Since CC samples were collected within the first week of primary case identification, samples were also tested by IgM-IIFT and all were negative.
     </p>
     <p>
      As recommended by the WHO, borderline and reactive samples were then tested for the presence of anti-MERS-CoV IgG using whole-virus and recombinant (r) S1-IIFT. Analysis with whole-virus IgG-IIFT confirmed only two (2/10) samples from BD as well as three (3/4) samples from CP. Interestingly, none (0/10) of the above BD reactive samples tested positive with neither rS1-IIFT nor ppNT assay. The positive IgG rS1-ELISA CC sample was only tested by ppNT and it was positive. All of the randomly selected IgG rS1-ELISA negative BD samples were also negative by whole-virus and rS1 IgG-IIFT (Tables
      <xref ref-type="table" rid="tab3">
       3
      </xref>
      and
      <xref ref-type="table" rid="tab4">
       4
      </xref>
      ).
     </p>
     <p>
      To determine the status of infection (recent versus older), all IgG rS1-ELISA reactive samples were further evaluated for the presence of IgM antibodies as an indication for recent infections using whole-virus IIFT (IgM-IIFT), and only one was marginally reactive and that was from a CP (
      <xref ref-type="table" rid="tab4">
       Table 4
      </xref>
      ). Strikingly, one of the 13 randomly selected IgG rS1-ELISA IgG-negative BD samples from the initial screening was found reactive for IgM antibodies (using IgM-IIFT) with a titer of 320. Positivity of this sample was further confirmed with ppNT, with EC50 titer of 500 (
      <xref ref-type="table" rid="tab3">
       Table 3
      </xref>
      ). The sample was obtained from a 35-year-old Syrian citizen residing in Qatar.
     </p>
     <p>
      Discrepancies in the results obtained from different binding assays could be due to cross-reactivity with other viruses. Hence, we evaluated the cross-reactivity of rS1-ELISA-reactive samples for IgG antibodies against all currently known human coronaviruses. All tested BD samples including the negative controls from the initial screening exhibited reactivity to at least 3 of 4 human coronaviruses. All rS1-ELISA-reactive samples were reactive to the four seasonal coronaviruses: 229E, HKU1, OC43-CoV, and NL63 (
      <xref ref-type="table" rid="tab5">
       Table 5
      </xref>
      ). The reactivity was also high in the negative controls from the initial screening reaching 100% (13/13) for 229E, 92% (12/13) for HKU1 and OC43, and 84% (11/13) for NL63 (partial data is shown in
      <xref ref-type="table" rid="tab5">
       Table 5
      </xref>
      ). None of the tested BD samples were reactive to SARS-CoV using whole-virus or rS1-IIFT IgG. Similarly, all samples from CP were also highly reactive with other human coronaviruses. Interestingly, two of the CP samples had considerable reactivity to SARS-CoV with titers of 320 and 3200 using IgG rS1-IIFT (
      <xref ref-type="table" rid="tab5">
       Table 5
      </xref>
      ).
     </p>
     <p>
      Discrepancies in cross-reactivity were also observed among different serological tests for human coronaviruses. For example, one sample from CP tested negative with whole-virus IIFT IgG for HCoV-229E, but it was reactive with recombinant S1 protein of the same virus using similar assay. Similarly, two samples from CP showed reactivity to SARS-CoV in the IgG rS1-IIFT, whereas only the sample with higher antibody titer reacted with the whole-virus IgG-IIFT assay. Further, all samples from CP reacted with HKU1 spike protein in rS1-ELISA, but only two samples yielded positive reaction with the IgG rS1-IIFT (
      <xref ref-type="table" rid="tab5">
       Table 5
      </xref>
      ).
     </p>
    </sec>
    <sec id="sec4">
     <title>
      4. Discussion
     </title>
     <p>
      Qatar reported a relatively low number of MERS cases in comparison to neighboring countries despite the fact that MERS-CoV continues to circulate in camels [
      <xref ref-type="bibr" rid="B23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B24">
       24
      </xref>
      ]. In the absence of a clear epidemiological view of MERS-CoV, we present here a comparative serological study for the prevalence of anti-MERS coronavirus antibodies in high- and low-risk groups in Qatar.
     </p>
     <p>
      Following the WHO recommendation, we run initial screening for IgG antibodies using rS1-ELISA, and reactive samples were then confirmed with full virus and rS1-IIFT IgG, followed by ppNT. Combined results from different serological tests indicate the low presence of neutralizing anti-MERS-CoV antibodies in the general population in Qatar (1/4719), while the rate increases to 1 : 135 in the high-risk group (CC). Our results revealed a few interesting observations. First, the only confirmed positive sample from the BD group was accidentally detected when we tested 13 randomly selected negative samples (originally selected to serve as a negative control) from the initial screening (using rS1-ELISA-IgG) for IgM response, where screening for IgM is not typically done in similar studies [
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ]. This mandates the development and utilization of assays that measure both classes of the antibodies for screening processes. Nonetheless, our results coincide with the low number of reported cases in Qatar (
      <italic>
       n
      </italic>
      = 21) compared to the neighboring countries such Saudi Arabia that has the highest number of reported MERS cases worldwide (
      <italic>
       n
      </italic>
      &gt; 1700) [
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ]. In a similar study using a similar approach in Saudi Arabia, 15/10009 (0.15%) were confirmed positive for anti-MERS antibodies in the general population. These numbers are slightly higher than what we observed in our study (1/4719; 0.02%); however, the low number of positive samples in both studies prevents a significant statistical analysis [
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ].
     </p>
     <p>
      Another interesting observation was the seropositivity in CC samples. Although those samples were collected within the first week of primary case identification, only one sample was positive for IgG but not for IgM antibodies, indicating previous exposure to the virus. It also confirms that infection with MERS-CoV can go unnoticed and that surveillance studies shall be done systematically to include screening for IgM and IgG responses. Similar to the above observation in the general population, the rate of seropositivity in the high-risk group (CC) in our analysis was lower (1/135; 0.74%) than that observed in Saudi Arabia (7/227; 3.08%). Several factors could explain the difference between both studies including the difference in sample size as well as the demographics and livestock population in both countries.
     </p>
     <p>
      One out of four MERS CP samples did not show antibody response using rS1-ELISA, whole virus, and rS1-IIFT assays. The sample was collected during the acute infection phase, which explains the absence of anti-MERS-CoV IgG response. A recent study from South Korea indicated that humoral response to MERS-CoV, as measured by binding and neutralizing assays, wean rapidly after one year of infection and becomes undetectable in about 67% of those who show mild illness upon infection [
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ]. In another study from Korea, it was shown that none of the asymptomatically infected individuals showed seroconversion; however, the seroconversion rates gradually increased with increasing disease severity reaching 60.0%, 93.8%, and 100% in symptomatic infection without pneumonia, pneumonia without respiratory failure, and pneumonia progressing to respiratory failure, respectively [
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      ]. Such studies indicate that human humoral immune response to MERS-CoV is a complicated phenomenon that requires further investigation. It further implies that the infection rate with MERS-CoV in the Middle East could be underestimated and that the fatality rate associated with MERS-CoV infection is most likely overestimated.
     </p>
     <p>
      As observed in other studies, the rS1-ELISA resulted in significant false-positive results. While 10/4719 (0.2%) samples were positive in this assay, only 2/10 (20%) were positive with whole-virus IgG-IIFT and null were confirmed with rS1-IIFT and ppNT (0%). Similarly, out of 10009 tested samples in the Saudi Arabia study, 152 were positive with rS1-ELISA (1.5%), 17 of which (11%) were positive with whole-virus IIFT and 15 were confirmed with neutralization assay [
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ]. These results indicate cross-reactivity between MERS-CoV and other human coronaviruses. To test this further, we employed several binding assays to test the reactivity of our samples with five known human coronaviruses, namely, SARS, HKU1, 229E, OC43, and NL63 CoV. Interestingly, all MERS-reactive samples from first screening, as well as most of the randomly selected negative control samples, had cross-reactivity to at least 3/4 seasonal human viruses, but none of them were cross-reactive with SARS-CoV. On the other hand, two of the CP samples were cross-reactive with SARS-CoV with intermediate titers. Accordingly, it is not clear which of the human coronavirus is inducing this cross-reactivity with MERS-CoV, which mandates further investigation. We also observed discrepancies in cross-reactivity when using different assays, where rS1-based IIFT were more sensitive than full virus counterparts. That could be due to the higher concentration of the specific S1 protein in the first assay, which also ensures the use of defined regents (purified proteins) for developing screening assays.
     </p>
     <p>
      On the other hand, cross-reactivity between SARS and MERS-CoV has been reported earlier. A 2013 study by Chan et al. indicated that 17/28 (60.7%) of SARS patients had significant binding antibody titers (using IIFT), of which seven (25%) had anti-MERS (EMC) neutralizing antibodies at low titers, which significantly correlated with that of HCoV-OC43 [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ]. In the same study, bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of spike protein between the two viruses [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ].
     </p>
     <p>
      We acknowledge few limitations to our study including the use of ELISA procedure to screen for anti-MERS-CoV IgG response, dominance of males over females (4642 versus 77), and non-Qataris over Qataris (3791 versus 928), as well as the screening at one-time point. Our findings affirm on the use of neutralization assay, and to a lower extent spike protein-specific IIFT, as confirmatory tests considering the high cross-reactivity among different human coronaviruses. Such findings were similar to what has been recently reported by Drosten et al. who showed that excess in IgG detection by anti-MERS rS1-ELISA IgG was not confirmed with IgG-IIFT assay [
      <xref ref-type="bibr" rid="B29">
       29
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec5">
     <title>
      5. Conclusion
     </title>
     <p>
      Our results indicate a high discrepancy between different assays available in the market to screen for anti-MERS-CoV antibodies. ELISA-based assay seems to be more prone to produce false-positive results, while results of IIFT should always be confirmed by neutralization test. Most of the available ELISA assays utilize S1 protein, which is part of the whole protein and in many cases is not well characterized before use. Using affinity purified and structurally defined protein might be more reliable to produce accurate results. The recent determination of several ectodomain structures from many coronaviruses should be instrumental to design better immunogens [
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      –
      <xref ref-type="bibr" rid="B36">
       36
      </xref>
      ], which can also be utilized to develop more specific screening assays. Lastly, further investigation of the possibility of MERS-CoV transmission through a blood transfusion from asymptomatic donors should also be assessed, though no cases have been reported so far with evidence of blood transfusion as a source of MERS-CoV infection.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We would like to express our appreciation and gratitude to Dr. Marawan Abu-Madi for his administrative supervisory role of Reham A. Al Kahlout. We are also grateful to Ms. Enas S. Alabsi for her administrative support of the grant, Mrs. Nadiam Haj Ali and Mrs. Rajaa Abdul-Hadi for their technical support, and Dr. Asmaa Al Marwani for her help in sample collection. Test kits were provided through funding from Qatar University intramural fund No. QUUG-BRC-2017-1 given to AAA and HMY and student grant # QUST-CAS-FALL-15/16-33 given to GKN.
      </p>
     </ack>
     <sec sec-type="data-availability">
      <title>
       Data Availability
      </title>
      <p>
       The data used to support the findings of this study are available from the corresponding author upon request.
      </p>
     </sec>
     <sec>
      <title>
       Disclosure
      </title>
      <p>
       The findings achieved herein are solely the responsibility of the authors.
      </p>
     </sec>
     <sec>
      <title>
       Conflicts of Interest
      </title>
      <p>
       All authors declare that they have no conflict of interest to disclose.
      </p>
     </sec>
     <ref-list>
      <ref id="B1">
       <label>
        1
       </label>
       <element-citation publication-type="other">
        <collab>
         WHO
        </collab>
        <article-title>
         WHO
        </article-title>
        <comment>
         2017,
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/en">
          http://www.who.int/emergencies/mers-cov/en
         </ext-link>
         /
        </comment>
       </element-citation>
      </ref>
      <ref id="B2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D. K. W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Longitudinal study of Middle East respiratory syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015
        </article-title>
        <source>
         <italic toggle="yes">
          Emerging Microbes &amp; Infections
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         6, article e56
        </volume>
        <pub-id pub-id-type="doi">
         10.1038/emi.2017.44
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85037356747
        </pub-id>
        <pub-id pub-id-type="pmid">
         28634355
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E. A.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014
        </article-title>
        <source>
         <italic toggle="yes">
          Emerging Infectious Diseases
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1339
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140663
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84902277248
        </pub-id>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           al Dhahiry
          </surname>
          <given-names>
           S. H. S.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B. E. M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         <italic toggle="yes">
          The Lancet Infectious Diseases
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84892538696
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gopal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B. L.
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses
        </article-title>
        <source>
         <italic toggle="yes">
          The Journal of Infectious Diseases
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         209
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         995
        </fpage>
        <lpage>
         1006
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit609
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84898978774
        </pub-id>
        <pub-id pub-id-type="pmid">
         24253287
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dea
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Verbeek
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Tijssen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic and genomic relationships among turkey and bovine enteric coronaviruses
        </article-title>
        <source>
         <italic toggle="yes">
          Journal of Virology
         </italic>
        </source>
        <year>
         1990
        </year>
        <volume>
         64
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         3112
        </fpage>
        <lpage>
         3118
        </lpage>
        <pub-id pub-id-type="pmid">
         2159566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F. W.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
        </article-title>
        <source>
         <italic toggle="yes">
          Journal of Infection
         </italic>
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         130
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.03.015
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84879302673
        </pub-id>
        <pub-id pub-id-type="pmid">
         23583636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Costabel
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
        </article-title>
        <source>
         <italic toggle="yes">
          Eurosurveillance
         </italic>
        </source>
        <year>
         2012
        </year>
        <volume>
         17
        </volume>
        <issue>
         49
        </issue>
       </element-citation>
      </ref>
      <ref id="B9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
        </article-title>
        <source>
         <italic toggle="yes">
          Eurosurveillance
         </italic>
        </source>
        <year>
         2012
        </year>
        <volume>
         17
        </volume>
        <issue>
         39
        </issue>
        <pub-id pub-id-type="doi">
         10.2807/ese.17.39.20285-en
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84867136420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Palm
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pereyaslov
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Vaz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Laboratory capability for molecular detection and confirmation of novel coronavirus in Europe, November 2012
        </article-title>
        <source>
         <italic toggle="yes">
          Eurosurveillance
         </italic>
        </source>
        <year>
         2012
        </year>
        <volume>
         17
        </volume>
        <issue>
         49
        </issue>
        <pub-id pub-id-type="doi">
         10.2807/ese.17.49.20335-en
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84871453474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G. J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Specific serology for emerging human coronaviruses by protein microarray
        </article-title>
        <source>
         <italic toggle="yes">
          Eurosurveillance
         </italic>
        </source>
        <year>
         2013
        </year>
        <volume>
         18
        </volume>
        <issue>
         14
        </issue>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2013.18.14.20441
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12">
       <label>
        12
       </label>
       <element-citation publication-type="other">
        <article-title>
         Laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/176982/1/WHO_MERS_LAB_15.1_eng.pdf?ua=1">
          http://apps.who.int/iris/bitstream/10665/176982/1/WHO_MERS_LAB_15.1_eng.pdf?ua=1
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B13">
       <label>
        13
       </label>
       <element-citation publication-type="other">
        <article-title>
         CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/coronavirus/mers/lab/lab-testing.html">
          http://www.cdc.gov/coronavirus/mers/lab/lab-testing.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        <source>
         <italic toggle="yes">
          The Lancet Infectious Diseases
         </italic>
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         559
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)70090-3
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84928213277
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B. E. M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E. A. B. A.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Occupational exposure to dromedaries and risk for MERS-CoV infection, Qatar, 2013–2014
        </article-title>
        <source>
         <italic toggle="yes">
          Emerging Infectious Diseases
         </italic>
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1422
        </fpage>
        <lpage>
         1425
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2108.150481
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84937414526
        </pub-id>
        <pub-id pub-id-type="pmid">
         26196891
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nasrallah
          </surname>
          <given-names>
           G. K.
          </given-names>
         </name>
         <name>
          <surname>
           Dargham
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           L. I.
          </given-names>
         </name>
         <name>
          <surname>
           Abu-Raddad
          </surname>
          <given-names>
           L. J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar
        </article-title>
        <source>
         <italic toggle="yes">
          Journal of Medical Virology
         </italic>
        </source>
        <year>
         2018
        </year>
        <volume>
         90
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         184
        </fpage>
        <lpage>
         190
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.24916
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85034024356
        </pub-id>
        <pub-id pub-id-type="pmid">
         28817197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Qahtani
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <name>
          <surname>
           Alabsi
          </surname>
          <given-names>
           E. S.
          </given-names>
         </name>
         <name>
          <surname>
           AbuOdeh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Thalib
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           El Zowalaty
          </surname>
          <given-names>
           M. E.
          </given-names>
         </name>
         <name>
          <surname>
           Nasrallah
          </surname>
          <given-names>
           G. K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of anelloviruses (TTV, TTMDV, and TTMV) in healthy blood donors and in patients infected with HBV or HCV in Qatar
        </article-title>
        <source>
         <italic toggle="yes">
          Virology Journal
         </italic>
        </source>
        <year>
         2016
        </year>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         p. 208
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12985-016-0664-6
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85007417160
        </pub-id>
        <pub-id pub-id-type="pmid">
         28031027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AbuOdeh
          </surname>
          <given-names>
           R. O.
          </given-names>
         </name>
         <name>
          <surname>
           al-Absi
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           N. H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection and phylogenetic analysis of human pegivirus (GBV-C) among blood donors and patients infected with hepatitis B virus (HBV) in Qatar
        </article-title>
        <source>
         <italic toggle="yes">
          Journal of Medical Virology
         </italic>
        </source>
        <year>
         2015
        </year>
        <volume>
         87
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         2074
        </fpage>
        <lpage>
         2081
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.24289
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84942887131
        </pub-id>
        <pub-id pub-id-type="pmid">
         26058920
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AbuOdeh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           al-Mawlawi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           al-Qahtani
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection and genotyping of torque teno virus (TTV) in healthy blood donors and patients infected with HBV or HCV in Qatar
        </article-title>
        <source>
         <italic toggle="yes">
          Journal of Medical Virology
         </italic>
        </source>
        <year>
         2015
        </year>
        <volume>
         87
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1184
        </fpage>
        <lpage>
         1191
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.24146
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84928759524
        </pub-id>
        <pub-id pub-id-type="pmid">
         25676255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smatti
          </surname>
          <given-names>
           M. K.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H. M.
          </given-names>
         </name>
         <name>
          <surname>
           AbuOdeh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar
        </article-title>
        <source>
         <italic toggle="yes">
          PLoS One
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         12
        </volume>
        <issue>
         12, article e0189033
        </issue>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0189033
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85038408050
        </pub-id>
        <pub-id pub-id-type="pmid">
         29228016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV
        </article-title>
        <source>
         <italic toggle="yes">
          Nature Communications
         </italic>
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         p. 7712
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms8712
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84938149041
        </pub-id>
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Afshar
          </surname>
          <given-names>
           P. T.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           W. H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COSINE: non-seeding method for mapping long noisy sequences
        </article-title>
        <source>
         <italic toggle="yes">
          Nucleic Acids Research
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         45
        </volume>
        <issue>
         14
        </issue>
        <fpage>
         p. e132
        </fpage>
        <pub-id pub-id-type="doi">
         10.1093/nar/gkx511
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85031850777
        </pub-id>
        <pub-id pub-id-type="pmid">
         28586438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sikkema
          </surname>
          <given-names>
           R. S.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E. A. B. A.
          </given-names>
         </name>
         <name>
          <surname>
           Himatt
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk factors for primary Middle East respiratory syndrome coronavirus infection in camel workers in Qatar during 2013–2014: a case-control study
        </article-title>
        <source>
         <italic toggle="yes">
          The Journal of Infectious Diseases
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         215
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1702
        </fpage>
        <lpage>
         1705
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jix174
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85029667796
        </pub-id>
        <pub-id pub-id-type="pmid">
         28387845
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mohran
          </surname>
          <given-names>
           K. A.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E. A. B. A.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B. E. M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction
        </article-title>
        <source>
         <italic toggle="yes">
          Revue Scientifique et Technique
         </italic>
        </source>
        <year>
         2016
        </year>
        <volume>
         35
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         905
        </fpage>
        <lpage>
         911
        </lpage>
        <pub-id pub-id-type="doi">
         10.20506/rst.35.3.2578
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85017135451
        </pub-id>
        <pub-id pub-id-type="pmid">
         28332641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25">
       <label>
        25
       </label>
       <element-citation publication-type="other">
        <collab>
         Health KMo
        </collab>
        <article-title>
         KSA Ministry of Health
        </article-title>
        <comment>
         2017,
         <ext-link ext-link-type="uri" xlink:href="http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx">
          http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B26">
       <label>
        26
       </label>
       <element-citation publication-type="other">
        <collab>
         Organization WH
        </collab>
        <article-title>
         WHO
        </article-title>
        <comment>
         2017,
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/27-april-2017-mers-saudi-arabia-and-qatar/en">
          http://www.who.int/csr/don/27-april-2017-mers-saudi-arabia-and-qatar/en
         </ext-link>
         /
        </comment>
       </element-citation>
      </ref>
      <ref id="B27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P. G.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R. A. P. M.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W. B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015
        </article-title>
        <source>
         <italic toggle="yes">
          Emerging Infectious Diseases
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1079
        </fpage>
        <lpage>
         1084
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2307.170310
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85021110525
        </pub-id>
        <pub-id pub-id-type="pmid">
         28585916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J. H.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Seok
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity
        </article-title>
        <source>
         <italic toggle="yes">
          Diagnostic Microbiology and Infectious Disease
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         89
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         111
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.diagmicrobio.2017.07.006
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85027411812
        </pub-id>
        <pub-id pub-id-type="pmid">
         28821364
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts
        </article-title>
        <source>
         <italic toggle="yes">
          The New England Journal of Medicine
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         371
        </volume>
        <fpage>
         828
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84907331317
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K. S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
        </article-title>
        <source>
         <italic toggle="yes">
          Proceedings of the National Academy of Sciences of the United States of America
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         114
        </volume>
        <issue>
         35
        </issue>
        <fpage>
         E7348
        </fpage>
        <lpage>
         E7357
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1707304114
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85028522287
        </pub-id>
        <pub-id pub-id-type="pmid">
         28807998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A. C.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
        </article-title>
        <source>
         <italic toggle="yes">
          Nature
         </italic>
        </source>
        <year>
         2016
        </year>
        <volume>
         531
        </volume>
        <issue>
         7592
        </issue>
        <fpage>
         114
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature16988
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84960090603
        </pub-id>
        <pub-id pub-id-type="pmid">
         26855426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R. N.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           C. A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pre-fusion structure of a human coronavirus spike protein
        </article-title>
        <source>
         <italic toggle="yes">
          Nature
         </italic>
        </source>
        <year>
         2016
        </year>
        <volume>
         531
        </volume>
        <issue>
         7592
        </issue>
        <fpage>
         118
        </fpage>
        <lpage>
         121
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature17200
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84960173062
        </pub-id>
        <pub-id pub-id-type="pmid">
         26935699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2
        </article-title>
        <source>
         <italic toggle="yes">
          PLoS Pathogens
         </italic>
        </source>
        <year>
         2018
        </year>
        <volume>
         14
        </volume>
        <issue>
         8, article e1007236
        </issue>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1007236
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85053079712
        </pub-id>
        <pub-id pub-id-type="pmid">
         30102747
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins
        </article-title>
        <source>
         <italic toggle="yes">
          PLoS Pathogens
         </italic>
        </source>
        <year>
         2018
        </year>
        <volume>
         14
        </volume>
        <issue>
         4, article e1007009
        </issue>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1007009
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85046421949
        </pub-id>
        <pub-id pub-id-type="pmid">
         29684066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cryo-electron microscopy structure of porcine deltacoronavirus spike protein in the prefusion state
        </article-title>
        <source>
         <italic toggle="yes">
          Journal of Virology
         </italic>
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01556-17
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85041170336
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
        </article-title>
        <source>
         <italic toggle="yes">
          Nature Communications
         </italic>
        </source>
        <year>
         2017
        </year>
        <volume>
         8, article 15092
        </volume>
        <pub-id pub-id-type="doi">
         10.1038/ncomms15092
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-85017378927
        </pub-id>
        <pub-id pub-id-type="pmid">
         28393837
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="fig1" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Number of reactive samples using rS1-ELISA (IgG) screening. A total of 4858 plasma samples were initially screened for anti-MERS S1 IgG using rS1-ELISA. The graph shows the number of reactive samples in three groups: blood donor (
        <italic>
         n
        </italic>
        = 4719), case contacts (
        <italic>
         n
        </italic>
        = 135), and confirmed cases (
        <italic>
         n
        </italic>
        = 4).
       </p>
      </caption>
      <graphic xlink:href="JIR2019-1386740.001">
      </graphic>
     </fig>
     <table-wrap id="tab1" orientation="portrait" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Characteristic profile of the study population.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th colspan="1" rowspan="2">
         </th>
         <th align="center" colspan="3" rowspan="1">
          BD (2012-2016)
         </th>
         <th align="center" colspan="3" rowspan="1">
          CC (2015-2016)
         </th>
         <th align="center" colspan="3" rowspan="1">
          CP (2015-2016)
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1">
          Number
         </th>
         <th align="center" colspan="1" rowspan="1">
          Age range (mean)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Exposure
         </th>
         <th align="center" colspan="1" rowspan="1">
          Number
         </th>
         <th align="center" colspan="1" rowspan="1">
          Age range (mean)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Exposure (
          <italic>
           n
          </italic>
          )
         </th>
         <th align="center" colspan="1" rowspan="1">
          Number
         </th>
         <th align="center" colspan="1" rowspan="1">
          Age range (mean)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Exposure
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Qatari males
         </td>
         <td align="center" colspan="1" rowspan="1">
          906
         </td>
         <td align="center" colspan="1" rowspan="4">
          19-88 (37)
         </td>
         <td align="center" colspan="1" rowspan="4">
          Unknown
         </td>
         <td align="center" colspan="1" rowspan="1">
          11
         </td>
         <td align="center" colspan="1" rowspan="4">
          14-49 (31)
         </td>
         <td align="center" colspan="1" rowspan="4">
          Family contact (37), healthcare worker (73), camel farm worker (25)
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="4">
          29-69 (51)
         </td>
         <td align="center" colspan="1" rowspan="4">
          Camel farm
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Qatari females
         </td>
         <td align="center" colspan="1" rowspan="1">
          22
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Non-Qatari males
         </td>
         <td align="center" colspan="1" rowspan="1">
          3736
         </td>
         <td align="center" colspan="1" rowspan="1">
          93
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Non-Qatari females
         </td>
         <td align="center" colspan="1" rowspan="1">
          55
         </td>
         <td align="center" colspan="1" rowspan="1">
          28
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Total
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           4719
          </bold>
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           135
          </bold>
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           4
          </bold>
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           4858
          </bold>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="tab2" orientation="portrait" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Number of reactive samples for anti-MERS S1 IgG using rS1-ELISA.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Sample source
         </th>
         <th align="center" colspan="1" rowspan="1">
          Year of collection (no. screened)
         </th>
         <th align="center" colspan="1" rowspan="1">
          No. borderline/no. screened (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          No. reactive/no. screened (%)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="5">
          BD
         </td>
         <td align="center" colspan="1" rowspan="1">
          2012 (120)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/120 (0.83)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/120 (0)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          2013 (28)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/28 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/28 (0)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          2014 (611)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/611 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/611 (0.16)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          2015 (3383)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/3383 (0.03)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           5/3383 (0.15)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          2016 (577)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/577 (0.17)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/577 (0.17)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Subtotal
         </td>
         <td align="center" colspan="1" rowspan="1">
          4719
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3/4719 (0.08)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           7/4719 (0.13)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="3">
          CC
         </td>
         <td align="center" colspan="1" rowspan="1">
          May-2015 (100)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/100 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/100 (1)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          Feb-2016 (10)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/10 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/10 (0)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          June-2016 (25)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/25 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/25 (0)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Subtotal
         </td>
         <td align="center" colspan="1" rowspan="1">
          135
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/135 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          1/135 (0.74)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          CP
         </td>
         <td align="center" colspan="1" rowspan="1">
          Mar-2015 (1)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/1 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/1 (100)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          May-2015 (1)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/1 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/1 (100)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          Feb-2016 (1)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/1 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1/1 (100)
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          May-2016 (1)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/1 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/1 (0)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Subtotal
         </td>
         <td align="center" colspan="1" rowspan="1">
          4
         </td>
         <td align="center" colspan="1" rowspan="1">
          0/4 (0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3/4
          </italic>
          (75)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Total
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           Total (4858)
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           3/4858 (0.06)
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <bold>
           12/4858 (0.25)
          </bold>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Positive samples are shown in
         <italic>
          italic
         </italic>
         .
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="tab3" orientation="portrait" position="float">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Comparative serological analysis of reactive and borderline samples from blood donors (BD).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th colspan="2" rowspan="1">
         </th>
         <th align="center" colspan="1" rowspan="1">
          rS1-ELISA
          <sup>
           ∗
          </sup>
         </th>
         <th align="center" colspan="2" rowspan="1">
          Full virus IIFT
         </th>
         <th align="center" colspan="1" rowspan="1">
          rS1-IIFT
         </th>
         <th align="center" colspan="1" rowspan="1">
          ppNT
         </th>
        </tr>
        <tr>
         <th colspan="1" rowspan="1">
         </th>
         <th align="center" colspan="1" rowspan="1">
          Sample identifier
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgG (OD, ratio, endpoint titer)
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgG titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgM titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgG titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          IC50 titer (EMC/JordanN3)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="7">
          Reactive (
          <italic>
           n
          </italic>
          = 7)
         </td>
         <td align="center" colspan="1" rowspan="1">
          BD 2014/597
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.905, 2.114, 201)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/1303
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.397, 1.3, 101)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           10000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3004
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.439, 1.26, 201)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3119
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.402, 1.06, 401)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3380
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.477, 1.1, 101)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           10000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3513
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.497, 1.39, 401)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/4435
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.661, 1.74, 201)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="3">
          Borderline (
          <italic>
           n
          </italic>
          = 3)
         </td>
         <td align="center" colspan="1" rowspan="1">
          BD 2012/2644
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.333, 0.83, 101)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/1816
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.456, 0.823,201)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/4708
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.408, 1.07, 101)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="3">
          Selected negative (showing 3/13)
          <sup>
           ∗∗
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/2859
         </td>
         <td align="center" colspan="1" rowspan="1">
          (0.034, 0.076, &lt;101)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/2988
         </td>
         <td align="center" colspan="1" rowspan="1">
          (0.039, 0.112, &lt;101)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          &lt;50
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3379
         </td>
         <td align="center" colspan="1" rowspan="1">
          (0.065, 0. 16, &lt;101)
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           531/502
          </italic>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         <sup>
          ∗
         </sup>
         Initial screening was done with rS1-ELISA, and reactive samples were further tested with various serological assays as indicated above.
         <sup>
          ∗∗
         </sup>
         13 negative samples from the initial screening with rS1-ELISA were selected for comparison, and one was found positive with full virus IgM and ppNT. Positive samples are shown in
         <italic>
          italic
         </italic>
         .
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="tab4" orientation="portrait" position="float">
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Comparative serological analysis of reactive samples from CC and CP.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th colspan="1" rowspan="1">
         </th>
         <th align="center" colspan="1" rowspan="1">
          rS1-ELISA
         </th>
         <th align="center" colspan="2" rowspan="1">
          Full virus IIFT
         </th>
         <th align="center" colspan="1" rowspan="1">
          rS1-IIFT
         </th>
         <th align="center" colspan="1" rowspan="1">
          ppNT
         </th>
        </tr>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Sample identifier
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgG (OD, ratio, endpoint titer)
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgG titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgM titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          IgG titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          IC50 titer (EMC/JordanN3)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          CC May.2015
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.61, 1.5, 101)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          Quantity not sufficient
         </td>
         <td align="center" colspan="1" rowspan="1">
          Quantity not sufficient
         </td>
         <td align="center" colspan="1" rowspan="1">
          Quantity not sufficient
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           76/149
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          CP Mar.2015
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (1.084, 2.86, 201)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           10000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           &gt;10000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           630/1707
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          CP May.2015
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (0.412, 1.37, ND
           <sup>
            ∗
           </sup>
           )
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           199/688
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          CP Feb.2016
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           (2.229, 6.517, ≥ 3201)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           &gt;32000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           100
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           &gt;10000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Positive samples are shown in
         <italic>
          italic
         </italic>
         . ND: not determined.
         <sup>
          ∗
         </sup>
         This samples showed controversial results in rS1-ELISA IgG and was considered positive based on IIFT.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="tab5" orientation="portrait" position="float">
      <label>
       Table 5
      </label>
      <caption>
       <p>
        Cross-reactivity of reactive samples with rS1-ELISA and other human coronaviruses.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th colspan="1" rowspan="2">
         </th>
         <th align="center" colspan="1" rowspan="2">
          Sample identifier
         </th>
         <th align="center" colspan="2" rowspan="1">
          Whole-virus IIFT IgG titer
         </th>
         <th align="center" colspan="1" rowspan="1">
          rS1-ELISA titer IgG
         </th>
         <th align="center" colspan="5" rowspan="1">
          rS1-IIFT titer IgG
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1">
          229E
         </th>
         <th align="center" colspan="1" rowspan="1">
          SARS
         </th>
         <th align="center" colspan="1" rowspan="1">
          HKU1
         </th>
         <th align="center" colspan="1" rowspan="1">
          229E
         </th>
         <th align="center" colspan="1" rowspan="1">
          OC43
         </th>
         <th align="center" colspan="1" rowspan="1">
          SARS
         </th>
         <th align="center" colspan="1" rowspan="1">
          NL63
         </th>
         <th align="center" colspan="1" rowspan="1">
          HKU1
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="7">
          Reactive BD
         </td>
         <td align="center" colspan="1" rowspan="1">
          BD 2014/597
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥100
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/1303
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3004
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥1000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3119
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3380
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3513
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥1000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/4435
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="3">
          Borderline BD
         </td>
         <td align="center" colspan="1" rowspan="1">
          BD 2012/2644
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥1000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/1816
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/4708
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="3">
          Selected negative BD (showing 3/13)
         </td>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/2859
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/2988
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          ND
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          BD 2015/3379
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320 (IgM = 0)
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0 (IgM = 0)
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="3">
          Reactive CP
         </td>
         <td align="center" colspan="1" rowspan="1">
          CP Mar.2015
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           100
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          CP May.2015
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           320
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          CP Feb.2016
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           1000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ≥101
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           &gt;10000
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           3200
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Positive samples are shown in
         <italic>
          italic
         </italic>
         . ND: not determined.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       BMC Vet Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       BMC Vet. Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        BMC Veterinary Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1746-6148
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27277214
      </article-id>
      <article-id pub-id-type="pmc">
       4898321
      </article-id>
      <article-id pub-id-type="publisher-id">
       716
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s12917-016-0716-6
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Methodology Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Development of monoclonal antibodies and serological assays including indirect ELISA and fluorescent microsphere immunoassays for diagnosis of porcine deltacoronavirus
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Okda
         </surname>
         <given-names>
          Faten
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Lawson
         </surname>
         <given-names>
          Steven
         </given-names>
        </name>
        <address>
         <phone>
          605-688-5171
         </phone>
         <email>
          steven.lawson@sdstate.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Xiaodong
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Singrey
         </surname>
         <given-names>
          Aaron
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Clement
         </surname>
         <given-names>
          Travis
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hain
         </surname>
         <given-names>
          Kyle
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          Julie
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Christopher-Hennings
         </surname>
         <given-names>
          Jane
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          Eric A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.263791.8
         </institution-id>
         <institution-id institution-id-type="ISNI">
          000000012167853X
         </institution-id>
         <institution>
          Veterinary &amp; Biomedical Sciences Department,
         </institution>
         <institution>
          South Dakota State University,
         </institution>
        </institution-wrap>
        Brookings, SD USA
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.419725.c
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121518157
         </institution-id>
         <institution>
          National Research Center,
         </institution>
        </institution-wrap>
        Giza, Egypt
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        8
       </day>
       <month>
        6
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        8
       </day>
       <month>
        6
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <elocation-id>
       95
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         10
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         1
        </day>
        <month>
         6
        </month>
        <year>
         2016
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s). 2016
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         ) applies to the data made available in this article, unless otherwise stated.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p id="Par1">
         A novel porcine deltacoronavirus (PDCoV), also known as porcine coronavirus HKU15, was reported in China in 2012 and identified in the U.S. in early 2014. Since then, PDCoV has been identified in a number of U.S. states and linked with clinical disease including acute diarrhea and vomiting in the absence of other identifiable pathogens. Since PDCoV was just recently linked with clinical disease, few specific antibody-based reagents were available to assist in diagnosis of PDCoV and limited serological capabilities were available to detect an antibody response to this virus. Therefore, the overall objective of this project was to develop and validate selected diagnostic reagents and assays for PDCoV antigen and antibody detection.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p id="Par2">
         The nucleoprotein of PDCoV was expressed as a recombinant protein and purified for use as an antigen to immunize mice for polyclonal, hyperimmune sera and monoclonal antibody (mAb) production. The resulting mAbs were evaluated for use in fluorescent antibody staining methods to detect PDCoV infected cells following virus isolation attempts and for immunohistochemistry staining of intestinal tissues of infected pigs. The same antigen was used to develop serological tests to detect the antibody response to PDCoV in pigs following infection. Serum samples from swine herds with recent documentation of PDCoV infection and samples from expected naïve herds were used for initial assay optimization. The tests were optimized in a checkerboard fashion to reduce signal to noise ratios using samples of known status. Statistical analysis was performed to establish assay cutoff values and assess diagnostic sensitivities and specificities. At least 629 known negative serum samples and 311 known positive samples were evaluated for each assay. The enzyme linked immunosorbent assay (ELISA) showed diagnostic sensitivity (DSe) of 96.1 % and diagnostic specificity (DSp) of 96.2 %. The fluorescent microsphere immunoassay (FMIA) showed a DSe of 95.8 % and DSp of 98.1 %. Both ELISA and FMIA detected seroconversion of challenged pigs between 8–14 days post-infection (DPI). An indirect fluorescent antibody (IFA) test was also developed using cell culture adapted PDCoV for comparative purposes.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p id="Par3">
         These new, specific reagents and serological assays will allow for improved diagnosis of PDCoV. Since many aspects of PDCoV infection and transmission are still not fully understood, the reagents and assays developed in this project should provide valuable tools to help understand this disease and to aid in the control and surveillance of porcine deltacoronavirus outbreaks.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Porcine deltacoronavirus (PDCoV)
       </kwd>
       <kwd>
        Monoclonal antibodies
       </kwd>
       <kwd>
        Serology
       </kwd>
       <kwd>
        ELISA
       </kwd>
       <kwd>
        Fluorescent microsphere immunoassay (FMIA)
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution-wrap>
          <institution-id institution-id-type="FundRef">
           http://dx.doi.org/http://dx.doi.org/10.13039/100008370
          </institution-id>
          <institution>
           National Pork Board
          </institution>
         </institution-wrap>
        </funding-source>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2016
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1" sec-type="introduction">
     <title>
      Background
     </title>
     <p id="Par4">
      Coronaviruses are enveloped, positive sense RNA viruses divided among several genera, including
      <italic>
       Alphacoronavirus
      </italic>
      ,
      <italic>
       Betacoronavirus
      </italic>
      ,
      <italic>
       Gammacoronavirus
      </italic>
      and the recently described genus
      <italic>
       Deltacoronavirus
      </italic>
      . A novel porcine deltacoronavirus (PDCoV) was reported in China in 2012 and designated HKU15 [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. Other important porcine coronaviruses include porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV); and are members of the genus
      <italic>
       Alphacoronavirus
      </italic>
      [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. In February 2014, the Ohio Department of Agriculture announced the identification of PDCoV in swine feces at five farms in Ohio and associated with enteric disease similar to PEDV in the U.S. [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. Since then, PDCoV has been identified in numerous U.S. states and Canada, linked with apparent clinical disease including acute diarrhea and vomiting in the absence of other identifiable pathogens. According to field observations in the U.S., PDCoV infections cause less severe clinical disease than PEDV, but analysis of the field data is complicated since co-infections with PEDV or other pathogens are common. PDCoV is currently diagnosed by real time PCR and clinical symptoms [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ].
     </p>
     <p id="Par5">
      The severity of disease in both gnotobiotic and conventional piglets has further defined the pathogenicity and pathogenesis of the virus [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      –
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. PDCoV causes diarrhea and vomiting in all age groups and mortality in nursing pigs but the mortality rates are less than that shown in cases of PEDV. Previously, there was little information about deltacoronavirus infections in pigs and only one surveillance study from Hong Kong reported its detection in pigs prior to its emergence in the U.S. The virus had not been reported to be associated with clinical disease in China. The newly emergent strain found on the Ohio farms, PorCoV HKU15 OH 1987, is closely related to the 2 strains from China, but it is unknown how this virus was introduced into the US [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ].
     </p>
     <p id="Par6">
      Recently, Jung et al. [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ] developed in-situ hybridization and immunofluorescence staining techniques to demonstrate the areas of PDCoV replication in tissues of infected pigs. The OH-FD22 and OH-FD100 PDCoV strains were confirmed as causing an acute infection through the entire intestine, but primarily the jejunum and ileum, and clinically lead to severe diarrhea and vomiting. Clinical signs and pathological features of PDCoV-infected pigs resemble those of PEDV and TGEV infections. Effective differential diagnosis between PDCoV, PEDV, and TGEV is important to control the diseases.
     </p>
     <p id="Par7">
      Polymerase chain reaction (PCR) assays were quickly developed for the detection of PDCoV infections following the initial U.S. identification in 2014 but available serological assays are limited. Thachil et al. [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ] developed an indirect anti-PDCoV IgG enzyme-linked immunosorbent assay (ELISA) based on the S1 portion of the spike protein. Although this assay was shown to be a highly sensitive (91 %) and specific test (95 %), there is need for other ELISAs utilizing alternative antigen targets, such as the nucleoprotein of PDCoV, to serve as primary serological surveillance or confirmatory assays. As noted in Thachil’s research, several serum samples collected in 2010 were found positive for PDCoV antibody by their ELISA, but all those collected in 2011 and 2012 tested negative by that assay. This finding is interesting since PDCoV was not thought to be circulating in North America prior to late 2013 [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. Therefore, availability of several serological assay formats targeting different viral antigens can be valuable as confirmatory assays in the investigation of unexpected laboratory findings.
     </p>
     <p id="Par8">
      Since no specific antibody-based reagents were available to assist in diagnosis of PDCoV, one purpose of the current study was to develop readily available reagents for detection of PDCoV antigen in diagnostic tests, such as virus isolation, immunohistochemistry and fluorescent antibody techniques. Serological tests for the detection of antibody responses to PDCoV were also very limited. Therefore, another objective of this study was to develop and optimize several serological assays including an indirect ELISA, a fluorescent microsphere immunoassay (FMIA), and an indirect fluorescent antibody (IFA) test.
     </p>
     <p id="Par9">
      Both specific antibody-based reagents and serological tests are essential for the further study and control of PDCoV and the differentiation of PDCoV infection from other related diseases such as PEDV or TGEV. The tools developed during the course of this study can be applied to many ongoing and future studies to better understand and control PDCoV.
     </p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Serum samples
      </title>
      <p id="Par10">
       Samples used for optimization and validation of the PDCoV ELISA and FMIA assays included samples from a large PDCoV challenge study associated with National Pork Board (NPB) research project 14–182. These samples and samples from another group of 30 pigs which were collected near the time of initial field exposure to PDCoV and 28 days later were used in a time course study.
      </p>
      <p id="Par11">
       For further validation and assessment of diagnostic sensitivity (DSe) and diagnostic specificity (DSp), samples of known PDCoV serostatus were used (
       <italic>
        n
       </italic>
       = 940). The expected positive samples were submitted field serum samples (
       <italic>
        n
       </italic>
       = 311) from herds previously testing PDCoV positive by PCR at least 3 weeks prior to sample collection. Expected negative samples included archived experimental serum collected prior to 2009 (
       <italic>
        n
       </italic>
       = 108) and field samples from high-health herds with no known history of PDCoV exposure (
       <italic>
        n
       </italic>
       = 521). The total number of expected negative samples was 629.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Viruses and cells
      </title>
      <p id="Par12">
       Swine testicle (ST) cells were cultured in Eagle’s minimum essential medium (MEM; Gibco BRL Life Technologies) supplemented with 10 % fetal bovine serum (FBS), and antibiotics (100 units/ml penicillin and 20 g/ml streptomycin). Cells were maintained at 37 °C in a humidified 5 % CO
       <sub>
        2
       </sub>
       incubator. Cell culture adapted PDCoV was provided by the National Veterinary Services Laboratories, designated porcine coronavirus HKU15 strain Michigan/8977/2014 (GenBank accession KM012168). PDCoV was propagated on ST cells utilizing 0.8 μg/ml trypsin (TPCK-treated, bovine derived (Sigma, St. Louis, MO)) in the inoculation and maintenance media. Virus infected cells were harvested 24–48 h after inoculation, when significant cytopathic effect (CPE) was noted.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Antigen production
      </title>
      <p id="Par13">
       The antigen used for the FMIA and indirect ELISA validation was a recombinantly expressed, full length, PDCoV nucleoprotein (NP). RNA isolated from semi-purified cultured virus corresponding to the PDCoV-NP was amplified by reverse transcriptase polymerase chain reaction (RT-PCR) and resulting DNA cloned into the pET-28a protein expression vector (Novagen, Madison, WI). Primers used for amplification of the nucleocapsid region are described:
      </p>
      <p id="Par14">
       PDCoV-NP fwd (5′-CGC
       <underline>
        GGATCC
       </underline>
       ATGGCCGCACCAGTAGTC - 3′);
      </p>
      <p id="Par15">
       PDCoV-NP rev (5′-CACA
       <underline>
        CTCGAG
       </underline>
       CGCGCTGCTGATTCCTGCTT- 3′).
      </p>
      <p id="Par16">
       The NP gene was prokaryotically expressed as an insoluble 41 kDa, 6x polyhistidine-tagged, fusion protein then purified according to previously described methods [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ]. Purified protein was analyzed by sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) to determine purity and linear integrity. The expressed PDCoV NP was recognized in Western blotting by convalescent serum and two separate monoclonal antibodies developed in our laboratory were used to confirm the specificity of the proteins.
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Refolding of the PDCoV NP purified protein
      </title>
      <p id="Par17">
       The purified protein was refolded by first solubilizing the recombinant protein expressed as insoluble inclusion bodies in
       <italic>
        E. coli.
       </italic>
       Briefly, the protein was solubilized in 50 mM 3-(Cyclohexylamino)-1-propanesulfonic acid (CAPS buffer, pH 11.0) containing 1.0 % N-lauroylsarcosine and 1.0 mM DTT. The protein was then dialyzed overnight at 4 °C in 20 mM Tris–HCl pH 8.5 containing 0.1 mM DTT to encourage correct disulfide bond formation and subsequent refolding of the protein. A second dialysis step was done in phosphate buffered saline (PBS) to remove excess reducing agent. Testing of the re-folded NP-based ELISA and FMIA began with checkerboard titrations of both the antigen and PDCoV convalescent sera to determine optimum concentrations of each. Depending on the calculation of signal to noise ratios, optimum concentration of NP antigen was identified for coating of the ELISA plates and coupling FMIA beads. We also identified optimum test serum dilutions and blocking agents.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Development and diagnostic application of rabbit antisera and monoclonal antibodies
      </title>
      <p id="Par18">
       Rabbits and mice were immunized with selected recombinant PDCoV proteins for production of hyperimmune antisera and monoclonal antibodies (mAbs) as previously described [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       –
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ]. Immunoglobulin isotyping of the resulting mAbs was performed using a commercial lateral flow assay (Serotec, Raleigh, NC).
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Indirect fluorescent antibody assay
      </title>
      <p id="Par19">
       An IFA assay was developed for reference purposes using pig serum of known serostatus. ST cells were grown in cultures for 2 to 3 days to 80 % confluence on 96-well plates. Odd numbered lanes were infected with PDCoV (approximately 1000 50 % tissue culture infective doses (TCID
       <sub>
        50
       </sub>
       )/ml) in MEM supplemented with 0.8 ug/ml TPCK-treated trypsin. The plates were incubated for 18 to 24 h. then fixed with 50 % (vol/vol) acetone/methanol for 20 min at −20 °C, air dried, and frozen with a desiccant at −20 °C until they were used. Serum dilutions of 1:20 and 1:40 were applied to infected and control wells of the IFA plates and incubated 1 h. After washing three times with 300 μl of phosphate buffered saline (PBS), 40 μl of fluorescein isothiocyanate (FITC)-labeled goat anti-swine immunoglobulin G (41.7 g/ml; KPL, West Chester, PA) was added to each well. The plates were incubated at 37 °C for 1 h and washed with PBS three times. The cells were examined for specific fluorescence with an inverted microscope and a UV light source (Nikon Eclipse TS100). Serum samples were considered positive if PDCoV specific fluorescence was observed at the 1:20 serum dilution.
      </p>
     </sec>
     <sec id="Sec9">
      <title>
       Antibody detection indirect ELISA
      </title>
      <p id="Par20">
       The refolded PDCoV NP antigen-based indirect ELISA was performed using methods previously described in Okda et al. [
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ]. Briefly, alternate wells of Immulon 1B, 96-well, microtiter plates (Thermo Labsystems, Franklin, MA) were coated for 1 h at 37 °C with 200 ng/well of purified, refolded PDCoV-NP antigen diluted in 15 mM sodium carbonate-35 mM sodium bicarbonate, antigen coating buffer (ACB) pH 9.6. Next, non-bound antigen was poured off and the plates washed 3X with PBS plus 0.05 % tween-20 (PBST), then the remaining free-binding sites were blocked with 200 μl of sample milk diluent ((SMD)-PBST plus 5 % nonfat dry milk) and incubated overnight at 4 °C. Test and control sera were diluted 1:50 in SMD, and 100 μl of the solution was added to each well of a washed plate. The plates were incubated for 1 h at 22 °C. Next, 100 μl of biotinylated, FC-specific, goat anti-swine detection antibody (Bethyl Laboratories, Montgomery, TX) was diluted 1:4000 in PBST and allowed to incubate at 22 °C for 1 h. Plates were washed 3X, then 100 μl of streptavidin-horseradish peroxidase conjugate (Pierce, Rockford, IL, diluted 1:4000) was added and incubated for 1 h at 22 °C, then washed and developed using TMB (Surmodics, Eden Prairie, MN). Colorimetric development was stopped using 2 N H
       <sub>
        2
       </sub>
       SO
       <sub>
        4
       </sub>
       , then OD’s were quantified spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek Instruments Inc., Winooski, VT). The raw OD’s were normalized and the corrected S/P values were calculated as follows: S/P = (OD of sample - OD of buffer)/(OD of positive control - OD of buffer).
      </p>
      <p id="Par21">
       The optimal dilution of the recombinant protein and secondary detection antibody was determined by a checkerboard titration that gave the highest signal to noise ratio. In addition, a single lot of pooled convalescent serum from PDCoV infected pigs was used to generate quality control standards that gave high, medium and low Sample to Positive (S/P) values. The negative, low and medium samples served as internal quality standards while the high standard served as a serum constant to mathematically calculate S/P values of individual unknowns. For the ELISA, a high positive S/P = 0.8–1.0; medium S/P = 0.6–0.8; low S/P = 0.4–0.6; and negative S/P &lt; 0.2.
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Microsphere coupling and FMIA procedure
      </title>
      <p id="Par22">
       The coupling of purified, recombinant, refolded PDCoV-NP antigen to fluorescent microspheres was performed using a two-step, carbodiimide coupling reaction as previously described [
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ]. Prior to performing large scale coupling reactions for test validation, the optimization of the amount of antigen used was obtained by performing a checkerboard titration of antigen-coupled microspheres against a two-fold titration of swine serum. It was found that initiating a coupling reaction having 12.5ug of purified protein per 3.125 × 10
       <sup>
        6
       </sup>
       microspheres was optimal in obtaining the highest signal-to-noise fluorescence ratio. The performance of the FMIA test was described in detail previously by Okda et al. [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. In the initial optimization of the FMIA test, we performed two-fold serial dilutions of swine serum and concluded that a dilution of 1:50 provided the highest signal-to-noise ratio. For the generation of sample fluorescence, antigen-coupled microsphere/antibody complexes were analyzed through a dual-laser Bio-Rad Bio-Plex 200 instrument. The median fluorescent intensity (MFI) for 100 microspheres corresponding to each individual bead analyte was recorded for each well. All reported MFI measurements were normalized by calculating individual S/P values using the following formula: S/P = MFI of sample - MFI of buffer control/MFI of high positive control - MFI of buffer control. The buffer control equated to the background signal determined from the fluorescence measurement of antigen-coated beads. Lastly, a single lot of pooled convalescent serum from PDCoV infected pigs was used to generate quality control standards that gave high, medium and low S/P values. The negative, low and medium samples served as internal quality standards while the high standard served as a serum constant to mathematically calculate S/P values of individual unknowns. For the FMIA, a high positive S/P = 0.8–1.0; medium S/P = 0.6–0.8; low S/P = 0.4–0.6; and negative S/P &lt; 0.2, is consistent with the data of the ELISA standards.
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       Antibody capture efficacy comparison between refolded vs linear PDCoV-NP antigen
      </title>
      <p id="Par23">
       An antibody capture titration assay was employed to compare the efficacy of refolded vs. linear antigen to capture anti-PDCoV-NP specific antibody in swine serum. Wells of a 96-well microtiter plate were coated with 10-fold decreasing concentrations of either linearly expressed or refolded PDCoV-NP antigen in ACB, pH 9.6., then allowed to incubate for 1 h at 37 °C. Each well was then blocked with 200 μl of SMD and allowed to incubate overnight at 4 °C. The following day, the plates were washed 3X with 300 μl of PBST. Well characterized positive control sera having a “high” positive OD was diluted 1/50 in SMD, mixed, and 100 μl of the solution was added to each well. The ELISA was continued pursuant to the stated protocol and the OD was recorded at each titration point, then a logarithmic regression curve was generated. Relative capture efficiencies for each antigen-coated well was determined by analyzing the OD at each dilution point and position under the linear portion of the curve.
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Assay validation
      </title>
      <p id="Par24">
       <list list-type="simple">
        <list-item>
         <label>
          (i)
         </label>
         <p id="Par25">
          <bold>
           Cutoff determination, DSe and DSp
          </bold>
          . To accurately assess the DSe and DSp of the assays, the assays were validated using known seronegative and seropositive samples from distinct animal populations. The expected positive samples used were field serum samples submitted to the ADRDL from herds previously testing PDCoV positive by PCR. Expected negative samples included archived experimental serum collected prior to 2009 and field samples from high-health herds with no known history of PDCoV exposure. Receiver operating characteristic (ROC) analysis was performed using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).
         </p>
        </list-item>
        <list-item>
         <label>
          (ii)
         </label>
         <p id="Par26">
          <bold>
           Measurement of repeatability
          </bold>
          . The repeatability of the FMIA and ELISA was assessed by running the same lot of internal quality control serum standards multiple times on the same plates and on different plates over time. The intra-assay repeatability was calculated using 36 replicates on a single plate and then repeated over a 3-day period for inter-assay repeatability assessment. Each assay was run in a single-plex format, and median fluorescence intensity values were expressed as percent coefficient of variation (CV) for repeated measurements. Percent CV was calculated using a method described earlier [
          <xref ref-type="bibr" rid="CR15">
           15
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       Statistical analyses and measurement of testing agreement
      </title>
      <p id="Par27">
       Multiple comparison, inter-rater agreement (kappa measure of association) was calculated among all three tests (ELISA, FMIA and IFA) using IBM, SPSS version 20 software (SPSS Inc., Chicago, IL). The sample cohort used included a set of archived serum samples collected from PDCoV “positive testing” experimentally infected pigs over time and from archived experimental control uninfected PDCoV “negative testing” animals. The interpretation of kappa can be rated as follows: Kappa less than 0.0, “poor” agreement; between 0.0 and 0.20, “slight” agreement; between 0.21 and 0.40, “fair” agreement; between 0.41 and 0.60, “moderate” agreement; between 0.61 and 0.80, “substantial” agreement; and between 0.81 and 1.0, “almost perfect” agreement [
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ].
      </p>
      <p id="Par28">
       Validation of the tests was performed by ROC analysis using Medcalc statistical software. Correlations between the tests and scatterplots for seroconversion were performed using SPSS 20.
      </p>
     </sec>
    </sec>
    <sec id="Sec14" sec-type="results">
     <title>
      Results
     </title>
     <sec id="Sec15">
      <title>
       Expression of recombinant full-length nucleoprotein
      </title>
      <p id="Par29">
       The full-length NP of PDCoV was cloned and expressed in
       <italic>
        E. coli
       </italic>
       as a polyhistidine fusion protein. Antigen purity was then evaluated using SDS-PAGE in which the His-tagged recombinant NP migrated through the gel according to its predicted molecular mass of 41 kDa upon staining with Coomassie brilliant blue R250 (Fig.
       <xref ref-type="fig" rid="Fig1">
        1a
       </xref>
       ). The recombinant protein was expressed in the form of insoluble inclusion bodies. It was purified by Nickel-NTA affinity column chromatography and yielded a calculated concentration of approximately 10 mg PDCoV-NP/liter of 2XYT medium and having a purity greater than 95 % as measured by the Lowry protein assay. The protein was subsequently refolded back to its soluble, conformational structure and its specificity was tested via Western blotting (Fig.
       <xref ref-type="fig" rid="Fig1">
        1b
       </xref>
       ). The figure illustrates the migration pattern and antigen specificity of the refolded PDCoV-NP/polyhistidine fusion protein as compared to the adjacent lane loaded with semi-purified, concentrated PDCoV. Both the rPDCoV-NP and native virus are recognized with equal intensity by a PDCoV-NP-specific monoclonal antibody (SD55-197) developed in our laboratory. Also, the recombinant nucleocapsid protein is shown to have a higher molecular mass than the native virus nucleocapsid due to its dual amino and carboxy terminus polyhistidine tags.
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Purification and antigen specificity of PDCoV-NP antibody capture antigen.
          <bold>
           a
          </bold>
          Coomassie blue staining of
          <italic>
           E. coli
          </italic>
          expressed and purified PDCoV-NP antigen used to coat ELISA microtiter plates and FMIA microspheres. Molecular weight ladder MW and PDCoV-NP (41 kDa).
          <bold>
           b
          </bold>
          Western blot showing antigen specificity of recombinant, refolded PDCoV-NP/polyhistidine fusion protein probed with mAb SD-55-197 (Lane 1). Lane 2 was loaded with semi-purified, concentrated PDCoV strain HKU15/Michigan/8977/2014 then probed with mAb SD-55-197
         </p>
        </caption>
        <graphic id="MO1" xlink:href="12917_2016_716_Fig1_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par30">
       Experiments were conducted to assess the immunoreactivity of refolded vs non-refolded PDCoV-NP antigen used for both tests. Specifically, an antibody capture titration ELISA was employed to compare the ability of a refolded and non-refolded version of the antigen to capture antibodies within swine serum. The immunoreactivity of antigen was determined by end-point titration and relative absorbance values as we observed differences in immunoreactivity based upon the conformational state of antigen tested. Figure
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       demonstrates in a dose-dependent fashion, that as the concentration of each antigen coated well decreases, the refolded antigen imparts a greater degree of antibody capture efficacy of swine antibodies than the non-refolded version. Specifically, a 27 fold difference was calculated at the end of the linear portion of the curve indicating that the refolded protein maintained a marked enhancement of immunoreactivity resulting in a greater dynamic range of the assay.
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Antibody capture efficacy comparison between refolded vs linear PDCoV-NP. An ELISA antibody capture titration assay was employed to compare the ability of refolded vs. linear antigen to capture anti-PDCoV-NP specific antibody in swine serum. Wells of a 96-well microtiter plate were coated with decreasing concentrations of either linearly expressed or refolded PDCoV-NP antigen. Refolded antigen demonstrated greater dynamic range of the assay and capture efficacy of swine antibody
         </p>
        </caption>
        <graphic id="MO2" xlink:href="12917_2016_716_Fig2_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec16">
      <title>
       Fluorescent microsphere immunoassay and indirect ELISA development
      </title>
      <p id="Par31">
       <list list-type="simple">
        <list-item>
         <label>
          (i)
         </label>
         <p id="Par32">
          <bold>
           Establishment of control standards:
          </bold>
          ELISA and FMIA test reference standards for PDCoV were developed for each of the respective prototype assays (Fig.
          <xref ref-type="fig" rid="Fig3">
           3a and b
          </xref>
          ). A control high positive standard was established by pooling several lots of serum collected from convalescent, seropositive pigs, and used to mathematically calculate S/P values of each assay. The medium and low positive samples served as internal quality control standards. The negative standard was pooled from a set of known seronegative pigs from a herd with no known prior PDCoV infection that also tested negative by PDCoV IFA and virus neutralization.
          <fig id="Fig3">
           <label>
            Fig. 3
           </label>
           <caption>
            <p>
             Production and reactivity of serological reference standards and internal quality control standards for both ELISA (
             <bold>
              a
             </bold>
             ) &amp; FMIA (
             <bold>
              b
             </bold>
             ). Reference serum standards were titrated 2-fold in antigen coated wells at a fixed concentration [250 ng/well] in order to gauge a maximum signal-to-noise ratios for each assay
             <bold>
              c
             </bold>
             ELISA, and
             <bold>
              d
             </bold>
             FMIA. Arrows indicate the optimal serum dilution that resulted in the greatest positive to negative (P/N) ratio for the test
            </p>
           </caption>
           <graphic id="MO3" xlink:href="12917_2016_716_Fig3_HTML">
           </graphic>
          </fig>
         </p>
        </list-item>
        <list-item>
         <label>
          (ii)
         </label>
         <p id="Par33">
          <bold>
           Test optimization:
          </bold>
          A series of coupling processes were performed using a two-fold titration of antigen to determine the optimum coupling concentration. A total of 3.125 x10
          <sup>
           6
          </sup>
          beads, were incubated with various concentrations (100 μg, 50 μg, 25 μg, and 12.5 μg) of purified NP. Based upon the highest signal-to-noise ratio reflecting the detection of PDCoV-specific antibodies in standard serum, 12.5 μg per reaction was the optimal concentration for microsphere coupling. ELISA microtiter plates were coated with an optimized concentration of 200 ng antigen per well.
         </p>
        </list-item>
       </list>
      </p>
      <p id="Par34">
       Testing the re-folded, NP antigen-based ELISA and FMIA began with checkerboard titration of both antigen and PDCoV convalescent and naïve swine serum to determine the optimum signal-to-noise ratio of each test. We also identified optimum test serum dilutions and blocking agents. The optimal serum dilution of each assay was determined by diluting serum samples two-fold in their respective blocking/detergent buffer diluent. For both the FMIA and ELISA, a serum dilution of 1:50 was shown to produce an optimal signal-to-noise ratio (Fig.
       <xref ref-type="fig" rid="Fig3">
        3c and d
       </xref>
       ). Testing field samples of known serological status was performed to gauge initial sensitivity of the assay. Our results showed a positive to negative sample ratio (P/N) of greater than 16-fold with ELISA and a P/N of greater than 40-fold with FMIA. The P/N is a relative measure of PDCoV antibody concentration between seropositive and seronegative samples. Having a diagnostic P/N of greater than 10 is highly desirable with any serological assay.
      </p>
     </sec>
     <sec id="Sec17">
      <title>
       Assessment of test repeatability
      </title>
      <p id="Par35">
       The intra-assay repeatability was calculated for 36 replicates on a single plate and then repeated over a 3-day period for inter-assay repeatability assessment. Internal control serum standards were used to determine the precision of each FMIA and ELISA. The inter-assay and intra-assay repeatability of each test demonstrated a coefficient of variation of less than 8.6 %. These results confirmed that the serological tests are highly repeatable in diagnostic applications.
      </p>
     </sec>
     <sec id="Sec18">
      <title>
       Validation methods and cutoff determination
      </title>
      <p id="Par36">
       ROC analysis of both FMIA and ELISA was performed using MedCalc software to calculate an optimized cutoff value that maximizes the DSe and DSp of each assay. Using known seronegative and seropositive serum samples (
       <italic>
        n
       </italic>
       = 940), the expected positive samples used were submitted as field serum samples (
       <italic>
        n
       </italic>
       = 311) from herds previously testing PDCoV positive by PCR. Expected negative samples included archived experimental serum collected prior to 2009 (
       <italic>
        n
       </italic>
       = 108) and field samples from high-health herds with no known history of PDCoV exposure (
       <italic>
        n
       </italic>
       = 521). ROC analysis was performed and DSe and DSp were shown to be 96.1 and 96.2 % respectively for the ELISA; and 95.8 and 98.1 % respectively for the FMIA (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       ). The similar cutoff values of both assays confirm the utility of these new diagnostic tests to aid in the control and surveillance of PDCoV outbreaks.
       <fig id="Fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Receiver operator characteristic (ROC) validation and determination of diagnostic sensitivity (DSe) and specificity (DSp) of the PDCoV-NP ELISA and FMIA assays. DSe and DSp were calculated using serum samples from known PDCoV-infected and known PDCoV-uninfected populations. ROC analysis was performed using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). In each panel, the dot plot on the left represents the negative population, and the plot on the right represents the positive population. The horizontal line bisecting the dot plots for each figure represents the tentative cutoff value that gives the optimal DSe and DSp
         </p>
        </caption>
        <graphic id="MO4" xlink:href="12917_2016_716_Fig4_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec19">
      <title>
       Evaluation of the kinetic swine antibody response in serum
      </title>
      <p id="Par37">
       Once validated, the assays were used to evaluate the kinetic antibody response over time using serum collected from experimentally infected pigs over weekly intervals. Serological responses detected by the PDCoV ELISA and FMIA following challenge show seroconversion between days 8 and 14 DPI (Fig.
       <xref ref-type="fig" rid="Fig5">
        5
       </xref>
       ). Both assays demonstrate a similar dynamic range using the same serum samples and “high” positive standard from which the S/P values are calculated. However, the FMIA appears to detect a slightly higher level of antibody over a longer period of time at days 35 and 42 post infection. Additional testing of seroconversion included serum samples collected from a group of 30 piglets near the time of initial field exposure to PDCoV then 28 days later. Figure
       <xref ref-type="fig" rid="Fig6">
        6
       </xref>
       shows clear seroconversion to the naturally circulating virus within the 28 day time-frame using the same diagnostic cutoff values previously determined by ROC analysis.
       <fig id="Fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Serum antibody kinetic time course evaluation. Antibody kinetic responses were calculated for the ELISA and FMIA tests using serum collected weekly over six weeks from experimentally infected pigs. Serological responses detected by PDCoV ELISA and FMIA tests show seroconversion between 8 and 14 DPI
         </p>
        </caption>
        <graphic id="MO5" xlink:href="12917_2016_716_Fig5_HTML">
        </graphic>
       </fig>
       <fig id="Fig6">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          ELISA (
          <bold>
           a
          </bold>
          ) and FMIA (
          <bold>
           b
          </bold>
          ) results from a group of 30 piglets sampled near the time of initial PDCoV field exposure then 28 days later. Both assays show clear seroconversion to naturally circulating PDCoV. The horizontal line between both positive and negative testing samples shows the diagnostic cutoff value for each test previously determined by ROC analysis
         </p>
        </caption>
        <graphic id="MO6" xlink:href="12917_2016_716_Fig6_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec20">
      <title>
       Measurement of statistical testing agreement
      </title>
      <p id="Par38">
       Multiple comparison, inter-rater (kappa) agreement is a statistical measure of testing agreement, and was calculated among all three tests (ELISA, FMIA &amp; IFA) using 629 positive testing and 311 negative testing serum samples. Statistical comparison calculated kappa values to be 0.940 between FMIA and IFA, 0.902 between ELISA and IFA, and 0.914 between ELISA and FMIA (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ). Because all three diagnostic platforms had kappa values above 0.81, it demonstrates that the tests are in “almost perfect” agreement with each other according to the interpretation of kappa by Landis et al. [
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ].
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Evaluation of statistical testing agreement among three serological testing platforms
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
           </th>
           <th>
            FMIA
           </th>
           <th>
            Indirect ELISA
           </th>
           <th>
            IFA
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            IFA
           </td>
           <td>
            0.940
           </td>
           <td>
            0.902
           </td>
           <td>
            1
           </td>
          </tr>
          <tr>
           <td>
            Indirect ELISA
           </td>
           <td>
            0.914
           </td>
           <td>
            1
           </td>
           <td>
            0.902
           </td>
          </tr>
          <tr>
           <td>
            FMIA
           </td>
           <td>
            1
           </td>
           <td>
            0.914
           </td>
           <td>
            0.940
           </td>
          </tr>
          <tr>
           <td>
            Number positive serum samples
           </td>
           <td>
            311
           </td>
           <td>
            311
           </td>
           <td>
            315
           </td>
          </tr>
          <tr>
           <td>
            Number negative serum samples
           </td>
           <td>
            629
           </td>
           <td>
            629
           </td>
           <td>
            625
           </td>
          </tr>
          <tr>
           <td>
            Total
           </td>
           <td>
            940
           </td>
           <td>
            940
           </td>
           <td>
            940
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          Multiple comparison, inter-rater agreement (kappa association) were calculated among all three tests, IFA, indirect ELISA and FMIA. Kappa values shown represent a statistical measure of test agreement and were calculated using MedCalc version 11.1.1.0
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec21">
      <title>
       Cross reactivity
      </title>
      <p id="Par39">
       Serological cross reactivity testing was performed between PDCoV and other closely related swine coronaviruses. There was no cross reactivity among the 93 TGEV positive serum samples, 20 PRCV positive serum samples, 167 PEDV field positive serum samples and 84 PEDV experimentally positive serum samples tested via ELISA and FMIA (Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ). The data show mean OD and MFI readings from ELISA and FMIA tests, respectively. The lack of cross reactivity between PDCoV and aforementioned alphacoronavirus species was also confirmed via western blotting using seropositive, convalescent sera from individual pigs (data not shown).
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Serological cross reactivity testing among related swine coronaviruses
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
           </th>
           <th>
            TGEV
           </th>
           <th>
            PRCV
           </th>
           <th>
            PEDV
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            ELISA Mean OD
           </td>
           <td>
            0.097
           </td>
           <td>
            0.132
           </td>
           <td>
            0.074
           </td>
          </tr>
          <tr>
           <td>
            FMIA Mean FI
           </td>
           <td>
            0.024
           </td>
           <td>
            0.016
           </td>
           <td>
            0.032
           </td>
          </tr>
          <tr>
           <td>
            Total No. serum samples tested
           </td>
           <td>
            93
           </td>
           <td>
            20
           </td>
           <td>
            251
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec22">
      <title>
       Development of reagents for detection of PDCoV antigen in diagnostic tests
      </title>
      <p id="Par40">
       Both denatured and refolded versions of the NP were used to immunize rabbits for hyperimmune serum and mice for monoclonal antibody production. Rabbit hyperimmune sera specifically recognize the NP and can be used in indirect fluorescent antibody staining at dilutions of 1:1000 to 1:5000. In addition, the polyclonal antisera was used successfully in immunohistochemical staining procedures for the detection of PDCoV antigen in intestinal tissues (Fig.
       <xref ref-type="fig" rid="Fig7">
        7b
       </xref>
       ). The resulting monoclonal antibodies all recognized native viral protein in infected ST cells demonstrated by bright cytoplasmic immunofluorescent staining (Fig.
       <xref ref-type="fig" rid="Fig7">
        7a
       </xref>
       ) and within intestinal enterocytes stained immunohistochemically (Fig.
       <xref ref-type="fig" rid="Fig7">
        7c
       </xref>
       ).
       <fig id="Fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Development of reagents used for indirect fluorescent antibody (IFA) testing and immunohistochemical (IHC) staining of PDCoV infected cells. Indirect fluorescent antibody staining of PDCoV infected ST cells with PDCoV anti-nucleoprotein monoclonal antibody SD-55-24 [
          <bold>
           a
          </bold>
          , 100X magnification]. Immunohistochemistry staining of intestinal enterocytes with PDCoV anti-nucleoprotein rabbit polyclonal hyperimmune sera [
          <bold>
           b
          </bold>
          , 100X magnification]. Immunohistochemistry staining of intestinal enterocytes with PDCoV anti-nucleoprotein monoclonal antibody 55–197 [
          <bold>
           c
          </bold>
          , 100X magnification]. Uninfected control showing hematoxylin staining of luminal, intestinal brush-border cross section [
          <bold>
           d
          </bold>
          , 100X magnification]
         </p>
        </caption>
        <graphic id="MO7" xlink:href="12917_2016_716_Fig7_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec23" sec-type="discussion">
     <title>
      Discussion
     </title>
     <p id="Par41">
      As a recently identified pathogen, the impact of PDCoV on the swine industry is not yet fully understood. Field observations and recent research studies have suggested that the virus can cause substantial morbidity and mortality in nursing piglets [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      –
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]. Specific antibody-based reagents and serological tests are essential for the further study and control of PDCoV, as well as the differentiation of PDCoV infection from other related coronaviruses such as PEDV or TGEV.
     </p>
     <p id="Par42">
      Therefore, the primary objective of this study was to develop an initial generation of antibody-based diagnostic reagents and serological assays for the further study of PDCoV, including NP-based indirect ELISA and FMIA tests that were developed and validated for diagnostic applications. Specific antibody-based reagents were also not yet available for PDCoV so monoclonal antibodies against selected PDCoV structural proteins were developed. The tools developed during the course of this study can be applied to many ongoing and future studies to better understand and control PDCoV.
     </p>
     <p id="Par43">
      The new monoclonal antibody reagents described here should be of substantial value in the detection of PDCoV antigen in a variety of applications including: early verification of virus isolation attempts and virus titrations; immunohistochemistry staining of fixed tissues; development of neutralization assays; fluorescent antibody staining of fresh tissues; development of field-based antigen capture assays such as lateral flow devices; and ELISA applications (competitive ELISA and antigen capture). Through extensive testing via ELISA (over 364 samples) and Western blot analysis, we were not able to demonstrate any cross-reactivity with other major swine coronaviruses including PEDV, PRCV and TGEV. However, since many described deltacoronaviruses of other species have not yet been adapted to cell culture replication or fully characterized, we do not yet know if these reagents may cross-react with other members of the genus.
     </p>
     <p id="Par44">
      Several new serological assays for detection of antibody responses to PDCoV were developed during the course of this study. The ELISA and FMIA tests were based on a recombinant nucleoprotein antigen since this protein is highly conserved among PDCoV isolates. In addition, the NP is known to be the most abundant viral protein within host cytoplasmic compartments [
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ]. The highly immunoreactive PDCoV-NP interacts with itself to form non-covalently linked oligomers and associates with the viral genome to serve as the architectural basis of the ribonucleoprotein complexes during virus assembly [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. These reasons provided the rationale for its utility as a target antigen for the serodiagnosis of PDCoV in indirect ELISA and FMIA platforms.
     </p>
     <p id="Par45">
      Antibody responses to the nucleoprotein of coronaviruses are very robust and have been reported to appear as soon as 7–9 days post infection. We originally hypothesized that antibody reactivity to PDCoV may be conformationally dependent so we designed an experiment to determine whether NP specific immunodominant epitopes tend to be present in greater abundance on conformationally or linearly expressed antigen. A refolded version of the NP was used as an antigen in both assays as it was shown to impart a higher degree of immunoreactivity than its unfolded, linear counterpart. This phenomenon was also observed by Johnson et al. [
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ] whereby the authors compared reactivity differences among single point serum titrations to provide a surrogate measure of antibody titer. They showed that the enhancement of immunoreactivity of PRRSV-N and nsp1 was completely dependent on refolding, and the reactivity of nsp2P was enhanced by twofold. Furthermore we confirmed their observations that there is a loss of immunoreactivity when the linear protein (solubilized in 8 M urea) was dialyzed in PBS prior to coating on microtiter plates or used for coupling to FMIA microspheres. This may indicate that using an antigen in its more native conformational state may present a higher number of immunoreactive epitopes that are able to capture a larger percentage of PDCoV-NP antibodies. Therefore, the production of a well purified, refolded recombinant protein maintained in a near-native conformation was required for the production of an efficacious assay.
     </p>
     <p id="Par46">
      Both assays provide the capability of high-throughput testing with reasonable DSe and DSp. ROC analysis was performed for both assays demonstrating DSe of greater than 95 %. The FMIA demonstrated good DSp of 98.1 % while the ELISA showed a slightly lower DSp of 96.2 %. Inter-rater (kappa) agreement, a statistical measure of test agreement demonstrated a significant level of agreement among the IFA, ELISA and FMIA. Furthermore, each of the antibody-capture assays was validated using a large number of well characterized serum samples (
      <italic>
       n
      </italic>
      = 940) based upon the suggested 5-stage validation methods of Jacobson, which is supported by the office International des Epizooties [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ].
     </p>
     <p id="Par47">
      Although preliminary DSe and DSp determinations for the first generation serological assays described here were slightly less than ideal, these new assays should provide valuable tools for assessment of PDCoV exposure on a herd level. One explanation for the approximately 95–96 % DSe values determined to date may be related to selection of the presumed positive field populations used for test validation. In this case, the initial stages of validation relied on characterizing the assay using known serum samples from experimentally infected pigs. Because this was the only sera of known serostatus we had at our disposal, we believe that the resulting initial ROC characteristics were of sufficient value to begin testing samples from other sources believed to not have been exposed to PDCoV and from field sources known to have seroconverted to PDCoV within a specific time frame. By following the methodology outlined by Jacobson [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ] in which he recommends the inclusion of these initial ROC cut-off values from experimentally infected pigs, we demonstrated similar assay characteristics on chosen field samples which substantiated our final cut-off value of the assay. These sample sets were collected at approximately 3 weeks after initial diagnosis of PDCoV by PCR. It is possible that PDCoV may not move through a herd at the very rapid rate seen with PEDV. Therefore, some animals in some herds may not have been infected until a week or more after initial detection in the population, resulting in delayed seroconversion in a percentage of the presumed positive population. Likewise, since the initial origination and distribution of PDCoV in the U.S. is not fully understood at this time, it is possible that a small percentage of our presumed seronegative population may have been subject to prior exposure. Many of the samples in our presumed negative population were archived samples collected prior to 2009. However, some originated from recent field submissions from high health, biosecure herds with no clinical or PCR evidence of prior PDCoV or PEDV exposure. The observed DSp values of approximately 98 % for FMIA and 96 % for indirect ELISA are within the expected range for first generation assays using these test formats. Apparent false positive reactions could also be due to an epitope on the expressed antigen having commonality with another low prevalence infectious agent or due to low levels of residual
      <italic>
       E. coli
      </italic>
      protein contaminants in the purified antigen preparations.
     </p>
     <p id="Par48">
      Recently, Thachil et al. [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ], developed an indirect anti-PDCoV IgG enzyme-linked immunosorbent assay based on the putative S1 portion of the spike protein and evaluated it using a total of 968 tested serum samples. Although it is a reasonably sensitive (91 %) and specific (95 %) test, there is room for other ELISAs utilizing other target antigens, such as the NP of PDCoV, to serve as primary serological surveillance or confirmatory assays. As noted in Thachil’s research, serum samples collected in 2010 were found positive for PDCoV antibody by their ELISA, but not those collected in 2011 and 2012. This was controversial because PDCoV was not thought to be circulating in North America in pigs before its identification in late 2013 [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. It will be very beneficial to have confirmatory assays to validate this finding. Additional screening of archived historical swine serum samples using multiple serological assays may provide further insight into the origin and epidemiology of PDCoV in North America.
     </p>
    </sec>
    <sec id="Sec24" sec-type="conclusion">
     <title>
      Conclusions
     </title>
     <p id="Par49">
      The monoclonal antibody reagents developed here provide important research and diagnostic tools for the industry. They are valuable for fluorescence and immunohistochemical staining methods associated with diagnostic and pathogenesis studies. The serological assays allow the detection of antibodies developed in response to PDCoV infection. The PDCoV indirect ELISA and FMIA will allow high-throughput screening of swine serum samples. These tests should be adequately optimized and validated for sero-surveillance on a herd level, but further improvement is needed for full confidence on an individual animal basis. The IFA or other tests may be required for confirmation of individual unexpected results. Work is ongoing to further validate these assays and to adapt them to different sample matrices such as milk or oral fluid samples. Since lactogenic immunity is likely critical for protection of nursing piglets, these assays will be modified for detection of IgA as well.
     </p>
    </sec>
    <sec id="Sec25">
     <title>
      Abbreviations
     </title>
     <p id="Par50">
      ACB, Antigen coating buffer; ADRDL, Animal Disease Research and Diagnostic Laboratory; CAPS, Cyclohexylamino-1-propanesulfonic acid; CPE, Cytopathic effect; CV, Coefficient of variation; DPI, Days post infection; DSe, Diagnostic sensitivity; DSp, Diagnostic specificity; ELISA, Enzyme linked immunosorbent assay; FBS, Fetal bovine serum; FITC, Fluorescein isothiocyanate; FMIA, Fluorescent microsphere immunoassay; HRP, Horseradish peroxidase; IACUC, Institutional Animal Care and Use Committee; IFA, Indirect fluorescent antibody; mAB, Monoclonal antibody; MEM, Eagle’s minimum essential medium; MFI, Mean fluorescent intensity; NP, Nucleoprotein; NPB, National Pork Board; OD, Optical density; P/N, Positive to negative; PBS, Phosphate buffered saline; PBST, PBS plus 0.05 % tween 20; PCR, Polymerase chain reaction; PDCoV, Porcine deltacoronavirus; PEDV, Porcine epidemic diarrhea virus; PRCV, Porcine respiratory coronavirus; ROC, Receiver operator characteristic; RT-PCR, Reverse transcriptase polymerase chain reaction; S/P, Sample to positive; SDS-PAGE, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SDSU, South Dakota State University; SMD, Sample milk diluent; ST, Swine testicle; TGEV, Transmissible gastroenteritis virus; TMB, 3,3′,5,5′-tetramethylbenzidine; TPCK, L-1-Tosylamide-2-phenylethyl chloromethyl ketone; UN-L, University of Nebraska-Lincoln; YT, Yeast extract tryptone
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       The authors thank Drs. Sabrina Swenson and Melinda Jenkins-Moore of the National Veterinary Services Laboratories for providing the cell culture adapted Michigan/8977/2014 isolate of PDCoV; Dr. Richard Hesse of the Kansas State University Veterinary Diagnostic Laboratory and Dr. Sarah Vitosh-Sillman and colleagues at the University of Nebraska-Lincoln for providing serum samples from PDCoV challenge studies; Dr. David Knudsen and Amanda Brock for immunohistochemistry; Dr. Volker Brozel for critical review of the manuscript and the South Dakota State University Animal Resource staff for animal assistance. The authors also thank numerous swine producers and practitioners for providing field samples and herd history information.
      </p>
      <sec id="FPar1">
       <title>
        Funding
       </title>
       <p id="Par51">
        Funding for this work was provided by the National Pork Board through grant #14-184, the South Dakota Agricultural Experiment Station, USDA Hatch funding and the South Dakota Animal Disease Research and Diagnostic Laboratory.
       </p>
      </sec>
      <sec id="FPar2" sec-type="data-availability">
       <title>
        Availability of data and materials
       </title>
       <p id="Par52">
        All data supporting the findings within this manuscript are archived within the Animal Disease Research and Diagnostic Laboratory’s data repository and will be shared upon request.
       </p>
      </sec>
      <sec id="FPar3">
       <title>
        Authors’ contributions
       </title>
       <p id="Par53">
        FO: Conducted ELISA and FMIA development/validation, statistical analysis and co-wrote paper. SL: Directed reagents and assay development and validation, co-wrote paper. XL: Assisted with ELISA and FMIA development/validation. AS: Assisted with sample acquisition, reagent and assay development and study design. TC: Assisted with sample acquisition and study design. KH: Assisted with assay development and validation. JN: Assisted with reagent development and characterization and manuscript preparation. JH: Assisted with study design and co-wrote paper. EAN: Developed study concept and design, co-wrote paper. All authors read and approved the final manuscript.
       </p>
      </sec>
      <sec id="FPar4" sec-type="COI-statement">
       <title>
        Competing interests
       </title>
       <p id="Par54">
        The authors are employed by South Dakota State University and the University may receive license fees or royalty payments associated with technologies described in this manuscript.
       </p>
      </sec>
      <sec id="FPar5">
       <title>
        Consent for publication
       </title>
       <p id="Par55">
        Not applicable.
       </p>
      </sec>
      <sec id="FPar6">
       <title>
        Ethics approval and consent to participate
       </title>
       <p id="Par56">
        Procedures involving animals at South Dakota State University (SDSU) were approved by the SDSU Institutional Animal Care and Use Committee (IACUC). Time course swine serum samples provided by Kansas State University and the University of Nebraska-Lincoln (UN-L) were part of a separate PDCoV challenge study approved by the UN-L IACUC. All other samples were obtained as routine diagnostic sample submissions at the South Dakota Animal Disease Research and Diagnostic Laboratory (ADRDL).
       </p>
      </sec>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus Deltacoronavirus supports bat coronaviruses as the gene source of Alphacoronavirus and Betacoronavirus and avian coronaviruses as the gene source of Gammacoronavirus and Deltacoronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06540-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="other">
        Saif L, Pensaert MB, Sestak K, Yeo S-G, Jung K. Coronaviruses. In: Zimmerman JL, Ramirez KA, Schwartz K, Stevenson G, editors. Diseases of Swine. 10th Edition. Chichester, West Sussex, UK: Wiley; 2012. p. 501–524.
       </mixed-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection and genetic characterization of Deltacoronavirus in pigs, Ohio, USA, 2014
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1227
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         24964136
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="other">
        Marthaler D, Raymond L, Jiang Y, Collins J, Rossow K, Rovira A. Rapid detection, complete genome sequencing, and phylogenetic analysis of Porcine Deltacoronavirus. Emerg Infec Dis. 2014;20(8). doi: 10.3201/eid2008.14-0526.
       </mixed-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Oglesbee
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Krakowka
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin, evolution, and virulence of porcine deltacoronaviruses in the United States
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         e00064
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00064-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25759498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Stafne
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Arruda
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Burrough
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenicity and pathogenesis of a United States porcine deltacoronavirus cell culture isolate in 5-day-old neonatal piglets
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2015
        </year>
        <volume>
         482
        </volume>
        <fpage>
         51
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2015.03.024
        </pub-id>
        <pub-id pub-id-type="pmid">
         25817405
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="other">
        Jung K, Hu H, Eyerly B, Lu Z, Chepngeno J, Saif LJ. Pathogenicity of 2 porcine deltacoronavirus strains in gnotobiotic pigs. Emerg Infect Dis. 2015. Doi: 10.3201/eid2104.141859.
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thachil
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           PF
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C-T
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y-W
          </given-names>
         </name>
         <name>
          <surname>
           Opriessnig
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and application of an ELISA for the detection of porcine deltacoronavirus IgG antibodies
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         e0124363
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0124363
        </pub-id>
        <pub-id pub-id-type="pmid">
         25881086
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="other">
        APHIS/USDA. Swine enteric coronavirus disease testing summary report. Sept 11, 2014. Available:
        <ext-link ext-link-type="uri" xlink:href="http://www.aphis.usda.gov/animal_health/animal_dis_spec/swine/downloads/secd_wkly_lab_%20rpt_09_11_14.pdf">
         http://www.aphis.usda.gov/animal_health/animal_dis_spec/swine/downloads/secd_wkly_lab_%20rpt_09_11_14.pdf
        </ext-link>
        ). Accessed 1 Dec 2015.
       </mixed-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Langenhorst
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kittawornrat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Zimmerman
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of a fluorescent microsphere immunoassay for detection of antibodies against porcine reproductive and respiratory syndrome virus using oral fluid samples as an alternative to serum-based assays
        </article-title>
        <source>
         Clin and Vacc Imm
        </source>
        <year>
         2012
        </year>
        <volume>
         19
        </volume>
        <fpage>
         180
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CVI.05372-11
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okda
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Singrey
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Clement
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Christopher-Hennings
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of an indirect ELISA, blocking ELISA, fluorescent microsphere immunoassay and fluorescent focus neutralization assay for serologic evaluation of exposure to North American strains of porcine epidemic diarrhea virus
        </article-title>
        <source>
         BMC Vet Res
        </source>
        <year>
         2015
        </year>
        <volume>
         11
        </volume>
        <fpage>
         180
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12917-015-0500-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         26232106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Christopher-Hennings
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Drew
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wensvoort
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Benfield
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differentiation of U.S. and European isolates of porcine reproductive and respiratory syndrome virus by monoclonal antibodies
        </article-title>
        <source>
         J Clin Micro
        </source>
        <year>
         1993
        </year>
        <volume>
         31
        </volume>
        <fpage>
         3184
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galfre
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Howe
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Milstein
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Butcher
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies to major histocompatibility antigens produced by hybrid cell lines
        </article-title>
        <source>
         Nature (London)
        </source>
        <year>
         1977
        </year>
        <volume>
         266
        </volume>
        <fpage>
         550
        </fpage>
        <lpage>
         2
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/266550a0
        </pub-id>
        <pub-id pub-id-type="pmid">
         558524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lunney
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zuckermann
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Osorio
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Welbon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of an 8-plex Luminex assay to detect swine cytokines for vaccine development: Assessment of immunity after porcine reproductive and respiratory syndrome virus (PRRSV) vaccination
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2010
        </year>
        <volume>
         28
        </volume>
        <fpage>
         5383
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2010.05.016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Welbon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gnanandarajah
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Murtaugh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibody response to porcine reproductive and respiratory syndrome virus (PRRSV) nonstructural proteins and implications for diagnostic detection and differentiation of PRRSV types I and II
        </article-title>
        <source>
         Clin and Vacc Imm
        </source>
        <year>
         2009
        </year>
        <volume>
         16
        </volume>
        <fpage>
         628
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CVI.00483-08
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Landis
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         The measurement of observer agreement for categorical data
        </article-title>
        <source>
         Biometrics
        </source>
        <year>
         1977
        </year>
        <volume>
         33
        </volume>
        <fpage>
         159
        </fpage>
        <lpage>
         74
        </lpage>
        <pub-id pub-id-type="doi">
         10.2307/2529310
        </pub-id>
        <pub-id pub-id-type="pmid">
         843571
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stevenson
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Hoang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Burrough
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Madson
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Emergence of porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences
        </article-title>
        <source>
         J Vet Diagn Invest
        </source>
        <year>
         2013
        </year>
        <volume>
         25
        </volume>
        <fpage>
         649
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1040638713501675
        </pub-id>
        <pub-id pub-id-type="pmid">
         23963154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional characterization and proteomic analysis of the nucleocapsid protein of porcine deltacoronavirus
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2015
        </year>
        <volume>
         208
        </volume>
        <fpage>
         136
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2015.06.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         26103099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McBride
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           van Zyl
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus nucleocapsid is a multifunctional protein
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2014
        </year>
        <volume>
         6
        </volume>
        <fpage>
         2991
        </fpage>
        <lpage>
         3018
        </lpage>
        <pub-id pub-id-type="doi">
         10.3390/v6082991
        </pub-id>
        <pub-id pub-id-type="pmid">
         25105276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Murtaugh
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-reactive antibody responses to nsp1 and nsp2 of porcine reproductive and respiratory syndrome virus
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         88
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1184
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.82587-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         17374762
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Validation of serological assays for diagnosis of infectious diseases
        </article-title>
        <source>
         Rev Sci Tech Of Int Epizoot
        </source>
        <year>
         1998
        </year>
        <volume>
         17
        </volume>
        <fpage>
         469
        </fpage>
        <lpage>
         526
        </lpage>
        <pub-id pub-id-type="doi">
         10.20506/rst.17.2.1119
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Virus Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Virus Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        Virus Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0168-1702
      </issn>
      <issn pub-type="epub">
       1872-7492
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24670324
      </article-id>
      <article-id pub-id-type="pmc">
       7114385
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0168-1702(14)00125-7
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.virusres.2014.03.018
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Serological assays for emerging coronaviruses: Challenges and pitfalls
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="aut0005">
        <name>
         <surname>
          Meyer
         </surname>
         <given-names>
          Benjamin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="aut0010">
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          Christian
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="aut0015">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          Marcel A.
         </given-names>
        </name>
        <email>
         muller@virology-bonn.de
        </email>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
      </aff>
      <author-notes>
       <corresp id="cor0005">
        <label>
         ⁎
        </label>
        Corresponding author at: Institute of Virology, University of Bonn Medical Centre, Sigmund Freud Str. 25, 53105 Bonn, Germany. Tel.: +49 22828713187.
        <email>
         muller@virology-bonn.de
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        23
       </day>
       <month>
        3
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        19
       </day>
       <month>
        12
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        23
       </day>
       <month>
        3
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       194
      </volume>
      <fpage>
       175
      </fpage>
      <lpage>
       183
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2014 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0005">
       <title>
        Highlights
       </title>
       <p>
        <list id="lis0005" list-type="simple">
         <list-item id="lsti0005">
          <label>
           •
          </label>
          <p id="par0005">
           Serological studies on SARS- and MERS-coronavirus (CoV) diagnostics were reviewed.
          </p>
         </list-item>
         <list-item id="lsti0010">
          <label>
           •
          </label>
          <p id="par0010">
           Different types of serological assays and variable antigens were compared.
          </p>
         </list-item>
         <list-item id="lsti0015">
          <label>
           •
          </label>
          <p id="par0015">
           Immunogenic epitopes of CoV spike proteins were less conserved than nucleocapsid proteins.
          </p>
         </list-item>
         <list-item id="lsti0020">
          <label>
           •
          </label>
          <p id="par0020">
           Use of spike proteins was found to be superior over nucleocapsid proteins.
          </p>
         </list-item>
         <list-item id="lsti0025">
          <label>
           •
          </label>
          <p id="par0025">
           Applicability of serological assays for analysis of animal sera was reviewed.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0010">
       <p>
        More than a decade after the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002/2003 the occurrence of a novel CoV termed Middle East respiratory syndrome (MERS) CoV challenges researchers and public health authorities. To control spread and finally contain novel viruses, rapid identification and subsequent isolation of infected individuals and their contacts is of utmost importance. Next to methods for nucleic acid detection, validated serological assays are particularly important as the timeframe for antibody detection is less restricted. During the SARS-CoV epidemic a wide variety of serological diagnostic assays were established using multiple methods as well as different viral antigens. Even though the majority of the developed assays showed high sensitivity and specificity, numerous studies reported on cross-reactive antibodies to antigens from wide-spread common cold associated CoVs. In order to improve preparedness and responsiveness during future outbreaks of novel CoVs, information and problems regarding serological diagnosis that occurred during the SARS-CoV should be acknowledged.
       </p>
       <p>
        In this review we summarize the performance of different serological assays as well as the applicability of the two main applied antigens (spike and nucleocapsid protein) used during the SARS-CoV outbreak. We highlight challenges and potential pitfalls that occur when dealing with a novel emerging coronavirus like MERS-CoV. In addition we describe problems that might occur when animal sera are tested in serological assays for the identification of putative reservoirs. Finally, we give a recommendation for a serological testing scheme and outline necessary improvements that should be implemented for a better preparedness.
       </p>
      </abstract>
      <kwd-group id="kwd0005">
       <title>
        Keywords
       </title>
       <kwd>
        SARS-Coronavirus
       </kwd>
       <kwd>
        MERS-Coronavirus
       </kwd>
       <kwd>
        Reservoir
       </kwd>
       <kwd>
        Serology
       </kwd>
       <kwd>
        Antibody
       </kwd>
       <kwd>
        Cross-reactivity
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="par0030">
      In 2002/2003, a new disease emerged in Southeast Asia that was subsequently termed severe acute respiratory syndrome (SARS). A previously unknown coronavirus (CoV) was identified as the etiological agent (
      <xref ref-type="bibr" rid="bib0115">
       Drosten et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0250">
       Ksiazek et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0345">
       Peiris et al., 2003
      </xref>
      ). It was only the concerted efforts of public health authorities that made it possible to break the chain of transmission. No new cases have been reported since May 2004. Overall, SARS-CoV infected 8422 people, of whom 916 died, giving a case fatality ratio of about 11% (
      <xref ref-type="bibr" rid="bib0050">
       Chan-Yeung and Xu, 2003
      </xref>
      ). Before the emergence of SARS-CoV, human pathogenic CoVs (HCoVs) such as HCoV-OC43 and HCoV-229E were known to cause mild upper respiratory diseases contributing to 5–30% of the seasonal common cold cases (
      <xref ref-type="bibr" rid="bib0235">
       Isaacs et al., 1983
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0255">
       Larson et al., 1980
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0305">
       Monto, 1974
      </xref>
      ). This explains why, globally, more than 90% of the population has antibodies against the common cold CoV (
      <xref ref-type="bibr" rid="bib0160">
       Gorse et al., 2010
      </xref>
      ).
     </p>
     <p id="par0035">
      SARS-CoV belongs to the
      <italic>
       Coronavirdae
      </italic>
      family within the order of
      <italic>
       Nidovirales
      </italic>
      . It harbors one of the largest known positive-strand RNA genomes comprising about 29 kb (
      <xref ref-type="bibr" rid="bib0390">
       Rota et al., 2003
      </xref>
      ). The first two-thirds of the genome contain nonstructural proteins (NSP) that are well conserved among different CoV species (
      <xref ref-type="bibr" rid="bib0390">
       Rota et al., 2003
      </xref>
      ). The NSPs include the RNA-dependent RNA polymerase and form the main part of the transcription/replication machinery. The last third of the genome encodes mainly the four structural proteins: spike (S), membrane (M), envelope (E) and nucleocapsid (N) (
      <xref ref-type="bibr" rid="bib0390">
       Rota et al., 2003
      </xref>
      ). Interspersed between the structural proteins are group-specific open reading frames (ORFs) encoding a subset of accessory proteins with mostly unknown function (
      <xref ref-type="bibr" rid="bib0320">
       Narayanan et al., 2008
      </xref>
      ). In the case of SARS-CoV, it was shown that, apart from the four structural proteins, some of the NSPs as well as the accessory proteins p3a and p7a, are incorporated into virions and may elicit an immune response in infected patients as it was shown for NSP13 (
      <xref ref-type="bibr" rid="bib0265">
       Leung et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0325">
       Neuman et al., 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0395">
       Schaecher et al., 2007
      </xref>
      ).
     </p>
     <p id="par0040">
      Diagnostic assays for SARS-CoV detection were rapidly developed after the identification of the virus. Testing of suspected cases helped considerably to contain the outbreak and understand the rapid disease progression that was observed in some of the patients. SARS patients had detectable viral RNA between three and 30 days after the first symptoms appeared, with high viral loads in lower respiratory tract and fecal samples. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) assays were the first assays that helped identify and subsequently isolate patients who were actively shedding the virus (
      <xref ref-type="bibr" rid="bib0115">
       Drosten et al., 2003
      </xref>
      ). It was reported that viral RNA could be detected by qRT-PCR up to 30 days post onset of illness (dpoi) (
      <xref ref-type="bibr" rid="bib0065">
       Chan et al., 2004a
      </xref>
      ). However, detection rates by these early qRT-PCR assays were often low as they relied on sampling during virus shedding and proper handling of samples (
      <xref ref-type="bibr" rid="bib0470">
       Yam et al., 2003
      </xref>
      ). The specificity of the qRT-PCR assays has also been questioned because of the potential for nucleic acid contamination in the laboratories where many SARS-CoV samples were processed (
      <xref ref-type="bibr" rid="bib0335">
       Patrick et al., 2006
      </xref>
      ).
     </p>
     <p id="par0045">
      As a consequence, the development of serological assays became crucial at the time. Many laboratories worldwide generated in-house assays using either virus-derived antigen or recombinant structural CoV proteins. For all laboratories, proper validation of serological assays was highly challenging because of its reliance on numerous well-characterized positive and negative serum samples. Furthermore, the exchange of patient serum samples was a major challenge during the outbreak for logistic and ethical reasons. Assay sensitivity (the number of positive samples that could be determined correctly) and specificity (measured by the number of negative samples that could be identified correctly) were therefore difficult to determine. Consequently, an external quality assurance study revealed that many laboratories had difficulties with SARS-CoV serodiagnostics (
      <xref ref-type="bibr" rid="bib0330">
       Niedrig et al., 2005
      </xref>
      ). In particular, the high seroprevalence in the population of antibodies against the common cold CoV combined with the presence of cross-reactive antibodies against conserved parts of the immunogenic CoV proteins could have contributed to false positive results.
     </p>
     <p id="par0050">
      Nevertheless, as antibodies can be detected over a long period, developing reliable post-infection serological assays for SARS-CoV became a high priority. Serodiagnostic assays were applied to address epidemiological questions about transmission patterns, to observe silent infections, to analyze disease progression and to identify the origin of SARS-CoV. Patients usually developed IgM and IgG antibodies within 17–21 dpoi (
      <xref ref-type="bibr" rid="bib0450">
       Woo et al., 2004b
      </xref>
      ). To identify infected contacts, including those that are asymptomatic, it is recommendable to analyze paired serum samples. Ideally, samples should be taken on day 0 and day 42 post exposure since it was shown that seroconversion of IgG or IgM occurred during that period (
      <xref ref-type="bibr" rid="bib0080">
       Chen et al., 2004a
      </xref>
      ). According to the WHO criteria for serological diagnosis, a patient was considered to have seroconverted if one of the following statements were true: “
      <italic>
       Negative antibody test on acute-phase serum followed by positive antibody test on convalescent-phase serum tested in parallel
      </italic>
      ” or a “
      <italic>
       Fourfold or greater rise in antibody titer between acute- and convalescent-phase sera tested in parallel
      </italic>
      ” (
      <xref ref-type="bibr" rid="bib0435">
       WHO, 2004
      </xref>
      ). Of note, WHO further recommended using a virus neutralization test (VNT) to exclude serological cross-reactions with other human or animal CoVs (
      <xref ref-type="bibr" rid="bib0435">
       WHO, 2004
      </xref>
      ).
     </p>
     <p id="par0055">
      In this review, we summarize the various types of serological assays that were developed during the SARS-CoV outbreak and analyze the challenges and potential pitfalls of serodiagnostics. It should be acknowledged that the multitude of developed assays and the lack of standardized procedures and assay validation make it difficult to directly compare all studies. Finally, we discuss the implications and challenges facing serodiagnosis of the novel Middle East respiratory syndrome (MERS-CoV).
     </p>
    </sec>
    <sec id="sec0010">
     <label>
      2
     </label>
     <title>
      Testing parameters: IgM vs. IgG subclasses
     </title>
     <p id="par0060">
      Testing for different immunoglobulin (Ig) subclasses is common in serodiagnostics. Being pentameric with ten antigen-binding sites, IgM is characterized by a higher antigen avidity but lower antigen affinity than IgG (
      <xref ref-type="bibr" rid="bib0315">
       Murphy et al., 2008
      </xref>
      ). As antibodies of IgM subclass are usually the first to develop following a primary challenge (
      <xref ref-type="bibr" rid="bib0315">
       Murphy et al., 2008
      </xref>
      ), IgM is considered a parameter of the early phase of infection. However,
      <xref ref-type="bibr" rid="bib0450">
       Woo et al. (2004b)
      </xref>
      found that IgM could not be detected earlier than IgA and IgG subclass antibodies in SARS-CoV serodiagnostic assays. The low affinity of IgM antibodies also carries the increased risk of cross-reactivity with antigenically related epitopes, which are common in CoVs. IgM detection has an added value for CoV serodiagnostics as it is only present in very recently infected patients, but does not allow differential diagnosis. In contrast IgG antibodies comprise a higher specificity than IgM and can be detected even years after the infection. In this review, we therefore focus on studies describing assays for the detection of IgG antibodies.
     </p>
    </sec>
    <sec id="sec0015">
     <label>
      3
     </label>
     <title>
      Virus-based serological assays
     </title>
     <p id="par0065">
      During the outbreak of SARS-CoV, a wide variety of serological assays were established, including immunofluorescence assays (IFAs), enzyme-linked immunosorbent assays (ELISAs) and Western blot (WB) analysis.
     </p>
     <p id="par0070">
      Conventional IFAs (cIFAs) using virus-infected African green monkey kidney cells (VERO E6) spotted on glass slides and ELISAs using extracts or supernatant of infected cells were among the first assays used in serological diagnosis of SARS-CoV (
      <xref ref-type="bibr" rid="bib0070">
       Chan et al., 2004b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0080">
       Chen et al., 2004a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0230">
       Hsueh et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0250">
       Ksiazek et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0345">
       Peiris et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0465">
       Wu et al., 2004
      </xref>
      ). Both cIFAs and ELISAs for SARS-CoV were relatively easy to set up for experienced laboratories, as they primarily only required susceptible cell cultures and the virus. An obvious disadvantage of virus-based serological assays is the need for a biosafety level (BSL) 3 facility. In addition, IFAs can neither be properly standardized because the interpretation of fluorescence staining patterns is subjective, nor are they appropriate for high-throughput screening. In the case of ELISAs, antigen production can be an obstacle if it necessitates ultracentrifugation under BSL3 conditions. Ensuring that the antigen is properly inactivated can also be problematic. Ultimately, validation of the ELISA is dependent on access to a well-characterized serum collection for the determination of the assay-specific cut-off value.
     </p>
     <p id="par0075">
      A detailed summary of studies applying SARS virus-based cIFAs and ELISAs is given in
      <xref ref-type="table" rid="tbl0005">
       Table 1
      </xref>
      . Since SARS-CoV seroconversion generally occurred during the second week of illness (
      <xref ref-type="bibr" rid="bib0230">
       Hsueh et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0250">
       Ksiazek et al., 2003
      </xref>
      ), only those studies in which sera was taken at least 14 dpoi are included in this overview. In the majority of cases, patient serum was tested in assays using virus-derived antigens. Most of the studies found that serum from between 85% and 100% of previously diagnosed SARS patients tested positive (
      <xref ref-type="table" rid="tbl0005">
       Table 1
      </xref>
      , column 3), suggesting that the cIFA and ELISA used were highly sensitive. Of note, the studies with the most reliable results were those that used a large number of patient serum samples (
      <italic>
       n
      </italic>
      = 90;
      <xref ref-type="bibr" rid="bib0070">
       Chan et al. (2004b)
      </xref>
      and
      <italic>
       n
      </italic>
      = 224;
      <xref ref-type="bibr" rid="bib0465">
       Wu et al. (2004)
      </xref>
      ), which found that 98.2% and 99.1%, respectively, were positive.
      <table-wrap id="tbl0005" position="float">
       <label>
        Table 1
       </label>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Antigen
          </th>
          <th align="left">
           Assay
          </th>
          <th align="left">
           SARS sera (≥14 dpoi)
          </th>
          <th align="left">
           Control sera from respiratory patients or SARS contacts
          </th>
          <th align="left">
           Control sera from healthy donors
          </th>
          <th align="left">
           Reference
          </th>
          <th align="left">
           Comment
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th>
          </th>
          <th align="left">
           No. positive/no. tested (%)
          </th>
          <th align="left">
           No. positive/no. tested (%)
          </th>
          <th align="left">
           No. positive/no. tested (%)
          </th>
          <th>
          </th>
          <th>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           89/90 (98.8)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/540 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/635 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Chan (2004, #6)
          </td>
          <td align="left">
           24 control sera were excluded due to unspecific reaction
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           34/34 (100)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           1/100 (1)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Che (2005, #9)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           6/7 (85.7)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           0/10 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Hsueh (2003, #22)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           10/10 (100)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/27 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/384 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Ksiazek (2003, #66)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           46/46 (100)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/40 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/16 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Leung (2004, #29)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           37/37 (100)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/80 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/200 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Peiris (2003, #86)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           222/224 (99.1)
           <xref ref-type="table-fn" rid="tblfn0010">
            b
           </xref>
          </td>
          <td align="left">
           30/245 (12.2)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
           ,
           <xref ref-type="table-fn" rid="tblfn0010">
            b
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           Wu (2004, #60)
          </td>
          <td align="left">
           Using VNT as gold standard
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           10/10 (100)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           0/27 (0)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           1/384 (0.3)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Ksiazek (2003, #66)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           42/46 (91.3)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           3/40 (7.5)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           1/38 (2.6)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           Leung (2004, #29)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           17/20 (85)
          </td>
          <td align="left">
           0/20 (0)
          </td>
          <td align="left">
           2/40 (5)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0425">
            Wang et al. (2004, #54)
           </xref>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Whole Virus
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           220/224 (98.2)
           <xref ref-type="table-fn" rid="tblfn0010">
            b
           </xref>
          </td>
          <td align="left">
           3/245 (1.2)
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
           ,
           <xref ref-type="table-fn" rid="tblfn0010">
            b
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           Wu (2004, #60)
          </td>
          <td align="left">
           Using VNT as gold standard
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          dpoi, days post onset of illness; IFA, immunofluorescence assay; n.d., not determined; ELISA, enzyme-linked immunosorbent assay; VNT, virus neutralization test.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tblfn0005">
         <label>
          a
         </label>
         <p id="npar0005">
          Calculated from information given in the paper.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tblfn0010">
         <label>
          b
         </label>
         <p id="npar0010">
          No differentiation between acute and convalescent sera.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="par0080">
      Specificity of serological assays is vital to avoid false positive diagnoses. Critically, some of the HCoVs are antigenically closely related (
      <xref ref-type="bibr" rid="bib0025">
       Bradburne, 1970
      </xref>
      ). This means, in combination with the observed high prevalence of HCoVs, such as HCoV-OC43, HCoV-229E and HCoV-NL63, in the population (
      <xref ref-type="bibr" rid="bib0075">
       Che et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0100">
       Dijkman et al., 2012
      </xref>
      ), that the specificity of the SARS-CoV assay is of particular concern. We therefore analyzed and summarized the rate of false positive results found in serological studies and differentiated between the two types of control groups used; sera from individuals with non-SARS respiratory infection or in contact with SARS patients, or from healthy donors (
      <xref ref-type="table" rid="tbl0005">
       Table 1
      </xref>
      , columns 4 and 5). One limitation of this analysis is that, in most of the studies, negative control sera were obtained from respiratory infection patients or blood donors, and therefore the inclusion of unidentified SARS cases cannot be completely discounted. Nevertheless, the detection rate of false positive samples gives a rough estimate of the specificity and allows the performance of these assays to be evaluated. In the various case control studies that were conducted during or after the SARS outbreak, cIFAs and viral antigen-based ELISAs detected between 0% and 12.2% false positives (
      <xref ref-type="table" rid="tbl0005">
       Table 1
      </xref>
      , columns 4 and 5). Assay outcomes were highly dependent on the study design and the negative cohort selected. Notably, in one study, the rate of false positive results of cIFA increased to 12.2% when a virus neutralization assay was used as a gold standard (
      <xref ref-type="bibr" rid="bib0465">
       Wu et al., 2004
      </xref>
      ). This could be explained by a lack of neutralizing capacity of certain cIFA-positive sera or indeed by cross-reactivity of sera with antigens from related HCoV in the cIFA.
     </p>
     <p id="par0085">
      A study by Guan and colleagues clearly emphasized the problems encountered when using whole virus-derived antigen. They applied whole viral lysates as antigen in WB analysis and observed a marked difference in reactivity to individual CoV proteins. N protein reactivity was detected in all SARS patient sera, indicating a sensitivity of 100%; however, it also gave false positive results in 17–66% of cases depending on the type of negative control subset tested. By contrast, serum from only 78% of SARS patients reacted with the S protein, but with no false positives, indicating that S protein detection by WB has a higher specificity. Interestingly, when, in one study, a recombinant glutathione S transferase (GST)-tagged N protein lacking a highly conserved part was used as the target there were no false positives. This clearly demonstrates that serological assays applying SARS-CoV-derived antigens should be interpreted with caution.
     </p>
    </sec>
    <sec id="sec0020">
     <label>
      4
     </label>
     <title>
      Recombinant protein-based assays
     </title>
     <p id="par0090">
      Serological assays that rely on recombinant proteins as antigen are widely used in laboratory diagnostics (
      <xref ref-type="bibr" rid="bib0125">
       Ecker et al., 1996
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0130">
       Farber et al., 1993
      </xref>
      ). As a prerequisite, single immunogenic viral genes have to be cloned into prokaryotic or eukaryotic expression plasmids to produce proteins in bacterial or mammalian cell cultures. They have a major advantage as they do not require BSL3 containment and are appropriate for assay standardization if protocols are closely followed. In SARS-CoV, the N and S are the major immunogenic proteins (
      <xref ref-type="bibr" rid="bib0370">
       Qiu et al., 2005
      </xref>
      ). Recombinant versions of both proteins have been used in IFAs, ELISAs and WB analysis (
      <xref ref-type="table" rid="tbl0010">
       Table 2
      </xref>
      ). Nevertheless, development and validation of assays using recombinant proteins may take longer and is also technically demanding as the necessary molecular cloning, transfection and protein purification techniques must first be optimized.
      <table-wrap id="tbl0010" position="float">
       <label>
        Table 2
       </label>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Antigen
          </th>
          <th align="left">
           Assay
          </th>
          <th align="left">
           SARS sera (≥14 dpoi unless otherwise indicated)
          </th>
          <th align="left">
           Control sera from respiratory patients or SARS contacts
          </th>
          <th align="left">
           Control sera from healthy donors
          </th>
          <th align="left">
           Reference
          </th>
          <th align="left">
           Comment
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th>
          </th>
          <th align="left">
           No. positive/no. tested (%)
          </th>
          <th align="left">
           No. positive/no. tested (%)
          </th>
          <th align="left">
           No. positive/no. tested (%)
          </th>
          <th>
          </th>
          <th>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           6/6 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/73 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/20 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0045">
            Carattoli (2005, #3)
           </xref>
          </td>
          <td align="left">
           Conflicting information: in the text two control sera mentioned as positive
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           56–61/76 (73.6–80.2)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           1–4/100 (1–4)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           8–23/1451 (0.6–1.6)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0170">
            Guan (2004a, #14)
           </xref>
          </td>
          <td align="left">
           Values depend on assay settings
          </td>
         </tr>
         <tr>
          <td align="left">
           N partial
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           74/74 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           1/210 (0.5)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0175">
            Guan (2004b, #15)
           </xref>
          </td>
          <td align="left">
           Highly conserved motif deleted in N protein
          </td>
         </tr>
         <tr>
          <td align="left">
           N partial
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           41/46 (89.1)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           2/40 (5)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           2/35 (5.7)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Leung (2004, #29)
          </td>
          <td align="left">
           N-terminal half
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           301/327 (92)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           4/2049 (0.2)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           3/1700 (0.2)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0275">
            Liu (2004, #73)
           </xref>
          </td>
          <td align="left">
           Antigen capture ELISA
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           121/135 (89.6)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
           ,
           <xref ref-type="table-fn" rid="tblfn0020">
            b
           </xref>
          </td>
          <td align="left">
           0/64 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           1/940 (0.1)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0400">
            Shi (2003, #44)
           </xref>
          </td>
          <td align="left">
           Antigen capture ELISA
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           100/106 (94.3)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           33/828 (4.0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
           ,
           <xref ref-type="table-fn" rid="tblfn0025">
            c
           </xref>
          </td>
          <td align="left">
           7/149 (4.7)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Woo (2004, #87)
          </td>
          <td align="left">
           29/33 false positive sera confirmed as false positives
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           34/34 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           2/100 (2)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Che (2005, #9)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           N partial
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           40/40 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/100 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/50 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Guan (2004, #16)
          </td>
          <td align="left">
           Highly conserved motif deleted
          </td>
         </tr>
         <tr>
          <td align="left">
           N partial
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           73/77 (94.8)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
           ,
           <xref ref-type="table-fn" rid="tblfn0030">
            d
           </xref>
          </td>
          <td align="left">
           4/134 (3)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/160 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0200">
            He (2004a, #18)
           </xref>
          </td>
          <td align="left">
           195 C-terminal aa
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           30/30 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           48/48 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Maache (2006, #33)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           74/74 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           0/99 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Tan (2004, #49)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           N
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           10/10 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0420">
            Wang et al. (2005, #53)
           </xref>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           S partial
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           15/15 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/42 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           0/100 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Manopo (2005, #36)
          </td>
          <td align="left">
           aa 441–700
          </td>
         </tr>
         <tr>
          <td align="left">
           S
          </td>
          <td align="left">
           IFA
          </td>
          <td align="left">
           74/74 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           0/100 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Tan (2004, #49)
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           S partial
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           6/46 (13)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           5/40 (12.5)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           2/38 (5.3)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Leung (2004, #29)
          </td>
          <td align="left">
           app. 315 C-terminal aa
          </td>
         </tr>
         <tr>
          <td align="left">
           S partial
          </td>
          <td align="left">
           ELISA
          </td>
          <td align="left">
           56/93 (60.2)
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           2/148 (1.4)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Woo (2005, #59)
          </td>
          <td align="left">
           aa 14–667
          </td>
         </tr>
         <tr>
          <td align="left">
           S1
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           30/30 (100)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           0/48 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Maache (2006, #33)
          </td>
          <td align="left">
           aa 14–760
          </td>
         </tr>
         <tr>
          <td align="left">
           S2
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           26/30 (86.7)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           0/48 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           Maache (2006, #33)
          </td>
          <td align="left">
           aa 761–1190
          </td>
         </tr>
         <tr>
          <td align="left">
           S1 subunit
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           15/20 (75)
          </td>
          <td align="left">
           6/20 (30)
          </td>
          <td align="left">
           6/40 (15)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0425">
            Wang et al. (2004, #54)
           </xref>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           S2 subunit
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           17/20 (85)
          </td>
          <td align="left">
           3/20 (15)
          </td>
          <td align="left">
           0/40 (0)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0425">
            Wang et al. (2004, #54)
           </xref>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           S1
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           5/10 (50)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0420">
            Wang et al. (2005, #53)
           </xref>
          </td>
          <td align="left">
           aa 14–403
          </td>
         </tr>
         <tr>
          <td align="left">
           S2
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           3/10 (30)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0420">
            Wang et al. (2005, #53)
           </xref>
          </td>
          <td align="left">
           aa 370–770
          </td>
         </tr>
         <tr>
          <td align="left">
           S3
          </td>
          <td align="left">
           WB
          </td>
          <td align="left">
           7/10 (70)
           <xref ref-type="table-fn" rid="tblfn0015">
            a
           </xref>
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           n.d.
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0420">
            Wang et al. (2005, #53)
           </xref>
          </td>
          <td align="left">
           aa 738–1196
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          dpoi, days post onset of illness; N, SARS-CoV nucleocapsid protein; ELISA, enzyme-linked immunosorbent assay; n.d., not determined, WB, Western blot analysis; S, SARS-CoV spike protein; IFA, immunofluorescence assay; app., approximately.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tblfn0015">
         <label>
          a
         </label>
         <p id="npar0015">
          Calculated from information given in the paper.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tblfn0020">
         <label>
          b
         </label>
         <p id="npar0020">
          10–61 dpoi.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tblfn0025">
         <label>
          c
         </label>
         <p id="npar0025">
          Includes 400 healthy blood donations from March–May 2003 since contact to SARS patients could not be excluded.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tblfn0030">
         <label>
          d
         </label>
         <p id="npar0030">
          4–71 dpoi.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="par0095">
      The N protein, as a major immunogenic protein of SARS-CoV (
      <xref ref-type="bibr" rid="bib0370">
       Qiu et al., 2005
      </xref>
      ), was widely used in recombinant serological assays. Its small size and lack of glycosylation sites make it easy to clone and purify in vast quantities from bacteria. Serum from between 73% and 100% of SARS patients reacted with the complete or partial N protein in ELISAs or WB analyses indicating that these assays had high sensitivity (
      <xref ref-type="table" rid="tbl0010">
       Table 2
      </xref>
      ). No marked difference could be found between studies using a partial or complete N protein as antigen. By contrast, the rate of false positive results differed grossly between the individual studies. Most studies claimed that N protein-based ELISA and WB analysis detected only between 0% and 5.7% false positives in the sera of the negative control groups (
      <xref ref-type="table" rid="tbl0010">
       Table 2
      </xref>
      ), suggesting a low to moderate specificity. Of note,
      <xref ref-type="bibr" rid="bib0445">
       Woo et al. (2004a)
      </xref>
      were able to show that 29 of 33 sera that were false positive in an N protein-based ELISA were not reactive in a confirmatory WB assay using a SARS spike polypeptide. Therefore these sera were confirmed to be truly false positives, making this study more reliable than others. Conversely there are several reports showing that cross-reactivity with other human pathogenic CoVs occurs when using N protein-based assays (
      <xref ref-type="bibr" rid="bib0075">
       Che et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0280">
       Maache et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0455">
       Woo et al., 2004c
      </xref>
      ). Of particular note is one study in which the N protein completely failed to differentiate serum from SARS patients and healthy individuals (
      <xref ref-type="bibr" rid="bib0280">
       Maache et al., 2006
      </xref>
      ). These findings further highlight the complexity of serum diagnostics for CoVs and emphasize that a valid diagnosis cannot rely on reactivity to a single antigenic protein.
     </p>
     <p id="par0100">
      The other major immunodominant protein of SARS-CoV is the S protein (
      <xref ref-type="bibr" rid="bib0370">
       Qiu et al., 2005
      </xref>
      ) which has been used in IFAs, ELISAs and WB analysis as well as for the generation of pseudotyped particles to develop a biosafe VNT (
      <xref ref-type="bibr" rid="bib0135">
       Fukushi et al., 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0210">
       Hofmann et al., 2004
      </xref>
      ). The majority of neutralizing antibodies were found to be directed against the S protein (
      <xref ref-type="bibr" rid="bib0035">
       Buchholz et al., 2004
      </xref>
      ). For IFA, it was possible to use both full-length S, stably expressed in mammalian cells (
      <xref ref-type="bibr" rid="bib0410">
       Tan et al., 2004
      </xref>
      ), and a fragment (amino acids (aa) 441–700) expressed in insect cells using baculovirus (
      <xref ref-type="bibr" rid="bib0285">
       Manopo et al., 2005
      </xref>
      ). By contrast, because of the technical difficulties in expressing the full-length protein in bacteria, only fragments were used in ELISAs and WB analysis.
     </p>
     <p id="par0105">
      In general, antibodies directed against the S protein appeared later in infection than those directed against the N protein (
      <xref ref-type="bibr" rid="bib0410">
       Tan et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0460">
       Woo et al., 2005
      </xref>
      ), indicating that S protein-based assays may be preferable for use with convalescent sera. Overall, reactivity of SARS patient sera with S protein differed grossly between different studies and types of assays, ranging from very low (13%) in one study (
      <xref ref-type="bibr" rid="bib0265">
       Leung et al., 2004
      </xref>
      ) to 100% in several other studies (
      <xref ref-type="table" rid="tbl0010">
       Table 2
      </xref>
      ). There was a marked difference between detection rates with IFAs (100%), ELISAs (13–96%) and WB analysis (40–100%) (
      <xref ref-type="table" rid="tbl0010">
       Table 2
      </xref>
      ). The advantage of an IFA can be explained by its use of transfected cells that facilitate correct folding and post-translational modifications (e.g., glycosylation) of the S protein, whereas an ELISA and WB analysis use only denatured linear forms without proper glycosylation. For glycoprotein 120 (gp120) of the human immunodeficiency virus (HIV), it was shown that altered glycosylation patterns influence the host immune response (
      <xref ref-type="bibr" rid="bib0165">
       Grundner et al., 2004
      </xref>
      ). Therefore patients that produce mainly antibodies recognizing conformational epitopes or glycosylation-dependent epitopes of the S protein could be tested as false negatives in an ELISA or WB analysis. That ELISAs and WB analysis are only able to use S protein fragments, as mentioned above, provides a plausible explanation for the variable results found between different assays.
     </p>
     <p id="par0110">
      Reactivity of negative control sera to the S protein varied widely between individual studies. Two studies using an IFA to test a sizeable control group of 100 and 142 sera did not detect any false positives (
      <xref ref-type="table" rid="tbl0010">
       Table 2
      </xref>
      ), which is indicative of the high specificity of the assays. By contrast, ELISAs and WB assays reported between 0% and 30% false positive results, although most studies used control groups of less than 60 sera making them less reliable to estimate the true performance of the assays. Interestingly, the only ELISA-based study that used a rather large control group (148 healthy donors), found only two false positive serum samples (
      <xref ref-type="bibr" rid="bib0460">
       Woo et al., 2005
      </xref>
      ). These results suggest that IFAs using the complete S protein have a specificity advantage over ELISAs or WB assays.
     </p>
    </sec>
    <sec id="sec0025">
     <label>
      5
     </label>
     <title>
      Cross-reactivity and cross-neutralization among coronaviruses
     </title>
     <p id="par0115">
      Immunogenic proteins of closely related viruses that share common structural or linear epitopes can elicit cross-reactive and cross-neutralizing antibodies in the host. That both occur with CoVs has been recognized for many decades (
      <xref ref-type="bibr" rid="bib0025">
       Bradburne, 1970
      </xref>
      ), and was reflected by the former classification of CoVs into serogroups (
      <xref ref-type="bibr" rid="bib0290">
       McIntosh et al., 1969
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0305">
       Monto, 1974
      </xref>
      ).
     </p>
     <p id="par0120">
      As a result assays that used full virus particles or extracts of infected cells as antigen encountered several problems. Two studies reported the appearance of bands at molecular weights of 60 and/or 97 kDa in WB assays using crude viral lysates that could not be attributed to structural proteins (
      <xref ref-type="bibr" rid="bib0180">
       Guan et al., 2004c
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0265">
       Leung et al., 2004
      </xref>
      ). It was speculated that these bands might represent NSPs recognized by SARS patient sera. In fact, it was shown that some NSPs and accessory ORF-encoded proteins can be incorporated into viral particles (
      <xref ref-type="bibr" rid="bib0325">
       Neuman et al., 2008
      </xref>
      ) and are possibly able to elicit an immune response. Indeed, reactive antibodies against SARS-CoV proteins 3a and 9b have been demonstrated in SARS patients by protein micro array (
      <xref ref-type="bibr" rid="bib0370">
       Qiu et al., 2005
      </xref>
      ). Antibodies directed against conserved NSPs or ORF proteins could contribute to false positive results in assays using whole virus as antigen. In addition, conserved structural proteins such as the N protein are produced at high levels in infected cells and viral particles, further increasing the potential for cross-reactivity between different CoVs. The influence of the N protein in serological assays will be outlined in detail below.
     </p>
     <p id="par0125">
      Particularly when using denatured antigens in serodiagnostic assays, cross-reactivity is more likely to occur when the applied target proteins are conserved among related viruses. To estimate the rate of conservation of the immunogenic proteins N and S, we analyzed the percentage of aa identity between all HCoV comprising of the genera alpha- and beta-CoV (
      <xref ref-type="table" rid="tbl0015">
       Table 3
      </xref>
      ; first column). Pairwise analysis of complete N sequences revealed that the SARS-CoV N protein had 25–29% aa identity with Alpha-CoV and 33–47% with the more closely related Beta-CoV. By comparison, the complete S protein sequence showed a lower degree of conservation with 23–25% aa identity with Alpha-CoV and around 29% with Beta-CoV. However, as antibodies are produced against the exposed domains of three-dimensional proteins, the overall degree of aa conservation alone cannot predict the occurrence of cross-reactivity. To gain a fuller picture, we therefore analyzed the available information on conserved aa sequences within known immunodominant regions of SARS-CoV N and S protein (
      <xref ref-type="table" rid="tbl0015">
       Table 3
      </xref>
      ). A study by Chen and colleagues revealed four immunodominant regions in the N protein termed EP1 aa 51–71, EP2 aa 134–208, EP3 aa 249–273 and EP4 aa 349–422 (
      <xref ref-type="bibr" rid="bib0085">
       Chen et al., 2004b
      </xref>
      ). Upon comparison with other human pathogenic Beta-CoVs, one immunodominant region of the N protein showed a low degree of conservation (11–28%) and three regions showed a high degree (40–67%) (
      <xref ref-type="table" rid="tbl0015">
       Table 3
      </xref>
      ). In addition, Rota et al. found a very conserved motif of eight amino acids present in the N protein of all CoVs, including animal CoVs (
      <xref ref-type="bibr" rid="bib0390">
       Rota et al., 2003
      </xref>
      ).
      <table-wrap id="tbl0015" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         % AA Pairwise-Identity to SARS-CoV in immunogenic regions.
        </p>
       </caption>
       <graphic xlink:href="fx1">
       </graphic>
      </table-wrap>
     </p>
     <p id="par0130">
      The S protein harbors five different immunogenic sites at aa positions 9–71, 171–224, 271–318, 528–635 and 842–913 (
      <xref ref-type="bibr" rid="bib0205">
       He et al., 2004b
      </xref>
      ). Compared to human pathogenic Beta-CoVs, three immunodominant regions of the S protein show a low degree of conservation (9–26%), one region shows a medium degree (33–42%), and one region shows a high degree (47–55%). Taken together, these findings may explain why N protein-based serological assays are more often associated with cross-reactivity than S protein-based assays.
     </p>
     <p id="par0135">
      There are several studies that address the question of whether there is cross-neutralization between related CoVs. Cross-neutralization has been shown between closely related animal CoVs, as in transmissible gastroenteritis virus (TGEV) and feline infectious peritonitis virus type 2 (
      <xref ref-type="bibr" rid="bib0220">
       Horzinek et al., 1982
      </xref>
      ) that have around 95% identity in the C-terminal 1150 aa of the S protein, and also HCoV-OC43 and bovine CoV (BCoV) (
      <xref ref-type="bibr" rid="bib0145">
       Gerna et al., 1981
      </xref>
      ). Interestingly, even HCoV-HKU1, which is closely related to HCoV-OC43, is neither neutralized by HCoV-OC43-reactive sera, despite an aa identity of 64.5% in the S protein, nor by sera reactive with the more distantly related HCoV-229E or SARS-CoV (
      <xref ref-type="bibr" rid="bib0055">
       Chan et al., 2009
      </xref>
      ). Similar results were found for the closely related CoVs HCoV-NL63 and HCoV-229E (
      <xref ref-type="bibr" rid="bib0215">
       Hofmann et al., 2005
      </xref>
      ). To our knowledge, there is only one study describing cross-neutralization between HCoVs, namely of MERS-CoV using SARS-CoV reactive sera. However, it should be noted that neutralizing titers were very low (1:10), indicating that an assay-specific cut-off should be determined with well-defined reference sera to avoid false positive results (
      <xref ref-type="bibr" rid="bib0060">
       Chan et al., 2013
      </xref>
      ). In conclusion, these data clearly show the value of VNTs as a tool to differentiate even between closely related CoVs and reaffirms their status as the gold standard in serological diagnostics.
     </p>
     <p id="par0140">
      To provide a valid serological diagnosis of infection with CoVs, it is vital to rule out cross-reactivity and cross-neutralization by using a second confirmatory assay. Widely accepted confirmatory assays like the VNT, which was recommended by WHO during the SARS outbreak (
      <xref ref-type="bibr" rid="bib0435">
       WHO, 2004
      </xref>
      ), are labor-intensive leading to a high workload in diagnostic laboratories and subsequently to slow sample processing. The latter, in particular, is unfavorable in an outbreak situation when rapid identification of infected individuals and their contacts is necessary to contain the infectious agent. Establishing highly specific primary serological screening assays that avoid false positive results, and thus the need for further confirmation, is therefore an important goal.
     </p>
    </sec>
    <sec id="sec0030">
     <label>
      6
     </label>
     <title>
      Serological assays for animal screening
     </title>
     <p id="par0145">
      Serological assays have been used successfully as a pre-screening tool for virus discovery (
      <xref ref-type="bibr" rid="bib0040">
       Burbelo et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0105">
       Drexler et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0310">
       Muller et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0340">
       Peel et al., 2013
      </xref>
      ). Antibody detection assays are particularly valuable because short phases of virus shedding or poor sample quality decrease the chances of detecting nucleic acids. In addition, they allow the distribution of pathogens in various species and the antigenic relatedness with already known pathogens to be defined (
      <xref ref-type="bibr" rid="bib0105">
       Drexler et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0110">
       Drexler et al., 2012
      </xref>
      ). Importantly, testing of livestock and wild animals can help to trace the source of infection during an outbreak of a zoonotic virus (
      <xref ref-type="bibr" rid="bib0270">
       Li et al., 2005
      </xref>
      ). The identification of the animal reservoir allows the pathogen to be contained by interrupting the chain of transmission; for example, by shutting down animal markets or culling infected animals. This has been a successful approach with outbreaks of avian Influenza and SARS-CoV (
      <xref ref-type="bibr" rid="bib0245">
       Kan et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0405">
       Tam, 2002
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0415">
       Tu et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0430">
       Watts, 2004
      </xref>
      ).
     </p>
     <p id="par0150">
      A zoonotic origin of SARS-CoV was suspected early on as the first cases occurred among people handling wild exotic animals in Guangdong Province, China (
      <xref ref-type="bibr" rid="bib0480">
       Zhong et al., 2003
      </xref>
      ). Shortly afterwards Guan and colleagues acquired the first evidence, using RT-PCR and a VNT, that Himalayan palm civets (
      <italic>
       Paguma larvata
      </italic>
      ) and raccoon dogs (
      <italic>
       Nyctereutes procyanoides
      </italic>
      ) harbor a SARS-CoV strain that is 99.8% identical to the human SARS-CoV strain (
      <xref ref-type="bibr" rid="bib0185">
       Guan et al., 2003
      </xref>
      ). The lack of viral genetic diversity in positive animals, along with the fact that wild and other farmed palm civets were SARS-CoV seronegative (
      <xref ref-type="bibr" rid="bib0415">
       Tu et al., 2004
      </xref>
      ), indicated that palm civets were not the natural reservoir of SARS-CoV. The search for the source of SARS-CoV continued by screening hundreds of animals from a multitude of species (
      <xref ref-type="bibr" rid="bib0360">
       Poon et al., 2005
      </xref>
      ). A decade later the natural reservoir of SARS-CoV was eventually confirmed to be
      <italic>
       Rhinolophus sinicus
      </italic>
      bats in China (
      <xref ref-type="bibr" rid="bib0140">
       Ge et al., 2013
      </xref>
      ). Valuable hints that facilitated the identification of the SARS-CoV reservoir were already provided in late 2005. Two studies found closely related SARS-CoV in Chinese rhinolophid bats in Asia by RT-PCR and serological methods (
      <xref ref-type="bibr" rid="bib0260">
       Lau et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0270">
       Li et al., 2005
      </xref>
      ) while another study found more distantly related CoVs in other bat families (
      <xref ref-type="bibr" rid="bib0360">
       Poon et al., 2005
      </xref>
      ).
      <xref ref-type="bibr" rid="bib0270">
       Li et al. (2005)
      </xref>
      used two different ELISAs, recombinant SARS-CoV N protein- and whole virus antigen-based, and detected a seroprevalence between 28% and 71% depending on the bat species. The second study by
      <xref ref-type="bibr" rid="bib0260">
       Lau et al. (2005)
      </xref>
      used an ELISA and WB analysis based on recombinant N protein derived from a bat SARS-like CoV and found a seroprevalence of 84% (ELISA) and 67% (WB) in bats. A marked difference between these two studies was observed in the neutralizing activity of bat sera toward human SARS-CoV. While Lau et al. could detect neutralizing antibodies in some bat sera (42%), Li et al. found no neutralizing activity despite positive serum titers by ELISA of up to 1:6400. Despite these differences, both studies indicated that there was a high level of cross-reactive antibodies when complete virus antigen- and recombinant N protein-based assays were used. VNTs showed a higher specificity, even for these closely related CoVs.
     </p>
     <p id="par0155">
      Several follow-up studies in bats were conducted after these findings. The first evidence of CoV in African bats came from the detection of antibodies that reacted against SARS-CoV proteins (
      <xref ref-type="bibr" rid="bib0310">
       Muller et al., 2007
      </xref>
      ). Different serological assays were employed including a SARS-CoV protein-based ELISA, a cIFA using SARS-CoV infected cells and WB assays using either recombinant N or S protein or whole virus antigen (
      <xref ref-type="bibr" rid="bib0310">
       Muller et al., 2007
      </xref>
      ). In this case, VNT revealed that African bats harbored antibodies that cross-reacted with different SARS-CoV antigens but were not able to neutralize SARS-CoV. In subsequent studies, we and others found that both Alpha- and Betacoronaviruses are highly diverse in African bats (
      <xref ref-type="bibr" rid="bib0355">
       Pfefferle et al., 2009
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0375">
       Quan et al., 2010
      </xref>
      ), including close ancestral relatives of HCoV-229E and distant relatives of SARS-CoV. This example shows how the detection of cross-reactive bat serum antibodies against SARS-CoV antigen resulted in the discovery of highly diverse bat CoVs including relatives of SARS-CoV.
     </p>
     <p id="par0160">
      In conclusion, most assays performed well with animal sera. However, outcomes have to be evaluated cautiously as testing of animal sera adds another level of complexity. Animals may harbor antibodies against unidentified CoVs that can cross-react with the target antigen especially without knowing the degree of epitope conservation between test antigen and the unidentified CoV. In many cases, secondary detection antibodies are not always available or their performance in serological assays has not been validated. This is particularly true when human serodiagnostic assays are modified for use in animal screening. In the absence of viral nucleic acids, outcomes of serological animal screening should be interpreted cautiously and should only be used as an initial indicator for targeted follow-up studies.
     </p>
    </sec>
    <sec id="sec0035">
     <label>
      7
     </label>
     <title>
      Diagnostics for newly emerged MERS-CoV
     </title>
     <p id="par0165">
      In June 2012, a previously unknown CoV, now termed MERS-CoV, emerged in the Middle East (
      <xref ref-type="bibr" rid="bib0475">
       Zaki et al., 2012
      </xref>
      ). To date, 180 people have been infected, of whom 77 have died (
      <xref ref-type="bibr" rid="bib0440">
       WHO, 2014
      </xref>
      ), resulting in a case fatality ratio of 43%. So far, the virus is only endemic in the Middle East with only a few cases imported into countries outside this region (
      <xref ref-type="bibr" rid="bib0020">
       Bermingham et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0030">
       Buchholz et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0120">
       Drosten et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0190">
       Guery et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0225">
       HPA, 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0365">
       Puzelli et al., 2013
      </xref>
      ).
     </p>
     <p id="par0170">
      Similar to the SARS outbreak, the first diagnostic assays, including PCR and serological, were developed rapidly (
      <xref ref-type="bibr" rid="bib0090">
       Corman et al., 2012a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0095">
       Corman et al., 2012b
      </xref>
      ). Different serological assays were established including cIFAs using virus-infected cells, IFAs using VERO cells expressing recombinant N or S protein of MERS-CoV, as well as a WB analysis of lysates from cells expressing recombinant N or S protein (
      <xref ref-type="bibr" rid="bib0095">
       Corman et al., 2012b
      </xref>
      ). A cell-free protein microarray was developed that uses the correctly folded and glycosylated S1 fragment of the MERS-CoV S protein as antigen (
      <xref ref-type="bibr" rid="bib0380">
       Reusken et al., 2013a
      </xref>
      ). Finally, MERS-CoV- and S protein-pseudotyped viruses were used in neutralization assays (
      <xref ref-type="bibr" rid="bib0030">
       Buchholz et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0120">
       Drosten et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0150">
       Gierer et al., 2013a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0350">
       Perera et al., 2013
      </xref>
      ).
     </p>
     <p id="par0175">
      A major problem that faced all groups at the time of assay development was the need for a well-characterized serum sample collection to enable thorough validation. This should include defined positive sera for all known human pathogenic CoVs and MERS-CoV convalescent sera along with negative control groups. As only a very small number of positive sera were available at the time of testing, determination of assay sensitivity currently requires more rigorous validation. Assay specificity has been addressed in all studies. Similar to the SARS-CoV serological assays, using whole virus or recombinant N protein gave false positive results for IgM detection (
      <xref ref-type="bibr" rid="bib0030">
       Buchholz et al., 2013
      </xref>
      ). In another study, 356 serum samples including those from 226 slaughterhouse workers in Saudi Arabia were screened using a cIFA followed by a recombinant S protein-based IFA and a VNT for confirmation. The cIFA in this study produced a significant number of false positives that required exclusion by confirmatory neutralization assay (
      <xref ref-type="bibr" rid="bib0005">
       Aburizaiza et al., 2013
      </xref>
      ). Another study conducted in Saudi Arabia made use of MERS-S pseudotyped lentiviruses to test for virus-neutralizing antibodies (
      <xref ref-type="bibr" rid="bib0155">
       Gierer et al., 2013b
      </xref>
      ). HCoV-NL63 S pseudotyped viruses were used as controls. All 268 tested serum samples were negative for MERS-CoV neutralizing antibodies. There was no unspecific cross-neutralization of MERS-S pseudotyped viruses by NL63-positive sera. Another study compared conventional VNT with the S pseudotyped lentivirus-based NT. In total, 1343 human serum samples collected from healthy donors in Egypt and, as controls, in Hong Kong were negative in both NT formats (
      <xref ref-type="bibr" rid="bib0350">
       Perera et al., 2013
      </xref>
      ). Both studies emphasize that NT are less prone to unspecific reactivity and that the use of pseudotyped viruses has the added advantage of not requiring a BSL3 laboratory. Large-scale serological studies of the population in affected countries are urgently needed to further examine spread, prevalence and transmission of MERS-CoV.
     </p>
     <p id="par0180">
      Despite several attempts to find the source of the outbreak, the origin of MERS-CoV remains enigmatic. Several studies, based on nucleic acid detection assays, found closely related CoVs in different bat species in Africa, Saudi Arabia and Northern America (
      <xref ref-type="bibr" rid="bib0010">
       Annan et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0015">
       Anthony et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0240">
       Ithete et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0295">
       Memish et al., 2013
      </xref>
      ). In parallel with PCR-based methods we took a serological approach and screened livestock animals from MERS-CoV-linked (Oman) and unlinked regions (Spain, The Netherlands). We showed that all tested dromedary camels from Oman as well as a few camels from the Canary Islands harbored MERS-CoV neutralizing antibodies (
      <xref ref-type="bibr" rid="bib0385">
       Reusken et al., 2013b
      </xref>
      ). As the Canary Islands are not linked to any MERS cases this finding was surprising. Additionally we were able to identify MERS-CoV specific antibodies in camel sera from the United Arab Emirates (UAE) collected more than 10 years ago (
      <xref ref-type="bibr" rid="bib0300">
       Meyer et al., 2014
      </xref>
      ). Importantly, since BCoV (a Beta-CoV of the A lineage) is commonly distributed among livestock, cross-neutralization of MERS-CoV by BCoV antibodies had to be excluded. Recently a study by Haagmans and colleagues could verify MERS-CoV infection in camels on a farm where human cases occurred by using RT-PCR detection methods (
      <xref ref-type="bibr" rid="bib0195">
       Haagmans et al., 2013
      </xref>
      ). Still, since the genetic distance between the human and the camels MERS-CoV from that cluster was very small, it was not possible to differentiate whether camels were infected by humans or vice versa. The value of a MERS-S pseudotyped lentivirus-based NT has been shown in an independent camel study conducted in Egypt, which also found a high percentage of neutralizing antibodies in those animals (
      <xref ref-type="bibr" rid="bib0350">
       Perera et al., 2013
      </xref>
      ). In conclusion, these data highlight the problem of interpreting CoV serological assays, especially if whole virus-derived antigen is used, and further stresses that demonstrating neutralization is indispensable to ultimately confirm seroconversion to a specific CoV.
     </p>
    </sec>
    <sec id="sec0040">
     <label>
      8
     </label>
     <title>
      Conclusion
     </title>
     <p id="par0185">
      Serological assays have proven valuable for a multitude of investigations, particularly as a complement to nucleic acid detection assays. Serology can help with the identification of the source of infection, the clarification of the epidemiology including transmission pattern analysis, patient contact studies and the identification of asymptomatic cases. All of these tasks can only be achieved with specific and sensitive serological assays. However, for properly validated assays, well-characterized serum samples from patients are necessary and they are not available in an outbreak scenario.
     </p>
     <p id="par0190">
      Despite the large number of assays developed in the aftermath of the outbreak of SARS- and MERS-CoV, serological differentiation of HCoVs remains challenging. Overall, it can be concluded that problems with cross-reactivity are more likely to arise with a more conserved antigen, and will often manifest as false positive results. Whether IF, ELISA or WB assays are the preferred screening tool depends on availability of molecular biological techniques, the exact study design as well as the number of samples. Compared to whole virus antigen, assays using recombinant proteins are in general more reliable and can be more easily standardized. Preferably, a recombinant serological assay should use an antigen which is highly immunogenic and provides epitopes specific for its virus species. In addition it is of importance that the protein is expressed in its natural conformation, i.e., displaying proper folding and glycosylation. As discussed above in case of coronaviruses only the S proteins combines all these features. Regardless of assay or antigen used, we recommend a thorough validation using a defined set of sera reactive with other HCoVs as well as a large number of negative serum samples from patients with other respiratory diseases. In any case, great care should be taken in selecting the most appropriate assay and the limitations of each assay should be considered when interpreting results. In our opinion to ultimately confirm serological results it is indispensable to perform a VNT as it is the most specific assay available.
     </p>
     <p id="par0195">
      To improve and coordinate the development of serological assays during future outbreaks of novel coronaviruses, a well-characterized subset of sera would be highly recommendable in order to implement a standardized protocol for validating new assays.
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aburizaiza
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mattes
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012
        </article-title>
        <source>
         The Journal of infectious diseases
        </source>
        <volume>
         209
        </volume>
        <issue>
         2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         243
        </fpage>
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="pmid">
         24218504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baldwin
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Klose
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Owusu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nkrumah
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Badu
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Anti
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Agbenyega
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sarkodie
          </surname>
          <given-names>
           Y.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kalko
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lina
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Godlevska
          </surname>
          <given-names>
           E.V.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Seebens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gloza-Rausch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Vallo
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tschapka
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         456
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="pmid">
         23622767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anthony
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ojeda-Flores
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Rico-Chavez
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Navarrete-Macias
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Zambrana-Torrelio
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Rostal
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tipps
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez-Leon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sotomayor-Bonilla
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Aguirre
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Avila-Flores
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Medellin
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses in bats from Mexico
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         94
        </volume>
        <issue>
         Pt 5
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1028
        </fpage>
        <lpage>
         1038
        </lpage>
        <pub-id pub-id-type="pmid">
         23364191
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Aarons
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Langrish
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hoschler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Pebody
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
         <name>
          <surname>
           Boddington
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gopal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Newsholme
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         17
        </volume>
        <issue>
         40
        </issue>
        <year>
         2012
        </year>
        <fpage>
         20290
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bradburne
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic relationships amongst coronaviruses
        </article-title>
        <source>
         Arch. Gesamte Virusforsch.
        </source>
        <volume>
         31
        </volume>
        <issue>
         3
        </issue>
        <year>
         1970
        </year>
        <fpage>
         352
        </fpage>
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="pmid">
         4321451
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sanewski
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wevering
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer-Balci
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bonin
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schweiger
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wolff
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Buda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Krause
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Schaade
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Haas
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October–November 2012
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         18
        </volume>
        <issue>
         8
        </issue>
        <year>
         2013
        </year>
        <comment>
         pii: 20406
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         101
        </volume>
        <issue>
         26
        </issue>
        <year>
         2004
        </year>
        <fpage>
         9804
        </fpage>
        <lpage>
         9809
        </lpage>
        <pub-id pub-id-type="pmid">
         15210961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burbelo
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Dubovi
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Simmonds
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Medina
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Henriquez
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Wagner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tokarz
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cullen
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Iadarola
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rice
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serology-enabled discovery of genetically diverse hepaciviruses in a new host
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <issue>
         11
        </issue>
        <year>
         2012
        </year>
        <fpage>
         6171
        </fpage>
        <lpage>
         6178
        </lpage>
        <pub-id pub-id-type="pmid">
         22491452
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carattoli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Di Bonito
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Grasso
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Blasi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant protein-based ELISA and immuno-cytochemical assay for the diagnosis of SARS
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         76
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         137
        </fpage>
        <lpage>
         142
        </lpage>
        <pub-id pub-id-type="pmid">
         15834868
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         8
        </volume>
        <year>
         2003
        </year>
        <fpage>
         S9
        </fpage>
        <lpage>
         S14
        </lpage>
        <pub-id pub-id-type="pmid">
         15018127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus
        </article-title>
        <source>
         J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
        </source>
        <volume>
         45
        </volume>
        <issue>
         1
        </issue>
        <year>
         2009
        </year>
        <fpage>
         54
        </fpage>
        <lpage>
         60
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
        </article-title>
        <source>
         J. Infect.
        </source>
        <volume>
         67
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         130
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="pmid">
         23583636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of SARS coronavirus in patients with suspected SARS
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         10
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         294
        </fpage>
        <lpage>
         299
        </lpage>
        <pub-id pub-id-type="pmid">
         15030700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yap
          </surname>
          <given-names>
           F.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunofluorescence assay for serologic diagnosis of SARS
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         10
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         530
        </fpage>
        <lpage>
         532
        </lpage>
        <pub-id pub-id-type="pmid">
         15109430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           Y.B.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         191
        </volume>
        <issue>
         12
        </issue>
        <year>
         2005
        </year>
        <fpage>
         2033
        </fpage>
        <lpage>
         2037
        </lpage>
        <pub-id pub-id-type="pmid">
         15897988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serology of severe acute respiratory syndrome: implications for surveillance and outcome
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         189
        </volume>
        <issue>
         7
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1158
        </fpage>
        <lpage>
         1163
        </lpage>
        <pub-id pub-id-type="pmid">
         15031782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein
        </article-title>
        <source>
         Clin. Chem.
        </source>
        <volume>
         50
        </volume>
        <issue>
         6
        </issue>
        <year>
         2004
        </year>
        <fpage>
         988
        </fpage>
        <lpage>
         995
        </lpage>
        <pub-id pub-id-type="pmid">
         15054081
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Eschbach-Bludau
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gopal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ballhause
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         17
        </volume>
        <issue>
         39
        </issue>
        <year>
         2012
        </year>
        <comment>
         pii: 20285
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <element-citation id="sbref0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Costabel
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Timm
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Binger
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Kreher
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Eschbach-Bludau
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Schweiger
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Bonin
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wolff
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         17
        </volume>
        <issue>
         49
        </issue>
        <year>
         2012
        </year>
        <comment>
         pii: 20334
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <element-citation id="sbref0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Gaunt
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rossen
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Templeton
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kuijpers
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The dominance of human coronavirus OC43 and NL63 infections in infants
        </article-title>
        <source>
         J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <year>
         2012
        </year>
        <fpage>
         135
        </fpage>
        <lpage>
         139
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <element-citation id="sbref0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lukashev
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Gmyl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Coutard
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Adam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Leijten
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Klose
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gloza-Rausch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Binger
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Adu-Sarkodie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bourgarel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rupp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Schlegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kummerer
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kruger
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Schmidt-Chanasit
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Setien
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hemachudha
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wacharapluesadee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Osterrieder
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Bartenschlager
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Matthee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Beer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Leroy
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ulrich
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for novel hepaciviruses in rodents
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         9
        </volume>
        <issue>
         6
        </issue>
        <year>
         2013
        </year>
        <fpage>
         e1003438
        </fpage>
        <pub-id pub-id-type="pmid">
         23818848
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <element-citation id="sbref0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Maganga
          </surname>
          <given-names>
           G.D.
          </given-names>
         </name>
         <name>
          <surname>
           Vallo
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Binger
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Gloza-Rausch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rasche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yordanov
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Seebens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sarkodie
          </surname>
          <given-names>
           Y.A.
          </given-names>
         </name>
         <name>
          <surname>
           Pongombo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lukashev
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Schmidt-Chanasit
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Stocker
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Carneiro
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Erbar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Maisner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fronhoffs
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Buettner
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kalko
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kruppa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Franke
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yandoko
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hassanin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kruger
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Matthee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ulrich
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Leroy
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats host major mammalian paramyxoviruses
        </article-title>
        <source>
         Nature Commun.
        </source>
        <volume>
         3
        </volume>
        <year>
         2012
        </year>
        <fpage>
         796
        </fpage>
        <pub-id pub-id-type="pmid">
         22531181
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <element-citation id="sbref0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Burguiere
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kramme
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rickerts
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sturmer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vieth
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Schmitz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         New Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <issue>
         20
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <element-citation id="sbref0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hartmann
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Scheible
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sack
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Guggemos
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Junglen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Haas
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Guberina
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Rohnisch
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schmid-Wendtner
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Aldabbagh
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Gold
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Graf
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bonin
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rambaut
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wendtner
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <issue>
         9
        </issue>
        <year>
         2013
        </year>
        <fpage>
         745
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <element-citation id="sbref0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ecker
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Vollenhofer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bares
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schalkhammer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schinkinger
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pittner
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overexpression and purification of a recombinant chimeric HIV type 2/HIV type 1 envelope peptide and application in an accelerated immunobased HIV type 1/2 antibody detection system (AIBS): a new rapid serological screening assay
        </article-title>
        <source>
         AIDS Res. Hum. Retrovir.
        </source>
        <volume>
         12
        </volume>
        <issue>
         12
        </issue>
        <year>
         1996
        </year>
        <fpage>
         1081
        </fpage>
        <lpage>
         1091
        </lpage>
        <pub-id pub-id-type="pmid">
         8844013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <element-citation id="sbref0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farber
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Wutzler
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlrabe
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wolf
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hinderer
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Sonneborn
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs
        </article-title>
        <source>
         J. Virol. Methods
        </source>
        <volume>
         42
        </volume>
        <issue>
         2–3
        </issue>
        <year>
         1993
        </year>
        <fpage>
         301
        </fpage>
        <lpage>
         307
        </lpage>
        <pub-id pub-id-type="pmid">
         8390476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <element-citation id="sbref0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Taguchi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <volume>
         454
        </volume>
        <year>
         2008
        </year>
        <fpage>
         331
        </fpage>
        <lpage>
         338
        </lpage>
        <pub-id pub-id-type="pmid">
         19057867
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <element-citation id="sbref0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         503
        </volume>
        <issue>
         7477
        </issue>
        <year>
         2013
        </year>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <element-citation id="sbref0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerna
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cereda
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Revello
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Cattaneo
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Battaglia
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gerna
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic and biological relationships between human coronavirus Oc43 and neonatal calf diarrhea coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         54
        </volume>
        <issue>
         May
        </issue>
        <year>
         1981
        </year>
        <fpage>
         91
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="pmid">
         6169790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <element-citation id="sbref0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaup
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wrensch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kramer-Kuhl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Welsch
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           von Hahn
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <issue>
         10
        </issue>
        <year>
         2013
        </year>
        <fpage>
         5502
        </fpage>
        <lpage>
         5511
        </lpage>
        <pub-id pub-id-type="pmid">
         23468491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <element-citation id="sbref0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hofmann-Winkler
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Albuali
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rubaish
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yousef
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Nafaie
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ali
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Obeid
          </surname>
          <given-names>
           O.E.
          </given-names>
         </name>
         <name>
          <surname>
           Alkharsah
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         12
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2034
        </fpage>
        <lpage>
         2036
        </lpage>
        <pub-id pub-id-type="pmid">
         24274664
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <element-citation id="sbref0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorse
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           G.B.
          </given-names>
         </name>
         <name>
          <surname>
           Vitale
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           O’Connor
          </surname>
          <given-names>
           T.Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum
        </article-title>
        <source>
         Clin. Vaccine Immunol.
        </source>
        <volume>
         17
        </volume>
        <issue>
         12
        </issue>
        <year>
         2010
        </year>
        <fpage>
         1875
        </fpage>
        <lpage>
         1880
        </lpage>
        <pub-id pub-id-type="pmid">
         20943876
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <element-citation id="sbref0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grundner
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pancera
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sodroski
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wyatt
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         330
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         248
        </lpage>
        <pub-id pub-id-type="pmid">
         15527849
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <element-citation id="sbref0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Phuah
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation and validation of an enzyme-linked immunosorbent assay and an immunochromatographic test for serological diagnosis of severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         699
        </fpage>
        <lpage>
         703
        </lpage>
        <pub-id pub-id-type="pmid">
         15242944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <element-citation id="sbref0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Foo
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Goh
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wee
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         287
        </fpage>
        <lpage>
         291
        </lpage>
        <pub-id pub-id-type="pmid">
         15013977
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <element-citation id="sbref0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Goh
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chin
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of viral lysate antigen combined with recombinant protein in Western immunoblot assay as confirmatory test for serodiagnosis of severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1148
        </fpage>
        <lpage>
         1153
        </lpage>
        <pub-id pub-id-type="pmid">
         15539520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <element-citation id="sbref0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Butt
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shortridge
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <volume>
         302
        </volume>
        <issue>
         5643
        </issue>
        <year>
         2003
        </year>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <element-citation id="sbref0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guery
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           el Mansouf
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sejourne
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ettahar
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Lemaire
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Vuotto
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Goffard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Behillil
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enouf
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Caro
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Mailles
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mathieu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         381
        </volume>
        <issue>
         9885
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2265
        </fpage>
        <lpage>
         2272
        </lpage>
        <pub-id pub-id-type="pmid">
         23727167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <element-citation id="sbref0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ghobashy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Thani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Marri
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Al Khal
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Alhajri
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <element-citation id="sbref0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chng
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kwang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a Western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         417
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="pmid">
         15013997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <element-citation id="sbref0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines
        </article-title>
        <source>
         J. Immunol.
        </source>
        <volume>
         173
        </volume>
        <issue>
         6
        </issue>
        <year>
         2004
        </year>
        <fpage>
         4050
        </fpage>
        <lpage>
         4057
        </lpage>
        <pub-id pub-id-type="pmid">
         15356154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <element-citation id="sbref0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hattermann
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gramberg
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krumbiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuate
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Uberla
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <issue>
         12
        </issue>
        <year>
         2004
        </year>
        <fpage>
         6134
        </fpage>
        <lpage>
         6142
        </lpage>
        <pub-id pub-id-type="pmid">
         15163706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <element-citation id="sbref0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         102
        </volume>
        <issue>
         22
        </issue>
        <year>
         2005
        </year>
        <fpage>
         7988
        </fpage>
        <lpage>
         7993
        </lpage>
        <pub-id pub-id-type="pmid">
         15897467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <element-citation id="sbref0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lutz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic relationships among homologous structural polypeptides of porcine, feline, and canine coronaviruses
        </article-title>
        <source>
         Infect. Immun.
        </source>
        <volume>
         37
        </volume>
        <issue>
         3
        </issue>
        <year>
         1982
        </year>
        <fpage>
         1148
        </fpage>
        <lpage>
         1155
        </lpage>
        <pub-id pub-id-type="pmid">
         6182101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <element-citation id="sbref0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hpa
          </surname>
          <given-names>
           H.P.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         18
        </volume>
        <issue>
         11
        </issue>
        <year>
         2013
        </year>
        <fpage>
         20427
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <element-citation id="sbref0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hsiao
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1163
        </fpage>
        <lpage>
         1167
        </lpage>
        <pub-id pub-id-type="pmid">
         14519257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <element-citation id="sbref0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Flowers
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Valman
          </surname>
          <given-names>
           H.B.
          </given-names>
         </name>
         <name>
          <surname>
           MacNaughton
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of coronavirus respiratory infections
        </article-title>
        <source>
         Arch. Dis. Child.
        </source>
        <volume>
         58
        </volume>
        <issue>
         7
        </issue>
        <year>
         1983
        </year>
        <fpage>
         500
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         6307189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <element-citation id="sbref0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Stoffberg
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schoeman
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Close relative of human middle East respiratory syndrome coronavirus in bat, South Africa
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         10
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1697
        </fpage>
        <lpage>
         1699
        </lpage>
        <pub-id pub-id-type="pmid">
         24050621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <element-citation id="sbref0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jing
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           X.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hai
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <issue>
         18
        </issue>
        <year>
         2005
        </year>
        <fpage>
         11892
        </fpage>
        <lpage>
         11900
        </lpage>
        <pub-id pub-id-type="pmid">
         16140765
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <element-citation id="sbref0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Humphrey
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fields
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           LeDuc
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         New Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <issue>
         20
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <element-citation id="sbref0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Tyrrell
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of rhinoviruses and coronaviruses from 38 colds in adults
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         5
        </volume>
        <issue>
         3
        </issue>
        <year>
         1980
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="pmid">
         6262450
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <element-citation id="sbref0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         102
        </volume>
        <issue>
         39
        </issue>
        <year>
         2005
        </year>
        <fpage>
         14040
        </fpage>
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <element-citation id="sbref0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           F.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         190
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         386
        </lpage>
        <pub-id pub-id-type="pmid">
         15216476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0270">
       <element-citation id="sbref0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McEachern
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Eaton
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <issue>
         5748
        </issue>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0275">
       <element-citation id="sbref0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         228
        </lpage>
        <pub-id pub-id-type="pmid">
         14715574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0280">
       <element-citation id="sbref0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maache
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Komurian-Pradel
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rajoharison
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perret
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Berland
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Pouzol
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bagnaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Duverger
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Osuna
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Paranhos-Baccala
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV
        </article-title>
        <source>
         Clin. Vaccine Immunol.
        </source>
        <volume>
         13
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         409
        </fpage>
        <lpage>
         414
        </lpage>
        <pub-id pub-id-type="pmid">
         16522785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0285">
       <element-citation id="sbref0285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Manopo
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chee
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kwang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV
        </article-title>
        <source>
         J. Immunol. Methods
        </source>
        <volume>
         296
        </volume>
        <issue>
         1–2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         37
        </fpage>
        <lpage>
         44
        </lpage>
        <pub-id pub-id-type="pmid">
         15680149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0290">
       <element-citation id="sbref0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kapikian
          </surname>
          <given-names>
           A.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hardison
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hartley
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chanock
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic relationships among the coronaviruses of man and between human and animal coronaviruses
        </article-title>
        <source>
         J. Immunol.
        </source>
        <volume>
         102
        </volume>
        <issue>
         5
        </issue>
        <year>
         1969
        </year>
        <fpage>
         1109
        </fpage>
        <lpage>
         1118
        </lpage>
        <pub-id pub-id-type="pmid">
         4306070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0295">
       <element-citation id="sbref0295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Durosinloun
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Asmari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         11
        </issue>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bib0300">
       <element-citation id="sbref0300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Siemens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           van Beek
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies against MERS Coronavirus in Dromedary Camels
        </article-title>
        <source>
         United Arab Emirates, 2003 and 2013. Emerging infectious diseases
        </source>
        <volume>
         20
        </volume>
        <issue>
         4
        </issue>
        <year>
         2014
        </year>
        <fpage>
         552
        </fpage>
        <lpage>
         559
        </lpage>
        <pub-id pub-id-type="pmid">
         24655412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0305">
       <element-citation id="sbref0305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical reviews. Coronaviruses
        </article-title>
        <source>
         Yale J. Biol. Med.
        </source>
        <volume>
         47
        </volume>
        <issue>
         4
        </issue>
        <year>
         1974
        </year>
        <fpage>
         234
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         4617423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0310">
       <element-citation id="sbref0310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Paweska
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leman
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kemp
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Braack
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sonnenberg
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Swanepoel
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus antibodies in African bat species
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <issue>
         9
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1367
        </fpage>
        <lpage>
         1370
        </lpage>
        <pub-id pub-id-type="pmid">
         18252111
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0315">
       <element-citation id="sbref0315" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Travers
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Walport
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Distribution and Functions of Immunoglobulin Classes. Janeway's Immunobiology
        </chapter-title>
        <edition>
         7th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Garland Science
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         400
        </fpage>
        <lpage>
         401
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0320">
       <element-citation id="sbref0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS coronavirus accessory proteins
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         133
        </volume>
        <issue>
         1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         121
        </lpage>
        <pub-id pub-id-type="pmid">
         18045721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0325">
       <element-citation id="sbref0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Saikatendu
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Serrano
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chatterjee
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Klaus
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yates
          </surname>
          <given-names>
           J.R.
          </given-names>
          <suffix>
           3rd
          </suffix>
         </name>
         <name>
          <surname>
           Wuthrich
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Stevens
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Buchmeier
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <issue>
         11
        </issue>
        <year>
         2008
        </year>
        <fpage>
         5279
        </fpage>
        <lpage>
         5294
        </lpage>
        <pub-id pub-id-type="pmid">
         18367524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0330">
       <element-citation id="sbref0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Leitmeyer
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First external quality assurance of antibody diagnostic for SARS-new coronavirus
        </article-title>
        <source>
         J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
        </source>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         22
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0335">
       <element-citation id="sbref0335" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patrick
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Skowronski
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Guasparini
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Krajden
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Gustafson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dubord
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Macdonald
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           David
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Srour
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Parker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Andonov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Isaac-Renton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Loewen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           McNabb
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           McNabb
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Goh
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Henwick
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Drebot
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Plummer
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus
        </article-title>
        <source>
         Journal canadien des maladies infectieuses et de la microbiologie medicale/AMMI Canada
        </source>
        <trans-source xml:lang="en">
         The Canadian Journal of Infectious Diseases &amp; Medical Microbiology
        </trans-source>
        <volume>
         17
        </volume>
        <issue>
         6
        </issue>
        <year>
         2006
        </year>
        <fpage>
         330
        </fpage>
        <lpage>
         336
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0340">
       <element-citation id="sbref0340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peel
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           McKinley
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Barr
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hayman
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y.R.
          </given-names>
         </name>
         <name>
          <surname>
           Broder
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cunningham
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of cross-reactive serological assays for detecting novel pathogens in wildlife: assessing an appropriate cutoff for henipavirus assays in African bats
        </article-title>
        <source>
         J. Virol. Methods
        </source>
        <volume>
         193
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         23835034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0345">
       <element-citation id="sbref0345" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yee
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           D.N.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9366
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0350">
       <element-citation id="sbref0350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bagato
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kayed
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Moatasim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Webby
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         18
        </volume>
        <issue>
         36
        </issue>
        <year>
         2013
        </year>
        <comment>
         pii=20574
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0355">
       <element-citation id="sbref0355" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Gloza-Rausch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Ipsen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Seebens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vallo
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Adu-Sarkodie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kruppa
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         15
        </volume>
        <issue>
         9
        </issue>
        <year>
         2009
        </year>
        <fpage>
         1377
        </fpage>
        <lpage>
         1384
        </lpage>
        <pub-id pub-id-type="pmid">
         19788804
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0360">
       <element-citation id="sbref0360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           O.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ellis
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Suen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in bats
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         2001
        </fpage>
        <lpage>
         2009
        </lpage>
        <pub-id pub-id-type="pmid">
         15681402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0365">
       <element-citation id="sbref0365" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Puzelli
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Azzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Santini
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Di Martino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Facchini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Castrucci
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Meola
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Arvia
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Corcioli
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Pierucci
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baretti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bartoloni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bartolozzi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Martino
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Galli
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pompa
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rezza
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Balocchini
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Investigation of an imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         18
        </volume>
        <issue>
         34
        </issue>
        <year>
         2013
        </year>
        <comment>
         pii: 20564
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0370">
       <element-citation id="sbref0370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dai
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Si
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody responses to individual proteins of SARS coronavirus and their neutralization activities
        </article-title>
        <source>
         Microbes Infect./Institut Pasteur
        </source>
        <volume>
         7
        </volume>
        <issue>
         5–6
        </issue>
        <year>
         2005
        </year>
        <fpage>
         882
        </fpage>
        <lpage>
         889
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0375">
       <element-citation id="sbref0375" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quan
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Firth
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Street
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Henriquez
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Petrosov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tashmukhamedova
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hutchison
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Egholm
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Osinubi
          </surname>
          <given-names>
           M.O.
          </given-names>
         </name>
         <name>
          <surname>
           Niezgoda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ogunkoya
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rupprecht
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria
        </article-title>
        <source>
         mBio
        </source>
        <volume>
         1
        </volume>
        <issue>
         4
        </issue>
        <year>
         2010
        </year>
        <comment>
         pii: e00208-10
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0380">
       <element-citation id="sbref0380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           de Sousa
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Schuurman
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Specific serology for emerging human coronaviruses by protein microarray
        </article-title>
        <source>
         Euro surveillance: bulletin Europeen sur les maladies transmissibles
        </source>
        <trans-source xml:lang="en">
         European Communicable Disease Bulletin
        </trans-source>
        <volume>
         18
        </volume>
        <issue>
         14
        </issue>
        <year>
         2013
        </year>
        <fpage>
         20441
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0385">
       <element-citation id="sbref0385" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Vries
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           El Tahir
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
         <name>
          <surname>
           De Sousa
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           van Beek
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nowotny
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           van Maanen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hidalgo-Hermoso
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gortazar-Schmidt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <issue>
         10
        </issue>
        <year>
         2013
        </year>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0390">
       <element-citation id="sbref0390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oberste
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Monroe
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nix
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Campagnoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Icenogle
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Penaranda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bankamp
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Maher
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lowe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frace
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liffick
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Holloway
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Limor
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McCaustland
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen-Rasmussen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pallansch
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <issue>
         5624
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1394
        </fpage>
        <lpage>
         1399
        </lpage>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0395">
       <element-citation id="sbref0395" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schaecher
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pekosz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         718
        </fpage>
        <lpage>
         731
        </lpage>
        <pub-id pub-id-type="pmid">
         17079322
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0400">
       <element-citation id="sbref0400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kuang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         41
        </volume>
        <issue>
         12
        </issue>
        <year>
         2003
        </year>
        <fpage>
         5781
        </fpage>
        <lpage>
         5782
        </lpage>
        <pub-id pub-id-type="pmid">
         14662982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0405">
       <element-citation id="sbref0405" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza A (H5N1) in Hong Kong: an overview
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         20
        </volume>
        <issue>
         Suppl. 2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         S77L 81
        </fpage>
        <pub-id pub-id-type="pmid">
         12110265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0410">
       <element-citation id="sbref0410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Goh
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Leong
          </surname>
          <given-names>
           H.N.
          </given-names>
         </name>
         <name>
          <surname>
           Leo
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         362
        </fpage>
        <lpage>
         371
        </lpage>
        <pub-id pub-id-type="pmid">
         15013989
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0415">
       <element-citation id="sbref0415" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Eaton
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies to SARS coronavirus in civets
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         10
        </volume>
        <issue>
         12
        </issue>
        <year>
         2004
        </year>
        <fpage>
         2244
        </fpage>
        <lpage>
         2248
        </lpage>
        <pub-id pub-id-type="pmid">
         15663874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0420">
       <element-citation id="sbref0420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ouyang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients
        </article-title>
        <source>
         DNA Cell Biol.
        </source>
        <volume>
         24
        </volume>
        <issue>
         8
        </issue>
        <year>
         2005
        </year>
        <fpage>
         521
        </fpage>
        <lpage>
         527
        </lpage>
        <pub-id pub-id-type="pmid">
         16101351
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0425">
       <element-citation id="sbref0425" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.D.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           G.B.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.A.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Z.R.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot
        </article-title>
        <source>
         Clin. Immunol.
        </source>
        <volume>
         113
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="pmid">
         15451470
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0430">
       <element-citation id="sbref0430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watts
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         China culls wild animals to prevent new SARS threat
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         363
        </volume>
        <issue>
         9403
        </issue>
        <year>
         2004
        </year>
        <fpage>
         134
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0435">
       <element-citation id="sbref0435" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           WHO
          </surname>
         </name>
        </person-group>
        <series>
         WHO Guidelines for the Global Surveillance of Severe Acute Respiratory Syndrome (SARS)
        </series>
        <volume>
         vol. 2013
        </volume>
        <year>
         2004
        </year>
       </element-citation>
      </ref>
      <ref id="bib0440">
       <element-citation id="sbref0440" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           WHO
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – update
        </chapter-title>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bib0445">
       <element-citation id="sbref0445" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         363
        </volume>
        <issue>
         9412
        </issue>
        <year>
         2004
        </year>
        <fpage>
         841
        </fpage>
        <lpage>
         845
        </lpage>
        <pub-id pub-id-type="pmid">
         15031027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0450">
       <element-citation id="sbref0450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         665
        </fpage>
        <lpage>
         668
        </lpage>
        <pub-id pub-id-type="pmid">
         15242938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0455">
       <element-citation id="sbref0455" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           W.T.
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Couch
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         42
        </volume>
        <issue>
         12
        </issue>
        <year>
         2004
        </year>
        <fpage>
         5885
        </fpage>
        <lpage>
         5888
        </lpage>
        <pub-id pub-id-type="pmid">
         15583332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0460">
       <element-citation id="sbref0460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         43
        </volume>
        <issue>
         7
        </issue>
        <year>
         2005
        </year>
        <fpage>
         3054
        </fpage>
        <lpage>
         3058
        </lpage>
        <pub-id pub-id-type="pmid">
         16000415
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0465">
       <element-citation id="sbref0465" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           W.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ferng
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         10
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         310
        </lpage>
        <pub-id pub-id-type="pmid">
         15030702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0470">
       <element-citation id="sbref0470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         41
        </volume>
        <issue>
         10
        </issue>
        <year>
         2003
        </year>
        <fpage>
         4521
        </fpage>
        <lpage>
         4524
        </lpage>
        <pub-id pub-id-type="pmid">
         14532176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0475">
       <element-citation id="sbref0475" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         New Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0480">
       <element-citation id="sbref0480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon Xie
          </surname>
          <given-names>
           Z.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <issue>
         9393
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1353
        </fpage>
        <lpage>
         1358
        </lpage>
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0005">
      <title>
       Acknowledgments
      </title>
      <p>
       The work was funded by a FP7-European research project on emerging diseases detection and response,
       <funding-source id="gs0005">
        EMPERIE
       </funding-source>
       ,
       <ext-link ext-link-type="uri" id="intr0005" xlink:href="http://www.emperie.eu/emp/">
        http://www.emperie.eu/emp/
       </ext-link>
       , contract number 223498 and
       <funding-source id="gs0010">
        ANTIGONE
       </funding-source>
       (contract number 278976). Author C.D. received infrastructural support as the German National Consulting Laboratory for Coronavirus. The Consulting Laboratory is appointed by the Robert Koch-Institut (RKI), Berlin, Germany.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-title-group>
       <journal-title>
        Biosafety and Health
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2590-0536
      </issn>
      <issn pub-type="epub">
       2590-0536
      </issn>
      <publisher>
       <publisher-name>
        Chinese Medical Association Publishing House. Published by Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7148641
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2590-0536(19)30050-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.bsheal.2019.12.006
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Wenling
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="fn" rid="fn0005">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Tianyu
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="fn" rid="fn0005">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Deng
         </surname>
         <given-names>
          Yao
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Niu
         </surname>
         <given-names>
          Peihua
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0025">
        <name>
         <surname>
          A
         </surname>
         <given-names>
          Ruhan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0030">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Jincun
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0035">
        <name>
         <surname>
          Peiris
         </surname>
         <given-names>
          Malik
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0040">
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          Shixing
         </given-names>
        </name>
        <email>
         tamgshixing@smu.edu.cn
        </email>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0045">
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          Wenjie
         </given-names>
        </name>
        <email>
         tanwj@ivdc.chinacdc.cn
        </email>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="aff" rid="af0025">
         e
        </xref>
        <xref ref-type="corresp" rid="cr0010">
         ⁎⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       <label>
        a
       </label>
       MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China
      </aff>
      <aff id="af0010">
       <label>
        b
       </label>
       Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou 510515, China
      </aff>
      <aff id="af0015">
       <label>
        c
       </label>
       State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, The first Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China
      </aff>
      <aff id="af0020">
       <label>
        d
       </label>
       School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
      </aff>
      <aff id="af0025">
       <label>
        e
       </label>
       Center for Biosafety Mega-science, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author: Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.
        <email>
         tamgshixing@smu.edu.cn
        </email>
       </corresp>
       <corresp id="cr0010">
        <label>
         ⁎⁎
        </label>
        Corresponding author: MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China; Center for Biosafety Mega-science, Chinese Academy of Sciences, Beijing 100101, China.
        <email>
         tanwj@ivdc.chinacdc.cn
        </email>
       </corresp>
       <fn id="fn0005">
        <label>
         1
        </label>
        <p id="np0020">
         Wenling Wang and Tianyu Wang contributed equally to this study.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        20
       </day>
       <month>
        12
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        12
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        20
       </day>
       <month>
        12
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       1
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       134
      </fpage>
      <lpage>
       143
      </lpage>
      <history>
       <date date-type="received">
        <day>
         15
        </day>
        <month>
         8
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         16
        </day>
        <month>
         12
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         16
        </day>
        <month>
         12
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 Chinese Medical Association Publishing House. Published by Elsevier B.V.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <p>
        The Middle East respiratory syndrome (MERS) is a lethal zoonosis caused by MERS coronavirus (MERS-CoV) and poses a significant threat to public health worldwide. Therefore, a rapid, sensitive, and specific serologic test for detecting anti-MERS-CoV antibodies in both humans and animals is urgently needed for the successful management of this illness. Here, we evaluated various novel luciferase immunosorbent assays (LISA) based on nucleocapsid protein (NP) as well as fragments derived from spike protein (S) including subunit 1 (S1), N terminal domain (NTD), receptor-binding domain (RBD) and subunit 2 (S2) of S for the detection of MERS-CoV-specific IgG. Fusion proteins, including nanoluciferase (NLuc) and various fragments derived from the NP or S protein of MERS-CoV, were expressed in human embryonic kidney 293 T cells. LISAs that detected anti-MERS-CoV IgG were further developed using cell lysates expressing various fusion proteins. Panels of human or animal samples infected with MERS-CoV were used to analyze the sensitivity and specificity of various LISAs in reference to a MERS-CoV RT-PCR, commercial S1-based ELISA, and pseudovirus particle neutralization test (ppNT). Our results showed that the S1-, RBD-, and NP-LISAs were more sensitive than the NTD- and S2-LISAs for the detection of anti-MERS-CoV IgG. Furthermore, the S1-, RBD-, and NP-LISAs were more sensitive (by at least 16-fold) than the commercially available S1-ELISA. Moreover, the S1-, RBD-, and NP-LISA specifically recognized anti-MERS-CoV IgG and did not cross-react with samples derived from other human CoV (OC43, 229E, HKU1, NL63)-infected patients. More importantly, these LISAs proved their applicability and reliability for detecting anti-MERS-CoV IgG in samples from camels, monkeys, and mice, among which the RBD-LISA exhibited excellent performance. The results of this study suggest that the novel MERS-CoV RBD- and S1- LISAs are highly effective platforms for the rapid and sensitive detection of anti-MERS-CoV IgG in human and animal samples. These assays have the potential to be used as serologic tests for the management and control of MERS-CoV infection.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="ab0105">
       <title>
        Highlights
       </title>
       <p>
        <list id="l0105" list-type="simple">
         <list-item id="li0105">
          <label>
           •
          </label>
          <p id="p1010">
           <bold>
            Scientific question
           </bold>
          </p>
          <p id="p1015">
           This study evaluated novel luciferase immunosorbent assays (LISAs) based on nucleocapsid protein (NP) as well as fragments derived from spike protein (S) for detection of MERS-CoV-specific IgG in humans and animals.
          </p>
         </list-item>
         <list-item id="li0110">
          <label>
           •
          </label>
          <p id="p1020">
           <bold>
            Evidence before this study
           </bold>
          </p>
          <p id="p1025">
           Enzyme-linked immunosorbent assay (ELISA), microneutralization (MN), immunofluorescence assay (IFA), and pseudovirus particle neutralization test (ppNT) have been performed to detect serum antibodies against MERS-CoV. There remains a need to develop novel serological assays independent of protein purification, special secondary antibody, virus cultivation and Biosafety Level 3 (BSL-3) laboratory.
          </p>
         </list-item>
         <list-item id="li0115">
          <label>
           •
          </label>
          <p id="p1030">
           <bold>
            New findings
           </bold>
          </p>
          <p id="p1035">
           In this study, novel LISAs based on the MERS-CoV S fragments and NP were developed. Human and animal samples infected with MERS-CoV were measured by the newly developed LISAs as well as reference methods including commercial S1-ELISA and ppNT. The results showed that the S1-, RBD-, and NP-LISAs were able to specifically distinguish MERS-CoV-infected samples from samples infected by other HCoV as consistent as the reference methods. Comparing with the commercially available S1-ELISA, the S1- and RBD-LISAs were 64-folds more sensitive. Moreover, the applicability and reliability of the LISAs were verified by detecting anti-MERS-CoV IgG in samples from camels, monkeys, and mice. The RBD-LISA exhibited superior sensitivity and specificity.
          </p>
         </list-item>
         <list-item id="li0120">
          <label>
           •
          </label>
          <p id="p1040">
           <bold>
            Significance of the study
           </bold>
          </p>
          <p id="p1045">
           The novel MERS-CoV RBD- and S1-LISAs were developed independent of protein purification and special secondary antibody, and showed super specificity and efficiency for the detection of anti-MERS-CoV IgG in human and animal samples. These assays are recommended for serological diagnosis of MERS-CoV infection in the investigation of epidemic characteristic, origin tracing and vaccine study of MERS-CoV, they would contribute to the scientific control and prevention of MERS.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="ks0005">
       <title>
        Keywords
       </title>
       <kwd>
        Luciferase immunosorbent assay (LISA)
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        Serological IgG detection
       </kwd>
       <kwd>
        Samples of humans and animals
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s8005">
     <title>
      HIGHLIGHTS
     </title>
     <p id="p8005">
      <boxed-text id="b0005">
       <sec id="s1005">
        <title>
         HIGHLIGHTS
        </title>
        <p id="p0010">
         <bold>
          Scientific question
         </bold>
        </p>
        <p id="p0015">
         This study evaluated novel luciferase immunosorbent assays (LISAs) based on nucleocapsid protein (NP) as well as fragments derived from spike protein (S) for detection of MERS-CoV-specific IgG in humans and animals.
        </p>
        <p id="p0020">
         <bold>
          Evidence before this study
         </bold>
        </p>
        <p id="p0025">
         Enzyme-linked immunosorbent assay (ELISA), microneutralization (MN), immunofluorescence assay (IFA), and pseudovirus particle neutralization test (ppNT) have been performed to detect serum antibodies against MERS-CoV. There remains a need to develop novel serological assays independent of protein purification, special secondary antibody, virus cultivation and Biosafety Level 3 (BSL-3) laboratory.
        </p>
        <p id="p0030">
         <bold>
          New findings
         </bold>
        </p>
        <p id="p0035">
         In this study, novel LISAs based on the MERS-CoV S fragments and NP were developed. Human and animal samples infected with MERS-CoV were measured by the newly developed LISAs as well as reference methods including commercial S1-ELISA and ppNT. The results showed that the S1-, RBD-, and NP-LISAs were able to specifically distinguish MERS-CoV-infected samples from samples infected by other HCoV as consistent as the reference methods. Comparing with the commercially available S1-ELISA, the S1- and RBD-LISAs were 64-folds more sensitive. Moreover, the applicability and reliability of the LISAs were verified by detecting anti-MERS-CoV IgG in samples from camels, monkeys, and mice. The RBD-LISA exhibited superior sensitivity and specificity.
        </p>
        <p id="p0040">
         <bold>
          Significance of the study
         </bold>
        </p>
        <p id="p0045">
         The novel MERS-CoV RBD- and S1-LISAs were developed independent of protein purification and special secondary antibody, and showed super specificity and efficiency for the detection of anti-MERS-CoV IgG in human and animal samples. These assays are recommended for serological diagnosis of MERS-CoV infection in the investigation of epidemic characteristic, origin tracing and vaccine study of MERS-CoV, they would contribute to the scientific control and prevention of MERS.
        </p>
       </sec>
       <notes id="al1005" notes-type="alt-text" specific-use="for-accessibility">
        <p>
         Alt-text: Unlabelled Box
        </p>
       </notes>
      </boxed-text>
     </p>
    </sec>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0005">
      The Middle East respiratory syndrome (MERS) is a lethal zoonosis caused by MERS coronavirus (CoV) [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0010">
       2
      </xref>
      ]. MERS-CoV infection in humans causes asymptomatic or mild respiratory illness, severe pneumonia, multi-organ failure, and even death [
      <xref ref-type="bibr" rid="bb0015">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0020">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0025">
       [5]
      </xref>
      ]. According to the World Health Organization (WHO), as of May 9, 2019, there were 2,419 laboratory-confirmed cases of MERS and 836 deaths (35% of case-fatality rate) reported from 27 countries (
      <ext-link ext-link-type="uri" id="ir0005" xlink:href="https://www.who.int/csr/don/09-may-2019-mers-saudi-arabia/en/">
       https://www.who.int/csr/don/09-may-2019-mers-saudi-arabia/en/
      </ext-link>
      ). The majority of MERS cases occurred in the Middle East, especially in Saudi Arabia [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0015">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0030">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0035">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0040">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0045">
       [9]
      </xref>
      ]. The largest epidemic of MERS outside of the Arabian Peninsula occurred in South Korea in May 2015, and the index case was a traveler who visited the Middle East [
      <xref ref-type="bibr" rid="bb0050">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0055">
       11
      </xref>
      ]. To date, all confirmed MERS cases have been linked to the Middle East. Human-to-human transmission of MERS-CoV has been well documented in family, community, and healthcare settings [
      <xref ref-type="bibr" rid="bb0025">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0060">
       [12]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0065">
       [13]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0070">
       [14]
      </xref>
      ]. MERS-CoV poses a significant threat to public health worldwide because of the high fatality rate of MERS infection and potential outbreaks of MERS-CoV infection in healthcare facilities. Furthermore, there are no specific vaccines or therapeutics for the prevention or treatment of MERS-CoV infection [
      <xref ref-type="bibr" rid="bb0075">
       [15]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0080">
       [16]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0085">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0090">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0095">
       [19]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0100">
       [20]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0105">
       [21]
      </xref>
      ].
     </p>
     <p id="p8010">
      Dromedary camels have been implicated as a zoonotic source of human infections [
      <xref ref-type="bibr" rid="bb0015">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0020">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0080">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0110">
       [22]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0115">
       [23]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0120">
       [24]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0125">
       [25]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0130">
       [26]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0135">
       [27]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0140">
       [28]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0145">
       [29]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0150">
       [30]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0155">
       [31]
      </xref>
      ], and MERS-CoV RNA and viable virus have been isolated from them [
      <xref ref-type="bibr" rid="bb0035">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0110">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0160">
       32
      </xref>
      ]. The seroprevalence of MERS-CoV antibodies is very high in dromedary camels within Eastern Africa and the Arabian Peninsula [
      <xref ref-type="bibr" rid="bb0110">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0120">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0125">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0145">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0165">
       [33]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0170">
       [34]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0175">
       [35]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0180">
       [36]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0185">
       [37]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0190">
       [38]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0195">
       [39]
      </xref>
      ]. The continuing MERS epidemic in the Middle East is believed to be related to the failure to control the zoonotic sources, particularly dromedary camels, resulting in ongoing camel-to-human transmission [
      <xref ref-type="bibr" rid="bb0010">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0130">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0200">
       [40]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0205">
       [41]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0210">
       [42]
      </xref>
      ]. Moreover, MERS-like CoVs have been detected in bat species globally, and thus, are thought to be the reservoirs of MERS-CoV [
      <xref ref-type="bibr" rid="bb0035">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0205">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0215">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0220">
       44
      </xref>
      ]. However, the exact source of many primary MERS cases remains unknown, and the transmission mechanisms are poorly understood.
     </p>
     <p id="p8015">
      The MERS-CoV genome encodes 16 non-structural proteins (nsp1–16) and four structural proteins, including the spike (S), small envelope (E), membrane (M), and nucleocapsid (N) proteins. The viral structural proteins, S and N, have the highest immunogenicity [
      <xref ref-type="bibr" rid="bb0225">
       45
      </xref>
      ]. The S protein undergoes protease cleavage into S1 and S2 subunits. The S1 and S2 subunits mediate coronavirus entry into host cells by binding to the receptor on the host-cell surface via the receptor-binding domain (RBD) of the S1 subunit [
      <xref ref-type="bibr" rid="bb0160">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0230">
       [46]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0235">
       [47]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0240">
       [48]
      </xref>
      ]. Both the S and N proteins are the major immunodominant regions of MERS-CoV, and are often applied as target antigens for detection of a humoral immune response after infection.
     </p>
     <p id="p8020">
      Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) is a common method for the diagnosis of MERS-CoV infection [
      <xref ref-type="bibr" rid="bb0030">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0245">
       49
      </xref>
      ]. However, it is not suitable for the detection of infection in some clinical units and large-scale epidemiological screening. Specific antibodies play important roles in determining the severity of human infection, and detection of these specific antibodies is used in the epidemiological investigation of MERS-CoV infection in animals and humans. Several methods can be used to detect serum antibodies against MERS-CoV, such as enzyme-linked immunosorbent assay (ELISA), microneutralization (MN), immunofluorescence assay (IFA), the plaque reduction neutralization test (PRNT), and the pseudovirus particle neutralization test (ppNT). Among these assays, MN, IFA, and PRNT depend on virus cultivation, and thus, require equipment and facilities located within a Biosafety Level 3 (BSL-3) laboratory [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0015">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0060">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0090">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0175">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0195">
       39
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0250">
       [50]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0255">
       [51]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0260">
       [52]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0265">
       [53]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0270">
       [54]
      </xref>
      ]. While there are commercial anti-MERS-CoV serologic test kits for humans and animals including ELISA and IFA, rapid and sensitive serological assays for the detection of anti-MERS-CoV IgG independent of purified protein, specific secondary antibody, virus cultivation and BSL-3 facilities are still urgently needed.
     </p>
     <p id="p8025">
      An ultrasensitive and high-throughput luciferase immunosorbent assay (LISA) based on recombinant antigens fused with NanoLuc luciferase (NLuc) has been reported to detect IgG against several pathogens [
      <xref ref-type="bibr" rid="bb0275">
       [55]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0280">
       [56]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0285">
       [57]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0290">
       [58]
      </xref>
      ]. This assay has the advantage of not requiring a BSL-3 laboratory facility and species-specific labeled secondary antibodies for detection. In this study, we developed various novel LISA platforms based on the MERS-CoV NP or fragments of S. The diagnostic performance of various MERS-CoV LISA were evaluated using serum panels from MERS-CoV-infected humans and animals, as well as sera from patients infected with other human CoV.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Materials and methods
     </title>
     <sec id="s0015">
      <label>
       2.1
      </label>
      <title>
       Samples and ethics
      </title>
      <p id="p8030">
       Several panels for anti-MERS-CoV IgG detection were collected and stored at −70 °C before testing. The detailed information is described in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       ,
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       . In brief, these panels included the following. 1) Normal serum samples from 40 healthy blood donors without MERS-CoV infection, which were stored in our laboratory. 2) Convalescent sera from five MERS-CoV infected patients. Sera from five MERS-CoV patients with high antibody titers and sera from five MERS-CoV patients with medium titers were mixed to prepare two pooled convalescent serum samples. Control sera from seven non-MERS-CoV patients were from individuals with antibodies to common human CoV (HCoV), namely, HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, all of which were supplied by the WHO [
       <xref ref-type="bibr" rid="bb0295">
        59
       </xref>
       ]. 3) Serum samples from confirmed MERS-CoV-infected camels from Saudi Arabia, were supplied by the University of Hong Kong. Serum samples from MERS-CoV-infected monkeys and mice were stored in our laboratory. Besides all the samples listed in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       ,
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       , one convalescent serum sample from the first imported MERS-CoV-infected patient in China was also detected in the study to characterize the LISAs. The present studies were approved by the Institutional Review Board of the National Institute for Viral Disease Control and Prevention, China CDC, and by the Ethics Committee of Southern Medical University (SMU No. 20160428).
       <table-wrap id="t0005" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Comparison of LISAs with ppNT and S1-ELISA.
          <xref ref-type="table-fn" rid="tf0005">
           a
          </xref>
         </p>
        </caption>
        <alt-text id="al0035">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Name
           </th>
           <th rowspan="2">
            Description
           </th>
           <th rowspan="2">
            Number
           </th>
           <th rowspan="2">
            Expected result
           </th>
           <th rowspan="2">
            ppNT
           </th>
           <th rowspan="2">
            ELISA
           </th>
           <th colspan="3">
            LISA
            <hr/>
           </th>
          </tr>
          <tr>
           <th>
            S1
           </th>
           <th>
            RBD
           </th>
           <th>
            NP
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Convalescent sera
           </td>
           <td>
            Individual serum from laboratory confirmed MERS patients
           </td>
           <td>
            5
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            Pooled convalescent sera
           </td>
           <td>
            Pooled serum samples from laboratory confirmed MERS patients
           </td>
           <td>
            2
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            Non-MERS-CoV sera
           </td>
           <td>
            Control sera from patients infected by common human coronaviruses
            <break>
            </break>
            (OC43, NL63, 229E, HKU1)
           </td>
           <td>
            7
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            Normal sera (negative) control
           </td>
           <td>
            Serum samples from 40 healthy blood donors
           </td>
           <td>
            40
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tf0005">
          <label>
           a
          </label>
          <p id="np0005">
           +, positive; −, negative.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
       <table-wrap id="t0010" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Summary of the detection results in animal samples.
         </p>
        </caption>
        <alt-text id="al0040">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Sample
            <xref ref-type="table-fn" rid="tf0010">
             a
            </xref>
           </th>
           <th>
            RT-PCR
            <xref ref-type="table-fn" rid="tf0015">
             b
            </xref>
           </th>
           <th>
            ppNT
           </th>
           <th>
            S1-LISA
           </th>
           <th>
            RBD-LISA
           </th>
           <th>
            NP-LISA
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            C1
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C2
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C3
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C4
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C5
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C6
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C7
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C8
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C9
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C10
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C11
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C12
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C13
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C14
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C15
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C16
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C17
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C18
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C19
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            C20
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
           <td>
            +
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            C21-C38
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            R1
           </td>
           <td>
            ND
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
           <td>
            −
           </td>
          </tr>
          <tr>
           <td>
            R2
           </td>
           <td>
            ND
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            R3
           </td>
           <td>
            ND
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            M1
           </td>
           <td>
            ND
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
          <tr>
           <td>
            M2
           </td>
           <td>
            ND
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
           <td>
            +
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tf0010">
          <label>
           a
          </label>
          <p id="np0010">
           C, camel serum; C21-C38, normal camel serum controls; R1, marmoset serum, infected 3 days; R2, rhesus serum, infected 14 days; R3, rhesus serum, infected 21 days; M, MERS-CoV-infected mice.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tf0015">
          <label>
           b
          </label>
          <p id="np0015">
           Detection of nucleic acid extracted from swab samples; ND, not determined; +, positive; −, negative.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="s0020">
      <label>
       2.2
      </label>
      <title>
       Construction and characterization of recombinant proteins comprised of various fragments of MERS-CoV proteins fused with luciferase
      </title>
      <p id="p8035">
       As shown in
       <xref ref-type="fig" rid="f0005">
        Figure 1
       </xref>
       A, MERS-CoV NP (1–414 aa) and fragments of MERS-CoV S [S1 (1–734aa), N-terminal domain (NTD) (18–353 aa), RBD (367–606 aa), and S2 (788–1353 aa)] were amplified by RT-PCR. All of these gene fragments were cloned into the luciferase expression vector pNLF-1-N (Promega, Madison, WI, USA). All recombinant plasmids were confirmed by DNA sequencing. Human embryonic kidney (HEK) 293 T cells were seeded in a cell culture plate and cultured until the confluence reached &gt;85%. Then recombinant plasmids were transfected into HEK 293 T cells using jetPRIME® transfection reagent (Polyplus, Illkirch, France) according to the manufacturer's instructions. After 48 h, cells were lysed on ice for 30 min in lysate buffer, and the supernatants were harvested after centrifugation at 12,000 × rpm for 5 min at 4 °C. The expression of NP or S fragments in the fusion proteins was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting (WB). Nluc activities in the supernatants were detected after reacting with the luciferase substrate mix (Promega). Relative fluorescence intensity (RFI) values were immediately determined using the Gaomax luminometer (Promega).
       <fig id="f0005">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Design diagrams of NLuc-fusion proteins and their expression in mammalian HEK 293 T cells. (A) Design diagram of five NLuc-antigen fusion proteins. The NLuc we used can be secreted. We list the marked “linker” as linker sequence (GSSG). (B) Expressions of the recombinant NLuc-S1, NLuc-NTD, NLuc-RBD, NLuc-S2, and NLuc-NP proteins were identified by a specific monoclonal antibody via WB.
         </p>
        </caption>
        <alt-text id="al0005">
         Figure 1
        </alt-text>
        <graphic xlink:href="gr1">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0025">
      <label>
       2.3
      </label>
      <title>
       Development of the LISAs based on MERS-CoV NP and fragments of S
      </title>
      <p id="p8040">
       Briefly, 96-well Costar flat-bottomed luminometry plates were coated with protein G (5 μg/mL, 100 μL/well) in carbonate buffer (pH 9.6) overnight at 4 °C. After three washes with phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBS-T), the plates were incubated with blocking solution (PBS containing 5% non-fat milk) for 1 h at 37 °C. Then the wells were washed, and aliquots of serially diluted sera (100 μL) were added to the wells and incubated for 1 h at 37 °C. The plates were washed and incubated with diluted Nluc-fusion proteins (50 μL) for 30 min at 37 °C. Then the plates were washed again, and luciferase substrate (50 μL) (Promega) was added to each well. RFI values were determined using a Gaomax luminometer (Promega). Each sample was tested in duplicate. The cut-off values were determined as two-fold the average of the normal controls. Negative controls were an equal volume mixture of sera from healthy blood donors. Results were expressed as the mean RFI from duplicate wells, and values were corrected by subtracting the RFI value of the background wells incubated with HEK 293 T cell extracts in the absence of sera.
      </p>
     </sec>
     <sec id="s0030">
      <label>
       2.4
      </label>
      <title>
       qRT-PCR screening assay
      </title>
      <p id="p8045">
       Detection of MERs-CoV-specific nucleic acid in the samples was performed using qRT-PCR targeting genes upstream of the envelope (upE) and NP (N) as previously reported [
       <xref ref-type="bibr" rid="bb0300">
        [60]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0305">
        [61]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0310">
        [62]
       </xref>
       ].
      </p>
     </sec>
     <sec id="s0035">
      <label>
       2.5
      </label>
      <title>
       Euroimmun S1-based ELISA for MERS-CoV
      </title>
      <p id="p0050">
       A commercially available anti-MERS-CoV ELISA IgG kit was based on the purified MERS-CoV spike protein S1 domain (S1-based ELISA, Euroimmun, Lübeck, Germany). The samples were serially diluted and tested according to the manufacturer's recommendations [
       <xref ref-type="bibr" rid="bb0315">
        63
       </xref>
       ]. Euroimmun recommends interpreting results in a semiquantitative way as follows: a ratio of the extinction of the control or patient sample over the extinction of the calibrator &lt;0.8, 0.8–1.1, and ≥1.1 were defined as negative, borderline, and positive, respectively.
      </p>
     </sec>
     <sec id="s0040">
      <label>
       2.6
      </label>
      <title>
       MERS-CoV S-based ppNT
      </title>
      <p id="p0055">
       A MERS-CoV S-based ppNT was used to detect the neutralization activities of serum samples as previously reported [
       <xref ref-type="bibr" rid="bb0315">
        63
       </xref>
       ]. The detection results were expressed as RLI. Serum neutralizing antibody activity was evaluated as the pseudovirus inhibition rate: Inhibition rate (%) = (RLI
       <sub>
        normal
       </sub>
       control − RLI
       <sub>
        samples
       </sub>
       )/RLI
       <sub>
        normal control
       </sub>
       ] × 100. An inhibition rate ≥ 50% was characterized as positive neutralization activity.
      </p>
     </sec>
     <sec id="s0045">
      <label>
       2.7
      </label>
      <title>
       Statistical analysis
      </title>
      <p id="p0060">
       All data were analyzed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) and SPSS (IBM, New York, NY, USA). Pearson's correlation coefficients among different assays were calculated, and statistical significance was defined as a
       <italic>
        p
       </italic>
       value &lt; 0.05.
      </p>
     </sec>
    </sec>
    <sec id="s0050">
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec id="s0055">
      <label>
       3.1
      </label>
      <title>
       Expression of recombinant MERS-CoV NP and fragmented S proteins fused with luciferase
      </title>
      <p id="p0065">
       To establish a novel detection method for MERS-CoV IgG, five recombinant plasmids based on NLuc were constructed, which separately contained the full-length of MERS-CoV NP or S1, NTD, RBD, and S2 of S, (
       <xref ref-type="fig" rid="f0005">
        Figure 1
       </xref>
       A). These plasmids were confirmed by restriction endonuclease digestion, gel electrophoresis and DNA sequencing. The recombinant plasmids were used to transfect HEK 293 T cells, and expression of the target proteins in the supernatants of the cell lysates were determined by WB using murine polyclonal antibodies against MERS-CoV (
       <xref ref-type="fig" rid="f0005">
        Figure 1
       </xref>
       B). These results confirmed the construction of the recombinant plasmids and expression of the target fusion proteins.
      </p>
     </sec>
     <sec id="s0060">
      <label>
       3.2
      </label>
      <title>
       The optimal antigen or antigenic domains needed for anti-MERS-CoV IgG detection
      </title>
      <p id="p0070">
       MERS-CoV NP and S1, NTD, RBD, and S2 of the S protein (
       <xref ref-type="fig" rid="f0005">
        Figure 1
       </xref>
       ) were used to develop the LISA by characterizing the binding domains needed for anti-MERS-CoV IgG. In order to avoid the difference in transfection efficiency and protein expression from different preparations, we measured the luciferase activity of crude cell lysates to determine the RFI, which was usually between 10
       <sup>
        8
       </sup>
       and 10
       <sup>
        11
       </sup>
       . For individual antigens, cell lysates with a minimum of 10
       <sup>
        7
       </sup>
       RFI were added to each reaction in the LISA. In addition, we included positive and negative controls in each reaction plate to ensure that the results were consistent and reproducible. Normal (negative) controls of serum samples from 40 healthy blood donors were diluted by 1:100 and used to determine the background values and calculate the cut-off levels of anti MERS-CoV IgG detection by LISA. The cut-off values were determined to be 2-fold of the average RFI value of normal adult controls, i.e., 21,388, 17,344, 15,748, 18,398 and 15,259 for S1-, RBD-, NP-, NTD-, and S2-LISAs for MERS-CoV IgG, respectively. The serum sample from the first imported
       <xref ref-type="fig" rid="f0010">
        Figure 2
       </xref>
       MERS-CoV-infected patient in China was serially diluted and detected. The S1- and RBD-LISAs confirmed the positivity of the sample at a dilution as low as 1:1600, which was slightly better than the NP-LISA. However, the NTD-LISA was unable to distinguish the positive sample from the normal control at the dilution of 1:400, and S2-LISA was not able to detect the difference at a dilution of 1:100 (
       <xref ref-type="fig" rid="f0010">
        Figure 2
       </xref>
       ). This indicated that the S1-, RBD-, and NP-LISAs were superior to the NTD- and S2-LISAs for detecting MRES-CoV IgG from human samples.
       <fig id="f0010">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Sensitivities of the LISAs based on different NLuc-antigens. Serum samples from the first imported MERS patient in China collected 28 days after admission to the hospital (positive; Pos) were serially diluted and detected. One sample from a healthy blood donor was used as negative control (negative; Neg). Cut-off values were determined from serum samples from 40 healthy blood donors. RFI, relative fluorescence intensity.
         </p>
        </caption>
        <alt-text id="al0010">
         Figure 2
        </alt-text>
        <graphic xlink:href="gr2">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0065">
      <label>
       3.3
      </label>
      <title>
       Comparison of the characteristics of MERS-CoV LISAs and the commercial S1-ELISA and ppNT for the detection of anti-MERS-CoV IgG
      </title>
      <p id="p0075">
       To further confirm the efficiency of S1-, RBD-, and NP-LISAs, a panel of samples supplied by the WHO (
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       ) were used to compare the efficacy of various LISAs in detecting anti-MERS-CoV IgG, together with the commercially available Euroimmune S1-ELISA and ppNT kits as controls. The results are summarized in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       and illustrated in
       <xref ref-type="fig" rid="f0015">
        Figure 3
       </xref>
       . The NP-, S1-, and RBD-LISAs showed high consistency with S1-ELISA and ppNT. All of these methods were able to specifically distinguish MERS-CoV-infected samples from other HCoV-infected samples (
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       and
       <xref ref-type="fig" rid="f0015">
        Figure 3
       </xref>
       ). Subsequently, correlations of S1-, RBD-, and NP-based LISAs with that based on the S1-ELISA were analyzed (
       <xref ref-type="fig" rid="f0020">
        Figure 4
       </xref>
       ). The scatter plots showed excellent correlations between the S1-ELISA and the S1-, RBD-, NP-LISAs, with Pearson's correlation coefficients of 0.8096, 0.8218, and 0.8731, respectively. To further evaluate the sensitivity of the S1-ELISA and S1-, RBD-, NP-LISAs, several serum samples supplied by the WHO were diluted serially and detected by each of these assays (
       <xref ref-type="fig" rid="f0025">
        Figure 5
       </xref>
       ). The RBD-LISA confirmed the positivity of all samples and S1-LISA confirmed two of four (the volume of the fifth serum was not enough for the detection) at a dilution as low as 1:25,600. RBD-LISA, and S1-LISA were highly superior to that of NP, which detected all samples as positive at a dilution of 1:1600. However, all four positive samples were not detected by the S1-ELISA, even at a 1:400 dilution, indicating that the lower limits of detection of the MERS-CoV LISAs were 16–64-fold higher than those of the S1-ELISA. Moreover, a receiver operating characteristic (ROC) analysis was conducted to determine the sensitivity and specificity of the S1-ELISA, S1-, RBD-, and NP-LISAs (
       <xref ref-type="fig" rid="f0030">
        Figure 6
       </xref>
       ). When the serum was diluted to 1:100, the area under the curve (AUC) was calculated to be 1.0 for all four assays, and both the percentage of sensitivity and specificity for each assay was estimated to be 100% at the given cut-off values. When the serum was diluted to 1:400, 1:1600, and even 1:6400, the AUC for the S1-LISA and RBD-LISA was calculated to be 1.0, while the AUC for the NP-LISA and S1-ELISA declined slightly to 0.98 and 0.88, respectively. Additionally, the percentage of sensitivity and specificity for the S1-LISA and RBD-LISA was maintained at 100% at the given cut-off values; however, the sensitivity for NP-LISA and S1-ELISA declined to about 80% and 70%, respectively, even though the specificity was still 100%. These results indicated that the S1- and RBD-LISAs were superior to the NP-LISA and S1-ELISA in sensitivity and specificity for detecting anti-MERS-CoV antibodies in human serum samples.
       <fig id="f0015">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          Specificity and cross-reactivity of a LISA and commercial S1-ELISA were tested with a panel of sera. The panel included single and pooled convalescent sera from confirmed MERS patients and negative control serum. The details of the sample descriptions are shown in
          <xref ref-type="table" rid="t0005">
           Table 1
          </xref>
          .
         </p>
        </caption>
        <alt-text id="al0015">
         Figure 3
        </alt-text>
        <graphic xlink:href="gr3">
        </graphic>
       </fig>
       <fig id="f0020">
        <label>
         Figure 4
        </label>
        <caption>
         <p>
          Correlation of the MERS-CoV LISAs (RFI) with the S1-ELISA (ratio) for detecting IgG antibody. Ratio of the S1-ELISA results was plotted against the RFI of the S1-LISA, RBD-LISA, and NP-LISA. The samples used in the plots included five convalescent serum samples from a MERS-CoV-infected patient with multiple dilutions and three sera from normal (negative) controls listed in
          <xref ref-type="table" rid="t0005">
           Table 1
          </xref>
          .
         </p>
        </caption>
        <alt-text id="al0020">
         Figure 4
        </alt-text>
        <graphic xlink:href="gr4">
        </graphic>
       </fig>
       <fig id="f0025">
        <label>
         Figure 5
        </label>
        <caption>
         <p>
          Analysis of the sensitivity of MERS-CoV S1-ELISA and LISAs. Five samples (four convalescent sera from MERS-CoV-infected patients and one normal serum used as negative control, the volume of the fifth convalescent serum was not enough for detection) were serially diluted and dispensed into the wells of the same plate. Each sample was tested in duplicate. Data are representatively from at least two independent experiments.
         </p>
        </caption>
        <alt-text id="al0025">
         Figure 5
        </alt-text>
        <graphic xlink:href="gr5">
        </graphic>
       </fig>
       <fig id="f0030">
        <label>
         Figure 6
        </label>
        <caption>
         <p>
          ROC analysis. AUC values for the WHO antibody panel were determined using a 1:100 dilution (left) or 1:100, 1:400, and 1:1600 to 1:6400 dilution (right) using commercial Euroimmun S1-ELISA (A), in-house S1-LISA (B), RBD-LISA (C), and NP-LISA (D).
         </p>
        </caption>
        <alt-text id="al0030">
         Figure 6
        </alt-text>
        <graphic xlink:href="gr6">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0070">
      <label>
       3.4
      </label>
      <title>
       Application of LISA in detecting anti-MERS-CoV IgG from animal samples
      </title>
      <p id="p0080">
       To further evaluate the efficiency of MERS-CoV-LISA, serum samples from uninfected camels (controls), MERS-CoV-infected camels (confirmed to be positive by RT-PCR), monkeys, and mice were detected using the above-mentioned LISAs, with ppNT as the control. The results are shown in
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       . All 18 normal camel samples (C21–C38) were confirmed to be negative by all the methods tested. A total of 17 of 20 MERS-CoV-infected camel samples were positive by ppNT, while C1, C7, and C13 were negative, which was inconsistent with RT-PCR results. Notably, C7 was positive for anti-MERS-CoV IgG based on the S1-, RBD-, and NP-LISAs, while C3 was detected as positive by ppNT but as negative for anti-MERS-CoV IgG based on S1-, RBD-, and NP-LISAs. Moreover, samples C11, C14, and C20 were determined to be positive by ppNT and RBD-LISA, but were negative by S1- and NP-LISA. Our results also showed that the two samples from MERS-CoV-infected marmoset monkeys (R2 and R3) and the two samples from MERS-CoV infected mice (M1 and M2) were positive via ppNT, as well as S1-, RBD-, and NP-LISAs. The results showed that if RT-PCR results served as the standard, the sensitivity of S1-, RBD-, and NP-LISA was 70%, 85%, and 60% respectively, and the specificity was 100% for all assays. When ppNT results served as the standard, the sensitivity was 81%, 95%, and 71%, respectively, and the specificity was 95% for all assays. The results showed that S1-, RBD-, and NP-LISAs were highly consistent with the ppNT results. In conclusion, MERS-CoV S1-, RBD-, and NP-LISAs showed high consistency with ppNT and RT-PCR. The RBD-LISA showed the highest consistency with ppNT (
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="s0075">
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p id="p0085">
      MERS is an emerging infectious disease with a high fatality rate [
      <xref ref-type="bibr" rid="bb0320">
       64
      </xref>
      ]. Diagnosis of MERS-CoV infection using anti-MERS-CoV IgG is typical for post-exposure epidemiologic studies or seroprevalence investigations [
      <xref ref-type="bibr" rid="bb0090">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0240">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0265">
       53
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0270">
       54
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0315">
       63
      </xref>
      ]. Although anti-MERS-CoV serologic test kits are commercially available, such as ELISA and IFA developed by Euroimmun (Lübeck, Germany), the performance (especially sensitivity as a screening test) of these kits needs to be optimized. In this study, we reported various novel MERS-CoV recombinant antigen-based LISAs that do not require a BSL-3 laboratory or species-specific secondary antibodies. Furthermore, these LISA-based assays are potentially useful for the rapid, specific, and sensitive detection of anti-MERS-CoV IgG in both humans and animals.
     </p>
     <p id="p0090">
      Traditionally, PRNT and MN have been the standards for detecting MERS-CoV-specific antibodies. However, these assays are time-consuming, laborious, and require high-level biosafety facilities [
      <xref ref-type="bibr" rid="bb0265">
       53
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0300">
       60
      </xref>
      ]. The performance of the commercial MERS-CoV S1-based ELISA has been assessed by different groups [
      <xref ref-type="bibr" rid="bb0090">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0175">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0255">
       51
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0325">
       65
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0330">
       66
      </xref>
      ], all of which have shown that the sensitivity of this assay needs to be improved, as it shows high cut-off values from the optical density (OD) ratio (the manufacturer's instructions provided a higher breakpoint for ELISA IgG to warrant specificity, with a borderline OD ratio cut-off of 0.8–1.1 and positive ≥1.1). LISA is characterized by rapid preparation, ultra-sensitivity, high-throughput, and simple operation [
      <xref ref-type="bibr" rid="bb0275">
       55
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0280">
       56
      </xref>
      ]. Cell lysates are directly used in the detection assay, which avoids purification and post-expression modifications [
      <xref ref-type="bibr" rid="bb0275">
       55
      </xref>
      ]. In the current study, we developed LISAs for the detection of anti-MERS-CoV IgG in human and animal sera based on novel and ultrasensitive NLuc approaches. We compared LISAs with the commercially available S1-based ELISA kit using a panel of anti-MERS-CoV IgG sera. Our data indicated that several LISAs (RBD-, S1-, and NP-LISAs) were highly correlated and more sensitive (by at least 16-fold) than the S1-based ELISA in detecting anti-MERS-CoV IgG in patient samples. We also confirmed that the RBD-, S1-, and NP-LISAs were able to specifically recognize anti-MERS-CoV IgG without cross-reactiondy with samples derived from other HCoV (OC43, 229E, HKU1, NL63)-infected patients.
     </p>
     <p id="p0095">
      Recently, Alagaili et al. [
      <xref ref-type="bibr" rid="bb0165">
       33
      </xref>
      ] and Okba et al. [
      <xref ref-type="bibr" rid="bb0335">
       67
      </xref>
      ] reported a luciferase immunoprecipitation system (LIPS) and detected MERS-CoV antibody with improved sensitivity and specificity. Compared to LIPS, LISA does not need pre-incubation of Ruc-antigen and samples and transfer of the mixture to a special 96-well filter plate containing the protein A/G beads. Moreover, LISA does not need a special plate washer with vacuum to capture the antigen-antibody-beads complex [
      <xref ref-type="bibr" rid="bb0275">
       55
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0340">
       68
      </xref>
      ]. In the LISA system, Nluc replaced the Renilla luciferase used in LIPS. NLuc has been shown to generate a glow-type luminescence (signal half-life &gt;2 h) with 150-fold greater activity than Renilla luciferase. It is also brighter than Firefly luciferase [
      <xref ref-type="bibr" rid="bb0280">
       56
      </xref>
      ]. Lastly, it is easy to construct fusion proteins based on Nluc enzyme with the full length of 171 amino acids, which makes it an excellent reporter protein [
      <xref ref-type="bibr" rid="bb0345">
       69
      </xref>
      ].
     </p>
     <p id="p0100">
      CoV structural proteins, especially S and NP proteins, play important roles in CoV infection and detection. In addition, NP is probably the most abundant antigen after CoV infection [
      <xref ref-type="bibr" rid="bb0225">
       45
      </xref>
      ], and antibodies to NP have been used as serological diagnostic biomarkers. To optimize the antigens for anti-MERS-CoV IgG detection, we constructed various NLuc fusion proteins based on MERS-CoV NP protein or fragments of S protein. Our results showed that S1-, RBD-, and NP-LISAs were more sensitive than the NTD- and S2-LISA for detecting anti-MERS-CoV IgG. Moreover, ROC analysis showed that S1- and RBD-LISAs were superior to the NP-LISA and S1-ELISA in regard to the sensitivity and specificity of detecting anti-MERS-CoV IgG in serum samples.
     </p>
     <p id="p0105">
      MERS-CoV is a zoonotic disease that causes global public health concerns. Dromedary camels, bats, and other animals are potentially involved in MERS-CoV transmission [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0060">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0175">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0210">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0300">
       60
      </xref>
      ]. Antibodies against MERS-CoV in domestic livestock (including dromedary camels) in the Middle-East and Africa were investigated using ppNT, MN, and IFA assays [
      <xref ref-type="bibr" rid="bb0035">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0135">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0145">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0170">
       [34]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0175">
       [35]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0180">
       [36]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0240">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0265">
       53
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0300">
       60
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0350">
       70
      </xref>
      ]. MERS-CoV IgG seropositivity gradually increased in dromedary calves from the Middle East with increasing age based on the S1-ELISA. Currently, there are several knowledge gaps regarding the zoonotic origin and animal-human interface of MERS-CoV infection due to limited tools and resources [
      <xref ref-type="bibr" rid="bb0060">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0245">
       49
      </xref>
      ]. It is very important to establish a platform to screen anti-MERS-CoV IgG among different species in endemic areas and conduct a traceable investigation of animal epidemic foci. Theoretically, samples from vectors, such as mites and mosquitoes, as well as other animals, including bats, mice, camels, and monkeys, could be detected by LISA; however, these may not be detected using a typical ELISA due to the lack of suitable enzyme-labeled secondary antibodies. In this study, the commercial S1 ELISA did not detect positive sera samples from camels, monkeys, or mice. However, the positive samples were successfully detected by several LISAs established in this study, which proved the applicability and reliability of LISAs. Additionally, anti-MERS-CoV IgG detected by LISAs demonstrated a strong correlation with ppNT and RT-PCR from several animal hosts including camels, mice, and monkeys. Furthermore, RBD-LISA was the most sensitive LISA developed in this study. In conclusion, we have developed several novel LISAs for the detection of anti-MERS-CoV IgG in humans and animals. These assays have the potential to be used for large-scale screening of anti-MERS-CoV IgG and study of serological epidemiology of MERS-CoV infection among all species.
     </p>
    </sec>
    <back>
     <ref-list id="bi0005">
      <title>
       References
      </title>
      <ref id="bb0005">
       <label>
        1
       </label>
       <element-citation id="rf0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tayib
          </surname>
          <given-names>
           O.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An overview of the most significant zoonotic viral pathogens transmitted from animal to human in Saudi Arabia
        </article-title>
        <source>
         Pathogens.
        </source>
        <volume>
         8
        </volume>
        <year>
         2019
        </year>
        <fpage>
         25
        </fpage>
       </element-citation>
      </ref>
      <ref id="bb0010">
       <label>
        2
       </label>
       <element-citation id="rf0010" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gossner
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Danielson
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Gervelmeyer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Berthe
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Faye
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Aaslav
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Adlhoch
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zeller
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Penttinen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Coulombier
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Human – Dromedary Camel Interactions and the Risk of Acquiring Zoonotic Middle East Respiratory Syndrome Coronavirus Infection
        </chapter-title>
        <volume>
         63
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0015">
       <label>
        3
       </label>
       <element-citation id="rf1005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Kahlout
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nasrallah
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           El Zowalaty
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           Al Thani
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar
        </article-title>
        <source>
         J. Immunol. Res.
        </source>
        <volume>
         2019
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0020">
       <label>
        4
       </label>
       <element-citation id="rf0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-taw
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic Middle East respiratory syndrome coronavirus (MERS-CoV ) infection: Extent and implications for infection control: a systematic review
        </article-title>
        <source>
         Travel Med. Infect. Dis.
        </source>
        <volume>
         27
        </volume>
        <year>
         2019
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         30550839
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0025">
       <label>
        5
       </label>
       <element-citation id="rf0020" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses: Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus in Travelers
        </chapter-title>
        <volume>
         27
        </volume>
        <year>
         2014
        </year>
        <fpage>
         411
        </fpage>
        <lpage>
         417
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0030">
       <label>
        6
       </label>
       <element-citation id="rf0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Al-jahdali
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Alaqeel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Siddiq
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Alsaab
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sakr
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alyahya
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alandonisi
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Subedar
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Aloudah
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alsalamah
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early identification of pneumonia patients at increased risk of Middle East respiratory syndrome coronavirus infection in Saudi Arabia
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <volume>
         70
        </volume>
        <year>
         2018
        </year>
        <fpage>
         51
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         29550445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0035">
       <label>
        7
       </label>
       <element-citation id="rf0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Al-tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction
        </article-title>
        <source>
         Pathog. Glob. Health.
        </source>
        <volume>
         109
        </volume>
        <year>
         2016
        </year>
        <fpage>
         354
        </fpage>
        <lpage>
         362
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0040">
       <label>
        8
       </label>
       <element-citation id="rf0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bazzi
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ahmed
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular aspects of MERS-CoV
        </article-title>
        <source>
         Front. Med.
        </source>
        <volume>
         11
        </volume>
        <year>
         2017
        </year>
        <fpage>
         365
        </fpage>
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="pmid">
         28500431
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0045">
       <label>
        9
       </label>
       <element-citation id="rf0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spanakis
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Pontikis
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Koutsoukou
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Koulouris
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Tsakris
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
        </article-title>
        <source>
         Int. J. Antimicrob. Agents
        </source>
        <volume>
         44
        </volume>
        <year>
         2014
        </year>
        <fpage>
         528
        </fpage>
        <lpage>
         532
        </lpage>
        <pub-id pub-id-type="pmid">
         25288266
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0050">
       <label>
        10
       </label>
       <element-citation id="rf0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of basic reproduction number of the Middle East respiratory syndrome coronavirus (MERS-CoV) during the outbreak in South Korea, 2015
        </article-title>
        <source>
         Biomed. Eng. Online.
        </source>
        <volume>
         16
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         28086973
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0055">
       <label>
        11
       </label>
       <element-citation id="rf0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yun
          </surname>
          <given-names>
           M. Ran
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Joh
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015
        </article-title>
        <source>
         BMC Infect. Dis.
        </source>
        <volume>
         17
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="pmid">
         28049444
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0060">
       <label>
        12
       </label>
       <element-citation id="rf0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kelly-Cirino
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mazzola
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Oxenford
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An updated roadmap for MERS-CoV research and product development: focus on diagnostics
        </article-title>
        <source>
         BMJ Glob. Heal.
        </source>
        <volume>
         4
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         e001105
        </object-id>
       </element-citation>
      </ref>
      <ref id="bb0065">
       <label>
        13
       </label>
       <element-citation id="rf0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         18
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e217
        </fpage>
        <lpage>
         e227
        </lpage>
        <pub-id pub-id-type="pmid">
         29680581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0070">
       <label>
        14
       </label>
       <element-citation id="rf0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Da Guan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           C.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           L.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ke
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           X.F.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Da Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of traveler with Middle East respiratory syndrome, China, 2015
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2278
        </fpage>
        <lpage>
         2280
        </lpage>
        <pub-id pub-id-type="pmid">
         26583433
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0075">
       <label>
        15
       </label>
       <element-citation id="rf0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain
        </article-title>
        <source>
         Viruses.
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         18
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0080">
       <label>
        16
       </label>
       <element-citation id="rf0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advancing priority research on the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         209
        </volume>
        <year>
         2014
        </year>
        <fpage>
         173
        </fpage>
        <lpage>
         176
        </lpage>
        <pub-id pub-id-type="pmid">
         24218505
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0085">
       <label>
        17
       </label>
       <element-citation id="rf1010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uyeki
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Erlandson
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Korch
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           O’Hara
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wathen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hu-Primmer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hojvat
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stemmy
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Donabedian
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of medical countermeasures to Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         e1
        </fpage>
        <lpage>
         e11
        </lpage>
        <pub-id pub-id-type="pmid">
         27649306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0090">
       <label>
        18
       </label>
       <element-citation id="rf0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           E.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Seong
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nam
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Microbiol. Immunol.
        </source>
        <volume>
         62
        </volume>
        <year>
         2018
        </year>
        <fpage>
         574
        </fpage>
        <lpage>
         584
        </lpage>
        <pub-id pub-id-type="pmid">
         30117617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0095">
       <label>
        19
       </label>
       <element-citation id="rf0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrov
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human monoclonal antibodies as candidate therapeutics against emerging viruses
        </article-title>
        <source>
         Front. Med.
        </source>
        <volume>
         11
        </volume>
        <year>
         2017
        </year>
        <fpage>
         462
        </fpage>
        <lpage>
         470
        </lpage>
        <pub-id pub-id-type="pmid">
         29159596
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0100">
       <label>
        20
       </label>
       <element-citation id="rf0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         215
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1807
        </fpage>
        <lpage>
         1815
        </lpage>
        <pub-id pub-id-type="pmid">
         28472421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0105">
       <label>
        21
       </label>
       <element-citation id="rf0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skariyachan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Challapilli
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Packirisamy
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         Front. Microbiol.
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <fpage>
         569
        </fpage>
        <pub-id pub-id-type="pmid">
         30984127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0110">
       <label>
        22
       </label>
       <element-citation id="rf0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dighe
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jombart
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Neil
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review of MERS-CoV (Middle East respiratory syndrome coronavirus) seroprevalence and viral RNA prevalence in dromedary camels: implications for animal vaccination
        </article-title>
        <source>
         Epidemics
        </source>
        <year>
         2019
        </year>
        <fpage>
         100350
        </fpage>
        <pub-id pub-id-type="pmid">
         31201040
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0115">
       <label>
        23
       </label>
       <element-citation id="rf0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kinne
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mclellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         88
        </volume>
        <year>
         2014
        </year>
        <fpage>
         9220
        </fpage>
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="pmid">
         24899185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0120">
       <label>
        24
       </label>
       <element-citation id="rf2005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamau
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Ongus
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gitau
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Galgalo
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lowther
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bitek
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Munyua
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Knowledge and practices regarding Middle East respiratory syndrome coronavirus among camel handlers in a slaughterhouse, Kenya, 2015
        </article-title>
        <source>
         Zoonoses Public Heal.
        </source>
        <volume>
         66
        </volume>
        <year>
         2019
        </year>
        <fpage>
         169
        </fpage>
        <lpage>
         173
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0125">
       <label>
        25
       </label>
       <element-citation id="rf0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gikonyo
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kimani
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Matere
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kimutai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kiambi
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Bitek
          </surname>
          <given-names>
           A.O.
          </given-names>
         </name>
         <name>
          <surname>
           Ngeiywa
          </surname>
          <given-names>
           K.J.Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Makonnen
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tripodi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Morzaria
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lubroth
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rugalema
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fasina
          </surname>
          <given-names>
           F.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mapping potential amplification and transmission hotspots for MERS-CoV
        </article-title>
        <source>
         Kenya, Ecohealth.
        </source>
        <volume>
         15
        </volume>
        <year>
         2018
        </year>
        <fpage>
         372
        </fpage>
        <lpage>
         387
        </lpage>
        <pub-id pub-id-type="pmid">
         29549589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0130">
       <label>
        26
       </label>
       <element-citation id="rf0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alexandersen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Soule
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <volume>
         61
        </volume>
        <year>
         2014
        </year>
        <fpage>
         105
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="pmid">
         24456414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0135">
       <label>
        27
       </label>
       <element-citation id="rf0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           David
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rotenberg
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Khinich
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Erster
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Bardenstein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Van Straten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           S.V.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Miculitzki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Davidson
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels
        </article-title>
        <source>
         One Heal.
        </source>
        <volume>
         5
        </volume>
        <year>
         2018
        </year>
        <fpage>
         65
        </fpage>
        <lpage>
         68
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0140">
       <label>
        28
       </label>
       <element-citation id="rf0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origins and pathogenesis of Middle East respiratory syndrome-associated coronavirus: recent advances [version 1; referees: 3 approved]
        </article-title>
        <source>
         F1000Res.
        </source>
        <volume>
         6
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1628
        </fpage>
        <pub-id pub-id-type="pmid">
         29026532
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0145">
       <label>
        29
       </label>
       <element-citation id="rf0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zohaib
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Saqib
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Athar
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sial
          </surname>
          <given-names>
           A. ur R.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Taj
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sadia
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tahir
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Tayyab
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Qureshi
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mansoor
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Naeem
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ujjan
          </surname>
          <given-names>
           I.D.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Waruhiu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sajid
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Countrywide survey for MERS-coronavirus antibodies in dromedaries and humans in Pakistan
        </article-title>
        <source>
         Virol. Sin.
        </source>
        <volume>
         33
        </volume>
        <year>
         2018
        </year>
        <fpage>
         410
        </fpage>
        <lpage>
         417
        </lpage>
        <pub-id pub-id-type="pmid">
         30311100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0150">
       <label>
        30
       </label>
       <element-citation id="rf0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Alsahafi
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Aldabbagh
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Beer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1012
        </fpage>
        <lpage>
         1015
        </lpage>
        <pub-id pub-id-type="pmid">
         24857749
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0155">
       <label>
        31
       </label>
       <element-citation id="rf0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Mason-sharma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Caty
          </surname>
          <given-names>
           S.N.
          </given-names>
         </name>
         <name>
          <surname>
           Kerry
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adapting global health aid in the face of climate change
        </article-title>
        <source>
         Lancet Glob. Heal.
        </source>
        <volume>
         5
        </volume>
        <year>
         2016
        </year>
        <fpage>
         e133
        </fpage>
        <lpage>
         e134
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0160">
       <label>
        32
       </label>
       <element-citation id="rf0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaup
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wrensch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kramer-Kuhl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Welsch
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           von Hahn
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         5502
        </fpage>
        <lpage>
         5511
        </lpage>
        <pub-id pub-id-type="pmid">
         23468491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0165">
       <label>
        33
       </label>
       <element-citation id="rf0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sameroff
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           WB
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        <source>
         mBio.
        </source>
        <volume>
         5
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e00884
        </fpage>
        <lpage>
         00814
        </lpage>
        <pub-id pub-id-type="pmid">
         24570370
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0170">
       <label>
        34
       </label>
       <element-citation id="rf0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harrath
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Abu Duhier
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sero-prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) specific antibodies in dromedary camels in Tabuk, Saudi Arabia
        </article-title>
        <source>
         J Med Virol.
        </source>
        <volume>
         90
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1285
        </fpage>
        <lpage>
         1289
        </lpage>
        <pub-id pub-id-type="pmid">
         29663439
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0175">
       <label>
        35
       </label>
       <element-citation id="rf0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           El Rasoul
          </surname>
          <given-names>
           Ih.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           E.Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jose
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Patteril
          </surname>
          <given-names>
           N.A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Elizabeth
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A phylogenetically distinct Middle East respiratory syndrome coronavirus detected in a dromedary calf from a closed dairy herd in Dubai with rising seroprevalence with age
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <volume>
         4
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e74
        </fpage>
        <pub-id pub-id-type="pmid">
         26632876
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0180">
       <label>
        36
       </label>
       <element-citation id="rf0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harcourt
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Rudoler
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Leshem
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Giladi
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel
        </article-title>
        <source>
         Zoonoses Public Heal.
        </source>
        <volume>
         65
        </volume>
        <year>
         2018
        </year>
        <fpage>
         749
        </fpage>
        <lpage>
         754
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0185">
       <label>
        37
       </label>
       <element-citation id="rf0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jores
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Younan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liljander
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hilali
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Musa
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bornstein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus neutralizing antibodies in camels, eastern Africa, 1983–1997
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         2093
        </fpage>
        <lpage>
         2095
        </lpage>
        <pub-id pub-id-type="pmid">
         25425139
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0190">
       <label>
        38
       </label>
       <element-citation id="rf0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           K.P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Miguel
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Dudas
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Oladipo
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
         <name>
          <surname>
           Traoré
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fassi-Fihri
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Demissié
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           M.C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kuranga
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mamo
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           R.T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Webby
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Roger
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rambaut
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chevalier
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity
        </article-title>
        <source>
         Proc. Natl. Acad. Sci.
        </source>
        <volume>
         115
        </volume>
        <year>
         2018
        </year>
        <fpage>
         3144
        </fpage>
        <lpage>
         3149
        </lpage>
        <pub-id pub-id-type="pmid">
         29507189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0195">
       <label>
        39
       </label>
       <element-citation id="rf0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aly
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Elrobh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Alzayer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Aljuhani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Occurrence of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) across the Gulf corporation council countries: four years update
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         12
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0200">
       <label>
        40
       </label>
       <element-citation id="rf0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           K.K.W. To
          </surname>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         28
        </volume>
        <year>
         2015
        </year>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0205">
       <label>
        41
       </label>
       <element-citation id="rf0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.-Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic characterization of betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese Pipistrelle: implications for the origin of the novel Middle East respiratory Sy
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         8638
        </fpage>
        <lpage>
         8650
        </lpage>
        <pub-id pub-id-type="pmid">
         23720729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0210">
       <label>
        42
       </label>
       <element-citation id="rf0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Channapannavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: emergence of a pathogenic human coronavirus
        </article-title>
        <source>
         Annu. Rev. Med.
        </source>
        <volume>
         68
        </volume>
        <year>
         2017
        </year>
        <fpage>
         387
        </fpage>
        <lpage>
         399
        </lpage>
        <pub-id pub-id-type="pmid">
         27576010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0215">
       <label>
        43
       </label>
       <element-citation id="rf0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           A.C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Global epidemiology of bat coronaviruses
        </article-title>
        <source>
         Viruses.
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         17
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0220">
       <label>
        44
       </label>
       <element-citation id="rf0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Banerjee
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rapin
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Lew
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Misra
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon regulatory factor 3-mediated signaling limits middle-east respiratory syndrome (MERS) insectivorous bat
        </article-title>
        <source>
         Viruses.
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         21
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0225">
       <label>
        45
       </label>
       <element-citation id="rf0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Paranhos-Baccalà
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection
        </article-title>
        <source>
         J. Inf. Secur.
        </source>
        <volume>
         71
        </volume>
        <year>
         2015
        </year>
        <fpage>
         599
        </fpage>
        <lpage>
         602
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0230">
       <label>
        46
       </label>
       <element-citation id="rf0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rajashankar
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Y.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         10777
        </fpage>
        <lpage>
         10783
        </lpage>
        <pub-id pub-id-type="pmid">
         23903833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0235">
       <label>
        47
       </label>
       <element-citation id="rf0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         500
        </volume>
        <year>
         2013
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0240">
       <label>
        48
       </label>
       <element-citation id="rf0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.S.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ghobashy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Thani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Marri
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Al Khal
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <year>
         2014
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0245">
       <label>
        49
       </label>
       <element-citation id="rf0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Sousa
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus: data gaps for laboratory preparedness
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         59
        </volume>
        <year>
         2014
        </year>
        <fpage>
         4
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         24286807
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0250">
       <label>
        50
       </label>
       <element-citation id="rf0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaoka
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Matsunaga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Matsushima
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuroyama
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kimura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chimuro
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ryo
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of monoclonal antibody and diagnostic test for Middle East respiratory syndrome coronavirus using cell-free synthesized nucleocapsid antigen
        </article-title>
        <source>
         Front. Microbiol.
        </source>
        <volume>
         7
        </volume>
        <year>
         2016
        </year>
        <fpage>
         509
        </fpage>
        <pub-id pub-id-type="pmid">
         27148198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0255">
       <label>
        51
       </label>
       <element-citation id="rf0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Seok
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baek
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jo
          </surname>
          <given-names>
           I.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hahn
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests
        </article-title>
        <source>
         Eur. J. Clin. Microbiol. Infect. Dis.
        </source>
        <volume>
         36
        </volume>
        <year>
         2017
        </year>
        <fpage>
         2179
        </fpage>
        <lpage>
         2186
        </lpage>
        <pub-id pub-id-type="pmid">
         28695355
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0260">
       <label>
        52
       </label>
       <element-citation id="rf0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trivedi
          </surname>
          <given-names>
           S.U.
          </given-names>
         </name>
         <name>
          <surname>
           Miao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Caidi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Thornburg
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and evaluation of a multiplexed immunoassay for simultaneous detection of serum IgG antibodies to six human coronaviruses
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <volume>
         9
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         30626917
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0265">
       <label>
        53
       </label>
       <element-citation id="rf0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bagato
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kayed
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Moatasim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Webby
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <volume>
         18
        </volume>
        <year>
         2013
        </year>
        <comment>
         pii=20574
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0270">
       <label>
        54
       </label>
       <element-citation id="rf0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serological assays for emerging coronaviruses: challenges and pitfalls
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         194
        </volume>
        <year>
         2014
        </year>
        <fpage>
         175
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="pmid">
         24670324
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0275">
       <label>
        55
       </label>
       <element-citation id="rf0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A simple and high-throughput luciferase immunosorbent assay for both qualitative and semi-quantitative detection of anti-HIV-1 antibodies
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         263
        </volume>
        <year>
         2019
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="pmid">
         30605754
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0280">
       <label>
        56
       </label>
       <element-citation id="rf0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           England
          </surname>
          <given-names>
           C.G.
          </given-names>
         </name>
         <name>
          <surname>
           Ehlerding
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         NanoLuc: a small luciferase is brightening up the field of bioluminescence
        </article-title>
        <source>
         Bioconjug. Chem.
        </source>
        <volume>
         27
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1175
        </fpage>
        <lpage>
         1187
        </lpage>
        <pub-id pub-id-type="pmid">
         27045664
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0285">
       <label>
        57
       </label>
       <element-citation id="rf0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and evaluation of a universal and supersensitive NS1- based luciferase immunosorbent assay to detect Zika virus-specific IgG
        </article-title>
        <source>
         Virol. Sin.
        </source>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bb0290">
       <label>
        58
       </label>
       <element-citation id="rf0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nath
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Flemming
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godat
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Urh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies
        </article-title>
        <source>
         J. Immunol. Methods
        </source>
        <volume>
         450
        </volume>
        <year>
         2017
        </year>
        <fpage>
         17
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="pmid">
         28733215
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0295">
       <label>
        59
       </label>
       <element-citation id="rf0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harvey
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mattiuzzo
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hassall
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Rigsby
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Oxenford
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of serologic assays for Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         25
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1878
        </fpage>
        <lpage>
         1883
        </lpage>
        <pub-id pub-id-type="pmid">
         31423969
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0300">
       <label>
        60
       </label>
       <element-citation id="rf0285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           El-Taweel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kayed
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Abiadh
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jrijer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Moatasim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kutkat
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Bagato
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Mahmoud
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Mostafa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Elsokary
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Allal
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sobhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           McKenzie
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
         <name>
          <surname>
           Webby
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <volume>
         8
        </volume>
        <year>
         2019
        </year>
        <fpage>
         103
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="pmid">
         30866764
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0305">
       <label>
        61
       </label>
       <element-citation id="rf0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Guizhen
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of laboratory methods used for identification of the first imported case of Middle East respiratory syndrome infection in China, 2015
        </article-title>
        <source>
         Chin. J. Exp. Clin. Virol.
        </source>
        <volume>
         29
        </volume>
        <year>
         2015
        </year>
        <fpage>
         193
        </fpage>
        <lpage>
         195
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0310">
       <label>
        62
       </label>
       <element-citation id="rf0295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Whitaker
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Sakthivel
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kamili
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lowe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Mohared
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Elassal
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-sanouri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           D.D.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         52
        </volume>
        <year>
         2014
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         24153118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0315">
       <label>
        63
       </label>
       <element-citation id="rf0300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <volume>
         5
        </volume>
        <year>
         2016
        </year>
        <fpage>
         e113
        </fpage>
        <pub-id pub-id-type="pmid">
         27826140
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0320">
       <label>
        64
       </label>
       <element-citation id="rf0305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dawson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Parvez
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         What have we learned about Middle East respiratory syndrome coronavirus emergence in humans? A systematic literature review
        </article-title>
        <source>
         Vector Borne Zoonotic Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2019
        </year>
        <fpage>
         174
        </fpage>
        <lpage>
         192
        </lpage>
        <pub-id pub-id-type="pmid">
         30676269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0325">
       <label>
        65
       </label>
       <element-citation id="rf0310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           H.K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <volume>
         4
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e26
        </fpage>
        <pub-id pub-id-type="pmid">
         26421268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0330">
       <label>
        66
       </label>
       <element-citation id="rf1020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ke
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Juan
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ming
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhen
          </surname>
          <given-names>
           W.G.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Jie
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serological study of an imported case of middle east respiratory syndrome and his close contacts in China, 2015
        </article-title>
        <source>
         Biomed. Environ. Sci.
        </source>
        <volume>
         29
        </volume>
        <year>
         2016
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         223
        </lpage>
        <pub-id pub-id-type="pmid">
         27109133
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0335">
       <label>
        67
       </label>
       <element-citation id="rf0315" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Widjaja
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Geurts van Kessel
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           de Bruin
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Chandler
          </surname>
          <given-names>
           F.D.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           N.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.B.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hajri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensitive and specific detection of low-level antibody responses in mild Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         25
        </volume>
        <year>
         2019
        </year>
        <fpage>
         22
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0340">
       <label>
        68
       </label>
       <element-citation id="rf0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burbelo
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Ching
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Klimavicz
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Iadarola
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody profiling by luciferase immunoprecipitation systems (LIPS)
        </article-title>
        <source>
         J. Vis. Exp.
        </source>
        <volume>
         32
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0345">
       <label>
        69
       </label>
       <element-citation id="rf0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Unch
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Binkowski
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Valley
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Otto
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zimmerman
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vidugiris
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           MacHleidt
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Robers
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Benink
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Eggers
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Slater
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Meisenheimer
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Klaubert
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Encell
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate
        </article-title>
        <source>
         ACS Chem. Biol.
        </source>
        <volume>
         7
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1848
        </fpage>
        <lpage>
         1857
        </lpage>
        <pub-id pub-id-type="pmid">
         22894855
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0350">
       <label>
        70
       </label>
       <element-citation id="rf0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Rostal
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rahman
          </surname>
          <given-names>
           M.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Enayet
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Uzzaman
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Flora
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Rahman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus antibodies in dromedary camels, Bangladesh, 2015
        </article-title>
        <volume>
         24
        </volume>
        <year>
         2018
        </year>
        <fpage>
         926
        </fpage>
        <lpage>
         928
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ac0005">
      <sec id="s0080">
       <title>
        Acknowledgements
       </title>
       <p id="p0110">
        This work was supported by the following grants: the
        <funding-source id="gts0005">
         National Major Project for Control and Prevention of Infectious Disease in China
        </funding-source>
        (No. 2018ZX10101002 and 2018ZX10732401), and the
        <funding-source id="gts0010">
         National Key Research and Development Program of China
        </funding-source>
        (No. 2016YFD0500301 and 2017YFC1200503). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
       </p>
      </sec>
      <sec id="s0090">
       <title>
        Conflict of interest statement
       </title>
       <p id="p0120">
        The authors declare that there are no conflicts of interest.
       </p>
      </sec>
      <sec id="s0085">
       <title>
        Author contributions
       </title>
       <p id="p0115">
        Conception and design of the study: W. Wang, T. Wang, W. Tan and S. Tang; Performance of experiment: T. Wang, W. Wang, Y. Deng, P. Niu, R. A and M. Peiris; Providing samples: W. Wang, J. Zhao and M. Peiris; Statistical analysis: W. Wang, T. Wang and W. Tan; Drafting the article: W. Wang, T. Wang and W. Tan; Revision of the draft: J. Zhao, M. Peiris and S. Tang; Final approval of the version to be submitted: All authors.
       </p>
      </sec>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerging Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       EID
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1080-6040
      </issn>
      <issn pub-type="epub">
       1080-6059
      </issn>
      <publisher>
       <publisher-name>
        Centers for Disease Control and Prevention
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15030702
      </article-id>
      <article-id pub-id-type="pmc">
       3322922
      </article-id>
      <article-id pub-id-type="publisher-id">
       03-0731
      </article-id>
      <article-id pub-id-type="doi">
       10.3201/eid1002.030731
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Serologic and Molecular Biologic Methods for SARS-associated Coronavirus Infection, Taiwan
       </article-title>
       <alt-title alt-title-type="running-head">
        Laboratory Studies
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Ho-Sheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chiu
         </surname>
         <given-names>
          Shu-Chun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tseng
         </surname>
         <given-names>
          Tsan-Chang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Szu-Fong
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Jih-Hui
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hsu
         </surname>
         <given-names>
          Yu-Fen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Mei-Ching
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Tsuey-Li
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Wen-Zieh
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ferng
         </surname>
         <given-names>
          Tian-Lin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          Kai-Hung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hsu
         </surname>
         <given-names>
          Li-Ching
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          Li-Li
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Jyh-Yuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Hour-Young
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Su
         </surname>
         <given-names>
          Shun-Pi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Shih-Yan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Ting-Hsiang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Su
         </surname>
         <given-names>
          Ih-Jen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         *
        </label>
        Center for Disease Control, Department of Health, Taiwan, Republic of China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address for correspondence: Ih-Jen Su, Center for Disease Control, Department of Health, Taiwan; No. 6, Lin-Shen South Road, Taipei, Taiwan; fax: 886-2-23918543; email:
        <email xlink:href="suihjen@cdc.gov.tw">
         suihjen@cdc.gov.tw
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        2
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <volume>
       10
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       305
      </fpage>
      <lpage>
       310
      </lpage>
      <abstract>
       <p>
        Severe acute respiratory syndrome (SARS) has raised a global alert since March 2003. After its causative agent, SARS-associated coronavirus (SARS-CoV), was confirmed, laboratory methods, including virus isolation, reverse transcriptase–polymerase chain reaction (RT-PCR), and serologic methods, have been quickly developed. In this study, we evaluated four serologic tests ( neutralization test, enzyme-linked immunosorbent assay [ELISA], immunofluorescent assay [IFA], and immunochromatographic test [ICT]) for detecting antibodies to SARS-CoV in sera of 537 probable SARS case-patients with correlation to the RT-PCR . With the neutralization test as a reference method, the sensitivity, specificity, positive predictive value, and negative predictive value were 98.2%, 98.7%, 98.7%, and 98.4% for ELISA; 99.1%, 87.8%, 88.1% and 99.1% for IFA; 33.6%, 98.2%, 95.7%, and 56.1% for ICT, respectively. We also compared the recombinant-based western blot with the whole virus–based IFA and ELISA; the data showed a high correlation between these methods, with an overall agreement of &gt;90%. Our results provide a systematic analysis of serologic and molecular methods for evaluating SARS-CoV infection.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        Keywords.
       </title>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        serodiagnostic methods
       </kwd>
       <kwd>
        neutralization test
       </kwd>
       <kwd>
        IFA
       </kwd>
       <kwd>
        ELISA
       </kwd>
       <kwd>
        immunochromatographic test
       </kwd>
       <kwd>
        Western blot
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Severe acute respiratory syndrome (SARS) is a new infectious disease with clinical symptoms indistinguishable from atypical pneumonia at the early stage of illness (
     <xref ref-type="bibr" rid="R1">
      <italic>
       1
      </italic>
     </xref>
     ). Because of its relatively high transmissibility and mortality rate on infection, &gt;8,400 SARS patients, including 810 deaths, have been reported by China, Vietnam, Hong Kong, Singapore, Canada, Taiwan, and other areas worldwide from March to July 2003 (
     <xref ref-type="bibr" rid="R2">
      <italic>
       2
      </italic>
     </xref>
     ). As of July 31, 668 probable SARS case-patients, including 71 deaths, were reported to the Center for Disease Control, Taiwan (Center for Disease Control-Taiwan) (
     <xref ref-type="bibr" rid="R3">
      <italic>
       3
      </italic>
     </xref>
     ). With the close cooperation of laboratories worldwide, the causative agent of SARS was quickly identified as a new coronavirus species, now referred to as SARS-associated coronavirus (SARS-CoV) (
     <xref ref-type="bibr" rid="R4">
      <italic>
       4
      </italic>
     </xref>
     –
     <xref ref-type="bibr" rid="R6">
      <italic>
       6
      </italic>
     </xref>
     ). With epidemiologic evidence, droplet and close contact transmission are the major routes for the spread of SARS (
     <xref ref-type="bibr" rid="R7">
      <italic>
       7
      </italic>
     </xref>
     ). Suspected SARS patients need to be quarantined and treated with intense care to minimize transmission to others. Therefore, sensitive and specific laboratory tests to differentiate SARS from other mild atypical pneumonia must be developed to shorten the quarantine period for contacts with SARS patients and further to contain SARS outbreaks.
    </p>
    <p>
     Even though the RT-PCR is the most sensitive technique to detect early SARS-CoV infection, the positive predictive rate for probable SARS cases is only 37.5% according to our data (Center for Disease Control-Taiwan). The other reported probable SARS cases, therefore, still have to rely on serologic diagnosis. We analyzed the results from immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), neutralization test, and immunochromatographic test (ICT) to detect antibodies against SARS-CoV in serum specimens of patients with probable SARS in Taiwan. The results of neutralization tests, ELISA, and IFA were highly correlated.
    </p>
    <sec sec-type="materials|methods">
     <title>
      Materials and Methods
     </title>
     <sec>
      <title>
       Specimens
      </title>
      <p>
       According to World Health Organization (WHO) criteria, a person seeking treatment after November 1, 2002, with a history of high fever (&gt;38°C), coughing, or breathing difficulty, and having resided in or traveled to an area with recent local transmission of SARS during the 10 days before onset of symptoms was classified as a suspected case-patient. A suspected case-patient with radiographic evidence of infiltrates consistent with pneumonia or respiratory distress syndrome on a chest x-ray was considered a probable case-patient (
       <xref ref-type="bibr" rid="R8">
        <italic>
         8
        </italic>
       </xref>
       ). In the study, 3,367 throat swab specimens from possible SARS patients reported to Center for Disease Control-Taiwan were tested for SARS-CoV by RT-PCR. Seven hundred and ninety-nine serum samples from 537 probable case-patients, fulfilling WHO criteria for probable SARS cases, were tested for antibodies to SARS-CoV by neutralization test, IFA, ELISA, and ICT. Of these patients, 262 had paired serum specimens, in which the acute- and convalescent-phase serum specimens were collected at day 1 to day 12 and at day 28 or more after the onset of illness, respectively. In the other 275 patients, only a single serum specimen was collected during their illness: 210 had the serum collected at the acute phase or at the early convalescent phase from day 1 to day 20, and 65 were collected during the late convalescent phase from day 28 to day 78 after the illness onset.
      </p>
     </sec>
     <sec>
      <title>
       RT-PCR
      </title>
      <p>
       The primers and probes used for SARS-CoV detection by RT-PCR and real-time RT-PCR were synthesized, according to the recommendations of the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA (
       <xref ref-type="bibr" rid="R5">
        <italic>
         5
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R9">
        <italic>
         9
        </italic>
       </xref>
       ). The viral RNA from the throat swab specimens was extracted by the MagNA LC Pure and MagNA Pure LC total nucleic acid isolation kit (Rouche, Mannheim, Germany). After extraction, 5 μL of RNA extract was used as the template in all PCR assays in 50-μL reaction volumes containing 10 μL of 5X buffer, 2 μL enzyme mix, 2 μL deoxynucleoside triphosphate (dNTP), and 0.6 μM each of sense and antisense primer. The reaction was subjected to precycle condition at 50°C for 30 min, and 95°C for 15 min. Forty cycles of amplification were then conducted at 95°C for 30 s, 50°C for 40 s, and 72°C for 1 min. For real-time quantitative RT-PCR assays, a 20-μL reaction volumes containing 12 μL of HPA (human pneumonia–associated coronavirus)-Coronavirus LC Master mix, 3 μL of HPA-Coronavirus LC Mg-Sol, and 0.5 μL of HPA-Coronavirus LC internal control were thermal-cycled by a Light Cycler (Rouche) at 50°C, for 10 min for RT reaction, at 95°C for 10 min for denaturation, and followed by 45 cycles of amplification at 95°C for 2 s, 55°C for 12 s, and 72°C for 10 s.
      </p>
     </sec>
     <sec>
      <title>
       Neutralization Test
      </title>
      <p>
       Serum specimens were tested for neutralizing activity, according to the procedures described by Marx et al. (
       <xref ref-type="bibr" rid="R10">
        <italic>
         10
        </italic>
       </xref>
       ), with modifications. The neutralization titer was determined in Vero E6 cells. Briefly, the serum specimens from patients with probable SARS were first incubated at 56°C for 30 min. Then, 50 μL of serial twofold diluted serum specimen, from 8-fold to 1,024-fold were added into equal volume of culture medium containing SARS-CoV (50 tissue culture infective dose [TCID
       <sub>
        50
       </sub>
       ] on a 96-well microtiter plate and incubated at 37°C for 1 h. Finally, 100 μL of Vero E6 cells (2.5 x 10
       <sup>
        5
       </sup>
       /μL) were added to each well of the plate. Cultures were held at 37°C and 5% CO
       <sub>
        2
       </sub>
       with daily observations for cytopathic effect (CPE). On day 5, the titer of antibody was calculated as the highest dilution that CPE was completely inhibited on the well. The neutralization test was carried out with each sample in duplicate along with both positive and negative controls. The positive control serum specimens were taken from patients with confirmed SARS in Taiwan, and the negative control serum specimens were from healthy volunteers. If a sample showed a 4-fold difference or greater in titers in the duplicated sample runs, it was judged as an invalid outcome and had to be retested. A sample is considered to be positive if its titer is
       <underline>
        &gt;
       </underline>
       1:16 in the case of single serum group, and at least a 4-fold increase in titers between the acute- and convalescent-phase serum specimens in the paired specimens group.
      </p>
     </sec>
     <sec>
      <title>
       IFA
      </title>
      <p>
       IFA testing was performed by using a diluted serum specimen reacted against SARS-CoV-infected Vero E6cells and uninfected Vero E6cells. Vero E6 cells were grown in minimum essential medium (MEM) containing 10% fetal bovine serum at 37°C. At a density of 80%, the cells were infected with SARS-CoV (TCID
       <sub>
        50
       </sub>
       , 10
       <sup>
        6
       </sup>
       /mL). After CPE appeared, the cells were washed with 0.025% trypsin and spotted on slides for IFA as previously described (
       <xref ref-type="bibr" rid="R11">
        <italic>
         11
        </italic>
       </xref>
       ). These slides were put in a closed heating container until completely drying, then were fixed in acetone for 15 min. 10 μL of 2-fold serial diluted serum starting from
       <underline>
        &gt;
       </underline>
       1:100 to 1:800 was placed onto each well of the slide, and incubated at 37°C for 30 min. After being washed twice with phosphate-buffered saline (PBS), for 5 min each, 10 μL of 1:100 diluted specific antihuman gamma globulins labeled with FITC (Zymed) was added onto each well, and incubated at 37°C for 30 min. After washing twice with PBS, slides were observed under a fluorescence microscope. Criteria for a positive IFA result included reactivity to infected cells. A sample with an antibody titer of 1:100 is positive. Sera that did not react to infected cells were considered negative. If nonspecific reactivity to both infected and uninfected cells were detected, the test was considered un-interpretable.
      </p>
     </sec>
     <sec>
      <title>
       ELISA
      </title>
      <p>
       An ELISA for the detection of coronavirus has been described (
       <xref ref-type="bibr" rid="R12">
        <italic>
         12
        </italic>
       </xref>
       ). In our study, the materials for the ELISA to detect SARS-CoV antibodies were provided by CDC in Atlanta. In brief, SARS-CoV Vero E6 cell lysates used as antigens were added to the top half of the wells in the plate overnight at 4°C. The Vero E6 cell lysates without SARS-CoV used as control antigens were simultaneously added to the wells in the bottom half of the plate. On the following day, 100 μL of diluted serum (starting from 1:100 to 1:1,600) was added to both test and control wells. Then each well of the plate was incubated at 37°C for 60 min. After washing the plate 3 times with 250 μL of wash buffer in each well, add 100 μL of conjugate dilution (1:4,000 of goat anti-human immunoglobulin (Ig)A, IgG, and IgM) to each well and incubate the plate at 37°C for 60 min. Again after washing, 100 μL of the substrate (a 1:1 mixture of 2,2-
       <underline>
        a
       </underline>
       zino-di [3-ethyl
       <underline>
        b
       </underline>
       enz
       <underline>
        t
       </underline>
       hiazoline]
       <underline>
        s
       </underline>
       ulfonic acid [ABTS] and hydrogen peroxide) were added to each wells, and incubated at 37°C for 30 min. Place the plate on ELISA reader, and read at 410 nm. A sample is positive if its adjusted optical density (OD) value (OD of test – OD of control) exceeds the mean plus 3 standard deviations of the normal controls and its titer is
       <underline>
        &gt;
       </underline>
       1:400.
      </p>
     </sec>
     <sec>
      <title>
       ICT
      </title>
      <p>
       The ICT generally refers to a rapid chromatographic technique based on a sandwich format using double antigens or double antibodies (
       <xref ref-type="bibr" rid="R13">
        <italic>
         13
        </italic>
       </xref>
       ). The SARS-CoV rapid test we adopted is a newly developed immunogold-based ICT device (Tyson Bioresearch, Inc.,Taipei, Taiwan). The antigen used in this test is a recombinant nucleocapsid (N) protein of SARS-CoV. The inside of the ICT device contains a nitrocellulose strip, on top of which is a detection zone. In the detection zone, the goat anti-mouse IgG and SARS-CoV N protein have been immobilized separately onto a control line and a test line. In the middle of the strip, the mouse IgG and SARS-CoV N protein are to be coupled respectively with some colloidal gold particles, which serve as a detector. At the bottom are two wells for the sample and the buffer, respectively. The ICT is carried out following the manufacture’s instruction. Briefly, 15 μL of undiluted serum sample is added to the sample well, and 220 μL of testing buffer to the buffer well. When the sample contains specific antibodies to SARS-CoV, they will react first with the antigen-gold complex. After lateral flow along the membrane, a colored complex of antibodies-antigen-gold will deposit on the test line containing the fixed antigen. The red signal from the gold will gradually appear on the test line and become visible by naked eye. A positive result will show two parallel lines; the upper one is the control line, which shows that the device works fine and the lower one is the test line, which indicates that the serum sample contains SARS-CoV antibodies. In case of a negative result, only red will be seen on the control line. If red is found only at the test line or no lines are visible, the test is invalid.
      </p>
     </sec>
     <sec>
      <title>
       Western Blot
      </title>
      <p>
       The preparation of recombinant proteins of SARS-CoV and the procedures for Western blot assay have been described recently (
       <xref ref-type="bibr" rid="R14">
        <italic>
         14
        </italic>
       </xref>
       ). Briefly, the amplified gene products of SARS-CoV including N, M (membrane), and S (spike), were gel purified and cloned into the pQE30 expression vector (Qiagen, Valancia, CA). The constructs were then transformed into
       <italic>
        Escherichia coli
       </italic>
       JM109 cells (Invitrogen, Carlsbad, CA). After induction by isopropyl-β-D-thiogalactopyranoside, the cells were sonicated, and the recombinant proteins were extracted with 1.5% sarcosine. Finally these recombinant proteins were bound by BD TALON metal affinity resins (BD Biosciences, San Jose, CA) and examined by 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The Western blot assay was carried out to examine the pattern of antibody development against different recombinant proteins of SARS-CoV.
      </p>
     </sec>
    </sec>
    <sec sec-type="results">
     <title>
      Results
     </title>
     <sec>
      <title>
       Detection of Viral RNA of SARS-CoV by RT-PCR
      </title>
      <p>
       A total of 3,367 possible SARS patients were reported to Center for Disease Control-Taiwan from March 10 through the end of July 2003. Of which, 668 were probable case-patients, 1,331 were suspected case-patients, 1,036 were rejected, and 332 case-patients were removed from reporting (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ). Throat swabs were collected from 590 of the 668 patients with probable cases. Of them, 221 had positive results on PCR, giving a positive rate of 37.5%. Throat swabs were also collected from 1,043 of the 1,331 patients with suspected cases. Of them, 38 had positive results by PCR, giving a positive rate of 3.6%.
       <xref ref-type="fig" rid="F1">
        Figure 1
       </xref>
       shows the PCR-positive rates of the throat swab specimens taken from patients with probable SARS between day 1 and day 13 after the illness onset. On the first day of onset, RT-PCR detected positive results in 32% of patients with suspected cases. The positive rates reached a peak of 50% to 60% on day 7 to day 10 and declined thereafter. However in a few specimens, virus RNA was still detected on day 18, day 20, and day 38 after illness onset (data not shown).
      </p>
      <table-wrap id="T1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Positive rates of RT-PCR for SARS-CoV in reported SARS cases in Taiwan
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="142"/>
        <col span="1" width="72"/>
        <col span="1" width="85"/>
        <col span="1" width="83"/>
        <col span="1" width="70"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="middle">
           Classification of reported cases
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="middle">
           Case no.
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="middle">
           Specimens collected
           <sup>
            a
           </sup>
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="middle">
           No. PCR (+)
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="middle">
           Positive rate (%)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="middle">
           Probable
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           668
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           590
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           221
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           37.5
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="middle">
           Suspected
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           1,331
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           1,043
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           38
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           3.6
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="middle">
           Ruled out
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           1,036
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           907
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           7
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           0.8
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="middle">
           Reporting cancelled
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           332
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           229
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           0.4
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="middle">
           Total
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           3,367
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           2,769
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           267
          </td>
          <td align="left" colspan="1" rowspan="1" valign="middle">
           9.6
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <sup>
          a
         </sup>
         Throat swab specimens were used for RT-PCR (reverse transcriptase–polymerase chain reaction). SARS-CoV, severe acute respiratory syndrome–associated coronavirus.
        </p>
       </table-wrap-foot>
      </table-wrap>
      <fig fig-type="figure" id="F1" position="float">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Polymerase chain reaction–positive rates of throat swab specimens collected on different days from probable SARS cases. If a patient had two or more specimens, the patient was only counted once.
        </p>
       </caption>
       <graphic xlink:href="03-0731-F1">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       Detection of Antibodies to SARS-CoV in Probable SARS Patients
      </title>
      <p>
       <xref ref-type="fig" rid="F2">
        Figure 2
       </xref>
       shows when antibodies to SARS-CoV appeared during the infection. Although in samples from 10% (14/138) of the probable case-patients, antibodies to SARS-CoV could be detected during the acute phase of illness (day 1 to day 7) by Nt, IFA, or ELISA, antibodies against SARS-CoV developed in most at the late convalescent stage. The positive rate of antibodies to SARS-CoV was raised to 50% at 3 weeks after illness onset and reached to a peak of over 70% at 10 weeks after onset. The overall antibody-positive rate was 54.2% (254/469).
      </p>
      <fig fig-type="figure" id="F2" position="float">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Antibody positive rate of serum specimens collected on different days from probable SARS case-patients. If a patient had two or more specimens, the patient was only counted once.
        </p>
       </caption>
       <graphic xlink:href="03-0731-F2">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       Relative Values of Different Serodiagnostic Methods
      </title>
      <p>
       Of the total 537 probable SARS case-patients, 469 had been tested for the antibody response to SARS-CoV by neutralization test, ELISA, and IFA in parallel, but only 244 patients were tested by ICT. With neutralization tests as a reference method, the overall characteristics of the evaluated methods, including ELISA, IFA, and ICT, are given in
       <xref ref-type="table" rid="T2">
        Table 2
       </xref>
       . For ELISA, the sensitivity was measured at 98.2%. Of the 224 serum specimens, which tested positive with neutralization test, 4 gave negative responses with ELISA. The specificity, positive predictive value, and negative predictive value were 98.7%, 98.7%, and 98.4%, respectively. For IFA, the sensitivity was evaluated at 99.1%. Two serum samples, which had been positive in neutralization test, were negative with IFA. The specificity, positive predictive value, and negative predictive value were of 87.8%, 88.1%, and 99.1%, respectively. The specificity of the ICT was calculated to be 98.2%; however, its sensitivity (33.6%) was low, leading to a negative predictive value of 56.1%. In the total of 245 negative neutralization tests were 3 positive results were detected with ELISA, 30 positive with IFA, and 2 positive with ICT tests. These 35 specimens were taken from 31 patients, in which two positive PCR results were found.
      </p>
      <table-wrap id="T2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <title>
         Specificity, sensitivity, positive and negative predictive values of the tests evaluated for the serodiagnosis of SARS, in comparison to the neutralization test
         <sup>
          a,b
         </sup>
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="60"/>
        <col span="1" width="68"/>
        <col span="1" width="63"/>
        <col span="1" width="62"/>
        <col span="1" width="68"/>
        <col span="1" width="75"/>
        <col span="1" width="53"/>
        <col span="1" width="75"/>
        <col span="1" width="53"/>
        <thead>
         <tr>
          <th align="left" colspan="3" rowspan="1" scope="colgroup" valign="top">
           <hr/>
          </th>
          <th align="left" colspan="2" rowspan="1" scope="colgroup" valign="top">
           Neutralization test
           <hr/>
          </th>
          <th align="left" colspan="4" rowspan="1" scope="colgroup" valign="top">
           Performances of methods evaluated
           <hr/>
          </th>
         </tr>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Method
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Results
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Number
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Positive
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Negative
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Sensitivity
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           PPV
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Specificity
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           NPV
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="col" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
           ELISA
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           223
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           220
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           98.2%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           98.7%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           98.7%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           98.4%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Negative
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           246
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           4
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           242
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
           IFA
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           252
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           222
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           30
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           99.1%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           88.1%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           87.8%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           99.1%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Negative
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           217
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           215
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
           ICT
           <sup>
            c
           </sup>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           46
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           44
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           33.6%
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           95.7%
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           98.2%
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           56.1%
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Negative
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           198
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           87
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           111
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Cross-Reactions with the Non-SARS Panel
      </title>
      <p>
       Ten normal serum samples from healthy volunteers tested negative for antibodies against SARS-CoV by neutralization test, IFA, ELISA, and ICT. In addition, 24 serum samples from patients with other diseases were used as a specificity panel to analyze whether these assays showed any cross reactions with SARS-CoV. These patients were definitely confirmed as non-SARS-CoV–associated diseases. As shown in
       <xref ref-type="table" rid="T3">
        Table 3
       </xref>
       , no positive results were detected to these serum specimens, and the measurements of specificity were all 100% for the neutralization test, ELISA, IFA, and ICT.
      </p>
      <table-wrap id="T3" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <title>
         Specificity of the tests evaluated for the serodiagnosis of SARS, in comparison to the neutralization test with regards to samples which tested positive for other diseases
         <sup>
          a,b
         </sup>
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="128"/>
        <col span="1" width="50"/>
        <col span="1" width="40"/>
        <col span="1" width="40"/>
        <col span="1" width="46"/>
        <col span="1" width="40"/>
        <col span="1" width="53"/>
        <col span="1" width="40"/>
        <col span="1" width="53"/>
        <col span="1" width="40"/>
        <col span="1" width="57"/>
        <thead>
         <tr>
          <th align="left" colspan="3" rowspan="1" scope="colgroup" valign="top">
           <hr/>
          </th>
          <th align="left" colspan="2" rowspan="1" scope="colgroup" valign="top">
           Neutralization test
           <hr/>
          </th>
          <th align="left" colspan="2" rowspan="1" scope="colgroup" valign="top">
           ELISA
           <hr/>
          </th>
          <th align="left" colspan="2" rowspan="1" scope="colgroup" valign="top">
           IFA
           <hr/>
          </th>
          <th align="left" colspan="2" rowspan="1" scope="colgroup" valign="top">
           ICT
           <hr/>
          </th>
         </tr>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Pathogen
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Parameter
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Number
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Positive
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Negative
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Positive
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Specificity
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Positive
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Specificity
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Positive
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Specificity
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Hepatitis B virus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HBs IgM
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Hepatitis C virus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           IgM
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Adenovirus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Total Ab
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Influenza A virus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Total Ab
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           3
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Influenza B virus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Total Ab
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Dengue virus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           IgM
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           JEV
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           IgM
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Hantavirus
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Total Ab
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           <italic>
            Chlamydia pneumoniae
           </italic>
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           IgM
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           4
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           4
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           <italic>
            Mycoplasma pneumoniae
           </italic>
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           IgM
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           4
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           4
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           <italic>
            Streptococcus pneumoniae
           </italic>
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Total Ab
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           1
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="2" rowspan="1" scope="row" valign="top">
           Total non-SARS pathogens
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           24
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           24
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           100%
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Values of RT-PCR and Neutralization Test
      </title>
      <p>
       <xref ref-type="table" rid="T4">
        Table 4
       </xref>
       compares results of the RT-PCR and the neutralization test in specimens from probable SARS case-patients. In this comparison, throat swab specimens from 381 probable SARS case-patients were used for RT-PCR, and their convalescent-phase serum specimens, collected on day 28 or longer after illness onset, were tested with neutralization test. Of the 207 cases, which were positive by neutralization test, 145 were tested positive with RT-PCR. The sensitivity, specificity, positive predictive value, and negative predictive value of RT-PCR compared with results with neutralization test were of 52.2%, 78.7%, 74.5%, and 58.1%, respectively.
      </p>
      <table-wrap id="T4" position="float">
       <label>
        Table 4
       </label>
       <caption>
        <title>
         Specificity, sensitivity, positive and negative predictive values of the RT-PCR for the diagnosis of SARS, in comparison to the neutralization test with convalescent-phase serum specimens
         <sup>
          a
         </sup>
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="69"/>
        <col span="1" width="72"/>
        <col span="1" width="41"/>
        <col span="1" width="66"/>
        <col span="1" width="72"/>
        <col span="1" width="79"/>
        <col span="1" width="56"/>
        <col span="1" width="79"/>
        <col span="1" width="56"/>
        <thead>
         <tr>
          <th align="left" colspan="3" rowspan="1" scope="colgroup" valign="top">
          </th>
          <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="top">
           Neutralization test
          </th>
          <th align="left" colspan="4" rowspan="1" scope="colgroup" valign="top">
           Performances of methods evaluated
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Method
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Results
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           No.
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Negative
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sensitivity
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           PPV
           <sup>
            b
           </sup>
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Specificity
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           NPV
           <sup>
            c
           </sup>
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
           RT-PCR
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           145
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           108
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           37
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           52.2%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           74.5%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Negative
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           236
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           99
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           137
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           78.7%
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           58.1%
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Laboratory Confirmation Rate for Probable SARS Case-Patients
      </title>
      <p>
       <xref ref-type="table" rid="T5">
        Table 5
       </xref>
       shows the laboratory confirmation rate of probable SARS cases in Taiwan. With 469 probable case-patients tested, the positive rate of RT-PCR is 33.7% (158/469). These patients had been also tested for the antibody response to SARS-CoV by neutralization test, ELISA, and IFA, but only 244 were tested by ICT. The seropositive rate for ELISA, IFA, neutralization test, and ICT were 47.5% (223/469), 57.7% (252/469), 47.8% (224/469), and 16.8% (41/224), respectively. If these results were combined with existing RT-PCR results, the laboratory confirmation rates of probable SARS cases went up to 57.4% (269/469), 63.3% (297/469), 57.8% (271/469), and 42.4% (103/244), respectively.
      </p>
      <table-wrap id="T5" position="float">
       <label>
        Table 5
       </label>
       <caption>
        <title>
         Laboratory confirmation rate in probable SARS cases, in combination of RT-PCR with different serologic methods
         <sup>
          a
         </sup>
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="125"/>
        <col span="1" width="93"/>
        <col span="1" width="93"/>
        <col span="1" width="191"/>
        <col span="1" width="93"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Results
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           ELISA
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           IFA
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Neutralization test
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           ICT
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           PCR (+)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           33.7% (158/469)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           33.7% (158/469)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           33.7% (158/469)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           35.7% (87/244)
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Antibody (+)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           47.5% (223/469)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           57.7% (252/469)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           47.8% (224/469)
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           16.8% (41/244)
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           PCR (+) or antibody (+)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           57.4% (269/469)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           63.3% (297/469)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           57.8% (271/469)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           42.4% (103/244)
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Recombinant Antigens for SARS Serologic Diagnosis
      </title>
      <p>
       As discussed above, all the neutralization tests, ELISA, and IFA are based on the whole viral extracts of SARS-CoV. Therefore, antigens for these serologic tests must be prepared in the biosafety level 3 laboratory. To provide a convenient tool and decrease the risk of infection, a Western blot with several SARS-CoV recombinant proteins was developed and evaluated. Cloned peptides carrying epitopes can be produced on a large scale and with an acceptable degree of purity.
       <xref ref-type="table" rid="T6">
        Table 6
       </xref>
       shows the comparison of recombinant protein- based Western blot with whole virus- based IFA, and ELISA. Ninety-five serum samples were used in this comparison. The sensitivities, specificities and overall agreements of Western blot were 91.3%, 89.88%, and 90.5%, compared with IFA results; 97.6%, 88.8%, and 92.6%, compared with ELISA results.
      </p>
      <table-wrap id="T6" position="float">
       <label>
        Table 6
       </label>
       <caption>
        <title>
         Comparison of recombinant protein–based Western blot with whole virus–based IFA and ELISA
         <sup>
          a,b
         </sup>
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="64"/>
        <col span="1" width="42"/>
        <col span="1" width="39"/>
        <col span="1" width="38"/>
        <col span="1" width="42"/>
        <col span="1" width="46"/>
        <col span="1" width="46"/>
        <col span="1" width="72"/>
        <col span="1" width="38"/>
        <col span="1" width="42"/>
        <col span="1" width="46"/>
        <col span="1" width="46"/>
        <col span="1" width="51"/>
        <thead>
         <tr>
          <th align="left" colspan="3" rowspan="1" scope="colgroup" valign="top">
          </th>
          <th align="center" colspan="5" rowspan="1" scope="colgroup" valign="top">
           IFA
          </th>
          <th align="center" colspan="5" rowspan="1" scope="colgroup" valign="top">
           ELISA
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Method
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Results
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Number
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Negative
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sensitivity
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Specificity
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overall agreement
           <sup>
            a
           </sup>
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Negative
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sensitivity
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Specificity
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overall agreement
           <sup>
            a
           </sup>
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Western blot
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Positive
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           47
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           42
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           5
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           91.3%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           89.8%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           90.5%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           97.6%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           88.8%
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           92.6%
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           Negative
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           48
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           4
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           44
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
          <td align="left" colspan="1" rowspan="2" valign="top">
           <hr/>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
    </sec>
    <sec sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      The study shows that in the first 2-week period after onset of SARS, RT-PCR is the most sensitive method of detecting the virus RNA, and the positive rate is the highest. However, during the convalescent phase of the disease, detecting antibodies in serum specimens is more important than detecting viral RNA. Four serologic diagnostic methods, including neutralization test, ELISA, IFA, and ICT were each evaluated and compared for antibody responses to SARS-CoV infection, in which the neutralization test was held as a reference method. The specificity of these methods is extremely good (100%), since no cross- reactions were detected with a non-SARS disease panel.
     </p>
     <p>
      However, some variations in sensitivity, positive predictive value, and negative predictive value were found among these methods. As shown in
      <xref ref-type="table" rid="T2">
       Table 2
      </xref>
      , ELISA results were highly correlated with results from the reference method, the neutralization test. The measured performance of ELISA was so outstanding, with the sensitivity, specificity, positive predictive value, and negative predictive value levels exceeding 98%, that ELISA was chosen as a confirmation alternative. In the case of IFA, both the sensitivity and negative predictive value levels were above 99%; however, the specificity of 87.8% implies that IFA may cause false-positive problems. Therefore, a weak positive IFA result should be retested by a neutralization test or ELISA. The ICT, though simple and quick to perform, is lacking in adequate sensitivity in our evaluation. Therefore, it was not a reliable test for detecting of antibodies to SARS-CoV.
     </p>
     <p>
      Since the neutralization test, ELISA, and IFA all use whole virus particles as the antigen, for safety reasons the preparation of SARS-CoV antigen must be conducted in a biosafety level 3 laboratory, which will prevent these test methods from being widely applied. Therefore, the trend in method development may lead toward the manufacturing of antigens with certain recombinant proteins. In this study, we compared a recombinant-based Western blot with the whole virus-based IFA and ELISA, and the data showed a high degree of correlation between these methods, with an overall agreement above 90% (
      <xref ref-type="table" rid="T6">
       Table 6
      </xref>
      ). Thus, using these recombinant antigens may become a much safer alternative to detect antibodies against SARS-CoV.
     </p>
     <p>
      Eight PCR-positive specimens were found in the group of the ruled out and group of those that were reported canceled (
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      ), and they were selected to test for antibodies to SARS-CoV by using acute-phase serum samples between day 1 and day 4 after the illness onset. However, no positive result was found by any of the IFA, ELISA, and neutralization test. Since no convalescent-phase serum specimens were collected from those patients, we do not know the negative results are truly negative or just resulted from the timing of gathering specimens when no antibodies were produced. Moreover, another 95 samples from the ruled-out category had been tested with ELISA, but no positive results were found. In addition, 283 specimens from 1,036 case-patients with suspected SARS were also assayed with ELISA and the neutralization test. Of them, 45 were positive with a positive rate of 15.9% (45/283). Among the 35 PCR-positive specimens in the suspected SARS category, 10 were also positive in detection of antibodies to SARS-CoV.
     </p>
     <p>
      Finally, in this study, the overall antibody positive rate for probable SARS patients was 54.2%. This rate was much lower than that reported in Hong Kong, which showed that the IgG seroconversion to SARS coronavirus was as high as 93% (70/75) at day 28 after the illness onset (
      <xref ref-type="bibr" rid="R15">
       <italic>
        15
       </italic>
      </xref>
      ). This difference may come from some different circumstances between Hong Kong and Taiwan. In the SARS outbreak of Hong Kong, the index case-patient and the infectious source leading to the outbreak were quite clear, and 75 patients were admitted to the same hospital within 4 days. From the epidemiologic point of view, therefore, the SARS outbreak was a typical cluster outbreak. In Taiwan, the samples from probable SARS case-patients were collected from over 50 hospitals between March and June 2003. Some might not have been true SARS patients but were reported as probable SARS cases. This result is likely due to the policy that suspicious SARS cases were to be reported to local health agency within 24 hours in Taiwan or the clinician who attended the patients would have been fined. In September 2003, according to the WHO criteria and the laboratory data, 346 patients were reclassified as probable SARS patients by the Center for Disease Control-Taiwan, and these data were readily accepted by WHO on September 26, 2003 (
      <xref ref-type="bibr" rid="R16">
       <italic>
        16
       </italic>
      </xref>
      ). With this new classification, the positive rate of antibodies to SARS-CoV in probable SARS patients in Taiwan was increased to 86.6% (227/262), by using the serum samples on day 28 or beyond after the onset of illness. These rates are closer to, though still lower than, rates from Hong Kong. Samples from the remaining 322 cases, excluded from the category of probable SARS cases, may have to be tested for other pathogens, such as
      <italic>
       Mycoplasma pneumoniae, Chlamydia pneumoniae,
      </italic>
      and human metapneumovirus to clarify a diagnosis.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="citation">
       <p>
        Suggested citation: Wu H-S, Chiu S-C, Tseng T-C, Lin S-F, Lin J-H, Hsu Y-F, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis [serial online] 2004 Feb [
        <italic>
         date cited
        </italic>
        ]. Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/EID/vol10no2/03-0731.htm">
         http://www.cdc.gov/ncidod/EID/vol10no2/03-0731.htm
        </ext-link>
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank the Centers for Disease Control and Prevention, Atlanta, Georgia, USA, and Tyson Bioresearch, Inc., for providing the ELISA and ICT kits to detect antibodies against SARS coronavirus.
      </p>
     </ack>
     <bio>
      <p>
       Dr. Wu is currently the deputy director of Division of Laboratory Research and Development, the Center for Disease Control, Taiwan. His research interests focus on antimicrobial resistance among
       <italic>
        Shigella
       </italic>
       , and reagent development for serologic diagnosis.
      </p>
     </bio>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <collab>
         CDC SARS Investigative Team
        </collab>
        <article-title>
         Fleischauer AT, Outbreak of severe acute respiratory syndrome—worldwide.
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         52
        </volume>
        :
        <fpage>
         226
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         12665115
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="webpage">
        Cumulative number of SARS probable cases. WHO. [
        <comment>
         Accessed July 3, 2003
        </comment>
        ] Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/2003_06_25/en/">
         http://www.who.int/csr/sars/country/2003_06_25 /en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="webpage">
        Cumulative number of SARS probable cases in Taiwan, SARS online information center, Center for Disease Control, Taiwan. [
        <comment>
         Accessed August 2, 2003
        </comment>
        ] Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov.tw/sarsen">
         http://www.cdc.gov.tw/sarsen
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Peiris
         </surname>
         <given-names>
          JS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lai
         </surname>
         <given-names>
          ST
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          LL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Guan
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yam
         </surname>
         <given-names>
          LY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lim
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1319
        </fpage>
        –
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13077-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Ksiazek
         </surname>
         <given-names>
          TG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Erdman
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Goldsmith
         </surname>
         <given-names>
          CS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          SR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peret
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Emery
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1953
        </fpage>
        –
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030781
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gunther
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Preiser
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van der Werf
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Brodt
         </surname>
         <given-names>
          HR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Becker
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1967
        </fpage>
        –
        <lpage>
         76
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030747
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Sampathkumar
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Temesgen
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Smith
         </surname>
         <given-names>
          TF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Thompson
         </surname>
         <given-names>
          RL
         </given-names>
        </string-name>
        <article-title>
         SARS: epidemiology, clinical presentation, management, and infection control measures.
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         78
        </volume>
        :
        <fpage>
         882
        </fpage>
        –
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="doi">
         10.4065/78.7.882
        </pub-id>
        <pub-id pub-id-type="pmid">
         12839084
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        Case definitions for surveillance of severe acute respiratory syndrome (SARS) [cited 2003 Sep10]. Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/casedefinition/en/">
         http://www.who.int/csr/sars/casedefinition/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        Use of laboratory methods for SARS diagnosis [cited 2003 Aug 2]. Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/labmethods/en/">
         http://www.who.int/csr/sars/labmethods/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Marx
         </surname>
         <given-names>
          PA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bryant
         </surname>
         <given-names>
          ML
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osborn
         </surname>
         <given-names>
          KG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Maul
         </surname>
         <given-names>
          DH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lerche
         </surname>
         <given-names>
          NW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lowenstine
         </surname>
         <given-names>
          LJ
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Isolation of a new serotype of simian acquired immune deficiency syndrome type D retrovirus from Celebes black macaques (
         <italic>
          Macaca nigra
         </italic>
         ) with immune deficiency and retroperitoneal fibromatosis.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         1985
        </year>
        ;
        <volume>
         56
        </volume>
        :
        <fpage>
         571
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         2997477
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Lerche
         </surname>
         <given-names>
          NW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yee
         </surname>
         <given-names>
          JL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jennings
         </surname>
         <given-names>
          MB
         </given-names>
        </string-name>
        <article-title>
         Establishing specific retrovirus-free breeding colonies of macaques: an approach to primary screening and surveillance.
        </article-title>
        <source>
         Lab Anim Sci
        </source>
        .
        <year>
         1994
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         217
        </fpage>
        –
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         7933966
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Pratelli
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Elia
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Martella
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Palmieri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cirone
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tinelli
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Prevalence of canine coronavirus antibodies by an enzyme-linked immunosorbent assay in dogs in the south of Italy.
        </article-title>
        <source>
         J Virol Methods
        </source>
        .
        <year>
         2002
        </year>
        ;
        <volume>
         102
        </volume>
        :
        <fpage>
         67
        </fpage>
        –
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0166-0934(01)00450-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         11879694
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Shyu
         </surname>
         <given-names>
          RH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shyu
         </surname>
         <given-names>
          HF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          HW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tang
         </surname>
         <given-names>
          SS
         </given-names>
        </string-name>
        <article-title>
         Colloidal gold-based immunochromatographic assay for detection of ricin.
        </article-title>
        <source>
         Toxicon
        </source>
        .
        <year>
         2002
        </year>
        ;
        <volume>
         40
        </volume>
        :
        <fpage>
         255
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0041-0101(01)00193-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         11711121
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Wu
         </surname>
         <given-names>
          HS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hsieh
         </surname>
         <given-names>
          YC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Su
         </surname>
         <given-names>
          IJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lin
         </surname>
         <given-names>
          TH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chiu
         </surname>
         <given-names>
          SC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hsu
         </surname>
         <given-names>
          YF
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients.
        </article-title>
        <source>
         J Biomed Sci
        </source>
        .
        <year>
         2004
        </year>
        <comment>
         In press
        </comment>
        <pub-id pub-id-type="doi">
         10.1007/BF02256554
        </pub-id>
        <pub-id pub-id-type="pmid">
         14730215
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Peiris
         </surname>
         <given-names>
          JS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          CM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cheng
         </surname>
         <given-names>
          VC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          KS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hung
         </surname>
         <given-names>
          IF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          LL
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1767
        </fpage>
        –
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13412-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July
        <year>
         2003
        </year>
        (revised 26 September 2003) [cited 2003 Sep 26]. Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/table2003_09_23/en/">
         http://www.who.int/csr/sars/country/table2003_09_23/en/
        </ext-link>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Microbiol Infect
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Microbiol. Infect
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Microbiology and Infection
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1198-743X
      </issn>
      <issn pub-type="epub">
       1469-0691
      </issn>
      <publisher>
       <publisher-name>
        The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30391583
      </article-id>
      <article-id pub-id-type="pmc">
       7128130
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1198-743X(18)30721-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.cmi.2018.10.016
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Remy
         </surname>
         <given-names>
          M.M.
         </given-names>
        </name>
        <email>
         Melissa.Remy@ifik.unibe.ch
        </email>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Alfter
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Chiem
         </surname>
         <given-names>
          M.-N.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Barbani
         </surname>
         <given-names>
          M.T.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Engler
         </surname>
         <given-names>
          O.B.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Suter-Riniker
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1)
       </label>
       Institute for Infectious Diseases, University of Bern, Bern CH-3001, Switzerland
      </aff>
      <aff id="aff2">
       <label>
        2)
       </label>
       Spiez Laboratory, Federal Office for Civil Protection, Spiez CH-3700, Switzerland
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author. Melissa M. Remy, Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland.
        <email>
         Melissa.Remy@ifik.unibe.ch
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        28
       </day>
       <month>
        10
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        7
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        28
       </day>
       <month>
        10
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <volume>
       25
      </volume>
      <issue>
       7
      </issue>
      <fpage>
       907.e7
      </fpage>
      <lpage>
       907.e12
      </lpage>
      <history>
       <date date-type="received">
        <day>
         30
        </day>
        <month>
         5
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         13
        </day>
        <month>
         9
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         23
        </day>
        <month>
         10
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2018 The Authors
       </copyright-statement>
       <copyright-year>
        2018
       </copyright-year>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <sec>
        <title>
         Objectives
        </title>
        <p>
         Highly pathogenic viruses such as EBOV are a threat to routine laboratory workers. Inactivation procedures with Triton X-100 0.1% and/or heat are currently recommended, but have unknown effects on the accuracy of serological testing. Furthermore, virus inactivation by Triton X-100 0.1% was shown to be ineffective in serum. This study aimed to demonstrate virus inactivation in serum by Triton X-100 1% and maintained accuracy of serological testing.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         A panel of 19 serological tests was run on patient serum samples after treatment with Triton X-100 1%, 0.1%, and 0.1% + heat inactivation at 60°C for 1 h. Mean differences between measurements (bias) were calculated applying the Bland–Altman method. To determine effectiveness of virus inactivation, herpes simplex virus 1 (HSV-1) was spiked into medium containing 90% or 1% serum, and treated with Triton X-100 0.1% or 1%. Infectious titres were then determined on Vero cells.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         Serological measurements showed good agreement between controls and samples treated with Triton X-100 0.1% and 1%, with an estimated bias of 0.6 ± 9.2% (
         <italic>
          n
         </italic>
         = 258) and –0.1 ± 18.6% (
         <italic>
          n
         </italic>
         = 174), respectively. Discordant qualitative results were rare. Conversely, heat inactivation alone and combined with Triton X-100 0.1% triggered a bias of 17.5 ± 66.4% (
         <italic>
          n
         </italic>
         = 200) and 37.9 ± 79.8% (
         <italic>
          n
         </italic>
         = 160), respectively. Triton X-100 1% completely inactivated HSV-1 in 1% and 90% serum while Triton X-100 0.1% failed to do so in 90% serum.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p>
         Unlike heat inactivation, Triton X-100 1% enabled accurate serological testing and completely inactivated HSV-1 in serum. This simple method could allow safe routine serological diagnostics in high-risk patients.
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="graphical" id="abs0015">
       <title>
        Graphical abstract
       </title>
       <p>
        <fig id="undfig1" position="anchor">
         <alt-text id="alttext0010">
          Image 1
         </alt-text>
         <graphic xlink:href="fx1_lrg">
         </graphic>
        </fig>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Biosafety
       </kwd>
       <kwd>
        Diagnosis of infections
       </kwd>
       <kwd>
        Serological tests
       </kwd>
       <kwd>
        Triton X-100
       </kwd>
       <kwd>
        Virus inactivation
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="misc0010">
       Editor: G. Greub
      </p>
     </notes>
    </front>
    <sec id="sec1">
     <title>
      Introduction
     </title>
     <p id="p0010">
      Highly pathogenic viruses such as EBOV or SARS coronavirus are a continuous threat to clinical laboratory workers. The current epidemic of Lassa virus in Nigeria is one of the latest concerns
      <xref ref-type="bibr" rid="bib1">
       [1]
      </xref>
      and European hospitals must be prepared to deal with potentially infected returning travellers. While the microbiological diagnosis of such viruses should be performed under the required biosafety measures in specialized laboratories, blood samples from patients arriving at the emergency rooms are often sent directly to the routine laboratory where biosafety levels are low.
     </p>
     <p id="p0015">
      Early symptoms caused by highly pathogenic viruses are usually non-specific and require differential diagnosis of other infectious diseases such as malaria, Dengue fever, HIV, HBV, or CMV infections. In confirmed cases, a potentially long stay in intensive care increases risks of secondary infections such as invasive fungal infections. Diagnosis of these pathologies remains mostly based on serology. Polymerase chain reaction (PCR) is an alternative diagnostic method that can be safely performed on infectious samples
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      ; however, it is only appropriate during the viraemic phase.
     </p>
     <p id="p0020">
      To inactivate highly pathogenic viruses in serum the World Health Organization (WHO) and the US Center for Diseases Control and Prevention (CDC) recommend chemical inactivation with Triton X-100 0.1%, heat inactivation at 56°C for 30 min, or a combination thereof
      <xref ref-type="bibr" rid="bib4">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . Triton X-100 is a non-ionic surfactant which can disrupt the lipid membrane of enveloped viruses without affecting proteins. It is therefore widely used in combination with tri-(
      <italic>
       N
      </italic>
      -butyl)-phosphate (TnBP) for solvent–detergent inactivation procedures of plasma products for transfusion
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      . Besides, Triton X-100 0.1% has been successfully evaluated for haematology and clinical chemistry
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      and for malaria rapid diagnostic tests (RDTs)
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       [12]
      </xref>
      . Accuracy of immunoassays after Triton X-100 treatment of serum was only partially assessed in 1988 and no decrease in sensitivity was reported
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      .
     </p>
     <p id="p0025">
      Heat inactivation was compatible with detection of EBOV-specific IgG and IgM
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      and other viral antigens
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      . However clinical chemistry studies showed that protein measurements and especially enzymatic activity measurements were mildly to severely affected by heat
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       [16]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      . Other easily applicable inactivation methods such as SDS treatment unfortunately denature proteins and are not suited for serological or clinical chemistry tests
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       [19]
      </xref>
      .
     </p>
     <p id="p0030">
      Efficacy of heat inactivation was demonstrated for several enveloped viruses
      <xref ref-type="bibr" rid="bib20">
       [20]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib21">
       [21]
      </xref>
      , including haemorrhagic fever viruses
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      . Concerning detergents, complete inactivation of HIV was achieved with 0.2% of Triton X-100
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      whereas EBOV treatment with 0.1% of Triton X-100 led to incomplete inactivation with a 4 log infectivity reduction
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      . Besides, it has been recently claimed that the inactivation potential of Triton X-100 0.1% was annulled in serum
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      . Inactivation tests were indeed performed on EBOV and herpes simplex virus type 1 (HSV-1) in 0.98%, 9.8%, or 98% serum, and viral inactivation by Triton X-100 only succeeded in medium with less than 10% serum, suggesting that some factors in serum interfere with detergent effects. In practice, Triton X-100 concentration is often increased to 1% to ensure a higher level of safety although no inactivation data support this choice. It thus remains to be determined if a higher concentration of Triton X-100 can overcome efficiency issues in serum.
     </p>
     <p id="p0035">
      The objective of our study was to assess the accuracy of a wide range of serological tests after chemical or thermal inactivation of serum. Triton X-100 0.1% or 1% final concentration and/or heat inactivation at 60°C for 60 min were selected as promising inactivation methods. In addition, HSV-1 inactivation tests were performed with Triton X-100 0.1% and 1% in medium containing 1% or 90% serum. We hypothesize that a tenfold increase of Triton X-100 final concentration might allow complete virus inactivation in serum.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Methods
     </title>
     <sec id="sec2.1">
      <title>
       Ethics and sample selection
      </title>
      <p id="p0040">
       All human blood samples were obtained for routine patient serological testing at the Institute for Infectious Diseases, University of Bern, Switzerland. There was no suspicion of highly pathogenic virus infection in these patients. Sera used in this study were stored at –20°C for less than 5 years. They were retrospectively identified using the electronic database of the Institute for Infectious Diseases of the University of Bern according to the serological tests originally performed and to the results obtained. Each selected serum sample was anonymized and tested for the same serological test as originally. Informed consent for use of anonymized leftover patient material was waived. This procedure has been approved by the Cantonal Research Ethics Committee of Bern, Switzerland (BASEC-No Req-2018-00288).
      </p>
     </sec>
     <sec id="sec2.2">
      <title>
       Serum inactivation for serological testing
      </title>
      <p id="p0045">
       The chemical inactivation procedure consisted of mixing patient serum 10:1 with PBS or Triton X-100 1% or 10% working solution (please see
       <xref ref-type="sec" rid="appsec1">
        Supplementary Materials
       </xref>
       ). Samples were incubated for 60 min at room temperature. Final concentrations of Triton X-100 were 0.1% and 1% (precisely 0.09% and 0.9%). Some of the samples treated with PBS or Triton X-100 1% were additionally thermally inactivated by incubation at 60°C for 1 h in a table top thermoblock without shaking. Samples were then kept a maximum of 24 h at 4°C before being used for different serological tests.
      </p>
     </sec>
     <sec id="sec2.3">
      <title>
       Serological tests
      </title>
      <p id="p0050">
       Pre-treated samples were analysed in parallel with the following methods. HIV, HCV, HBV, EBV, CMV, and toxoplasmosis markers (Ag, total Ig, IgM and/or IgG) were analysed on an Architect® system (Abbott Diagnostics), a fully automated immuno-analyser based on chemiluminescent microparticle immunoassays (CMIAs). Antibodies to
       <italic>
        Brucella
       </italic>
       species (IgM and IgG) were tested by indirect chemiluminescent immunoassay (CLIA) on another fully automated analyser (VirClia®, VirCell, Granada, Spain). For aspergillosis, a galactomanan test (PLATELIA™ ASPERGILLUS Ag, Biorad 62794, Hercules, CA, USA) was performed manually. Antibodies to Dengue virus (IgM, IgG) were detected by a manual ELISA (Euroimmun EI 266b-9601).
      </p>
      <p id="p0055">
       Reactivity to
       <italic>
        Francisella tularensis
       </italic>
       was evaluated by a rapid test (Virapid Tularemia, Viracell Microbiologists VR006) and by a microagglutination test using
       <italic>
        F. tularensis
       </italic>
       Ag (Becton Dickinson 241050, Franklin Lakes, NJ, USA). All manual tests were performed according to the manufacturer's instructions.
      </p>
      <p id="p0060">
       Please see
       <xref ref-type="sec" rid="appsec1">
        Supplementary Materials
       </xref>
       for further details.
      </p>
     </sec>
     <sec id="sec2.4">
      <title>
       HSV-1 inactivation and titration
      </title>
      <p id="p0065">
       Concentrated HSV-1 stock was spiked in MEM containing 1% FBS or in pure human serum from an HSV-1 seronegative donor. It was then mixed 10:1 with Triton X-100 working solution and incubated for 1 h at room temperature. Final concentrations of Triton X-100 were 0.1% and 1% (precisely 0.09% and 0.9%). Final concentrations of serum were 90% for human serum and 1% for FBS. Initial viral titre in these samples ranged between 1.4 × 10
       <sup>
        7
       </sup>
       and 7.6 × 10
       <sup>
        7
       </sup>
       TCID
       <sub>
        50
       </sub>
       /mL. Excess detergent was removed from inactivated viral samples (please see
       <xref ref-type="sec" rid="appsec1">
        Supplementary Materials
       </xref>
       ) and each sample was then titrated on Vero cells (please see
       <xref ref-type="sec" rid="appsec1">
        Supplementary Materials
       </xref>
       ). Each experiment was repeated twice. Controls containing Triton X-100 without virus were also filtered and titrated to evaluate cytotoxicity caused by residual detergent.
      </p>
     </sec>
     <sec id="sec2.5">
      <title>
       Statistics
      </title>
      <p id="p0070">
       Graphpad Prism (version 7.04) was used to plot and analyse data. For serological test results, Bland–Altman plots were constructed to evaluate differences between treated and untreated samples as percentage of differences from the mean (bias). Serological results from chemically inactivated samples were additionally analysed by the Deming linear regression model. Spearman's correlation coefficients were calculated (data did not pass the D'Agostino and Pearson normality test). To assess agreement of qualitative items Cohen's weighted kappa coefficients were calculated with GraphPad QuickCalcs.
      </p>
      <p id="p0075">
       HSV-1 titres were log-converted to obtain a near-normal distribution for statistical analysis. One-way analysis of variance (ANOVA) was performed followed by Dunnett's post test to compare multiple groups to a control group. A p value &gt;0.05 was considered not significant (ns); p &lt; 0.001 was considered highly significant (***).
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <title>
      Results
     </title>
     <sec id="sec3.1">
      <title>
       Serological test results of chemically or thermally inactivated patient serum samples
      </title>
      <p id="p0080">
       Patient serum samples received for routine serological testing were chemically inactivated with Triton X-100 at a final concentration of 0.1% or 1% and compared with PBS-treated controls by several ELISA-based serological assays (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). Samples were carefully selected to cover a wide range of concentrations. Qualitative results were assessed for each sample and a false result rate (FRR) was calculated by computing false-negative and false-positive results compared with controls for each test.
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Accuracy of ELISA-based serological tests after chemical and/or thermal inactivation of serum
         </p>
        </caption>
        <alt-text id="alttext0010a">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
           </th>
           <th rowspan="2">
            Baseline values
           </th>
           <th colspan="4">
            Triton X-100 0.1%
            <hr/>
           </th>
           <th colspan="4">
            Triton X-100 1%
            <hr/>
           </th>
           <th colspan="4">
            Heat
            <hr/>
           </th>
           <th colspan="4">
            Triton X-100 0.1% + heat
            <hr/>
           </th>
          </tr>
          <tr>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            % Bias ± SD
           </th>
           <th>
            95% LoA
           </th>
           <th>
            FRR, % (95% CI)
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            % Bias ± SD
           </th>
           <th>
            95% LoA
           </th>
           <th>
            FRR, % (95% CI)
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            % Bias ± SD
           </th>
           <th>
            95% LoA
           </th>
           <th>
            FRR, % (95% CI)
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            % Bias ± SD
           </th>
           <th>
            95% LoA
           </th>
           <th>
            FRR, % (95% CI)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            <bold>
             CMIA
            </bold>
           </td>
           <td>
           </td>
           <td>
            <bold>
             201
            </bold>
           </td>
           <td>
            <bold>
             –0.9 ± 9.4
            </bold>
           </td>
           <td>
            <bold>
             –19.4; 17.6
            </bold>
           </td>
           <td>
            <bold>
             0
            </bold>
            <break>
            </break>
            <bold>
             (0–1.9)
            </bold>
           </td>
           <td>
            <bold>
             117
            </bold>
           </td>
           <td>
            <bold>
             –2.7 ± 20.8
            </bold>
           </td>
           <td>
            <bold>
             –43.4; 38.1
            </bold>
           </td>
           <td>
            <bold>
             0.9
            </bold>
            <break>
            </break>
            <bold>
             (0–4.7)
            </bold>
           </td>
           <td>
            <bold>
             200
            </bold>
           </td>
           <td>
            <bold>
             17.5 ± 66.4
            </bold>
           </td>
           <td>
            <bold>
             –112.6; 147.5
            </bold>
           </td>
           <td>
            <bold>
             14.5
            </bold>
            <break>
            </break>
            <bold>
             (10.3–20)
            </bold>
           </td>
           <td>
            <bold>
             160
            </bold>
           </td>
           <td>
            <bold>
             37.9 ± 79.8
            </bold>
           </td>
           <td>
            <bold>
             –118.4; 194.2
            </bold>
           </td>
           <td>
            <bold>
             25.6
            </bold>
            <break>
            </break>
            <bold>
             (19.5–32.9)
            </bold>
           </td>
          </tr>
          <tr>
           <td>
            HIV Ag + Ab
           </td>
           <td>
            0.2–837.9 S/CO
           </td>
           <td>
            17
           </td>
           <td>
            0.3 ± 1.6
           </td>
           <td>
            –2.9; 3.5
           </td>
           <td>
            0
            <break>
            </break>
            (0–18.4)
           </td>
           <td>
            10
           </td>
           <td>
            4.2 ± 6
           </td>
           <td>
            –7.4; 15.9
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            17
           </td>
           <td>
            –8.2 ± 34.8
           </td>
           <td>
            –76.5; 60
           </td>
           <td>
            5.9
            <break>
            </break>
            (0.3–27)
           </td>
           <td>
            10
           </td>
           <td>
            –15.2 ± 44
           </td>
           <td>
            –101.4; 70.9
           </td>
           <td>
            10
            <break>
            </break>
            (0.5–40.4)
           </td>
          </tr>
          <tr>
           <td>
            HCV IgG
           </td>
           <td>
            0.2–14.1 S/CO
           </td>
           <td>
            17
           </td>
           <td>
            –2.2 ± 7.5
           </td>
           <td>
            –16.9; 12.4
           </td>
           <td>
            0
            <break>
            </break>
            (0–18.4)
           </td>
           <td>
            10
           </td>
           <td>
            –1.2 ± 4.3
           </td>
           <td>
            –9.7; 7.2
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            17
           </td>
           <td>
            41 ± 62
           </td>
           <td>
            –80.6; 162.6
           </td>
           <td>
            11.8
            <break>
            </break>
            (2.1–34.3)
           </td>
           <td>
            11
           </td>
           <td>
            84.8 ± 61.2
           </td>
           <td>
            –35.1; 204.8
           </td>
           <td>
            63.6
            <break>
            </break>
            (35.4–84.8)
           </td>
          </tr>
          <tr>
           <td>
            HBV HBs Ag
           </td>
           <td>
            0.22–5410.5 S/CO
           </td>
           <td>
            22
           </td>
           <td>
            –7.6 ± 10.2
           </td>
           <td>
            –27.5; 12.3
           </td>
           <td>
            0
            <break>
            </break>
            (0–14.9)
           </td>
           <td>
            10
           </td>
           <td>
            –14.5 ± 34.4
           </td>
           <td>
            –81.9; 53
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            22
           </td>
           <td>
            10 ± 20.1
           </td>
           <td>
            –29.4; 49.4
           </td>
           <td>
            0
            <break>
            </break>
            (0–14.9)
           </td>
           <td>
            15
           </td>
           <td>
            12.4 ± 26.3
           </td>
           <td>
            –39.1; 63.9
           </td>
           <td>
            0
            <break>
            </break>
            (0–20.4)
           </td>
          </tr>
          <tr>
           <td>
            HBV HBs IgG
           </td>
           <td>
            0.5–900 mIU/mL
           </td>
           <td>
            22
           </td>
           <td>
            2.9 ± 8.9
           </td>
           <td>
            –14.6; 20.3
           </td>
           <td>
            0
            <break>
            </break>
            (0–14.9)
           </td>
           <td>
            10
           </td>
           <td>
            –11.6 ± 32.2
           </td>
           <td>
            –74.7; 51.6
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            21
           </td>
           <td>
            –12.2 ± 24.7
           </td>
           <td>
            –60.7; 36.2
           </td>
           <td>
            4.8
            <break>
            </break>
            (0.2–22.7)
           </td>
           <td>
            8
           </td>
           <td>
            –16.9 ± 43.7
           </td>
           <td>
            –102.6; 68.8
           </td>
           <td>
            0
            <break>
            </break>
            (0–32.4)
           </td>
          </tr>
          <tr>
           <td>
            HBV HBc Ig
           </td>
           <td>
            0.2–10.1 S/CO
           </td>
           <td>
            22
           </td>
           <td>
            –1.1 ± 6.3
           </td>
           <td>
            –13.4; 11.3
           </td>
           <td>
            0
            <break>
            </break>
            (0–14.9)
           </td>
           <td>
            10
           </td>
           <td>
            –16.8 ± 43.9
           </td>
           <td>
            –102.7; 69.2
           </td>
           <td>
            10
            <break>
            </break>
            (0.5–40.4)
           </td>
           <td>
            22
           </td>
           <td>
            24.9 ± 47.6
           </td>
           <td>
            –68.4; 118.1
           </td>
           <td>
            9.1
            <break>
            </break>
            (1.6–27.8)
           </td>
           <td>
            15
           </td>
           <td>
            66.8 ± 59.7
           </td>
           <td>
            –50.2; 183.7
           </td>
           <td>
            26.7
            <break>
            </break>
            (10.9–52)
           </td>
          </tr>
          <tr>
           <td>
            EBV VCA IgM
           </td>
           <td>
            0.2–19.2 S/CO
           </td>
           <td>
            15
           </td>
           <td>
            0.2 ± 3.3
           </td>
           <td>
            –6.2; 6.6
           </td>
           <td>
            0
            <break>
            </break>
            (0–20.4)
           </td>
           <td>
            9
           </td>
           <td>
            2.5 ± 4.2
           </td>
           <td>
            –5.7; 10.7
           </td>
           <td>
            0
            <break>
            </break>
            (0–29.9)
           </td>
           <td>
            15
           </td>
           <td>
            –35.7 ± 37.8
           </td>
           <td>
            –109.8; 38.4
           </td>
           <td>
            0
            <break>
            </break>
            (0–20.4)
           </td>
           <td>
            15
           </td>
           <td>
            –37.5 ± 47.9
           </td>
           <td>
            –131.4; 56.5
           </td>
           <td>
            0
            <break>
            </break>
            (0–20.4)
           </td>
          </tr>
          <tr>
           <td>
            EBV VCA IgG
           </td>
           <td>
            0.2–68.8 S/CO
           </td>
           <td>
            15
           </td>
           <td>
            2.3 ± 16.5
           </td>
           <td>
            –30; 34.7
           </td>
           <td>
            0
            <break>
            </break>
            (0–20.4)
           </td>
           <td>
            9
           </td>
           <td>
            –2.7 ± 3.4
           </td>
           <td>
            –9.2; 3.9
           </td>
           <td>
            0
            <break>
            </break>
            (0–29.9)
           </td>
           <td>
            15
           </td>
           <td>
            69 ± 83.3
           </td>
           <td>
            –94.4; 232.3
           </td>
           <td>
            13.3
            <break>
            </break>
            (2.4–37.9)
           </td>
           <td>
            15
           </td>
           <td>
            84 ± 78.3
           </td>
           <td>
            –69.4; 237.5
           </td>
           <td>
            13.3
            <break>
            </break>
            (2.4–37.9)
           </td>
          </tr>
          <tr>
           <td>
            EBV EBNA IgG
           </td>
           <td>
            0.2–21.2 S/CO
           </td>
           <td>
            15
           </td>
           <td>
            1.4 ± 3.9
           </td>
           <td>
            –6.3; 9.1
           </td>
           <td>
            0
            <break>
            </break>
            (0–20.4)
           </td>
           <td>
            9
           </td>
           <td>
            –1.9 ± 4.4
           </td>
           <td>
            –10.6; 6.8
           </td>
           <td>
            0
            <break>
            </break>
            (0–29.9)
           </td>
           <td>
            15
           </td>
           <td>
            50.3 ± 55.2
           </td>
           <td>
            –57.9; 158.6
           </td>
           <td>
            40
            <break>
            </break>
            (19.8–64.3)
           </td>
           <td>
            15
           </td>
           <td>
            72.1 ± 66.6
           </td>
           <td>
            –58.4; 202.5
           </td>
           <td>
            60
            <break>
            </break>
            (35.7–80.2)
           </td>
          </tr>
          <tr>
           <td>
            CMV IgM
           </td>
           <td>
            0.2–8.7 S/CO
           </td>
           <td>
            14
           </td>
           <td>
            1.6 ± 4.9
           </td>
           <td>
            –8; 11.2
           </td>
           <td>
            0
            <break>
            </break>
            (0–21.5)
           </td>
           <td>
            10
           </td>
           <td>
            4 ± 7.6
           </td>
           <td>
            –10.9; 18.9
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            14
           </td>
           <td>
            –0.8 ± 80.8
           </td>
           <td>
            –159.1; 157.5
           </td>
           <td>
            21.4
            <break>
            </break>
            (7.6–47.6)
           </td>
           <td>
            14
           </td>
           <td>
            60.1 ± 72.5
           </td>
           <td>
            –81.9; 202.2
           </td>
           <td>
            21.4
            <break>
            </break>
            (7.6–47.6)
           </td>
          </tr>
          <tr>
           <td>
            CMV IgG
           </td>
           <td>
            0.27–225 AU/mL
           </td>
           <td>
            14
           </td>
           <td>
            –2.8 ± 19.4
           </td>
           <td>
            –40.8; 35.2
           </td>
           <td>
            0
            <break>
            </break>
            (0–21.5)
           </td>
           <td>
            10
           </td>
           <td>
            11.8 ± 17.3
           </td>
           <td>
            –22; 45.6
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            14
           </td>
           <td>
            95.2 ± 92.9
           </td>
           <td>
            –86.8; 277.2
           </td>
           <td>
            50
            <break>
            </break>
            (26.8–73.2)
           </td>
           <td>
            14
           </td>
           <td>
            109.3 ± 95.2
           </td>
           <td>
            –77.3; 295.9
           </td>
           <td>
            57.1
            <break>
            </break>
            (32.6–78.6)
           </td>
          </tr>
          <tr>
           <td>
            Toxo IgM
           </td>
           <td>
            0.2–19.1 S/CO
           </td>
           <td>
            14
           </td>
           <td>
            –1.6 ± 4.5
           </td>
           <td>
            –10.4; 7.3
           </td>
           <td>
            0
            <break>
            </break>
            (0–21.5)
           </td>
           <td>
            10
           </td>
           <td>
            –1.8 ± 6.8
           </td>
           <td>
            –15.1; 11.6
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            14
           </td>
           <td>
            –44.6 ± 33.3
           </td>
           <td>
            –109.7; 20.6
           </td>
           <td>
            21.4
            <break>
            </break>
            (7.6–47.6)
           </td>
           <td>
            14
           </td>
           <td>
            –49.1 ± 36.5
           </td>
           <td>
            –120.6; 22.5
           </td>
           <td>
            21.4
            <break>
            </break>
            (7.6–47.6)
           </td>
          </tr>
          <tr>
           <td>
            Toxo IgG
           </td>
           <td>
            0.2–180 IU/mL
           </td>
           <td>
            14
           </td>
           <td>
            –2.8 ± 7.7
           </td>
           <td>
            –17.9; 12.3
           </td>
           <td>
            0
            <break>
            </break>
            (0–21.5)
           </td>
           <td>
            10
           </td>
           <td>
            –3.6 ± 9.8
           </td>
           <td>
            –22.8; 15.5
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            14
           </td>
           <td>
            33.7 ± 72.8
           </td>
           <td>
            –109.1; 176.4
           </td>
           <td>
            14.3
            <break>
            </break>
            (2.5–39.9)
           </td>
           <td>
            14
           </td>
           <td>
            54.4 ± 77.8
           </td>
           <td>
            –98.1; 207
           </td>
           <td>
            28.6
            <break>
            </break>
            (11.7–54.6)
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             CLIA
            </bold>
           </td>
           <td>
           </td>
           <td>
            <bold>
             26
            </bold>
           </td>
           <td>
            <bold>
             1.3 ± 7.7
            </bold>
           </td>
           <td>
            <bold>
             –13.7; 16.4
            </bold>
           </td>
           <td>
            <bold>
             0
            </bold>
            <break>
            </break>
            <bold>
             (0–12.9)
            </bold>
           </td>
           <td>
            <bold>
             26
            </bold>
           </td>
           <td>
            <bold>
             3.4 ± 11.2
            </bold>
           </td>
           <td>
            <bold>
             –18.4; 25.3
            </bold>
           </td>
           <td>
            <bold>
             0
            </bold>
            <break>
            </break>
            <bold>
             (0–12.9)
            </bold>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Brucella IgM
           </td>
           <td>
            0.2–5.3 index
           </td>
           <td>
            13
           </td>
           <td>
            2.4 ± 5.6
           </td>
           <td>
            –8.4; 13.3
           </td>
           <td>
            0
            <break>
            </break>
            (0–22.8)
           </td>
           <td>
            13
           </td>
           <td>
            5.5 ± 9.7
           </td>
           <td>
            –13.5; 24.6
           </td>
           <td>
            0
            <break>
            </break>
            (0–22.8)
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Brucella IgG
           </td>
           <td>
            0.2–10 index
           </td>
           <td>
            13
           </td>
           <td>
            0.2 ± 9.5
           </td>
           <td>
            –18.4; 18.7
           </td>
           <td>
            0
            <break>
            </break>
            (0–22.8)
           </td>
           <td>
            13
           </td>
           <td>
            1.3 ± 12.5
           </td>
           <td>
            –23.1; 25.7
           </td>
           <td>
            0
            <break>
            </break>
            (0–22.8)
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Manual ELISA
            </bold>
           </td>
           <td>
           </td>
           <td>
            <bold>
             31
            </bold>
           </td>
           <td>
            <bold>
             0.1 ± 8.7
            </bold>
           </td>
           <td>
            <bold>
             –16.9; 17
            </bold>
           </td>
           <td>
            <bold>
             3.2
            </bold>
            <break>
            </break>
            <bold>
             (0.2–16.2)
            </bold>
           </td>
           <td>
            <bold>
             31
            </bold>
           </td>
           <td>
            <bold>
             6.4 ± 12.2
            </bold>
           </td>
           <td>
            <bold>
             –17.6; 30.3
            </bold>
           </td>
           <td>
            <bold>
             6.5
            </bold>
            <break>
            </break>
            <bold>
             (1.1–20.7)
            </bold>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Aspergillus
           </td>
           <td>
            0.1–7.9 index
           </td>
           <td>
            11
           </td>
           <td>
            –1.5 ± 12.7
           </td>
           <td>
            –26.4; 23.5
           </td>
           <td>
            0
            <break>
            </break>
            (0–25.9)
           </td>
           <td>
            11
           </td>
           <td>
            5.9 ± 18
           </td>
           <td>
            –29.5; 41.2
           </td>
           <td>
            9.1
            <break>
            </break>
            (0.5–37.7)
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            DENV IgM
           </td>
           <td>
            0.1–6.4 index
           </td>
           <td>
            10
           </td>
           <td>
            2 ± 6.7
           </td>
           <td>
            –11.2; 15.1
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
            10
           </td>
           <td>
            10 ± 8.8
           </td>
           <td>
            –7.2; 27.4
           </td>
           <td>
            0
            <break>
            </break>
            (0–27.8)
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            DENV IgG
           </td>
           <td>
            0.1–3.9 index
           </td>
           <td>
            10
           </td>
           <td>
            –0.2 ± 4.2
           </td>
           <td>
            –8.5; 8.1
           </td>
           <td>
            10
            <break>
            </break>
            (0.5–40.4)
           </td>
           <td>
            10
           </td>
           <td>
            3.2 ± 5.7
           </td>
           <td>
            –8; 14.3
           </td>
           <td>
            10
            <break>
            </break>
            (0.5–40.4)
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Total
            </bold>
           </td>
           <td>
           </td>
           <td>
            <bold>
             258
            </bold>
           </td>
           <td>
            <bold>
             –0.6 ± 9.2
            </bold>
           </td>
           <td>
            <bold>
             –18.6; 17.4
            </bold>
           </td>
           <td>
            <bold>
             0.4
            </bold>
            <break>
            </break>
            <bold>
             (0–2.2)
            </bold>
           </td>
           <td>
            <bold>
             174
            </bold>
           </td>
           <td>
            <bold>
             –0.1 ± 18.6
            </bold>
           </td>
           <td>
            <bold>
             –36.7; 36.4
            </bold>
           </td>
           <td>
            <bold>
             1.7
            </bold>
            <break>
            </break>
            <bold>
             (0.5–4.9)
            </bold>
           </td>
           <td>
            <bold>
             200
            </bold>
           </td>
           <td>
            <bold>
             17.5 ± 66.4
            </bold>
           </td>
           <td>
            <bold>
             –112.6; 147.5
            </bold>
           </td>
           <td>
            <bold>
             14.5
            </bold>
            <break>
            </break>
            <bold>
             (10.3–20)
            </bold>
           </td>
           <td>
            <bold>
             160
            </bold>
           </td>
           <td>
            <bold>
             37.9 ± 79.8
            </bold>
           </td>
           <td>
            <bold>
             –118.4; 194.2
            </bold>
           </td>
           <td>
            <bold>
             25.6
            </bold>
            <break>
            </break>
            <bold>
             (19.5–32.9)
            </bold>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tspara0015">
          <p>
           Bias, mean difference (Treated – Control) vs. average in %; LoA, Bland–Altman limits of agreement (mean ± 1.96SD); SD, standard deviation; CI, confidence interval; FRR, false results rate or percentage at which the qualitative results of the treated samples differed from that of the controls; CMIA, chemiluminescent microparticle immunoassays (Architect®, Abbott Diagnostics); CLIA, chemiluminescent immunoassay (VirClia®, VirCell); S/CO, signal-to-cutoff ratio; HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; EBV, Epstein–Barr virus; CMV, human cytomegalovirus; Toxo,
           <italic>
            Toxoplasma gondii
           </italic>
           ; DENV, Dengue virus; Ag, antigen; Ab, antibody.
          </p>
         </fn>
         <fn id="tspara0020">
          <p>
           Control samples were treated with PBS.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="p0085">
       The bias of test results compared with controls (mean differences versus average) was –0.6 ± 9.2% after treatment with 0.1% of Triton X-100 and –0.1 ± 18.6% after treatment with 1% of Triton X-100 (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ,
       <xref ref-type="fig" rid="fig1">
        Figs. 1
       </xref>
       a,b). This good agreement was confirmed by other statistical methods including Deming linear regression with Spearman correlation coefficient &gt;0.99 (
       <xref ref-type="sec" rid="appsec1">
        Table S1
       </xref>
       ). Automated chemiluminescent assays (CMIA and CLIA) gave similar results to manually performed ELISAs. Only one discordant qualitative result was observed for Dengue IgG after treatment with Triton X-100 0.1% and concerned a sample which was around the borderline cut-off (
       <xref ref-type="sec" rid="appsec1">
        Table S2
       </xref>
       ). The overall false result rate after treatment with 0.1% of Triton X-100 was 0.4% (0–2.2%,
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). Increasing concentration of Triton X-100 to 1% led to a non-significant increase of this false result rate to 1.7% (0.5–4.9%,
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). Accordingly, serology results were not substantially altered (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       b). False results concerned the same borderline Dengue IgG sample: one sample with an
       <italic>
        Aspergillus
       </italic>
       test value around the positive cut-off and one sample for which HBV anti-HBc total Ig changed from weak positive in the control to negative in Triton X-100 1% (
       <xref ref-type="sec" rid="appsec1">
        Table S2
       </xref>
       ).
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Agreement of serological test results after chemical or thermal inactivation of patient serum samples. Bland–Altman plots showing differences versus average of treated and control samples in percent (bias). Patient serum samples inactivated with Triton X-100 0.1% (a), Triton X-100 1% (b), heat inactivation at 60°C for 1 h (c), or a combination of Triton X-100 0.1% and heat inactivation (d) were used for a panel of ELISA-based serological assays including automated chemiluminescence immunoassays (CMIA and CLIA) and manual ELISAs (Man.) Control samples received an equivalent amount of PBS. Solid lines indicate mean bias, dashed lines indicate 95% limits of agreement (mean ± 1.96 SD), dotted lines indicate 0 (no bias). Abbreviations: HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; EBV, Epstein-Barr virus; CMV, human cytomegalovirus; Toxo,
          <italic>
           Toxoplasma gondii
          </italic>
          ; DENV, Dengue virus; Ag, antigen; Ab, antibody.
         </p>
        </caption>
        <alt-text id="alttext0020">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0090">
       In contrast, thermal inactivation by incubation of serum samples at 60°C for 1 h yielded aberrant serological test results with a mean bias of 17.5 ± 66.4%, which further increased to 37.9 ± 79.8% when combined with Triton X-100 0.1% (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ,
       <xref ref-type="fig" rid="fig1">
        Figs. 1
       </xref>
       c,d). Since results did not fulfil the assumption of homoscedasticity (
       <xref ref-type="fig" rid="fig1">
        Figs. 1
       </xref>
       c,d), no regression analysis was performed. The most relevant changes were seen for CMV IgG with biases of more than 95% (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). Accordingly, high false result rates were observed for most of the assays with an average of 14.5% (10.3–20.0) after heat inactivation and 25.6% (19.5–32.9) after the combination treatment (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). HIV antigen + antibody (Ag+Ab), HBV HBs Ag, and IgG test results, however, remained relatively unaffected by heat inactivation with minimal bias and no discordant qualitative results (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ).
      </p>
      <p id="p0095">
       In addition to the ELISA-based assays, we analysed the performances of a rapid test and a microagglutination test for the diagnosis of tularaemia after chemical or thermal inactivation of serum samples (
       <xref ref-type="table" rid="tbl2">
        Table 2
       </xref>
       ). Triton X-100 0.1% did not have an effect on the accuracy of both tests. Triton X-100 1%, however, yielded acceptable rapid test results but disturbed microagglutination results. End titres were affected and several prozone and partial agglutination effects were observed. Heat inactivation yielded both poor rapid test and poor microagglutination results with many prozone effects.
       <table-wrap id="tbl2" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Effect of inactivation treatments on Tularemia rapid test and microagglutination test
         </p>
        </caption>
        <alt-text id="alttext0035">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Patient
           </th>
           <th colspan="4">
            Rapid test
            <hr/>
           </th>
           <th colspan="4">
            Microagglutination
            <hr/>
           </th>
          </tr>
          <tr>
           <th>
            Control
           </th>
           <th>
            Triton X-100 0.1%
           </th>
           <th>
            Triton X-100 1%
           </th>
           <th>
            Heat
           </th>
           <th>
            Control
           </th>
           <th>
            Triton X-100 0.1%
           </th>
           <th>
            Triton X-100 1%
           </th>
           <th>
            Heat
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            1
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            &lt;10
           </td>
           <td>
            &lt;10
           </td>
           <td>
            &lt;10
            <xref ref-type="table-fn" rid="tbl2fna">
             a
            </xref>
           </td>
           <td>
            &lt;10
           </td>
          </tr>
          <tr>
           <td>
            2
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            1+
           </td>
           <td>
            2560
           </td>
           <td>
            2560
           </td>
           <td>
            1280
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
           <td>
            1280
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td>
            3
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            &lt;10
           </td>
           <td>
            &lt;10
           </td>
           <td>
            &lt;10
            <xref ref-type="table-fn" rid="tbl2fna">
             a
            </xref>
           </td>
           <td>
            &lt;10
           </td>
          </tr>
          <tr>
           <td>
            4
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            1+
           </td>
           <td>
            1280
           </td>
           <td>
            1280
           </td>
           <td>
            1280
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
           <td>
            640
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td>
            5
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            1+
           </td>
           <td>
            <bold>
             –
            </bold>
           </td>
           <td>
            160
           </td>
           <td>
            160
           </td>
           <td>
            <bold>
             &lt;10
            </bold>
            <xref ref-type="table-fn" rid="tbl2fna">
             a
            </xref>
           </td>
           <td>
            <bold>
             &lt;10
            </bold>
           </td>
          </tr>
          <tr>
           <td>
            6
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            1+
           </td>
           <td>
            ±
           </td>
           <td>
            320
           </td>
           <td>
            320
           </td>
           <td>
            <bold>
             40
            </bold>
            <xref ref-type="table-fn" rid="tbl2fna">
             a
            </xref>
           </td>
           <td>
            <bold>
             &lt;10
            </bold>
           </td>
          </tr>
          <tr>
           <td>
            7
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            –
           </td>
           <td>
            &lt;10
           </td>
           <td>
            &lt;10
           </td>
           <td>
            <bold>
             80
            </bold>
            <xref ref-type="table-fn" rid="tbl2fna">
             a
            </xref>
           </td>
           <td>
            &lt;10
           </td>
          </tr>
          <tr>
           <td>
            8
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            1+
           </td>
           <td>
            640
           </td>
           <td>
            640
           </td>
           <td>
            1280
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
           <td>
            320
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td>
            9
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            2+
           </td>
           <td>
            ±
           </td>
           <td>
            2560
           </td>
           <td>
            2560
           </td>
           <td>
            1280
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
           <td>
            1280
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td>
            10
            <hr/>
           </td>
           <td>
            2+
            <hr/>
           </td>
           <td>
            2+
            <hr/>
           </td>
           <td>
            2+
            <hr/>
           </td>
           <td>
            1+
            <hr/>
           </td>
           <td>
            5120
            <hr/>
           </td>
           <td>
            5120
            <hr/>
           </td>
           <td>
            10240
            <hr/>
           </td>
           <td>
            5120
            <xref ref-type="table-fn" rid="tbl2fnb">
             b
            </xref>
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Weighted kappa
            </bold>
           </td>
           <td>
           </td>
           <td>
            1.000
           </td>
           <td>
            0.851
           </td>
           <td>
            0.353
           </td>
           <td>
           </td>
           <td>
            1.000
           </td>
           <td>
            0.657
           </td>
           <td>
            0.684
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tspara0030">
          <p>
           Bold indicates false-qualitative result.
          </p>
         </fn>
         <fn id="tspara0035">
          <p>
           Controls and heat-inactivated samples were treated with an equivalent volume of PBS.
          </p>
         </fn>
         <fn id="tspara0040">
          <p>
           A negative result in the rapid test is indicated by a dash (–), whereas positive test results are indicated by ±, 1+, or 2+ (scale from weakly positive test to strongly positive test).
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tbl2fna">
          <label>
           a
          </label>
          <p id="ntpara0010">
           Partial agglutination.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tbl2fnb">
          <label>
           b
          </label>
          <p id="ntpara0015">
           Prozone effect.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec3.2">
      <title>
       Effect of serum concentration on the chemical inactivation of HSV-1
      </title>
      <p id="p0100">
       To evaluate the inactivation potential of Triton X-100 on enveloped viruses we chose HSV-1 as a model virus. HSV is indeed a prototypic enveloped virus that grows easily to high titres and for which rapid and accurate infectivity assays are available
       <xref ref-type="bibr" rid="bib23">
        [23]
       </xref>
       . For these reasons it has been widely used for inactivation studies with various detergents
       <xref ref-type="bibr" rid="bib10">
        [10]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        [24]
       </xref>
       . Since it has been recently shown that serum annulled the inactivation effect of Triton X-100 0.1%
       <xref ref-type="bibr" rid="bib10">
        [10]
       </xref>
       we performed our assays in 90% human serum or in medium containing 1% serum.
      </p>
      <p id="p0105">
       As previously shown, Triton X-100 0.1% could completely inactivate HSV-1 in medium containing 1% serum with a titre reduction of at least 5 log
       <sub>
        10
       </sub>
       but it had no effect on HSV-1 in 90% serum (
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       ). On the contrary, a Triton X-100 concentration of 1% led to complete HSV-1 inactivation in both 1% and 90% serum with a titre reduction of at least 5 log
       <sub>
        10
       </sub>
       (
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       ).
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Influence of serum concentration on the chemical inactivation of herpes simplex virus type 1 (HSV-1). Reduction in HSV-1 titres in samples containing either 1% fetal bovine serum (FBS) or 90% human serum after treatment with 0.1% or 1% Triton X-100 for 1 h at room temperature. Controls received an equivalent amount of PBS. Before titration, samples were filtrated through 100-kDa membranes to remove residual Triton X-100. Unfiltered PBS controls are shown to account for eventual virus loss through the filter. TCID
          <sub>
           50
          </sub>
          /ml titres presented as mean ± SD were determined in three independent experiments with 4-8 replicates per experiment. Abbreviations: HSV-1, herpes simplex virus type 1; TCID
          <sub>
           50
          </sub>
          , 50% Tissue Culture Infectious Dose.
         </p>
        </caption>
        <alt-text id="alttext0025">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="sec4">
     <title>
      Discussion
     </title>
     <p id="p0110">
      Recent events including Ebola and Lassa outbreaks in West Africa
      <xref ref-type="bibr" rid="bib1">
       [1]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      and two cases of Andes Hantavirus infection in a returning traveller at our hospital
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      drew our attention to issues regarding biosafety for laboratory workers and optimal diagnostics for high-risk patients. In our routine laboratory we noticed a lack of protocols for virus inactivation and a lack of data regarding effect of inactivation on the accuracy of serological tests.
     </p>
     <p id="p0115">
      Here we demonstrate that heat inactivation is not a suitable method for the serological diagnosis of infectious diseases. On the contrary routine ELISA-based-serological tests and rapid tests can be accurately performed after a treatment with Triton X-100 0.1% or 1% final concentration. Both quantitative and qualitative results remained relatively unaffected and false results mostly concerned borderline samples. These results should prompt further studies about the effect of Triton X-100 1% on clinical chemistry parameters, haematological tests, and malaria tests for which only Triton X-100 0.1% has been tested so far
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       [12]
      </xref>
      . As recently published
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      , Triton X-100 0.1% is not sufficient to inactivate HSV-1 in high concentrations of serum. Increasing Triton X-100 final concentration to 1% however led to complete inactivation of HSV-1 in 90% serum samples. This is of primordial importance for the safety of laboratory workers, considering that they receive and process undiluted serum samples, which are potentially infectious.
     </p>
     <p id="p0120">
      Since Triton X-100 exerts its inactivation effect at the level of the viral envelope only, complete inactivation of HSV-1 with 1% of Triton X-100 suggests that other enveloped viruses such as HIV, influenza, SARS, or EBOV could also be completely inactivated by the same procedure. This remains, however, to be tested especially for EBOV, which is a rather stable virus
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      . Preliminary results of EBOV inactivation with Triton X-100 1% for 20 min are promising
      <xref ref-type="bibr" rid="bib27">
       [27]
      </xref>
      . Other proven inactivation methods such as the combination of Triton X-100 and heat against EBOV
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       [28]
      </xref>
      are unfortunately not compatible with serological diagnosis and should be limited to molecular diagnosis. Moreover, although this combination allowed detection of EBOV-specific IgG and IgM
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      , our study suggests that inactivation procedures used for EBOV serology should be further evaluated and compared to inactivation with Triton X-100 alone.
     </p>
     <p id="p0125">
      If proven efficient for enveloped viruses in general, this simple inactivation procedure based on a single pipetting step could be implemented in basic microbiology laboratories and in the field diagnostics during outbreaks of highly pathogenic viruses where a safe and rapid diagnosis is of primordial importance
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      . The initial step of adding detergent to the serum sample does however require trained personnel, rigorous safety practices, and a biosafety cabinet of level 2. Triton X-100 has a long history of usage in diagnostic procedures; nevertheless, it is unknown if high concentrations of detergent could potentially affect routine laboratory analysers. Another limitation to the broad usage of Triton X-100 consists in environmental concerns. This reagent will soon be forbidden in Europe because of its endocrine disruption effects in aquatic organisms
      <xref ref-type="bibr" rid="bib29">
       [29]
      </xref>
      . Restricted usage for well-defined procedures and appropriate waste treatment solutions will most probably still be possible in future. Ecofriendly alternatives such as lauryldimethylamine
      <italic>
       N
      </italic>
      -oxide (LDAO)
      <xref ref-type="bibr" rid="bib30">
       [30]
      </xref>
      have been shown to exhibit effective virus inactivation in a broad range of protein concentrations but need further evaluation with different viruses and conditions.
     </p>
     <p id="p0130">
      In conclusion, we showed that addition of 1% Triton X-100 to serum samples enables complete inactivation of HSV-1 and is compatible with accurate results of a wide range of routine serological tests. This study provides basis to the development of safe serological assays for the rapid and accurate differential diagnosis of infectious diseases in patients with suspected or confirmed infection with highly pathogenic viruses.
     </p>
    </sec>
    <sec id="sec5" sec-type="supplementary-material">
     <title>
      Transparency declaration
     </title>
     <p id="p0135">
      The authors declare no conflicts of interest. The authors declare no external funding.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nigeria hit by unprecedented Lassa fever outbreak
        </article-title>
        <source>
         Science
        </source>
        <volume>
         359
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1201
        </fpage>
        <lpage>
         1202
        </lpage>
        <pub-id pub-id-type="pmid">
         29590055
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effective chemical inactivation of Ebola virus
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1292
        </fpage>
        <lpage>
         1294
        </lpage>
        <pub-id pub-id-type="pmid">
         27070504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smither
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weller
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Phelps
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Eastaugh
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ngugi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           O'Brien
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Buffer AVL alone does not inactivate Ebola virus in a representative clinical sample type
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         3148
        </fpage>
        <lpage>
         3154
        </lpage>
        <pub-id pub-id-type="pmid">
         26179307
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pan American Health Organization WHO
          </surname>
         </name>
        </person-group>
        <chapter-title>
         General procedures for inactivation of potentially infectious samples with Ebola virus and other highly pathogenic viral agents
        </chapter-title>
        <year>
         2015
        </year>
        <publisher-name>
         Regional Office for the Americas of the World Health Organization
        </publisher-name>
        <publisher-loc>
         Washington, DC
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease C, Prevention
          </surname>
         </name>
        </person-group>
        <article-title>
         Update: management of patients with suspected viral hemorrhagic fever--United States
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         44
        </volume>
        <year>
         1995
        </year>
        <fpage>
         475
        </fpage>
        <lpage>
         479
        </lpage>
        <pub-id pub-id-type="pmid">
         7783731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           Y.T.
          </given-names>
         </name>
         <name>
          <surname>
           Mullin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Greenhalgh
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cunningham
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Goodrich
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Shea
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single-use technology for solvent/detergent virus inactivation of industrial plasma products
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         56
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1384
        </fpage>
        <lpage>
         1393
        </lpage>
        <pub-id pub-id-type="pmid">
         27125447
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mifsud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peelen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Brincat
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Abela
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Debattista
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Laspina
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A feasibility study on the effects of Triton X-100 for the in vitro inactivation of Ebola virus on haematological assays
        </article-title>
        <source>
         J Clin Pathol
        </source>
        <volume>
         69
        </volume>
        <year>
         2016
        </year>
        <fpage>
         637
        </fpage>
        <lpage>
         642
        </lpage>
        <pub-id pub-id-type="pmid">
         26670745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hersberger
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nusbaumer
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Scholer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Knopfli
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           von Eckardstein
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of practicable virus inactivation procedures on tests for frequently measured analytes in plasma
        </article-title>
        <source>
         Clin Chem
        </source>
        <volume>
         50
        </volume>
        <year>
         2004
        </year>
        <fpage>
         944
        </fpage>
        <lpage>
         946
        </lpage>
        <pub-id pub-id-type="pmid">
         15105356
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tempestilli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pucci
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Notari
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Castilletti
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Rivelli
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients
        </article-title>
        <source>
         Clin Chem Lab Med
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1967
        </fpage>
        <lpage>
         1973
        </lpage>
        <pub-id pub-id-type="pmid">
         26053010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Kampen
          </surname>
          <given-names>
           J.J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tintu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Russcher
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fraaij
          </surname>
          <given-names>
           P.L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Rijken
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ebola virus inactivation by detergents is annulled in serum
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         216
        </volume>
        <year>
         2017
        </year>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         28961947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chong-Kit
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ralevski
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Boggild
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of Ebola virus inactivation procedures for Plasmodium falciparum malaria diagnostics
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1387
        </fpage>
        <lpage>
         1390
        </lpage>
        <pub-id pub-id-type="pmid">
         25631810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Assmar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hay Burgess
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Kain
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of viral hemorrhagic fever inactivation methods on the performance of rapid diagnostic tests for Plasmodium falciparum
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         178
        </volume>
        <year>
         1998
        </year>
        <fpage>
         1852
        </fpage>
        <lpage>
         1855
        </lpage>
        <pub-id pub-id-type="pmid">
         9815250
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ukkonen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Korpela
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Suni
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hedman
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         7
        </volume>
        <year>
         1988
        </year>
        <fpage>
         518
        </fpage>
        <lpage>
         523
        </lpage>
        <pub-id pub-id-type="pmid">
         3141160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cutts
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Grolla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Theriault
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inactivation of zaire ebolavirus variant makona in human serum samples analyzed by enzyme-linked immunosorbent assay
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         214
        </volume>
        <year>
         2016
        </year>
        <fpage>
         S218
        </fpage>
        <lpage>
         S221
        </lpage>
        <pub-id pub-id-type="pmid">
         27571899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saluzzo
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Leguenno
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Van der Groen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of heat inactivated viral haemorrhagic fever antigens in serological assays
        </article-title>
        <source>
         J Virol Method
        </source>
        <volume>
         22
        </volume>
        <year>
         1988 Dec
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         172
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhagat
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Lewer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Prins
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Beilby
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of heating plasma at 56 degrees C for 30 min and at 60 degrees C for 60 min on routine biochemistry analytes
        </article-title>
        <source>
         Ann Clin Biochem
        </source>
        <volume>
         37
        </volume>
        <year>
         2000 Nov
        </year>
        <fpage>
         802
        </fpage>
        <lpage>
         804
        </lpage>
        <pub-id pub-id-type="pmid">
         11085629
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gleeson
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Herd
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of heat inactivation of HIV on specific serum proteins and tumour markers
        </article-title>
        <source>
         Ann Clin Biochem
        </source>
        <volume>
         27
        </volume>
        <year>
         1990
        </year>
        <fpage>
         592
        </fpage>
        <lpage>
         594
        </lpage>
        <pub-id pub-id-type="pmid">
         2080860
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           McCormick
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         20
        </volume>
        <year>
         1984
        </year>
        <fpage>
         486
        </fpage>
        <lpage>
         489
        </lpage>
        <pub-id pub-id-type="pmid">
         6490832
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Howett
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Neely
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Christensen
          </surname>
          <given-names>
           N.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wigdahl
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Krebs
          </surname>
          <given-names>
           F.C.
          </given-names>
         </name>
         <name>
          <surname>
           Malamud
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         43
        </volume>
        <year>
         1999
        </year>
        <fpage>
         314
        </fpage>
        <lpage>
         321
        </lpage>
        <pub-id pub-id-type="pmid">
         9925525
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spire
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Dormont
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Barre-Sinoussi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Montagnier
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chermann
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         1
        </volume>
        <year>
         1985
        </year>
        <fpage>
         188
        </fpage>
        <lpage>
         189
        </lpage>
        <pub-id pub-id-type="pmid">
         2857267
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thermal stability and inactivation of hepatitis C virus grown in cell culture
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         7
        </volume>
        <year>
         2010
        </year>
        <fpage>
         40
        </fpage>
        <pub-id pub-id-type="pmid">
         20167059
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colavita
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Quartu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lalle
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bordi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lapa
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Meschi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of the inactivation effect of Triton X-100 on Ebola virus infectivity
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         86
        </volume>
        <year>
         2017
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         27912126
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blaho
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Morton
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yedowitz
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Herpes simplex virus: propagation, quantification, and storage
        </article-title>
        <source>
         Curr Protoc Microbiol
        </source>
        <year>
         2005
        </year>
        <comment>
         Chapter 14: Unit 14E 1
        </comment>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sacks
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preclinical evaluation of docusate as protective agent from herpes simplex viruses
        </article-title>
        <source>
         Antivir Res
        </source>
        <volume>
         52
        </volume>
        <year>
         2001
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         11530185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gire
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Goba
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Andersen
          </surname>
          <given-names>
           K.G.
          </given-names>
         </name>
         <name>
          <surname>
           Sealfon
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kanneh
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak
        </article-title>
        <source>
         Science
        </source>
        <volume>
         345
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1369
        </fpage>
        <lpage>
         1372
        </lpage>
        <pub-id pub-id-type="pmid">
         25214632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuenzli
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Marschall
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Schefold
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Engler
          </surname>
          <given-names>
           O.B.
          </given-names>
         </name>
         <name>
          <surname>
           Ackermann-Gaumann
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hantavirus cardiopulmonary syndrome due to imported Andes Hantavirus infection in Switzerland: a multidisciplinary challenge, two cases and a literature review
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         67
        </volume>
        <year>
         2018 Nov 13
        </year>
        <fpage>
         1788
        </fpage>
        <lpage>
         1795
        </lpage>
        <pub-id pub-id-type="pmid">
         30084955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burton
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Easterbrook
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pitman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Roddy
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples
        </article-title>
        <source>
         J Virol Method
        </source>
        <volume>
         250
        </volume>
        <year>
         2017
        </year>
        <fpage>
         34
        </fpage>
        <lpage>
         40
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenstierne
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
         <name>
          <surname>
           Karlberg
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bragstad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lindegren
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Stoltz
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Salata
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid bedside inactivation of Ebola virus for safe nucleic acid tests
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         54
        </volume>
        <year>
         2016
        </year>
        <fpage>
         2521
        </fpage>
        <lpage>
         2529
        </lpage>
        <pub-id pub-id-type="pmid">
         27466385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nimrod
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Benson
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Environmental estrogenic effects of alkylphenol ethoxylates
        </article-title>
        <source>
         Crit Rev Toxicol
        </source>
        <volume>
         26
        </volume>
        <year>
         1996
        </year>
        <fpage>
         335
        </fpage>
        <lpage>
         364
        </lpage>
        <comment>
         [Research Support, Non-U.S Gov't]
        </comment>
        <pub-id pub-id-type="pmid">
         8726166
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conley
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Koepf
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Cecchini
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pieracci
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation
        </article-title>
        <source>
         Biotechnol Bioeng
        </source>
        <volume>
         114
        </volume>
        <year>
         2017
        </year>
        <fpage>
         813
        </fpage>
        <lpage>
         820
        </lpage>
        <pub-id pub-id-type="pmid">
         27800626
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="appsec1" sec-type="supplementary-material">
      <label>
       Appendix A
      </label>
      <title>
       Supplementary data
      </title>
      <p id="p0145">
       The following is the Supplementary data to this article:
       <supplementary-material content-type="local-data" id="mmc1">
        <caption>
         <title>
          Multimedia component 1
         </title>
        </caption>
        <media xlink:href="mmc1.docx">
         <alt-text>
          Multimedia component 1
         </alt-text>
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ack0010">
      <title>
       Acknowledgements
      </title>
      <p>
       We wish to thank the laboratory staff of the Serology and Virology departments of the Institute for Infectious Diseases and especially Richard Kamgang and Sabine Funez for excellent technical assistance. We are also thankful to Johanna Signer from Spiez Laboratory for her technical advices. A special thanks goes to Désirée Mayor who provided HSV-1 seronegative serum. Some icons used for the graphical abstract are protected by a Creative Commons license. A previous version of this data was presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain on 22 April.
      </p>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="appsec2">
       <label>
        Appendix A
       </label>
       <p id="p0150">
        Supplementary data to this article can be found online at
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://doi.org/10.1016/j.cmi.2018.10.016">
         https://doi.org/10.1016/j.cmi.2018.10.016
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <?properties manuscript?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">
       7705876
      </journal-id>
      <journal-id journal-id-type="pubmed-jr-id">
       4750
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       J Med Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Med. Virol.
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of medical virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0146-6615
      </issn>
      <issn pub-type="epub">
       1096-9071
      </issn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28906003
      </article-id>
      <article-id pub-id-type="pmc">
       6158782
      </article-id>
      <article-id pub-id-type="doi">
       10.1002/jmv.24948
      </article-id>
      <article-id pub-id-type="manuscript">
       HHSPA988743
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Trivedi
         </surname>
         <given-names>
          Suvang
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Miao
         </surname>
         <given-names>
          Congrong
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Al-Abdallat
         </surname>
         <given-names>
          Mohammad M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Haddadin
         </surname>
         <given-names>
          Aktham
         </given-names>
        </name>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Alqasrawi
         </surname>
         <given-names>
          Sultan
         </given-names>
        </name>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Iblan
         </surname>
         <given-names>
          Ibrahim
         </given-names>
        </name>
        <xref ref-type="aff" rid="A4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nsour
         </surname>
         <given-names>
          Mohannad A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="A5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Alsanouri
         </surname>
         <given-names>
          Tarek
         </given-names>
        </name>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ali
         </surname>
         <given-names>
          Sami S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rha
         </surname>
         <given-names>
          Brian
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gerber
         </surname>
         <given-names>
          Susan I.
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Payne
         </surname>
         <given-names>
          Daniel C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tamin
         </surname>
         <given-names>
          Azaibi
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Thornburg
         </surname>
         <given-names>
          Natalie J.
         </given-names>
        </name>
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0003-3523-3616
        </contrib-id>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
      </contrib-group>
      <aff id="A1">
       <label>
        1
       </label>
       ORISE Fellowship Training Program, Oak Ridge, Tennessee
      </aff>
      <aff id="A2">
       <label>
        2
       </label>
       Respiratory Viruses Branch, Div. of Viral Diseases, Natl. Ctr. for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia
      </aff>
      <aff id="A3">
       <label>
        3
       </label>
       Jordan Ministry of Health, Amman, Jordan
      </aff>
      <aff id="A4">
       <label>
        4
       </label>
       Jordan Field Epidemiology Training Program, Amman, Jordan
      </aff>
      <aff id="A5">
       <label>
        5
       </label>
       Eastern Mediterranean Public Health Network, Amman, Jordan
      </aff>
      <author-notes>
       <corresp id="CR1">
        <bold>
         Correspondence
        </bold>
        : Natalie J. Thornburg, Respiratory Viruses Branch, Div. of Viral Diseases, Natl. Ctr. for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, NE, Mailstop G-18, Atlanta, GA 30329.
        <email>
         nax3@cdc.gov
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
       <day>
        19
       </day>
       <month>
        9
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        9
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        2
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        27
       </day>
       <month>
        9
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <volume>
       90
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       367
      </fpage>
      <lpage>
       371
      </lpage>
      <!--elocation-id from pubmed: 10.1002/jmv.24948-->
      <abstract id="ABS1">
       <p id="P1">
        The Centers for Disease Control and Prevention (CDC) algorithm for detecting presence of serum antibodies against Middle East Respiratory Syndrome coronavirus (MERS-CoV) in subjects with potential infections with the virus has included screening by indirect ELISA against recombinant nucleocapsid (N) protein and confirmation by immunofluorescent staining of infected monolayers and/or micro-neutralization titration. Other international groups include indirect ELISA assays using the spike (S) protein, as part of their serological determinations. In the current study, we describe development and validation of an indirect MERS-CoV S ELISA to be used as part of our serological determination for evidence of previous exposure to the virus.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        antibodies
       </kwd>
       <kwd>
        coronaviruses
       </kwd>
       <kwd>
        immunity
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        serology
       </kwd>
       <kwd>
        surveillance
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Vet Microbiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Vet. Microbiol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Veterinary Microbiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0378-1135
      </issn>
      <issn pub-type="epub">
       1873-2542
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15019110
      </article-id>
      <article-id pub-id-type="pmc">
       7117189
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0378-1135(03)00381-X
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.vetmic.2003.07.009
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Safety and efficacy of a modified-live canine coronavirus vaccine in dogs
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pratelli
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <email>
         a.pratelli@veterinaria.uniba.it
        </email>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
        <xref ref-type="corresp" rid="COR1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tinelli
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Decaro
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Martella
         </surname>
         <given-names>
          V
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Camero
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tempesta
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Martini
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Carmichael
         </surname>
         <given-names>
          L.E
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Buonavoglia
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
         a
        </xref>
       </contrib>
      </contrib-group>
      <aff id="AFF1">
       <label>
        a
       </label>
       Department of Animal Health and Well-being, Faculty of Veterinary Medicine, Strada per Casamassima km 3, 70010 Valenzano, Bari, Italy
      </aff>
      <aff id="AFF2">
       <label>
        b
       </label>
       Department of Public Health, Comparative Pathology and Veterinary Hygiene, Faculty of Veterinary Medicine, Padua, Italy
      </aff>
      <aff id="AFF3">
       <label>
        c
       </label>
       James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
      </aff>
      <author-notes>
       <corresp id="COR1">
        <label>
         *
        </label>
        Corresponding author. Tel.: +39-080-4679833; fax: +39-080-4679843.
        <email>
         a.pratelli@veterinaria.uniba.it
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        15
       </day>
       <month>
        1
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        1
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <volume>
       99
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       43
      </fpage>
      <lpage>
       49
      </lpage>
      <history>
       <date date-type="received">
        <day>
         7
        </day>
        <month>
         3
        </month>
        <year>
         2003
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         10
        </day>
        <month>
         7
        </month>
        <year>
         2003
        </year>
       </date>
       <date date-type="accepted">
        <day>
         21
        </day>
        <month>
         7
        </month>
        <year>
         2003
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2003 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2003
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        The safety and the efficacy of a modified-live (ML) canine coronavirus (CCoV) vaccine strain 257/98-3c was evaluated in 14 dogs seronegative and virus negative for CCoV. For the safety test, four dogs were inoculated, two by intramuscular and two by oronasal route, with 10 times the vaccinal dose. During the observation period (28 days) all dogs did not display any local or systemic reaction. For the efficacy test, eight dogs were vaccinated by intramuscular (four dogs—group A) or by oronasal route (four dogs—group B). Two dogs were maintained as non-vaccinated controls. In the dogs of group A, vaccinal virus was not detected in faecal samples by virus isolation (VI) and by PCR assay, while in the dogs of group B, the virus was revealed for six median days only by PCR. Twenty-eight days later, the vaccinated and control dogs were challenged with a field CCoV strain. After the challenge, the vaccinated dogs did not display clinical signs and the dogs of group A shed virus for 5.5 median days, evaluated by VI, and for 10 median days evaluated by PCR. Virus shedding was not observed, both by VI and PCR assay, in the dogs of group B. The two control dogs displayed moderate clinical signs and the virus was detected by VI for 14.5 median days starting from day 3 post-challenge (dpc 3) and by PCR assay for 23 median days starting from dpc 1.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Canine coronavirus
       </kwd>
       <kwd>
        Vaccine
       </kwd>
       <kwd>
        Efficacy
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      Coronaviruses are positive-stranded RNA viruses recently classified in the order
      <italic>
       Nidovirales
      </italic>
      , mainly on the basis of their genomic organization and their replication strategy (
      <xref ref-type="bibr" rid="BIB3">
       de Vries et al., 1997
      </xref>
      ). The coronavirus genome consists of a large open reading frame (ORF) at the 5′-end which encodes the replicase gene (ORF1a and ORF1b). Downstream from the replicase gene, there are smaller ORFs which encode the structural proteins S, E, M, the nucleocapsid (N) protein and a number of presumptive non-structural proteins of largely unknown function (
      <xref ref-type="bibr" rid="BIB9">
       Luytjes, 1995
      </xref>
      ).
     </p>
     <p>
      Most research has focused on the S protein as a candidate antigen for coronavirus vaccines, since it is the major inducer of virus-neutralizing antibodies (
      <xref ref-type="bibr" rid="BIB7">
       Gebauer et al., 1991
      </xref>
      ). The function of the M protein is still not clear. Although a major immunological role has been attributed to the S protein, both the amino- and the carboxy-termini of the M protein elicit strong immune responses (
      <xref ref-type="bibr" rid="BIB5">
       Enjuanes et al., 2000
      </xref>
      ), inducing antibody-dependent, complement-mediated, virus neutralization (VN) (
      <xref ref-type="bibr" rid="BIB23">
       Woods et al., 1987
      </xref>
      ).
     </p>
     <p>
      The role of CCoV in inducing enteric illness in canids has been the subject of active investigation for over two decades. The virus is responsible for mild to moderate enteritis in dogs; in young pups, or in combination with other pathogens, illness may be severe with diarrhoea, vomiting, dehydration, loss of appetite and even death (
      <xref ref-type="bibr" rid="BIB6">
       Evermann et al., 1980
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB1">
       Appel, 1988
      </xref>
      ). Shedding of CCoV in faeces occurs over a range of 6–14 days post-infection (
      <xref ref-type="bibr" rid="BIB8">
       Keenan et al., 1976
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB21">
       Tennant et al., 1991
      </xref>
      ), however, faecal shedding in infected pups has been detected by n-PCR for periods from 37 to 150 days (
      <xref ref-type="bibr" rid="BIB16">
       Pratelli et al., 2001
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB17">
       Pratelli et al., 2002a
      </xref>
      ). The value of CCoV vaccines in providing adequate immunity under field conditions is controversial. Although the efficacy and the duration of immunity engendered by inactivated vaccines have not been substantiated, killed CCoV vaccines have been licensed in the USA. In a recent study, the low efficacy of an inactivated CCoV vaccine in reducing the viral shedding in faeces of dogs after CCoV infection is described (
      <xref ref-type="bibr" rid="BIB19">
       Pratelli et al., 2003
      </xref>
      ). A modified-live (ML) CCoV vaccine was licensed in USA in 1983, but was rapidly withdrawn due to a high rate (about 5%) of serious adverse reactions (
      <xref ref-type="bibr" rid="BIB11">
       Martin, 1985
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB22">
       Wilson et al., 1986
      </xref>
      ). A ML CCoV vaccine, available in California and recently licensed in USA, appears to be safe and 1-year duration of immunity is claimed by the manufacturer. Unfortunately, the CCoV vaccine, when combined with canine cell-grown distemper vaccine (Rockborn strain), resulted in a high frequency of post-distemper encephalitis (
      <xref ref-type="bibr" rid="BIB2">
       Carmichael, 1997
      </xref>
      ).
     </p>
     <p>
      In the present note, we report the results of a study on the safety and efficacy of a ML CCoV vaccine in dogs, administered by intramuscular or oronasal route.
     </p>
    </sec>
    <sec>
     <label>
      2
     </label>
     <title>
      Materials and methods
     </title>
     <sec>
      <label>
       2.1
      </label>
      <title>
       Animals
      </title>
      <p>
       Fourteen conventional dogs, 3 months of age were used. They were negative for CCoV antigen in the faeces, and CCoV antibodies before the experiment. Baseline body temperature and white blood cell (WBC) count were established for each dog averaging results of the 3 days before vaccination. The experimental study was performed according to the animal health and well-being regulations and was authorized by the Minister of Health of Italy (authorization no. 67/2002-C).
      </p>
     </sec>
     <sec>
      <label>
       2.2
      </label>
      <title>
       Vaccine
      </title>
      <p>
       A modified-live CCoV vaccine, strain 257/98-3c, was used. The virus was originally isolated from a faecal sample of a dog with mild enteritis and was serially passaged 40 times on canine cells (A-72). The virus at the 40th passage had an infectivity titer of 10
       <sup>
        4.50
       </sup>
       TCID
       <sub>
        50
       </sub>
       /50 μl and was used throughout the study. The stock vaccine had been tested for sterility from aerobe and anaerobe bacteria, mycoplasmas, mycetes and contaminant viruses using standardized methods.
      </p>
     </sec>
     <sec>
      <label>
       2.3
      </label>
      <title>
       Safety test
      </title>
      <p>
       To test the safety of the ML CCoV vaccine, four dogs (nos. 1–4) were inoculated, two by intramuscular (nos. 1 and 2) and two by oronasal route (nos. 3 and 4), with 10 times the vaccinal dose inoculated in the efficacy test. Following inoculation, dogs were individually isolated and daily observed for 28 days for signs of illness, WBC count and body temperature. For virological assays, individual faecal samples were collected from 3 days before the test through day 28. On day 28 all dogs were bled for serology.
      </p>
     </sec>
     <sec>
      <label>
       2.4
      </label>
      <title>
       Challenge
      </title>
      <p>
       The field CCoV strain 144/01 was isolated from a faecal sample of a diarrhoeic pup (
       <xref ref-type="bibr" rid="BIB10">
        Marsilio et al., 2002
       </xref>
       ) and was used to challenge the dogs. The virus was propagated on primary canine embryonic kidney (CEK) cells for three passages and stored at −70 °C. All dogs (immunized and control) were challenged 28 days after vaccination. Each animal received 4 ml of viral suspension (2 ml intranasally and 2 ml orally) with a titer of 10
       <sup>
        5
       </sup>
       TCID
       <sub>
        50
       </sub>
       /50 μl.
      </p>
     </sec>
     <sec>
      <label>
       2.5
      </label>
      <title>
       Efficacy test
      </title>
      <p>
       After an acclimatizing period of 10 days, 10 dogs were housed separately. Eight dogs, randomly chosen, were vaccinated by intramuscular injection (four dogs—group A) or by oronasal route (four dogs—group B), each with 2 ml of ML CCoV strain 257/98-3c. Two dogs were maintained non-vaccinated. Following vaccination, the dogs were observed for any adverse local or systemic reactions and faecal samples were collected daily for 28 days post-vaccination (dpv).
      </p>
      <p>
       Twenty-eight days later, the vaccinated and control dogs were challenged with CCoV strain 144/01. On the day of challenge, and for 28 days post-challenge (dpc), the dogs were examined clinically and virus shedding was monitored.
      </p>
      <p>
       Because dogs are generally refractory to clinical disease after experimental infection with CCoV, protective immunity was assessed also by monitoring of virus shedding (median days of virus shedding). The experimental design is reported in
       <xref ref-type="table" rid="TBL1">
        Table 1
       </xref>
       .
       <table-wrap id="TBL1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Experimental design and sampling
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td>
            Groups
           </td>
           <td>
            Dogs
           </td>
           <td>
            Vaccination route
           </td>
           <td>
            Faecal sampling for VI and PCR
           </td>
           <td>
            Serum sampling for VN and ELISA
           </td>
          </tr>
          <tr>
           <td colspan="5">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            A
           </td>
           <td>
            4
           </td>
           <td>
            im
           </td>
           <td>
            Daily, for dpv 28 and dpc 28
           </td>
           <td>
            Weekly, for dpv 28 and dpc 28
           </td>
          </tr>
          <tr>
           <td>
            B
           </td>
           <td>
            4
           </td>
           <td>
            o/n
           </td>
           <td>
            Daily, for dpv 28 and dpc 28
           </td>
           <td>
            Weekly, for dpv 28 and dpc 28
           </td>
          </tr>
          <tr>
           <td>
            Controls
           </td>
           <td>
            2
           </td>
           <td>
            no
           </td>
           <td>
            Daily, for dpc 28
           </td>
           <td>
            Weekly, for dpc 28
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           im: intramuscular; o/n: oronasal; VI: virus isolation; VN: virus neutralization test; dpv: days post-vaccination; dpc: days post-challenge; no: not vaccinated.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec>
      <label>
       2.6
      </label>
      <title>
       Samples analysis
      </title>
      <p>
       For virus isolation (VI), faecal samples were homogenized (10% w/v) in minimal essential medium (MEM). After centrifugation for 10 min at 4000×
       <italic>
        g
       </italic>
       , 200 μl of the supernatant, with antibiotics (5000 IU/ml penicillin, 2500 μg/ml streptomycin, 10 μg/ml amphotericin B), were inoculated in duplicate onto freshly trypsinised A-72 cells in 24 well-plates containing glass slides. The cells were observed daily for cytopathic effects (cpe) and, after 72 h, were fixed with cold acetone and tested by an immunofluorescence test (IF) using a CCoV monoclonal antibody (gently supplied by Dr. Gilles Chappuis, Merial, France). Each sample was considered negative if cpe or IF was not observed after three serial passages.
      </p>
      <p>
       Additionally, a PCR test (
       <xref ref-type="bibr" rid="BIB14">
        Pratelli et al., 1999a
       </xref>
       ) was used to detect CCoV in faecal samples. Briefly, reverse transcription was performed in a total reaction volume of 20 μl containing PCR buffer 1X (KCl 50 mM, Tris–HCl 10 mM, pH 8.3), MgCl
       <sub>
        2
       </sub>
       5 mM, 1 mM of each deoxynucleotide (dATP, dCTP, dGTP, dTTP), RNase 1 U, MuLV reverse transcriptase 2.5 U, random hexamers 2.5 U. Synthesis of cDNA was carried out at 42 °C for 30 min, followed by a denaturation step at 99 °C for 5 min. The mixture was brought up to a total volume of 100 μl, containing PCR buffer 1X, MgCl
       <sub>
        2
       </sub>
       2 mM,
       <italic>
        Amplitaq Gold DNA polymerase
       </italic>
       2.5 U and 50 pmol of each primer, CCoV1 and CCoV2. The PCR mixture was subjected to 35 cycles (94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min) in a DNA thermal cycler.
      </p>
     </sec>
     <sec>
      <label>
       2.7
      </label>
      <title>
       Serological tests
      </title>
      <p>
       Blood samples were collected from the 10 dogs for serological tests on the day of vaccination and, later, on dpv 7, 14, 21 and 28.
      </p>
      <p>
       Additional samples were collected on the day of challenge and at 7, 14, 21 and 28 dpc. ELISA and virus neutralization tests were carried out as described (
       <xref ref-type="bibr" rid="BIB4">
        Elia et al., 2002
       </xref>
       ,
       <xref ref-type="bibr" rid="BIB18">
        Pratelli et al., 2002b
       </xref>
       ); VN titers are expressed as geometric means and OD values as median values.
      </p>
     </sec>
     <sec>
      <label>
       2.8
      </label>
      <title>
       Statistical analysis
      </title>
      <p>
       Given the small size of the comparison groups and the non-normal distribution of data, as verified by the Kolmogorov–Smirnov test, the non-parametric Mann–Whitney
       <italic>
        U
       </italic>
       -test was used to compare the duration of CCoV shedding, the VN titers and the ELISA OD values after vaccination and after challenge. A
       <italic>
        P
       </italic>
       -value&lt;0.05 was considered as significant.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec>
      <label>
       3.1
      </label>
      <title>
       Safety
      </title>
      <p>
       Following intramuscular or oronasal inoculation of 10 times the vaccinal dose, all dogs remained normal and alert throughout the observation period and no local or generalized reactions to the vaccine were observed. WBC counts, performed daily in order to evaluate total leukocyte, remained normal.
      </p>
      <p>
       Virus isolation and PCR assay performed on the faecal samples of the two dogs inoculated by intramuscular route were negative. The faecal samples of the two dogs inoculated by oronasal route were PCR positive for 6 days, starting from dpv 2 to 7. Serologic tests (VN and ELISA) carried out at dpv 28 indicated that all dogs had developed CCoV antibody titers (
       <xref ref-type="table" rid="TBL2">
        Table 2
       </xref>
       ).
       <table-wrap id="TBL2" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Results of the safety test of the CCoV vaccine in dogs
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td>
            Dogs
           </td>
           <td>
            Route
           </td>
           <td colspan="2">
            Virus shedding (days)
            <hr/>
           </td>
           <td colspan="2">
            Antibodies (dpv 28)
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
           </td>
           <td>
            VI
           </td>
           <td>
            PCR
           </td>
           <td>
            VN
           </td>
           <td>
            ELISA
           </td>
          </tr>
          <tr>
           <td colspan="6">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            1
           </td>
           <td>
            im
           </td>
           <td>
            0
           </td>
           <td>
            0
           </td>
           <td>
            4
           </td>
           <td>
            0.152
           </td>
          </tr>
          <tr>
           <td>
            2
           </td>
           <td>
            im
           </td>
           <td>
            0
           </td>
           <td>
            0
           </td>
           <td>
            8
           </td>
           <td>
            0.164
           </td>
          </tr>
          <tr>
           <td>
            3
           </td>
           <td>
            o/n
           </td>
           <td>
            0
           </td>
           <td>
            6
           </td>
           <td>
            8
           </td>
           <td>
            0.190
           </td>
          </tr>
          <tr>
           <td>
            4
           </td>
           <td>
            o/n
           </td>
           <td>
            0
           </td>
           <td>
            6
           </td>
           <td>
            8
           </td>
           <td>
            0.215
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           im: intramuscular; o/n: oronasal; VI: virus isolation; VN: virus neutralization titer; dpv: days post-vaccination.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec>
      <label>
       3.2
      </label>
      <title>
       Efficacy in dogs vaccinated by intramuscular route (group A)
      </title>
      <p>
       After vaccination, VI and PCR of the faecal samples were negative in all the dogs (
       <xref ref-type="table" rid="TBL3">
        Table 3
       </xref>
       a). By the VN test, at dpv 28 all dogs had slight increases (1:4) in VN antibodies titers. By the ELISA test, the highest antibody values were observed at dpv 28 (OD=0.143) (
       <xref ref-type="fig" rid="FIG1">
        Fig. 1
       </xref>
       ).
       <table-wrap id="TBL3" position="float">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Results of the efficacy test in dogs after CCoV vaccination (a) and CCoV challenge (b)
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td>
            Group
           </td>
           <td>
            Dogs
           </td>
           <td colspan="6">
            Virus shedding
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
           </td>
           <td colspan="3">
            VI
            <hr/>
           </td>
           <td colspan="3">
            PCR
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
           </td>
           <td>
            Onset
            <xref ref-type="table-fn" rid="TBLFN1">
             a
            </xref>
           </td>
           <td>
            Duration
           </td>
           <td>
            Mean
            <xref ref-type="table-fn" rid="TBLFN2">
             b
            </xref>
           </td>
           <td>
            Onset
            <xref ref-type="table-fn" rid="TBLFN1">
             a
            </xref>
           </td>
           <td>
            Duration
           </td>
           <td>
            Mean
            <xref ref-type="table-fn" rid="TBLFN2">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td colspan="8">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="8">
            (a) CCoV vaccination
           </td>
          </tr>
          <tr>
           <td>
            Group A
           </td>
           <td>
            1
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            2
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            3
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            4
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Group B
           </td>
           <td>
            1
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            6
           </td>
           <td>
            6
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            2
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            6
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            3
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            6
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            4
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            5
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Group
           </td>
           <td>
            Dogs
           </td>
           <td colspan="6">
            Virus shedding
            <hr/>
           </td>
           <td>
            <hr/>
           </td>
           <td>
            <hr/>
           </td>
           <td>
            <hr/>
           </td>
           <td>
            <hr/>
           </td>
           <td>
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
           </td>
           <td colspan="3">
            VI
            <hr/>
           </td>
           <td colspan="3">
            PCR
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
           </td>
           <td>
            Onset
            <xref ref-type="table-fn" rid="TBLFN3">
             c
            </xref>
           </td>
           <td>
            Duration
           </td>
           <td>
            Mean
            <xref ref-type="table-fn" rid="TBLFN2">
             b
            </xref>
           </td>
           <td>
            Onset
            <xref ref-type="table-fn" rid="TBLFN3">
             c
            </xref>
           </td>
           <td>
            Duration
           </td>
           <td>
            Mean
            <xref ref-type="table-fn" rid="TBLFN2">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td colspan="8">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="8">
            (b) CCoV challenge
           </td>
          </tr>
          <tr>
           <td>
            Group A
           </td>
           <td>
            1
           </td>
           <td>
            4
           </td>
           <td align="char">
            6
           </td>
           <td align="char">
            5.5
           </td>
           <td>
            2
           </td>
           <td align="char">
            11
           </td>
           <td>
            10
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            2
           </td>
           <td>
            4
           </td>
           <td align="char">
            5
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            8
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            3
           </td>
           <td>
            4
           </td>
           <td align="char">
            5
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            9
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            4
           </td>
           <td>
            4
           </td>
           <td align="char">
            7
           </td>
           <td align="char">
           </td>
           <td>
            2
           </td>
           <td align="char">
            11
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Group B
           </td>
           <td>
            1
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            2
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            3
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            4
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td align="char">
           </td>
           <td>
            nd
           </td>
           <td align="char">
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Control
           </td>
           <td>
            1
           </td>
           <td>
            3
           </td>
           <td align="char">
            14
           </td>
           <td align="char">
            14.5
           </td>
           <td>
            1
           </td>
           <td align="char">
            22
           </td>
           <td>
            23
           </td>
          </tr>
          <tr>
           <td>
            Control
           </td>
           <td>
            2
           </td>
           <td>
            3
           </td>
           <td align="char">
            15
           </td>
           <td align="char">
           </td>
           <td>
            1
           </td>
           <td align="char">
            24
           </td>
           <td>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           Group A: dogs vaccinated by intramuscular route; Group B: dogs vaccinated by oronasal route; VI: virus isolation; nd: not detected.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="TBLFN1">
          <label>
           a
          </label>
          <p>
           Days post-vaccination.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="TBLFN2">
          <label>
           b
          </label>
          <p>
           Median days.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="TBLFN3">
          <label>
           c
          </label>
          <p>
           Days post-challenge.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
       <fig id="FIG1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Serological responses in dogs after CCoV vaccination and CCoV challenge: (◆) dogs vaccinated by intramuscular route; (•) dogs vaccinated by oronasal route; (○) unvaccinated dogs. VN titers are expressed as the reciprocal (log
          <sub>
           2
          </sub>
          ) of the geometric means. ELISA OD median values are shown in brackets.
         </p>
        </caption>
        <graphic xlink:href="gr1">
        </graphic>
       </fig>
      </p>
      <p>
       After the challenge, the vaccinated dogs displayed no clinical signs and they shed virus for 5.5 days (median value) from dpc 4 to 10. By PCR, CCoV was detected for 10 days (median value), starting from dpc 2 to 12 (
       <xref ref-type="table" rid="TBL3">
        Table 3
       </xref>
       b). Antibody titers in the vaccinated dogs, as evaluated by VN test, increased progressively to 1:64 (three dogs) and 1:128 (one dog) (geometric mean=75.9) at dpc 28. ELISA test showed progressively increasing OD values, reaching the highest values at dpc 28 (OD=0.211) (
       <xref ref-type="fig" rid="FIG1">
        Fig. 1
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       3.3
      </label>
      <title>
       Efficacy in dogs vaccinated by oronasal route (group B)
      </title>
      <p>
       After vaccination, VI from faecal samples was negative, while the PCR assay revealed CCoV in the samples for 6 days (median value) from dpv 2 to 7 (
       <xref ref-type="table" rid="TBL3">
        Table 3
       </xref>
       a). By VN test, antibodies reached values of 1:8 between dpv 21 and 28. By ELISA test, antibodies reached the highest value at dpv 28 (OD=0.210) (
       <xref ref-type="fig" rid="FIG1">
        Fig. 1
       </xref>
       ).
      </p>
      <p>
       After challenge, the vaccinated dogs did not have any clinical signs or virus shedding by either VI or PCR assays (
       <xref ref-type="table" rid="TBL3">
        Table 3
       </xref>
       b). However, there was seroconversion in all dogs by both VN and ELISA tests, with VN titers 1:16 (two dogs) and 1:32 (two dogs) (geometric mean=22.4) and OD=0.225, at 28 dpc (
       <xref ref-type="fig" rid="FIG1">
        Fig. 1
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       3.4
      </label>
      <title>
       Unvaccinated dogs (controls)
      </title>
      <p>
       The two control dogs inoculated with the field strain developed hyperthermia from dpc 2 to 4 and mild diarrhoea from dpc 3 to 6. In the faecal samples, virus was isolated, respectively, from dpc 3 to 16–17 (median value=14.5). By PCR, virus was detected, respectively, from dpc 1 to 22–24 (median value=23) (
       <xref ref-type="table" rid="TBL3">
        Table 3
       </xref>
       b).
      </p>
      <p>
       Antibodies by VN test increased at 28 dpc (geometric mean=22.4). By ELISA test the highest OD values were reached at dpc 28 (OD median value=0.250) (
       <xref ref-type="fig" rid="FIG1">
        Fig. 1
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       3.5
      </label>
      <title>
       Statistical analysis
      </title>
      <p>
       The length of CCoV shedding as well as the antibody levels detected by VN and by ELISA tests after vaccination showed statistically significant differences between groups A and B. The
       <italic>
        P
       </italic>
       -value of the Mann–Whitney
       <italic>
        U
       </italic>
       -test was 0.029 for all comparisons.
      </p>
      <p>
       Statistically significant differences were observed after CCoV challenge, between groups A and B, regarding the length of CCoV shedding, as detected by VI and by PCR, and in regarding the VN antibody titers (the
       <italic>
        P
       </italic>
       -value of the Mann–Whitney
       <italic>
        U
       </italic>
       -test was 0.029 in all cases).
      </p>
      <p>
       Differences in length of viral shedding between group A and control dogs (
       <italic>
        P
       </italic>
       =0.133) and between group B and control dogs (
       <italic>
        P
       </italic>
       =0.067) were not significant.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p>
      In the present study we report the safety and the efficacy of a ML CCoV vaccine in dogs. No local or systemic adverse reactions were observed in the vaccinated dogs. After vaccination, infectious virus was not detected in faecal samples by VI or CCoV nucleic acid by the PCR assay in dogs inoculated by the intramuscular route (group A). However, virus nucleic acid was revealed by PCR for six median days in the dogs inoculated by the oronasal route (group B), suggesting low viral titers or viral reminds in the samples (
      <xref ref-type="bibr" rid="BIB14">
       Pratelli et al., 1999a
      </xref>
      ). In general, the efficacy of the vaccine appeared satisfactory. Considering that the protection against coronavirus infections has been generally correlated with the presence of specific antibodies in the mucosal surface (
      <xref ref-type="bibr" rid="BIB13">
       Ogra et al., 1980
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB20">
       Saif, 1996
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB12">
       Murphy, 1999
      </xref>
      ), a significant difference was observed between dogs of groups A (intramuscular vaccination) and B (oronasal vaccination) (
      <italic>
       P
      </italic>
      =0.029).
     </p>
     <p>
      It should be stressed that no CCoV shedding, after challenge, was observed by either VI or PCR in the dogs vaccinated by oronasal route (group B).
     </p>
     <p>
      The sera of dogs from group A showed high OD values in the ELISA test, confirming that this test is substantially more sensitive than the VN test in detecting antibodies to CCoV (
      <xref ref-type="bibr" rid="BIB18">
       Pratelli et al., 2002b
      </xref>
      ). After CCoV challenge, evaluation of the reduction of challenge virus shed in faeces revealed a decrease in virus in the vaccinated dogs, compared with the control dogs.
     </p>
     <p>
      In the dogs vaccinated by oronasal route (group B) high antibody values were detected by the ELISA test. Protection from CCoV infection was complete since challenge virus was never detected by VI or by PCR assay. It seems plausible that the protection observed in the vaccinated groups might be modulated by the production of mucosal IgA (
      <xref ref-type="bibr" rid="BIB13">
       Ogra et al., 1980
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB12">
       Murphy, 1999
      </xref>
      ).
     </p>
     <p>
      We do not have data on the production of faecal IgA in dogs after intramuscular or oronasal administration of ML CCoV vaccine. However, it may be speculated that dogs vaccinated by the intramuscular route had low levels of faecal IgA which provided partial protection to challenge, but insufficient to confer complete protection as observed in TGEV pigs (
      <xref ref-type="bibr" rid="BIB20">
       Saif, 1996
      </xref>
      ).
     </p>
     <p>
      While the immune mechanisms of the protection from CCoV infection are still not clear, we can hypothesize that a ML vaccine inoculated by the oronasal route might generate a strong IgA production in the gut conferring a complete protection from the infection. The results of this study are interesting for several reasons. CCoV infection alone is considered of minor clinical relevance, but in the past, dual infections between CCoV and CPV2 (
      <xref ref-type="bibr" rid="BIB15">
       Pratelli et al., 1999b
      </xref>
      ) and CCoV and CAdV1 (
      <xref ref-type="bibr" rid="BIB16">
       Pratelli et al., 2001
      </xref>
      ) have been observed in dogs that had severe clinical illness due to the enhanced pathogenicity of dual infections. Polymicrobial infections are common in high density populations, such as unvaccinated kennels.
     </p>
     <p>
      An additional epidemiological consideration is related to recent findings where CCoV shedding in the faeces of infected pups occurred over a period of 37 days (
      <xref ref-type="bibr" rid="BIB16">
       Pratelli et al., 2001
      </xref>
      ). It, therefore, seems likely that immunization of dogs against CCoV would have positive epidemiological effects.
     </p>
     <p>
      Our studies suggest that effective vaccines which are able to induce truly protective and long-lived immunity to infection should be sought to control the spread of CCoV in high risk dog populations.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="BIB1">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Appel
          </surname>
          <given-names>
           M.J.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does canine coronavirus augment the effect of subsequent parvovirus infection?
        </article-title>
        <source>
         Vet. Med.
        </source>
        <volume>
         83
        </volume>
        <year>
         1988
        </year>
        <fpage>
         360
        </fpage>
        <lpage>
         366
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB2">
       <mixed-citation publication-type="other">
        Carmichael, L.E., 1997. Vaccines for dogs. In: Pastoret, P.-P., Blancou, J., Vannier, P., Verschueren, C. (Eds.), Veterinary Vaccinology. Elsevier, New York, pp. 326–335.
       </mixed-citation>
      </ref>
      <ref id="BIB3">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Vries
          </surname>
          <given-names>
           A.A.F.
          </given-names>
         </name>
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The genome organization of the
         <italic>
          Nidovirales
         </italic>
         : similarities and differences between arteri-, toro-, and coronaviruses
        </article-title>
        <source>
         Semin. Virol.
        </source>
        <volume>
         8
        </volume>
        <year>
         1997
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         47
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB4">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Decaro
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tinelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Martella
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of antibody response to canine coronavirus infection in dogs by Western blotting analysis
        </article-title>
        <source>
         New Microbiol.
        </source>
        <volume>
         25
        </volume>
        <year>
         2002
        </year>
        <fpage>
         275
        </fpage>
        <lpage>
         280
        </lpage>
        <pub-id pub-id-type="pmid">
         12173767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB5">
       <mixed-citation publication-type="other">
        Enjuanes, L., Brian, D., Cavanagh, D., Holmes, K., Lai, M.M.C., Laude, H., Masters, P., Rottier, P., Siddell, S., Spaan, W.J.M., Taguchi, F., Talbot, P., 2000. Coronaviridae. In: van Regenmortel, M.H.V., Fauquet, C.M., Bishop, D.H.L., Carstens, E.B., Estes, M.K., Lemon, S.M., Maniloff, J., Mayo, M.A., McGeoch, D.J., Pringle, C.R., Wickner, R.B. (Eds.), Virus Taxonomy, Classification and Nomenclature of Viruses. Academic Press, New York, pp. 835–849.
       </mixed-citation>
      </ref>
      <ref id="BIB6">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Evermann
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Foreyt
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Maag-Miller
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Leathers
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           McKeirnan
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           LeaMaster
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute hemorrhagic enteritis associated with canine coronavirus and parvovirus in a captive coyote population
        </article-title>
        <source>
         J. Am. Vet. Med. Assoc.
        </source>
        <volume>
         177
        </volume>
        <year>
         1980
        </year>
        <fpage>
         784
        </fpage>
        <lpage>
         786
        </lpage>
        <pub-id pub-id-type="pmid">
         6256330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB7">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gebauer
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Posthumus
          </surname>
          <given-names>
           W.A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Correa
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Suñé
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sánchez
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Smerdou
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lenstra
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Meloen
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Residues involved in the formation of the antigenic sites of the S protein of transmissible gastroenteritis coronavirus
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         183
        </volume>
        <year>
         1991
        </year>
        <fpage>
         225
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="pmid">
         1711257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB8">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keenan
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Jervis
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Marchwicki
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Binn
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intestinal infection of neonatal dogs with canine coronavirus 1–71: studies by virologic, histologic, histochemical and immunofluorescent techniques
        </article-title>
        <source>
         Am. J. Vet. Res.
        </source>
        <volume>
         37
        </volume>
        <year>
         1976
        </year>
        <fpage>
         247
        </fpage>
        <lpage>
         256
        </lpage>
        <pub-id pub-id-type="pmid">
         1259219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB9">
       <mixed-citation publication-type="other">
        Luytjes, W., 1995. Coronavirus gene expression: genome organization and protein expression. In: Siddell, S.G. (Ed.), The Coronaviridae. Plenum Press, New York, pp. 33–49.
       </mixed-citation>
      </ref>
      <ref id="BIB10">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marsilio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ricci
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enterite da coronavirus del cane: caratterizzazione del virus isolato
        </article-title>
        <source>
         Veterinaria
        </source>
        <volume>
         2
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB11">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Canine coronavirus enteritis and a recent outbreak following modified-live virus vaccination
        </article-title>
        <source>
         Comp. Cont. Educ. Pract. Vet.
        </source>
        <volume>
         7
        </volume>
        <year>
         1985
        </year>
        <fpage>
         1013
        </fpage>
        <lpage>
         1017
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB12">
       <mixed-citation publication-type="other">
        Murphy, B.R., 1999. Mucosal immunity to viruses. In: Ogra, P.L., Mestecky, J., Lamm, M.E., Strober, W., Bienenstock, J., McGhee, J.R. (Eds.), Mucosal Immunology. Academic Press, New York, pp. 695–707.
       </mixed-citation>
      </ref>
      <ref id="BIB13">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ogra
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Fishaut
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral vaccination via the mucosal route
        </article-title>
        <source>
         Rev. Infect. Dis.
        </source>
        <volume>
         2
        </volume>
        <year>
         1980
        </year>
        <fpage>
         352
        </fpage>
        <lpage>
         369
        </lpage>
        <pub-id pub-id-type="pmid">
         6997965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB14">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tempesta
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Greco
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Martella
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a nested PCR for the detection of canine coronavirus
        </article-title>
        <source>
         J. Virol. Meth.
        </source>
        <volume>
         80
        </volume>
        <year>
         1999
        </year>
        <fpage>
         11
        </fpage>
        <lpage>
         15
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB15">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tempesta
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Roperto
          </surname>
          <given-names>
           F.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sagazio
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Carmichael
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fatal coronavirus infection in puppies following canine parvovirus 2b infection
        </article-title>
        <source>
         J. Vet. Diagn. Invest.
        </source>
        <volume>
         11
        </volume>
        <year>
         1999
        </year>
        <fpage>
         550
        </fpage>
        <lpage>
         553
        </lpage>
        <pub-id pub-id-type="pmid">
         12968743
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB16">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Martella
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Elia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Tempesta
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Guarda
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Capucchio
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Carmichael
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe enteric disease in an animal shelter associated with dual infections by canine adenovirus type 1 and canine coronavirus
        </article-title>
        <source>
         J. Vet. Med. B
        </source>
        <volume>
         48
        </volume>
        <year>
         2001
        </year>
        <fpage>
         385
        </fpage>
        <lpage>
         392
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB17">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Martella
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Tinelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Decaro
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Marsilio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tempesta
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         M gene evolution of canine coronavirus in naturally infected dogs
        </article-title>
        <source>
         Vet. Rec.
        </source>
        <volume>
         151
        </volume>
        <year>
         2002
        </year>
        <fpage>
         758
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         12521247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB18">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Martella
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Palmieri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cirone
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Tinelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Corrente
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of canine coronavirus (CCoV) antibodies in dogs in Bari, Italy, by an enzyme-linked immunosorbent assay
        </article-title>
        <source>
         J. Virol. Meth.
        </source>
        <volume>
         102
        </volume>
        <year>
         2002
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         71
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB19">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tinelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Decaro
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cirone
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Elia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Roperto
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tempesta
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Buonavoglia
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of an inactivated canine coronavirus vaccine in pups
        </article-title>
        <source>
         New Microbiol.
        </source>
        <volume>
         26
        </volume>
        <year>
         2003
        </year>
        <fpage>
         151
        </fpage>
        <lpage>
         155
        </lpage>
        <pub-id pub-id-type="pmid">
         12737196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB20">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mucosal immunity: an overview and studies of enteric and respiratory coronavirus infections in a swine model of enteric disease
        </article-title>
        <source>
         Vet. Immunol. Immunopathol.
        </source>
        <volume>
         54
        </volume>
        <year>
         1996
        </year>
        <fpage>
         163
        </fpage>
        <lpage>
         169
        </lpage>
        <pub-id pub-id-type="pmid">
         8988861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB21">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tennant
          </surname>
          <given-names>
           B.J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Gaskell
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           D.F.
          </given-names>
         </name>
         <name>
          <surname>
           Carter
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Gaskell
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Canine coronavirus infection in dog following oronasal inoculation
        </article-title>
        <source>
         Res. Vet. Sci.
        </source>
        <volume>
         51
        </volume>
        <year>
         1991
        </year>
        <fpage>
         11
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         1654584
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB22">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Holladay
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cave
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A neurologic syndrome associated with use of a canine coronavirus–parvovirus vaccine in dogs
        </article-title>
        <source>
         Comp. Cont. Educ. Pract. Vet.
        </source>
        <volume>
         8
        </volume>
        <year>
         1986
        </year>
        <fpage>
         117
        </fpage>
        <lpage>
         122
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB23">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woods
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wesley
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kapke
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complement-dependent neutralization of transmissible gastroenteritis virus by monoclonal antibodies
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <volume>
         218
        </volume>
        <year>
         1987
        </year>
        <fpage>
         493
        </fpage>
        <lpage>
         500
        </lpage>
        <pub-id pub-id-type="pmid">
         2829565
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported by grants from Ministry of University, Italy (project: Enteriti virali del cane).
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerging Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       EID
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1080-6040
      </issn>
      <issn pub-type="epub">
       1080-6059
      </issn>
      <publisher>
       <publisher-name>
        Centers for Disease Control and Prevention
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24655412
      </article-id>
      <article-id pub-id-type="pmc">
       3966379
      </article-id>
      <article-id pub-id-type="publisher-id">
       13-1746
      </article-id>
      <article-id pub-id-type="doi">
       10.3201/eid2004.131746
      </article-id>
      <article-categories>
       <subj-group subj-group-type="second-type">
        <subject>
         Expedited
        </subject>
       </subj-group>
       <subj-group subj-group-type="heading">
        <subject>
         Research
        </subject>
       </subj-group>
       <subj-group subj-group-type="article-type">
        <subject>
         Research
        </subject>
       </subj-group>
       <subj-group subj-group-type="TOC-title">
        <subject>
         Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013
       </article-title>
       <alt-title alt-title-type="running-head">
        Antibodies against MERS Coronavirus in Camels
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Meyer
         </surname>
         <given-names>
          Benjamin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          Marcel A.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Corman
         </surname>
         <given-names>
          Victor M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Reusken
         </surname>
         <given-names>
          Chantal B.E.M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ritz
         </surname>
         <given-names>
          Daniel
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Godeke
         </surname>
         <given-names>
          Gert-Jan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lattwein
         </surname>
         <given-names>
          Erik
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kallies
         </surname>
         <given-names>
          Stephan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Siemens
         </surname>
         <given-names>
          Artem
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          van Beek
         </surname>
         <given-names>
          Janko
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Drexler
         </surname>
         <given-names>
          Jan F.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Muth
         </surname>
         <given-names>
          Doreen
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bosch
         </surname>
         <given-names>
          Berend-Jan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wernery
         </surname>
         <given-names>
          Ulrich
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Koopmans
         </surname>
         <given-names>
          Marion P.G.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wernery
         </surname>
         <given-names>
          Renate
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          Christian
         </given-names>
        </name>
       </contrib>
       <aff id="aff1">
        University of Bonn Medical Centre, Bonn, Germany (B. Meyer, M.A. Müller, V.M. Corman, D. Ritz, S. Kallies, A. Siemens, J.F. Drexler, D. Muth, C. Drosten);
       </aff>
       <aff id="aff2">
        National Institute for Public Health and the Environment, Bilthoven, the Netherlands. (C.B.E.M. Reusken, G.-J. Godeke, J. van Beek, M.P.G. Koopmans);
       </aff>
       <aff id="aff3">
        Erasmus Medical Centre, Rotterdam, the Netherlands (C.B.E.M. Reusken, J.F. Drexler, M.P.G. Koopmans);
       </aff>
       <aff id="aff4">
        EUROIMMUN AG, Lübeck, Germany (E. Lattwein);
       </aff>
       <aff id="aff5">
        Utrecht University, Utrecht, the Netherlands (B.-J. Bosch);
       </aff>
       <aff id="aff6">
        Central Veterinary Research Laboratory, Dubai, United Arab Emirates (U. Wernery, R. Wernery)
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address for correspondence: Christian Drosten, Institute of Virology, University of Bonn Medical Centre, Sigmund Freud Strasse 25, 53105 Bonn, Germany; email:
        <email xlink:href="drosten@virology-bonn.de">
         drosten@virology-bonn.de
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        4
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       20
      </volume>
      <issue>
       4
      </issue>
      <fpage>
       552
      </fpage>
      <lpage>
       559
      </lpage>
      <abstract abstract-type="toc">
       <p>
        Camels were infected with this virus &gt;10 years before the first human cases.
       </p>
      </abstract>
      <abstract>
       <p>
        Middle East respiratory syndrome coronavirus (MERS-CoV) has caused an ongoing outbreak of severe acute respiratory tract infection in humans in the Arabian Peninsula since 2012. Dromedary camels have been implicated as possible viral reservoirs. We used serologic assays to analyze 651 dromedary camel serum samples from the United Arab Emirates; 151 of 651 samples were obtained in 2003, well before onset of the current epidemic, and 500 serum samples were obtained in 2013. Recombinant spike protein–specific immunofluorescence and virus neutralization tests enabled clear discrimination between MERS-CoV and bovine CoV infections. Most (632/651, 97.1%) camels had antibodies against MERS-CoV. This result included all 151 serum samples obtained in 2003. Most (389/651, 59.8%) serum samples had MERS-CoV–neutralizing antibody titers &gt;1,280. Dromedary camels from the United Arab Emirates were infected at high rates with MERS-CoV or a closely related, probably conspecific, virus long before the first human MERS cases.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <kwd>
        Middle East respiratory syndrome
       </kwd>
       <kwd>
        MERS
       </kwd>
       <kwd>
        Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        viruses
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        dromedary camels
       </kwd>
       <kwd>
        camels
       </kwd>
       <kwd>
        antibodies
       </kwd>
       <kwd>
        serologic analysis
       </kwd>
       <kwd>
        United Arab Emirates
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging pathogen associated with severe respiratory symptoms and renal failure in infected patients (
     <xref ref-type="bibr" rid="R1">
      <italic>
       1
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R2">
      <italic>
       2
      </italic>
     </xref>
     ). Globally, 156 laboratory-confirmed cases of infection with MERS-CoV, including 65 deaths, were reported as of early November 2013. All human cases were linked to the Arabian Peninsula (Saudi Arabia, Jordan, Oman, Qatar, Kuwait, and the United Arab Emirates). Imported cases were detected in countries in Europe and Africa (United Kingdom, Germany, Italy, France, and Tunisia) (
     <xref ref-type="bibr" rid="R3">
      <italic>
       3
      </italic>
     </xref>
     ).
    </p>
    <p>
     Transmission patterns, including the putative zoonotic source of the virus, remain unclear. Hypotheses include frequent zoonotic infections with limited subsequent human-to-human transmission chains and existence of a self-sustained epidemic in humans (
     <xref ref-type="bibr" rid="R4">
      <italic>
       4
      </italic>
     </xref>
     ). A recent study found evidence to support the existence of epidemiologically unlinked cases in a large outbreak in the al-Hasa region, Saudi Arabia (
     <xref ref-type="bibr" rid="R5">
      <italic>
       5
      </italic>
     </xref>
     ). It was speculated that zoonotic introductions of MERS-CoV from an unknown reservoir might occur at high rates, in addition to obvious human-to-human transmission.
    </p>
    <p>
     Coronaviruses (CoV) are positive-sense RNA viruses. Viruses in the genera
     <italic>
      Alphacoronavirus
     </italic>
     and
     <italic>
      Betacoronavirus
     </italic>
     are associated with mammals and show a particularly high level of diversification in bats. Viruses in the genera
     <italic>
      Gammacoronavirus
     </italic>
     and
     <italic>
      Deltacoronavirus
     </italic>
     are mostly avian-associated viruses (
     <xref ref-type="bibr" rid="R6">
      <italic>
       6
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R7">
      <italic>
       7
      </italic>
     </xref>
     ). MERS-CoV belongs to
     <italic>
      Betacoronavirus
     </italic>
     phylogenetic lineage C that, in addition to MERS-CoV, contains 2 distinct bat-associated CoV species (HKU4 and HKU5) (
     <xref ref-type="bibr" rid="R1">
      <italic>
       1
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R8">
      <italic>
       8
      </italic>
     </xref>
     ).
    </p>
    <p>
     Insectivorous bats of the family Vespertilionidae were recently shown to carry viruses that are probably conspecific with MERS-CoV (
     <xref ref-type="bibr" rid="R9">
      <italic>
       9
      </italic>
     </xref>
     ). However, the limited rate of contact between humans and insectivorous bats makes a continuous and frequent acquisition of MERS-CoV from bats an unlikely scenario. In a manner similar to observations regarding severe acute respiratory syndrome CoV (SARS-CoV), an intermediate reservoir host might exist from which human infections are acquired. Dromedary camels from different regions in Africa and the Arabian Peninsula have been shown to have antibodies against MERS-CoV (
     <xref ref-type="bibr" rid="R10">
      <italic>
       10
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R11">
      <italic>
       11
      </italic>
     </xref>
     ). Animals from the Arabian Peninsula had high neutralizing serum activities overall and reciprocal antibody titers ≤320–1,280, which support recent infection with MERS-CoV or a highly related virus. Thus, dromedary camels might serve as intermediate hosts. However, detailed serologic studies in countries with actual incidence of MERS-CoV infections in humans have not been conducted.
    </p>
    <p>
     Serologic analysis of CoVs is challenging because of cross-reactivity between CoVs infecting the same host and the broad distribution of CoVs in diverse mammalian species (
     <xref ref-type="bibr" rid="R6">
      <italic>
       6
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R7">
      <italic>
       7
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R12">
      <italic>
       12
      </italic>
     </xref>
     –
     <xref ref-type="bibr" rid="R14">
      <italic>
       14
      </italic>
     </xref>
     ). Antibodies directed against some of the major antigens of different CoVs are known to cross-react in standard serologic assays (
     <xref ref-type="bibr" rid="R15">
      <italic>
       15
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R16">
      <italic>
       16
      </italic>
     </xref>
     ). Potential cross-reactivity is a diagnostic challenge because camelids are known to be infected with bovine CoV (BCoV), a distinct betacoronavirus of phylogenetic lineage A unrelated to the MERS-CoV (
     <xref ref-type="bibr" rid="R17">
      <italic>
       17
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R18">
      <italic>
       18
      </italic>
     </xref>
     ). As an additional challenge, camel immunoglobulins lack a light chain peptide, which affects specific physical properties, such as altered size and stability, compared with immunoglobulins of other mammals (
     <xref ref-type="bibr" rid="R19">
      <italic>
       19
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R20">
      <italic>
       20
      </italic>
     </xref>
     ). The influence of this feature on serologic assays has not been thoroughly investigated. Thus, serologic assays should be applied with caution, and different assay formats should be tested concurrently.
    </p>
    <p>
     We reported a 2-staged approach for MERS-CoV serologic analysis in humans (
     <xref ref-type="bibr" rid="R15">
      <italic>
       15
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R16">
      <italic>
       16
      </italic>
     </xref>
     ). Expanding upon these studies, we used in the present study a recombinant MERS-CoV spike protein immunofluroescence assay (rIFA) augmented by a validated protein microarray (
     <xref ref-type="bibr" rid="R10">
      <italic>
       10
      </italic>
     </xref>
     ,
     <xref ref-type="bibr" rid="R21">
      <italic>
       21
      </italic>
     </xref>
     ), followed by MERS-CoV–specific neutralization assay, to screen 651 dromedary camel serum samples from the United Arabian Emirates. Cross-reactivity against clade A betacoronaviruses was assessed by using a immunofluorescence assay (IFA) and a BCoV-specific neutralization assay. Serum samples obtained in 2003 and 2013 were compared to obtain information for the time in which MERS-related CoV has been circulating in camels.
    </p>
    <sec sec-type="methods">
     <title>
      Methods
     </title>
     <sec>
      <title>
       Sampling
      </title>
      <p>
       A total of 651 dromedary camel (
       <italic>
        Camelus dromedarius
       </italic>
       ) serum samples were systematically sampled in Dubai, United Arab Emirates and the surrounding area in 2003 (collection 4, n = 151) and in 2013 (collections 1A, 1B, 2, and 3; n = 500). The total number of camels in that area was 360,000 in 2010 (
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       ). Fecal samples were also available for collections 1A and 1B (n = 182), all obtained in 2013. Animals in collection 1B were born and raised at the Dubai Central Veterinary Research Laboratory, which tests ≈70,000 camels per year (
       <xref ref-type="bibr" rid="R23">
        <italic>
         23
        </italic>
       </xref>
       ) and had no contact with other camels. Camels in collection 2 were racing camels (age range 2–8 years), and camels in collection 3 were adult livestock camels originally purchased from Saudi Arabia, Sudan, Pakistan and Oman.
      </p>
      <p>
       Dromedary camel blood was obtained for routine health screening by jugular vein puncture according to standard veterinary procedures by trained personnel. For most serum samples, animal owners requested sample codes to be anonymous. All samples obtained during 2003 and 2013 were stored at −80°C until further analysis. For comparison, 16 serum samples from
       <italic>
        C. bactrianus
       </italic>
       camels in zoologic gardens in Germany were included in the study. All serum samples were shipped in agreement with German import regulations.
      </p>
     </sec>
     <sec>
      <title>
       Recombinant Spike IFA
      </title>
      <p>
       For screening purposes, an rIFA was used (
       <xref ref-type="bibr" rid="R15">
        <italic>
         15
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R24">
        <italic>
         24
        </italic>
       </xref>
       ). In brief, Vero B4 cells were transfected with pCG1 eukaryotic expression vector that contained the complete spike sequence of MERS-CoV or human CoV-OC43. Cells were fixed 24-h post-transfection with ice-cold acetone/methanol and stored dry at 4°C. Serum samples were applied at a dilution of 1:80 for 1 h at 37°C, which was optimal for reducing nonspecific reactions and maintaining sensitivity. Secondary detection was conducted by using a goat anti-llama IgG fluorescein isothiocyanate–conjugated antibody. For some negative serum samples, dilutions of 1:20 and 1:40 were also tested.
      </p>
     </sec>
     <sec>
      <title>
       Spike Protein Microarray
      </title>
      <p>
       A confirmatory assay based on a protein microarray was performed as described (
       <xref ref-type="bibr" rid="R10">
        <italic>
         10
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R21">
        <italic>
         21
        </italic>
       </xref>
       ) by using the spike S1 subunits of MERS-CoV, human CoV-OC43, and SARS-CoV. Serum samples were used at 1:20 dilutions on microarray chips. Relative light units were determined by using secondary cyanine 5–conjugated goat anti-llama IgG.
      </p>
     </sec>
     <sec>
      <title>
       MERS-CoV Conventional IFA
      </title>
      <p>
       A MERS-CoV IFA with infected Vero cells was conducted as described (
       <xref ref-type="bibr" rid="R15">
        <italic>
         15
        </italic>
       </xref>
       ) by using commercially available MERS-CoV IFA slides (EUROIMMUNAG, Lübeck Germany). Serum samples were used at dilutions of 1:20–1:5,120. Secondary detection was conducted by using goat anti-llama fluorescein isothiocyanate–labeled IgG (1:200 dilution; Agrisera, Vännas, Sweden).
      </p>
     </sec>
     <sec>
      <title>
       Serum Neutralization Test
      </title>
      <p>
       Serum neutralization tests were conducted as described (
       <xref ref-type="bibr" rid="R10">
        <italic>
         10
        </italic>
       </xref>
       ) by using Vero B4 (MERS-CoV) or PT (BCoV) cells. To reduce volumes of serum needed, all neutralization tests were performed in a 96-well format. Reactions contained 50 PFUs of MERS-CoV (EMC/2012 strain) or BCoV (Nebraska strain) in 25 μL of medium mixed 1:1 with camel serum diluted in 25 μL serum-free Dulbecco minimum essential medium. The starting dilution was 1:40. After incubation for 1 h at 37°C, each well was infected for 1 h at 37°C with a 50 μL virus–serum mixture. Supernatants were removed and fresh complete Dulbecco minimum essential medium was added. Assays were terminated by fixation with 8% paraformaldehyde for 30 min and stained with crystal violet after 3 days. Neutralization titers were defined as serum dilutions reducing cytopathic effects in 2 parallel wells.
      </p>
     </sec>
     <sec>
      <title>
       Detection of Virus Nucleic Acid
      </title>
      <p>
       Viral RNA was extracted from serum and fecal samples by using the MagNA Pure System (Roche, Basel, Switzerland) and an input volume of 100 μL of serum or fecal material suspended 1:10 in phosphate-buffered saline buffer. The elution volume was 100 μL for serum and fecal suspensions. To identify CoV-specific nucleic acids, 2 generic CoV PCRs were performed as described (
       <xref ref-type="bibr" rid="R25">
        <italic>
         25
        </italic>
       </xref>
       –
       <xref ref-type="bibr" rid="R27">
        <italic>
         27
        </italic>
       </xref>
       ), followed by subsequent Sanger sequencing of the amplified DNA.
      </p>
     </sec>
    </sec>
    <sec sec-type="results">
     <title>
      Results
     </title>
     <p>
      To characterize reactivity of camel serum samples with MERS-CoV in different assay formats, we chose 11 camel serum samples with weak and strong reactivity predetermined by using a simple IFA. The 11 serum samples were titrated in a 2-fold dilution series in all applied assays. The reactivity pattern of the MERS-CoV spike protein (MERS-S) was compared against that of the human CoV-OC43 spike protein (OC43-S). As in our previous study (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ), human CoV-OC43 was used instead of BCoV in these initial experiments because it is serologically indistinguishable from BCoV and is not subject to handling restrictions of German Animal Diseases Protection Act (
      <xref ref-type="bibr" rid="R28">
       <italic>
        28
       </italic>
      </xref>
      ). Overall titers against MERS-S were higher than those against OC43-S, and several serum samples reacted exclusively against 1 of the 2 viruses (
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      ), suggesting the absence of general cross-reactivity between spike proteins of both viruses by IFA. Typical patterns of reactivity observed for camel serum samples are shown in the
      <xref ref-type="fig" rid="F1">
       Figure
      </xref>
      , panel A.
     </p>
     <table-wrap id="T1" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <title>
        Validation of serologic assays for coronaviruses with differentially reactive dromedary serum samples, United Arab Emirates, 2013*
       </title>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" width="53"/>
       <col span="1" width="50"/>
       <col span="1" width="50"/>
       <col span="1" width="6"/>
       <col span="1" width="50"/>
       <col span="1" width="50"/>
       <col span="1" width="50"/>
       <col span="1" width="8"/>
       <col span="1" width="50"/>
       <col span="1" width="9"/>
       <col span="1" width="50"/>
       <col span="1" width="50"/>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
          Serum no.
         </th>
         <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
          rIFA titer†‡
          <hr/>
         </th>
         <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
         </th>
         <th align="center" colspan="3" rowspan="1" scope="colgroup" valign="bottom">
          Protein array (RFU) ‡§
          <hr/>
         </th>
         <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          vIFA titer†‡
          <hr/>
         </th>
         <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
         </th>
         <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
          Neutralization test titer¶#
          <hr/>
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          MERS-S
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          OC43-S
         </th>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          MERS-S1
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          OC43-S1
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          SARS-S1
         </th>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          MERS-CoV
         </th>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          MERS-CoV
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          BCoV
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,555
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3,868
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,606
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          40
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,770
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          18,896
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,776
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          80
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          640
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3,950
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,751
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          160
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3,921
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1,726
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          640
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          40
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          –
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;10,240
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          7,247
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,306
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,560
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          160
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5,120
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          640
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5,069
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,098
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,560
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          640
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          160
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;10,240
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          160
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          7,179
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,198
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          640
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          40
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5,120
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          55,826
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,412
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1,280
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          160
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5,120
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,087
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1,280
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          10
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;10,240
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          22,695
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,303
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1,280
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          320
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          11
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5,120
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1,280
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          65,535
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          28,391
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2,858
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          &gt;5,120
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          640
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          40
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        *rIFA, recombinant immunofluorescence assay (antigen used was complete spike protein); RFU, relative fluorescence units; vIFA, Middle East respiratory syndrome coronavirus–based immunofluorescence assay (antigen used complete virus); MERS-S, spike protein from Middle East respiratory syndrome coronavirus; OC43-S, spike protein from human coronavirus OC34; SARS-S, spike protein from severe acute respiratory syndrome virus; MERS-CoV, Middle East respiratory syndrome coronavirus; BCoV, bovine coronavirus; –, negative.  †Serum dilutions started at 1:20.  ‡Assay was used for screening purposes. §RFU &lt;4,000 were considered negative. The serum dilution used in this assay was 1:20 (antigen used was S1 subunit of spike protein). ¶Serum dilutions started at 1:40. #Assay applied for confirmation purposes.
       </p>
      </table-wrap-foot>
     </table-wrap>
     <fig fig-type="figure" id="F1" position="float">
      <label>
       Figure
      </label>
      <caption>
       <p>
        Immunofluorescence and microarray reactivity patterns for antibodies (SF74, H40, H97, and S11) against Middle East respiratory syndrome coronavirus (MERS-CoV) in serum samples from camels, United Arab Emirates, 2013. A) Serum samples tested against overexpressed MERS-CoV spike protein (MERS-S), overexpressed human CoV-OC43 spike protein (OC43-S), and Vero cells infected with MERS-CoV (MERS-V). Fluorescence intensities were evaluated as follows: –, negative; +, weakly reactive; ++, reactive; +++, strongly reactive. Scale bar indicates 20 μm. B) Relative fluorescence units (RFU) were determined for the same serum samples by microarray using S1 domains of MERS-CoV and human CoV-OC43.
       </p>
      </caption>
      <graphic xlink:href="13-1746-F">
      </graphic>
     </fig>
     <p>
      A previously published microarray-based assay that used the receptor-binding S1 spike subunit of MERS-CoV (MERS-S1), human CoV-OC43 (OC43-S1), and SARS-CoV (SARS-S1) was also evaluated. In contrast to our previous studies (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R21">
       <italic>
        21
       </italic>
      </xref>
      ) we chose a lower fluorescence intensity cutoff of 4,000 instead of 20,000 relative fluorescence units (RFU) to maximize the sensitivity and thereby challenge the target specificity. All 3 MERS IFA-negative serum samples had signal intensities &lt;4000 RFU at serum dilutions of 1:20 (
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      ). All rIFA-positive serum samples had saturated signals &gt;65,535 RFU. The OC43-S1 reactivity pattern across the serum panel was comparable with that for the OC43-S rIFA. As expected, all serum samples were negative against the SARS-S1 control antigen. A comparison of typical reactivity patterns in the microarray with those of the IFA is shown in the
      <xref ref-type="fig" rid="F1">
       Figure
      </xref>
      , panel B. Results for the rIFA and protein microarray were highly congruent.
     </p>
     <p>
      The panel of camel serum samples was additionally tested in a commercially available IFA that used cells infected with MERS-CoV (vIFA) (EUROIMMUN AG). The use of whole virus provides additional structural and nonstructural protein antigens, including envelope, membrane, nucleocapsid, and diverse replicase proteins. However, because of conserved features of nonstructural proteins among even distantly related CoVs (
      <xref ref-type="bibr" rid="R7">
       <italic>
        7
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R12">
       <italic>
        12
       </italic>
      </xref>
      ), cross-reactivity was possible with this assay (
      <xref ref-type="bibr" rid="R15">
       <italic>
        15
       </italic>
      </xref>
      ). In the tested panel of camel serum samples, vIFA titers corresponded well to titers determined by rIFA and generally equal to or higher than titers in the rIFA (
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      ). Despite the absence of cross-reactivity between MERS-S–positive and OC43-S–positive serum samples in this test (
      <xref ref-type="fig" rid="F1">
       Figure
      </xref>
      , panel A), in previous studies the vIFA showed false-positive results with human CoV-OC43–positive serum samples, in particular if used at lower dilutions, such as 1:10 or 1:20 (
      <xref ref-type="bibr" rid="R15">
       <italic>
        15
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R16">
       <italic>
        16
       </italic>
      </xref>
      ).
     </p>
     <p>
      To confirm results from affinity assays with results from a functional test, we determined endpoint virus neutralization titers by using a microneutralization test against MERS-CoV and BCoV. In most animals MERS-CoV serum neutralization titers were higher than titers against BCoV (serum samples 4–11) (
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      ). High IFA titers generally corresponded with high neutralization titers, with exceptions for some BCoV antibody–positive serum samples. Divergence between affinity and neutralization assays can result from waning neutralizing antibody activity for infections that occurred long ago. Neutralization assays confirmed the absence of cross-neutralization between MERS-CoV and BCoV antibodies in either direction even at low dilutions, such as 1:40. However, sample no. 1 (
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      ) neutralized BCoV at a dilution of 1:40 despite showing negative results in all other serologic assays. This finding indicates that nonspecific neutralization activities might be encountered with camel serum samples, suggesting that higher serum dilutions should be used when conducting critical investigations such as viral reservoir studies.
     </p>
     <p>
      On the basis of the validation studies, we investigated 4 collections of serum samples from dromedary camels from the United Arab Emirates that were sampled in 2003 and 2013. For initial screening, we chose the rIFA because of its proven sensitivity and decreased chances of generating false-positive results. All 667 camel serum samples from the United Arab Emirates and Germany were initially screened at dilutions of 1:80. A total of 89.0%–100.0% of serum samples in 4 collections showed positive results (
      <xref ref-type="table" rid="T2">
       Table 2
      </xref>
      ). Seroprevalence was higher for collections from exclusively adult animals (collections 3 and 4) than for a collection from young racing camels (2–8 years of age, collection 2). Clear seropositive results included 151 dromedary camel serum samples obtained in 2003 (collection 4). All 16 serum samples from German zoologic gardens were tested at the same dilution and showed no reactivity in the rIFA. Re-testing at lower dilutions of 1:20 and 1:40 confirmed absence of reactivity in these serum samples. Subcollection 1B contained serum samples from 5 animals that were born in, and had never left, a closed animal research facility in Dubai; these animals were seronegative.
     </p>
     <table-wrap id="T2" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <title>
        MERS-CoV serologic results for dromedary serum and fecal samples, United Arab Emirates, 2003 and 2013*
       </title>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" width="43"/>
       <col span="1" width="31"/>
       <col span="1" width="40"/>
       <col span="1" width="40"/>
       <col span="1" width="72"/>
       <col span="1" width="40"/>
       <col span="1" width="65"/>
       <col span="1" width="6"/>
       <col span="1" width="45"/>
       <col span="1" width="48"/>
       <col span="1" width="48"/>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="3" scope="col" valign="bottom">
          Collection
         </th>
         <th align="center" colspan="1" rowspan="3" scope="col" valign="bottom">
          Year
         </th>
         <th align="center" colspan="1" rowspan="3" scope="col" valign="bottom">
          No. camels/ sex
         </th>
         <th align="center" colspan="1" rowspan="3" scope="col" valign="bottom">
          Camel age
         </th>
         <th align="center" colspan="1" rowspan="3" scope="col" valign="bottom">
          Feature
         </th>
         <th align="center" colspan="1" rowspan="3" scope="col" valign="bottom">
          No. samples
         </th>
         <th align="center" colspan="5" rowspan="1" scope="colgroup" valign="bottom">
          Serum dilution, no. (%) positive
          <hr/>
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          rIFA, MERS-S†
          <hr/>
         </th>
         <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
         </th>
         <th align="center" colspan="3" rowspan="1" scope="colgroup" valign="bottom">
          Neutralization test, MERS-CoV
          <hr/>
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          80
         </th>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          &lt;640
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          640–1,280
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          &gt;1,280
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          1A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/M, F
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          A, J
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          Paired serum and fecal samples
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          177
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          175 (98.9)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          24 (13.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          74 (41.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          79 (44.6)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          1B
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/M, F
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          A, J
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          Animals raised at CVRL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          5 (100.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/M, F
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2–8 y
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          Racing camels
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          100
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          89 (89.0)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          55 (55.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3 (3.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          42 (42.0)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/M, F
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          Livestock camels‡
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          218
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          217 (99.5)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          23 (10.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13 (6.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          182 (83.5)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1/F
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          Systematically sampled
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          151
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          151 (100.0)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          35 (23.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          30 (19.9)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          86 (57.0)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          Total
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          651
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          632 (97.1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          142 (21.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          120 (18.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          389 (59.8)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        *MERS-CoV, Middle East respiratory syndrome coronavirus; rIFA, recombinant immunofluorescence assay with MERS-CoV spike protein; MERS-S, spike protein from MERS-CoV; A, adult; J, juvenile; CVRL, Dubai Central Veterinary Research Laboratory. †Fluorescence signal intensity was rated as negative, +, ++, +++, and ++++. ‡Originally purchased from Saudi Arabia, Sudan, Pakistan, and Oman.
       </p>
      </table-wrap-foot>
     </table-wrap>
     <p>
      A confirmatory microneutralization test was conducted at dilutions of 1:640 and 1:1,280 for all IFA-reactive serum samples. These high dilutions were chosen on the basis of our observation of high levels of neutralizing serum activity in camels (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ). Most (59.8%, 389/651) serum samples had high neutralizing titers &gt;1,280 (
      <xref ref-type="table" rid="T2">
       Table 2
      </xref>
      ). In 18.4% (120/651) of all serum samples, neutralization titers ranged from 640 through 1,280, and 21.8% (142/651) of rIFA-positive serum samples had neutralizing titers &lt;640.
     </p>
     <p>
      To rule out cross-reactivity and to study additional exposure of MERS-CoV–positive camels with BCoV (
      <xref ref-type="bibr" rid="R17">
       <italic>
        17
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R18">
       <italic>
        18
       </italic>
      </xref>
      ), all serum samples having MERS-CoV neutralizing titers &gt;640 were tested by using a BCoV-specific microneutralization assay. At a dilution of 1:640, a total of 19.2% (23/120) of MERS-CoV–neutralizing serum samples had concomitant neutralizing activities against BCoV (
      <xref ref-type="table" rid="T3">
       Table 3
      </xref>
      ). Of serum samples that had MERS-CoV neutralizing antibody titers &gt;1,280, a total of 24.2% (94/389) had concomitant neutralizing activities against BCoV.
     </p>
     <table-wrap id="T3" position="float">
      <label>
       Table 3
      </label>
      <caption>
       <title>
        BCoV neutralization test results for MERS-CoV–positive dromedary serum samples, United Arab Emirates, 2003 and 2013*
       </title>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" width="79"/>
       <col span="1" width="79"/>
       <col span="1" width="79"/>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="bottom">
          Collection
          <hr/>
         </td>
         <td align="center" colspan="2" rowspan="1" valign="bottom">
          No. BCoV positive/no. MERS-CoV positive (serum dilution, %)
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="bottom">
          640–1,280
          <hr/>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="bottom">
          &gt;1,280
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          1A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          15/74 (20.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          14/79 (17.7)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          1B
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0/3 (0.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          14/42 (33.3)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/13 (15.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          52/182 (28.6)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          4
          <hr/>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          6/30 (20.0)
          <hr/>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          14/86 (16.3)
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          Total
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          23/120 (19.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          94/389 (24.2)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        *BCoV, bovine coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus.
       </p>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Fecal samples were available for 182 dromedary camels in collection 1. All samples were tested by using a subfamily
      <italic>
       Coronavirinae
      </italic>
      –specific broad-range reverse transcription PCR (RT-PCR) and a highly sensitive RT-PCR specific for genus
      <italic>
       Betacoronavirus
      </italic>
      phylogenetic lineage C. Both assays were specific for the viral RNA-dependent RNA polymerase gene. Two positive fecal samples were identified by both assays. Sequencing of amplified cDNA fragments of 182 nt and 404 nt identified sequences 99% identical with BCoV strain Mebus (GenBank accession nos. KF894801 and U00735.2). To further confirm virus identity, we amplified a region within the spike protein gene (positions 24303–24702 in BCoV strain Mebus) by using RT-PCR and sequencing it. Amplicons from both animals were 97% identical at nucleotide level with BCoV strain Mebus, indicating the presence of BCoV in camels as reported (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ). We tested all serum samples in the same way by RT-PCR and obtained uniformly negative results.
     </p>
    </sec>
    <sec sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      We have shown that dromedary camels from the United Arab Emirates, a country with human cases of MERS-CoV infection, have antibodies that can neutralize MERS-CoV at high rates. Antibodies were detected in serum samples obtained in 2013 and in serum samples obtained &gt;10 years earlier, which indicated the long-standing presence of MERS-CoV or a closely related virus in dromedary camels in that region. Our data add to previous studies in which our group and others have reported wide antibody prevalence in camels in various regions, including Oman, Egypt, and the Canary Islands (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R11">
       <italic>
        11
       </italic>
      </xref>
      ). A 10% lower seroprevalence in collection 2, which contained young racing camels, suggests that animals might be infected as juveniles. However, because only limited data were made available by owners, a definite statement awaits confirmation.
     </p>
     <p>
      The absence of antibodies in a control cohort from Germany might be explained by the fact that these animals belonged to a different camelid species (
      <italic>
       C. bactrianus
      </italic>
      vs.
      <italic>
       C. dromedarius
      </italic>
      ). However, because MERS-CoV has a highly conserved receptor structure, we did not assign high priority to the hypothesis that the closely related camel species
      <italic>
       C. bactrianus
      </italic>
      , should be less susceptible than
      <italic>
       C. dromedarius
      </italic>
      camels to MERS-CoV (
      <xref ref-type="bibr" rid="R29">
       <italic>
        29
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R30">
       <italic>
        30
       </italic>
      </xref>
      ). Differences in antibody prevalence rates might reflect a restricted geographic distribution of the virus, which corresponds to our previous finding of a relatively lower prevalence of antibodies against MERS CoV in camels from the Canary Islands, which have been isolated from their point of origin in Africa for many years (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ). Therefore, MERS-CoV–like viruses in camelids might be spreading across a region covering at least the eastern Arabian Peninsula, including Oman, the United Arab Emirates, Egypt, and Morocco from where some of the antibody-positive camels described by Reusken et al. originated (
      <xref ref-type="bibr" rid="R10">
       <italic>
        10
       </italic>
      </xref>
      ).
     </p>
     <p>
      The high rates of antibody prevalence in contemporary serum samples and samples from 2003 suggest that the virus has spread in camelids for some time. However, recognition of camelids as the bona fide reservoir for MERS-CoV has to await sequencing of camelid-associated MERS-related CoV. In this context, only animals infected with conspecific viruses can be regarded as reservoirs for a given virus. Although neutralization assays can provide evidence of infection with a virus belonging to the same serotype, no systematic studies have defined whether serotypes correlate with CoVs species. Nevertheless, for several CoV clades, serotypes defined by neutralization assay will not include &gt;1 viral species. Members of the species
      <italic>
       Betacoronavirus 1
      </italic>
      , including CoV-OC43 and BCoV, show cross-neutralization with each other, but the closely related sister species (human CoV-HKU1) does not show cross-neutralization (
      <xref ref-type="bibr" rid="R31">
       <italic>
        31
       </italic>
      </xref>
      ).
     </p>
     <p>
      Feline CoV (FCoV) comprises 2 subserotypes that show limited cross-reactivity but are considered 1 virus species. Transmissible gastroenteritis virus of swine shows more efficient cross-neutralization with 1 of these FCoV subserotypes than the other and is classified as 1 species with FCoV even though it is carried by a different host (
      <xref ref-type="bibr" rid="R32">
       <italic>
        32
       </italic>
      </xref>
      ). Human CoVs 229E and NL63, which form 2 closely related sister taxa, do not show cross-neutralization and concordantly form 2 different species by genetic criteria (
      <xref ref-type="bibr" rid="R33">
       <italic>
        33
       </italic>
      </xref>
      ). Therefore, our finding of high neutralizing antibody titers in camelids is suggestive (but not evidentiary) of the presence of viruses conspecific with MERS-CoV in camelids. Final confirmation will depend on the identification of virus sequences in camelids, which should expectably be closely related to human-specific MERS-CoV sequences.
     </p>
     <p>
      Camels probably acquired MERS-CoV at some unknown time. Potential sources include bats of the family Vespertilionidae, in which a virus with a close phylogenetic relationship with MERS-CoV has been detected (
      <xref ref-type="bibr" rid="R9">
       <italic>
        9
       </italic>
      </xref>
      ). This virus, which is carried by vespertilionid bats of the genus
      <italic>
       Neoromicia
      </italic>
      , has been confirmed to be conspecific with MERS-CoV. Lineage C betacoronaviruses in other bat taxa have also been proposed to be related to MERS-CoV (
      <xref ref-type="bibr" rid="R34">
       <italic>
        34
       </italic>
      </xref>
      ,
      <xref ref-type="bibr" rid="R35">
       <italic>
        35
       </italic>
      </xref>
      ). However, although these viruses cluster phylogenetically with MERS-CoV, they are not conspecific with MERS-CoV on the basis of sequence distance criteria, such as that were proposed by Drexler et al. (
      <xref ref-type="bibr" rid="R36">
       <italic>
        36
       </italic>
      </xref>
      ).
     </p>
     <p>
      In vespertilionid bats, including those in the genus
      <italic>
       Neoromicia
      </italic>
      , virus conspecific with MERS-CoV differs from human MERS-CoV, even if formally a member of the same species. The observed degree of sequence divergence between this virus and MERS-CoV makes any direct and recent transmission from bats to humans seem unlikely. Nevertheless, it cannot be excluded from available data that the virus source population in bats has not been detected. For example, a recent investigation of
      <italic>
       Rhinolophus
      </italic>
      bats in China identified viruses with close relationships to the bona fide ancestor of SARS-CoV, and viruses described in many studies yielded only conspecific yet less related viruses (
      <xref ref-type="bibr" rid="R37">
       <italic>
        37
       </italic>
      </xref>
      ). In that study, viruses from civet cats, which are deemed to be intermediary hosts in the transition of SARS-CoV from bats to humans, were still more closely related to human SARS-CoV than even the closest bat-borne virus.
     </p>
     <p>
      If camelids should function as intermediary hosts in a similar manner, we should expect a virus in camelids that has a closer phylogenetic relationship with any bat-borne CoV and thus should be easily detectable with available RT-PCRs. Larger studies to confirm the presence of MERS-CoV in camelids should receive high priority so as to define the animal reservoir of MERS-CoV and possibly control it by such measures as vaccination or control of animal movement. However, before implementation of any control measures, whether camelids are a continuous source of infection for humans needs to be firmly established.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="citation">
       <p>
        <italic>
         Suggested citation for this article
        </italic>
        : Meyer B, Müller MA, Corman VM, Reusken CBEM, Ritz D, Godeke G-D, et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis [Internet]. 2014 Apr [
        <italic>
         date cited
        </italic>
        ].
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid2004.131746">
         http://dx.doi.org/10.3201/eid2004.131746
        </ext-link>
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgment
      </title>
      <p>
       We thank Tobias Bleicker for providing excellent technical assistance.
      </p>
      <p>
       The work was supported by a European research project on emerging diseases detection and response (EMPERIE;
       <ext-link ext-link-type="uri" xlink:href="http://www.emperie.eu/emp/">
        www.emperie.eu/emp/
       </ext-link>
       ) (contract no. 223498) and ANTIGONE (contract no. 278976). C.D. has received infrastructural support from the German Centre for Infection Research, the German Ministry for Research and Education, and the German Research Council (grants 01KIO701 and DR 772/3-1).
      </p>
     </ack>
     <bio id="d35e1230">
      <p>
       Mr Meyer is a doctoral student at the Bonn Institute of Virology, Boon, Germany. His research interests are spike protein–mediated entry of bat-borne coronaviruses into cells and advancement of specific serologic tests for antibodies against coronaviruses.
      </p>
     </bio>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van Boheemen
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bestebroer
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          AD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        .
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seilmaier
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hartmann
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Scheible
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sack
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         745
        </fpage>
        –
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70154-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV)—update,
        </article-title>
        <year>
         2013
        </year>
        [cited 2013 Dec 10].
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2013_06_26/en/index.html">
         http://www.who.int/csr/don/2013_06_26/en/index.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Van Kerkhove
         </surname>
         <given-names>
          MD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Riley
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Donnelly
         </surname>
         <given-names>
          CA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fraser
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ferguson
         </surname>
         <given-names>
          NM
         </given-names>
        </string-name>
        .
        <article-title>
         Transmission scenarios for Middle East respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20503
        </fpage>
        <pub-id pub-id-type="pmid">
         23787162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Cotten
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Watson
         </surname>
         <given-names>
          SJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kellam
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Makhdoom
         </surname>
         <given-names>
          HQ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Assiri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         1993
        </fpage>
        –
        <lpage>
         2002
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(13)61887-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         24055451
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Woo
         </surname>
         <given-names>
          PC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lam
         </surname>
         <given-names>
          CS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          CC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsang
         </surname>
         <given-names>
          AK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          JH
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         3995
        </fpage>
        –
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06540-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Drexler
         </surname>
         <given-names>
          JF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gloza-Rausch
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Glende
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Goettsche
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Genomic characterization of SARS-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         84
        </volume>
        :
        <fpage>
         11336
        </fpage>
        –
        <lpage>
         49
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00650-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20686038
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          van Boheemen
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          de Graaf
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lauber
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bestebroer
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans.
        </article-title>
        <source>
         MBio
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e00473
        </fpage>
        –
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00473-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23170002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Ithete
         </surname>
         <given-names>
          NL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stoffberg
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cottontail
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Richards
         </surname>
         <given-names>
          LR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schoeman
         </surname>
         <given-names>
          MC
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Close relative of human middle East respiratory syndrome coronavirus in bat, South Africa.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         1697
        </fpage>
        –
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1910.130946
        </pub-id>
        <pub-id pub-id-type="pmid">
         24050621
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          BL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gutierrez
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Godeke
         </surname>
         <given-names>
          GJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         859
        </fpage>
        –
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70164-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Perera
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gomaa
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Shesheny
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kandeil
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bagato
         </surname>
         <given-names>
          O
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20574
        </fpage>
        <pub-id pub-id-type="pmid">
         24079378
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Woo
         </surname>
         <given-names>
          PC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          KS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          RW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          BH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsoi
         </surname>
         <given-names>
          HW
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Molecular diversity of coronaviruses in bats.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         180
        </fpage>
        –
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2006.02.041
        </pub-id>
        <pub-id pub-id-type="pmid">
         16647731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Pfefferle
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Oppong
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Drexler
         </surname>
         <given-names>
          JF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gloza-Rausch
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ipsen
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seebens
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         1377
        </fpage>
        –
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1509.090224
        </pub-id>
        <pub-id pub-id-type="pmid">
         19788804
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Gloza-Rausch
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ipsen
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seebens
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gottsche
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Panning
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Felix Drexler
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Detection and prevalence patterns of group I coronaviruses in bats, northern Germany.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         626
        </fpage>
        –
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1404.071439
        </pub-id>
        <pub-id pub-id-type="pmid">
         18400147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Buchholz
         </surname>
         <given-names>
          U
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nitsche
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sanewski
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wevering
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bauer-Balci
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October–November 2012.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20406
        </fpage>
        <pub-id pub-id-type="pmid">
         23449231
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="webpage">
        <string-name>
         <surname>
          Aburizaiza
         </surname>
         <given-names>
          AS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mattes
         </surname>
         <given-names>
          FM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Azhar
         </surname>
         <given-names>
          EI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hassan
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Investigation of anti–Middle East respiratory syndrome antibodies in blood donors and slaughtethouse workers in Jeddah and Makkah, Saudi Arabia, fall 2013.
        </article-title>
        [Epub ahead of print]. J Infect Dis.
        <year>
         2013
        </year>
        <ext-link ext-link-type="uri" xlink:href="http://">
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Jin
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cebra
         </surname>
         <given-names>
          CK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Baker
         </surname>
         <given-names>
          RJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mattson
         </surname>
         <given-names>
          DE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cohen
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alvarado
         </surname>
         <given-names>
          DE
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Analysis of the genome sequence of an alpaca coronavirus.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         365
        </volume>
        :
        <fpage>
         198
        </fpage>
        –
        <lpage>
         203
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.03.035
        </pub-id>
        <pub-id pub-id-type="pmid">
         17459444
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Wünschmann
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Frank
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pomeroy
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kapil
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        .
        <article-title>
         Enteric coronavirus infection in a juvenile dromedary (
         <italic>
          Camelus dromedarius
         </italic>
         ).
        </article-title>
        <source>
         J Vet Diagn Invest
        </source>
        .
        <year>
         2002
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         441
        </fpage>
        –
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/104063870201400518
        </pub-id>
        <pub-id pub-id-type="pmid">
         12296403
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          van der Linden
         </surname>
         <given-names>
          RH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Frenken
         </surname>
         <given-names>
          LG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          de Geus
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Harmsen
         </surname>
         <given-names>
          MM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ruuls
         </surname>
         <given-names>
          RC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stok
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies.
        </article-title>
        <source>
         Biochim Biophys Acta
        </source>
        .
        <year>
         1999
        </year>
        ;
        <volume>
         1431
        </volume>
        :
        <fpage>
         37
        </fpage>
        –
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0167-4838(99)00030-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         10209277
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Hamers-Casterman
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Atarhouch
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muyldermans
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Robinson
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hamers
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Songa
         </surname>
         <given-names>
          EB
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Naturally occurring antibodies devoid of light chains.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         1993
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         446
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/363446a0
        </pub-id>
        <pub-id pub-id-type="pmid">
         8502296
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mou
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Godeke
         </surname>
         <given-names>
          GJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van der Hoek
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Specific serology for emerging human coronaviruses by protein microarray.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         20441
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23594517
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         FAOSTAT
        </collab>
        <year>
         2013
        </year>
        [cited 2013 Dec16].
        <ext-link ext-link-type="uri" xlink:href="http://faostat3.fao.org/faostat-gateway/go/to/download/Q/QA/E">
         http://faostat3.fao.org/faostat-gateway/go/to/download/Q/QA/E
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         CVRL
        </collab>
        <article-title>
         26th annual report 2012.
        </article-title>
        <year>
         2013
        </year>
        [cited 2013 Dec 16].
        <ext-link ext-link-type="uri" xlink:href="http://www.cvrl.ae/%5Can%5Canrp%5C2012%5CANRP2012.pdf">
         http://www.cvrl.ae/%5Can%5Canrp%5C2012%5CANRP2012.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eckerle
         </surname>
         <given-names>
          I
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bleicker
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Landt
         </surname>
         <given-names>
          O
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eschbach-Bludau
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         20285
        </fpage>
        <pub-id pub-id-type="pmid">
         23041020
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Annan
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Baldwin
         </surname>
         <given-names>
          HJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Klose
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Owusu
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nkrumah
         </surname>
         <given-names>
          EE
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         456
        </fpage>
        –
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1903.121503
        </pub-id>
        <pub-id pub-id-type="pmid">
         23622767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muller
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Costabel
         </surname>
         <given-names>
          U
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Timm
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Binger
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         20334
        </fpage>
        <pub-id pub-id-type="pmid">
         23231891
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          de Souza Luna
         </surname>
         <given-names>
          LK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Heiser
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Regamey
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Panning
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Drexler
         </surname>
         <given-names>
          JF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mulangu
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription–PCR and nonfluorescent low-density microarray.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         45
        </volume>
        :
        <fpage>
         1049
        </fpage>
        –
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.02426-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17229859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Gerna
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cereda
         </surname>
         <given-names>
          PM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Revello
         </surname>
         <given-names>
          MG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cattaneo
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Battaglia
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gerna
         </surname>
         <given-names>
          MT
         </given-names>
        </string-name>
        .
        <article-title>
         Antigenic and biological relationships between human coronavirus OC43 and neonatal calf diarrhoea coronavirus.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         1981
        </year>
        ;
        <volume>
         54
        </volume>
        :
        <fpage>
         91
        </fpage>
        –
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-54-1-91
        </pub-id>
        <pub-id pub-id-type="pmid">
         6169790
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kallies
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Smits
         </surname>
         <given-names>
          SL
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines.
        </article-title>
        <source>
         MBio
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e00515
        </fpage>
        –
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00515-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23232719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mou
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Smits
         </surname>
         <given-names>
          SL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dekkers
         </surname>
         <given-names>
          DH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dijkman
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         495
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          CM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tse
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          SS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Woo
         </surname>
         <given-names>
          PC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus.
        </article-title>
        <source>
         J Clin Virol
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         45
        </volume>
        :
        <fpage>
         54
        </fpage>
        –
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2009.02.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         19342289
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Horzinek
         </surname>
         <given-names>
          MC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lutz
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pedersen
         </surname>
         <given-names>
          NC
         </given-names>
        </string-name>
        .
        <article-title>
         Antigenic relationships among homologous structural polypeptides of porcine, feline, and canine coronaviruses.
        </article-title>
        <source>
         Infect Immun
        </source>
        .
        <year>
         1982
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         1148
        </fpage>
        –
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         6182101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Hofmann
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pyrc
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van der Hoek
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Geier
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Berkhout
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pohlmann
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        .
        <article-title>
         Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         102
        </volume>
        :
        <fpage>
         7988
        </fpage>
        –
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0409465102
        </pub-id>
        <pub-id pub-id-type="pmid">
         15897467
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Anthony
         </surname>
         <given-names>
          SJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ojeda-Flores
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rico-Chavez
         </surname>
         <given-names>
          O
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Navarrete-Macias
         </surname>
         <given-names>
          I
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zambrana-Torrelio
         </surname>
         <given-names>
          CM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rostal
         </surname>
         <given-names>
          MK
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Coronaviruses in bats from Mexico.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         1028
        </fpage>
        –
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.049759-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         23364191
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Wacharapluesadee
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sintunawa
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kaewpom
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Khongnomnan
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Olival
         </surname>
         <given-names>
          KJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Epstein
         </surname>
         <given-names>
          JH
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Group C betacoronavirus in bat guano fertilizer, Thailand.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         1349
        </fpage>
        –
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1908.130119
        </pub-id>
        <pub-id pub-id-type="pmid">
         23880503
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Drexler
         </surname>
         <given-names>
          JF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gloza-Rausch
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Glende
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Goettsche
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         84
        </volume>
        :
        <fpage>
         11336
        </fpage>
        –
        <lpage>
         49
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00650-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20686038
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Ge
         </surname>
         <given-names>
          XY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          JL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yang
         </surname>
         <given-names>
          XL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chmura
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Epstein
         </surname>
         <given-names>
          JH
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         503
        </volume>
        :
        <fpage>
         535
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12711
        </pub-id>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Vet Med Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Vet. Med. Sci
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JVMS
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of Veterinary Medical Science
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0916-7250
      </issn>
      <issn pub-type="epub">
       1347-7439
      </issn>
      <publisher>
       <publisher-name>
        The Japanese Society of Veterinary Science
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       31685722
      </article-id>
      <article-id pub-id-type="pmc">
       6943330
      </article-id>
      <article-id pub-id-type="publisher-id">
       19-0436
      </article-id>
      <article-id pub-id-type="doi">
       10.1292/jvms.19-0436
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Virology
        </subject>
        <subj-group>
         <subject>
          Full Paper
         </subject>
        </subj-group>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Evaluation of serological assays available in a biosafety level 2 laboratory
and their application for survey of Middle East respiratory syndrome coronavirus among
livestock in Ethiopia
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          TERAMICHI
         </surname>
         <given-names>
          Takurou
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          FUKUSHI
         </surname>
         <given-names>
          Shuetsu
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          HACHIYA
         </surname>
         <given-names>
          Yuma
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          MELAKU
         </surname>
         <given-names>
          Simenew Keskes
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          OGUMA
         </surname>
         <given-names>
          Keisuke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          SENTSUI
         </surname>
         <given-names>
          Hiroshi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1)
        </label>
        Laboratory of Veterinary Epizootiology, Department of
Veterinary Medicine, Nihon University, Kameino 1866, Fujisawa, Kanagawa 252-0880,
Japan
       </aff>
       <aff id="aff2">
        <label>
         2)
        </label>
        Department of Virology I, National Institute of Infectious
Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan
       </aff>
       <aff id="aff3">
        <label>
         3)
        </label>
        Addis Ababa Science and Technology University, Akaky Kaliti
Sub-city, Kilinto area, Addis Ababa, Ethiopia
       </aff>
       <aff id="aff4">
        <label>
         4)
        </label>
        Present Address: Isahaya Meat Inspection Center, 79-20,
Sakaimachi 79-20, Isahaya, Nagasaki 854-0022, Japan
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Correspondence to: Sentsui, H.:
        <email xlink:href="sentsui.hiroshi@nihon-u.ac.jp">
         sentsui.hiroshi@nihon-u.ac.jp
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        05
       </day>
       <month>
        11
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        12
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       81
      </volume>
      <issue>
       12
      </issue>
      <fpage>
       1887
      </fpage>
      <lpage>
       1891
      </lpage>
      <history>
       <date date-type="received">
        <day>
         07
        </day>
        <month>
         8
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         24
        </day>
        <month>
         10
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        ©2019 The Japanese Society of Veterinary Science
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0:
         <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          https://creativecommons.org/licenses/by-nc-nd/4.0/
         </ext-link>
         )
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        A serological survey of Middle East respiratory syndrome coronavirus (MERS-CoV) was
conducted among dromedary camels and herbivorous animals sharing the same pasturage in
Ethiopia. The pseudotyped vesicular stomatitis virus coated with the spike protein of
MERS-CoV was used in virus neutralization (VN) tests performed in a biosafety level
(BSL)-2 laboratory. The results were similar to those obtained from the VN test using live
MERS-CoV and were more sensitive than the ELISA performed using synthetic MERS S1 fragment
as the antigen as well as the competitive ELISA performed using a monoclonal antibody
against MERS-CoV. According to the comprehensive results of the four types of
serodiagnosis methods, positive antibodies were detected only in dromedary camels and the
remaining herbivorous animals were not infected with the virus. Moreover, using the
present procedure, serological tests for MERS-CoV can be conducted even in BSL 2
laboratory.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        camel
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        Ethiopia
       </kwd>
       <kwd>
        Middle East respiratory syndrome
       </kwd>
       <kwd>
        serological survey
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Middle East respiratory syndrome (MERS), first confirmed in Saudi Arabia in 2012, is an
emerging viral infection that causes severe respiratory symptoms in humans [
     <xref ref-type="bibr" rid="r1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="r5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="r19">
      19
     </xref>
     ]. The pathogen, MERS-coronavirus (MERS-CoV), is
identified as a novel coronavirus species [
     <xref ref-type="bibr" rid="r5">
      5
     </xref>
     ], and the
dromedary camel is considered a natural host [
     <xref ref-type="bibr" rid="r10">
      10
     </xref>
     ,
     <xref ref-type="bibr" rid="r11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="r14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="r15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="r18">
      18
     </xref>
     ]. Patients
with MERS have mainly been identified in and near the Arabian Peninsula [
     <xref ref-type="bibr" rid="r2">
      2
     </xref>
     ]. However, several cases have been detected in other countries among the
travelers who have visited the Arabian Peninsula, and MERS-CoV has been reported to spread
from patients to others via close contact [
     <xref ref-type="bibr" rid="r3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="r4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="r7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="r12">
      12
     </xref>
     ]. Therefore, MERS-CoV has been classified as a biosafety
level (BSL)-3 pathogen and its handling requires a high-containment laboratory that ensures
biosecurity. Therefore, developing a serological diagnostic method that can be used even in a
BSL-2 laboratory and exhibits the same specificity and sensitivity as the conventional
serological test is crucial. A neutralization test using a pseudotyped virus integrated with
green fluorescent protein (GFP) gene and coated with the spike protein of MERS-CoV
(VSV-MERS/GFP) has recently been developed [
     <xref ref-type="bibr" rid="r8">
      8
     </xref>
     ]. In the
present study, the specificity and sensitivity of the neutralization test using VSV-MERS/GFP
were confirmed using serum obtained from livestock that share a grazing area with the
dromedary camel in Ethiopia. The results were compared with three other antibody
tests—neutralization test using live MERS-CoV [
     <xref ref-type="bibr" rid="r16">
      16
     </xref>
     ],
S1-ELISA [
     <xref ref-type="bibr" rid="r17">
      17
     </xref>
     ], and competitive ELISA using a monoclonal
antibody against MERS-CoV (cELISA) [
     <xref ref-type="bibr" rid="r9">
      9
     </xref>
     ]. Based on these
serological tests, the MERS-CoV susceptibility of other herbivores sharing pasture lands with
the dromedary camel to infection and to become a source of infection to humans was
examined.
    </p>
    <sec id="s1" sec-type="materials|methods">
     <title>
      MATERIALS AND METHODS
     </title>
     <sec>
      <title>
       Pseudovirus
      </title>
      <p>
       VSV-MERS/GFP, a recombinant vesicular stomatitis virus pseudotype, integrated with the
GFP gene and coated with the spike protein of MERS-CoV was used in the neutralization test
[
       <xref ref-type="bibr" rid="r8">
        8
       </xref>
       ]. The infectivity of VSV-MERS/GFP was detected
based on GFP expression observed using fluorescence microscopy. GFP-expressing cells in
photographic images were counted using VH analyzer. The VSV-MERS/GFP titers were then
expressed as focus forming units (FFU) per m
       <italic>
        l
       </italic>
       .
      </p>
     </sec>
     <sec>
      <title>
       Cell culture
      </title>
      <p>
       293T and Vero cells were cultivated in Dulbecco’s modified Eagle’s medium supplemented
with 5% fetal bovine serum (FBS), 100 U/m
       <italic>
        l
       </italic>
       of penicillin, and 100
       <italic>
        µ
       </italic>
       g/m
       <italic>
        l
       </italic>
       of streptomycin at 37°C [
       <xref ref-type="bibr" rid="r8">
        8
       </xref>
       ]. 293T cells were used to prepare VSV-MERS/GFP and MERS-CoV
recombinant receptor binding domain (RBD) for the cELISA antigen. Vero cells were used for
neutralization tests by live MERS-CoV and VSV-MERS/GFP, respectively.
      </p>
     </sec>
     <sec>
      <title>
       Serum samples
      </title>
      <p>
       Serum samples were collected from dromedary camels (n=38; mean age, 4.3 years; range,
1–13 years), goats (n=25; mean age, 3.9 years; range, 1–8 years), sheep (n=25; mean age,
2.7 years; range, 1–4 years), and cattle (n=15; mean age, 6.7 years; range, 1–11 years)
from two herds in Bati district, Amhara region, and one herd in Fafen district, Somali
region, Ethiopia. All animals appeared healthy, shared the same pasturage during the day,
and stayed in barns or small grounds specific for each animal species surrounded by fences
at night.
      </p>
      <p>
       Transportation of the serum samples to Japan was conducted with the permission of the
Japanese government (Animal quarantine inspection number NFIB070602-011) and followed the
rules and regulations of the OIE/FAO for biological sample transportation.
      </p>
      <p>
       Serum from a rabbit immunized with recombinant MERS-CoV S protein was used as a positive
control for neutralization [
       <xref ref-type="bibr" rid="r8">
        8
       </xref>
       ]. Sera from animals (5
cattle, 5 sheep and 5 goats) reared on the attached farm of Nihon University were used as
negative controls.
      </p>
     </sec>
     <sec>
      <title>
       Neutralization test
      </title>
      <p>
       The neutralization test using VSV-MERS/GFP was performed as previously described [
       <xref ref-type="bibr" rid="r8">
        8
       </xref>
       ]. A medium composed of Eagle’s MEM supplemented with
5% FBS was used for virus and serum dilution. Serially diluted 0.05 m
       <italic>
        l
       </italic>
       of
test sera were mixed with equal volumes of 3,000 FFU of VSV-MERS/GFP and incubated at 37°C
for 1 hr. The mixture was inoculated to Vero cells seeded on a 96-well culture plate and
incubated at 37°C for 24 hr in a CO
       <sub>
        2
       </sub>
       incubator. GFP-positive cells were then
detected using a fluorescence microscope. The number of positive GFP cells was counted as
described above. The neutralization titer was determined as the highest serum dilution
showing ≤50% of the number of GFP-positive cells compared with the no serum control.
      </p>
      <p>
       Neutralization test using live MERS-CoV was performed as previously described except
using Vero cells instead of Vero-TMPRSS2 cells [
       <xref ref-type="bibr" rid="r16">
        16
       </xref>
       ]. Briefly, 0.05 m
       <italic>
        l
       </italic>
       of serially diluted test sera was mixed
with an equal volume of 100 TCID
       <sub>
        50
       </sub>
       of MERS-CoV (EMC isolate) in a 96-well
culture plate and incubated at 37°C for 1 hr; thereafter,Vero cells were added in each
well and cultivated at 37°C. Cytopathic effects (CPE) on the Vero cells were observed at 3
days after infection. The neutralization titer was determined as the highest serum
dilution showing at least 50% CPE on the inoculated cells.
      </p>
     </sec>
     <sec>
      <title>
       S1-ELISA
      </title>
      <p>
       Synthetic S1 fragment of MERS-CoV was obtained from Sino Biolobical Inc. (Beijing, China)
and used as the antigen [
       <xref ref-type="bibr" rid="r17">
        17
       </xref>
       ]. ELISA microplates
were coated with 50
       <italic>
        µl
       </italic>
       of 50
       <italic>
        n
       </italic>
       g/m
       <italic>
        l
       </italic>
       antigen per well at 4°C overnight, following which the wells were incubated with PBS
containing 2% Block Ace and 0.05% Tween 20 for 2 hr at 37°C. Following the removal of
blocking reagent, diluted serum samples were added and incubated for 1 hr at 37°C. After
washing the wells thrice with 0.05% Tween 20 in PBS (PBS-T), a peroxidase-labeled protein
AG (Thermo Fisher Scientific, Waltham, MA, U.S.A.) was added and incubated for 1 hr at
37°C. Following further washing thrice with PBS-T, 100
       <italic>
        µl
       </italic>
       of
2,2′-azinobis-3-ethylbenzthiazolinesulfonic acid (ABTS) substrate solution (Roche Applied
Science, Penzberg, Germany) was added and incubated for 20 min at room temperature. The
optical density (O.D.) of each well was measured at 450 nm using a microplate reader, and
mean absorbance was determined for each serum sample. One of camel serum that showed a
high antibody titer in the neutralization test by live MERS-CoV was treated as a positive
control.
      </p>
     </sec>
     <sec>
      <title>
       Competitive ELISA
      </title>
      <p>
       The MERS-CoV RBD was used as the antigen of the cELISA. For the preparation of
recombinant RBD, the mammalian expression plasmid pCAGGS-RBD, which encodes
histidine-tagged MERS-CoV RBD (amino acid 358–588), was transfected to 293T cells. At 2
days after transfection, the recombinant RBD was purified from the supernatant of
transfected cells using His-Bind Purification Kit (Merck, Damastadt, Germany). The cELISA
was performed as described by Fukushi
       <italic>
        et al
       </italic>
       . [
       <xref ref-type="bibr" rid="r9">
        9
       </xref>
       ]. Briefly, MERS-CoV recombinant RBD with pre-determined optimal
quantity was coated on a 96-well ELISA plate at 4°C for overnight, following which the
wells were incubated with PBS containing 2% bovine serum albumin and 0.05% tween 20
(blocking reagent) for 2 hr at 37°C. Following the removal of the blocking reagent, 100
       <italic>
        µl
       </italic>
       of a biotin-labeled monoclonal antibody mixed with serially diluted
serum samples was added and incubated for 1 hr at 37°C. One of camel serum that showed a
high antibody titer in the neutralization test by live MERS-CoV was treated as a positive
control. After washing the wells, a streptavidin-HRP (Thermo Fisher Scientific) was added
and incubated for 1 hr at 37°C. Following further washing, 100
       <italic>
        µl
       </italic>
       of ABTS
substrate solution was added and incubated for 20 min at room temperature. The O.D. at 405
nm was measured against a reference of 490 nm using a microplate reader (Model 680
Microplate Reader; Bio-Rad Laboratories Inc., Hercules, CA, U.S.A.).
      </p>
      <p>
       Percent inhibition at each serum dilution was calculated as follows:
      </p>
      <p>
       Percent inhibition=100−[O.D. (405–490 nm) of test sample]/[O.D. (405–490 nm) of no serum
control] × 100
      </p>
     </sec>
    </sec>
    <sec id="s2" sec-type="results">
     <title>
      RESULTS
     </title>
     <sec>
      <title>
       Neutralization test using VSV-MERS/GFP
      </title>
      <p>
       According to the results of the previous study, antibody titers of ≥16 are treated as
positive in neutralization test using VSV-MERS/GFP. In dromedary camels and cattle, 31 out
of 38 and 1 out of 15, respectively, were MERS antibody positive. Goats and sheep were all
MERS antibody negative (
       <xref ref-type="table" rid="tbl_001">
        Table l
       </xref>
       <table-wrap id="tbl_001" orientation="portrait" position="float">
        <label>
         Table 1.
        </label>
        <caption>
         <title>
          Distribution of antibody titers in the neutralization test using VSV-MERS/GFP
          <sup>
           a)
          </sup>
          among animals sharing grazing area with camels
         </title>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="center" colspan="1" rowspan="3" valign="middle">
            Antibody titer
           </th>
           <th align="center" colspan="4" rowspan="1" valign="middle">
            Animals (test sample numbers)
           </th>
          </tr>
          <tr>
           <th colspan="4" rowspan="1">
            <hr/>
           </th>
          </tr>
          <tr>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            Camel (38)
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            Cattle (15)
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            Goat (25)
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            Sheep (25)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            &lt;16
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            14
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            20
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            20
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            16
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            15
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            64
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            ≥256
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            9
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          a) Pseudotyped vesicular stomatitis virus coated with the spike protein of Middle
East respiratory syndrome coronavirus.
         </p>
        </table-wrap-foot>
       </table-wrap>
       ). Moreover, in 15 camels, the antibody titer was 16 or 32; in 7, it was 64
or 128; and in 9 and control positive rabbit serum, it was ≥256. The antibody titer and
the positive rate of antibody against MERS-CoV increased with the age of the camels. The
antibody titer in one cow was 64. All sera collected from animals on the attached farm of
Nihon University were negative.
      </p>
     </sec>
     <sec>
      <title>
       Comparison of other serological tests with the neutralization test using
VSV-MERS/GFP
      </title>
      <p>
       Overall, 31 camels and control positive rabbit serum were found to be antibody positive
in the neutralization test using MERS-CoV, and 16 camels were positive in S1-ELISA. In the
cELISA, 26 camels and 1 cow were positive (
       <xref ref-type="table" rid="tbl_002">
        Table
2
       </xref>
       <table-wrap id="tbl_002" orientation="portrait" position="float">
        <label>
         Table 2.
        </label>
        <caption>
         <title>
          Comparison of other serological tests with the neutralization test using
VSV-MERS/GFP
          <sup>
           a)
          </sup>
         </title>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            Animals
            <break>
            </break>
            (test sample numbers)
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            NT
            <sup>
             b)
            </sup>
            <break>
            </break>
            (VSV-MERS/GFP)
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            NT
            <break>
            </break>
            (MERS-CoV)
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            S1-ELISA
           </th>
           <th align="center" colspan="1" rowspan="1" valign="middle">
            cELISA
            <sup>
             c)
            </sup>
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Camel (38)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            31
            <sup>
             d)
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            31
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            16
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            26
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Cattle (15)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Goat (25)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            ND
            <sup>
             e)
            </sup>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Sheep (25)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            ND
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          a) Pseudotyped vesicular stomatitis virus coated with the spike protein of Middle
East respiratory syndrome coronavirus. b) Neutralization test. c) Competitive ELISA.
d) Positive sample numbers. e) Not done.
         </p>
        </table-wrap-foot>
       </table-wrap>
       ). The sera collected as negative controls from animals on the attached farm
of Nihon University were all negative in S1-ELISA and cELISA.
      </p>
      <p>
       Each camel that was antibody positive in S1-ELISA or in neutralization tests using
MERS-CoV was found to be positive in neutralization tests using VSV-MERS/GFP. Cows that
were antibody positive in the neutralization test using VSV-MERS/GFP or cELISA were
different animals and both were antibody negative in the neutralization test using
MERS-CoV.
      </p>
      <p>
       A comparison of the antibody titers detected in the neutralization tests using
VSV-MERS/GFP with those detected using live MERS-CoV showed a high correlation between
both antibody titers, with a correlation coefficient of 0.9753.
      </p>
     </sec>
    </sec>
    <sec id="s3" sec-type="discussion">
     <title>
      DISCUSSION
     </title>
     <p>
      All camel sera that were positive in any one of the tests—the S1-ELISA, cELISA, or
neutralization tests using live MERS-CoV—were positive in the neutralization test using
VSV-MERS/GFP. One cow serum was positive for cELISA and another cow was positive in the
neutralization test using VSV-MERS/GFP, but negative in all other tests. Because the
neutralization test using live MERS-CoV is considered the most accurate serological test and
because the two positive reactions were observed in only one serological test among the
four, these two bovine sera should be considered as nonspecific reactors. The exact reason
of nonspecific reaction of these sera remains unclear. The nonspecific reaction may result
from differences in immunological conditions of animals or in the degree of hemolysis during
the preparation of samples. For example, a nonspecific reaction sometimes appears in cattle
after injection with a certain inactivated vaccine in the ELISA kit for Johne’s disease
diagnosis in Japan. Some rhabdovirus cross react with VSV [
      <xref ref-type="bibr" rid="r6">
       6
      </xref>
      ] and such a virus might be subclinically infected in Ethiopian cattle.
     </p>
     <p>
      There are reports that MERS-CoV specific antibodies were not detected in sera from cattle,
goat and sheep in Jordan and Saudi Arabia, the MERS-CoV prevalence region [
      <xref ref-type="bibr" rid="r11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="r13">
       13
      </xref>
      ]. However,
they were kept indoor or did not share the pastureland. Present results indicate that
MERS-CoV infects only dromedary camels and is unlikely to infect other domestic animals even
sharing the pastureland. Since the antibody positive rate and antibody titer of MERS
increased with age, it is considered that MERS-CoV establishes an infection cycle and
inapparently present only among dromedary camels [
      <xref ref-type="bibr" rid="r11">
       11
      </xref>
      ]. In present studies, the limited numbers of samples were tested because the
import of animal sera from the foot-and-mouth disease endemic region is regulated in Japan.
Further studies using additional samples from other countries would be required to clarify
the role of other animal on the ecology and epidemiology of MERS-CoV.
     </p>
     <p>
      A comparison of the two neutralization tests using VSV-MERS/GFP and MERS-CoV showed a high
correlation between both antibody titers. The former showed an antibody titer of ≥256,
whereas the latter showed an antibody titer of ≥512. S1-ELISA was not sensitive compared to
other tests because only 16 serum samples were positive and they required an antibody titer
of ≥64 in VSV-MERS/GFP. However, the sensitivity of S1-ELISA would be improved by examining
the cut-off value and dilution of the test serum. In cELISA, five serum samples were
negative out of the 31 positive samples in the neutralization tests, and an antibody titer
of 16 was observed in both neutralization tests. Therefore, neutralization test using
VSV-MERS/GFP exhibits sensitivity similar to the neutralization test using MERS-CoV and is
more sensitive compared with the S1-ELISA as well as cELISA.
     </p>
     <p>
      The present study shows that the neutralization test using VSV-MERS/GFP, S1-ELISA, and
cELISA are as specific to MERS-CoV infection as the serological tests, although their
sensitivities slightly differ. The detection of antibody and epidemiological survey of
MERS-CoV could be possible by appropriately selecting these tests according to the desired
purpose, without using a BSL-3 laboratory.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       This work was partly supported by JSPS KAKENHI (grant number 17H04642),
Japan Agency for Medical Research and Development (grant number JP18fk0108058) and the
Academic Frontier Project for Private Universities (S1491007) from the Ministry of
Education, Culture, Sports, Science and Technology of Japan.
      </p>
     </ack>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="r1">
       <label>
        1
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           A. N.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sameroff
          </surname>
          <given-names>
           S. C.
          </given-names>
         </name>
         <name>
          <surname>
           Burbelo
          </surname>
          <given-names>
           P. D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V. J.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L. E.
          </given-names>
         </name>
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           I. S.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J. H.
          </given-names>
         </name>
         <name>
          <surname>
           Karesh
          </surname>
          <given-names>
           W. B.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           O. B.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W. I.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        .
        <article-title>
         Middle East respiratory syndrome
coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        .
        <source>
         <italic>
          MBio
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         e00884
        </fpage>
        –
        <lpage>
         e14
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/mBio.01002-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24570370
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r2">
       <label>
        2
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Al Hammadi
          </surname>
          <given-names>
           Z. M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D. K.
          </given-names>
         </name>
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           Y. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Al Mulla
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tarnini
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Abdelkhalek
          </surname>
          <given-names>
           M. M.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J. S.
          </given-names>
         </name>
         <name>
          <surname>
           Al Muhairi
          </surname>
          <given-names>
           S. S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L. L.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        .
        <article-title>
         Asymptomatic MERS-CoV infection in humans
possibly linked to infected dromedaries imported from Oman to United Arab
Emirates
        </article-title>
        .
        <source>
         <italic>
          Emerg. Infect.
Dis.
         </italic>
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         2197
        </fpage>
        –
        <lpage>
         2200
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2112.151132
        </pub-id>
        <pub-id pub-id-type="pmid">
         26584223
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r3">
       <label>
        3
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T. M.
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D. A.
          </given-names>
         </name>
         <name>
          <surname>
           Alabdullatif
          </surname>
          <given-names>
           Z. N.
          </given-names>
         </name>
         <name>
          <surname>
           Assad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Almulhim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S. J.
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A. I.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
        </person-group>
        , KSA MERS-CoV Investigation Team
        <year>
         2013
        </year>
        .
        <article-title>
         Hospital
outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         <italic>
          N. Engl. J. Med.
         </italic>
        </source>
        <volume>
         369
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         416
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1306742
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r4">
       <label>
        4
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E. I.
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Saeed
          </surname>
          <given-names>
           M. S.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           T. A.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        .
        <article-title>
         Evidence for camel-to-human transmission
of MERS coronavirus
        </article-title>
        .
        <source>
         <italic>
          N. Engl. J.
Med.
         </italic>
        </source>
        <volume>
         370
        </volume>
        :
        <fpage>
         2499
        </fpage>
        –
        <lpage>
         2505
        </lpage>
        .
doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1401505
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r5">
       <label>
        5
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R. J.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S. C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R. S.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A. E.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L. L.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E. J.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           G. M.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        .
        <article-title>
         Middle East respiratory syndrome
coronavirus (MERS-CoV): announcement of the Coronavirus Study Group
        </article-title>
        .
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         7790
        </fpage>
        –
        <lpage>
         7792
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/JVI.01244-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r6">
       <label>
        6
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Dragúnová
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Závada
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <year>
         1979
        </year>
        .
        <article-title>
         Cross-neutralization between vesicular
stomatitis virus type Indiana and Chandipura virus
        </article-title>
        .
        <source>
         <italic>
          Acta
Virol.
         </italic>
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         319
        </fpage>
        –
        <lpage>
         328
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         40419
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r7">
       <label>
        7
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hossain
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R. F.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Hajomar
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A. I.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        .
        <article-title>
         Transmission of MERS-coronavirus in
household contacts
        </article-title>
        .
        <source>
         <italic>
          N. Engl. J.
Med.
         </italic>
        </source>
        <volume>
         371
        </volume>
        :
        <fpage>
         828
        </fpage>
        –
        <lpage>
         835
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r8">
       <label>
        8
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Fukuma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Taniguchi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shimojima
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Saijo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        .
        <article-title>
         Inability of rat DPP4 to allow MERS-CoV
infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike
protein
        </article-title>
        .
        <source>
         <italic>
          Arch.
Virol.
         </italic>
        </source>
        <volume>
         160
        </volume>
        :
        <fpage>
         2293
        </fpage>
        –
        <lpage>
         2300
        </lpage>
        .
doi:
        <pub-id pub-id-type="doi">
         10.1007/s00705-015-2506-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         26138557
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r9">
       <label>
        9
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fukuma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kurosu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shimojima
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Iwata-Yoshikawa
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ohnishi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ato
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Melaku
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         <name>
          <surname>
           Sentsui
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Saijo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <year>
         2018
        </year>
        .
        <article-title>
         Characterization of novel monoclonal
antibodies against the MERS-coronavirus spike protein and their application in
species-independent antibody detection by competitive ELISA
        </article-title>
        .
        <source>
         <italic>
          J. Virol. Methods
         </italic>
        </source>
        <volume>
         251
        </volume>
        :
        <fpage>
         22
        </fpage>
        –
        <lpage>
         29
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jviromet.2017.10.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         28993122
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r10">
       <label>
        10
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S. H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G. J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ghobashy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Thani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Marri
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           H. E.
          </given-names>
         </name>
         <name>
          <surname>
           Al Khal
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           M. M.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M. P.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        .
        <article-title>
         Middle East respiratory syndrome
coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        .
        <source>
         <italic>
          Lancet Infect. Dis.
         </italic>
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         140
        </fpage>
        –
        <lpage>
         145
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r11">
       <label>
        11
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Alhammadi
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           L. Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L. L.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        .
        <article-title>
         Middle East Respiratory Syndrome (MERS)
coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to
2013
        </article-title>
        .
        <source>
         <italic>
          Euro
Surveill.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         20659
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2013.18.50.20659
        </pub-id>
        <pub-id pub-id-type="pmid">
         24342517
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r12">
       <label>
        12
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H. Q.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R. F.
          </given-names>
         </name>
         <name>
          <surname>
           AlRabiah
          </surname>
          <given-names>
           F. A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hajjar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Flemban
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Barry
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Alhassan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alsubaie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        .
        <article-title>
         Screening for Middle East respiratory
syndrome coronavirus infection in hospital patients and their healthcare worker and
family contacts: a prospective descriptive study
        </article-title>
        .
        <source>
         <italic>
          Clin.
Microbiol. Infect.
         </italic>
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         474
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/1469-0691.12562
        </pub-id>
        <pub-id pub-id-type="pmid">
         24460984
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r13">
       <label>
        13
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B.
          </given-names>
         </name>
         <name>
          <surname>
           Ababneh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Eljarah
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abutarbush
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G. J.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T. M.
          </given-names>
         </name>
         <name>
          <surname>
           Zutt
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P. J.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M. P.
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        .
        <article-title>
         Middle East Respiratory Syndrome
coronavirus (MERS-CoV) serology in major livestock species in an affected region in
Jordan, June to September 2013
        </article-title>
        .
        <source>
         <italic>
          Euro
Surveill.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         20662
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2013.18.50.20662
        </pub-id>
        <pub-id pub-id-type="pmid">
         24342516
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r14">
       <label>
        14
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G. J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits-De Vries
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J. F.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S. L.
          </given-names>
         </name>
         <name>
          <surname>
           El Tahir
          </surname>
          <given-names>
           Y. E.
          </given-names>
         </name>
         <name>
          <surname>
           De Sousa
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           van Beek
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nowotny
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           van Maanen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hidalgo-Hermoso
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gortázar-Schmidt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M. P.
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        .
        <article-title>
         Middle East respiratory syndrome
coronavirus neutralising serum antibodies in dromedary camels: a comparative serological
study
        </article-title>
        .
        <source>
         <italic>
          Lancet Infect.
Dis.
         </italic>
        </source>
        <volume>
         13
        </volume>
        :
        <fpage>
         859
        </fpage>
        –
        <lpage>
         866
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70164-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r15">
       <label>
        15
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C. B.
          </given-names>
         </name>
         <name>
          <surname>
           Messadi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Feyisa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ularamu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G. J.
          </given-names>
         </name>
         <name>
          <surname>
           Danmarwa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dawo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jemli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Melaku
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shamaki
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Woma
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wungak
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gebremedhin
          </surname>
          <given-names>
           E. Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zutt
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M. P.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        .
        <article-title>
         Geographic distribution of MERS
coronavirus among dromedary camels,
         <italic>
          Africa
         </italic>
        </article-title>
        .
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         1370
        </fpage>
        –
        <lpage>
         1374
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140590
        </pub-id>
        <pub-id pub-id-type="pmid">
         25062254
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r16">
       <label>
        16
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Azumano
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nakao
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hagihara
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tamai
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yamazaki
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Okamoto
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kawakami
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Okada
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fukushima
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nakajima
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        .
        <article-title>
         Middle East respiratory syndrome
coronavirus infection not found in camels in Japan
        </article-title>
        .
        <source>
         <italic>
          Jpn.
J. Infect. Dis.
         </italic>
        </source>
        <volume>
         68
        </volume>
        :
        <fpage>
         256
        </fpage>
        –
        <lpage>
         258
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.7883/yoken.JJID.2015.094
        </pub-id>
        <pub-id pub-id-type="pmid">
         25993975
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r17">
       <label>
        17
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <year>
         2016
        </year>
        .
        <article-title>
         Characterization of anti-MERS-CoV
antibodies against various recombinant structural antigens of MERS-CoV in an imported
case in China
        </article-title>
        .
        <source>
         <italic>
          Emerg. Microbes
Infect.
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         e113
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1038/emi.2016.114
        </pub-id>
        <pub-id pub-id-type="pmid">
         27826140
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r18">
       <label>
        18
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           E. Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A. K.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         <name>
          <surname>
           Khazanehdari
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zirkel
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Juhasz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Syriac
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Elizabeth
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         <name>
          <surname>
           Patteril
          </surname>
          <given-names>
           N. A.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        .
        <article-title>
         Acute middle East respiratory syndrome
coronavirus infection in livestock Dromedaries, Dubai, 2014
        </article-title>
        .
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         1019
        </fpage>
        –
        <lpage>
         1022
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2106.150038
        </pub-id>
        <pub-id pub-id-type="pmid">
         25989145
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="r19">
       <label>
        19
       </label>
       <mixed-citation publication-type="journal">
        <person-group>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T. M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        .
        <article-title>
         Isolation of a novel coronavirus from a
man with pneumonia in Saudi Arabia
        </article-title>
        .
        <source>
         <italic>
          N. Engl. J.
Med.
         </italic>
        </source>
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         1820
        </lpage>
        .
doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Blood Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Blood Rev
      </journal-id>
      <journal-title-group>
       <journal-title>
        Blood Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0268-960X
      </issn>
      <issn pub-type="epub">
       1532-1681
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26381318
      </article-id>
      <article-id pub-id-type="pmc">
       7115716
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0268-960X(15)00059-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.blre.2015.07.004
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders
        <sup>
         <xref ref-type="fn" rid="d32e3268">
          ☆
         </xref>
        </sup>
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Di Minno
         </surname>
         <given-names>
          Giovanni
         </given-names>
        </name>
        <email>
         diminno@unina.it
        </email>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Perno
         </surname>
         <given-names>
          Carlo Federico
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Tiede
         </surname>
         <given-names>
          Andreas
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Navarro
         </surname>
         <given-names>
          David
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0025">
        <name>
         <surname>
          Canaro
         </surname>
         <given-names>
          Mariana
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0025">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0030">
        <name>
         <surname>
          Güertler
         </surname>
         <given-names>
          Lutz
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0030">
         f
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0035">
        <name>
         <surname>
          Ironside
         </surname>
         <given-names>
          James W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0035">
         g
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       <label>
        a
       </label>
       Dipartimento di Medicina Clinica e Chirurgia, Regional Reference Centre for Coagulation Disorders, Federico II University, Via S. Pansini 5, 80131 Naples, Italy
      </aff>
      <aff id="af0010">
       <label>
        b
       </label>
       Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
      </aff>
      <aff id="af0015">
       <label>
        c
       </label>
       Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany
      </aff>
      <aff id="af0020">
       <label>
        d
       </label>
       Department of Microbiology, Microbiology Service, Hospital Clínico Universitario, School of Medicine, University of Valencia, Av Blasco Ibáñez 17, 46010 Valencia, Spain
      </aff>
      <aff id="af0025">
       <label>
        e
       </label>
       Department of Hemostasis and Thrombosis, Son Espases University Hospital, Carretera de Valdemossa, 79, 07120 Palma de Mallorca, Spain
      </aff>
      <aff id="af0030">
       <label>
        f
       </label>
       Max von Pettenkofer Institute for Hygiene and Medical Microbiology, University of München, Pettenkofer Str 9A, 80336 Munich, Germany
      </aff>
      <aff id="af0035">
       <label>
        g
       </label>
       National Creutzfeldt–Jakob Disease Research and Surveillance Unit, School of Clinical Sciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author. Tel.: + 39 081 746 2060; fax:
        <bold>
         +
        </bold>
        39 081 5466152.
        <email>
         diminno@unina.it
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        20
       </day>
       <month>
        7
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        1
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        20
       </day>
       <month>
        7
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       30
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       35
      </fpage>
      <lpage>
       48
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2015 Published by Elsevier Ltd.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <p>
        The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community. Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations of pathogens do not necessarily imply a low level of risk for the patient and so the overall challenge of minimising risk remains. This review aims to discuss the variable level of pathogenic risk and describes the current screening methods used to prevent/detect the presence of pathogens in blood/plasma-derived products.
       </p>
      </abstract>
      <kwd-group id="ks0005">
       <title>
        Keywords
       </title>
       <kwd>
        Pathogen
       </kwd>
       <kwd>
        Transfusion
       </kwd>
       <kwd>
        Blood safety
       </kwd>
       <kwd>
        Clotting
       </kwd>
       <kwd>
        Haemophilia
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0005">
      Acute bleeding episodes can arise either because of inherited bleeding disorders (e.g. haemophilia, von Willebrand disease), acquired deficiency of haemostatic components (e.g. due to infection, malignancy or autoimmune disease), trauma, surgery or as a result of infection with an organism that causes haemorrhagic disease (e.g. Ebola or Marburg virus)
      <xref ref-type="bibr" rid="bb0005">
       [1]
      </xref>
      . Various treatment options exist for preventing or treating acute bleeding episodes, including fresh-frozen plasma/cryoprecipitate, platelets and plasma-derived/recombinant clotting factor concentrates
      <xref ref-type="bibr" rid="bb0010">
       [2]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0015">
       [3]
      </xref>
      . The use of blood-derived and recombinant haemostatic products has increased markedly over recent years, as exemplified by the global use of factor VIII products (
      <xref ref-type="fig" rid="f0005">
       Fig. 1
      </xref>
      )
      <xref ref-type="bibr" rid="bb0020">
       [4]
      </xref>
      . This increased use has been driven by improved availability of clotting factors, increased life expectancy of people with bleeding disorders
      <xref ref-type="bibr" rid="bb0025">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0030">
       [6]
      </xref>
      , increased use of prophylaxis for severe bleeding disorders
      <xref ref-type="bibr" rid="bb0035">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0040">
       [8]
      </xref>
      and decreased risk of transmission of infectious agents.
      <fig id="f0005">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Use of plasma-derived and recombinant factor VIII products in selected countries.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
       <attrib>
        Results are from Stonebraker et al. (1996–2006)
        <xref ref-type="bibr" rid="bb0020">
         [4]
        </xref>
        and WFH Annual Global Surveys (2007–2012)
        <xref ref-type="bibr" rid="bb0980">
         [196]
        </xref>
        .
       </attrib>
      </fig>
     </p>
     <p id="p0010">
      Historically, the risk of transmission of infectious agents via blood/plasma-derived products has been of great concern to the medical community. This risk has reduced dramatically since the implementation of stricter donation screening/donor selection procedures and improved purification procedures, but cannot be fully eradicated. Furthermore, the implementation of pathogen inactivation technology for blood/plasma-derived products has further reduced the risk of transmission of both known and emerging pathogens, although results can be variable according to the methods used
      <xref ref-type="bibr" rid="bb0045">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0050">
       [10]
      </xref>
      . However, it is important to note that patient risk is highly dependent on the circumstances under which blood products are collected, handled and used. In general, clinicians assess the level of risk associated with the use of blood/plasma-derived products by evaluating factors such as patient characteristics (e.g. age, immune status, geographical location, lifestyle) and the nature of the pathogen (e.g. physical characteristics, level of virulence, chronicity of infection, prevalence). The presence of a particular pathogen within blood/plasma-derived products may pose a significant threat to specific patient groups (e.g. the elderly or immunocompromised), while being of low risk to the general population (e.g. HEV).
     </p>
     <p id="p0015">
      While the clinical assessment of risk is based on a variety of factors, the virological assessment of risk is based solely on the presence or absence of pathogens. The presence of pathogens implies the possibility of infection, so only pathogen-free products can be described as entirely risk-free. Adopting the virological approach (i.e. discarding all products which may contain infectious agents) is effective in reducing the rate of pathogen transmission, but may result in the unnecessary wastage of blood/plasma-derived products.
     </p>
     <p id="p0020">
      Since recombinant clotting factors are not derived from blood or plasma, they present a minimal risk of pathogen transmission (particularly third generation factors, which have no contact with blood/plasma-derived components whatsoever) and can therefore be considered safer than using plasma-derived clotting factor concentrates
      <xref ref-type="bibr" rid="bb0055">
       [11]
      </xref>
      . However, there has been concern that the use of recombinant clotting factors may be associated with an increased rate of inhibitor formation in patients who regularly receive these products
      <xref ref-type="bibr" rid="bb0060">
       [12]
      </xref>
      ; this is another factor that may influence the overall clinical assessment of patient risk.
     </p>
     <p id="p0025">
      Recombinant clotting factors are available for the treatment of haemophilia A (FVIII) and B (FIX) and factor VII/XIII deficiency, while plasma-derived concentrates are available for most other clotting factors (including von Willebrand factor, fibrinogen and the vitamin K dependent clotting factors). In some cases only fresh frozen plasma and cryoprecipitate are available for replacement therapy (e.g. factor V deficiency). Ideally, plasma and plasma-derived products would be completely replaced by recombinant products in order to minimise the risk of pathogen transmission; however, this is not always possible. A recent article comprehensively reviewed the pathogen safety of plasma-derived and recombinant clotting factors
      <xref ref-type="bibr" rid="bb0065">
       [13]
      </xref>
      .
     </p>
     <p id="p0030">
      This review examines the potential for transmission of infectious agents that might be present in blood/plasma-derived products used to treat haemostatic disorders. We focus on the identities of these agents and the screening procedures used for their detection, as well as the limitations of screening. Current unmet needs in the field of pathogen safety of blood/plasma-derived products are also discussed.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Methodology
     </title>
     <p id="p0035">
      The PubMed database was interrogated from 1 January 2000 to the present using the search strings ‘bleeding disorders OR haemophilia’ and ‘pathogens AND blood safety’. The search terms ‘virus’, ‘bacteria’, ‘haemorrhagic disorders’, ‘von Willebrand disease’, ‘FVII deficiency’ and ‘FXIII deficiency’ were added to this search but did not yield any additional pertinent result. The bibliographies of reviews were also used to identify relevant references and individual searches were conducted for information on specific pathogens. Information and opinions were also provided by the authors.
     </p>
    </sec>
    <sec id="s0015">
     <label>
      3
     </label>
     <title>
      Infectious agents present in blood/plasma-derived products: lessons from the past and current concerns
     </title>
     <p id="p0040">
      A large number of pathogenic agents (including viruses, protozoan parasites and prions) can be transmitted via blood/plasma-derived products and are capable of causing disease in humans (
      <xref ref-type="table" rid="t0005">
       Table 1
      </xref>
      ). The presence of viruses in plasma-derived products became a concern in the 1980s, when 60–70% of patients with severe haemophilia became infected with human immunodeficiency virus (HIV-1)
      <xref ref-type="bibr" rid="bb0030">
       [6]
      </xref>
      . This concern continued with the discovery that 80% of patients treated with plasma-derived products prior to 1992 had become infected with hepatitis C virus (HCV)
      <xref ref-type="bibr" rid="bb0025">
       [5]
      </xref>
      . Current donor selection and screening practices have improved our ability to detect or reduce the presence of pathogens in blood/plasma-derived products; for example, the residual risk of transfusion-transmitted infection (TTI) with HIV/HBV/HCV has fallen to near or less than 1 per million transfused units
      <xref ref-type="bibr" rid="bb0070">
       [14]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0075">
       [15]
      </xref>
      . Despite this success, however, a residual risk still remains.
      <table-wrap id="t0005" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Blood-transmissible pathogens.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Transmissible agent
          </th>
          <th align="left">
           Geographic distribution (% of global population infected)
          </th>
          <th align="left">
           Testing procedure
          </th>
          <th align="left">
           Detection level in general clinical use
          </th>
          <th align="left">
           Minimum detection level possible (in development)
          </th>
          <th align="left">
           Testing sensitivity
          </th>
          <th align="left">
           Testing specificity
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="7">
           <bold>
            Prions
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           vCJD
          </td>
          <td align="left">
           Rare
           <xref ref-type="bibr" rid="bb0470">
            [94]
           </xref>
          </td>
          <td align="left">
           Solid state binding matrix/immuno-assay
           <xref ref-type="bibr" rid="bb0275">
            [55]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0475">
            [95]
           </xref>
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           ≥ 71%
           <xref ref-type="bibr" rid="bb0275">
            [55]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0475">
            [95]
           </xref>
          </td>
          <td align="left">
           ≥ 98%
           <xref ref-type="bibr" rid="bb0275">
            [55]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0475">
            [95]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="7">
          </td>
         </tr>
         <tr>
          <td align="left" colspan="7">
           <bold>
            Viruses
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           Chikungunya virus
          </td>
          <td align="left">
           Widespread (prevalent in Africa, Asia and Latin-America)
           <xref ref-type="bibr" rid="bb0480">
            [96]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
           <xref ref-type="bibr" rid="bb0480">
            [96]
           </xref>
          </td>
          <td align="left">
           NAT: 40–350 copies/ml
           <xref ref-type="bibr" rid="bb0485">
            [97]
           </xref>
          </td>
          <td align="left">
           NAT: 10–100 copies/ml
           <xref ref-type="bibr" rid="bb0490">
            [98]
           </xref>
          </td>
          <td align="left">
           Antibody: varies according to disease stage and test type.
           <break>
           </break>
           Immuno-chromatographic test: 1.9–3.9% (acute infection)
           <break>
           </break>
           ELISA: 3.9% (acute), 84.1% (convalescent)
           <break>
           </break>
           NAT: RT-PCR — 88.5% (acute)
           <xref ref-type="bibr" rid="bb0495">
            [99]
           </xref>
          </td>
          <td align="left">
           Antibody: varies according to disease stage and test type.
           <break>
           </break>
           Immuno-chromatographic test: 92.5–95.0% (acute infection)
           <break>
           </break>
           ELISA: 92.5% (acute), 91.0% (convalescent)
           <break>
           </break>
           NAT: RT-PCR — 100% (acute)
           <xref ref-type="bibr" rid="bb0495">
            [99]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Cytomegalovirus (CMV)
          </td>
          <td align="left">
           Widespread
           <xref ref-type="bibr" rid="bb0345">
            [69]
           </xref>
          </td>
          <td align="left">
           Antigen/NAT
          </td>
          <td align="left">
           NAT: 446 copies/ml (whole blood)
           <xref ref-type="bibr" rid="bb0500">
            [100]
           </xref>
          </td>
          <td align="left">
           139 copies/ml (NAT; qPCR)
           <xref ref-type="bibr" rid="bb0505">
            [101]
           </xref>
          </td>
          <td align="left">
           Not available
          </td>
          <td align="left">
           Not available
          </td>
         </tr>
         <tr>
          <td align="left">
           Dengue virus
          </td>
          <td align="left">
           Widespread; 50% of global population at risk
           <xref ref-type="bibr" rid="bb0510">
            [102]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 160–600 copies/ml (DENV-1, 3 and 4)
           <break>
           </break>
           2000–6000 copies/ml (DENV-2)
           <xref ref-type="bibr" rid="bb0515">
            [103]
           </xref>
           based on 1 PFU = 1000–3000 RNA copies
           <xref ref-type="bibr" rid="bb0520">
            [104]
           </xref>
          </td>
          <td align="left">
           N/A: current main research focus is on developing serotype-specific tests
          </td>
          <td align="left">
           Antibody: 96–98% (IgM)
           <xref ref-type="bibr" rid="bb0525">
            [105]
           </xref>
           <break>
           </break>
           NAT: High for DENV-1, 3 and 4; lower for DENV-2
           <xref ref-type="bibr" rid="bb0515">
            [103]
           </xref>
          </td>
          <td align="left">
           Antibody: 78–91% (IgM)
           <xref ref-type="bibr" rid="bb0525">
            [105]
           </xref>
           <break>
           </break>
           NAT: 100%
           <xref ref-type="bibr" rid="bb0515">
            [103]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis B virus (HBV)
          </td>
          <td align="left">
           Widespread; 29% infected, 5% chronically infected
           <xref ref-type="bibr" rid="bb0530">
            [106]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: Reliable (≥ 99% detection) from 84 copies/ml
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
           based on 1 IU/ml = 5.6 copies/ml
           <xref ref-type="bibr" rid="bb0540">
            [108]
           </xref>
          </td>
          <td align="left">
           NAT: 42–52 copies/ml (Ultrio); 4–10 copies/ml (Ampliscreen/UltraQual)
           <xref ref-type="bibr" rid="bb0290">
            [58]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 90% (anti-HBc assay), 98% (anti-HBsAg assay)
           <xref ref-type="bibr" rid="bb1000">
            [109]
           </xref>
           <break>
           </break>
           NAT: 99.3% (Procleix Ultrio)
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 78.9 (anti-HBc assay), up to 100% (anti-HBsAg assay)
           <xref ref-type="bibr" rid="bb1000">
            [109]
           </xref>
           <break>
           </break>
           NAT: 99.8% (Procleix Ultrio)
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis C virus (HCV)
          </td>
          <td align="left">
           Widespread; 3%
           <xref ref-type="bibr" rid="bb0550">
            [110]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 17 copies/ml (4-reaction kit format), 1664 copies/ml (primary pool format), 8806 copies/ml (master pool format), based on 1 IU/ml = 2.5 copies/ml
           <xref ref-type="bibr" rid="bb0555">
            [111]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0560">
            [112]
           </xref>
          </td>
          <td align="left">
           NAT: 6.1 copies/ml (50% detection point, individual samples)
          </td>
          <td align="left">
           Antibody: 99% (anti-HCV-cAg)
           <xref ref-type="bibr" rid="bb0565">
            [113]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0570">
            [114]
           </xref>
           <break>
           </break>
           NAT: 70.7–90.2%
           <xref ref-type="bibr" rid="bb0555">
            [111]
           </xref>
           , 99.9% (Procleix Ultrio)
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
          </td>
          <td align="left">
           Antibody: 99.2% (anti-HCV-cAg)
           <xref ref-type="bibr" rid="bb0565">
            [113]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0570">
            [114]
           </xref>
           <break>
           </break>
           NAT: High
           <xref ref-type="bibr" rid="bb0555">
            [111]
           </xref>
           , 98.1% (Procleix Ultrio)
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis E virus (HEV)
          </td>
          <td align="left">
           Widespread
           <xref ref-type="bibr" rid="bb0575">
            [115]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 5.9–114 copies/ml (MP-NAT), 47.3–226 copies/ml (ID-NAT)
           <xref ref-type="bibr" rid="bb0580">
            [116]
           </xref>
           based on 1 IU/ml = 1.25 copies/ml
           <xref ref-type="bibr" rid="bb0585">
            [117]
           </xref>
          </td>
          <td align="left">
           NAT: ≥ 5.8 copies/ml
           <xref ref-type="bibr" rid="bb0590">
            [118]
           </xref>
           based on 1 IU/ml = 1.25 copies/ml
           <xref ref-type="bibr" rid="bb0585">
            [117]
           </xref>
          </td>
          <td align="left">
           Antibody: 72-98%
           <xref ref-type="bibr" rid="bb0595">
            [119]
           </xref>
           <break>
           </break>
           NAT: High. Varies from 5.9 copies/ml (Real-Star HEV RT-PCR) to 114 copies/ml (Ceeram) for MP-NAT and from 47.3 copies/ml (Real-Star HEV RT-PCR ) to 226 copies/ml (ampliCube HEV RT-PCR) for ID-NAT
           <xref ref-type="bibr" rid="bb0580">
            [116]
           </xref>
          </td>
          <td align="left">
           Antibody: 78-96%
           <xref ref-type="bibr" rid="bb0595">
            [119]
           </xref>
           <break>
           </break>
           NAT: High
           <xref ref-type="bibr" rid="bb0580">
            [116]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Human Herpesvirus-8 (KSHV)
          </td>
          <td align="left">
           Widespread, with variable prevalence (≤ 5–50%); endemic in sub-Saharan Africa, parts of Asia and Oceania
           <xref ref-type="bibr" rid="bb0600">
            [120]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 63 copies/ml (Viracor IBT)
           <xref ref-type="bibr" rid="bb0605">
            [121]
           </xref>
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           Antibody: 65-100%
           <xref ref-type="bibr" rid="bb0610">
            [122]
           </xref>
           <break>
           </break>
           NAT: High (63 copies/ml)
           <xref ref-type="bibr" rid="bb0605">
            [121]
           </xref>
          </td>
          <td align="left">
           Antibody: 96-99%
           <xref ref-type="bibr" rid="bb0610">
            [122]
           </xref>
           <break>
           </break>
           NAT: High — no cross reactivity detected against adenoviruses, BKV, CMV, EBV, HSV-1, HSV-2, HHV-6 variant A, HHV-6 variant B, HHV-7, JCV, parvovirus B19, SV-40 or VZV.
           <xref ref-type="bibr" rid="bb0605">
            [121]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Human immunodeficiency virus (HIV-1 and HIV-2)
          </td>
          <td align="left">
           Worldwide (0.5%); endemic in sub-Saharan Africa (5%)
           <xref ref-type="bibr" rid="bb0615">
            [123]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 20-50 copies/ml
           <xref ref-type="bibr" rid="bb0620">
            [124]
           </xref>
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           Antibody: ≥ 99.9%
           <xref ref-type="bibr" rid="bb0625">
            [125]
           </xref>
           <break>
           </break>
           NAT: 99.9% (Procleix Ultrio)
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
          </td>
          <td align="left">
           Antibody: 99.5–99.9%
           <xref ref-type="bibr" rid="bb0625">
            [125]
           </xref>
           <break>
           </break>
           NAT: 99.8% (Procleix Ultrio)
           <xref ref-type="bibr" rid="bb0535">
            [107]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Human T-lymphotropic virus 1 and 2 (HTLV-1/2)
          </td>
          <td align="left">
           HTLV-1: Endemic in Japan, Africa, South America and Caribbean
           <break>
           </break>
           HTLV-2: Prevalent in Central/West Africa, the Americas and Europe
           <xref ref-type="bibr" rid="bb0630">
            [126]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           Not specified: antibody detection kits routinely used
           <xref ref-type="bibr" rid="bb0635">
            [127]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0640">
            [128]
           </xref>
          </td>
          <td align="left">
           NAT: HTLV-1–1.2 copies/reaction (i.e. 12–48 copies/ml, based on a reaction volume of 10–50 μl); HTLV-2–19 copies/reaction (i.e. 76–191 copies/ml, based on a reaction volume of 10–50 μl)
           <xref ref-type="bibr" rid="bb0645">
            [129]
           </xref>
          </td>
          <td align="left">
           Antibody: 100%
           <xref ref-type="bibr" rid="bb0650">
            [130]
           </xref>
           <break>
           </break>
           NAT: 99.4% (HTLV-1 and 2)
           <xref ref-type="bibr" rid="bb0655">
            [131]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 99.4%
           <xref ref-type="bibr" rid="bb0650">
            [130]
           </xref>
           <break>
           </break>
           NAT: 98.5% (HTLV-1 and 2)
           <xref ref-type="bibr" rid="bb0655">
            [131]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Parvovirus B-19
          </td>
          <td align="left">
           Widespread, variable prevalence (0.2–40% in European and Asian blood donors)
           <xref ref-type="bibr" rid="bb0185">
            [37]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 668 copies/ml (based on 1 IU/ml = 3.34 copies/ml)
           <xref ref-type="bibr" rid="bb0660">
            [132]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0665">
            [133]
           </xref>
          </td>
          <td align="left">
           NAT: 10 copies/reaction (i.e. 100–500 copies/ml, based on a reaction volume of 10–50 μl)
           <xref ref-type="bibr" rid="bb0670">
            [134]
           </xref>
          </td>
          <td align="left">
           Antibody: 89.1%
           <xref ref-type="bibr" rid="bb0675">
            [135]
           </xref>
           <break>
           </break>
           NAT: ≥ 93%
           <xref ref-type="bibr" rid="bb0660">
            [132]
           </xref>
          </td>
          <td align="left">
           Antibody: 99.4%
           <xref ref-type="bibr" rid="bb0675">
            [135]
           </xref>
           <break>
           </break>
           NAT: ≥ 97%
           <xref ref-type="bibr" rid="bb0660">
            [132]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Parvovirus 4
          </td>
          <td align="left">
           Widespread, variable prevalence (2–35%)
           <xref ref-type="bibr" rid="bb0680">
            [136]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0685">
            [137]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0690">
            [138]
           </xref>
          </td>
          <td align="left">
           NAT
          </td>
          <td align="left">
           NAT: 200–500 copies/ml
           <xref ref-type="bibr" rid="bb0695">
            [139]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0700">
            [140]
           </xref>
          </td>
          <td align="left">
           NAT: 10 copies/reaction (i.e. 100–500 copies/ml, based on a reaction volume of 10–50 μl)
           <xref ref-type="bibr" rid="bb0670">
            [134]
           </xref>
          </td>
          <td align="left">
           Not available
          </td>
          <td align="left">
           Not available
          </td>
         </tr>
         <tr>
          <td align="left">
           Torque-tenovirus (TTV)
          </td>
          <td align="left">
           Present worldwide at variable prevalence (higher in developing countries)
           <xref ref-type="bibr" rid="bb0705">
            [141]
           </xref>
          </td>
          <td align="left">
           NAT
          </td>
          <td align="left">
           NAT: no general test — PCR used to confirm presence.
          </td>
          <td align="left">
           NAT: ≥ 100 copies/reaction (i.e. 1000–5000 copies/ml, based on a reaction volume of 10–50 μl)
           <xref ref-type="bibr" rid="bb0710">
            [142]
           </xref>
          </td>
          <td align="left">
           NAT: Up to 100%
           <xref ref-type="bibr" rid="bb0710">
            [142]
           </xref>
          </td>
          <td align="left">
           NAT: ≥ 96%
           <xref ref-type="bibr" rid="bb0710">
            [142]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           West Nile virus (WNV)
          </td>
          <td align="left">
           Widespread (Africa, West Asia, Middle East, Europe and North and South America)
           <xref ref-type="bibr" rid="bb0450">
            [90]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: 100 copies/ml
           <xref ref-type="bibr" rid="bb0715">
            [143]
           </xref>
          </td>
          <td align="left">
           NAT: ≥ 9.8 copies/ml
           <xref ref-type="bibr" rid="bb0720">
            [144]
           </xref>
          </td>
          <td align="left">
           Antibody: 50% (IgM), 86% (IgG)
           <xref ref-type="bibr" rid="bb0725">
            [145]
           </xref>
           <break>
           </break>
           NAT: High
           <xref ref-type="bibr" rid="bb0720">
            [144]
           </xref>
          </td>
          <td align="left">
           Antibody: 95% (IgM), 69% (IgG)
           <xref ref-type="bibr" rid="bb0725">
            [145]
           </xref>
           <break>
           </break>
           NAT: High
           <xref ref-type="bibr" rid="bb0720">
            [144]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="7">
          </td>
         </tr>
         <tr>
          <td align="left" colspan="7">
           <bold>
            Bacteria
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Treponema pallidum
           </italic>
           subspecies
           <italic>
            pallidum
           </italic>
          </td>
          <td align="left">
           Widespread; (0.5% of global population infected)
           <xref ref-type="bibr" rid="bb0730">
            [146]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT/dark ground microscopy DGM)
          </td>
          <td>
          </td>
          <td align="left">
           NAT: 32,000 copies/ml
           <break>
           </break>
           <xref ref-type="bibr" rid="bb0735">
            [147]
           </xref>
          </td>
          <td align="left">
           NAT: 82%
           <xref ref-type="bibr" rid="bb0740">
            [148]
           </xref>
           <break>
           </break>
           Antibody: 78–88% (primary syphilis), 100% (secondary), 95–100% (latent), 71–96 (late)
           <xref ref-type="bibr" rid="bb0745">
            [149]
           </xref>
           <break>
           </break>
           DGM: 79–97%
           <xref ref-type="bibr" rid="bb0735">
            [147]
           </xref>
          </td>
          <td align="left">
           NAT: 95%
           <xref ref-type="bibr" rid="bb0740">
            [148]
           </xref>
           <break>
           </break>
           Antibody: 96–99%
           <break>
           </break>
           DGM: 77–100%
           <xref ref-type="bibr" rid="bb0735">
            [147]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0745">
            [149]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Yersinia enterocolitica,
           </italic>
           <break>
           </break>
           <italic>
            Salmonella enterica, Listeria monocytogenes, Coxiella burnetii
           </italic>
           (only during outbreaks)
          </td>
          <td align="left">
           Rare, donor selection dependent
          </td>
          <td align="left">
           Not done
          </td>
          <td>
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           N/A
          </td>
         </tr>
         <tr>
          <td align="left" colspan="7">
          </td>
         </tr>
         <tr>
          <td align="left" colspan="7">
           <bold>
            Protozoa
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Babesia
           </italic>
           spp
          </td>
          <td align="left">
           Widespread; predominantly in United States and (less frequently) Europe
           <xref ref-type="bibr" rid="bb0750">
            [150]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           Antibody: 10000–100000 parasites/ml (Giemsa staining)
           <xref ref-type="bibr" rid="bb0755">
            [151]
           </xref>
          </td>
          <td align="left">
           NAT: 5000–10000 parasites/ml
           <xref ref-type="bibr" rid="bb0755">
            [151]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 97%
           <xref ref-type="bibr" rid="bb0760">
            [152]
           </xref>
           <break>
           </break>
           NAT: High
           <xref ref-type="bibr" rid="bb0755">
            [151]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 97%
           <xref ref-type="bibr" rid="bb0760">
            [152]
           </xref>
           <break>
           </break>
           NAT: 100%
           <xref ref-type="bibr" rid="bb0755">
            [151]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Leishmania
           </italic>
           spp
          </td>
          <td align="left">
           Widespread; 1.3 million new cases per year
           <xref ref-type="bibr" rid="bb0765">
            [153]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: ≥ 10 parasites/ml (PCR; sensitivity varies according to method)
           <xref ref-type="bibr" rid="bb0770">
            [154]
           </xref>
          </td>
          <td align="left">
           NAT: ≥ 10 parasites/ml
           <xref ref-type="bibr" rid="bb0770">
            [154]
           </xref>
          </td>
          <td align="left">
           Antibody: 75-95%
           <xref ref-type="bibr" rid="bb0775">
            [155]
           </xref>
           <break>
           </break>
           NAT: 98.7% (kinetoplast DNA PCR), 91% (ITS1 PCR), 53.8% (SLME PCR)
           <xref ref-type="bibr" rid="bb0780">
            [156]
           </xref>
          </td>
          <td align="left">
           Antibody: 70-98%
           <xref ref-type="bibr" rid="bb0775">
            [155]
           </xref>
           <break>
           </break>
           NAT: 57.1% (kinetoplast DNA PCR), 100% (ITS1 PCR and SLME PCR)
           <xref ref-type="bibr" rid="bb0780">
            [156]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Plasmodium
           </italic>
           spp
          </td>
          <td align="left">
           Widespread (most common in sub-Saharan Africa). 30% at risk
           <xref ref-type="bibr" rid="bb0785">
            [157]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           Microscopy: 50000 parasites/ml
           <xref ref-type="bibr" rid="bb0790">
            [158]
           </xref>
          </td>
          <td align="left">
           NAT: &lt; 10 parasites/ml
           <xref ref-type="bibr" rid="bb0790">
            [158]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 95%
           <xref ref-type="bibr" rid="bb0795">
            [159]
           </xref>
           <break>
           </break>
           NAT: 76.1–100%
           <xref ref-type="bibr" rid="bb0790">
            [158]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 97.7%
           <xref ref-type="bibr" rid="bb0795">
            [159]
           </xref>
           <break>
           </break>
           NAT: 89.6–100%
           <xref ref-type="bibr" rid="bb0790">
            [158]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Trypanosoma brucei gambiense/
           </italic>
           <italic>
            rhodiense
           </italic>
          </td>
          <td align="left">
           Regional in Africa, 10% at risk
           <xref ref-type="bibr" rid="bb0800">
            [160]
           </xref>
          </td>
          <td align="left">
           Direct microscopic visualisation/Antibody/NAT
          </td>
          <td align="left">
           NAT: &lt; 100 trypanosomes/ml
           <xref ref-type="bibr" rid="bb0805">
            [161]
           </xref>
          </td>
          <td align="left">
           NAT: 1–10 trypanosomes/ml
           <xref ref-type="bibr" rid="bb0810">
            [162]
           </xref>
          </td>
          <td align="left">
           Antibody: CATT — 87–98%
           <xref ref-type="bibr" rid="bb0805">
            [161]
           </xref>
           <break>
           </break>
           NAT: 88%
           <xref ref-type="bibr" rid="bb0815">
            [163]
           </xref>
          </td>
          <td align="left">
           Antibody: CATT — 95%
           <xref ref-type="bibr" rid="bb0805">
            [161]
           </xref>
           <break>
           </break>
           NAT: 99.2%
           <xref ref-type="bibr" rid="bb0815">
            [163]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Trypanosoma cruzi
           </italic>
          </td>
          <td align="left">
           0.1–0.2% (mostly Latin and South America)
           <xref ref-type="bibr" rid="bb0820">
            [164]
           </xref>
          </td>
          <td align="left">
           Antibody/NAT
          </td>
          <td align="left">
           NAT: ≥ 0.5 parasites/ml
           <xref ref-type="bibr" rid="bb0825">
            [165]
           </xref>
          </td>
          <td align="left">
           NAT: 0.05 parasites/ml
           <xref ref-type="bibr" rid="bb0825">
            [165]
           </xref>
          </td>
          <td align="left">
           Antibody:75–100% (majority &gt; 90%)
           <xref ref-type="bibr" rid="bb0830">
            [166]
           </xref>
           <break>
           </break>
           NAT: 83.3–94.4%
           <xref ref-type="bibr" rid="bb0825">
            [165]
           </xref>
          </td>
          <td align="left">
           Antibody: ≥ 97%
           <xref ref-type="bibr" rid="bb0830">
            [166]
           </xref>
           <break>
           </break>
           NAT: 85–95%
           <xref ref-type="bibr" rid="bb0825">
            [165]
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="sp0015">
         <p>
          In cases where no overall figures are available, specificity/sensitivity has been described as low, medium or high (as appropriate).
         </p>
        </fn>
        <fn id="sp0020">
         <p>
          CATT, card agglutination test for Trypanosomiasis; ID-NAT, individual donation NAT; MP-NAT, mini-pool NAT; NAT, nucleic acid testing; PCR, polymerase chain reaction; PFU, plaque-forming unit.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="s0020">
      <label>
       3.1
      </label>
      <title>
       Potential risk
      </title>
      <p id="p0045">
       The pathogenic agents shown in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       (and the Supplementary Appendix) do not form an exhaustive list. Many microorganisms that are normally non-pathogenic have the potential to cause disease when responding to changes in the biological environment, or when transfused to an immunosuppressed patient. In addition, there is still a risk that new and emerging pathogens may enter the blood supply (
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       ).
       <table-wrap id="t0010" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Emerging blood-transmissible pathogens.
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Recently emerging pathogen
           </th>
           <th align="left">
            Pathogen structure/classification
           </th>
           <th align="left">
            Year of emergence
           </th>
           <th align="left">
            Mode of transmission
           </th>
           <th align="left">
            References
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            Bas Congo virus
           </td>
           <td align="left">
            Enveloped; rhabdovirus
           </td>
           <td align="left">
            2009
           </td>
           <td align="left">
            Direct contact (human–human and zoonotic), nosocomial
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0835">
             [167]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Huaiyangshan Bunyavirus
           </td>
           <td align="left">
            Enveloped; bunyavirus
           </td>
           <td align="left">
            2010
           </td>
           <td align="left">
            Direct contact (human–human), vector-borne, blood-borne, airborne (potentially)
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0840">
             [168]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0845">
             [169]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Influenza H5N1
           </td>
           <td align="left">
            Enveloped; orthomyxovirus
           </td>
           <td align="left">
            2005
           </td>
           <td align="left">
            Airborne, direct contact (human–human and zoonotic)
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0850">
             [170]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0855">
             [171]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0860">
             [172]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Influenza H7N9
           </td>
           <td align="left">
            Enveloped; orthomyxovirus
           </td>
           <td align="left">
            2012
           </td>
           <td align="left">
            Direct contact (zoonotic and potentially human–human),airborne
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0860">
             [172]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0865">
             [173]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Lujo virus
           </td>
           <td align="left">
            Enveloped; arenavirus
           </td>
           <td align="left">
            2008
           </td>
           <td align="left">
            Airborne, direct contact (human–human and zoonotic), nosocomial, blood-borne (potentially)
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0870">
             [174]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0875">
             [175]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Marseillevirus
            <xref ref-type="table-fn" rid="tf0005">
             a
            </xref>
           </td>
           <td align="left">
            Marseillevirus
           </td>
           <td align="left">
            2010
           </td>
           <td align="left">
            Blood-borne, faecal–oral (?)
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0880">
             [176]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0885">
             [177]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            MERS coronavirus
           </td>
           <td align="left">
            Enveloped; coronavirus
           </td>
           <td align="left">
            2013
           </td>
           <td align="left">
            Airborne, direct contact (human–human and zoonotic), nosocomial
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0890">
             [178]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0895">
             [179]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            SARS coronavirus
           </td>
           <td align="left">
            Enveloped; coronavirus
           </td>
           <td align="left">
            2003
           </td>
           <td align="left">
            Faecal/oral, airborne, direct contact (human–human and zoonotic), nosocomial
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0900">
             [180]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0905">
             [181]
            </xref>
            ,
            <xref ref-type="bibr" rid="bb0910">
             [182]
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            NJ polyomavirus
           </td>
           <td align="left">
            Non-enveloped polyomavirus
           </td>
           <td align="left">
            2014
           </td>
           <td align="left">
            Direct contact, saliva, blood?
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bb0915">
             [183]
            </xref>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tf0005">
          <label>
           a
          </label>
          <p id="np0005">
           Unconfirmed — may have been the result of laboratory contamination
           <xref ref-type="bibr" rid="bb0920">
            [184]
           </xref>
           .
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
    </sec>
    <sec id="s0025">
     <label>
      4
     </label>
     <title>
      Screening for pathogens
     </title>
     <p id="p0050">
      The standard assays commonly used for blood screening are nucleic acid amplification technology (NAT) and immunoassays for detection of antibody and/or antigen. Immunoassays are frequently used for screening purposes as multiple samples can be processed together and they may yield semi-quantitative results. NAT assays allow earlier pathogen detection than with immunoassays, but they are also more costly and complex. Assay selection is generally determined by the level of accuracy/speed required, but factors such as the resources available (e.g. staff, infrastructure), assay complexity and cost considerations (e.g. consumables) must also be considered. Most assays for blood donation screening are mandatory (particularly in Europe and North America) and the World Health Organization (WHO) recommends that all whole blood (and blood which has been processed by apheresis) should undergo pathogen screening before it is used for clinical or manufacturing purposes. Screening for HIV-1, HIV-2, HBV, HCV and
      <italic>
       Treponema pallidum
      </italic>
      subspecies
      <italic>
       pallidum
      </italic>
      (
      <italic>
       T. pallidum
      </italic>
      ; the causative agent of syphilis) is strongly advised. The WHO and World Federation of Hemophilia (WFH) suggest that countries should carry out individual routine screening for further pathogens based on epidemiological information for their region e.g. HTLV-1 and
      <italic>
       Trypanosoma cruzi
      </italic>
      <xref ref-type="bibr" rid="bb0080">
       [16]
      </xref>
      . The WFH also acknowledges the positive impact of HIV, HBV and HCV screening on global blood safety and recommends that these screening tests be implemented whenever possible
      <xref ref-type="bibr" rid="bb0010">
       [2]
      </xref>
      . Details of the serological tests carried out on individual donor plasma and NAT testing of plasma mini-pools are shown in
      <xref ref-type="table" rid="t0015">
       Table 3
      </xref>
      ,
      <xref ref-type="table" rid="t0020">
       Table 4
      </xref>
      <xref ref-type="bibr" rid="bb0085">
       [17]
      </xref>
      .
      <table-wrap id="t0015" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Summarised table of serologic tests on individual donor plasma (WFH 2012)
         <xref ref-type="bibr" rid="bb0085">
          [17]
         </xref>
         .
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Plasma source
          </th>
          <th align="left">
           Serologic tests performed on individual donor plasma
           <xref ref-type="table-fn" rid="tf0010">
            a
           </xref>
           <sup>
            ,
           </sup>
           <xref ref-type="table-fn" rid="tf0015">
            b
           </xref>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           US paid apheresis (Talecris, Grifols, others)
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           United States, recovered, unpaid
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBcAb, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           Baxter BioScience: United States, Austria, Germany, Sweden, Czech Republic, Switzerland, Norway
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           CSL Behring: Austria, Denmark, Germany, United States
          </td>
          <td align="left">
           Syphilis (US), HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Biotest: Austria, Belgium, Germany, United States, Switzerland
          </td>
          <td align="left">
           HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Intersero: Austria, Belgium, Germany
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           Germany unpaid
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HbsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           Octapharma: Sweden, Austria, Germany
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBcAb, HBsAg, HBcAb, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           American Community Blood Centers, unpaid (Octapharma)
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBcAb = anti-HBc, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Finnish Red Cross BS: Finland, unpaid
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb. HTLV-1&amp;2 1st donation.
          </td>
         </tr>
         <tr>
          <td align="left">
           Sanquin: The Netherlands
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBsAg, HBcAb, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           LFB: France
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBcAb, HBsAb, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Grifols: Spain, Czech Republic, Slovakia
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Kedrion: Italy
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           National Bioproducts Institute: South Africa
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Australian Red Cross Blood Service
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           New Zealand Blood Service
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb. HTLV-1&amp;2 (1st donation only)
          </td>
         </tr>
         <tr>
          <td align="left">
           Centre for Transfusion Medicine, Singapore
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           National Blood Center, Malaysia
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Hong Kong Red Cross BTS
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBsAb, HBsAg, HCVAb
          </td>
         </tr>
         <tr>
          <td align="left">
           Taiwan Blood Services Foundation
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1&amp;2, HBsAb, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           Japan
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HTLV-1, HBcAb, HBsAb, HBsAg, HCVAb, ALT, B-19 parvovirus
          </td>
         </tr>
         <tr>
          <td align="left">
           Korean Red Cross: South Korea
          </td>
          <td align="left">
           Syphilis, HIV-1/2, p-24 antigen, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           Shanghai RAAS Blood Products Co: China
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
          </td>
         </tr>
         <tr>
          <td align="left">
           Bio Products Laboratory, UK: US paid apheresis
          </td>
          <td align="left">
           Syphilis, HIV-1/2, HBsAg, HCVAb. HTLV-1&amp;2, HBcAb (recovered only)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="tf0010">
         <label>
          a
         </label>
         <p id="np0010">
          Serological targets for HIV detection include p24 antigen and anti-HIV-1/2 antibodies
          <xref ref-type="bibr" rid="bb0925">
           [185]
          </xref>
          ,
          <xref ref-type="bibr" rid="bb0930">
           [186]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0015">
         <label>
          b
         </label>
         <p id="np0015">
          Nontreponemal tests are routinely used to screen blood for the presence of
          <italic>
           Treponema pallidum
          </italic>
          subspecies
          <italic>
           pallidum
          </italic>
          (
          <italic>
           T. pallidum
          </italic>
          , the causative agent of syphilis). These tests measure both proteins from the
          <italic>
           Treponema
          </italic>
          cell surface and IgG/IgM antiphospholipid antibodies which are produced by the host in response to cell damage in the early stages of infection
          <xref ref-type="bibr" rid="bb0750">
           [150]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="t0020" position="float">
       <label>
        Table 4
       </label>
       <caption>
        <p>
         Plasma inventory hold and NAT testing of mini-pools (WFH 2012)
         <xref ref-type="bibr" rid="bb0085">
          [17]
         </xref>
         .
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Company or Fractionator
          </th>
          <th align="left">
           Mini-Pool NAT Tests
           <xref ref-type="table-fn" rid="tf0020">
            a
           </xref>
          </th>
          <th align="left">
           Manufacturing Pool NAT Tests
           <xref ref-type="table-fn" rid="tf0025">
            b
           </xref>
          </th>
          <th align="left">
           NAT on Final Product
           <xref ref-type="table-fn" rid="tf0030">
            c
           </xref>
          </th>
          <th align="left">
           Inventory Hold
           <xref ref-type="table-fn" rid="tf0035">
            d
           </xref>
          </th>
          <th align="left">
           Mini-Pool Size
           <xref ref-type="table-fn" rid="tf0040">
            e
           </xref>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           CSL Behring: United States, Germany
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV, B-19 parvovirus
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           512 or fewer
          </td>
         </tr>
         <tr>
          <td align="left">
           Baxter BioScience: United States, Austria, Italy
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1/2, B-19 parvovirus
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           512 or fewer
          </td>
         </tr>
         <tr>
          <td align="left">
           Talecris: United States
          </td>
          <td align="left">
           HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           96 or 480
          </td>
         </tr>
         <tr>
          <td align="left">
           Grifols: United States, Spain, Czech Republic, Slovakia
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV, B-19 parvovirus
          </td>
          <td align="left">
           HBV, HCV, HIV, B-19 parvovirus
          </td>
          <td>
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           512 or fewer
          </td>
         </tr>
         <tr>
          <td align="left">
           Bio Products Laboratory, UK
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1/2, B-19 parvovirus
          </td>
          <td align="left">
           HCV
          </td>
          <td>
          </td>
          <td align="left">
           60 days
          </td>
          <td align="left">
           512 or fewer
          </td>
         </tr>
         <tr>
          <td align="left">
           Biotest: Germany
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1/2, B-19 parvovirus
          </td>
          <td align="left">
           HBV, HCV, HIV
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           60 days
          </td>
          <td align="left">
           960
          </td>
         </tr>
         <tr>
          <td align="left">
           Intersero, Germany
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV 1, B-19 parvovirus
          </td>
          <td align="left">
           HBV, HCV, HIV
          </td>
          <td>
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           960
          </td>
         </tr>
         <tr>
          <td align="left">
           German Red Cross BSO NSTOB
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV 1, B-19 parvovirus
          </td>
          <td align="left">
           HCV
          </td>
          <td>
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           48
          </td>
         </tr>
         <tr>
          <td align="left">
           Octapharma: Sweden, Austria, Germany, USA
          </td>
          <td align="left">
           HBV, B-19 parvovirus, HAV, HCV, HIV-1
          </td>
          <td align="left">
           HCV
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           16-512
          </td>
         </tr>
         <tr>
          <td align="left">
           Finnish Red Cross BS: Finland
          </td>
          <td align="left">
           HBV, HCV, HIV (individual)
           <break>
           </break>
           HAV, B-19 parvovirus (mini-pool)
          </td>
          <td align="left">
           FRC BS does not make plasma pools
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           1 or 96
          </td>
         </tr>
         <tr>
          <td align="left">
           Sanquin: The Netherlands
          </td>
          <td align="left">
           HCV (6), HIV (6), HBV (6), B-19 parvovirus (480), HAV (480)
          </td>
          <td align="left">
           HBV, HCV, HIV, B-19 parvovirus
          </td>
          <td align="left">
           No
          </td>
          <td>
          </td>
          <td align="left">
           480 or 6
          </td>
         </tr>
         <tr>
          <td align="left">
           LFB: France
          </td>
          <td align="left">
           1: B-19 parvovirus 2: HAV, HCV
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td>
          </td>
          <td align="left">
           80 + days
          </td>
          <td align="left">
           1: 300
           <break>
           </break>
           2: 1000
          </td>
         </tr>
         <tr>
          <td align="left">
           Kedrion: Italy
          </td>
          <td align="left">
           HBV, HCV, HIV 1, B-19 parvovirus (HAV if required)
          </td>
          <td align="left">
           HCV
          </td>
          <td>
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           480 or fewer
          </td>
         </tr>
         <tr>
          <td align="left">
           National Bioproducts Institute: South Africa
          </td>
          <td align="left">
           HAV, HCV, HIV, B-19 parvovirus
          </td>
          <td align="left">
           HAV, HCV, HIV
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           1 and 216
          </td>
         </tr>
         <tr>
          <td align="left">
           CSL Biotherapies: Australia
          </td>
          <td align="left">
           HCV, HIV
          </td>
          <td align="left">
           HCV, HIV, B-19 parvovirus
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           480
          </td>
         </tr>
         <tr>
          <td align="left">
           Australian Red Cross Blood Service Fractionated at CSL Biotherapies
          </td>
          <td align="left">
           HCV, HIV, B-19 parvovirus (optional)
          </td>
          <td align="left">
           HCV, HIV, B-19 parvovirus
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           480/512
          </td>
         </tr>
         <tr>
          <td align="left">
           New Zealand Blood Service Fractionated at CSL Biotherapies
          </td>
          <td align="left">
           HCV, HIV, B-19 parvovirus (optional)
          </td>
          <td align="left">
           HCV, HIV, B-19 parvovirus
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           480/512
          </td>
         </tr>
         <tr>
          <td align="left">
           Hong Kong Red Cross BTS Fractionated at CSL Biotherapies
          </td>
          <td>
          </td>
          <td align="left">
           HCV, HIV
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           Blood Services Group, Singapore Fractionated at CSL Biotherapies
          </td>
          <td align="left">
           HCV, HIV
          </td>
          <td align="left">
           HCV, HIV
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           480/512
          </td>
         </tr>
         <tr>
          <td align="left">
           National Blood Centre of Malaysia Fractionated at CSL Biotherapies
          </td>
          <td align="left">
           HCV, HIV
          </td>
          <td align="left">
           HCV, HIV
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           480/512
          </td>
         </tr>
         <tr>
          <td align="left">
           Taiwan Blood Services Foundation Fractionated at CSL Biotherapies
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV, B-19 parvovirus
          </td>
          <td align="left">
           HCV, HIV (optional HBV, HAV, B-19 parvovirus)
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           480/512
          </td>
         </tr>
         <tr>
          <td align="left">
           GreenCross: South Korea
          </td>
          <td align="left">
           HAV, HCV
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV
          </td>
          <td align="left">
           45 days
          </td>
          <td align="left">
           &lt; 450
          </td>
         </tr>
         <tr>
          <td align="left">
           Japanese Red Cross: Japan
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           20
          </td>
         </tr>
         <tr>
          <td align="left">
           Kaketsuken: Japan
          </td>
          <td align="left">
           1: HBV, HCV, HIV-1 2: HAV, B-19 parvovirus
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           1: 50 2: 500
          </td>
         </tr>
         <tr>
          <td align="left">
           Benesis: Japan
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           HAV, HBV, HCV, HIV-1, B-19 parvovirus
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           50
          </td>
         </tr>
         <tr>
          <td align="left">
           Shanghai RAAS Blood Products: China
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           HBV, HCV, HIV-1
          </td>
          <td align="left">
           60 + days
          </td>
          <td align="left">
           48
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus-1; NAT, nucleic acid testing.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0020">
         <label>
          a
         </label>
         <p id="np0020">
          The viruses which are screened for by the company or fractionator using NAT at mini-pool stage. Numbers in brackets indicate the mini-pool sizes for each NAT type (if applicable).
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0025">
         <label>
          b
         </label>
         <p id="np0025">
          The viruses which are screened for by the company or fractionator using NAT at manufacturing pool stage.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0030">
         <label>
          c
         </label>
         <p id="np0030">
          The viruses which are screened for by the company or fractionator using NAT within the final product (if any).
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0035">
         <label>
          d
         </label>
         <p id="np0035">
          Length of time that plasma is retained between donation and processing stages for donor information gathering.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0040">
         <label>
          e
         </label>
         <p id="np0040">
          A mini-pool is a pool of donor samples, formed by directly pooling samples from individual donors or by pooling of samples from subpools. The numbers in the table indicate the number of samples present in the pool
          <xref ref-type="bibr" rid="bb0935">
           [187]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="p0055">
      It is recommended that the minimum evaluated sensitivity/specificity level of any assay used for blood donation screening should be 99.5% or higher
      <xref ref-type="bibr" rid="bb0080">
       [16]
      </xref>
      . However, not all assays fulfil these criteria as sensitivity/specificity levels vary according to assay type and type of micro-organism being tested for (see
      <xref ref-type="table" rid="t0005">
       Table 1
      </xref>
      for details). Therefore, the general advice is to screen donated blood to as high a standard as possible
      <xref ref-type="bibr" rid="bb0080">
       [16]
      </xref>
      .
     </p>
     <sec id="s0030">
      <label>
       4.1
      </label>
      <title>
       Blood donation screening: assays for key pathogens
      </title>
      <sec id="s0035">
       <label>
        4.1.1
       </label>
       <title>
        HIV, HBV and HCV testing
       </title>
       <p id="p0060">
        In the early stages of infection with HIV, HBV or HCV, viraemia occurs in the host's bloodstream at variable levels. Viral antigens may appear at the same time as DNA/RNA, but more often become detectable several weeks later. Specific antibodies are measurable 2 to 6 weeks after infection; the time between initial infection and the appearance of detectable parameters of infection (e.g. viral nucleic acid/antigens/antibodies) is known as the ‘window period’
        <xref ref-type="bibr" rid="bb0090">
         [18]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0095">
         [19]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0100">
         [20]
        </xref>
        .
       </p>
       <sec id="s0040">
        <label>
         4.1.1.1
        </label>
        <title>
         HIV
        </title>
        <p id="p0065">
         When screening blood for the presence of HIV-1/HIV-2, the use of a combined antigen/antibody assay is advised (combined HIV p24 Ag and anti-HIV-1 + anti-HIV-2 antibodies) as it allows earlier detection of infection. The performance of NAT testing is mandatory in many countries and further reduces the window period (from around 20 to 11 days)
         <xref ref-type="bibr" rid="bb0100">
          [20]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0105">
          [21]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0110">
          [22]
         </xref>
         .
        </p>
       </sec>
       <sec id="s0045">
        <label>
         4.1.1.2
        </label>
        <title>
         HBV
        </title>
        <p id="p0070">
         The majority of diagnostic laboratories focus on the detection of HBsAg, which is the first detectable serological marker of infection. However, there is a risk that the HBsAg concentration may decline to undetectable levels during the course of infection, yielding a false negative result
         <xref ref-type="bibr" rid="bb0115">
          [23]
         </xref>
         . Screening for antibodies to HBc is the most conservative approach for identifying potentially exposed donors, as this identifies all individuals who have ever immunologically experienced any type of HBV infection (either current, chronic or resolved) and who may experience viral reactivation during their lifetime (particularly under conditions of immunosuppression). However, assays to measure HBc antibodies are relatively non-specific and do not always correlate with the presence of HBV virus in plasma
         <xref ref-type="bibr" rid="bb0090">
          [18]
         </xref>
         . Also, we cannot exclude the possibility that donors who test positive for anti-HBc do not have pulsed recurrences of virus replication, resulting in the presence of low levels of HBV-DNA in plasma. For these reasons, national transfusion services do not always routinely screen donations for anti-HBc. NAT assays can be carried out, but their use is restricted by potentially low levels of viral DNA
         <xref ref-type="bibr" rid="bb0080">
          [16]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0090">
          [18]
         </xref>
         . The combined use of HBsAg screening tests and NAT assays has reduced the window period for detection of HBV infection from approximately 60 to 35.5 days
         <xref ref-type="bibr" rid="bb0100">
          [20]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0120">
          [24]
         </xref>
         . Mutant HBV strains (escape variants) should also be considered, as they may occasionally escape serological detection (although most can be detected by NAT assays)
         <xref ref-type="bibr" rid="bb0120">
          [24]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0125">
          [25]
         </xref>
         . These HBV-variants are rare, but therefore more likely to enter and contaminate the blood supply as they are more difficult to detect
         <xref ref-type="bibr" rid="bb0125">
          [25]
         </xref>
         . In summary, the screening of blood supplies for the presence of HBV is effective, but an optimal screening system has not yet been defined.
        </p>
       </sec>
       <sec id="s0050">
        <label>
         4.1.1.3
        </label>
        <title>
         HCV
        </title>
        <p id="p0075">
         HCV (both recent and chronic infection) can be detected by screening blood for the presence of both HCV antigen and HCV antibody (anti-HCV). Seroconversion occurs at approximately 6–8 weeks post-infection; however, steady improvements in screening technology (including the adoption of NAT assays) have reduced the window period to approximately 1–3 weeks
         <xref ref-type="bibr" rid="bb0100">
          [20]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0130">
          [26]
         </xref>
         . As with HIV, NAT assays are more useful for detecting early infection, although the issue of low viral RNA concentration persists
         <xref ref-type="bibr" rid="bb0135">
          [27]
         </xref>
         ,
         <xref ref-type="bibr" rid="bb0140">
          [28]
         </xref>
         .
        </p>
       </sec>
      </sec>
      <sec id="s0055">
       <label>
        4.1.2
       </label>
       <title>
        HTLV-1 testing
       </title>
       <p id="p0080">
        HTLV-1 and HTLV-2 are endemic in some regions, but very rare in others, and therefore screenings are conducted on a geographical or at-risk basis. The presence of virus is mostly inferred by the detection of virus-specific antibodies, using sensitive immunoassays
        <xref ref-type="bibr" rid="bb0080">
         [16]
        </xref>
        .
       </p>
      </sec>
      <sec id="s0060">
       <label>
        4.1.3
       </label>
       <title>
        Syphilis testing
       </title>
       <p id="p0085">
        In this instance, screening involves detection of non-specific, non-treponemal or specific treponemal antibodies. NAT assays are generally not used
        <xref ref-type="bibr" rid="bb0145">
         [29]
        </xref>
        . Specific antibody tests identify all individuals who have ever been exposed to this bacterium (and may continue to yield positive results for more than ten years following initial infection), while the non-specific tests (e.g. VDRL or cardiolipin tests) are primarily of use in identifying donors who may have an active infection. Since
        <italic>
         T. pallidum
        </italic>
        is heat-sensitive and cannot readily withstand extended storage at low temperatures, storage at 4 °C for more than three days is sufficient to render the pathogen non-infectious. However, blood components (e.g. platelets) that are stored at temperatures of around 20 °C do present a risk of
        <italic>
         T. pallidum
        </italic>
        persistence. Therefore screening for antibodies of this organism is recommended
        <xref ref-type="bibr" rid="bb0080">
         [16]
        </xref>
        .
       </p>
      </sec>
     </sec>
     <sec id="s0065">
      <label>
       4.2
      </label>
      <title>
       Testing for emerging viral pathogens
      </title>
      <sec id="s0070">
       <label>
        4.2.1
       </label>
       <title>
        West Nile virus
       </title>
       <p id="p0090">
        Blood can be screened for further pathogens as appropriate, according to geographical location, seasonal activity of the vector and also patient risk factors. A current viral pathogen of interest is the mosquito-borne flavivirus West Nile virus (WNV), which was confirmed to have been transmitted via transfusion in 2002
        <xref ref-type="bibr" rid="bb0150">
         [30]
        </xref>
        . An immediate screening policy was put in place in the USA in order to reduce the risk of further transmission. This policy included deferral of any individual displaying symptoms of infection, quarantine of plasma collected during periods of high mosquito activity (when WNV is most prevalent) and the rapid development/use of WNV-specific NAT and serological assays. These measures were highly effective and caused a significant reduction in the number of confirmed cases of WNV transfusion-related transmission. However, WNV outbreaks still occur within the Americas, indicating a potential need for seasonal blood screening for WNV
        <xref ref-type="bibr" rid="bb0155">
         [31]
        </xref>
        . WNV outbreaks have also occurred in Europe (including Italy and Greece), prompting the implementation of seasonal blood screening procedures in the affected regions of those countries
        <xref ref-type="bibr" rid="bb0160">
         [32]
        </xref>
        .
       </p>
      </sec>
      <sec id="s0075">
       <label>
        4.2.2
       </label>
       <title>
        Chikungunya virus
       </title>
       <p id="p0095">
        This is another mosquito-borne pathogen that could potentially pose a risk to transfusion safety, although to date reports of transfusion-related transmission of this virus are rare
        <xref ref-type="bibr" rid="bb0165">
         [33]
        </xref>
        . A mutated form of the Chikungunya virus has been responsible for several epidemics in the past decade, spreading to the Reunion Islands in the Indian Ocean (2005), Italy (2007) and the Caribbean area (2012/2013)
        <xref ref-type="bibr" rid="bb0170">
         [34]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0175">
         [35]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0180">
         [36]
        </xref>
        . The virus may be detected in blood donors by NAT, which will help to reduce the level of transmission risk
        <xref ref-type="bibr" rid="bb0175">
         [35]
        </xref>
        .
       </p>
      </sec>
      <sec id="s0080">
       <label>
        4.2.3
       </label>
       <title>
        Parvovirus B19
       </title>
       <p id="p0100">
        There is also concern about the possibility of parvovirus B19 in the blood supply. B19 is prevalent worldwide, with seroprevalence in blood donors varying from between 0.2–1.3% in the USA, Europe and Africa and 25–40% in Asia
        <xref ref-type="bibr" rid="bb0185">
         [37]
        </xref>
        . The risk of parvovirus transmission is higher when units of blood are pooled (e.g. to create batches of clotting factor concentrates, albumin etc.) and so individuals with bleeding disorders are at a higher risk of infection. B19 DNA was detected in 26% of clotting factor concentrates in a recent German study
        <xref ref-type="bibr" rid="bb0190">
         [38]
        </xref>
        , and another study found that populations receiving blood-derived products were 1.7 times more likely to display antibodies to B19 than populations who had not received blood products
        <xref ref-type="bibr" rid="bb0195">
         [39]
        </xref>
        . B19 lacks a lipid envelope, which renders it highly resistant to some methods of pathogen inactivation
        <xref ref-type="bibr" rid="bb0200">
         [40]
        </xref>
        . Screening of blood donations for B19 DNA is not currently routine, but many manufacturers only process plasma that has been screened for the absence of B19 DNA in order to reduce the risk of transmission
        <xref ref-type="bibr" rid="bb0205">
         [41]
        </xref>
        . Given the prevalence of B19 in different populations, it is difficult to define the residual TTI risk of this virus. However, it is clear that a transmission risk does exist.
       </p>
      </sec>
      <sec id="s0085">
       <label>
        4.2.4
       </label>
       <title>
        Hepatitis E virus
       </title>
       <p id="p0105">
        The potential presence of hepatitis E virus (HEV) in blood or blood-derived products is relevant. Currently there seems to be a discrepancy between the number of HEV-RNA positive blood donations in Europe (ranging from 1 in 1240 in Germany to 1 in 1761 donations in the Netherlands)
        <xref ref-type="bibr" rid="bb0210">
         [42]
        </xref>
        , and the low number of confirmed cases of hepatitis E in blood transfusion recipients (one confirmed case in the UK [2006], one in France [2007] and two in Germany [2014])
        <xref ref-type="bibr" rid="bb0215">
         [43]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0220">
         [44]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0225">
         [45]
        </xref>
        . This indicates that the subject of HEV infectivity and pathogenicity needs to be investigated further
        <xref ref-type="bibr" rid="bb0230">
         [46]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0235">
         [47]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0240">
         [48]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0245">
         [49]
        </xref>
        . There is also a debate over the necessity of introducing screening blood for the presence of HEV; the virus is not currently screened for in the UK and other European countries, although one study of English donors found HEV to be widespread (1 in 2848 donations) within the donor population
        <xref ref-type="bibr" rid="bb0250">
         [50]
        </xref>
        . Since infection with this virus can be harmful to immunocompromised individuals, the potential need for introducing HEV screening should be considered
        <xref ref-type="bibr" rid="bb0210">
         [42]
        </xref>
        .
       </p>
       <p id="p0110">
        The residual risk for TTI of HBV, HCV, HIV and HEV in selected countries is given in
        <xref ref-type="table" rid="t0025">
         Table 5
        </xref>
        .
        <table-wrap id="t0025" position="float">
         <label>
          Table 5
         </label>
         <caption>
          <p>
           Approximate residual risk of HBV, HCV, HIV and HEV TTI in selected countries.
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th align="left">
             Virus
            </th>
            <th align="left">
             Country
            </th>
            <th align="left">
             Residual risk, or prevalence in blood donations (dependent on testing) per 100,000
            </th>
            <th align="left">
             Reference
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td align="left" rowspan="7">
             HBV
            </td>
            <td align="center">
             Congo-Kinshasa
            </td>
            <td align="center">
             390
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0940">
              [188]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Brazil
            </td>
            <td align="center">
             289
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0945">
              [189]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             USA
            </td>
            <td align="center">
             5.9–7.5
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0290">
              [58]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             England/North Wales
            </td>
            <td align="center">
             &lt; 3.7
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0950">
              [190]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Australia
            </td>
            <td align="center">
             2
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0955">
              [191]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Germany
            </td>
            <td align="center">
             0.4
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0960">
              [192]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Portugal
            </td>
            <td align="center">
             0.2
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0965">
              [193]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="3">
             HCV
            </td>
            <td align="center">
             Brazil
            </td>
            <td align="center">
             191
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0945">
              [189]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Germany
            </td>
            <td align="center">
             0.9
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0960">
              [192]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Portugal
            </td>
            <td align="center">
             0.03
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0965">
              [193]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="2">
             HIV
            </td>
            <td align="center">
             Congo-Kinshasa
            </td>
            <td align="center">
             22
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0940">
              [188]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Germany
            </td>
            <td align="center">
             0.9–2.4
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0105">
              [21]
             </xref>
             ,
             <xref ref-type="bibr" rid="bb0960">
              [192]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="6">
             HEV
            </td>
            <td align="center">
             Germany
            </td>
            <td align="center">
             81
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0210">
              [42]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Netherlands
            </td>
            <td align="center">
             57
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0210">
              [42]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             England
            </td>
            <td align="center">
             35
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0250">
              [50]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Scotland
            </td>
            <td align="center">
             6.9
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0970">
              [194]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             Portugal
            </td>
            <td align="center">
             0.6
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0965">
              [193]
             </xref>
            </td>
           </tr>
           <tr>
            <td align="center">
             USA
            </td>
            <td align="center">
             &lt; 2
            </td>
            <td align="center">
             <xref ref-type="bibr" rid="bb0975">
              [195]
             </xref>
            </td>
           </tr>
          </tbody>
         </table>
         <table-wrap-foot>
          <fn>
           <p>
            HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus-1; TTI, transfusion-transmitted infection.
           </p>
          </fn>
         </table-wrap-foot>
        </table-wrap>
       </p>
      </sec>
     </sec>
     <sec id="s0090">
      <label>
       4.3
      </label>
      <title>
       Prions
      </title>
      <p id="p0115">
       Despite recent advances in methods for the detection of prions, no single method has been developed as a screening test for blood, although several methods in animal models show great promise
       <xref ref-type="bibr" rid="bb0255">
        [51]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0260">
        [52]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0265">
        [53]
       </xref>
       . In humans, a protocol for the evaluation of a blood-based test for its suitability in the diagnosis of variant Creutzfeldt–Jakob disease (vCJD) has been established, but no test yet appears to satisfy the requirements of sensitivity and specificity
       <xref ref-type="bibr" rid="bb0270">
        [54]
       </xref>
       . The only report so far of a blood-based diagnostic test for vCJD claimed an assay sensitivity of 71.4% and a specificity of 100% in symptomatic patients and its potential applicability as a screening test to detect asymptomatic vCJD infection has recently been investigated
       <xref ref-type="bibr" rid="bb0275">
        [55]
       </xref>
       . There is currently no strategy for confirming a positive screening result, although the protein misfolding cyclical amplification technique has recently been shown to yield positive results in buffy coat/white blood cell samples from a small number of patients with vCJD
       <xref ref-type="bibr" rid="bb0280">
        [56]
       </xref>
       .
      </p>
     </sec>
     <sec id="s0095">
      <label>
       4.4
      </label>
      <title>
       Interpretation of test results and practicalities of screening
      </title>
      <sec id="s0100">
       <label>
        4.4.1
       </label>
       <title>
        Assay specificity and sensitivity
       </title>
       <p id="p0120">
        Extensive use of blood donor selection and testing does not always guarantee a safe product. If the test is insufficiently sensitive, then false negatives may occur. Alternatively, tests which are not sufficiently specific (e.g. anti-HBc assay for HBV) may cause false positive results, leading to an unnecessary decrease in the number of clotting products available
        <xref ref-type="bibr" rid="bb0080">
         [16]
        </xref>
        . Torque Tenovirus (TTV) is an example where testing specificity has been an issue, as this virus exists in various divergent forms (23 distinct genotypes have been identified thus far)
        <xref ref-type="bibr" rid="bb0285">
         [57]
        </xref>
        . Since TTV is often detected in healthy individuals and is not associated with any particular disease, routine screening for this virus is not considered to be necessary; even a test with excellent sensitivity/specificity would not contribute to increase the level of safety of blood/plasma-derived products with regard to TTV.
       </p>
       <p id="p0125">
        Insufficient assay sensitivity remains a rare but potential problem when blood donations are screened during the window period of initial HBV, HCV or HIV infection. An increase in testing sensitivity threshold is needed to prevent HBV transmission via blood/plasma-derived products and by blood transfusion, as extremely low concentrations of HBV (e.g. 1.6 copies/ml) is capable of viral transmission (see above section on anti-HBc positive patients)
        <xref ref-type="bibr" rid="bb0290">
         [58]
        </xref>
        . In the case of HIV and HCV, even NAT testing may not always be sufficient to ensure sufficiently high levels of safety as virus transmission has previously occurred after transfusion of blood with undetectable levels of viraemia
        <xref ref-type="bibr" rid="bb0295">
         [59]
        </xref>
        .
       </p>
       <p id="p0130">
        Recent reports have highlighted concerns about the inability of NAT assays to detect different variants of HIV. There have been at least four cases in which the presence of HIV-1 RNA was undetected by NAT assay screening, potentially putting transfusion recipients at risk
        <xref ref-type="bibr" rid="bb0105">
         [21]
        </xref>
        . Two of these false-negative results occurred due to genetic mutation in the viral RNA regions targeted by NAT assay primers (although in the majority of cases serology yielded a positive result)
        <xref ref-type="bibr" rid="bb0300">
         [60]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0305">
         [61]
        </xref>
        . False-negative results can be avoided by designing NAT assays that target a minimum of two amplification regions; such testing will be mandatory in Germany from 2015
        <xref ref-type="bibr" rid="bb0105">
         [21]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0310">
         [62]
        </xref>
        . It is hoped that as the sensitivity and specificity of NAT tests continue to improve, cases of undetected infection may become less of an issue in the future.
       </p>
      </sec>
      <sec id="s0105">
       <label>
        4.4.2
       </label>
       <title>
        The need for multiple methods of screening
       </title>
       <p id="p0135">
        A recent report suggests that it is not necessary to carry out serological screening for multiple HBV markers, and that NAT based screening is preferred
        <xref ref-type="bibr" rid="bb0290">
         [58]
        </xref>
        . However, there is a risk that the practice of relying upon a single method of screening may lead to a higher incidence of false-negative results. In one case of transfusion-associated parvovirus B19 transmission, donated blood was screened for the presence of B19 antigen and deemed to be safe since no antigen was detected. Since the recipient subsequently developed B19 infection, the donation was re-analysed and found to contain B19 DNA
        <xref ref-type="bibr" rid="bb0315">
         [63]
        </xref>
        . Reports such as this support the argument for multiple parameter testing.
       </p>
       <p id="p0140">
        The localisation of pathogens within blood may also influence ease of detection. For example, WNV is present at 10-fold higher levels in whole blood than in plasma in viraemic seropositive donors. The situation is reversed in viraemic seronegative donors, who display higher WNV levels (4-fold) in plasma than in whole blood
        <xref ref-type="bibr" rid="bb0320">
         [64]
        </xref>
        . Also, cell-associated viruses such as CMV and HTLV-1 are less frequently transmitted with the use of leukoreduced products
        <xref ref-type="bibr" rid="bb0325">
         [65]
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0330">
         [66]
        </xref>
        , indicating that these viruses are less likely to be found in blood/plasma-derived products. The minimum infective dose (MID: the lowest number of pathogenic particles required to successfully infect a host) of a particular pathogen is more likely to be reached in whole blood or blood-derived components, making the use of plasma-derived or recombinant clotting factors the safest option.
       </p>
      </sec>
      <sec id="s0110">
       <label>
        4.4.3
       </label>
       <title>
        Infective dose
       </title>
       <p id="p0145">
        To date, studies attempting to measure human MID values have generally determined the viral concentration needed to infect a particular percentage of the exposed population (e.g. 50%). This value (the human infective dose for 50% of the population) is referred to as HID
        <sub>
         50
        </sub>
        and is often described as the human MID
        <xref ref-type="bibr" rid="bb0335">
         [67]
        </xref>
        . The HID
        <sub>
         50
        </sub>
        value varies greatly between pathogens (even if they are physically similar)
        <xref ref-type="bibr" rid="bb0340">
         [68]
        </xref>
        and also varies depending upon the immune status of the recipient, as immunocompromised individuals, neonates and the elderly are at greater risk of infection than healthy individuals
        <xref ref-type="bibr" rid="bb0335">
         [67]
        </xref>
        . When this finding and the prevalence of immunocompromised patients receiving blood products are both taken into account, it implies a need for screening tests to have the highest sensitivity possible.
       </p>
      </sec>
      <sec id="s0115">
       <label>
        4.4.4
       </label>
       <title>
        Patient characteristics
       </title>
       <p id="p0150">
        The impact of transmission on morbidity and mortality is dependent on patient characteristics. For example, although the vast majority of cases of CMV infection are not clinically important, influencing factors such as genetic predisposition, malnutrition and pre-existing infection can lead to the development of severe disease
        <xref ref-type="bibr" rid="bb0345">
         [69]
        </xref>
        . National screening programmes do not currently screen for CMV as standard, but NAT assays exist and may be carried out if required, e.g. if blood is specifically intended for vulnerable recipients, such as pregnant women or transplant patients
        <xref ref-type="bibr" rid="bb0350">
         [70]
        </xref>
        . It is the opinion of the authors that both serological assays and NAT tests should be used in order to reach the highest level of safety possible, particularly when in the case of immunosuppressed patients.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="s0120">
     <label>
      5
     </label>
     <title>
      Other means of reducing and managing pathogen risk
     </title>
     <p id="p0155">
      As well as blood donation testing, a range of other measures are used to increase the pathogen safety of blood- and plasma-derived products. These include donor selection and screening, recipient vaccination and the use of blood product purification/inactivation methods. The choice of inactivation method also impacts upon the level of risk.
     </p>
     <sec id="s0125">
      <label>
       5.1
      </label>
      <title>
       Selection and screening of donors
      </title>
      <p id="p0160">
       Questionnaires are often used to attempt to assess donors' health status and their potential exposure to various risks. Donors can be accepted or rejected on the basis of these answered questionnaires, or alternatively their blood may be put through additional screening tests as appropriate
       <xref ref-type="bibr" rid="bb0080">
        [16]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0155">
        [31]
       </xref>
       .
      </p>
     </sec>
     <sec id="s0130">
      <label>
       5.2
      </label>
      <title>
       Vaccination
      </title>
      <p id="p0165">
       Patients with bleeding disorders should be vaccinated against HAV and HBV. European studies have reported that universal HBV vaccination of blood donors could be cost-effective as this measure would reduce the risk of HBV transmission in general and might even remove the necessity for general HBV NAT testing; however, this would not reduce the risk posed by HBV escape variants (as described earlier)
       <xref ref-type="bibr" rid="bb0355">
        [71]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0360">
        [72]
       </xref>
       .
      </p>
     </sec>
     <sec id="s0135">
      <label>
       5.3
      </label>
      <title>
       Purification and inactivation techniques
      </title>
      <p id="p0170">
       Blood/plasma-derived products typically undergo various procedures designed to reduce the pathogen level, although these procedures are not effective against all pathogens. Plasma donations undergo quarantine (approximately 4–6 months) prior to fractionation and when the donor is again screened negative FFP can then be subjected to chromatographic fractionation, solvent-detergent treatment, nanofiltration and/or heat inactivation
       <xref ref-type="bibr" rid="bb0365">
        [73]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0370">
        [74]
       </xref>
       . Prolongation of product storage time can be effective in reducing the infectivity of temperature-sensitive pathogens (such as
       <italic>
        T. pallidum
       </italic>
       ). Production of recombinant products also follows strict protocols to remove and inactivate any viruses that might be present, even though the risk of viral presence is minimal.
      </p>
      <p id="p0175">
       Although current purification/inactivation techniques (such as solvent-detergent treatment, nanofiltration and heat activation) do reduce the risk of pathogen transmission, they are not always sufficient to render blood/plasma-derived products safe
       <xref ref-type="bibr" rid="bb0375">
        [75]
       </xref>
       . Small non-enveloped viruses (e.g. HAV, B19 and picornavirus) are often highly resistant to inactivation procedures and may still be infectious in some plasma-derived concentrates
       <xref ref-type="bibr" rid="bb0375">
        [75]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0380">
        [76]
       </xref>
       .
      </p>
      <p id="p0180">
       The presence of prions is also a concern. Attempts to remove prions from plasma-derived products have involved several techniques, including ion-exchange chromatography and nanofiltration
       <xref ref-type="bibr" rid="bb0385">
        [77]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0390">
        [78]
       </xref>
       . Several problems exist with these approaches, in particular the use of exogenous “spikes” derived from prion-infected brain homogenates to measure prion clearance, which may result in an overestimation of the amount of prion removal, and the methods used for the estimation of the reduction in prion load, which ideally should involve bioassay to measure infectivity
       <xref ref-type="bibr" rid="bb0395">
        [79]
       </xref>
       . Further developments in this field are required to address these issues.
      </p>
      <p id="p0185">
       A recently proposed approach for the inactivation of infectious agents in blood is whole-blood treatment with ultraviolet (UV) light in combination with a photosensitiser such as riboflavin or amotosalen
       <xref ref-type="bibr" rid="bb0400">
        [80]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0405">
        [81]
       </xref>
       . The main disadvantage of this approach is that UV treatment has been linked to the formation of neoantigens, which may be generated via modification of the surface antigens of platelets. The presence of neoantigens may provoke a recipient immune response during transfusion of UV-treated platelets, causing them to be rapidly cleared from the circulation
       <xref ref-type="bibr" rid="bb0405">
        [81]
       </xref>
       . While this approach to pathogen inactivation is currently used for platelets and is effective, it needs further refinement for the inactivation of whole blood
       <xref ref-type="bibr" rid="bb0405">
        [81]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0410">
        [82]
       </xref>
       .
      </p>
     </sec>
     <sec id="s0140">
      <label>
       5.4
      </label>
      <title>
       Product choice
      </title>
      <p id="p0190">
       The WFH strongly recommends the use of plasma-derived or recombinant products in preference to cryoprecipitate or fresh frozen plasma, as the infectious load of any infectious human pathogen is lower in plasma-derived products than in cryoprecipitate, and even lower in recombinant products
       <xref ref-type="bibr" rid="bb0010">
        [2]
       </xref>
       .In some European countries, recombinant products have almost completely replaced plasma-derived products
       <xref ref-type="bibr" rid="bb0060">
        [12]
       </xref>
       . The use of recombinant products, which have been manufactured and formulated with minimal addition of human/animal-derived materials, greatly reduces the risk of recipient exposure to plasma-derived infectious agents and after they have undergone virus removal/inactivation processes, recombinant products can be considered to be as safe as currently possible
       <xref ref-type="bibr" rid="bb0415">
        [83]
       </xref>
       . Despite these benefits, the use of recombinant products may be limited by higher costs and perceived problems of inhibitor formation
       <xref ref-type="bibr" rid="bb0415">
        [83]
       </xref>
       . For indications where no recombinant factor concentrates are available, the use of inactivated plasma-derived concentrates is safer than fresh frozen plasma and will reduce the risk of other adverse effects such as hypervolemia, transfusion-related lung injury (TRALI) and hypersensitivity
       <xref ref-type="bibr" rid="bb0420">
        [84]
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec id="s0145">
     <label>
      6
     </label>
     <title>
      Barriers to a minimal risk approach
     </title>
     <p id="p0195">
      A minimal risk approach would ensure that patients receive effective treatment with the lowest possible risk, but this is difficult to achieve in practical terms. Regulatory needs in different European countries are usually based on recommendations from the medical community, so in order to achieve minimal risk, it would be ideal for these regulations to be standardised and mandatory in all countries. Directives issued by the European Union Commission describe the regulatory requirements for the safety of whole blood and plasma, stating that “all precautionary measures during their collection, processing, distribution and use need to be taken making appropriate use of scientific progress in the detection and inactivation and elimination of transfusion transmissible pathogenic agents”
      <xref ref-type="bibr" rid="bb0425">
       [85]
      </xref>
      . However, the relative safety of different screening tests, products and processing methods is not discussed and so individual countries may adopt different approaches towards minimising risk. Although recombinant products are associated with the highest level of pathogen safety, higher costs for development and production may make them too expensive for some healthcare systems
      <xref ref-type="bibr" rid="bb0430">
       [86]
      </xref>
      . Inhibitor formation also remains an important element of concern with both plasma-derived and recombinant products, particularly with regard to FVIII in haemophilia A
      <xref ref-type="bibr" rid="bb0435">
       [87]
      </xref>
      . The risk of inhibitor formation was shown to be greater with recombinant versus plasma-derived factor VIII concentrates in some cohort studies
      <xref ref-type="bibr" rid="bb0440">
       [88]
      </xref>
      , but similar in others
      <xref ref-type="bibr" rid="bb0445">
       [89]
      </xref>
      .
     </p>
     <p id="p0200">
      In light of these considerations (availability, adverse reactions and cost), it appears that the issue of pathogen safety of blood/plasma-derived products is highly important but may not be the limiting factor with respect to overall patient safety. The benefits of treatment with a hypothetically ‘unsafe’ plasma-derived product may outweigh the risk of a negative outcome (e.g. bleeding, inhibitor formation), although we suggest that it may be clinically simpler to deal with inhibitor formation than to combat an infection from an unknown or untreatable pathogen.
     </p>
    </sec>
    <sec id="s0150">
     <label>
      7
     </label>
     <title>
      Current knowledge gaps and areas of unmet need
     </title>
     <p id="p0205">
      There are still significant knowledge gaps and areas of unmet need with respect to the pathogen safety of blood/plasma-derived and recombinant products. The incidence of HBV, HCV and HIV TTI has fallen to near or below 1 per million transfused units in the industrialised world, indicating that current donor selection and blood screening strategies have had a positive impact on blood safety
      <xref ref-type="bibr" rid="bb0070">
       [14]
      </xref>
      . However, it is clear that screening both donors and donated blood cannot exclude all known pathogens or eliminate all risks from emerging pathogens
      <xref ref-type="bibr" rid="bb0315">
       [63]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0450">
       [90]
      </xref>
      . Historical precedent indicates that the blood supply is always vulnerable to contamination by hitherto non-prevalent/unknown pathogens, and that this risk cannot be accurately gauged
      <xref ref-type="bibr" rid="bb0455">
       [91]
      </xref>
      . As we identify new infectious agents of concern and develop new tests for their detection, it will also be necessary to clearly define the infectious dose range for each agent and use appropriately sensitive tests for their identification. For example, in suspected cases of vCJD infection, considerable challenges remain in the development of screening and confirmatory tests that have sufficient sensitivity and specificity to be of use in both a clinical setting and within blood banks
      <xref ref-type="bibr" rid="bb0460">
       [92]
      </xref>
      .
     </p>
     <p id="p0210">
      Surveillance of people with haemophilia is required to monitor pathogen safety issues related to blood and plasma products. The European Haemophilia Safety Surveillance system (EUHASS), which began in 2008, is a pharmacovigilance programme which spans 25 European countries and is designed to detect, monitor and investigate adverse drug reactions. Reports of adverse events (such as acute/allergic events, TTIs and inhibitors) are submitted to EUHASS by participating centres and cumulative patient and clotting factor data are recorded annually
      <xref ref-type="bibr" rid="bb0465">
       [93]
      </xref>
      .
     </p>
     <p id="p0215">
      A formal coordinated risk-assessment and management action plan, in addition to a task force, should be developed to respond quickly to any emerging infections. Such a plan should include long-term storage of samples from produced batches (for retesting in the case of outbreaks with known or recently emerged infectious agents) and guidance on responsibility for developing/performing tests for emerging pathogens (industry vs. regulatory agencies). Guidance on approaching patients who have potentially been infected and surveillance strategies for patients at high risk would also be beneficial.
     </p>
    </sec>
    <sec id="s0155">
     <label>
      8
     </label>
     <title>
      Conclusions
     </title>
     <p id="p0220">
      The majority of evidence indicates that the concept of clinical safety of blood/plasma derivatives does not necessarily correspond to the concept of pathogen safety; blood can only be classed as microbially safe in reference to the infectious agents that are known and have been screened for. Establishing whether the presence of undetected microbes in the blood is clinically relevant will require further long-term, detailed studies. It should also be noted that even though the risk of transmission of key detectable viruses (such as HIV, HBV and HCV) via transfusion has fallen significantly, transmission does still occur.
     </p>
     <p id="p0225">
      In general, balancing safety, efficacy and practicalities is a difficult goal to achieve — patient safety is typically the key driver, but striving for near-complete safety at the expense of the patient's health or quality of life may not be the best course of action for patients or clinicians. The lack of a cohesive international strategy for blood donation and screening is a pressing concern that needs to be addressed. Furthermore, a formal coordinated continuous risk-assessment and management action plan needs to be developed to deal with the constant potential risk of emerging infections. Establishing an international registry (or harmonising data collection in National Registries) and dedicated task force may help to identify newly emerging pathogens more rapidly than in the past and to further improve pathogen safety of blood/plasma-derived products and the blood supply in general.
     </p>
    </sec>
    <sec id="s0160">
     <title>
      Practice points
     </title>
     <p id="p0230">
      <list id="l0005" list-type="simple">
       <list-item id="u0005">
        <label>
         •
        </label>
        <p id="p0235">
         The use of blood/plasma-derived products for the treatment of bleeding disorders carries a risk of pathogen transmission.
        </p>
       </list-item>
       <list-item id="u0010">
        <label>
         •
        </label>
        <p id="p0240">
         Blood donations are screened for key pathogens such as HBV, HCV, HIV and the causative agent of syphilis, but other screening tests should be conducted as required according to geographical location and patient risk factors.
        </p>
       </list-item>
       <list-item id="u0015">
        <label>
         •
        </label>
        <p id="p0245">
         Screening tests for pathogens may lack sensitivity/specificity and so false negatives may occur, resulting in a residual pathogen risk to patients.
        </p>
       </list-item>
       <list-item id="u0020">
        <label>
         •
        </label>
        <p id="p0250">
         In terms of pathogen safety, recombinant products (products which have had minimal exposure to blood/plasma-derived proteins) are considered to pose the lowest level of risk to patients.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="s0165">
     <title>
      Research agenda
     </title>
     <p id="p0255">
      <list id="l0010" list-type="simple">
       <list-item id="u0025">
        <label>
         •
        </label>
        <p id="p0260">
         Regional and international rates of transfusion-transmitted infection for key pathogens and emerging pathogens
        </p>
       </list-item>
       <list-item id="u0030">
        <label>
         •
        </label>
        <p id="p0265">
         Safety and efficacy of blood/plasma-derived products and recombinant products for treatment of bleeding disorders.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="s0170">
     <title>
      Conflict of interest statement
     </title>
     <p id="p0270">
      A.T. has received grants and personal fees from Bayer, grants and personal fees from Baxter, grants and personal fees from Biotest, grants and personal fees from CSL Behring, grants and personal fees from Novo Nordisk, grants and personal fees from Pfizer, and grants and personal fees from Octapharma, during the conduct of the study.
     </p>
     <p id="p0275">
      C.F.P. has received grants as bureau speaker, consultant, or advisor, from Gilead, Merck Sharp and Dohme, Roche, Pfizer, Abbott, Bristol-Myers Squibb, VIIV, and Boehringer-Ingelheim. None of these personal activities is in conflict with the opinions he expressed in this manuscript.
     </p>
     <p id="p0280">
      D.N. has received honoraria for conferences from Pfizer, Roche Pharma, Roche Diagnostics, Abbott, MSD, and Astellas.
     </p>
     <p id="p0285">
      G.D.M. has disclosed the following financial relationships — speaker or a member of a speaker bureau for: Boehringer-Ingelheim, Sanofi-Aventis, Bayer, Novo Nordisk, Pfizer,
     </p>
     <p id="p0290">
      Biotest, and Grifols. Consultant or ad hoc speaker/consultant for: Boehringer-Ingelheim, Eli-Lilly, Sanofi-Aventis, Bayer, CSL Behring, Novo Nordisk, Pfizer, Biotest, and Grifols.
     </p>
     <p id="p0295">
      J.W.I. has received personal fees from Piramal and grants from the Department of Health, UK, outside the submitted work.
     </p>
     <p id="p0300">
      L.G. reports no potential conflicts of interest.
     </p>
     <p id="p0305">
      M.C. has received research grants, lecture fees, and honoraria for consultancy from Baxter, Bayer, and Pfizer.
     </p>
    </sec>
    <sec id="s0175">
     <title>
      Role of funding source
     </title>
     <p id="p0310">
      Funding for medical writing assistance and two author meetings were provided by
      <funding-source id="gts0005">
       Pfizer
      </funding-source>
      . Pfizer had no editorial influence regarding the contents of this manuscript and did not comment on the outline or any drafts prior to journal submission.
     </p>
    </sec>
    <back>
     <ref-list id="bi0005">
      <title>
       References
      </title>
      <ref id="bb0005">
       <label>
        1
       </label>
       <element-citation id="rf0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paessler
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Walker
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of the viral hemorrhagic fevers
        </article-title>
        <source>
         Annu Rev Pathol
        </source>
        <volume>
         8
        </volume>
        <year>
         2013
        </year>
        <fpage>
         411
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="pmid">
         23121052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0010">
       <label>
        2
       </label>
       <element-citation id="rf0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Srivastava
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Brewer
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Mauser-Bunschoten
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Key
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kitchen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Llinas
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guidelines for the management of hemophilia
        </article-title>
        <source>
         Haemophilia
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         e1
        </fpage>
        <lpage>
         e47
        </lpage>
        <pub-id pub-id-type="pmid">
         22776238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0015">
       <label>
        3
       </label>
       <element-citation id="rf0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benjamin
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           McLaughlin
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Plasma components: properties, differences, and uses
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         52
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         2012
        </year>
        <fpage>
         9S
        </fpage>
        <lpage>
         19S
        </lpage>
        <pub-id pub-id-type="pmid">
         22578375
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0020">
       <label>
        4
       </label>
       <element-citation id="rf0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stonebraker
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Brooker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Amand
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Farrugia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Srivastava
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A study of reported factor VIII use around the world
        </article-title>
        <source>
         Haemophilia
        </source>
        <volume>
         16
        </volume>
        <year>
         2010
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         19845774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0025">
       <label>
        5
       </label>
       <element-citation id="rf0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plug
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Van Der Bom
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mauser-Bunschoten
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           De Goede-Bolder
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Heijnen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study
        </article-title>
        <source>
         J Thromb Haemost
        </source>
        <volume>
         4
        </volume>
        <year>
         2006
        </year>
        <fpage>
         510
        </fpage>
        <lpage>
         516
        </lpage>
        <pub-id pub-id-type="pmid">
         16460432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0030">
       <label>
        6
       </label>
       <element-citation id="rf0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Franchini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mannucci
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Past, present and future of hemophilia: a narrative review
        </article-title>
        <source>
         Orphanet J Rare Dis
        </source>
        <volume>
         7
        </volume>
        <year>
         2012
        </year>
        <fpage>
         24
        </fpage>
        <pub-id pub-id-type="pmid">
         22551339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0035">
       <label>
        7
       </label>
       <element-citation id="rf0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Franchini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tagliaferri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mannucci
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The management of hemophilia in elderly patients
        </article-title>
        <source>
         Clin Interv Aging
        </source>
        <volume>
         2
        </volume>
        <year>
         2007
        </year>
        <fpage>
         361
        </fpage>
        <lpage>
         368
        </lpage>
        <pub-id pub-id-type="pmid">
         18044186
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0040">
       <label>
        8
       </label>
       <element-citation id="rf0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trimble
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Parker
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Soucie
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Reyes
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessing emerging infectious threats to blood safety for the blood disorders community
        </article-title>
        <source>
         Am J Prev Med
        </source>
        <volume>
         38
        </volume>
        <year>
         2010
        </year>
        <fpage>
         S468
        </fpage>
        <lpage>
         S474
        </lpage>
        <pub-id pub-id-type="pmid">
         20331945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0045">
       <label>
        9
       </label>
       <element-citation id="rf0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hardwick
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Blood processing
        </article-title>
        <source>
         ISBT Sci Ser
        </source>
        <volume>
         3
        </volume>
        <year>
         2008
        </year>
        <fpage>
         148
        </fpage>
        <lpage>
         176
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0050">
       <label>
        10
       </label>
       <element-citation id="rf0050" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         WHO Technical Report: Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir8000" xlink:href="http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf">
         http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf
        </ext-link>
        <year>
         2004
        </year>
       </element-citation>
      </ref>
      <ref id="bb0055">
       <label>
        11
       </label>
       <element-citation id="rf0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Di Minno
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Canaro
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ironside
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Navarro
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Perno
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Tiede
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice
        </article-title>
        <source>
         Haematologica
        </source>
        <volume>
         98
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1495
        </fpage>
        <lpage>
         1498
        </lpage>
        <pub-id pub-id-type="pmid">
         24091928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0060">
       <label>
        12
       </label>
       <element-citation id="rf0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gringeri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factor VIII safety: plasma-derived versus recombinant products
        </article-title>
        <source>
         Blood Transfus
        </source>
        <volume>
         9
        </volume>
        <year>
         2011
        </year>
        <fpage>
         366
        </fpage>
        <lpage>
         370
        </lpage>
        <pub-id pub-id-type="pmid">
         21627925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0065">
       <label>
        13
       </label>
       <element-citation id="rf0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Di Minno
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Canaro
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ironside
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Navarro
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Perno
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Tiede
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats
        </article-title>
        <source>
         Semin Thromb Hemost
        </source>
        <volume>
         39
        </volume>
        <year>
         2013
        </year>
        <fpage>
         973
        </fpage>
       </element-citation>
      </ref>
      <ref id="bb0070">
       <label>
        14
       </label>
       <element-citation id="rf0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2375
        </fpage>
        <lpage>
         2383
        </lpage>
        <pub-id pub-id-type="pmid">
         23926897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0075">
       <label>
        15
       </label>
       <element-citation id="rf0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hourfar
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Jork
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schottstedt
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Weber-Schehl
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Brixner
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Busch
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         48
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1558
        </fpage>
        <lpage>
         1566
        </lpage>
        <pub-id pub-id-type="pmid">
         18466173
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0080">
       <label>
        16
       </label>
       <element-citation id="rf0080" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Recommendations: Screening Donated Blood for Transfusion-Transmissible Infections
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0145" xlink:href="http://www.who.int/bloodsafety/ScreeningTTI.pdf">
         http://www.who.int/bloodsafety/ScreeningTTI.pdf
        </ext-link>
        <year>
         2009
        </year>
       </element-citation>
      </ref>
      <ref id="bb0085">
       <label>
        17
       </label>
       <element-citation id="rf0085" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Federation of Hemophilia (WFH)
          </surname>
         </name>
        </person-group>
        <article-title>
         Registry of Clotting Factor Concentrates
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0150" xlink:href="http://www1.wfh.org/publications/files/pdf-1227.pdf">
         http://www1.wfh.org/publications/files/pdf-1227.pdf
        </ext-link>
        <year>
         2012
        </year>
       </element-citation>
      </ref>
      <ref id="bb0090">
       <label>
        18
       </label>
       <element-citation id="rf0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerlich
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical virology of hepatitis B: how it began and where we are now
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         10
        </volume>
        <year>
         2013
        </year>
        <fpage>
         239
        </fpage>
        <pub-id pub-id-type="pmid">
         23870415
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0095">
       <label>
        19
       </label>
       <element-citation id="rf0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ananworanich
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fletcher
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Pinyakorn
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           van Griensven
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Vandergeeten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schuetz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel acute HIV infection staging system based on 4th generation immunoassay
        </article-title>
        <source>
         Retrovirology
        </source>
        <volume>
         10
        </volume>
        <year>
         2013
        </year>
        <fpage>
         56
        </fpage>
        <pub-id pub-id-type="pmid">
         23718762
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0100">
       <label>
        20
       </label>
       <element-citation id="rf0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klamroth
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Groner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Simon
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         54
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1406
        </fpage>
        <lpage>
         1417
        </lpage>
        <pub-id pub-id-type="pmid">
         24117799
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0105">
       <label>
        21
       </label>
       <element-citation id="rf0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Nubling
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kress
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           De Zolt
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pichl
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <issue>
         Suppl. 3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2422
        </fpage>
        <lpage>
         2430
        </lpage>
        <pub-id pub-id-type="pmid">
         23782012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0110">
       <label>
        22
       </label>
       <element-citation id="rf0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bruhn
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lelie
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Custer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Busch
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleinman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           International NATSG
          </surname>
         </name>
        </person-group>
        <article-title>
         Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2399
        </fpage>
        <lpage>
         2412
        </lpage>
        <pub-id pub-id-type="pmid">
         23782054
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0115">
       <label>
        23
       </label>
       <element-citation id="rf0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Datta
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chatterjee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Veer
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in molecular diagnostics of hepatitis B virus
        </article-title>
        <source>
         World J Gastroenterol
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         14615
        </fpage>
        <lpage>
         14625
        </lpage>
        <pub-id pub-id-type="pmid">
         25356025
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0120">
       <label>
        24
       </label>
       <element-citation id="rf0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lieshout-Krikke
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Molenaar-de Backer
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
         <name>
          <surname>
           van Swieten
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zaaijer
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surface antigen-negative hepatitis B virus infection in Dutch blood donors
        </article-title>
        <source>
         Eur J Clin Microbiol
        </source>
        <volume>
         33
        </volume>
        <year>
         2014
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         77
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0125">
       <label>
        25
       </label>
       <element-citation id="rf0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teo
          </surname>
          <given-names>
           C.G.
          </given-names>
         </name>
         <name>
          <surname>
           Locarnini
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential threat of drug-resistant and vaccine-escape HBV mutants to public health
        </article-title>
        <source>
         Antivir Ther
        </source>
        <volume>
         15
        </volume>
        <year>
         2010
        </year>
        <fpage>
         445
        </fpage>
        <lpage>
         449
        </lpage>
        <pub-id pub-id-type="pmid">
         20516564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0130">
       <label>
        26
       </label>
       <element-citation id="rf0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bajpai
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choudhary
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays
        </article-title>
        <source>
         Asian J Transfus Sci
        </source>
        <volume>
         8
        </volume>
        <year>
         2014
        </year>
        <fpage>
         19
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         24678168
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0135">
       <label>
        27
       </label>
       <element-citation id="rf0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kleinman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Busch
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Korelitz
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Schreiber
          </surname>
          <given-names>
           G.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection
        </article-title>
        <source>
         Transfus Med Rev
        </source>
        <volume>
         11
        </volume>
        <year>
         1997
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         172
        </lpage>
        <pub-id pub-id-type="pmid">
         9243769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0140">
       <label>
        28
       </label>
       <element-citation id="rf0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Krysztof
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Brodsky
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Fickett
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Reynolds
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of triplex nucleic acid test assays in United States blood donors
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <issue>
         Suppl. 3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2525
        </fpage>
        <lpage>
         2537
        </lpage>
        <pub-id pub-id-type="pmid">
         23550838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0145">
       <label>
        29
       </label>
       <element-citation id="rf0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sena
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sparling
          </surname>
          <given-names>
           P.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         51
        </volume>
        <year>
         2010
        </year>
        <fpage>
         700
        </fpage>
        <lpage>
         708
        </lpage>
        <pub-id pub-id-type="pmid">
         20687840
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0150">
       <label>
        30
       </label>
       <element-citation id="rf0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pealer
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Marfin
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Petersen
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lanciotti
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of West Nile virus through blood transfusion in the United States in 2002
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         349
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1236
        </fpage>
        <lpage>
         1245
        </lpage>
        <pub-id pub-id-type="pmid">
         14500806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0155">
       <label>
        31
       </label>
       <element-citation id="rf0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glynn
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Busch
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Katz
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <year>
         2013
        </year>
        <fpage>
         438
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         22690676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0160">
       <label>
        32
       </label>
       <element-citation id="rf0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pupella
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pisani
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cristiano
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Catalano
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Grazzini
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         West Nile virus in the transfusion setting with a special focus on Italian preventive measures adopted in 2008-2012 and their impact on blood safety
        </article-title>
        <source>
         Blood Transfus
        </source>
        <volume>
         11
        </volume>
        <year>
         2013
        </year>
        <fpage>
         563
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         24120610
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0165">
       <label>
        33
       </label>
       <element-citation id="rf0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parola
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jourdan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rovery
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Vaillant
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Minodier
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel chikungunya virus variant in travelers returning from Indian Ocean islands
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1493
        </fpage>
        <lpage>
         1499
        </lpage>
        <pub-id pub-id-type="pmid">
         17176562
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0170">
       <label>
        34
       </label>
       <element-citation id="rf0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liumbruno
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Calteri
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Petropulacos
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mattivi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Po
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Macini
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Chikungunya epidemic in Italy and its repercussion on the blood system
        </article-title>
        <source>
         Blood Transfus
        </source>
        <volume>
         6
        </volume>
        <year>
         2008
        </year>
        <fpage>
         199
        </fpage>
        <lpage>
         210
        </lpage>
        <pub-id pub-id-type="pmid">
         19112735
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0175">
       <label>
        35
       </label>
       <element-citation id="rf0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Petersen
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chikungunya virus: new risk to transfusion safety in the Americas
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         54
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1911
        </fpage>
        <lpage>
         1915
        </lpage>
        <pub-id pub-id-type="pmid">
         25130331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0180">
       <label>
        36
       </label>
       <element-citation id="rf0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsetsarkin
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Vanlandingham
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           McGee
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Higgs
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A single mutation in chikungunya virus affects vector specificity and epidemic potential
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <volume>
         3
        </volume>
        <year>
         2007
        </year>
        <fpage>
         e201
        </fpage>
        <pub-id pub-id-type="pmid">
         18069894
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0185">
       <label>
        37
       </label>
       <element-citation id="rf0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Norja
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lassila
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Makris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Parvovirus transmission by blood products - a cause for concern?
        </article-title>
        <source>
         Br J Haematol
        </source>
        <volume>
         159
        </volume>
        <year>
         2012
        </year>
        <fpage>
         385
        </fpage>
        <lpage>
         393
        </lpage>
        <pub-id pub-id-type="pmid">
         23025427
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0190">
       <label>
        38
       </label>
       <element-citation id="rf0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Modrow
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wenzel
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Schimanski
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Schwarzbeck
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Oldenburg
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         100
        </volume>
        <year>
         2011
        </year>
        <fpage>
         351
        </fpage>
        <lpage>
         358
        </lpage>
        <pub-id pub-id-type="pmid">
         21133933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0195">
       <label>
        39
       </label>
       <element-citation id="rf0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soucie
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Monahan
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kulkarni
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           De Staercke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Recht
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chitlur
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1143
        </fpage>
        <lpage>
         1144
        </lpage>
        <pub-id pub-id-type="pmid">
         23659532
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0200">
       <label>
        40
       </label>
       <element-citation id="rf0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heegaard
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human parvovirus B19
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <volume>
         15
        </volume>
        <year>
         2002
        </year>
        <fpage>
         485
        </fpage>
        <lpage>
         505
        </lpage>
        <pub-id pub-id-type="pmid">
         12097253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0205">
       <label>
        41
       </label>
       <element-citation id="rf0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ragni
          </surname>
          <given-names>
           M.V.
          </given-names>
         </name>
         <name>
          <surname>
           Sherman
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Jordan
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral pathogens
        </article-title>
        <source>
         Haemophilia
        </source>
        <volume>
         16
        </volume>
        <issue>
         Suppl. 5
        </issue>
        <year>
         2010
        </year>
        <fpage>
         40
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         20590855
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0210">
       <label>
        42
       </label>
       <element-citation id="rf0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pawlotsky
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis E screening for blood donations: an urgent need?
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         384
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1729
        </fpage>
        <lpage>
         1730
        </lpage>
        <pub-id pub-id-type="pmid">
         25078305
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0215">
       <label>
        43
       </label>
       <element-citation id="rf0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boxall
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Herborn
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kochethu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ijaz
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country
        </article-title>
        <source>
         Transfus Med
        </source>
        <volume>
         16
        </volume>
        <year>
         2006
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         16623913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0220">
       <label>
        44
       </label>
       <element-citation id="rf0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Coze
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gallian
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           De Micco
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tamalet
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfusion-associated hepatitis E, France
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         13
        </volume>
        <year>
         2007
        </year>
        <fpage>
         648
        </fpage>
        <lpage>
         649
        </lpage>
        <pub-id pub-id-type="pmid">
         17561564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0225">
       <label>
        45
       </label>
       <element-citation id="rf0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huzly
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Umhau
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bettinger
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cathomen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emmerich
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Hasselblatt
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfusion-transmitted hepatitis E in Germany, 2013
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         19
        </volume>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bb0230">
       <label>
        46
       </label>
       <element-citation id="rf0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Schechterly
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shih
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <issue>
         Suppl. 3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2505
        </fpage>
        <lpage>
         2511
        </lpage>
        <pub-id pub-id-type="pmid">
         23829163
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0235">
       <label>
        47
       </label>
       <element-citation id="rf0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dreier
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Juhl
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Autochthonous Hepatitis E Virus Infections: A New Transfusion-Associated Risk?
        </article-title>
        <source>
         Transfus Med Hemother
        </source>
        <volume>
         41
        </volume>
        <year>
         2014
        </year>
        <fpage>
         29
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="pmid">
         24659945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0240">
       <label>
        48
       </label>
       <element-citation id="rf0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Matsubayashi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sakata
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A nationwide survey for prevalence of hepatitis E virus antibody in qualified blood donors in Japan
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         99
        </volume>
        <year>
         2010
        </year>
        <fpage>
         307
        </fpage>
        <lpage>
         313
        </lpage>
        <pub-id pub-id-type="pmid">
         20576022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0245">
       <label>
        49
       </label>
       <element-citation id="rf0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mansuy
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bendall
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand-Abravanel
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Saune
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Miedouge
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ellis
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis E virus antibodies in blood donors, France
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         17
        </volume>
        <year>
         2011
        </year>
        <fpage>
         2309
        </fpage>
        <lpage>
         2312
        </lpage>
        <pub-id pub-id-type="pmid">
         22172156
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0250">
       <label>
        50
       </label>
       <element-citation id="rf0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hewitt
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ijaz
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brailsford
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Brett
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Dicks
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haywood
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis E virus in blood components: a prevalence and transmission study in southeast England
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         384
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1766
        </fpage>
        <lpage>
         1773
        </lpage>
        <pub-id pub-id-type="pmid">
         25078306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0255">
       <label>
        51
       </label>
       <element-citation id="rf0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Orru
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wilham
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Vascellari
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hughson
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Caughey
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New generation QuIC assays for prion seeding activity
        </article-title>
        <source>
         Prion
        </source>
        <volume>
         6
        </volume>
        <year>
         2012
        </year>
        <fpage>
         147
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         22421206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0260">
       <label>
        52
       </label>
       <element-citation id="rf0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morales
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Duran-Aniotz
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Diaz-Espinoza
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Camacho
          </surname>
          <given-names>
           M.V.
          </given-names>
         </name>
         <name>
          <surname>
           Soto
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protein misfolding cyclic amplification of infectious prions
        </article-title>
        <source>
         Nat Protoc
        </source>
        <volume>
         7
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1397
        </fpage>
        <lpage>
         1409
        </lpage>
        <pub-id pub-id-type="pmid">
         22743831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0265">
       <label>
        53
       </label>
       <element-citation id="rf0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Segarra
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bougard
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Moudjou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Beringue
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Coste
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Plasminogen-based capture combined with amplification technology for the detection of PrP(TSE) in the pre-clinical phase of infection
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         8
        </volume>
        <year>
         2013
        </year>
        <fpage>
         e69632
        </fpage>
        <pub-id pub-id-type="pmid">
         23894513
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0270">
       <label>
        54
       </label>
       <element-citation id="rf0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Andrews
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ladhani
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Bujaki
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Minor
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         105
        </volume>
        <year>
         2013
        </year>
        <fpage>
         196
        </fpage>
        <lpage>
         204
        </lpage>
        <pub-id pub-id-type="pmid">
         23772892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0275">
       <label>
        55
       </label>
       <element-citation id="rf0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Burk-Rafel
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Edgeworth
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sicilia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abdilahi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Korteweg
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test: Diagnostic Accuracy and Feasibility Study
        </article-title>
        <source>
         JAMA Neurol
        </source>
        <volume>
         71
        </volume>
        <year>
         2014
        </year>
        <fpage>
         421
        </fpage>
        <lpage>
         428
        </lpage>
        <pub-id pub-id-type="pmid">
         24590363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0280">
       <label>
        56
       </label>
       <element-citation id="rf0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lacroux
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comoy
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Moudjou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Perret-Liaudet
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lugan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Litaise
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preclinical detection of variant CJD and BSE prions in blood
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <volume>
         10
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e1004202
        </fpage>
        <pub-id pub-id-type="pmid">
         24945656
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0285">
       <label>
        57
       </label>
       <element-citation id="rf0285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Irshad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Joshi
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Dhar
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfusion transmitted virus: A review on its molecular characteristics and role in medicine
        </article-title>
        <source>
         World J Gastroenterol
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         5122
        </fpage>
        <lpage>
         5134
        </lpage>
        <pub-id pub-id-type="pmid">
         16937521
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0290">
       <label>
        58
       </label>
       <element-citation id="rf0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Notari
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Krysztof
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <issue>
         Suppl. 3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2449
        </fpage>
        <lpage>
         2458
        </lpage>
        <pub-id pub-id-type="pmid">
         23607261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0295">
       <label>
        59
       </label>
       <element-citation id="rf0295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salles
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Levi
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Barreto
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sampaio
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <name>
          <surname>
           Romano
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sabino
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human immunodeficiency virus transfusion transmission despite nucleic acid testing
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <issue>
         Suppl. 3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         2593
        </fpage>
        <lpage>
         2595
        </lpage>
        <pub-id pub-id-type="pmid">
         24099406
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0300">
       <label>
        60
       </label>
       <element-citation id="rf0300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schmidt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Korn
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nubling
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chudy
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kress
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Horst
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         49
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1836
        </fpage>
        <lpage>
         1844
        </lpage>
        <pub-id pub-id-type="pmid">
         19453990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0305">
       <label>
        61
       </label>
       <element-citation id="rf0305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chudy
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Weber-Schehl
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pichl
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jork
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kress
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Heiden
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         52
        </volume>
        <year>
         2012
        </year>
        <fpage>
         431
        </fpage>
        <lpage>
         439
        </lpage>
        <pub-id pub-id-type="pmid">
         21810100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0310">
       <label>
        62
       </label>
       <element-citation id="rf0310" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paul-Ehrlich-Institut
          </surname>
         </name>
        </person-group>
        <article-title>
         Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0155" xlink:href="http://www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/bescheide/2012-06-15-implementation-hiv-1-nat-test-systems-dual-target.pdf?__blob=publicationFile&amp;v=3">
         http://www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/bescheide/2012-06-15-implementation-hiv-1-nat-test-systems-dual-target.pdf?__blob=publicationFile&amp;v=3
        </ext-link>
        <year>
         2012
        </year>
       </element-citation>
      </ref>
      <ref id="bb0315">
       <label>
        63
       </label>
       <element-citation id="rf0315" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsukada
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yokoyama
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Handa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mori
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kizaki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Erythroid crisis caused by parvovirus B19 transmitted via red blood cell transfusion
        </article-title>
        <source>
         Intern Med
        </source>
        <volume>
         50
        </volume>
        <year>
         2011
        </year>
        <fpage>
         2379
        </fpage>
        <lpage>
         2382
        </lpage>
        <pub-id pub-id-type="pmid">
         22001470
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0320">
       <label>
        64
       </label>
       <element-citation id="rf0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tobler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Alexander
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Relative distribution of West Nile virus RNA in blood compartments: implications for blood donor nucleic acid amplification technology screening
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         52
        </volume>
        <year>
         2012
        </year>
        <fpage>
         447
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         21827506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0325">
       <label>
        65
       </label>
       <element-citation id="rf0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goncalves
          </surname>
          <given-names>
           D.U.
          </given-names>
         </name>
         <name>
          <surname>
           Proietti
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ribas
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Araujo
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Pinheiro
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Guedes
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <volume>
         23
        </volume>
        <year>
         2010
        </year>
        <fpage>
         577
        </fpage>
        <lpage>
         589
        </lpage>
        <pub-id pub-id-type="pmid">
         20610824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0330">
       <label>
        66
       </label>
       <element-citation id="rf0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lindholm
          </surname>
          <given-names>
           P.F.
          </given-names>
         </name>
         <name>
          <surname>
           Annen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ramsey
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Approaches to minimize infection risk in blood banking and transfusion practice
        </article-title>
        <source>
         Infect Disord Drug Targets
        </source>
        <volume>
         11
        </volume>
        <year>
         2011
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         21303341
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0335">
       <label>
        67
       </label>
       <element-citation id="rf0335" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           SaJAO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment
        </article-title>
        <source>
         Food Environ Virol
        </source>
        <volume>
         3
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         30
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0340">
       <label>
        68
       </label>
       <element-citation id="rf0340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leggett
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cornwallis
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           West
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of pathogenesis, infective dose and virulence in human parasites
        </article-title>
        <source>
         PLoS Pathol
        </source>
        <volume>
         8
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e1002512
        </fpage>
       </element-citation>
      </ref>
      <ref id="bb0345">
       <label>
        69
       </label>
       <element-citation id="rf0345" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boeckh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Geballe
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cytomegalovirus: pathogen, paradigm, and puzzle
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         121
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1673
        </fpage>
        <lpage>
         1680
        </lpage>
        <pub-id pub-id-type="pmid">
         21659716
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0350">
       <label>
        70
       </label>
       <element-citation id="rf0350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Souza
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Passos
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Treitinger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Spada
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil
        </article-title>
        <source>
         Rev Soc Bras Med Trop
        </source>
        <volume>
         43
        </volume>
        <year>
         2010
        </year>
        <fpage>
         359
        </fpage>
        <lpage>
         361
        </lpage>
        <pub-id pub-id-type="pmid">
         20802930
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0355">
       <label>
        71
       </label>
       <element-citation id="rf0355" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ringwald
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mertz
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Zimmermann
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Weisbach
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Strasser
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Achenbach
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis B virus vaccination of blood donors--what costs may be expected?
        </article-title>
        <source>
         Transfus Med
        </source>
        <volume>
         15
        </volume>
        <year>
         2005
        </year>
        <fpage>
         83
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         15859973
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0360">
       <label>
        72
       </label>
       <element-citation id="rf0360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fischinger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Stephan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wasserscheid
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Eichler
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gartner
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         28
        </volume>
        <year>
         2010
        </year>
        <fpage>
         7797
        </fpage>
        <lpage>
         7802
        </lpage>
        <pub-id pub-id-type="pmid">
         20875488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0365">
       <label>
        73
       </label>
       <element-citation id="rf0365" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         WHO Technical Report, Series No. 924, 2004. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0160" xlink:href="http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf">
         http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0370">
       <label>
        74
       </label>
       <element-citation id="rf0370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quarantine Plasma: Quo vadis?
        </article-title>
        <source>
         Transfus Med Hemother
        </source>
        <volume>
         37
        </volume>
        <year>
         2010
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         122
        </lpage>
        <pub-id pub-id-type="pmid">
         20577600
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0375">
       <label>
        75
       </label>
       <element-citation id="rf0375" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogen inactivation technology: cleansing the blood supply
        </article-title>
        <source>
         J Intern Med
        </source>
        <volume>
         257
        </volume>
        <year>
         2005
        </year>
        <fpage>
         224
        </fpage>
        <lpage>
         237
        </lpage>
        <pub-id pub-id-type="pmid">
         15715679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0380">
       <label>
        76
       </label>
       <element-citation id="rf0380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Brackmann
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Eis-Hubinger
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2
        </article-title>
        <source>
         Thromb Haemost
        </source>
        <volume>
         92
        </volume>
        <year>
         2004
        </year>
        <fpage>
         838
        </fpage>
        <lpage>
         845
        </lpage>
        <pub-id pub-id-type="pmid">
         15467916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0385">
       <label>
        77
       </label>
       <element-citation id="rf0385" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dalton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ternouth
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Removal of TSE agent from plasma products manufactured in the United Kingdom
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         104
        </volume>
        <year>
         2013
        </year>
        <fpage>
         299
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         23170907
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0390">
       <label>
        78
       </label>
       <element-citation id="rf0390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Osheroff
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Buczynski
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hotta
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of Thrombate III(R), a pasteurized and nanofiltered therapeutic human antithrombin concentrate
        </article-title>
        <source>
         Biologicals
        </source>
        <volume>
         42
        </volume>
        <year>
         2014
        </year>
        <fpage>
         133
        </fpage>
        <lpage>
         138
        </lpage>
        <pub-id pub-id-type="pmid">
         24477183
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0395">
       <label>
        79
       </label>
       <element-citation id="rf0395" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cardone
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Simoneau
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Arzel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Puopolo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Berardi
          </surname>
          <given-names>
           V.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abdel-Haq
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263 K scrapie-infected brain homogenates in "spiked" albumin solutions
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         52
        </volume>
        <year>
         2012
        </year>
        <fpage>
         953
        </fpage>
        <lpage>
         962
        </lpage>
        <pub-id pub-id-type="pmid">
         22082124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0400">
       <label>
        80
       </label>
       <element-citation id="rf0400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marschner
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Goodrich
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light
        </article-title>
        <source>
         Transfus Med Hemother
        </source>
        <volume>
         38
        </volume>
        <year>
         2011
        </year>
        <fpage>
         8
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         21779202
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0405">
       <label>
        81
       </label>
       <element-citation id="rf0405" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seltsam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma
        </article-title>
        <source>
         Transfus Med Hemother
        </source>
        <volume>
         38
        </volume>
        <year>
         2011
        </year>
        <fpage>
         43
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         21779205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0410">
       <label>
        82
       </label>
       <element-citation id="rf0410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reddy
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Doane
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Keil
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Marschner
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Goodrich
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a riboflavin and ultraviolet light-based device to treat whole blood
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         2013
        </year>
        <fpage>
         131S
        </fpage>
        <lpage>
         136S
        </lpage>
        <pub-id pub-id-type="pmid">
         23301965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0415">
       <label>
        83
       </label>
       <element-citation id="rf0415" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keeling
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tait
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Makris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology
        </article-title>
        <source>
         Haemophilia
        </source>
        <volume>
         14
        </volume>
        <year>
         2008
        </year>
        <fpage>
         671
        </fpage>
        <lpage>
         684
        </lpage>
        <pub-id pub-id-type="pmid">
         18422612
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0420">
       <label>
        84
       </label>
       <element-citation id="rf0420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Uruma
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Okuyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fujita
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Handa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tomiyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence of transfusion-related adverse reactions per patient reflects the potential risk of transfusion therapy in Japan
        </article-title>
        <source>
         Am J Clin Pathol
        </source>
        <volume>
         140
        </volume>
        <year>
         2013
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         224
        </lpage>
        <pub-id pub-id-type="pmid">
         23897258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0425">
       <label>
        85
       </label>
       <element-citation id="rf0425" publication-type="other">
        <article-title>
         Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0165" xlink:href="http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32002L0098">
         http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32002L0098
        </ext-link>
        <comment>
         [accessed Feb 2015]
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0430">
       <label>
        86
       </label>
       <element-citation id="rf0430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grillberger
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kreil
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Nasr
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Reiter
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells
        </article-title>
        <source>
         Biotechnol J
        </source>
        <volume>
         4
        </volume>
        <year>
         2009
        </year>
        <fpage>
         186
        </fpage>
        <lpage>
         201
        </lpage>
        <pub-id pub-id-type="pmid">
         19226552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0435">
       <label>
        87
       </label>
       <element-citation id="rf0435" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aledort
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is the incidence and prevalence of inhibitors greater with recombinant products? Yes
        </article-title>
        <source>
         J Thromb Haemost
        </source>
        <volume>
         2
        </volume>
        <year>
         2004
        </year>
        <fpage>
         861
        </fpage>
        <lpage>
         862
        </lpage>
        <pub-id pub-id-type="pmid">
         15140115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0440">
       <label>
        88
       </label>
       <element-citation id="rf0440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goudemand
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rothschild
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Demiguel
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Vinciguerrat
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chambost
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
        </article-title>
        <source>
         Blood
        </source>
        <volume>
         107
        </volume>
        <year>
         2006
        </year>
        <fpage>
         46
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         16166584
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0445">
       <label>
        89
       </label>
       <element-citation id="rf0445" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gouw
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           van den Berg
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Auerswald
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Carcao
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
        </article-title>
        <source>
         Blood
        </source>
        <volume>
         121
        </volume>
        <year>
         2013
        </year>
        <fpage>
         4046
        </fpage>
        <lpage>
         4055
        </lpage>
        <pub-id pub-id-type="pmid">
         23553768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0450">
       <label>
        90
       </label>
       <element-citation id="rf0450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ludlam
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Powderly
          </surname>
          <given-names>
           W.G.
          </given-names>
         </name>
         <name>
          <surname>
           Bozzette
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Diamond
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Koerper
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kulkarni
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical perspectives of emerging pathogens in bleeding disorders
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         367
        </volume>
        <year>
         2006
        </year>
        <fpage>
         252
        </fpage>
        <lpage>
         261
        </lpage>
        <pub-id pub-id-type="pmid">
         16427495
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0455">
       <label>
        91
       </label>
       <element-citation id="rf0455" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knight
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Stanley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dolan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hemophilia therapy and blood-borne pathogen risk
        </article-title>
        <source>
         Semin Thromb Hemost
        </source>
        <volume>
         32
        </volume>
        <issue>
         Suppl. 2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         3
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0460">
       <label>
        92
       </label>
       <element-citation id="rf0460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy
        </article-title>
        <source>
         Haemophilia
        </source>
        <volume>
         13
        </volume>
        <issue>
         Suppl. 5
        </issue>
        <year>
         2007
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         18078395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0465">
       <label>
        93
       </label>
       <element-citation id="rf0465" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Makris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Calizzani
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hay
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lassila
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         EUHASS: The European Haemophilia Safety Surveillance system
        </article-title>
        <source>
         Thromb Res
        </source>
        <volume>
         127
        </volume>
        <issue>
         Suppl. 2
        </issue>
        <year>
         2011
        </year>
        <fpage>
         S22
        </fpage>
        <lpage>
         S25
        </lpage>
        <pub-id pub-id-type="pmid">
         21193110
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0470">
       <label>
        94
       </label>
       <element-citation id="rf0470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peden
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McCardle
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Head
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Cousens
          </surname>
          <given-names>
           S.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia
        </article-title>
        <source>
         Haemophilia
        </source>
        <volume>
         16
        </volume>
        <year>
         2010
        </year>
        <fpage>
         296
        </fpage>
        <lpage>
         304
        </lpage>
        <pub-id pub-id-type="pmid">
         20070383
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0475">
       <label>
        95
       </label>
       <element-citation id="rf0475" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Edgeworth
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Farmer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sicilia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tavares
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         377
        </volume>
        <year>
         2011
        </year>
        <fpage>
         487
        </fpage>
        <lpage>
         493
        </lpage>
        <pub-id pub-id-type="pmid">
         21295339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0480">
       <label>
        96
       </label>
       <element-citation id="rf0480" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 327 - Chikungunya
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0170" xlink:href="http://www.who.int/mediacentre/factsheets/fs327/en/">
         http://www.who.int/mediacentre/factsheets/fs327/en/
        </ext-link>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bb0485">
       <label>
        97
       </label>
       <element-citation id="rf0485" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Laurent
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Le Roux
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Grivard
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bertil
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Naze
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Picard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus
        </article-title>
        <source>
         Clin Chem
        </source>
        <volume>
         53
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1408
        </fpage>
        <lpage>
         1414
        </lpage>
        <pub-id pub-id-type="pmid">
         17586592
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0490">
       <label>
        98
       </label>
       <element-citation id="rf0490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santhosh
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Parida
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Dash
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Pateriya
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Pattnaik
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Pradhan
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and evaluation of SYBR Green I-based one-step real-time RT-PCR assay for detection and quantification of Chikungunya virus
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         39
        </volume>
        <year>
         2007
        </year>
        <fpage>
         188
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         17553740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0495">
       <label>
        99
       </label>
       <element-citation id="rf0495" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blacksell
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Tanganuchitcharnchai
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jarman
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gibbons
          </surname>
          <given-names>
           R.V.
          </given-names>
         </name>
         <name>
          <surname>
           Paris
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Poor diagnostic accuracy of commercial antibody-based assays for the diagnosis of acute Chikungunya infection
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        <volume>
         18
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1773
        </fpage>
        <lpage>
         1775
        </lpage>
        <pub-id pub-id-type="pmid">
         21865416
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0500">
       <label>
        100
       </label>
       <element-citation id="rf0500" publication-type="other">
        <article-title>
         CMV HHV6,7,8 R-gene® Real-Time PCR Kit Technicial Specifications
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0175" xlink:href="http://www.biomerieux-diagnostics.com/cmv-hhv678-r-gener">
         http://www.biomerieux-diagnostics.com/cmv-hhv678-r-gener
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0505">
       <label>
        101
       </label>
       <element-citation id="rf0505" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Michelin
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
         <name>
          <surname>
           Hadzisejdic
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bozic
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Grahovac
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hess
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Grahovac
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of cytomegalovirus (CMV) DNA in EDTA whole-blood samples: evaluation of the quantitative artus CMV LightCycler PCR kit in conjunction with automated sample preparation
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         46
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1241
        </fpage>
        <lpage>
         1245
        </lpage>
        <pub-id pub-id-type="pmid">
         18272703
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0510">
       <label>
        102
       </label>
       <element-citation id="rf0510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teoh
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Sam
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Johari
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Danlami
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Hooi
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of dengue viruses using reverse transcription-loop-mediated isothermal amplification
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         387
        </fpage>
        <pub-id pub-id-type="pmid">
         23964963
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0515">
       <label>
        103
       </label>
       <element-citation id="rf0515" publication-type="other">
        <article-title>
         Simplexa™ Dengue Kit Technical Specifications
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0180" xlink:href="http://www.focusdx.com/product/MOL3100/ous">
         http://www.focusdx.com/product/MOL3100/ous
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0520">
       <label>
        104
       </label>
       <element-citation id="rf0520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of multiplex real-time reverse transcriptase PCR assays for detecting eight medically important flaviviruses in mosquitoes
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         45
        </volume>
        <year>
         2007
        </year>
        <fpage>
         584
        </fpage>
        <lpage>
         589
        </lpage>
        <pub-id pub-id-type="pmid">
         17108075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0525">
       <label>
        105
       </label>
       <element-citation id="rf0525" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunsperger
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Yoksan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Buchy
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sekaran
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Enria
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody
        </article-title>
        <source>
         PLoS Negl Trop Dis
        </source>
        <volume>
         8
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e3171
        </fpage>
        <pub-id pub-id-type="pmid">
         25330157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0530">
       <label>
        106
       </label>
       <element-citation id="rf0530" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 360 - HIV/AIDS
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0185" xlink:href="http://www.who.int/mediacentre/factsheets/fs360/en/">
         http://www.who.int/mediacentre/factsheets/fs360/en/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0535">
       <label>
        107
       </label>
       <element-citation id="rf0535" publication-type="other">
        <article-title>
         Procleix® Ultrio® Assay
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0190" xlink:href="http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm335285.pdf">
         http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm335285.pdf
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0540">
       <label>
        108
       </label>
       <element-citation id="rf0540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           S.M.S.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis B virus serology: Use and interpretation
        </article-title>
        <source>
         Hep B Annual
        </source>
        <volume>
         4
        </volume>
        <year>
         2007
        </year>
        <fpage>
         39
        </fpage>
        <lpage>
         54
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb1000">
       <label>
        109
       </label>
       <element-citation id="rf5545" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ba Alawi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           LePage
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Jayamaha
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baleriola
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Rawlinson
          </surname>
          <given-names>
           W.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The reliability of HBV core antibody in serological screening for hepatitis B virus
        </article-title>
        <source>
         Pathology
        </source>
        <volume>
         45
        </volume>
        <year>
         2013
        </year>
        <fpage>
         501
        </fpage>
        <lpage>
         505
        </lpage>
        <pub-id pub-id-type="pmid">
         23842045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0550">
       <label>
        110
       </label>
       <element-citation id="rf0550" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 164 - Hepatitis C
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0195" xlink:href="http://www.who.int/mediacentre/factsheets/fs164/en/">
         http://www.who.int/mediacentre/factsheets/fs164/en/
        </ext-link>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bb0555">
       <label>
        111
       </label>
       <element-citation id="rf0555" publication-type="other">
        <article-title>
         NGI UltraQualTM HCV RT-PCR assay
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0200" xlink:href="http://www.fda.gov/downloads/biologicsbloodvaccines/ucm148271.pdf">
         http://www.fda.gov/downloads/biologicsbloodvaccines/ucm148271.pdf
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0560">
       <label>
        112
       </label>
       <element-citation id="rf0560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamili
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Drobeniuc
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Araujo
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory diagnostics for hepatitis C virus infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         55
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         2012
        </year>
        <fpage>
         S43
        </fpage>
        <lpage>
         S48
        </lpage>
        <pub-id pub-id-type="pmid">
         22715213
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0565">
       <label>
        113
       </label>
       <element-citation id="rf0565" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tillmann
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment
        </article-title>
        <source>
         World J Gastroenterol
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         6701
        </fpage>
        <lpage>
         6706
        </lpage>
        <pub-id pub-id-type="pmid">
         24944462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0570">
       <label>
        114
       </label>
       <element-citation id="rf0570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Helden
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Weiskirchen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis C diagnostics: clinical evaluation of the HCV-core antigen determination
        </article-title>
        <source>
         Z Gastroenterol
        </source>
        <volume>
         52
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1164
        </fpage>
        <lpage>
         1170
        </lpage>
        <pub-id pub-id-type="pmid">
         25313628
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0575">
       <label>
        115
       </label>
       <element-citation id="rf0575" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bajpai
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfusion-transmitted hepatitis E: is screening warranted?
        </article-title>
        <source>
         Indian J Med Microbiol
        </source>
        <volume>
         29
        </volume>
        <year>
         2011
        </year>
        <fpage>
         353
        </fpage>
        <lpage>
         358
        </lpage>
        <pub-id pub-id-type="pmid">
         22120793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0580">
       <label>
        116
       </label>
       <element-citation id="rf0580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vollmer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Knabbe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dreier
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of real-time PCR and antigen assays for detection of hepatitis E virus in blood donors
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         52
        </volume>
        <year>
         2014
        </year>
        <fpage>
         2150
        </fpage>
        <lpage>
         2156
        </lpage>
        <pub-id pub-id-type="pmid">
         24740079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0585">
       <label>
        117
       </label>
       <element-citation id="rf0585" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abravanel
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Sandres-Saune
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lhomme
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dubois
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mansuy
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Izopet
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genotype 3 diversity and quantification of hepatitis E virus RNA
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         50
        </volume>
        <year>
         2012
        </year>
        <fpage>
         897
        </fpage>
        <lpage>
         902
        </lpage>
        <pub-id pub-id-type="pmid">
         22205792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0590">
       <label>
        118
       </label>
       <element-citation id="rf0590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vollmer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Diekmann
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johne
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Eberhardt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Knabbe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dreier
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel approach for detection of hepatitis E virus infection in German blood donors
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         50
        </volume>
        <year>
         2012
        </year>
        <fpage>
         2708
        </fpage>
        <lpage>
         2713
        </lpage>
        <pub-id pub-id-type="pmid">
         22675127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0595">
       <label>
        119
       </label>
       <element-citation id="rf0595" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drobeniuc
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Reuter
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Greene-Montfort
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Khudyakova
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrova
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         51
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e24
        </fpage>
        <lpage>
         e27
        </lpage>
        <pub-id pub-id-type="pmid">
         20578874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0600">
       <label>
        120
       </label>
       <element-citation id="rf0600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Henke-Gendo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schulz
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission and disease association of Kaposi's sarcoma-associated herpesvirus: recent developments
        </article-title>
        <source>
         Curr Opin Infect Dis
        </source>
        <volume>
         17
        </volume>
        <year>
         2004
        </year>
        <fpage>
         53
        </fpage>
        <lpage>
         57
        </lpage>
        <pub-id pub-id-type="pmid">
         15090892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0605">
       <label>
        121
       </label>
       <element-citation id="rf0605" publication-type="other">
        <article-title>
         HHV-8 Quantitative Real-time PCR
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0205" xlink:href="http://www.viracoribt.com/Test-Catalog/Detail/Human-Herpes-Virus-8-HHV-8-Quantitative-PCR-8000">
         http://www.viracoribt.com/Test-Catalog/Detail/Human-Herpes-Virus-8-HHV-8-Quantitative-PCR-8000
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0610">
       <label>
        122
       </label>
       <element-citation id="rf0610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mbisa
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Miley
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gamache
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gillette
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Esposito
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hopkins
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA
        </article-title>
        <source>
         J Immunol Methods
        </source>
        <volume>
         356
        </volume>
        <year>
         2010
        </year>
        <fpage>
         39
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         20211626
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0615">
       <label>
        123
       </label>
       <element-citation id="rf0615" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           United Nations (UN)
          </surname>
         </name>
        </person-group>
        <article-title>
         Global report: UNAIDS report on the global AIDS epidemic
        </article-title>
        <comment>
         Accessible from
        </comment>
        <ext-link ext-link-type="uri" id="ir0210" xlink:href="http://www.unaids.org/en/resources/publications/2013/name,85053,en.asp">
         http://www.unaids.org/en/resources/publications/2013/name,85053,en.asp
        </ext-link>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bb0620">
       <label>
        124
       </label>
       <element-citation id="rf0620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Naeth
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ehret
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Braun
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Knechten
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia
        </article-title>
        <source>
         Med Microbiol Immunol
        </source>
        <volume>
         202
        </volume>
        <year>
         2013
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         22699843
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0625">
       <label>
        125
       </label>
       <element-citation id="rf0625" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Butto
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Suligoi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Fanales-Belasio
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Raimondo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory diagnostics for HIV infection
        </article-title>
        <source>
         Ann Ist Super Sanita
        </source>
        <volume>
         46
        </volume>
        <year>
         2010
        </year>
        <fpage>
         24
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         20348616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0630">
       <label>
        126
       </label>
       <element-citation id="rf0630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lairmore
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Anupam
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bowden
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Haines
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           R.A.
          </given-names>
          <suffix>
           2nd
          </suffix>
         </name>
         <name>
          <surname>
           Ratner
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular determinants of human T-lymphotropic virus type 1 transmission and spread
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         3
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1131
        </fpage>
        <lpage>
         1165
        </lpage>
        <pub-id pub-id-type="pmid">
         21994774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0635">
       <label>
        127
       </label>
       <element-citation id="rf0635" publication-type="other">
        <article-title>
         Abbott Prism Human T-Lymphotrophic Virus Types I and II assay
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0215" xlink:href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM298517.pdf">
         http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM298517.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0640">
       <label>
        128
       </label>
       <element-citation id="rf0640" publication-type="other">
        <article-title>
         Avioq HTLV-I/II Microelisa system
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0220" xlink:href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM298517.pdf">
         http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM298517.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0645">
       <label>
        129
       </label>
       <element-citation id="rf0645" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rocha-Junior MH
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wagatsuma
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Takayanagui
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Slavov
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Otaguiri
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rodrigues
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and validation of a Multiplex Real-Time PCR for HTLV-1/2 confirmatory diagnosis
        </article-title>
        <source>
         Retrovirology
        </source>
        <volume>
         11
        </volume>
        <year>
         2014
        </year>
        <fpage>
         105
        </fpage>
        <pub-id pub-id-type="pmid">
         25575025
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0650">
       <label>
        130
       </label>
       <element-citation id="rf0650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malm
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kjerstadius
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a new screening assay for HTLV-1 and -2 antibodies for large-scale use
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         82
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1606
        </fpage>
        <lpage>
         1611
        </lpage>
        <pub-id pub-id-type="pmid">
         20648617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0655">
       <label>
        131
       </label>
       <element-citation id="rf0655" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andrade
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Ribeiro
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Namen-Lopes
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Basques
          </surname>
          <given-names>
           F.V.
          </given-names>
         </name>
         <name>
          <surname>
           Ribas
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors
        </article-title>
        <source>
         Rev Soc Bras Med Trop
        </source>
        <volume>
         43
        </volume>
        <year>
         2010
        </year>
        <fpage>
         111
        </fpage>
        <lpage>
         115
        </lpage>
        <pub-id pub-id-type="pmid">
         20464136
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0660">
       <label>
        132
       </label>
       <element-citation id="rf0660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonvicini
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Manaresi
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bua
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Venturoli
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallinella
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Keeping pace with Parvovirus B19 Genetic Variability: a Multiplex Genotype-Specific qPCR Assay
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bb0665">
       <label>
        133
       </label>
       <element-citation id="rf0665" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koppelman
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cuypers
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Emrich
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zaaijer
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quantitative real-time detection of parvovirus B19 DNA in plasma
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         44
        </volume>
        <year>
         2004
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         14692974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0670">
       <label>
        134
       </label>
       <element-citation id="rf0670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of human parvovirus B19, human bocavirus and human parvovirus 4 infections in blood samples among 95 patients with liver disease in Nanjing by nested PCR
        </article-title>
        <source>
         Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
        </source>
        <volume>
         27
        </volume>
        <year>
         2013
        </year>
        <fpage>
         135
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         24044222
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0675">
       <label>
        135
       </label>
       <element-citation id="rf0675" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Doyle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kerr
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           O'Keeffe
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           O'Carroll
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Daly
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kilty
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis
        </article-title>
        <source>
         J Virol Methods
        </source>
        <volume>
         90
        </volume>
        <year>
         2000
        </year>
        <fpage>
         143
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         11064115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0680">
       <label>
        136
       </label>
       <element-citation id="rf0680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         17
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1954
        </fpage>
        <lpage>
         1956
        </lpage>
        <pub-id pub-id-type="pmid">
         22000381
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0685">
       <label>
        137
       </label>
       <element-citation id="rf0685" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lahtinen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kivela
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hedman
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kantele
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lappalainen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serodiagnosis of primary infections with human parvovirus 4, Finland
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         17
        </volume>
        <year>
         2011
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         21192859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0690">
       <label>
        138
       </label>
       <element-citation id="rf0690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lavoie
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sharp
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Pepin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pennington
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Foupouapouognigni
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pybus
          </surname>
          <given-names>
           O.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human parvovirus 4 infection, Cameroon
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         18
        </volume>
        <year>
         2012
        </year>
        <fpage>
         680
        </fpage>
        <lpage>
         683
        </lpage>
        <pub-id pub-id-type="pmid">
         22469425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0695">
       <label>
        139
       </label>
       <element-citation id="rf0695" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           May
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Reber
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Sarpong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Adjei
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human parvovirus 4 viremia in young children, Ghana
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         18
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1690
        </fpage>
        <lpage>
         1692
        </lpage>
        <pub-id pub-id-type="pmid">
         23017590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0700">
       <label>
        140
       </label>
       <element-citation id="rf0700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fryer
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Minor
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Delwart
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Baylis
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel parvovirus and related variant in human plasma
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         151
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="pmid">
         16494735
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0705">
       <label>
        141
       </label>
       <element-citation id="rf0705" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmonds
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Davidson
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lycett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           MacDonald
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ellender
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of a novel DNA virus (TTV) in blood donors and blood products
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         352
        </volume>
        <year>
         1998
        </year>
        <fpage>
         191
        </fpage>
        <lpage>
         195
        </lpage>
        <pub-id pub-id-type="pmid">
         9683208
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0710">
       <label>
        142
       </label>
       <element-citation id="rf0710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tyagi
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Pradier
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baumer
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Uppugunduri
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Huezo-Diaz
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Posfay-Barbe
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         10
        </volume>
        <year>
         2013
        </year>
        <fpage>
         191
        </fpage>
        <pub-id pub-id-type="pmid">
         23758761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0715">
       <label>
        143
       </label>
       <element-citation id="rf0715" publication-type="other">
        <article-title>
         West Nile Virus: Detection with Serologic and Real-time PCR Assays. Quest Diagnostics
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0225" xlink:href="http://www.questdiagnostics.com/testcenter/testguide.action?dc=CF_WestNileVirus">
         http://www.questdiagnostics.com/testcenter/testguide.action?dc=CF_WestNileVirus
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0720">
       <label>
        144
       </label>
       <element-citation id="rf0720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sambri
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Capobianchi
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cavrini
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Charrel
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Donoso-Mantke
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Escadafal
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis of west nile virus human infections: overview and proposal of diagnostic protocols considering the results of external quality assessment studies
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         5
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2329
        </fpage>
        <lpage>
         2348
        </lpage>
        <pub-id pub-id-type="pmid">
         24072061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0725">
       <label>
        145
       </label>
       <element-citation id="rf0725" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanchini
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Donoso-Mantke
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Papa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sambri
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Teichmann
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Second international diagnostic accuracy study for the serological detection of West Nile virus infection
        </article-title>
        <source>
         PLoS Negl Trop Dis
        </source>
        <volume>
         7
        </volume>
        <year>
         2013
        </year>
        <fpage>
         e2184
        </fpage>
        <pub-id pub-id-type="pmid">
         23638205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0730">
       <label>
        146
       </label>
       <element-citation id="rf0730" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Global incidence and prevalence of selected curable sexually transmitted infections
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0230" xlink:href="http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf">
         http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf
        </ext-link>
        <year>
         2008
        </year>
       </element-citation>
      </ref>
      <ref id="bb0735">
       <label>
        147
       </label>
       <element-citation id="rf0735" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Palmer
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Higgins
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Herring
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kingston
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of PCR in the diagnosis of early syphilis in the United Kingdom
        </article-title>
        <source>
         Sex Transm Infect
        </source>
        <volume>
         79
        </volume>
        <year>
         2003
        </year>
        <fpage>
         479
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         14663125
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0740">
       <label>
        148
       </label>
       <element-citation id="rf0740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grange
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gressier
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dion
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Farhi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Benhaddou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Gerhardt
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a PCR test for detection of treponema pallidum in swabs and blood
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         50
        </volume>
        <year>
         2012
        </year>
        <fpage>
         546
        </fpage>
        <lpage>
         552
        </lpage>
        <pub-id pub-id-type="pmid">
         22219306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0745">
       <label>
        149
       </label>
       <element-citation id="rf0745" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ratnam
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The laboratory diagnosis of syphilis
        </article-title>
        <source>
         Can J Infect Dis Med Microbiol
        </source>
        <volume>
         16
        </volume>
        <year>
         2005
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         18159528
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0750">
       <label>
        150
       </label>
       <element-citation id="rf0750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mosqueda
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Olvera-Ramirez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Aguilar-Tipacamu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Canto
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current advances in detection and treatment of babesiosis
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <volume>
         19
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1504
        </fpage>
        <lpage>
         1518
        </lpage>
        <pub-id pub-id-type="pmid">
         22360483
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0755">
       <label>
        151
       </label>
       <element-citation id="rf0755" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teal
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Habura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ennis
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Keithly
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Madison-Antenucci
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new real-time PCR assay for improved detection of the parasite Babesia microti
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         50
        </volume>
        <year>
         2012
        </year>
        <fpage>
         903
        </fpage>
        <lpage>
         908
        </lpage>
        <pub-id pub-id-type="pmid">
         22170915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0760">
       <label>
        152
       </label>
       <element-citation id="rf0760" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Priest
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Won
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Todd
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Henderson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiplex assay detection of immunoglobulin G antibodies that recognize Babesia microti antigens
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        <volume>
         19
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1539
        </fpage>
        <lpage>
         1548
        </lpage>
        <pub-id pub-id-type="pmid">
         22855390
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0765">
       <label>
        153
       </label>
       <element-citation id="rf0765" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 375 - Leishmaniasis
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0235" xlink:href="http://www.who.int/mediacentre/factsheets/fs375/en/">
         http://www.who.int/mediacentre/factsheets/fs375/en/
        </ext-link>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bb0770">
       <label>
        154
       </label>
       <element-citation id="rf0770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kobets
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Grekov
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Lipoldova
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Leishmaniasis: prevention, parasite detection and treatment
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <volume>
         19
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1443
        </fpage>
        <lpage>
         1474
        </lpage>
        <pub-id pub-id-type="pmid">
         22360481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0775">
       <label>
        155
       </label>
       <element-citation id="rf0775" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abbasi
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Aramin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hailu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shiferaw
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Kassahun
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Belay
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of PCR procedures for detecting and quantifying Leishmania donovani DNA in large numbers of dried human blood samples from a visceral leishmaniasis focus in Northern Ethiopia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         153
        </fpage>
        <pub-id pub-id-type="pmid">
         23530965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0780">
       <label>
        156
       </label>
       <element-citation id="rf0780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bensoussan
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Nasereddin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jonas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Schnur
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Jaffe
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of PCR assays for diagnosis of cutaneous leishmaniasis
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         44
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1435
        </fpage>
        <lpage>
         1439
        </lpage>
        <pub-id pub-id-type="pmid">
         16597873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0785">
       <label>
        157
       </label>
       <element-citation id="rf0785" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 94 - Malaria
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0240" xlink:href="http://www.who.int/mediacentre/factsheets/fs094/en/">
         http://www.who.int/mediacentre/factsheets/fs094/en/
        </ext-link>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bb0790">
       <label>
        158
       </label>
       <element-citation id="rf0790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cordray
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Richards-Kortum
          </surname>
          <given-names>
           R.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging nucleic acid-based tests for point-of-care detection of malaria
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         87
        </volume>
        <year>
         2012
        </year>
        <fpage>
         223
        </fpage>
        <lpage>
         230
        </lpage>
        <pub-id pub-id-type="pmid">
         22855751
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0795">
       <label>
        159
       </label>
       <element-citation id="rf0795" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodrigues
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cunha
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           O.C.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Rodrigues
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Soares
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1
        </article-title>
        <source>
         Malar J
        </source>
        <volume>
         2
        </volume>
        <year>
         2003
        </year>
        <fpage>
         39
        </fpage>
        <pub-id pub-id-type="pmid">
         14617378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0800">
       <label>
        160
       </label>
       <element-citation id="rf0800" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 259 -Trypanosomiasis
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0245" xlink:href="http://www.who.int/mediacentre/factsheets/fs259/en/">
         http://www.who.int/mediacentre/factsheets/fs259/en/
        </ext-link>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bb0805">
       <label>
        161
       </label>
       <element-citation id="rf0805" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chappuis
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Loutan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Simarro
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lejon
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Buscher
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Options for field diagnosis of human african trypanosomiasis
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <volume>
         18
        </volume>
        <year>
         2005
        </year>
        <fpage>
         133
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="pmid">
         15653823
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0810">
       <label>
        162
       </label>
       <element-citation id="rf0810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mugasa
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Laurent
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schoone
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kager
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lubega
          </surname>
          <given-names>
           G.W.
          </given-names>
         </name>
         <name>
          <surname>
           Schallig
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nucleic acid sequence-based amplification with oligochromatography for detection of Trypanosoma brucei in clinical samples
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         47
        </volume>
        <year>
         2009
        </year>
        <fpage>
         630
        </fpage>
        <lpage>
         635
        </lpage>
        <pub-id pub-id-type="pmid">
         19116352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0815">
       <label>
        163
       </label>
       <element-citation id="rf0815" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deborggraeve
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lejon
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Ekangu
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mumba Ngoyi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pati Pyana
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Ilunga
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study
        </article-title>
        <source>
         PLoS Negl Trop Dis
        </source>
        <volume>
         5
        </volume>
        <year>
         2011
        </year>
        <fpage>
         e972
        </fpage>
        <pub-id pub-id-type="pmid">
         21364966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0820">
       <label>
        164
       </label>
       <element-citation id="rf0820" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organisation (WHO)
          </surname>
         </name>
        </person-group>
        <article-title>
         Factsheet No 340 - Chagas Disease
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0250" xlink:href="http://www.who.int/mediacentre/factsheets/fs340/en/">
         http://www.who.int/mediacentre/factsheets/fs340/en/
        </ext-link>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bb0825">
       <label>
        165
       </label>
       <element-citation id="rf0825" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schijman
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Bisio
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Orellana
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sued
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Duffy
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mejia Jaramillo
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients
        </article-title>
        <source>
         PLoS Negl Trop Dis
        </source>
        <volume>
         5
        </volume>
        <year>
         2011
        </year>
        <fpage>
         e931
        </fpage>
        <pub-id pub-id-type="pmid">
         21264349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0830">
       <label>
        166
       </label>
       <element-citation id="rf0830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Caballero
          </surname>
          <given-names>
           Z.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sousa
          </surname>
          <given-names>
           O.E.
          </given-names>
         </name>
         <name>
          <surname>
           Marques
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Saez-Alquezar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Umezawa
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        <volume>
         14
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1045
        </fpage>
        <lpage>
         1049
        </lpage>
        <pub-id pub-id-type="pmid">
         17522327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0835">
       <label>
        167
       </label>
       <element-citation id="rf0835" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grard
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fair
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Slikas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Muyembe
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel rhabdovirus associated with acute hemorrhagic fever in central Africa
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <volume>
         8
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e1002924
        </fpage>
        <pub-id pub-id-type="pmid">
         23028323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0840">
       <label>
        168
       </label>
       <element-citation id="rf0840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel bunyavirus in China
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         365
        </volume>
        <year>
         2011
        </year>
        <fpage>
         862
        </fpage>
        <lpage>
         863
        </lpage>
        <comment>
         [author reply 864–865]
        </comment>
        <pub-id pub-id-type="pmid">
         21879913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0845">
       <label>
        169
       </label>
       <element-citation id="rf0845" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.Z.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Dai
          </surname>
          <given-names>
           Y.A.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         54
        </volume>
        <year>
         2012
        </year>
        <fpage>
         527
        </fpage>
        <lpage>
         533
        </lpage>
        <pub-id pub-id-type="pmid">
         22144540
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0850">
       <label>
        170
       </label>
       <element-citation id="rf0850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ijaz
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chitale
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bresee
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         What we are watching--five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center
        </article-title>
        <source>
         Emerg Health Threats J
        </source>
        <volume>
         6
        </volume>
        <year>
         2013
        </year>
        <fpage>
         20632
        </fpage>
        <pub-id pub-id-type="pmid">
         23827387
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0855">
       <label>
        171
       </label>
       <element-citation id="rf0855" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Zoghby
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Aly
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nasef
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Arafa
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Selim
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surveillance on A/H5N1 virus in domestic poultry and wild birds in Egypt
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         10
        </volume>
        <year>
         2013
        </year>
        <fpage>
         203
        </fpage>
        <pub-id pub-id-type="pmid">
         23799999
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0860">
       <label>
        172
       </label>
       <element-citation id="rf0860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         382
        </volume>
        <year>
         2013
        </year>
        <fpage>
         129
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         23803488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0865">
       <label>
        173
       </label>
       <element-citation id="rf0865" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral lung infections: Epidemiology, virology, clinical features, and management of avian influenza A(H7N9)
        </article-title>
        <source>
         Curr Opin Pulm Med
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         225
        </fpage>
        <lpage>
         232
        </lpage>
        <pub-id pub-id-type="pmid">
         24637225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0870">
       <label>
        174
       </label>
       <element-citation id="rf0870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Paweska
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           McMullan
          </surname>
          <given-names>
           L.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hutchison
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Street
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Palacios
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <volume>
         5
        </volume>
        <year>
         2009
        </year>
        <fpage>
         e1000455
        </fpage>
        <pub-id pub-id-type="pmid">
         19478873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0875">
       <label>
        175
       </label>
       <element-citation id="rf0875" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paweska
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Sewlall
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Blumberg
          </surname>
          <given-names>
           L.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hale
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial outbreak of novel arenavirus infection, southern Africa
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         15
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1598
        </fpage>
        <lpage>
         1602
        </lpage>
        <pub-id pub-id-type="pmid">
         19861052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0880">
       <label>
        176
       </label>
       <element-citation id="rf0880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Popgeorgiev
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Boyer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fancello
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Monteil
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Robert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Rivet
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Marseillevirus-like virus recovered from blood donated by asymptomatic humans
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         208
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1042
        </fpage>
        <lpage>
         1050
        </lpage>
        <pub-id pub-id-type="pmid">
         23821720
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0885">
       <label>
        177
       </label>
       <element-citation id="rf0885" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Popgeorgiev
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Thuret
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Chiarioni
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gallian
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Marseillevirus prevalence in multitransfused patients suggests blood transmission
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         58
        </volume>
        <year>
         2013
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         725
        </lpage>
        <pub-id pub-id-type="pmid">
         24183312
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0890">
       <label>
        178
       </label>
       <element-citation id="rf0890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bb0895">
       <label>
        179
       </label>
       <element-citation id="rf0895" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breban
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         382
        </volume>
        <year>
         2013
        </year>
        <fpage>
         694
        </fpage>
        <lpage>
         699
        </lpage>
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0900">
       <label>
        180
       </label>
       <element-citation id="rf0900" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease Control and Prevention (CDC)
          </surname>
         </name>
        </person-group>
        <article-title>
         Severe Acute Respiratory Syndrome (SARS) - frequently asked questions
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0255" xlink:href="http://www.cdc.gov/sars/about/faq.html">
         http://www.cdc.gov/sars/about/faq.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0905">
       <label>
        181
       </label>
       <element-citation id="rf0905" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Q.H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           X.D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current status of severe acute respiratory syndrome in China
        </article-title>
        <source>
         World J Gastroenterol
        </source>
        <volume>
         9
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1635
        </fpage>
        <lpage>
         1645
        </lpage>
        <pub-id pub-id-type="pmid">
         12918094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0910">
       <label>
        182
       </label>
       <element-citation id="rf0910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Confronting SARS: a view from Hong Kong
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        <volume>
         359
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1075
        </fpage>
        <lpage>
         1079
        </lpage>
        <pub-id pub-id-type="pmid">
         15306392
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0915">
       <label>
        183
       </label>
       <element-citation id="rf0915" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pereira
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rhodes
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           An
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Pipas
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jain
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel polyomavirus in a pancreatic transplant recipient with retinal blindness and vasculitic myopathy
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         210
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1595
        </fpage>
        <lpage>
         1599
        </lpage>
        <pub-id pub-id-type="pmid">
         24795478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0920">
       <label>
        184
       </label>
       <element-citation id="rf0920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sauvage
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Livartowski
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Boizeau
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Servant-Delmas
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lionnet
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lefrere
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         No evidence of Marseillevirus-like virus presence in blood donors and recipients of multiple blood transfusions
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         210
        </volume>
        <year>
         2014
        </year>
        <fpage>
         2017
        </fpage>
        <lpage>
         2018
        </lpage>
        <pub-id pub-id-type="pmid">
         25267981
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0925">
       <label>
        185
       </label>
       <element-citation id="rf0925" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Busch
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hecht
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The detection of acute HIV infection
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         202
        </volume>
        <issue>
         Suppl. 2
        </issue>
        <year>
         2010
        </year>
        <fpage>
         S270
        </fpage>
        <lpage>
         S277
        </lpage>
        <pub-id pub-id-type="pmid">
         20846033
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0930">
       <label>
        186
       </label>
       <element-citation id="rf0930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ciccaglione
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Miceli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pisani
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Bruni
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Iudicone
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Costantino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Improving HIV-2 detection by a combination of serological and nucleic acid amplification test assays
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         48
        </volume>
        <year>
         2010
        </year>
        <fpage>
         2902
        </fpage>
        <lpage>
         2908
        </lpage>
        <pub-id pub-id-type="pmid">
         20573872
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0935">
       <label>
        187
       </label>
       <element-citation id="rf0935" publication-type="other">
        <article-title>
         Food and Drug Administration (FDA) Guidance for Industry: Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0260" xlink:href="http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm327850.htm">
         http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm327850.htm
        </ext-link>
        <year>
         Jan 2015
        </year>
       </element-citation>
      </ref>
      <ref id="bb0940">
       <label>
        188
       </label>
       <element-citation id="rf0940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Namululi
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           Guerrieri
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dramaix
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence and incidence of HIV and hepatitis B among blood donors and estimated residual risk of transmission of HIV and HBV virus by blood transfusion. A study at the Provincial General Referee Hospital Bukavu, Democratic Republic of the Congo
        </article-title>
        <source>
         Rev Epidemiol Sante Publique
        </source>
        <volume>
         61
        </volume>
        <year>
         2013
        </year>
        <fpage>
         139
        </fpage>
        <lpage>
         144
        </lpage>
        <pub-id pub-id-type="pmid">
         23498094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0945">
       <label>
        189
       </label>
       <element-citation id="rf0945" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Almeida-Neto
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Goncalez
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
         <name>
          <surname>
           Birch
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           de Carvalho
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Capuani
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Leao
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for human immunodeficiency virus infection among Brazilian blood donors: a multicentre case-control study using audio computer-assisted structured interviews
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         105
        </volume>
        <year>
         2013
        </year>
        <fpage>
         91
        </fpage>
        <lpage>
         99
        </lpage>
        <pub-id pub-id-type="pmid">
         23517235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0950">
       <label>
        190
       </label>
       <element-citation id="rf0950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenberg
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lattimore
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brailsford
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hewitt
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Tettmar
          </surname>
          <given-names>
           K.I.
          </given-names>
         </name>
         <name>
          <surname>
           Kitchen
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The diversity of chronic hepatitis B virus infections within blood donors in England and North Wales 2005 through 2010
        </article-title>
        <source>
         Transfusion
        </source>
        <volume>
         53
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2467
        </fpage>
        <lpage>
         2476
        </lpage>
        <pub-id pub-id-type="pmid">
         23216332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0955">
       <label>
        191
       </label>
       <element-citation id="rf0955" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seed
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Kiely
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         105
        </volume>
        <year>
         2013
        </year>
        <fpage>
         290
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="pmid">
         23802710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0960">
       <label>
        192
       </label>
       <element-citation id="rf0960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Offergeld
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ritter
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hamouda
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010]. Bundesgesundheitsblatt, Gesundheitsforschung
        </article-title>
        <source>
         Gesundheitsschutz
        </source>
        <volume>
         55
        </volume>
        <year>
         2012
        </year>
        <fpage>
         907
        </fpage>
        <lpage>
         913
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0965">
       <label>
        193
       </label>
       <element-citation id="rf0965" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Araujo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. Joao, EPE, Porto, Portugal
        </article-title>
        <source>
         Acta Med Port
        </source>
        <volume>
         26
        </volume>
        <year>
         2013
        </year>
        <fpage>
         371
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="pmid">
         24016646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0970">
       <label>
        194
       </label>
       <element-citation id="rf0970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cleland
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Crossan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Blatchford
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Dalton
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Scobie
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis E virus in Scottish blood donors
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         105
        </volume>
        <year>
         2013
        </year>
        <fpage>
         283
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="pmid">
         23763589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0975">
       <label>
        195
       </label>
       <element-citation id="rf0975" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baylis
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gartner
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Nick
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ovemyr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Blumel
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States
        </article-title>
        <source>
         Vox Sang
        </source>
        <volume>
         103
        </volume>
        <year>
         2012
        </year>
        <fpage>
         89
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         22220775
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0980">
       <label>
        196
       </label>
       <element-citation id="rf0980" publication-type="other">
        <article-title>
         World Federation of Hemophilia (WFH) Annual Global Surveys
        </article-title>
        <comment>
         Accessible from:
        </comment>
        <ext-link ext-link-type="uri" id="ir0265" xlink:href="http://www.wfh.org/en/page.aspx?pid=878">
         http://www.wfh.org/en/page.aspx?pid=878
        </ext-link>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="s0180" sec-type="supplementary-material">
      <label>
       Appendix A
      </label>
      <title>
       Supplementary data
      </title>
      <p id="p0320">
       <supplementary-material content-type="local-data" id="ec0005">
        <caption>
         <p>
          Supplementary material
         </p>
        </caption>
        <media xlink:href="mmc1.docx">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ac0005">
      <title>
       Acknowledgements
      </title>
      <p>
       We wish to thank Professor Hermann Eichler for his appraisal of this manuscript and helpful suggestions. Medical writing assistance was provided by Hanna Mourad-Agha of inScience Communications, Springer Healthcare. This assistance was funded by Pfizer.
      </p>
     </ack>
     <fn-group>
      <fn id="d32e3268">
       <label>
        ☆
       </label>
       <p id="np0045">
        REVIEW
       </p>
      </fn>
      <fn fn-type="supplementary-material" id="s0000">
       <label>
        Appendix A
       </label>
       <p id="p0000">
        Supplementary data to this article can be found online at
        <ext-link ext-link-type="doi" id="ir0005" xlink:href="10.1016/j.blre.2015.07.004">
         http://dx.doi.org/10.1016/j.blre.2015.07.004
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerging Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       EID
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1080-6040
      </issn>
      <issn pub-type="epub">
       1080-6059
      </issn>
      <publisher>
       <publisher-name>
        Centers for Disease Control and Prevention
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27191038
      </article-id>
      <article-id pub-id-type="pmc">
       4982159
      </article-id>
      <article-id pub-id-type="publisher-id">
       15-2015
      </article-id>
      <article-id pub-id-type="doi">
       10.3201/eid2208.152015
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research
        </subject>
       </subj-group>
       <subj-group subj-group-type="article-type">
        <subject>
         Research
        </subject>
       </subj-group>
       <subj-group subj-group-type="TOC-title">
        <subject>
         Middle East Respiratory Syndrome Coronavirus Transmission in Extended Family, Saudi Arabia, 2014
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East Respiratory Syndrome Coronavirus Transmission in Extended Family, Saudi Arabia, 2014
       </article-title>
       <alt-title alt-title-type="running-head">
        MERS-CoV Transmission in Extended Family
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Arwady
         </surname>
         <given-names>
          M. Allison
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Alraddadi
         </surname>
         <given-names>
          Basem
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Basler
         </surname>
         <given-names>
          Colin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Azhar
         </surname>
         <given-names>
          Esam I.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Abuelzein
         </surname>
         <given-names>
          Eltayb
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sindy
         </surname>
         <given-names>
          Abdulfattah I.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sadiq
         </surname>
         <given-names>
          Bakr M. Bin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Althaqafi
         </surname>
         <given-names>
          Abdulhakeem O.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shabouni
         </surname>
         <given-names>
          Omaima
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Banjar
         </surname>
         <given-names>
          Ayman
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Haynes
         </surname>
         <given-names>
          Lia M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gerber
         </surname>
         <given-names>
          Susan I.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Feikin
         </surname>
         <given-names>
          Daniel R.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Madani
         </surname>
         <given-names>
          Tariq A.
         </given-names>
        </name>
       </contrib>
       <aff id="aff1">
        Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.A. Arwady, C. Basler, L.M. Haynes, S.I. Gerber, D.R. Feikin);
       </aff>
       <aff id="aff2">
        King Faisal Specialist Hospital and Research Center, Jeddah (B. Alraddadi);
       </aff>
       <aff id="aff3">
        Ministry of Health, Jeddah, Saudi Arabia (B. Alraddadi, E.I. Azhar, E. Abuelzein, A.I. Sindy, B.M. Bin Sadiq, A.O. Althaqafi, O. Shabouni, A. Banjar, T.A. Madani);
       </aff>
       <aff id="aff4">
        King Abdulaziz University, Jeddah (E.I. Azhar, T.A. Madani);
       </aff>
       <aff id="aff5">
        Ministry of National Guard, Jeddah (A.O. Althaqafi)
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address for correspondence: Tariq A. Madani, Department of Medicine, Faculty of Medicine, King Abdulaziz University, PO Box 80215, Jeddah 21589, Saudi Arabia; email:
        <email xlink:href="tmadani@kau.edu.sa">
         tmadani@kau.edu.sa
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        8
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       22
      </volume>
      <issue>
       8
      </issue>
      <fpage>
       1395
      </fpage>
      <lpage>
       1402
      </lpage>
      <abstract abstract-type="toc">
       <p>
        Casual contact was not associated with transmission, and serologic methods were more sensitive than real-time reverse transcription-PCR.
       </p>
      </abstract>
      <abstract>
       <p>
        Risk factors for human-to-human transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) are largely unknown. After MERS-CoV infections occurred in an extended family in Saudi Arabia in 2014, relatives were tested by using real-time reverse transcription PCR (rRT-PCR) and serologic methods. Among 79 relatives, 19 (24%) were MERS-CoV positive; 11 were hospitalized, and 2 died. Eleven (58%) tested positive by rRT-PCR; 8 (42%) tested negative by rRT-PCR but positive by serology. Compared with MERS-CoV–negative adult relatives, MERS-CoV–positive adult relatives were older and more likely to be male and to have chronic medical conditions. Risk factors for household transmission included sleeping in an index patient’s room and touching respiratory secretions from an index patient. Casual contact and simple proximity were not associated with transmission. Serology was more sensitive than standard rRT-PCR for identifying infected relatives, highlighting the value of including serology in future investigations.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        Keywords:
       </title>
       <kwd>
        Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        disease transmission
       </kwd>
       <kwd>
        infectious
       </kwd>
       <kwd>
        serologic tests
       </kwd>
       <kwd>
        RT-PCR
       </kwd>
       <kwd>
        viruses
       </kwd>
       <kwd>
        Saudi Arabia
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported in September 2012 in a patient in Saudi Arabia (
     <xref ref-type="bibr" rid="R1">
      <italic>
       1
      </italic>
     </xref>
     <italic>
      ,
     </italic>
     <xref ref-type="bibr" rid="R2">
      <italic>
       2
      </italic>
     </xref>
     ). MERS-CoV is known to cause a severe acute febrile respiratory illness in humans after an incubation period of 2–14 days (
     <xref ref-type="bibr" rid="R3">
      <italic>
       3
      </italic>
     </xref>
     ). As of May 1, 2016, a total of 1,728 laboratory-confirmed cases, including 624 deaths, had been reported globally (
     <xref ref-type="bibr" rid="R4">
      <italic>
       4
      </italic>
     </xref>
     ); all patients have been linked to the Arabian Peninsula (
     <xref ref-type="bibr" rid="R5">
      <italic>
       5
      </italic>
     </xref>
     <italic>
      ,
     </italic>
     <xref ref-type="bibr" rid="R6">
      <italic>
       6
      </italic>
     </xref>
     ). Studies suggest dromedary camels as a possible natural host (
     <xref ref-type="bibr" rid="R7">
      <italic>
       7
      </italic>
     </xref>
     ), although most patients report no exposure to camels (
     <xref ref-type="bibr" rid="R8">
      <italic>
       8
      </italic>
     </xref>
     ). Sustained human-to-human transmission in community settings has not been observed (
     <xref ref-type="bibr" rid="R6">
      <italic>
       6
      </italic>
     </xref>
     ), but transmission has been documented in healthcare settings (
     <xref ref-type="bibr" rid="R9">
      <italic>
       9
      </italic>
     </xref>
     <italic>
      ,
     </italic>
     <xref ref-type="bibr" rid="R10">
      <italic>
       10
      </italic>
     </xref>
     ) and in households (
     <xref ref-type="bibr" rid="R11">
      <italic>
       11
      </italic>
     </xref>
     <italic>
      –
     </italic>
     <xref ref-type="bibr" rid="R14">
      <italic>
       14
      </italic>
     </xref>
     ). Specific risk factors for secondary transmission remain unknown.
    </p>
    <p>
     In Saudi Arabia, real-time reverse transcription PCR (rRT-PCR) of nasopharyngeal or oropharyngeal swabs is used for routine MERS-CoV diagnosis and contact tracing. rRT-PCR identifies and amplifies viral RNA, indicating active infection. More recently developed serologic assays identify antibodies to MERS-CoV, indicating previous infection. MERS-CoV antibodies are rare in the general population; a nationwide serosurvey in Saudi Arabia in 2013 found antibodies in 15 (0.15%) of 10,009 persons (
     <xref ref-type="bibr" rid="R15">
      <italic>
       15
      </italic>
     </xref>
     ).
    </p>
    <p>
     MERS-CoV cases in Saudi Arabia increased substantially during March–April 2014 (
     <xref ref-type="bibr" rid="R16">
      <italic>
       16
      </italic>
     </xref>
     ) in association with transmission in healthcare settings (
     <xref ref-type="bibr" rid="R9">
      <italic>
       9
      </italic>
     </xref>
     <italic>
      ,
     </italic>
     <xref ref-type="bibr" rid="R10">
      <italic>
       10
      </italic>
     </xref>
     ). In May 2014, as the number of urban cases decreased (
     <xref ref-type="bibr" rid="R10">
      <italic>
       10
      </italic>
     </xref>
     <italic>
      ,
     </italic>
     <xref ref-type="bibr" rid="R17">
      <italic>
       17
      </italic>
     </xref>
     ), a new cluster was identified 400 km south of Jeddah, in an area that had not previously reported cases. All identified patients were members of 1 extended family from the town of Al-Qouz, near Al-Qunfudah. The first MERS-CoV diagnosis was reported on May 20, 2014, in a hospitalized patient after 14 days of worsening respiratory symptoms and impending respiratory failure; by May 29, this man’s wife, brother, and nephew and the nephew’s paternal uncle had been hospitalized with confirmed MERS-CoV. These 5 relatives lived in 4 different households within Al-Qouz.
    </p>
    <p>
     On June 4–5, 2014, representatives from the Saudi Arabia Ministry of Health (Jeddah), US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), and King Abdulaziz University (Jeddah) joined the Al-Qunfudah Regional Health Department to investigate the family cluster. The objectives were to characterize the cluster by identifying additional cases through both rRT-PCR for viral RNA and serologic testing for MERS-CoV antibodies; to determine transmission risk factors for MERS-CoV within the affected households; and to assess possible MERS-CoV infections in the larger community, sampling both local healthcare settings and local animal workers.
    </p>
    <sec sec-type="methods">
     <title>
      Methods
     </title>
     <sec>
      <title>
       Cluster Investigation
      </title>
      <p>
       To find cases, we interviewed clinicians, reviewed regional records, and searched a national laboratory database. We interviewed all persons who had received a MERS-CoV diagnosis in the region and reviewed hospitalized patients’ medical charts; proxy interviews were conducted for patients who were in the intensive care unit or who had died. We then conducted a retrospective cohort study to assess infection risk factors among household members. We aimed to interview and test all members of the 4 households of the 5 known MERS-CoV–infected patients, as well as relatives who regularly visited these households and were present on the day of the on-site investigation.
      </p>
      <p>
       On June 5, trained nurses collected 1 oropharyngeal and 1 nasopharyngeal swab for rRT-PCR and 1 blood sample for serologic testing from all available household members and visiting relatives. Hospitalized persons, persons who previously had tested positive by rRT-PCR, and children &lt;14 years of age did not undergo serologic testing. Local public health officials had previously collected oropharyngeal swabs for rRT-PCR in the households during May 20–29; we reviewed these records. On June 5, trained physicians administered a standardized questionnaire to household members and visiting relatives to identify symptoms and healthcare exposures and infection risk factors, including animal contact, recent travel, underlying medical conditions, tobacco use, and details of exposure to each household’s index patient. An index patient was defined as the person with rRT-PCR confirmation of MERS-CoV who had the earliest date of symptom onset in the household.
      </p>
     </sec>
     <sec>
      <title>
       Healthcare Worker and Community Transmission
      </title>
      <p>
       To understand whether this outbreak was affecting the broader community, we collected data at the town’s hospital, at the outpatient clinic nearest the family’s homes, at 2 local slaughterhouse facilities, and at the town’s weekly livestock animal market. All hospital staff members who had treated the first identified MERS-CoV patient from his admission on May 9 until his MERS-CoV diagnosis on May 20 underwent hospital-based rRT-PCR of oropharyngeal swabs May 21–23; serologic testing was not performed. At the outpatient clinic, all staff and a convenience sample of patients who visited the clinic on June 4 with respiratory symptoms or fever were interviewed with a standardized questionnaire and tested for MERS-CoV by using nasopharyngeal and oropharyngeal swabs for rRT-PCR and blood for serologic testing. All animal workers at 2 local slaughterhouse facilities and a convenience sample of persons with daily animal contact who were present at the town’s weekly livestock animal market on June 4 were interviewed and tested by using the same methods.
      </p>
     </sec>
     <sec>
      <title>
       Laboratory Testing
      </title>
      <p>
       Specimens from hospitalized patients and hospital staff members underwent rRT-PCR at the Ministry of Health’s Jeddah regional laboratory, according to Ministry of Health protocol (
       <xref ref-type="bibr" rid="R18">
        <italic>
         18
        </italic>
       </xref>
       ). Nasopharyngeal and oropharyngeal flocked swabs collected in the households, at the community clinic, and in animal workers were placed in viral transport media and transferred at 4°C to King Abdulaziz University, where rRT-PCR amplification of consensus viral RNA targets (upstream of E and open reading frame 1a) was undertaken (
       <xref ref-type="bibr" rid="R19">
        <italic>
         19
        </italic>
       </xref>
       ). Serum samples were sent to CDC and screened for MERS-CoV antibodies by the recombinant MERS-CoV nucleocapsid protein ELISA, and confirmatory testing was conducted with immunofluorescence assay and microneutralization (
       <xref ref-type="bibr" rid="R20">
        <italic>
         20
        </italic>
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Data Analysis and Ethics Review
      </title>
      <p>
       We analyzed questionnaire data using Epi Info 7.0 (CDC, Atlanta, GA, USA). Proportions were compared by using the χ
       <sup>
        2
       </sup>
       or Fischer exact test and medians by using Wilcoxon rank-sum. Risk ratios (RRs) were calculated. We compared questionnaire data for all MERS-CoV–positive (by rRT-PCR or serology) relatives
       <underline>
        &gt;
       </underline>
       14 years of age with questionnaire data for all MERS-CoV–negative relatives
       <underline>
        &gt;
       </underline>
       14 years of age. We excluded children from analysis because they had not had antibody testing of serum. A household secondary transmission analysis comprised relatives
       <underline>
        &gt;
       </underline>
       14 years of age residing only in the 4 affected households. Results for MERS-CoV–positive household members who had illness onset (or tested MERS-CoV–positive) at least 2 days after the household’s index patient’s illness onset were compared with results for MERS-CoV–negative household members.
      </p>
      <p>
       Because this investigation was part of a public health response, it was not considered by CDC and the Saudi Arabia Ministry of Health to be research that was subject to review by an institutional review board. Participants gave verbal consent.
      </p>
     </sec>
    </sec>
    <sec sec-type="results">
     <title>
      Results
     </title>
     <p>
      Nineteen extended family members had evidence of MERS-CoV by rRT-PCR or presence of MERS-CoV antibodies (
      <xref ref-type="fig" rid="F1">
       Figure 1
      </xref>
      ). Seventy-nine relatives were interviewed and tested for MERS-CoV by both rRT-PCR and (unless already positive by rRT-PCR or &lt;14 years of age) serology. These persons comprised 50 (96%) of the 52 relatives living in the 4 original households (including 13 children &lt;14 years of age); 26 relatives visiting those households (including 6 children &lt;14 years of age); and 3 ill adults identified in a separate branch of the family tree (J, K, and O;
      <xref ref-type="fig" rid="F1">
       Figure 1
      </xref>
      ) after the household investigation. All 26 visiting relatives were MERS-CoV–negative by both rRT-PCR and (for adults) serology.
     </p>
     <fig fig-type="figure" id="F1" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Family relationships and household distribution of persons infected with MERS-CoV, Al-Qouz, Saudi Arabia, 2014. Black lines denote standard family tree relationships. Patients are lettered in order of symptom onset or, if asymptomatic, by test date. Green boxes indicate households; all persons living in households 1–4 were tested, except for 2 adults living in household 4 (not shown). Index patient (person with earliest symptom onset diagnosed by rRT-PCR) in each household is underlined. Uninfected indicates person in household with negative rRT-PCR results and (if
        <underline>
         &gt;
        </underline>
        14 years of age) negative serologic testing for MERS-CoV. Visiting relatives indicates extended family members who regularly visited the 4 households and were present in the households on the day of the field investigation. MERS-CoV, Middle East respiratory syndrome coronavirus; rRT-PCR, real-time reverse transcription PCR.
       </p>
      </caption>
      <graphic xlink:href="15-2015-F1">
      </graphic>
     </fig>
     <sec>
      <title>
       Standard Diagnosis and Disease Presentation
      </title>
      <p>
       MERS-CoV was diagnosed in 11 (58%) of the 19 patients by rRT-PCR, the standard method in Saudi Arabia (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ). For 7 of these, including the 5 original patients, illness was diagnosed during May 20–June 9 while they were hospitalized (
       <xref ref-type="fig" rid="F2">
        Figure 2
       </xref>
       ). For the other 4 patients (L, M, N, and O), MERS-CoV infection was diagnosed during May 22–June 11 through routine contact tracing and rRT-PCR by regional health officers. One of these contacts denied symptoms, 2 reported mild symptoms (i.e., cough, subjective fever) but had not sought medical care, and 1 (N, the only child given a MERS-CoV diagnosis) had visited an emergency department with fever. In the 4 households, all nonhospitalized family members were rRT-PCR–negative when tested on June 5, indicating little risk for ongoing household transmission.
      </p>
      <table-wrap id="T1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Clinical and laboratory characteristics of 19 family members who received a MERS-CoV diagnosis, Al-Qouz, Saudi Arabia, 2014*
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="36"/>
        <col span="1" width="50"/>
        <col span="1" width="63"/>
        <col span="1" width="109"/>
        <col span="1" width="45"/>
        <col span="1" width="9"/>
        <col span="1" width="63"/>
        <col span="1" width="45"/>
        <col span="1" width="81"/>
        <col span="1" width="93"/>
        <col span="1" width="88"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
           Patient
          </th>
          <th align="center" colspan="1" rowspan="2" scope="col" valign="bottom">
           Age, y/sex
          </th>
          <th align="center" colspan="1" rowspan="2" scope="col" valign="bottom">
           Underlying condition
          </th>
          <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
           Symptoms
           <hr/>
          </th>
          <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
          </th>
          <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
           Hospitalization
           <hr/>
          </th>
          <th align="center" colspan="1" rowspan="2" scope="col" valign="bottom">
           Disposition
          </th>
          <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
           Test result
           <hr/>
          </th>
         </tr>
         <tr>
          <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
           Presenting
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Onset date
          </th>
          <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
           Admission date
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Intubated
          </th>
          <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
           rRT-PCR†
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Antibody‡
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           A
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           32/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, diarrhea
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Apr 18
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Apr 21
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged Apr 28
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: Apr 21, Apr 23, Apr 24, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pas; MNT 80
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           B
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           70/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           HTN
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, diarrhea, shortness of breath
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 1
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 1
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged May 7
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: May 2, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA&gt;6,400; IFA pos; MNT 320
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           C
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           54/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           DM, HTN, CAD
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, shortness of breath
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 6
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 9
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Yes
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged Jun 23
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 20
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           D
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           65/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, abdominal distention, night sweats
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 9
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 18
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged May 21
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 20 Neg: Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pos; MNT 320
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           E
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           34/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, shortness of breath
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 14
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 17
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged May 30
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 21 Neg: Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pos; MNT 160
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           F
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           50/F
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           HTN, CAD
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Diarrhea, fever, cough, headache
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 17
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 21
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Yes
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Died May 31
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 22
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           G
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           29/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           DM
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Abdominal pain, diarrhea
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 20
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 21
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged May 26
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: May 22, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pos; MNT 160
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           H
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           16/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, sore throat, diarrhea
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 20
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 21
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged May 26
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: May 22, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA 6,400; IFA pos; MNT 40
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           I
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           48/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           DM, HTN
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, shortness of breath
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 21
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 26
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Yes
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged Jul 1
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg; May 27 Pos: May 29
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           J
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           39/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           DM, HTN
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, sore throat, chest pain
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 22
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           May 27
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Yes
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Discharged Jul 1
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 28
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           K
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           73/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           DM, HTN, CAD
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, hypoglycemia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Jun 4
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Jun 6
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Yes
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Died Jun 20
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: Jun 9
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           L
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           27/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Tested as a contact; no symptoms
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No medical care
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 22 Neg: Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           25/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Tested as a contact; cough
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Unknown
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No medical care
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 23 Neg: Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pos; MNT 20
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           N
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Tested as a contact; fever
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Unknown
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ED care, not admitted
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: May 25 Neg: Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           O
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           36/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Tested as a contact; subjective fever
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Jun 6
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No medical care
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Pos: Jun 11
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Not tested
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           P
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           50/F
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Tested as a contact; no symptoms
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No medical care
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: once during May 20–29, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pos; MNT &lt;20
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Q
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           38/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Asthma
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Tested as a contact; no symptoms
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No medical care
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: once during May 20–29; Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA 1,600; IFA pos; MNT 40
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           R
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           29/M
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, diarrhea
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Unknown
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ED care, not admitted
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: once during May 20–29, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA 400; IFA indeterminate; MNT 20
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           S
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           34/F
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           None
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Fever, cough, sore throat, diarrhea, shortness of breath
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Unknown
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ED care, not admitted
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           No
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Well
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Neg: once during May 20–29, Jun 5
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           ELISA &gt;6,400; IFA pos; MNT 20
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         *CAD, coronary artery disease; DM, diabetes mellitus; ED, emergency department; HTN, hypertension; IFA, immunofluorescence assay; MERS-CoV, Middle East respiratory syndrome coronavirus; MNT, microneutralization testing; neg, negative; pos, positive; rRT-PCR, real-time reverse transcription PCR. †Initial rRT-PCR for all persons was conducted at the time of illness (or among asymptomatic persons as part of routine contact tracing). ‡All serologic specimens were collected on June 5, 2014.
        </p>
       </table-wrap-foot>
      </table-wrap>
      <fig fig-type="figure" id="F2" position="float">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Timeline of illness onset and testing for MERS-CoV–positive family members, Al-Qouz, Saudi Arabia, 2014. Patients M and N had mild symptoms during 2 weeks before their rRT-PCR–positive results but did not identify a specific onset date; their illness dates are estimated. Patients R and S reported symptoms during the month preceding their positive serology tests but also without a specific onset date; their illness dates are not displayed. Patients L, P, and Q denied symptoms at any time. HH, household; MERS-CoV, Middle East respiratory syndrome coronavirus; Pt, patient; rRT-PCR, real-time reverse transcription PCR; S, positive serology date for rRT-PCR–negative persons.
        </p>
       </caption>
       <graphic xlink:href="15-2015-F2">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       Serologic Diagnosis and Disease Presentation
      </title>
      <p>
       For 8 (42%) of the 19 positive family members, MERS-CoV infection was diagnosed only retrospectively by using serology. All 8 previously had tested negative by rRT-PCR during April 21–May 29 while hospitalized or during routine contact tracing, and all again tested negative on June 5. Two of these rRT-PCR–negative patients (A and B) had extended hospitalizations; 2 patients (G and H) had brief hospitalizations; 2 patients (R and S) had sought medical care but not required hospitalization; and 2 (P and Q) denied symptoms. Some of these patients had multiple negative tests; during an April 2014 hospitalization in Jeddah, patient A, the first patient in this family to become ill, had 3 negative rRT-PCR results of nasopharyngeal swabs.
      </p>
      <p>
       Among the 19 relatives in whom MERS-CoV infection was diagnosed, 11 (58%) were hospitalized; 3 (16%) were treated in an emergency department for symptoms but not hospitalized; 2 (11%) reported mild symptoms but had not sought medical care; and 3 (16%) were asymptomatic. Five (26%) were intubated, 2 of whom (11%) died while hospitalized. Fever was the most commonly reported symptom (74%), followed by cough (63%), shortness of breath (44%), and diarrhea (44%). The 11 hospitalized patients were ill at home for a median of 3 days before hospital admission (range 0–9 days) (
       <xref ref-type="fig" rid="F2">
        Figure 2
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Infection Risk Factors among Adults
      </title>
      <p>
       Fifteen (83%) of 18 MERS-CoV–positive adults were male, compared with 15 (37%) of 41 MERS-CoV–negative adults (p = 0.0009;
       <xref ref-type="table" rid="T2">
        Table 2
       </xref>
       ). MERS-CoV–positive adults were more likely to have smoked sheesha, the traditional water pipe for flavored tobacco, than were MERS-CoV–negative adults (2/18 [11%] vs. 0/41; p = 0.003) and were more likely to have traveled to Jeddah (10 [56%] vs. 9 [22%]; p = 0.011) and visited a hospital there (7 [39%] vs. 5 [12%]; p = 0.019) during the month before becoming ill. MERS-CoV–positive adults were older (median age 37 years vs. 25 years; p = 0.0011) and more likely to report chronic medical problems (8 [44%] vs. 5 [12%]; p = 0.006), including diabetes mellitus and heart disease. All MERS-CoV–positive relatives denied animal contact during the 14 days before testing.
      </p>
      <table-wrap id="T2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <title>
         Demographic, risk factor and symptom characteristics of adults with MERS-CoV–positive and MERS-CoV–negative test results in an extended family, Al-Qouz, Saudi Arabia, 2014*
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="218"/>
        <col span="1" width="94"/>
        <col span="1" width="81"/>
        <col span="1" width="88"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
           Characteristic†
          </th>
          <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
           Test results, no. (%)
           <hr/>
          </th>
          <th align="center" colspan="1" rowspan="2" scope="col" valign="bottom">
           Risk ratio (95% CI)
          </th>
         </tr>
         <tr>
          <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
           Positive, n = 18
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Negative, n = 41
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Male sex
           <hr/>
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           15 (83)
           <hr/>
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           15 (37)
           <hr/>
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            4.8 (1.6–15.0)
           </bold>
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Reported chronic medical problem
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (12)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            2.8 (1.4–5.7)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Diabetes mellitus
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (28)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (2)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            3.4 (1.9–6.1)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Hypertension
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (22)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3 (7)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            2.1 (1.0–4.6)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Asthma
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (6)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (2)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.7 (0.4
           <bold>
            –
           </bold>
           7.1)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Heart disease
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (22)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            3.1 (1.6–5.8)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Smoked cigarettes
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2 (11)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (2)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.3 (0.9
           <bold>
            –
           </bold>
           5.7)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Smoked sheesha
           <hr/>
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2 (11)
           <hr/>
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
           <hr/>
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            3.6 (2.4–5.4)
           </bold>
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Reported activities
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Visited animal market during preceding 14 d
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2 (5)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0 (undefined)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Touched live animal during preceding 14 d
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (2)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0 (undefined)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Touched camel during preceding 14 d
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0 (undefined)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Traveled to Jeddah during preceding month
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           10 (56)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           9 (22)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            2.6 (1.2–5.6)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Visited Jeddah hospital during preceding month
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (39)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (12)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            2.5 (1.2–5.0)
           </bold>
          </td>
         </tr>
        </tbody>
       </table>
       <table frame="hsides" rules="groups">
        <col span="1" width="218"/>
        <col span="1" width="94"/>
        <col span="1" width="81"/>
        <col span="1" width="88"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Illness at any time during preceding month
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Sought medical care
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           13 (72)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (10)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            6.4 (2.7–15.2)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Admitted to hospital
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           11 (61)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0 (0)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            6.9 (3.5–13.6)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Fever
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           13 (72)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3 (7)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            7.0 (3.0–16.5)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Cough
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           12 (67)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (23)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            4.9 (2.2–11.0)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shortness of breath
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (2)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            4.4 (2.4–8.1)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Diarrhea
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (47)‡
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3 (8)§
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            3.7 (1.9–7.4)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Vomiting
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2 (12)‡
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (3)§
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            2.4 (1.0–6.0)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Chills
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (29)‡
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (3)§
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            3.5 (1.9–6.5)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Body aches
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           9 (53)‡
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (3)§
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            5.3 (2.7–10.3)
           </bold>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         *Bold indicates statistical significance. Analysis includes all relatives 14 y of age tested for MERS-CoV (n = 59), regardless of household or visitor status. Positive indicates positive rRT-PCR or serologic antibody testing for MERS-CoV; negative indicates negative rRT-PCR and serologic antibody testing. Children (one 2-year-old rRT-PCR–positive child and 19 rRT-PCR–negative children) were excluded because they did not have serologic antibody testing. Listed chronic medical problems were self-reported; no one reported chronic lung or kidney disease, and other self-reported problems (hyperthyroidism, allergies, and solitary kidney) were excluded. MERS-CoV, Middle East respiratory syndrome coronavirus; rRT-PCR, real-time reverse transcription PCR.  †Ages were as follows: MERS-CoV positive: median 37 y (range 16–73 y); MERS-CoV-negative: median 25 y (range 14–60y). ‡Of the 17 persons for whom this information was reported. §Of the 40 persons for whom this information was reported.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Household Transmission
      </title>
      <p>
       In household 1, eight of the 12 adults (a husband and wife, 5 of their adult sons, and 1 son’s wife) and 1 of the 7 children received a MERS-CoV diagnosis (household attack rate 44%; household adult attack rate 64%) (
       <xref ref-type="fig" rid="F1">
        Figure 1
       </xref>
       ). In household 2, five of the 12 adults (a husband and wife and 3 of their adult sons) received a MERS-CoV diagnosis (household attack rate 29%; household adult attack rate 42%). In households 3 and 4, only the index patients (both adult men) tested positive; no secondary patients were identified. All family members in whom MERS-CoV symptoms developed or who had positive rRT-PCR results reported contact with at least 1 ill relative in the preceding 14 days (
       <xref ref-type="fig" rid="F3">
        Figure 3
       </xref>
       ).
      </p>
      <fig fig-type="figure" id="F3" position="float">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Reported contact among family members who received a MERS-CoV diagnosis and illness onset timeline, Al-Qouz, Saudi Arabia, 2014. Patients L, M, and N, as well as the infected nurse, reported no or mild symptoms and could not identify onset dates; for these 4 persons, the rRT-PCR–positive date is listed. All persons were questioned about ill family members with whom they had close contact during illness. Solid arrows indicate contact between persons within 14 days (MERS–CoV incubation period is
         <underline>
          &lt;
         </underline>
         14 days) and indicate a likely infection source. Dashed arrows indicate contact after the 14-day incubation period; they are included for patients M and N because these patients could not identify their precise illness onset dates. MERS-CoV, Middle East respiratory syndrome coronavirus; rRT-PCR, reverse transcription PCR.
        </p>
       </caption>
       <graphic xlink:href="15-2015-F3">
       </graphic>
      </fig>
      <p>
       When we compared results for the 9 secondary adult patients (adults who tested MERS-CoV–positive with illness onset after the presumed index patient) in these 4 households with the results for 21 adults in the households who tested negative, we identified several major risk factors for MERS-CoV transmission in univariate analysis (
       <xref ref-type="table" rid="T3">
        Table 3
       </xref>
       ). These risk factors included sleeping in the same room as an index patient (RR 4.1, 95% CI 1.5–11.2), touching his respiratory secretions (RR 4.0, 95% CI 1.6–9.8), and removing his biological waste (RR 3.2, 95% CI 1.2–8.4). Notable variables not associated with being a secondary patient included hugging or social kissing; sharing plates, cups, meals, sheesha, or a toilet; and cleaning or feeding the index patient.
      </p>
      <table-wrap id="T3" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <title>
         Exposures to MERS-CoV index patients by household adult members with and without secondary MERS-CoV infection living in 4 households, Al-Qouz, Saudi Arabia, 2014*
        </title>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" width="218"/>
        <col span="1" width="108"/>
        <col span="1" width="81"/>
        <col span="1" width="74"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="bottom">
           Exposure/activity
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Infected by secondary transmission, no. (%), n = 9
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Uninfected, no. (%), n = 21
          </th>
          <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
           Risk ratio (95% CI)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Daily household activities
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Treated index patient during time he was ill at home before hospitalization
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (89)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           13 (62)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3.4 (0.5–23.5)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shared meal
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (67)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           11 (52)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.5 (0.5–5.0)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Ate from same plate with hands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (67)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (38)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.3 (0.7–7.5)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Hugged
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (78)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (38)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3.5 (0.9–14.2)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Kissed
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (78)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           9 (43)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3.1 (0.8–12.4)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shook hands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (67)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           11 (52)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.5 (0.5–5.0)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shared drinking cup
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           9 (43)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.0 (0.3–3.1)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shared sheesha
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           Undefined
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shared utensils
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (11)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (33)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           0.3 (0.1–2.3)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Slept in same room
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (56)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2 (10)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            4.1 (1.5
           </bold>
           –
           <bold>
            11.2)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Shared toilet
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (29)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.6 (0.5–4.7)
          </td>
         </tr>
        </tbody>
       </table>
       <table frame="hsides" rules="groups">
        <col span="1" width="218"/>
        <col span="1" width="108"/>
        <col span="1" width="81"/>
        <col span="1" width="74"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Caregiving activities
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Helped care for index patient at home
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (67)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (38)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.3 (0.7–7.5)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Changed or washed clothes, sheets
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (56)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (19)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            2.9 (1.0–8.4)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Cleaned index patient
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (15)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.6 (0.9–7.3)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Cleaned in room
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (19)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.2 (0.8–6.2)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Administered medicine
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (56)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (29)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.2 (0.7–6.4)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Fed index patient
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5 (56)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (33)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.9 (0.6–5.6)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Touched index patient’s respiratory secretions
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1 (5)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            4.0 (1.6
           </bold>
           –
           <bold>
            9.8)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Removed index patient’s waste
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4 (44)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2 (10)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           <bold>
            3.2 (1.2
           </bold>
           –
           <bold>
            8.4)
           </bold>
          </td>
         </tr>
        </tbody>
       </table>
       <table frame="hsides" rules="groups">
        <col span="1" width="218"/>
        <col span="1" width="108"/>
        <col span="1" width="81"/>
        <col span="1" width="74"/>
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
           Proximity to index patient
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
          <th align="left" colspan="1" rowspan="1" scope="col" valign="top">
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Within 1 m during time he was sick at home
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8 (89)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           12 (57)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4.0 (0.6–27.8)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Within 1 m every day
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (78)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           9 (43)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           3.1 (0.8–12.4)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Within 1 m on day preceding hospitalization
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7 (78)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           11 (52)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2.3 (0.6–9.3)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
           Visited index patient in the hospital
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6 (67)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           10 (48)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1.8 (0.5–5.7)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         *Bold indicates statistical significance. This household transmission analysis included relatives
         <underline>
          &gt;
         </underline>
         14 y of age living in the 4 households of the index patients, defined as the first patient in the household who received a MERS-CoV diagnosis by rRT-PCR. Secondary transmission is defined as onset of illness or testing positive for MERS-CoV after the household’s index patient had received a diagnosis. Two MERS-CoV–infected household members were excluded from analysis because they had illness onsets before the presumed household index patient’s illness and were subsequently reported to have MERS-CoV antibodies. MERS-CoV, Middle East respiratory syndrome coronavirus; rRT-PCR, real-time reverse transcription PCR.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Community Transmission
      </title>
      <p>
       Except for members of this extended family, the regional hospital admitted no other MERS-CoV patients. Of 131 hospital workers who cared for patient C, 1 (0.8%), a nurse who remained asymptomatic, tested positive by rRT-PCR on May 23. All 44 persons tested at the outpatient clinic (21 patients with respiratory complaints and 23 staff) were MERS-CoV–negative by both rRT-PCR and serology. All 11 slaughterhouse workers and 10 livestock market participants tested negative by rRT-PCR. One (5%) asymptomatic slaughterhouse worker demonstrated antibodies to MERS-CoV by serology. He had no known contact with any family members in the cluster.
      </p>
     </sec>
    </sec>
    <sec sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      This investigation defined the epidemiology of a large family cluster of MERS-CoV infection in Saudi Arabia, identified multiple possible household transmission risk factors, and highlighted the useful role of serology in describing the extent of family clusters and spectrum of illness. For approximately half (42%) of the 19 MERS-CoV–infected family members, rRT-PCR results were negative while they were ill or after recognized exposure, and infection was diagnosed only retrospectively by serology; this included patients tested during extended hospitalizations and demonstrates real-world limitations in rRT-PCR or timing of specimen collection, transport, and testing. This finding highlights the need for clinicians to consider MERS-CoV diagnoses in appropriate clinical settings, even in patients with negative rRT-PCR results. Clinicians should consider obtaining lower respiratory tract specimens to improve the sensitivity of rRT-PCR, particularly if nasopharyngeal and oropharyngeal test results are negative and clinical suspicion is high, and they should consider follow-up serologic testing. Most importantly, clinicians should apply appropriate infection control practices for patients with clinically suspected illness, regardless of initial rRT-PCR results.
     </p>
     <p>
      Only 3 of the 19 MERS-CoV–infected family members were women, all wives of patients. Infection predominance in males has characterized MERS-CoV since its identification (64% of patients globally have been male [
      <xref ref-type="bibr" rid="R5">
       <italic>
        5
       </italic>
      </xref>
      ]) and might reflect biologic or behavior differences, such as men and women socializing separately (
      <xref ref-type="bibr" rid="R21">
       <italic>
        21
       </italic>
      </xref>
      <italic>
       ,
      </italic>
      <xref ref-type="bibr" rid="R22">
       <italic>
        22
       </italic>
      </xref>
      ). Underlying illness has previously been linked to more severe MERS-CoV symptoms and signs (
      <xref ref-type="bibr" rid="R23">
       <italic>
        23
       </italic>
      </xref>
      ), but whether underlying illness also makes persons more susceptible to initial MERS-CoV infection is less clear. This study, in which 96% of household members were tested, found an increased infection risk among persons with underlying chronic illnesses.
     </p>
     <p>
      Our data indicate close contact (e.g., sleeping in the same room as an index patient) and direct patient care activities (e.g., touching a patient’s respiratory secretions and removing his body waste), rather than casual contact or simple proximity, increases risk for transmission. Although smoking sheesha was a statistically significant risk factor for infection, the 2 infected family members who smoked sheesha denied smoking together, making it an unlikely mechanism of transmission. Guidance on preventing household transmission of MERS-CoV should emphasize minimizing close contact with patients. Outside of this extended family (and 1 asymptomatic exposed nurse and 1 asymptomatic camel slaughterhouse worker), we did not find evidence for wider community transmission of MERS-CoV.
     </p>
     <p>
      Two (11%) of the infected family members died. As of May 1, 2016, Saudi Arabia had reported 588 deaths among 1,380 confirmed MERS-CoV patients, for an overall 43% case-fatality rate (
      <xref ref-type="bibr" rid="R17">
       <italic>
        17
       </italic>
      </xref>
      ). The substantially lower fatality rate in this family most likely reflects aggressive contact tracing and use of serology to identify mildly symptomatic and asymptomatic patients. Patients in this family also were younger (median age 37 years) than MERS-CoV patients globally (median 48 years [
      <xref ref-type="bibr" rid="R5">
       <italic>
        5
       </italic>
      </xref>
      ]). The case-fatality rate in this cluster might reflect the broader population across the spectrum of illness.
     </p>
     <p>
      Previously described MERS-CoV family clusters and household contact investigations have reported household attack rates ranging from
      <underline>
       &lt;
      </underline>
      1% to 19% (
      <xref ref-type="bibr" rid="R11">
       <italic>
        11
       </italic>
      </xref>
      <italic>
       –
      </italic>
      <xref ref-type="bibr" rid="R14">
       <italic>
        14
       </italic>
      </xref>
      ). Household attack rates in this investigation were markedly higher; 64% and 42% of the adults in 2 households were infected. This difference could be due to methodologic differences in our investigation; serology identified mildly symptomatic and asymptomatic patients, which would increase the attack rate over investigations that relied only on rRT-PCR. The attack rate, however, could have actually been higher in this cluster for several reasons. First, MERS-CoV diagnoses were missed or delayed among the first cases in the family. The first 2 patients to become ill (patients A and B) were hospitalized but had negative rRT-PCR results during illness; their subsequent positive serologic results confirmed that the earlier illness had in fact been undiagnosed MERS-CoV. The third patient (patient C) was ill for 14 days before receiving a diagnosis, a time during which many other family members reported contact with him. Because this community had not previously experienced MERS-CoV infections, family members and local hospital staff might have had limited suspicion for MERS-CoV infection and not limited close contact. In contrast, when MERS-CoV infection was diagnosed in index patients in households 3 and 4, the family (and local hospital staff) was highly attuned to the possibility of MERS-CoV infection and took precautions to prevent its spread.
     </p>
     <p>
      Second, patient C might have been part of a super-spreading event because up to 8 other infected persons might have been infected through contact with him (
      <xref ref-type="fig" rid="F3">
       Figure 3
      </xref>
      ). The concept of a super-spreading event was described during the outbreak of severe acute respiratory syndrome coronavirus in 2003 (
      <xref ref-type="bibr" rid="R24">
       <italic>
        24
       </italic>
      </xref>
      <italic>
       ,
      </italic>
      <xref ref-type="bibr" rid="R25">
       <italic>
        25
       </italic>
      </xref>
      ) and more recently was observed in the MERS-CoV outbreak in healthcare facilities in South Korea, where each of 3 patients was associated with infection in &gt;20 other persons (
      <xref ref-type="bibr" rid="R26">
       <italic>
        26
       </italic>
      </xref>
      <italic>
       ,
      </italic>
      <xref ref-type="bibr" rid="R27">
       <italic>
        27
       </italic>
      </xref>
      ). Finally, although all infected persons denied animal contact and the range of symptom onset dates indicated ongoing person-to-person spread, an environmental point-source of infection might have been missed.
     </p>
     <p>
      Our study had several limitations. First, in household 1, two persons had, in fact, been ill with MERS-CoV before the presumed household index patient received a diagnosis. These persons had negative rRT-PCR results while ill, and infection was diagnosed retrospectively when later serologic test results were positive. The study questionnaire focused primarily on household exposures to the presumed index patient, but persons in this household might have had a range of exposures to all 3 persons, making isolation of the specific exposure that resulted in secondary infection more difficult. Second, the small sample size did not enable multivariable risk factor analysis and confounding and collinearity could not be evaluated. Third, serologic testing was not conducted for children &lt;14 years of age, and they were excluded from risk factor analysis; the observed lower incidence of infection among children could be investigated by including children in future serologic investigations. Fourth, sequential serologic testing was not performed, so it is possible that persons identified as MERS-CoV-negative might not yet have seroconverted, although none had developed respiratory illnesses before or after testing. Finally, specimens were not available for genome sequencing, which might have helped to clarify transmission chains within the family.
     </p>
     <p>
      More studies are needed to define the virologic and epidemiologic factors involved in household transmission of MERS-CoV to inform future public health response. Including serologic methods in these investigations will help better identify the spectrum of MERS-CoV clinical presentations. As testing methods evolve, maintaining strict infection control practices for ill patients with strong epidemiologic risk factors for MERS-CoV remains crucial to containing further spread.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="citation">
       <p>
        <italic>
         Suggested citation for this article
        </italic>
        : Arwady MA, Alraddadi B, Basler C, Azhar EI, Abuelzein E, Sindy AI, et al. Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014. Emerg Infect Dis. 2016 Aug [
        <italic>
         date cited
        </italic>
        ].
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid2208.152015">
         http://dx.doi.org/10.3201/eid2208.152015
        </ext-link>
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       The Saudi Arabia Ministry of Health and CDC provided funding for the study.
      </p>
      <p>
       Dr. Arwady, who completed this work while in CDC’s Epidemic Intelligence Service, is now the chief medical officer at the Chicago Department of Public Health (Chicago, Illinois). Her research interests include improving communicable disease outbreak responses and promoting health equity in the United States and globally.
      </p>
     </ack>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="webpage">
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        . Novel coronavirus—Saudi Arabia: human isolate. ProMED.
        <year>
         2012
        </year>
        Sep 20 [cited 2016 May 1].
        <ext-link ext-link-type="uri" xlink:href="http://www.promedmail.org">
         http://www.promedmail.org
        </ext-link>
        , archive no. 20120920.1302733.
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van Boheemen
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bestebroer
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          AD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        .
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Assiri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          McGeer
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perl
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Price
         </surname>
         <given-names>
          CS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cummings
         </surname>
         <given-names>
          DA
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         369
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         16
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1306742
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        . Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2016 May 1].
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
         http://www.who.int/emergencies/mers-cov/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        . Middle East respiratory syndrome coronavirus (MERS-CoV): summary of current situation, literature update and risk assessment—7 July
        <year>
         2015
        </year>
        [cited 2016 Feb 28].
        <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.pdf">
         http://apps.who.int/iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         European Centre for Disease Control and Prevention
        </collab>
        . Rapid risk assessment: severe respiratory disease associated with Middle East respiratory syndrome-coronavirus, 21 October
        <year>
         2015
        </year>
        Figure 2 [cited 2016 Feb 28].
        <ext-link ext-link-type="uri" xlink:href="http://ecdc.europa.eu/en/publications/Publications/MERS-rapid-risk-assessment-update-october-2015.pdf">
         http://ecdc.europa.eu/en/publications/Publications/MERS-rapid-risk-assessment-update-october-2015.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Azhar
         </surname>
         <given-names>
          EI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Kafrawy
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farraj
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hassan
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Saeed
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hashem
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         370
        </volume>
        :
        <fpage>
         2499
        </fpage>
        –
        <lpage>
         505
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1401505
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Kayali
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peiris
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        .
        <article-title>
         A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         495
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)70128-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863563
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="webpage">
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hussain
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Masri
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        . HajOmar W, et al. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014. Clin Infect Dis.
        <year>
         2015
        </year>
        ;60:369–77.
        <ext-link ext-link-type="uri" xlink:href="http://">
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Oboho
         </surname>
         <given-names>
          IK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tomczyk
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Asmari
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Banjar
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Mugti
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Aloraini
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—a link to health care facilities.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         372
        </volume>
        :
        <fpage>
         846
        </fpage>
        –
        <lpage>
         54
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zumla
         </surname>
         <given-names>
          AI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Hakeem
         </surname>
         <given-names>
          RF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stephens
         </surname>
         <given-names>
          GM
         </given-names>
        </string-name>
        .
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         368
        </volume>
        :
        <fpage>
         2487
        </fpage>
        –
        <lpage>
         94
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1303729
        </pub-id>
        <pub-id pub-id-type="pmid">
         23718156
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Masri
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hossain
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Transmission of MERS-coronavirus in household contacts.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         371
        </volume>
        :
        <fpage>
         828
        </fpage>
        –
        <lpage>
         35
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Abroug
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Slim
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ouanes-Besbes
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hadj Kacem
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dachraoui
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ouanes
         </surname>
         <given-names>
          I
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections, Tunisia, 2013.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1527
        </fpage>
        –
        <lpage>
         30
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2009.140378
        </pub-id>
        <pub-id pub-id-type="pmid">
         25148113
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Omrani
         </surname>
         <given-names>
          AS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Matin
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haddad
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Nakhli
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Albarrak
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        .
        <article-title>
         A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case.
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         e668
        </fpage>
        –
        <lpage>
         72
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2013.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         23916548
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Masri
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Turkestani
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ritz
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         599
        </fpage>
        –
        <lpage>
         64
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)70090-3
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Gulland
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        .
        <article-title>
         WHO voices concern over rising numbers of MERS-CoV cases.
        </article-title>
        <source>
         BMJ
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         g2968
        </fpage>
        and.
        <pub-id pub-id-type="doi">
         10.1136/bmj.g2968
        </pub-id>
        <pub-id pub-id-type="pmid">
         24778282
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         Kingdom of Saudi Arabia Ministry of Health
        </collab>
        . MERS-CoV statistics [cited 2016 May 1].
        <ext-link ext-link-type="uri" xlink:href="http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx">
         http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         Kingdom of Saudi Arabia Ministry of Health
        </collab>
        . Case definition and surveillance guidance for MERS-CoV testing in Saudi Arabia. 13 May
        <year>
         2014
        </year>
        [cited 2015 Apr 15].
        <ext-link ext-link-type="uri" xlink:href="http://www.moh.gov.sa/en/Documents/MoHCaseDefinitionMERSCoVVersionMay132014.pdf">
         http://www.moh.gov.sa/en/Documents/MoHCaseDefinitionMERSCoVVersionMay132014.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Costabel
         </surname>
         <given-names>
          U
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Timm
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Binger
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         pii20334
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23231891
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Kapoor
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pringle
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kumar
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dearth
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lovchik
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         1511
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu635
        </pub-id>
        <pub-id pub-id-type="pmid">
         25100864
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        . Middle East respiratory syndrome coronavirus (MERS–CoV) summary and literature update—as of 9 May
        <year>
         2014
        </year>
        [cited 2015 Apr 15].
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua=1">
         http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua=1
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Tawfiq
         </surname>
         <given-names>
          JA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Makhdoom
         </surname>
         <given-names>
          HQ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Assiri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alhakeem
         </surname>
         <given-names>
          RF
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         74
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1111/1469-0691.12562
        </pub-id>
        <pub-id pub-id-type="pmid">
         24460984
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Assiri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Tawfiq
         </surname>
         <given-names>
          JA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Rabiah
         </surname>
         <given-names>
          FA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Hajjar
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Barrak
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         752
        </fpage>
        –
        <lpage>
         61
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70204-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Chow
         </surname>
         <given-names>
          KY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          CE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ling
         </surname>
         <given-names>
          ML
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Heng
         </surname>
         <given-names>
          DM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yap
         </surname>
         <given-names>
          SG
         </given-names>
        </string-name>
        .
        <article-title>
         Outbreak of severe acute respiratory syndrome in a tertiary hospital in Singapore, linked to an index patient with atypical presentation: epidemiological study.
        </article-title>
        <source>
         BMJ
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         328
        </volume>
        :
        <fpage>
         195
        </fpage>
        .
        <pub-id pub-id-type="doi">
         10.1136/bmj.37939.465729.44
        </pub-id>
        <pub-id pub-id-type="pmid">
         14726369
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          SX
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          YM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sun
         </surname>
         <given-names>
          BC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          SW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhao
         </surname>
         <given-names>
          WH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wei
         </surname>
         <given-names>
          MT
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         The SARS outbreak in a general hospital in Tianjin, China—the case of super-spreader.
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         134
        </volume>
        :
        <fpage>
         786
        </fpage>
        –
        <lpage>
         91
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1017/S095026880500556X
        </pub-id>
        <pub-id pub-id-type="pmid">
         16371174
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Cowling
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Park
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fang
         </surname>
         <given-names>
          VJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wu
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leung
         </surname>
         <given-names>
          GM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wu
         </surname>
         <given-names>
          JT
         </given-names>
        </string-name>
        .
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         7
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2015.20.25.21163
        </pub-id>
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         Korea Centers for Disease Control and Prevention
        </collab>
        . Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect.
        <year>
         2015
        </year>
        ;6:269–78.
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Microbes Infect
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerg Microbes Infect
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       TEMI
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       temi20
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Microbes &amp; Infections
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2222-1751
      </issn>
      <publisher>
       <publisher-name>
        Taylor &amp; Francis
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       31645223
      </article-id>
      <article-id pub-id-type="pmc">
       6818114
      </article-id>
      <article-id pub-id-type="publisher-id">
       1679610
      </article-id>
      <article-id pub-id-type="doi">
       10.1080/22221751.2019.1679610
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Serological evidence of MERS-CoV and HKU8-related CoV co-infection in Kenyan camels
       </article-title>
       <alt-title alt-title-type="running-title">
        Emerging Microbes &amp; Infections
       </alt-title>
       <alt-title alt-title-type="running-authors">
        W. Zhang et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="AN1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zheng
         </surname>
         <given-names>
          Xiao-Shuang
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AF2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="AN1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Agwanda
         </surname>
         <given-names>
          Bernard
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF3">
         <sup>
          c
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="AN1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ommeh
         </surname>
         <given-names>
          Sheila
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF4">
         <sup>
          d
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="AN1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Kai
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AF2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lichoti
         </surname>
         <given-names>
          Jacqueline
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF5">
         <sup>
          e
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Ning
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Jing
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AF2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Bei
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Xing-Lou
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0001-8541-8315
        </contrib-id>
        <name>
         <surname>
          Mani
         </surname>
         <given-names>
          Shailendra
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF7">
         <sup>
          g
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ngeiywa
         </surname>
         <given-names>
          Kisa-Juma
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF5">
         <sup>
          e
         </sup>
        </xref>
        <xref ref-type="aff" rid="AF6">
         <sup>
          f
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Yan
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Ben
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Onyuok
         </surname>
         <given-names>
          Samson Omondi
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yan
         </surname>
         <given-names>
          Bing
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0003-4791-5024
        </contrib-id>
        <name>
         <surname>
          Anderson
         </surname>
         <given-names>
          Danielle E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF7">
         <sup>
          g
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0003-2752-0535
        </contrib-id>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Lin-Fa
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF7">
         <sup>
          g
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0001-9863-4201
        </contrib-id>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Peng
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor2">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          Zheng-Li
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         <sup>
          CONTACT
         </sup>
        </xref>
       </contrib>
       <aff id="AF1">
        <label>
         a
        </label>
        <institution>
         CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences
        </institution>
        , Wuhan,
        <country>
         People's Republic of China
        </country>
       </aff>
       <aff id="AF2">
        <label>
         b
        </label>
        <institution>
         University of Chinese Academy of Sciences
        </institution>
        , Beijing,
        <country>
         People’s Republic of China
        </country>
       </aff>
       <aff id="AF3">
        <label>
         c
        </label>
        <institution>
         Department of Zoology, National Museums of Kenya
        </institution>
        , Nairobi,
        <country>
         Kenya
        </country>
       </aff>
       <aff id="AF4">
        <label>
         d
        </label>
        <institution>
         Institute for Biotechnology Research, Jomo Kenyatta University of Agriculture and Technology
        </institution>
        , Nairobi,
        <country>
         Kenya
        </country>
       </aff>
       <aff id="AF5">
        <label>
         e
        </label>
        <institution>
         Directorate of Veterinary Services, State Department of Livestock, Ministry of Agriculture
        </institution>
        , Livestock and Fisheries,
        <country>
         Kenya
        </country>
       </aff>
       <aff id="AF6">
        <label>
         f
        </label>
        <institution>
         Kenya Camel Association
        </institution>
        , Nairobi,
        <country>
         Kenya
        </country>
       </aff>
       <aff id="AF7">
        <label>
         g
        </label>
        <institution>
         Programme in Emerging Infectious Diseases Duke-NUS Medical School
        </institution>
        , Singapore,
        <country>
         Singapore
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <label>
         CONTACT
        </label>
        Zheng-Li Shi
        <email xlink:href="zlshi@wh.iov.cn">
         zlshi@wh.iov.cn
        </email>
        <institution>
         CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences
        </institution>
        , Wuhan 430071,
        <country>
         People’s Republic of China
        </country>
       </corresp>
       <corresp id="cor2">
        Peng Zhou
        <email xlink:href="peng.zhou@wh.iov.cn">
         peng.zhou@wh.iov.cn
        </email>
        <institution>
         CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences
        </institution>
        , Wuhan 430071,
        <country>
         People’s Republic of China
        </country>
       </corresp>
       <fn id="AN1">
        <label>
         *
        </label>
        <p>
         These authors contributed equally to this article.
        </p>
       </fn>
       <fn>
        <p>
         Supplemental data for this article can be accessed at
         <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/22221751.2019.1679610">
          https://doi.org/10.1080/22221751.2019.1679610
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        24
       </day>
       <month>
        10
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       8
      </volume>
      <issue>
       1
      </issue>
      <fpage seq="148">
       1528
      </fpage>
      <lpage>
       1534
      </lpage>
      <history>
       <date date-type="received">
        <day>
         07
        </day>
        <month>
         4
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         08
        </day>
        <month>
         9
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         09
        </day>
        <month>
         9
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <copyright-holder>
        The Author(s)
       </copyright-holder>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="TEMI_8_1679610.pdf">
      </self-uri>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        Dromedary camels are important reservoir hosts of various coronaviruses, including Middle East respiratory syndrome coronavirus (MERS-CoV) that cause human infections. CoV genomes regularly undergo recombination during infection as observed in bat SARS-related CoVs. Here we report for the first time that only a small proportion of MERS-CoV receptor-binding domain positive (RBD) of spike protein positive camel sera in Kenya were also seropositive to MERS-CoV nucleocapsid (NP). In contrast, many of them contain antibodies against bat HKU8-related (HKU8r)-CoVs. Among 584 camel samples that were positive against MERS-CoV RBD, we found only 0.48 (8.22%) samples were also positive for NP. Furthermore, we found bat HKU8r-CoV NP antibody in 73 (12.5%) of the MERS-CoV RBD positive and NP negative samples, yet found only 3 (0.43%) of the HKU8r-CoV S1 antibody in the same samples. These findings may indicate co-infection with MERS-CoV and a HKU8r-CoV in camels. It may also raise the possibility of the circulation of a recombinant coronavirus virus with the spike of MERS-CoV and the NP of a HKU8r-CoV in Kenya. We failed to find molecular evidence of an HKU8r-CoV or a putative recombinant virus. Our findings should alert other investigators to look for molecular evidence of HKU8r-CoV or recombinants.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        KEYWORDS
       </title>
       <kwd>
        MERS
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        bat
       </kwd>
       <kwd>
        camel
       </kwd>
       <kwd>
        HKU8
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          National Natural Science Foundation of China
         </named-content>
        </funding-source>
        <award-id>
         81822028
        </award-id>
        <award-id>
         81661148058
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          Strategic Priority Research Program of the CAS
         </named-content>
        </funding-source>
        <award-id>
         XDB29010101
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          The National Science and Technology Major Project
         </named-content>
        </funding-source>
        <award-id>
         2018ZX10101004
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          Sino-Africa Joint Research Center
         </named-content>
        </funding-source>
        <award-id>
         SAJC201605
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          NRF
         </named-content>
        </funding-source>
        <award-id>
         NRF2016NRF-NSFC002-013
        </award-id>
        <award-id>
         NRF2012NRF-CRP001–056
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          CD-PHRG
         </named-content>
        </funding-source>
        <award-id>
         CDPHRG/0006/2014
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          NMRC
         </named-content>
        </funding-source>
        <award-id>
         ZRRF16006
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          MINDEF
         </named-content>
        </funding-source>
        <award-id>
         DIRP2015-9016102060
        </award-id>
       </award-group>
       <funding-statement>
        This study was supported by the National Natural Science Foundation of China [grant numbers: Excellent Young Scholars 81822028 and 81661148058] to PZ, Strategic Priority Research Program of the CAS [grant numbers XDB29010101 to ZLS and XDB29010204 to PZ]. The National Science and Technology Major Project [grant number 2018ZX10101004] to XLY, Sino-Africa Joint Research Center [grant number SAJC201605] to ZLS. The work conducted at Duke-NUS was supported in part by NRF grants NRF2016NRF-NSFC002-013 and NRF2012NRF-CRP001–056, CD-PHRG grant CDPHRG/0006/2014, NMRC grant ZRRF16006 and MINDEF grant DIRP2015-9016102060 to L-FW.
       </funding-statement>
      </funding-group>
      <counts>
       <fig-count count="3">
       </fig-count>
       <table-count count="0">
       </table-count>
       <equation-count count="0">
       </equation-count>
       <ref-count count="31">
       </ref-count>
       <page-count count="7">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <sec id="S001">
     <title>
      Introduction
     </title>
     <p>
      Since September 2012, Middle East Respiratory Syndrome (MERS) has spread from the Middle East to 27 countries, causing more than 2374 laboratory-confirmed cases of infection with an average mortality of 35.4% (as of February 2019) [
      <xref ref-type="bibr" rid="CIT0001">
       1
      </xref>
      ] . The WHO recommendation for laboratory detection of the causal agent, MERS coronavirus (MERS-CoV) includes real-time RT–PCR targeting upstream of the E protein gene or nucleocapsid protein (NP) gene, complemented with ORF1a and ORF1b [
      <xref ref-type="bibr" rid="CIT0002">
       2
      </xref>
      ]. Serological tests are also recommended when a viral nucleic acid test was not applicable, or for population-based serosurveys and investigations of past exposures. Viral spike (S) protein-based indirect ELISA followed by a confirmatory virus neutralization test (VNT) is the mostly widely used serological test for MERS-CoV. In contrast, NP based serological assays are seldom used because of their greater cross-reactivity [
      <xref ref-type="bibr" rid="CIT0002">
       2–7
      </xref>
      ].
     </p>
     <p>
      Tracing the source of human MERS infection is pivotal to prevent transmission of this disease. Dromedary camels have been identified as an important source for zoonotic transmission of MERS-CoV after detection of neutralizing antibodies (76–100% seropositive) and almost identical viruses were identified in Middle East camels [
      <xref ref-type="bibr" rid="CIT0003">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0008">
       8
      </xref>
      ]. It is widely believed that MERS-CoV could have originated from Africa as most of these animals were originally bred and exported from Africa [
      <xref ref-type="bibr" rid="CIT0009">
       9
      </xref>
      ]. Although, MERS-CoV neutralizing antibodies and viral RNA have been found in camels from West and East African countries, zoonotic human infections have not been reported in Africa [
      <xref ref-type="bibr" rid="CIT0004">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0009">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0010">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0011">
       11
      </xref>
      ]. The majority of these studies used an S-based serosurvey and showed high positivity for MERS-CoV infection in camels [
      <xref ref-type="bibr" rid="CIT0003">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0004">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0008">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0009">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0011">
       11
      </xref>
      ].
     </p>
     <p>
      There are two studies which have previously tested both S and NP IgG antibodies in Middle East camels. Of the two studies, one reported a strong correlation between NP positives by Western blot (97%) and S-based VNT positives (98%) using camel samples from the United Arab Emirates [
      <xref ref-type="bibr" rid="CIT0012">
       12
      </xref>
      ]. The second study tested camel sera from Saudi Arabia, and found more samples seropositive for S than NP by ELISA, Western blot or the Luciferase Immunoprecipitation System (LIPS) [
      <xref ref-type="bibr" rid="CIT0013">
       13
      </xref>
      ]. The latter study did not proceed with further analysis.
     </p>
     <p>
      In this study, we conducted a nationwide serosurvey for coronavirus infection from samples first screened for MERS-CoV by ELISA and VNT [
      <xref ref-type="bibr" rid="CIT0014">
       14
      </xref>
      ]. Our aim was to investigate the possible new genotype of MERS-CoV in Kenyan camels using a serology-predicted pathogen discovery strategy.
     </p>
    </sec>
    <sec id="S002">
     <title>
      Materials and methods
     </title>
     <sec id="S002-S2001">
      <title>
       Sample collection
      </title>
      <p>
       The Director of Veterinary Service at the Ministry of Agriculture Livestock and Fisheries in Kenya granted permission to conduct this study. The camel sampling was performed in 2016 and 2018 across 13 counties where camels are reared, taking into account breed types [
       <xref ref-type="bibr" rid="CIT0014">
        14
       </xref>
       ]. Four distinct breeds of camel are recognized in Kenya: Somali, Turkana, Gabbra/Rendille, and Imported Pakistani (which were imported from Pakistan in the 1980s). The sampling locations were recorded and confirmed by GPS. Other information such as age, sex, pregnancy, and migration was collected. A total of 894 camel serum samples were used in this study. In addition, 1136 camel nasal swabs collected in January–February 2016 and 286 camel nasal swabs collected in February–March 2018 were used for molecular tests. All camel samples were collected in compliance with local regulations, and then transported to Wuhan Institute of Virology (WIV) according to IATA international regulations for transporting biological samples [
       <xref ref-type="bibr" rid="CIT0014">
        14
       </xref>
       ].
      </p>
     </sec>
     <sec id="S002-S2002">
      <title>
       Serological tests
      </title>
      <p>
       An in-house anti-MERS-CoV IgG ELISA kit was developed based on the purified receptor-binding domain (RBD) of spike protein, and validated for Kenya and Pakistan camels [
       <xref ref-type="bibr" rid="CIT0014">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0015">
        15
       </xref>
       ]. Purified NP of MERS-CoV, SARS-like CoV Rp3, human coronaviruses (OC43, HKU1, 229E, and NL63), and bat CoVs (HKU2 and HKU9) were produced and applied to ELISA or Western blot in this and previous studies [
       <xref ref-type="bibr" rid="CIT0016">
        16–18
       </xref>
       ]. A bat HKU8r-CoV (ID: 4050 from China) NP gene that shares a 93% amino acid sequence identity to the
       <italic>
        Miniopterus
       </italic>
       bat coronavirus HKU8-CoV NP (GenBank accession number YP_001718616), was inserted into pET-28a+ (Novagen) for prokaryotic expression. Kenyan HKU8r-CoV strain BtKy33 NP and S1 (synthesized from GenBank accession no.HQ728485.1) were inserted into pCAGGS or pHCMV vector with N-terminal S-tag. BtKy33 NP and S1 plasmids transiently transfected HEK293T-17 cell supernatant was used in Western blot. Camel serum samples were tested in the ELISA (1:20 dilution) or Western blot (1:100 dilution) and goat anti-camel IgG-HRP conjugate (Alpha Diagnostic International) was used as the secondary antibody at 1:3000 dilution. A cut-off value for each antigen was determined in ELISA after validation.
      </p>
      <p>
       Lysates of MERS-CoV infected Vero cells were generated in the biosafety level 3 laboratory at WIV, loaded onto 12% SDS-PAGE gels, and transferred onto nitrocellulose membranes. Membranes were incubated with selected MERS-CoV RBD positive and NP positive or negative camel sera for 1 h at 37°C (1:100 dilution) after blocking. Membranes were then washed and then incubated with anti-camel IgG-HRP secondary antibody (as above) for another 1 h at 37°C, followed by three more washes.
      </p>
      <p>
       MERS-CoV NP, China HKU8r-CoV NP (above) and S1 (amino acid 1–150 of S protein) (synthesized from GenBank accession no. YP_001718612.1) were codon-optimized and inserted in the pREN2 vector [
       <xref ref-type="bibr" rid="CIT0015">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0019">
        19
       </xref>
       ]. Plasmids were transfected into HEK293T-17 cells using Lipofectamine 3000 (Thermo Fisher Scientific). Cells were then collected, lysed and incubated with camel serum samples. Serum (1 μl) was incubated with 10 million units of Rluc alone (vector) or Rluc-N or S1, respectively, together with 3.5 μl of a 30% protein A/G UltraLink resin suspension (Pierce, Thermo Fisher Scientific). The ratio of Rluc-N or S1: Rluc (vector) was used to determine the specific antigen reactivity of camel sera. HKU8r-CoV S1 protein was expressed from the pCAGGS vector and was purified using S-tag resin (generated in-house). Mouse anti-serum against purified protein was used as a positive control in LIPS.
      </p>
     </sec>
     <sec id="S002-S2003">
      <title>
       Molecular detection
      </title>
      <p>
       Viral RNA was extracted from camel nasal swabs using a viral RNA extraction kit (Roche, Germany) according to the manufacturer's instructions. Three primer pairs were used to screen the samples in RT–PCR, two targeting the conserved RNA-dependent RNA polymerase gene of CoVs and another targeting the MERS-CoV S2 region [
       <xref ref-type="bibr" rid="CIT0020">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0021">
        21
       </xref>
       ]. Twelve pools of RNA were made from 139 MERS-CoV negative samples (roughly every 10 samples were pooled) and libraries for next-generation sequencing were prepared using Illumina Truseq mRNA kit (TruSeq Stranded mRNA Library Prep Kit, Cat # RS-122-2101) following the manufacturer's instructions. The sequencing was performed on a HiSeq 3000 sequencer and data was analysed using the Galaxy platform.
      </p>
     </sec>
     <sec id="S002-S2004">
      <title>
       Statistical analysis
      </title>
      <p>
       All analyses were performed using IBM SPSS Statistics (version 25). Two-tailed Mann–Whitney
       <italic>
        U
       </italic>
       exact test and two-tailed Student's
       <italic>
        t
       </italic>
       exact test were used to calculate the 95% confidence interval (CI) of positive rate. The association
       <italic>
        p
       </italic>
       values between viral seropositive samples and camel information were calculated using Chi-square test followed with Yates correction two-tailed test and Fisher's exact test.
      </p>
     </sec>
    </sec>
    <sec id="S003">
     <title>
      Results
     </title>
     <p>
      We previously performed a nationwide serosurvey for MERS-CoV in Kenyan camels using an in-house MERS-CoV RBD IgG ELISA, plus a confirmatory VNT [
      <xref ref-type="bibr" rid="CIT0014">
       14
      </xref>
      ]. A correlation in results obtained using the two methods was observed whereby almost all ELISA positive sera were capable of neutralizing MERS-CoV (103/105, 98.1%). Our data revealed 584 of 891 (65.54%) Kenyan camel samples had MERS-CoV RBD antibodies (
      <xref ref-type="fig" rid="F0001">
       Figure 1
      </xref>
      (A)). We then tested all camel sera using a MERS-CoV NP-based ELISA. In contrast, only 54 of 891 samples (6.04%), or 48 of the RBD positive samples (8.22%) were NP positive (
      <xref ref-type="fig" rid="F0001">
       Figure 1
      </xref>
      (A)). To confirm the finding, we developed an additional antibody assay based on mammalian expressed MERS-CoV NP using LIPS, a fast and sensitive serological tool which has previously been successfully used in SADS-CoV serosurvey [
      <xref ref-type="bibr" rid="CIT0018">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0019">
       19
      </xref>
      ]. All NP ELISA positive sera were also positive in LIPS, while those negative samples remained negative (
      <xref ref-type="fig" rid="F0001">
       Figure 1
      </xref>
      (B)). This observation was confirmed by a MERS-CoV virus-based Western blot using RBD positive samples. Two major structural proteins, NP and membrane protein were observed in the NP positive group, but not in the NP negative group (
      <xref ref-type="fig" rid="F0001">
       Figure 1
      </xref>
      (C) and supplementary Figure 1(A)). Above all, only a small proportion of the MERS-CoV RBD positive serum samples were also NP positive, different to that observed in human infection cases [
      <xref ref-type="bibr" rid="CIT0006">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0022">
       22
      </xref>
      ]. This observation indicated that the majority of the camels may only maintain NP antibodies for a short time or be co-infected by another CoV.
      <fig id="F0001" orientation="portrait" position="float">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         . Absence of MERS-CoV nucleotide protein (NP) antibody in most of the MERS-CoV receptor-binding domain (RBD) positive camel sera. (A) ELISA screening of MERS-CoV RBD and NP antibodies (
         <italic>
          n
         </italic>
         = 891 camels). Cutoff (dashed line, same as below) shown as five times the mean value of the negative samples, it was further adjusted to 0.35 for RBD in line with results from neutralization assay. (B) Luciferase Immunoprecipitation System (LIPS) test for NP antibodies. Eight NP ELISA positive and 12 negative samples (all MERS-CoV RBD positive) were used in the LIPS test. Five RBD and NP ELISA negative samples were used as controls (shown as blue dots), and alpaca anti-serum against MERS-CoV was used as positive controls (red dots). Cutoff was determined as the sum of mean value plus three times the standard deviations of the negative samples. (C) Western blot using whole virus proteins. Lysates of MERS-CoV infected Vero cells were separated on 12% polyacrylamide gel, transferred to nitrocellulose membranes and analysed with MERS-CoV RBD positive, NP positive/negative camel serum samples, or NP mAb. MP, membrane protein. Molecular markers were indicated (kDa). Information for sample applied to WB, LIPS or ELISA can be found in Supplementary Table 1.
        </p>
       </caption>
       <graphic xlink:href="TEMI_A_1679610_F0001_OC">
       </graphic>
      </fig>
     </p>
     <p>
      In searching for possible new genotype of MERS viruses that share the same or a related S but a different NP, we performed a CoV NP protein array serology test. Selected MERS-CoV RBD positive samples were analysed by Western blot using NP proteins from representative alpha and beta CoVs (see method section). The successful expression of these proteins was confirmed by anti-tag antibodies (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (A)). No other CoV besides HKU8r-CoV (China strain) NP was detected in two out of three selected MERS-CoV NP negative camel serum samples (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (A) and Supplementary Figure 1(B)). In particular, HKU8r-CoV NP antibody was not cross-reactive with 229E-related CoV, which is also known to be enzootic in camels (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (A)). HKU8r-CoV has previously been found only in
      <italic>
       Miniopterus
      </italic>
      bats in China or Kenya [
      <xref ref-type="bibr" rid="CIT0023">
       23–25
      </xref>
      ].
      <fig id="F0002" orientation="portrait" position="float">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         . Presence of HKU8r-CoV antibodies in MERS-CoV RBD positive camel sera. (A) Coronavirus NP protein array. Successful expression was determined using anti-HIS tag (all CoVs except HKU2-CoV) or anti-FLAG tag (HKU2-CoV) antibodies. Samples seropositive (C0184) or negative (C0039) for MERS-CoV NP were used. Markers were indicated (kDa). (B) LIPS test for HKU8r-CoV (China strain) NP and S1 antibodies. Twelve NP ELISA positive and eight negative samples (all MERS-CoV RBD positive) were used in LIPS test. Five MERS-CoV RBD and NP ELISA negative samples were used as control in each panel (shown as blue dots), and rabbit anti-serum against HKU8r-CoV S1 protein was used as positive control (red dot). Cutoff was determined as the sum of mean value plus three times the standard deviations of the negative samples. (C) ELISA screening for HKU8r-CoV (China strain) NP and S1 antibody in MERS-CoV RBD positive camel serum samples (
         <italic>
          n
         </italic>
         = 584). Cutoff shown as five times the mean value of the negative samples. Information for sample applied to WB, LIPS or ELISA can be found in Supplementary Table 1.
        </p>
       </caption>
       <graphic xlink:href="TEMI_A_1679610_F0002_OC">
       </graphic>
      </fig>
     </p>
     <p>
      To further investigate the results observed in the Western blot, HKU8r-CoV NP and S1 based LIPS assays were developed. The LIPS results demonstrated clear HKU8r-CoV NP positive in some camel sera, consistent with Western blot results (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (B)). However, no HKU8r-CoV S1 positives were found within the HKU8r-CoV NP positive samples (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (B)). To rule out the possible false-negative results using China HKU8r-CoV as detection antigen, a Kenyan bat HKU8r-CoV BtKY33 was also used. Results indicated that the above conclusion was not HKU8r-CoV strain-specific (Supplementary Figure 2). The data indicates that some of the Kenyan camels have both MERS-CoV S and HKU8r-CoV NP antibodies. We then performed a nationwide serosurvey for HKU8r-CoV in camels using a HKU8r-CoV NP and S1 ELISA. Of the 584 MERS-CoV RBD positive samples tested, 73 (12.5%) were positive for HKU8r-CoV NP (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (C)). In contrast, only 3 (0.51%) were seropositive for HKU8r-CoV S1 (
      <xref ref-type="fig" rid="F0002">
       Figure 2
      </xref>
      (C)). The data suggested the idea of the co-infection of MERS/HKU8r-CoVs, alternatively, we can't rule out the existence of a chimeric MERS-CoV carrying MERS-CoV S gene but a NP gene from HKU8r-CoV in Kenyan camels (
      <xref ref-type="fig" rid="F0003">
       Figure 3
      </xref>
      and Supplementary Table 1). Although, we cannot rule the possibility of a novel CoV that was not detected in molecular assays but can cross-react with HKU8r or MERS coronavirus positive serum samples. It is worth to mention, another camel alphacoronaviruses, 229E-like coronaviruses were previously found in camels [
      <xref ref-type="bibr" rid="CIT0026">
       26
      </xref>
      ]. We then tested cross-reactivity of antibodies to the N proteins of HKU8r and 229E as the two are closely related phylogenetically. Our data demonstrated only 10/90 of the HKU8r-CoV NP positive camel serum were also 229E-NP positive (Supplementary Figure 3(A)), which was probably true positive for the later as NP of the two viruses showed no cross-reactivity using positive control samples (Supplementary Figure 3(B)).
      <fig id="F0003" orientation="portrait" position="float">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         . Venn diagram for virus serum positivity of MERS-CoV or HKU8r-CoV. Totally 605 out of 891 camel sera that were positive for at least one of the viral proteins were included.
        </p>
       </caption>
       <graphic xlink:href="TEMI_A_1679610_F0003_OC">
       </graphic>
      </fig>
     </p>
     <p>
      We then investigated factors that may associate with MERS-CoV (positive for both S and NP) seropositivity and distribution, which may also be important for the detection of this MERS/HKU8r-CoV co-infection cases. Distribution of MERS-CoV sero-positive samples was not found to be associated with sex, age, birthplace, migration or pregnancy of camels but may be associated with the breed (
      <italic>
       P
      </italic>
      = .003) (Supplementary Table 2).
     </p>
     <p>
      We also screened nucleic acid by RT–PCR targeting the conserved regions of all known coronaviruses on 1422 camel nasal swabs collected from Kenya 2016–2018. In addition, 12 pooled camel nasal swabs (10 samples for each pool) RNA were also tested in next-generation sequencing (NGS). We found MERS-CoV nucleic acid by both RT–PCR and NGS, yet so far we have not found nucleic acid positive for HKU8r-coronavirus.
     </p>
    </sec>
    <sec id="S004">
     <title>
      Discussion
     </title>
     <p>
      In a nationwide MERS-CoV sero-surveillance of Kenyan camels, we have demonstrated that most of the MERS-CoV RBD positive samples (91.78%) were not MERS-CoV NP positive by multiple serological assays. In contrast, 12.5% of the MERS-CoV RBD positive samples also carried NP antibodies to HKU8r-CoV, a virus that has only so far been found in bats. For the first time, we demonstrate the presence of a HKU8r-CoV infection in camels.
     </p>
     <p>
      Our study is the first to compare the seroprevalence of MERS-CoV in camels using both S and NP serological assays. As one of the four major structural proteins in CoV, NP is widely used as a diagnostic target due to its high abundance upon infection. Although NP showed good reactivity with human MERS patient serum in some studies, S-based serological tests are recommended by WHO for diagnosis due to its greater specificity [
      <xref ref-type="bibr" rid="CIT0002">
       2
      </xref>
      ]. In line with these recommendations, most camel serosurveys were conducted using only S-based assays [
      <xref ref-type="bibr" rid="CIT0003">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0008">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0009">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0011">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0013">
       13
      </xref>
      ]. In human cases, samples showing neutralizing activity were also NP positive [
      <xref ref-type="bibr" rid="CIT0006">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0022">
       22
      </xref>
      ]. However, our data clearly demonstrate that most of the MERS-CoV neutralizing samples were not MERS-CoV NP positive in camels. Similarly, unmatched S and NP positive serological patterns have also been observed in another study using Saudi Arabia camel serum samples [
      <xref ref-type="bibr" rid="CIT0013">
       13
      </xref>
      ]. A possible interpretation is that the duration of the NP antibody responses is more short-lived than S antibody in camels.
     </p>
     <p>
      The seropositive of HKU8r-CoV in camels is another example linking a bat CoV to camels besides MERS-CoV and 229E-related coronavirus, thereby strengthening the bat-camel connection theory [
      <xref ref-type="bibr" rid="CIT0027">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0028">
       28
      </xref>
      ]. The finding of two closely related NeoCoV and PREDICT/PDF-2180 CoV in bats suggested that MERS-CoV descended from an ancestral virus of African bats, while the host switch from bats to dromedary camels likely occurred in Africa years ago [
      <xref ref-type="bibr" rid="CIT0027">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0029">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0030">
       30
      </xref>
      ]. However, there has been no other reported virus spillover from bats to camels beside this ancestral MERS-CoV and 229E-related coronaviruses. Our data demonstrated that the HKU8r-CoV NP antibody is not caused by cross-reactive antibody responses to camel 229E. Our discovery of HKU8r-CoV in camels is, therefore, an important finding. HKU8r-CoV was described first in Hong Kong and later in Kenya, and so far it has only been reported in
      <italic>
       Miniopterus
      </italic>
      bat species [
      <xref ref-type="bibr" rid="CIT0023">
       23–25
      </xref>
      ]. Kenyan bats carry multiple CoVs including SARS-related, HKU2-related, HKU7-related, HKU8-related and HKU9-related CoVs that may spillover to other species in rural areas where bats roost in close proximity to humans or are consumed by humans as bush meat [
      <xref ref-type="bibr" rid="CIT0024">
       24
      </xref>
      ].
     </p>
     <p>
      It is worth mentioning that we observed much less HKU8r-CoV S protein IgG antibodies in any of the HKU8r-CoV NP positive and MERS-CoV RBD positive samples. The chance of MERS/HKU8r-CoV co-infected camels simultaneously lost both HKU8r-CoV S and MERS-CoV NP antibodies should be low. The presence of a chimeric MERS/HKU8r-CoV would be a possible explanation, although there could be other explanations. For example, camel may generate a different S and NP antibody responses that resulted in a stronger S but weak and short-lasting NP antibody titres. It could also be two separated events of infection by MERS-CoV and HKU8r-CoV instead of a co-infection. Nonetheless, even the occurrence of a chimeric MERS/HKU8r-CoV is not surprising as it is known that CoV genomes regularly undergo recombination during infection as observed in CoVs such as bat SARS-related CoVs [
      <xref ref-type="bibr" rid="CIT0031">
       31
      </xref>
      ]. Three CoVs, including MERS-CoV, 229E-like and HKU23-CoV had also been reported to co-circulate in Middle East camels, increased chance of recombination [
      <xref ref-type="bibr" rid="CIT0028">
       28
      </xref>
      ]. Yet it is worth noting that recombination between an alpha-CoV (HKU8r-CoV e.g.) and beta-CoV (MERS-CoV e.g.) has never been reported. Our observation should be more supported by molecular evidence in future studies.
     </p>
     <p>
      Molecular detection of these serology-predicted novel CoVs containing MERS-CoV S protein is hampered by the lack of genetic sequences of this possible recombinant virus at the present time. Our Western blot results suggest at least some of the MERS-CoV neutralizing samples did not have NP or M protein antibodies. It is unknown what genetic backbone these viruses will have. For example, viruses may maintain the MERS-CoV backbone and only replace the NP gene with HKU8r-CoV (or unidentified CoVs) or vice versa. In the latter example, these viruses would have a HKU8r-CoV backbone with S gene replaced by the MERS-CoV. With this hypothesis in consideration, the current molecular diagnosis tools for MERS-CoV do not detect other genotype of MERS-CoVs circulating in animals, partially explaining the failure in our attempt to find molecular evidence of novel chimeric CoVs using qPCR targeting MERS-CoV S gene or metagenome NGS. Concerted efforts to identify and sequence these viruses are needed in future studies.
     </p>
     <p>
      In conclusion, we showed evidence for HKU8r-CoV virus infection in camels in Kenya. It is possible that this virus co-circulates with MERS-CoV. But the possibility of a MERS-CoV-HKU8r recombinant virus cannot be excluded. Future research should seek to demonstrate molecular evidence of such viruses.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supplementary Material
     </title>
     <supplementary-material content-type="local-data" id="SM2505">
      <caption>
       <title>
        Supplemental Material
       </title>
      </caption>
      <media id="d37e362" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" mimetype="application" orientation="portrait" position="anchor" xlink:href="TEMI_A_1679610_SM2505.docx">
      </media>
     </supplementary-material>
    </sec>
    <back>
     <sec>
      <title>
       Acknowledgements
      </title>
      <p>
       We thank all staff of the Ministry of Agriculture Livestock Fisheries and Irrigation, Chiefs and local assistants from County governments of West Pokot, Turkana, Baringo, Samburu, Laikipia, Isiolo, Marsabit, Mandera, Wajir, Garissa, Tana River, Kitui, and Makueni; Kenya camel association; Kenya Wildlife Service; and National Museums of Kenya.
      </p>
     </sec>
     <sec id="S005">
      <title>
       Disclosure statement
      </title>
      <p>
       No potential conflict of interest was reported by the authors.
      </p>
     </sec>
     <sec id="S006">
      <title>
       ORCID
      </title>
      <p>
       <italic>
        Shailendra Mani
       </italic>
       <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-8541-8315">
        http://orcid.org/0000-0001-8541-8315
       </ext-link>
      </p>
      <p>
       <italic>
        Danielle E. Anderson
       </italic>
       <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0003-4791-5024">
        http://orcid.org/0000-0003-4791-5024
       </ext-link>
      </p>
      <p>
       <italic>
        Lin-Fa Wang
       </italic>
       <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0003-2752-0535">
        http://orcid.org/0000-0003-2752-0535
       </ext-link>
      </p>
      <p>
       <italic>
        Peng Zhou
       </italic>
       <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-9863-4201">
        http://orcid.org/0000-0001-9863-4201
       </ext-link>
      </p>
     </sec>
     <ref-list>
      <title>
       References
      </title>
      <ref id="CIT0001">
       <label>
        1
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organisation
         </collab>
        </person-group>
        <comment>
         MERS situation update, February 2019 2019
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0002">
       <label>
        2
       </label>
       <mixed-citation publication-type="standard">
        <person-group person-group-type="author">
         <collab>
          orld Health Organisation
         </collab>
        </person-group>
        <comment>
         (Geneva S. Laboratory Testing for Middle East Respiratory Syndrome Coronavirus, Interim guidance (WHO/MERS/LAB/15.1/Rev1/2018). 2018
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0003">
       <label>
        3
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2013 Oct
        </year>
        ;
        <volume>
         13
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         859
        </fpage>
        –
        <lpage>
         866
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70164-6
        </pub-id>
        .
        <comment>
         PubMed PMID: 23933067
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70164-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0004">
       <label>
        4
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Messadi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Feyisa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Geographic distribution of MERS coronavirus among dromedary camels, Africa
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014 Aug
        </year>
        ;
        <volume>
         20
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         1370
        </fpage>
        –
        <lpage>
         1374
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140590
        </pub-id>
        .
        <comment>
         PubMed PMID: 25062254; PubMed Central PMCID: PMC4111168
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140590
        </pub-id>
        <pub-id pub-id-type="pmid">
         25062254
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0005">
       <label>
        5
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015 Jun
        </year>
        ;
        <volume>
         15
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         629
        </fpage>
        DOI:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)00029-8
        </pub-id>
        .
        <comment>
         PubMed PMID: 26008827
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)00030-4
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0006">
       <label>
        6
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Costabel
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2012 Dec 6
        </year>
        ;
        <volume>
         17
        </volume>
        (
        <issue>
         49
        </issue>
        ).
        <comment>
         PubMed PMID: 23231891
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.2807/ese.17.49.20334-en
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0007">
       <label>
        7
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Trivedi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Miao
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection
        </article-title>
        .
        <source>
         J Med Virol
        </source>
        .
        <year>
         2018 Feb
        </year>
        ;
        <volume>
         90
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         367
        </fpage>
        –
        <lpage>
         371
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1002/jmv.24948
        </pub-id>
        .
        <comment>
         PubMed PMID: 28906003; PubMed Central PMCID: PMC6158782
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/jmv.24948
        </pub-id>
        <pub-id pub-id-type="pmid">
         28906003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0008">
       <label>
        8
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2014 Feb
        </year>
        ;
        <volume>
         14
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         140
        </fpage>
        –
        <lpage>
         145
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        .
        <comment>
         PubMed PMID: 24355866
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0009">
       <label>
        9
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jores
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014 Aug
        </year>
        ;
        <volume>
         20
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         1319
        </fpage>
        –
        <lpage>
         1322
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140596
        </pub-id>
        .
        <comment>
         PubMed PMID: 25075637; PubMed Central PMCID: PMC4111164
        </comment>
        .
        <pub-id pub-id-type="pmid">
         25075637
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0010">
       <label>
        10
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Munyua
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bitek
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         No serologic evidence of Middle East respiratory syndrome coronavirus infection among camel farmers exposed to highly seropositive camel herds: a household linked study, Kenya
        </article-title>
        .
        <source>
         Am J Trop Med Hyg
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         96
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         1318
        </fpage>
        –
        <lpage>
         1324
        </lpage>
        .
        <comment>
         2017 Jun;
        </comment>
        DOI:
        <pub-id pub-id-type="doi">
         10.4269/ajtmh.16-0880
        </pub-id>
        .
        <comment>
         PubMed PMID: 28719257; PubMed Central PMCID: PMC5462565
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0011">
       <label>
        11
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           KPY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Perera
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2018 Mar 20
        </year>
        ;
        <volume>
         115
        </volume>
        (
        <issue>
         12
        </issue>
        ):
        <fpage>
         3144
        </fpage>
        –
        <lpage>
         3149
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1073/pnas.1718769115
        </pub-id>
        .
        <comment>
         PubMed PMID: 29507189; PubMed Central PMCID: PMC5866576
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1073/pnas.1718769115
        </pub-id>
        <pub-id pub-id-type="pmid">
         29507189
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0012">
       <label>
        12
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wernery
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Novel betacoronavirus in dromedaries of the Middle East, 2013
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014 Apr
        </year>
        ;
        <volume>
         20
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         560
        </fpage>
        –
        <lpage>
         572
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.3201/eid2004.131769
        </pub-id>
        .
        <comment>
         PubMed PMID: 24655427; PubMed Central PMCID: PMCPMC3966378
        </comment>
        .
        <pub-id pub-id-type="pmid">
         24655427
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0013">
       <label>
        13
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Alagaili
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Briese
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        .
        <source>
         MBio
        </source>
        .
        <year>
         2014 Feb 25
        </year>
        ;
        <volume>
         5
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         e00884-14
        </fpage>
        DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00884-14
        </pub-id>
        .
        <comment>
         PubMed PMID: 24570370; PubMed Central PMCID: PMC3940034
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00884-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24570370
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0014">
       <label>
        14
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ommeh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zohaib
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Genetic evidence of Middle East respiratory syndrome coronavirus (MERS-CoV) and widespread seroprevalence among camels in Kenya
        </article-title>
        .
        <source>
         Vriol Sin
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         33
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         484
        </fpage>
        –
        <lpage>
         492
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0076-4
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0015">
       <label>
        15
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zohaib
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saqib
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Athar
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Countrywide Survey for MERS-coronavirus antibodies in Dromedaries and humans in Pakistan
        </article-title>
        .
        <source>
         Virol Sin
        </source>
        .
        <year>
         2018 Oct
        </year>
        ;
        <volume>
         33
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         410
        </fpage>
        –
        <lpage>
         417
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0051-0
        </pub-id>
        .
        <comment>
         PubMed PMID: 30311100
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0051-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         30311100
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0016">
       <label>
        16
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Luo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jiang
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Longitudinal surveillance of betacoronaviruses in fruit bats in Yunnan Province, China during 2009–2016
        </article-title>
        .
        <source>
         Virol Sin
        </source>
        .
        <year>
         2018 Feb
        </year>
        ;
        <volume>
         33
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         87
        </fpage>
        –
        <lpage>
         95
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0017-2
        </pub-id>
        .
        <comment>
         PubMed PMID: 29500692
        </comment>
        .
        <pub-id pub-id-type="pmid">
         29500692
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0017">
       <label>
        17
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Serological evidence of bat SARS-related coronavirus infection in humans, China
        </article-title>
        .
        <source>
         Virol Sin
        </source>
        .
        <year>
         2018 Feb
        </year>
        ;
        <volume>
         33
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         104
        </fpage>
        –
        <lpage>
         107
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0012-7
        </pub-id>
        .
        <comment>
         PubMed PMID: 29500691
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0012-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         29500691
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0018">
       <label>
        18
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin
        </article-title>
        .
        <source>
         Nature
        </source>
        .
        <year>
         2018 Apr
        </year>
        ;
        <volume>
         556
        </volume>
        (
        <issue>
         7700
        </issue>
        ):
        <fpage>
         255
        </fpage>
        –
        <lpage>
         258
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1038/s41586-018-0010-9
        </pub-id>
        . .
        <comment>
         PubMed PMID: 29618817
        </comment>
        .
        <pub-id pub-id-type="pmid">
         29618817
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0019">
       <label>
        19
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Burbelo
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hoshino
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leahy
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay
        </article-title>
        .
        <source>
         Clin Vaccine Immunol
        </source>
        .
        <year>
         2009 Mar
        </year>
        ;
        <volume>
         16
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         366
        </fpage>
        –
        <lpage>
         371
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1128/cvi.00350-08
        </pub-id>
        .
        <comment>
         PubMed PMID: 19129469; PubMed Central PMCID: PMC2650866
        </comment>
        .
        <pub-id pub-id-type="pmid">
         19129469
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0020">
       <label>
        20
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Luna LK
          </surname>
          <given-names>
           dS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heiser
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Regamey
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and nonfluorescent low-density microarray
        </article-title>
        .
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2007 Mar
        </year>
        ;
        <volume>
         45
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         1049
        </fpage>
        –
        <lpage>
         1052
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1128/jcm.02426-06
        </pub-id>
        .
        <comment>
         PubMed PMID: 17229859; PubMed Central PMCID: PMCPMC1829107
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/JCM.02426-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17229859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0021">
       <label>
        21
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Perera
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Coronavirus infections in horses in Saudi Arabia and Oman
        </article-title>
        .
        <source>
         Transbound Emerg Dis
        </source>
        .
        <year>
         2017 Dec
        </year>
        ;
        <volume>
         64
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         2093
        </fpage>
        –
        <lpage>
         2103
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1111/tbed.12630
        </pub-id>
        .
        <comment>
         PubMed PMID: 28296228
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/tbed.12630
        </pub-id>
        <pub-id pub-id-type="pmid">
         28296228
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0022">
       <label>
        22
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2014 Nov 1
        </year>
        ;
        <volume>
         59
        </volume>
        (
        <issue>
         9
        </issue>
        ):
        <fpage>
         1225
        </fpage>
        –
        <lpage>
         1233
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu359
        </pub-id>
        .
        <comment>
         PubMed PMID: 24829216; PubMed Central PMCID: PMCPMC4834865
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu359
        </pub-id>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0023">
       <label>
        23
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Coronaviruses in bent-winged bats (
         <italic>
          Miniopterus
         </italic>
         spp
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2006 Sep
        </year>
        ;
        <volume>
         87
        </volume>
        (
        <issue>
         Pt 9
        </issue>
        ):
        <fpage>
         2461
        </fpage>
        –
        <lpage>
         2466
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1099/vir.0.82203-0
        </pub-id>
        .
        <comment>
         PubMed PMID: 16894183
        </comment>
        .
        <pub-id pub-id-type="pmid">
         16894183
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0024">
       <label>
        24
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Conrardy
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ruone
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Detection of novel SARS-like and other coronaviruses in bats from Kenya
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2009 Mar
        </year>
        ;
        <volume>
         15
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         482
        </fpage>
        –
        <lpage>
         485
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.3201/eid1503.081013
        </pub-id>
        .
        <comment>
         PubMed PMID: 19239771; PubMed Central PMCID: PMC2681120
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid1503.081013
        </pub-id>
        <pub-id pub-id-type="pmid">
         19239771
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0025">
       <label>
        25
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Coexistence of multiple coronaviruses in several bat colonies in an abandoned mineshaft
        </article-title>
        .
        <source>
         Virol Sin
        </source>
        .
        <year>
         2016 Feb
        </year>
        ;
        <volume>
         31
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         31
        </fpage>
        –
        <lpage>
         40
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1007/s12250-016-3713-9
        </pub-id>
        .
        <comment>
         PubMed PMID: 26920708
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s12250-016-3713-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         26920708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0026">
       <label>
        26
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Link of a ubiquitous human coronavirus to dromedary camels
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2016 Aug 30
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         35
        </issue>
        ):
        <fpage>
         9864
        </fpage>
        –
        <lpage>
         9869
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1073/pnas.1604472113
        </pub-id>
        .
        <comment>
         PubMed PMID: 27528677; PubMed Central PMCID: PMCPMC5024591
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1073/pnas.1604472113
        </pub-id>
        <pub-id pub-id-type="pmid">
         27528677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0027">
       <label>
        27
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mohd
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Memish
          </surname>
          <given-names>
           ZA.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir
        </article-title>
        .
        <source>
         Virol J
        </source>
        .
        <year>
         2016 Jun 3
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         87
        </fpage>
        DOI:
        <pub-id pub-id-type="doi">
         10.1186/s12985-016-0544-0
        </pub-id>
        .
        <comment>
         PubMed PMID: 27255185; PubMed Central PMCID: PMC4891877
        </comment>
        .
        <pub-id pub-id-type="pmid">
         27255185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0028">
       <label>
        28
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sabir
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           TT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ahmed
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        .
        <source>
         Science
        </source>
        .
        <year>
         2016 Jan 1
        </year>
        ;
        <volume>
         351
        </volume>
        (
        <issue>
         6268
        </issue>
        ):
        <fpage>
         81
        </fpage>
        –
        <lpage>
         84
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1126/science.aac8608
        </pub-id>
        .
        <comment>
         PubMed PMID: 26678874
        </comment>
        .
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0029">
       <label>
        29
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chafekar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fielding
          </surname>
          <given-names>
           BC.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV: understanding the latest human coronavirus threat
        </article-title>
        .
        <source>
         Viruses
        </source>
        .
        <year>
         2018 Feb 24
        </year>
        ;
        <volume>
         10
        </volume>
        (
        <issue>
         2
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.3390/v10020093
        </pub-id>
        .
        <comment>
         PubMed PMID: 29495250; PubMed Central PMCID: PMC5850400
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0030">
       <label>
        30
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Group F-O-WMTW
         </collab>
        </person-group>
        <article-title>
         MERS: progress on the global response, remaining challenges and the way forward
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2018 Nov
        </year>
        ;
        <volume>
         159
        </volume>
        :
        <fpage>
         35
        </fpage>
        –
        <lpage>
         44
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2018.09.002
        </pub-id>
        .
        <comment>
         PubMed PMID: 30236531
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2018.09.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         30236531
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0031">
       <label>
        31
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zeng
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2017 Nov
        </year>
        ;
        <volume>
         13
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         e1006698
        </fpage>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006698
        </pub-id>
        .
        <comment>
         PubMed PMID: 29190287; PubMed Central PMCID: PMC5708621
        </comment>
        . doi:
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006698
        </pub-id>
        <pub-id pub-id-type="pmid">
         29190287
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>